tokens,ner_tags,id,bert_tokens,word_ids,bert_ner_tags,text
"['Glutamatergic', 'Mechanisms', ':', 'aim2.^', '\n', 'Schizophrenia', '(', 'Sz', ')', 'is', 'associated', 'with', 'psychotic', 'symptoms', ',', 'such', 'as', 'hearing', 'voices', 'and', 'paranoid', 'beliefs', 'that', 'remain', 'partially', 'or', 'fully', 'refractory', 'to', 'standard', 'antipsychotic', 'medications', 'for', '2/3', 'of', 'patients', '.', 'Alternative', ',', 'glutamatergic', 'approaches', 'for', 'treatment', 'development', 'have', 'been', 'proposed', 'but', 'have', 'not', 'yet', 'led', 'to', 'FDA‐approved', 'medications', '.', 'Moreover', ',', 'several', 'glutamate‐targeted', 'medications', ',', 'such', 'as', 'pomaglumetad', '(', 'POMA', ')', ',', 'have', 'failed', 'in', 'pivotal', 'clinical', 'trials', 'despite', 'robust', 'effectiveness', 'in', 'preclinical', 'models', '.', 'A', 'major', 'barrier', 'to', 'effective', 'glutamatergic', 'treatment', 'development', 'is', 'the', 'absence', 'of', 'validated', 'measures', 'for', 'target', 'engagement', 'that', 'can', 'identify', 'effective', 'compounds', 'and', 'guide', 'dose', 'selection', '.', 'Target', '""', 'refers', 'to', 'a', 'factor', 'that', 'an', 'intervention', 'is', 'intended', 'to', 'modify', ',', 'leading', 'to', 'improvement', 'in', 'symptoms', ',', 'and', 'target', 'engagement', 'biomarkers', 'are', 'a', 'measure', 'of', 'the', 'ability', 'of', 'the', 'intervention', 'to', '""', 'engage', '""', 'the', 'target', '.', 'As', 'part', 'of', 'the', 'recently', 'completed', 'NIMH', 'multicenter', 'FAST‐PS', 'initiative', 'and', 'a', 'parallel', 'industry', 'sponsored', 'project', ',', 'we', 'evaluated', 'ketamine‐induced', 'pharmacoBOLD', '(', 'phBOLD', ')', 'in', 'healthy', 'volunteers', '(', 'HV', ')', 'as', 'a', 'potential', 'target', 'engagement', 'biomarker', 'for', 'development', 'of', 'metabotropic', 'glutamate', '(', 'mGluR2/3', ')', 'agonists', ',', 'as', 'a', 'prelude', 'to', 'planned', 'studies', 'in', 'Sz', '.', 'BOLD', 'imaging', 'indirectly', 'measures', 'brain', 'energy', ',', 'as', 'a', 'proxy', 'for', 'glutamate', 'target', 'engagement', '.', 'The', 'structure', 'of', 'the', 'R01', 'grant', 'funding', 'this', 'protocol', 'was', 'split', 'into', 'three', 'studies', ',', 'specific', 'aim', '(', 'SA', ')', '1', ',', '2', 'and', '3', '.', 'In', 'FAST‐PS', ',', 'a', 'high', 'dose', 'of', 'ketamine', '(', '0.23', 'mg', '/', 'kg', ')', 'was', 'used', 'in', 'order', 'to', 'produce', 'robust', 'pharmacological', 'effects', '.', 'Under', 'SA1', ',', 'which', 'was', 'conducted', 'under', 'IRB', '8063', ',', 'this', 'dose', 'was', 'titrated', 'downward', 'in', 'across', 'two', 'phBOLD', 'sessions', 'in', 'HV', 'in', 'order', 'to', 'determine', 'the', 'lowest', 'dose', 'of', 'ketamine', 'that', 'still', 'produces', 'a', 'phBOLD', 'response', 'of', 'Cohen', ""'s"", 'd≥1.5', ',', 'hypothesizing', 'that', 'this', 'dose', 'would', 'provide', 'the', 'best', 'signal', 'to', 'noise', 'for', 'use', 'in', 'SA2', '.', 'The', 'study', 'was', 'conducted', 'in', 'groups', 'of', '10', 'subject', 'per', 'dose', 'cohort', ',', 'and', 'the', 'analysis', 'supports', 'using', 'a', 'low', 'dose', 'of', '0.06', 'mg', '/', 'kg', 'for', 'SA2', '.', 'SA2', 'experiments', 'are', 'modeled', 'after', 'our', 'preliminary', 'TS‐134', 'studies', '.', 'SA2', 'will', 'be', 'randomized', ',', 'double‐blind', ',', 'and', 'placebo', 'controlled', '.', '120', 'HV', 'will', 'be', 'randomized', 'to', 'one', 'of', 'three', 'ketamine', 'arms', ':', 'low', ',', 'medium', ',', 'and', 'high', '.', 'Based', 'on', 'SA1', ',', 'the', 'low', 'dose', 'will', 'be', '0.06', 'mg', '/', 'kg', '.', 'The', 'medium', 'dose', ',', '0.125', 'mg', '/', 'kg', ',', 'is', 'based', 'the', 'previously', 'published', 'mGluR2/3', 'target', 'engagement', 'study', 'and', 'the', 'high', 'dose', 'is', 'equal', 'to', '0.23', 'mg', '/', 'kg', ',', 'the', 'same', 'as', 'in', 'the', 'FAST‐PS', 'study', '.', 'Within', 'each', 'ketamine', 'arm', ',', 'subjects', 'will', 'be', 'randomized', 'to', '4', 'days', 'of', 'TS‐134', '20', 'mg', 'or', 'placebo', 'in', 'a', '5:3', 'ratio', '(', '25', 'TS‐134:15', 'placebo', ')', '.', 'Following', 'an', 'outpatient', 'Screening', 'Period', '(', 'up', 'to', '31', 'days', ')', ',', 'eligible', 'subjects', 'will', 'undergo', 'a', '5‐day', 'inpatient', 'Treatment', 'Period', '.', 'During', 'the', 'study', ',', 'each', 'subject', 'will', 'undergo', 'a', 'total', 'of', 'two', 'ketamine', 'sessions', ':', 'a', 'first', 'session', 'during', 'the', 'Screening', 'Period', 'and', 'a', 'second', 'session', 'on', 'Day', '4', 'of', 'the', 'Treatment', 'Period', ',', 'conducted', 'at', 'least', '7', 'days', 'apart', '.', 'All', 'randomized', 'subjects', 'will', 'be', 'dosed', 'with', 'TS‐134', 'or', 'placebo', 'daily', 'in', 'a', 'fed', 'state', 'for', '4', 'days', 'during', 'the', 'study', ',', 'titrated', 'to', '20', 'mg', 'over', 'the', 'first', '2', 'days', '.', 'As', 'before', ',', 'subjects', ""'"", 'general', 'health', 'and', 'safety', 'status', 'will', 'be', 'confirmed', 'by', 'a', 'phone', 'call', 'following', 'discharge', 'from', 'the', 'Treatment', 'Period', '.', 'Primary', 'outcomes', 'will', 'be', '(', '1', ')', 'suppression', 'of', 'the', 'phBOLD', 'response', 'and', '(', '2', ')', 'psychiatric', 'symptoms', 'after', '4', 'days', 'of', 'TS‐134', ',', 'relative', 'to', 'ketamine', 'screening', 'session', 'effects', '.', 'In', 'parallel', ',', 'we', 'will', 'evaluate', 'the', 'interactions', 'between', 'glutamate', 'and', 'DA', 'systems', 'using', 'ketamine‐induced', 'phBOLD', 'and', 'sLASER', 'MRS', 'to', 'interrogate', 'the', 'glutamate', 'system', 'and', 'neuromelanin', 'MRI', '(', 'NM‐MRI', ')', 'to', 'interrogate', 'the', 'DA', 'system', '.', 'These', 'additional', 'measures', 'will', 'be', 'collected', 'at', 'baseline', ',', 'pre', 'ketamine', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6220,"['[CLS]', 'glutamate', '##rg', '##ic', 'mechanisms', ':', 'aim', '##2', '.', '^', 'schizophrenia', '(', 'sz', ')', 'is', 'associated', 'with', 'psychotic', 'symptoms', ',', 'such', 'as', 'hearing', 'voices', 'and', 'paran', '##oid', 'beliefs', 'that', 'remain', 'partially', 'or', 'fully', 'refractory', 'to', 'standard', 'antipsychotic', 'medications', 'for', '2', '/', '3', 'of', 'patients', '.', 'alternative', ',', 'glutamate', '##rg', '##ic', 'approaches', 'for', 'treatment', 'development', 'have', 'been', 'proposed', 'but', 'have', 'not', 'yet', 'led', 'to', 'fda', '‐', 'approved', 'medications', '.', 'moreover', ',', 'several', 'glutamate', '‐', 'targeted', 'medications', ',', 'such', 'as', 'pom', '##ag', '##lu', '##met', '##ad', '(', 'pom', '##a', ')', ',', 'have', 'failed', 'in', 'pivotal', 'clinical', 'trials', 'despite', 'robust', 'effectiveness', 'in', 'preclinical', 'models', '.', 'a', 'major', 'barrier', 'to', 'effective', 'glutamate', '##rg', '##ic', 'treatment', 'development', 'is', 'the', 'absence', 'of', 'validated', 'measures', 'for', 'target', 'engagement', 'that', 'can', 'identify', 'effective', 'compounds', 'and', 'guide', 'dose', 'selection', '.', 'target', '""', 'refers', 'to', 'a', 'factor', 'that', 'an', 'intervention', 'is', 'intended', 'to', 'modify', ',', 'leading', 'to', 'improvement', 'in', 'symptoms', ',', 'and', 'target', 'engagement', 'biomarkers', 'are', 'a', 'measure', 'of', 'the', 'ability', 'of', 'the', 'intervention', 'to', '""', 'engage', '""', 'the', 'target', '.', 'as', 'part', 'of', 'the', 'recently', 'completed', 'nim', '##h', 'multicenter', 'fast', '‐', 'ps', 'initiative', 'and', 'a', 'parallel', 'industry', 'sponsored', 'project', ',', 'we', 'evaluated', 'ketamine', '‐', 'induced', 'pharmac', '##ob', '##old', '(', 'ph', '##bold', ')', 'in', 'healthy', 'volunteers', '(', 'hv', ')', 'as', 'a', 'potential', 'target', 'engagement', 'biomarker', 'for', 'development', 'of', 'metab', '##otropic', 'glutamate', '(', 'mgl', '##ur', '##2', '/', '3', ')', 'agonists', ',', 'as', 'a', 'prel', '##ude', 'to', 'planned', 'studies', 'in', 'sz', '.', 'bold', 'imaging', 'indirectly', 'measures', 'brain', 'energy', ',', 'as', 'a', 'proxy', 'for', 'glutamate', 'target', 'engagement', '.', 'the', 'structure', 'of', 'the', 'r', '##01', 'grant', 'funding', 'this', 'protocol', 'was', 'split', 'into', 'three', 'studies', ',', 'specific', 'aim', '(', 'sa', ')', '1', ',', '2', 'and', '3', '.', 'in', 'fast', '‐', 'ps', ',', 'a', 'high', 'dose', 'of', 'ketamine', '(', '0', '.', '23', 'mg', '/', 'kg', ')', 'was', 'used', 'in', 'order', 'to', 'produce', 'robust', 'pharmacological', 'effects', '.', 'under', 'sa', '##1', ',', 'which', 'was', 'conducted', 'under', 'ir', '##b', '80', '##63', ',', 'this', 'dose', 'was', 'titr', '##ated', 'downward', 'in', 'across', 'two', 'ph', '##bold', 'sessions', 'in', 'hv', 'in', 'order', 'to', 'determine', 'the', 'lowest', 'dose', 'of', 'ketamine', 'that', 'still', 'produces', 'a', 'ph', '##bold', 'response', 'of', 'cohen', ""'"", 's', 'd', '##≥', '##1', '.', '5', ',', 'hypothe', '##si', '##zing', 'that', 'this', 'dose', 'would', 'provide', 'the', 'best', 'signal', 'to', 'noise', 'for', 'use', 'in', 'sa', '##2', '.', 'the', 'study', 'was', 'conducted', 'in', 'groups', 'of', '10', 'subject', 'per', 'dose', 'cohort', ',', 'and', 'the', 'analysis', 'supports', 'using', 'a', 'low', 'dose', 'of', '0', '.', '06', 'mg', '/', 'kg', 'for', 'sa', '##2', '.', 'sa', '##2', 'experiments', 'are', 'modeled', 'after', 'our', 'preliminary', 'ts', '‐', '134', 'studies', '.', 'sa', '##2', 'will', 'be', 'randomized', ',', 'double', '‐', 'blind', ',', 'and', 'placebo', 'controlled', '.', '120', 'hv', 'will', 'be', 'randomized', 'to', 'one', 'of', 'three', 'ketamine', 'arms', ':', 'low', ',', 'medium', ',', 'and', 'high', '.', 'based', 'on', 'sa', '##1', ',', 'the', 'low', 'dose', 'will', 'be', '0', '.', '06', 'mg', '/', 'kg', '.', 'the', 'medium', 'dose', ',', '0', '.', '125', 'mg', '/', 'kg', ',', 'is', 'based', 'the', 'previously', 'published', 'mgl', '##ur', '##2', '/', '3', 'target', 'engagement', 'study', 'and', 'the', 'high', 'dose', 'is', 'equal', 'to', '0', '.', '23', 'mg', '[SEP]']","[None, 0, 0, 0, 1, 2, 3, 3, 3, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 33, 33, 34, 35, 36, 37, 38, 39, 39, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 53, 53, 54, 55, 56, 57, 58, 59, 59, 59, 60, 61, 62, 63, 64, 64, 64, 64, 64, 65, 66, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 87, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 156, 157, 157, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 168, 168, 169, 169, 169, 170, 171, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 188, 189, 190, 191, 191, 191, 191, 191, 192, 193, 194, 195, 196, 197, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 246, 246, 247, 248, 249, 250, 251, 252, 253, 254, 254, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 270, 271, 272, 273, 274, 275, 276, 276, 277, 277, 278, 279, 280, 281, 282, 282, 283, 284, 285, 286, 287, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 304, 305, 306, 307, 308, 308, 309, 309, 309, 309, 309, 310, 311, 311, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 349, 349, 350, 351, 352, 353, 354, 354, 355, 356, 356, 357, 358, 359, 360, 361, 362, 363, 363, 363, 364, 365, 366, 366, 367, 368, 369, 370, 371, 371, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 398, 399, 400, 401, 402, 403, 404, 405, 405, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 414, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 424, 424, 424, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 435, 435, 436, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, -100]","Glutamatergic Mechanisms: aim2.^
Schizophrenia (Sz) is associated with psychotic symptoms, such as hearing voices and paranoid beliefs that remain partially or fully refractory to standard antipsychotic medications for 2/3 of patients. Alternative, glutamatergic approaches for treatment development have been proposed but have not yet led to FDA‐approved medications. Moreover, several glutamate‐targeted medications, such as pomaglumetad (POMA), have failed in pivotal clinical trials despite robust effectiveness in preclinical models. A major barrier to effective glutamatergic treatment development is the absence of validated measures for target engagement that can identify effective compounds and guide dose selection. Target"" refers to a factor that an intervention is intended to modify, leading to improvement in symptoms, and target engagement biomarkers are a measure of the ability of the intervention to ""engage"" the target. As part of the recently completed NIMH multicenter FAST‐PS initiative and a parallel industry sponsored project, we evaluated ketamine‐induced pharmacoBOLD (phBOLD) in healthy volunteers (HV) as a potential target engagement biomarker for development of metabotropic glutamate (mGluR2/3) agonists, as a prelude to planned studies in Sz. BOLD imaging indirectly measures brain energy, as a proxy for glutamate target engagement. The structure of the R01 grant funding this protocol was split into three studies, specific aim (SA) 1, 2 and 3. In FAST‐PS, a high dose of ketamine (0.23 mg/kg) was used in order to produce robust pharmacological effects. Under SA1, which was conducted under IRB 8063, this dose was titrated downward in across two phBOLD sessions in HV in order to determine the lowest dose of ketamine that still produces a phBOLD response of Cohen's d≥1.5, hypothesizing that this dose would provide the best signal to noise for use in SA2. The study was conducted in groups of 10 subject per dose cohort, and the analysis supports using a low dose of 0.06 mg/kg for SA2. SA2 experiments are modeled after our preliminary TS‐134 studies. SA2 will be randomized, double‐blind, and placebo controlled. 120 HV will be randomized to one of three ketamine arms: low, medium, and high. Based on SA1, the low dose will be 0.06 mg/kg. The medium dose, 0.125 mg/kg, is based the previously published mGluR2/3 target engagement study and the high dose is equal to 0.23 mg/kg, the same as in the FAST‐PS study. Within each ketamine arm, subjects will be randomized to 4 days of TS‐134 20 mg or placebo in a 5:3 ratio (25 TS‐134:15 placebo). Following an outpatient Screening Period (up to 31 days), eligible subjects will undergo a 5‐day inpatient Treatment Period. During the study, each subject will undergo a total of two ketamine sessions: a first session during the Screening Period and a second session on Day 4 of the Treatment Period, conducted at least 7 days apart. All randomized subjects will be dosed with TS‐134 or placebo daily in a fed state for 4 days during the study, titrated to 20 mg over the first 2 days. As before, subjects' general health and safety status will be confirmed by a phone call following discharge from the Treatment Period. Primary outcomes will be (1) suppression of the phBOLD response and (2) psychiatric symptoms after 4 days of TS‐134, relative to ketamine screening session effects. In parallel, we will evaluate the interactions between glutamate and DA systems using ketamine‐induced phBOLD and sLASER MRS to interrogate the glutamate system and neuromelanin MRI (NM‐MRI) to interrogate the DA system. These additional measures will be collected at baseline, pre ketamine."
"['Reduced', 'memory', 'skills', 'and', 'increased', 'hair', 'cortisol', 'levels', 'in', 'recent', 'Ecstasy', '/', 'MDMA', 'users', ':', 'Significant', 'but', 'independent', 'neurocognitive', 'and', 'neurohormonal', 'deficits.^', '\n', 'Objectives', 'The', 'goals', 'of', 'this', 'study', 'were', 'to', 'measure', 'the', 'neurocognitive', 'performance', 'of', 'recent', 'users', 'of', 'recreational', 'Ecstasy', 'and', 'investigate', 'whether', 'it', 'was', 'associated', 'with', 'the', 'stress', 'hormone', 'cortisol', '.', 'Methods', 'The', '101', 'participants', 'included', '27', 'recent', 'light', 'users', 'of', 'Ecstasy', '(', 'one', 'to', 'four', 'times', 'in', 'the', 'last', '3', 'months', ')', ',', '23', 'recent', 'heavier', 'Ecstasy', 'users', '(', 'five', 'or', 'more', 'times', ')', 'and', '51', 'non', '-', 'users', '.', 'Rivermead', 'paragraph', 'recall', 'provided', 'an', 'objective', 'measure', 'for', 'immediate', 'and', 'delayed', 'recall', '.', 'The', 'prospective', 'and', 'retrospective', 'memory', 'questionnaire', 'provided', 'a', 'subjective', 'index', 'of', 'memory', 'deficits', '.', 'Cortisol', 'levels', 'were', 'taken', 'from', 'near', '-', 'scalp', '3', '-', 'month', 'hair', 'samples', '.', 'Results', 'Cortisol', 'was', 'significantly', 'raised', 'in', 'recent', 'heavy', 'Ecstasy', 'users', 'compared', 'with', 'controls', ',', 'whereas', 'hair', 'cortisol', 'in', 'light', 'Ecstasy', 'users', 'was', 'not', 'raised', '.', 'Both', 'Ecstasy', 'groups', 'were', 'significantly', 'impaired', 'on', 'the', 'Rivermead', 'delayed', 'word', 'recall', ',', 'and', 'both', 'groups', 'reported', 'significantly', 'more', 'retrospective', 'and', 'prospective', 'memory', 'problems', '.', 'Stepwise', 'regression', 'confirmed', 'that', 'lifetime', 'Ecstasy', 'predicted', 'the', 'extent', 'of', 'these', 'memory', 'deficits', '.', 'Conclusions', 'Recreational', 'Ecstasy', 'is', 'associated', 'with', 'increased', 'levels', 'of', 'the', 'bio', '-', 'energetic', 'stress', 'hormone', 'cortisol', 'and', 'significant', 'memory', 'impairments', '.', 'No', 'significant', 'relationship', 'between', 'cortisol', 'and', 'the', 'cognitive', 'deficits', 'was', 'observed', '.', 'Ecstasy', 'users', 'did', 'display', 'evidence', 'of', 'a', 'metacognitive', 'deficit', ',', 'with', 'the', 'strength', 'of', 'the', 'correlations', 'between', 'objective', 'and', 'subjective', 'memory', 'performances', 'being', 'significantly', 'lower', 'in', 'the', 'Ecstasy', 'users', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",2176,"['[CLS]', 'reduced', 'memory', 'skills', 'and', 'increased', 'hair', 'cortisol', 'levels', 'in', 'recent', 'ecs', '##tas', '##y', '/', 'mdm', '##a', 'users', ':', 'significant', 'but', 'independent', 'neuro', '##cognitive', 'and', 'neuro', '##horm', '##onal', 'deficits', '.', '^', 'objectives', 'the', 'goals', 'of', 'this', 'study', 'were', 'to', 'measure', 'the', 'neuro', '##cognitive', 'performance', 'of', 'recent', 'users', 'of', 'recreational', 'ecs', '##tas', '##y', 'and', 'investigate', 'whether', 'it', 'was', 'associated', 'with', 'the', 'stress', 'hormone', 'cortisol', '.', 'methods', 'the', '101', 'participants', 'included', '27', 'recent', 'light', 'users', 'of', 'ecs', '##tas', '##y', '(', 'one', 'to', 'four', 'times', 'in', 'the', 'last', '3', 'months', ')', ',', '23', 'recent', 'heavier', 'ecs', '##tas', '##y', 'users', '(', 'five', 'or', 'more', 'times', ')', 'and', '51', 'non', '-', 'users', '.', 'river', '##me', '##ad', 'paragraph', 'recall', 'provided', 'an', 'objective', 'measure', 'for', 'immediate', 'and', 'delayed', 'recall', '.', 'the', 'prospective', 'and', 'retrospective', 'memory', 'questionnaire', 'provided', 'a', 'subjective', 'index', 'of', 'memory', 'deficits', '.', 'cortisol', 'levels', 'were', 'taken', 'from', 'near', '-', 'scalp', '3', '-', 'month', 'hair', 'samples', '.', 'results', 'cortisol', 'was', 'significantly', 'raised', 'in', 'recent', 'heavy', 'ecs', '##tas', '##y', 'users', 'compared', 'with', 'controls', ',', 'whereas', 'hair', 'cortisol', 'in', 'light', 'ecs', '##tas', '##y', 'users', 'was', 'not', 'raised', '.', 'both', 'ecs', '##tas', '##y', 'groups', 'were', 'significantly', 'impaired', 'on', 'the', 'river', '##me', '##ad', 'delayed', 'word', 'recall', ',', 'and', 'both', 'groups', 'reported', 'significantly', 'more', 'retrospective', 'and', 'prospective', 'memory', 'problems', '.', 'stepwise', 'regression', 'confirmed', 'that', 'lifetime', 'ecs', '##tas', '##y', 'predicted', 'the', 'extent', 'of', 'these', 'memory', 'deficits', '.', 'conclusions', 'recreational', 'ecs', '##tas', '##y', 'is', 'associated', 'with', 'increased', 'levels', 'of', 'the', 'bio', '-', 'energetic', 'stress', 'hormone', 'cortisol', 'and', 'significant', 'memory', 'impairments', '.', 'no', 'significant', 'relationship', 'between', 'cortisol', 'and', 'the', 'cognitive', 'deficits', 'was', 'observed', '.', 'ecs', '##tas', '##y', 'users', 'did', 'display', 'evidence', 'of', 'a', 'metac', '##ognitive', 'deficit', ',', 'with', 'the', 'strength', 'of', 'the', 'correlations', 'between', 'objective', 'and', 'subjective', 'memory', 'performances', 'being', 'significantly', 'lower', 'in', 'the', 'ecs', '##tas', '##y', 'users', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10, 10, 11, 12, 12, 13, 14, 15, 16, 17, 18, 18, 19, 20, 20, 20, 21, 21, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 33, 34, 35, 36, 37, 38, 39, 40, 40, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 63, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 79, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 93, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 142, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 153, 153, 154, 155, 156, 157, 158, 159, 160, 160, 160, 161, 162, 163, 164, 165, 166, 167, 167, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 189, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 200, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 231, 231, 232, 233, 234, 235, 236, 237, 238, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 258, 258, 259, 260, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Reduced memory skills and increased hair cortisol levels in recent Ecstasy/MDMA users: Significant but independent neurocognitive and neurohormonal deficits.^
Objectives The goals of this study were to measure the neurocognitive performance of recent users of recreational Ecstasy and investigate whether it was associated with the stress hormone cortisol. Methods The 101 participants included 27 recent light users of Ecstasy (one to four times in the last 3 months), 23 recent heavier Ecstasy users (five or more times) and 51 non-users. Rivermead paragraph recall provided an objective measure for immediate and delayed recall. The prospective and retrospective memory questionnaire provided a subjective index of memory deficits. Cortisol levels were taken from near-scalp 3-month hair samples. Results Cortisol was significantly raised in recent heavy Ecstasy users compared with controls, whereas hair cortisol in light Ecstasy users was not raised. Both Ecstasy groups were significantly impaired on the Rivermead delayed word recall, and both groups reported significantly more retrospective and prospective memory problems. Stepwise regression confirmed that lifetime Ecstasy predicted the extent of these memory deficits. Conclusions Recreational Ecstasy is associated with increased levels of the bio-energetic stress hormone cortisol and significant memory impairments. No significant relationship between cortisol and the cognitive deficits was observed. Ecstasy users did display evidence of a metacognitive deficit, with the strength of the correlations between objective and subjective memory performances being significantly lower in the Ecstasy users."
"['The', 'acute', 'effects', 'of', 'MDMA', 'and', 'ethanol', 'administration', 'on', 'electrophysiological', 'correlates', 'of', 'performance', 'monitoring', 'in', 'healthy', 'volunteers.^', '\n', 'RATIONALE', ':', 'Knowing', 'how', 'commonly', 'used', 'drugs', 'affect', 'performance', 'monitoring', 'is', 'of', 'great', 'importance', ',', 'because', 'drug', 'use', 'is', 'often', 'associated', 'with', 'compromised', 'behavioral', 'control', '.', 'Two', 'of', 'the', 'most', 'commonly', 'used', 'recreational', 'drugs', 'in', 'the', 'western', 'world', ',', '3,4', '-', 'methylenedioxymethamphetamine', '(', 'MDMA', 'or', '""', 'ecstasy', '""', ')', 'and', 'ethanol', '(', 'alcohol', ')', ',', 'are', 'also', 'often', 'used', 'in', 'combination', '.', 'The', 'error', '-', 'related', 'negativity', '(', 'ERN', ')', ',', 'correct', '-', 'related', 'negativity', '(', 'CRN', ')', ',', 'and', 'N2', 'are', 'electrophysiological', 'indices', 'of', 'performance', 'monitoring', '.', 'OBJECTIVES', ':', 'The', 'present', 'study', 'aimed', 'to', 'investigate', 'how', 'ethanol', ',', 'MDMA', ',', 'and', 'their', 'co', '-', 'administration', 'affect', 'performance', 'monitoring', 'as', 'indexed', 'by', 'the', 'electrophysiological', 'correlates', '.', 'METHODS', ':', 'Behavioral', 'and', 'EEG', 'data', 'were', 'obtained', 'from', '14', 'healthy', 'volunteers', 'during', 'execution', 'of', 'a', 'speeded', 'choice', '-', 'reaction', '-', 'time', 'task', 'after', 'administration', 'of', 'ethanol', ',', 'MDMA', ',', 'and', 'combined', 'ethanol', 'and', 'MDMA', ',', 'in', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'randomized', 'crossover', 'design', '.', 'RESULTS', ':', 'Ethanol', 'significantly', 'reduced', 'ERN', 'amplitudes', ',', 'while', 'administration', 'of', 'MDMA', 'did', 'not', 'affect', 'the', 'ERN', '.', 'Co', '-', 'administration', 'of', 'MDMA', 'and', 'ethanol', 'did', 'not', 'further', 'impair', 'nor', 'ameliorate', 'the', 'effect', 'of', 'ethanol', 'alone', '.', 'No', 'drug', 'effects', 'on', 'CRN', 'nor', 'N2', 'were', 'observed', '.', 'DISCUSSION', ':', 'A', 'decreased', 'ERN', 'following', 'ethanol', 'administration', 'is', 'in', 'line', 'with', 'previous', 'work', 'and', 'offers', 'further', 'support', 'for', 'the', 'impairing', 'effects', 'of', 'alcohol', 'intoxication', 'on', 'performance', 'monitoring', '.', 'This', 'impairment', 'may', 'underlie', 'maladaptive', 'behavior', 'in', 'people', 'who', 'are', 'under', 'influence', '.', 'Moreover', ',', 'these', 'data', 'demonstrate', 'for', 'the', 'first', 'time', 'that', 'MDMA', 'does', 'not', 'affect', 'performance', 'monitoring', 'nor', 'does', 'it', 'interact', 'with', 'ethanol', 'in', 'this', 'process', '.', 'These', 'findings', 'corroborate', 'the', 'notion', 'that', 'MDMA', 'leaves', 'central', 'executive', 'functions', 'relatively', 'unaffected', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8221,"['[CLS]', 'the', 'acute', 'effects', 'of', 'mdm', '##a', 'and', 'ethanol', 'administration', 'on', 'electroph', '##ysiological', 'correlates', 'of', 'performance', 'monitoring', 'in', 'healthy', 'volunteers', '.', '^', 'rationale', ':', 'knowing', 'how', 'commonly', 'used', 'drugs', 'affect', 'performance', 'monitoring', 'is', 'of', 'great', 'importance', ',', 'because', 'drug', 'use', 'is', 'often', 'associated', 'with', 'compromised', 'behavioral', 'control', '.', 'two', 'of', 'the', 'most', 'commonly', 'used', 'recreational', 'drugs', 'in', 'the', 'western', 'world', ',', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', 'or', '""', 'ecs', '##tas', '##y', '""', ')', 'and', 'ethanol', '(', 'alcohol', ')', ',', 'are', 'also', 'often', 'used', 'in', 'combination', '.', 'the', 'error', '-', 'related', 'neg', '##ativity', '(', 'ern', ')', ',', 'correct', '-', 'related', 'neg', '##ativity', '(', 'cr', '##n', ')', ',', 'and', 'n', '##2', 'are', 'electroph', '##ysiological', 'indices', 'of', 'performance', 'monitoring', '.', 'objectives', ':', 'the', 'present', 'study', 'aimed', 'to', 'investigate', 'how', 'ethanol', ',', 'mdm', '##a', ',', 'and', 'their', 'co', '-', 'administration', 'affect', 'performance', 'monitoring', 'as', 'indexed', 'by', 'the', 'electroph', '##ysiological', 'correlates', '.', 'methods', ':', 'behavioral', 'and', 'eeg', 'data', 'were', 'obtained', 'from', '14', 'healthy', 'volunteers', 'during', 'execution', 'of', 'a', 'speed', '##ed', 'choice', '-', 'reaction', '-', 'time', 'task', 'after', 'administration', 'of', 'ethanol', ',', 'mdm', '##a', ',', 'and', 'combined', 'ethanol', 'and', 'mdm', '##a', ',', 'in', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'randomized', 'crossover', 'design', '.', 'results', ':', 'ethanol', 'significantly', 'reduced', 'ern', 'amplitudes', ',', 'while', 'administration', 'of', 'mdm', '##a', 'did', 'not', 'affect', 'the', 'ern', '.', 'co', '-', 'administration', 'of', 'mdm', '##a', 'and', 'ethanol', 'did', 'not', 'further', 'impair', 'nor', 'amelior', '##ate', 'the', 'effect', 'of', 'ethanol', 'alone', '.', 'no', 'drug', 'effects', 'on', 'cr', '##n', 'nor', 'n', '##2', 'were', 'observed', '.', 'discussion', ':', 'a', 'decreased', 'ern', 'following', 'ethanol', 'administration', 'is', 'in', 'line', 'with', 'previous', 'work', 'and', 'offers', 'further', 'support', 'for', 'the', 'impair', '##ing', 'effects', 'of', 'alcohol', 'intox', '##ication', 'on', 'performance', 'monitoring', '.', 'this', 'impairment', 'may', 'underlie', 'mal', '##adaptive', 'behavior', 'in', 'people', 'who', 'are', 'under', 'influence', '.', 'moreover', ',', 'these', 'data', 'demonstrate', 'for', 'the', 'first', 'time', 'that', 'mdm', '##a', 'does', 'not', 'affect', 'performance', 'monitoring', 'nor', 'does', 'it', 'interact', 'with', 'ethanol', 'in', 'this', 'process', '.', 'these', 'findings', 'corrobor', '##ate', 'the', 'notion', 'that', 'mdm', '##a', 'leaves', 'central', 'executive', 'functions', 'relatively', 'unaffected', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 4, 5, 6, 7, 8, 9, 9, 10, 11, 12, 13, 14, 15, 16, 16, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 57, 57, 58, 59, 59, 59, 59, 59, 60, 61, 61, 62, 63, 64, 64, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 84, 85, 86, 87, 88, 89, 90, 91, 92, 92, 93, 94, 94, 95, 96, 97, 98, 98, 99, 100, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 162, 163, 164, 165, 166, 167, 168, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 206, 207, 208, 209, 210, 211, 212, 213, 214, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 225, 226, 227, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 251, 252, 253, 254, 255, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 301, 302, 303, 304, 305, 305, 306, 307, 308, 309, 310, 311, 312, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","The acute effects of MDMA and ethanol administration on electrophysiological correlates of performance monitoring in healthy volunteers.^
RATIONALE: Knowing how commonly used drugs affect performance monitoring is of great importance, because drug use is often associated with compromised behavioral control. Two of the most commonly used recreational drugs in the western world, 3,4-methylenedioxymethamphetamine (MDMA or ""ecstasy"") and ethanol (alcohol), are also often used in combination. The error-related negativity (ERN), correct-related negativity (CRN), and N2 are electrophysiological indices of performance monitoring. OBJECTIVES: The present study aimed to investigate how ethanol, MDMA, and their co-administration affect performance monitoring as indexed by the electrophysiological correlates. METHODS: Behavioral and EEG data were obtained from 14 healthy volunteers during execution of a speeded choice-reaction-time task after administration of ethanol, MDMA, and combined ethanol and MDMA, in a double-blind, placebo-controlled, randomized crossover design. RESULTS: Ethanol significantly reduced ERN amplitudes, while administration of MDMA did not affect the ERN. Co-administration of MDMA and ethanol did not further impair nor ameliorate the effect of ethanol alone. No drug effects on CRN nor N2 were observed. DISCUSSION: A decreased ERN following ethanol administration is in line with previous work and offers further support for the impairing effects of alcohol intoxication on performance monitoring. This impairment may underlie maladaptive behavior in people who are under influence. Moreover, these data demonstrate for the first time that MDMA does not affect performance monitoring nor does it interact with ethanol in this process. These findings corroborate the notion that MDMA leaves central executive functions relatively unaffected."
"['Acute', 'effects', 'of', 'intravenous', 'DMT', 'in', 'a', 'randomized', 'placebo', '-', 'controlled', 'study', 'in', 'healthy', 'participants.^', '\n', 'N', ',', 'N', '-', 'dimethyltryptamine', '(', 'DMT', ')', 'is', 'distinct', 'among', 'classic', 'serotonergic', 'psychedelics', 'because', 'of', 'its', 'short', '-', 'lasting', 'effects', 'when', 'administered', 'intravenously', '.', 'Despite', 'growing', 'interest', 'in', 'the', 'experimental', 'and', 'therapeutic', 'use', 'of', 'intravenous', 'DMT', ',', 'data', 'are', 'lacking', 'on', 'its', 'clinical', 'pharmacology', '.', 'We', 'conducted', 'a', 'double', '-', 'blind', ',', 'randomized', ',', 'placebo', '-', 'controlled', 'crossover', 'trial', 'in', '27', 'healthy', 'participants', 'to', 'test', 'different', 'intravenous', 'DMT', 'administration', 'regimens', ':', 'placebo', ',', 'low', 'infusion', '(', '0.6', 'mg', '/', 'min', ')', ',', 'high', 'infusion', '(', '1', 'mg', '/', 'min', ')', ',', 'low', 'bolus', '+', 'low', 'infusion', '(', '15', 'mg', '+', '0.6', 'mg', '/', 'min', ')', ',', 'and', 'high', 'bolus', '+', 'high', 'infusion', '(', '25', 'mg', '+', '1', 'mg', '/', 'min', ')', '.', 'Study', 'sessions', 'lasted', 'for', '5', 'h', 'and', 'were', 'separated', 'by', 'at', 'least', '1', 'week', '.', 'Participant', ""'s"", 'lifetime', 'use', 'of', 'psychedelics', 'was', '≤20', 'times', '.', 'Outcome', 'measures', 'included', 'subjective', ',', 'autonomic', ',', 'and', 'adverse', 'effects', ',', 'pharmacokinetics', 'of', 'DMT', ',', 'and', 'plasma', 'levels', 'of', 'brain', '-', 'derived', 'neurotropic', 'factor', '(', 'BDNF', ')', 'and', 'oxytocin', '.', 'Low', '(', '15', 'mg', ')', 'and', 'high', '(', '25', 'mg', ')', 'DMT', 'bolus', 'doses', 'rapidly', 'induced', 'very', 'intense', 'psychedelic', 'effects', 'that', 'peaked', 'within', '2', 'min', '.', 'DMT', 'infusions', '(', '0.6', 'or', '1', 'mg', '/', 'min', ')', 'without', 'a', 'bolus', 'induced', 'slowly', 'increasing', 'and', 'dose', '-', 'dependent', 'psychedelic', 'effects', 'that', 'reached', 'plateaus', 'after', '30', 'min', '.', 'Both', 'bolus', 'doses', 'produced', 'more', 'negative', 'subjective', 'effects', 'and', 'anxiety', 'than', 'infusions', '.', 'After', 'stopping', 'the', 'infusion', ',', 'all', 'drug', 'effects', 'rapidly', 'decreased', 'and', 'completely', 'subsided', 'within', '15', 'min', ',', 'consistent', 'with', 'a', 'short', 'early', 'plasma', 'elimination', 'half', '-', 'life', '(', 't(1/2α', ')', ')', 'of', '5.0', '-', '5.8', 'min', ',', 'followed', 'by', 'longer', 'late', 'elimination', '(', 't(1/2β', ')', '=', '14', '-', '16', 'min', ')', 'after', '15', '-', '20', 'min', '.', 'Subjective', 'effects', 'of', 'DMT', 'were', 'stable', 'from', '30', 'to', '90', 'min', ',', 'despite', 'further', 'increasing', 'plasma', 'concentrations', ',', 'thus', 'indicating', 'acute', 'tolerance', 'to', 'continuous', 'DMT', 'administration', '.', 'Intravenous', 'DMT', ',', 'particularly', 'when', 'administered', 'as', 'an', 'infusion', ',', 'is', 'a', 'promising', 'tool', 'for', 'the', 'controlled', 'induction', 'of', 'a', 'psychedelic', 'state', 'that', 'can', 'be', 'tailored', 'to', 'the', 'specific', 'needs', 'of', 'patients', 'and', 'therapeutic', 'sessions', '.', 'Trial', 'registration', ':', 'ClinicalTrials.gov', 'identifier', ':', 'NCT04353024', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8889,"['[CLS]', 'acute', 'effects', 'of', 'intravenous', 'dm', '##t', 'in', 'a', 'randomized', 'placebo', '-', 'controlled', 'study', 'in', 'healthy', 'participants', '.', '^', 'n', ',', 'n', '-', 'dimethyl', '##try', '##pt', '##amine', '(', 'dm', '##t', ')', 'is', 'distinct', 'among', 'classic', 'serot', '##one', '##rg', '##ic', 'psych', '##ede', '##lic', '##s', 'because', 'of', 'its', 'short', '-', 'lasting', 'effects', 'when', 'administered', 'intravenously', '.', 'despite', 'growing', 'interest', 'in', 'the', 'experimental', 'and', 'therapeutic', 'use', 'of', 'intravenous', 'dm', '##t', ',', 'data', 'are', 'lacking', 'on', 'its', 'clinical', 'pharmacology', '.', 'we', 'conducted', 'a', 'double', '-', 'blind', ',', 'randomized', ',', 'placebo', '-', 'controlled', 'crossover', 'trial', 'in', '27', 'healthy', 'participants', 'to', 'test', 'different', 'intravenous', 'dm', '##t', 'administration', 'regimens', ':', 'placebo', ',', 'low', 'infusion', '(', '0', '.', '6', 'mg', '/', 'min', ')', ',', 'high', 'infusion', '(', '1', 'mg', '/', 'min', ')', ',', 'low', 'bolus', '+', 'low', 'infusion', '(', '15', 'mg', '+', '0', '.', '6', 'mg', '/', 'min', ')', ',', 'and', 'high', 'bolus', '+', 'high', 'infusion', '(', '25', 'mg', '+', '1', 'mg', '/', 'min', ')', '.', 'study', 'sessions', 'lasted', 'for', '5', 'h', 'and', 'were', 'separated', 'by', 'at', 'least', '1', 'week', '.', 'participant', ""'"", 's', 'lifetime', 'use', 'of', 'psych', '##ede', '##lic', '##s', 'was', '≤', '##20', 'times', '.', 'outcome', 'measures', 'included', 'subjective', ',', 'autonomic', ',', 'and', 'adverse', 'effects', ',', 'pharmacokinetic', '##s', 'of', 'dm', '##t', ',', 'and', 'plasma', 'levels', 'of', 'brain', '-', 'derived', 'neurot', '##ropic', 'factor', '(', 'bdnf', ')', 'and', 'oxytocin', '.', 'low', '(', '15', 'mg', ')', 'and', 'high', '(', '25', 'mg', ')', 'dm', '##t', 'bolus', 'doses', 'rapidly', 'induced', 'very', 'intense', 'psych', '##ede', '##lic', 'effects', 'that', 'peaked', 'within', '2', 'min', '.', 'dm', '##t', 'infusions', '(', '0', '.', '6', 'or', '1', 'mg', '/', 'min', ')', 'without', 'a', 'bolus', 'induced', 'slowly', 'increasing', 'and', 'dose', '-', 'dependent', 'psych', '##ede', '##lic', 'effects', 'that', 'reached', 'plateau', '##s', 'after', '30', 'min', '.', 'both', 'bolus', 'doses', 'produced', 'more', 'negative', 'subjective', 'effects', 'and', 'anxiety', 'than', 'infusions', '.', 'after', 'stopping', 'the', 'infusion', ',', 'all', 'drug', 'effects', 'rapidly', 'decreased', 'and', 'completely', 'subsid', '##ed', 'within', '15', 'min', ',', 'consistent', 'with', 'a', 'short', 'early', 'plasma', 'elimination', 'half', '-', 'life', '(', 't', '(', '1', '/', '2', '##α', ')', ')', 'of', '5', '.', '0', '-', '5', '.', '8', 'min', ',', 'followed', 'by', 'longer', 'late', 'elimination', '(', 't', '(', '1', '/', '2', '##β', ')', '=', '14', '-', '16', 'min', ')', 'after', '15', '-', '20', 'min', '.', 'subjective', 'effects', 'of', 'dm', '##t', 'were', 'stable', 'from', '30', 'to', '90', 'min', ',', 'despite', 'further', 'increasing', 'plasma', 'concentrations', ',', 'thus', 'indicating', 'acute', 'tolerance', 'to', 'continuous', 'dm', '##t', 'administration', '.', 'intravenous', 'dm', '##t', ',', 'particularly', 'when', 'administered', 'as', 'an', 'infusion', ',', 'is', 'a', 'promising', 'tool', 'for', 'the', 'controlled', 'induction', 'of', 'a', 'psych', '##ede', '##lic', 'state', 'that', 'can', 'be', 'tailored', 'to', 'the', 'specific', 'needs', 'of', 'patients', 'and', 'therapeutic', 'sessions', '.', 'trial', 'registration', ':', 'clinical', '##trials', '.', 'go', '##v', 'identifier', ':', 'nct', '##04', '##35', '##30', '##24', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 14, 16, 17, 18, 19, 20, 20, 20, 20, 21, 22, 22, 23, 24, 25, 26, 27, 28, 28, 28, 28, 29, 29, 29, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 93, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 117, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 156, 157, 158, 159, 159, 159, 159, 160, 161, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 175, 176, 177, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 205, 206, 207, 208, 209, 210, 211, 212, 212, 212, 213, 214, 215, 216, 217, 218, 219, 220, 220, 221, 222, 223, 223, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 240, 240, 241, 242, 243, 244, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 290, 290, 290, 290, 290, 291, 292, 293, 294, 294, 294, 295, 296, 296, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 305, 305, 305, 305, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 343, 344, 345, 346, 347, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 366, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 385, 385, 385, 385, 386, 387, 388, 388, 388, 388, 388, 389, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 3, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 3, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants.^
N,N-dimethyltryptamine (DMT) is distinct among classic serotonergic psychedelics because of its short-lasting effects when administered intravenously. Despite growing interest in the experimental and therapeutic use of intravenous DMT, data are lacking on its clinical pharmacology. We conducted a double-blind, randomized, placebo-controlled crossover trial in 27 healthy participants to test different intravenous DMT administration regimens: placebo, low infusion (0.6 mg/min), high infusion (1 mg/min), low bolus + low infusion (15 mg + 0.6 mg/min), and high bolus + high infusion (25 mg + 1 mg/min). Study sessions lasted for 5 h and were separated by at least 1 week. Participant's lifetime use of psychedelics was ≤20 times. Outcome measures included subjective, autonomic, and adverse effects, pharmacokinetics of DMT, and plasma levels of brain-derived neurotropic factor (BDNF) and oxytocin. Low (15 mg) and high (25 mg) DMT bolus doses rapidly induced very intense psychedelic effects that peaked within 2 min. DMT infusions (0.6 or 1 mg/min) without a bolus induced slowly increasing and dose-dependent psychedelic effects that reached plateaus after 30 min. Both bolus doses produced more negative subjective effects and anxiety than infusions. After stopping the infusion, all drug effects rapidly decreased and completely subsided within 15 min, consistent with a short early plasma elimination half-life (t(1/2α)) of 5.0-5.8 min, followed by longer late elimination (t(1/2β) = 14-16 min) after 15-20 min. Subjective effects of DMT were stable from 30 to 90 min, despite further increasing plasma concentrations, thus indicating acute tolerance to continuous DMT administration. Intravenous DMT, particularly when administered as an infusion, is a promising tool for the controlled induction of a psychedelic state that can be tailored to the specific needs of patients and therapeutic sessions.Trial registration: ClinicalTrials.gov identifier: NCT04353024."
"['MDMA', 'and', 'alcohol', 'effects', ',', 'combined', 'and', 'alone', ',', 'on', 'objective', 'and', 'subjective', 'measures', 'of', 'actual', 'driving', 'performance', 'and', 'psychomotor', 'function.^', '\n', 'RATIONALE', ':', 'The', 'party', 'drug', 'ecstasy', 'is', 'frequently', 'used', 'in', 'combination', 'with', 'other', 'drugs', 'like', 'marihuana', 'and', 'alcohol', '.', 'In', 'addition', ',', 'a', 'substantial', 'proportion', 'of', 'the', 'MDMA', 'users', 'has', 'claimed', 'to', 'drive', 'a', 'car', 'when', 'under', 'the', 'influence', 'of', 'MDMA', 'and/or', 'other', 'drugs', '.', 'OBJECTIVE', ':', 'To', 'assess', 'the', 'effects', 'of', 'MDMA', 'and', 'alcohol', ',', 'combined', 'and', 'alone', ',', 'on', 'actual', 'driving', 'performance', 'and', 'laboratory', 'tasks', 'related', 'to', 'driving', '.', 'METHODS', ':', 'Eighteen', 'healthy', 'subjects', 'participated', 'in', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'six', '-', 'way', 'cross', '-', 'over', 'study', '.', 'Treatments', 'consisted', 'of', 'MDMA', '0', ',', '75', ',', 'and', '100', 'mg', 'with', 'and', 'without', 'alcohol', ',', 'aiming', 'at', '0.06', 'mg', '/', 'ml', 'BAC', '.', 'Laboratory', 'tests', '(', 'critical', 'tracking', 'task', ',', 'object', 'movement', 'estimation', 'task', ')', 'were', 'conducted', 'between', '1.5', 'and', '2', 'h', 'postdrug', '(', '0.5', 'and', '1', 'h', 'postalcohol', ')', '.', 'Actual', 'driving', 'tests', '(', 'road', 'tracking', 'test', ',', 'car', '-', 'following', 'test', ')', 'were', 'conducted', 'between', '3', 'and', '5', 'h', 'postdrug', '(', '2', 'and', '4', 'h', 'postalcohol', ')', '.', 'Subjects', 'completed', 'the', 'addiction', 'research', 'center', 'inventory', '(', 'ARCI', ')', 'and', 'rated', 'their', 'driving', 'quality', 'and', 'mental', 'effort', 'during', 'driving', '.', 'RESULTS', ':', 'Alcohol', 'alone', 'impaired', 'critical', 'tracking', 'performance', ',', 'as', 'well', 'as', 'a', 'number', 'of', 'actual', 'driving', 'performance', 'parameters', '[', 'i.e.', ',', 'standard', 'deviation', 'of', 'lateral', 'position', '(', 'SDLP', ')', ',', 'brake', 'reaction', 'time', ',', 'and', 'coherence', ']', '.', 'MDMA', 'alone', 'reduced', 'SDLP', 'and', 'standard', 'deviation', 'of', 'speed', '.', 'MDMA', 'significantly', 'moderated', 'alcohol', 'induced', 'impairment', 'of', 'road', 'tracking', 'performance', 'but', 'did', 'not', 'affect', 'alcohol', 'impairments', 'of', 'car', '-', 'following', 'and', 'laboratory', 'task', 'performance', '.', 'Subjective', 'data', 'seemed', 'to', 'support', 'objective', 'data', '.', 'CONCLUSION', ':', 'MDMA', 'moderated', 'the', 'impairing', 'effects', 'of', 'a', 'low', 'dose', 'of', 'alcohol', 'on', 'road', 'tracking', 'performance', 'but', 'it', 'could', 'not', 'overcome', 'alcohol', '-', 'induced', 'impairment', 'on', 'other', 'aspects', 'of', 'driving', 'behavior', 'or', 'driving', 'related', 'performance', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",4641,"['[CLS]', 'mdm', '##a', 'and', 'alcohol', 'effects', ',', 'combined', 'and', 'alone', ',', 'on', 'objective', 'and', 'subjective', 'measures', 'of', 'actual', 'driving', 'performance', 'and', 'psycho', '##motor', 'function', '.', '^', 'rationale', ':', 'the', 'party', 'drug', 'ecs', '##tas', '##y', 'is', 'frequently', 'used', 'in', 'combination', 'with', 'other', 'drugs', 'like', 'mari', '##hua', '##na', 'and', 'alcohol', '.', 'in', 'addition', ',', 'a', 'substantial', 'proportion', 'of', 'the', 'mdm', '##a', 'users', 'has', 'claimed', 'to', 'drive', 'a', 'car', 'when', 'under', 'the', 'influence', 'of', 'mdm', '##a', 'and', '/', 'or', 'other', 'drugs', '.', 'objective', ':', 'to', 'assess', 'the', 'effects', 'of', 'mdm', '##a', 'and', 'alcohol', ',', 'combined', 'and', 'alone', ',', 'on', 'actual', 'driving', 'performance', 'and', 'laboratory', 'tasks', 'related', 'to', 'driving', '.', 'methods', ':', 'eighteen', 'healthy', 'subjects', 'participated', 'in', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'six', '-', 'way', 'cross', '-', 'over', 'study', '.', 'treatments', 'consisted', 'of', 'mdm', '##a', '0', ',', '75', ',', 'and', '100', 'mg', 'with', 'and', 'without', 'alcohol', ',', 'aiming', 'at', '0', '.', '06', 'mg', '/', 'ml', 'bac', '.', 'laboratory', 'tests', '(', 'critical', 'tracking', 'task', ',', 'object', 'movement', 'estimation', 'task', ')', 'were', 'conducted', 'between', '1', '.', '5', 'and', '2', 'h', 'post', '##drug', '(', '0', '.', '5', 'and', '1', 'h', 'post', '##alcohol', ')', '.', 'actual', 'driving', 'tests', '(', 'road', 'tracking', 'test', ',', 'car', '-', 'following', 'test', ')', 'were', 'conducted', 'between', '3', 'and', '5', 'h', 'post', '##drug', '(', '2', 'and', '4', 'h', 'post', '##alcohol', ')', '.', 'subjects', 'completed', 'the', 'addiction', 'research', 'center', 'inventory', '(', 'arc', '##i', ')', 'and', 'rated', 'their', 'driving', 'quality', 'and', 'mental', 'effort', 'during', 'driving', '.', 'results', ':', 'alcohol', 'alone', 'impaired', 'critical', 'tracking', 'performance', ',', 'as', 'well', 'as', 'a', 'number', 'of', 'actual', 'driving', 'performance', 'parameters', '[', 'i', '.', 'e', '.', ',', 'standard', 'deviation', 'of', 'lateral', 'position', '(', 'sd', '##lp', ')', ',', 'bra', '##ke', 'reaction', 'time', ',', 'and', 'coherence', ']', '.', 'mdm', '##a', 'alone', 'reduced', 'sd', '##lp', 'and', 'standard', 'deviation', 'of', 'speed', '.', 'mdm', '##a', 'significantly', 'moderate', '##d', 'alcohol', 'induced', 'impairment', 'of', 'road', 'tracking', 'performance', 'but', 'did', 'not', 'affect', 'alcohol', 'impairments', 'of', 'car', '-', 'following', 'and', 'laboratory', 'task', 'performance', '.', 'subjective', 'data', 'seemed', 'to', 'support', 'objective', 'data', '.', 'conclusion', ':', 'mdm', '##a', 'moderate', '##d', 'the', 'impair', '##ing', 'effects', 'of', 'a', 'low', 'dose', 'of', 'alcohol', 'on', 'road', 'tracking', 'performance', 'but', 'it', 'could', 'not', 'overcome', 'alcohol', '-', 'induced', 'impairment', 'on', 'other', 'aspects', 'of', 'driving', 'behavior', 'or', 'driving', 'related', 'performance', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 19, 20, 20, 20, 22, 23, 24, 25, 26, 27, 27, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 37, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 62, 63, 63, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 135, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 156, 156, 157, 158, 159, 160, 160, 161, 162, 162, 162, 163, 164, 165, 166, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 189, 190, 191, 192, 193, 194, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 239, 239, 239, 240, 241, 242, 243, 244, 245, 246, 247, 247, 248, 249, 250, 250, 251, 252, 253, 254, 255, 256, 257, 258, 258, 259, 260, 261, 261, 262, 263, 264, 265, 266, 267, 268, 268, 269, 270, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 303, 304, 304, 305, 306, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function.^
RATIONALE: The party drug ecstasy is frequently used in combination with other drugs like marihuana and alcohol. In addition, a substantial proportion of the MDMA users has claimed to drive a car when under the influence of MDMA and/or other drugs. OBJECTIVE: To assess the effects of MDMA and alcohol, combined and alone, on actual driving performance and laboratory tasks related to driving. METHODS: Eighteen healthy subjects participated in a double-blind, placebo-controlled, six-way cross-over study. Treatments consisted of MDMA 0, 75, and 100 mg with and without alcohol, aiming at 0.06 mg/ml BAC. Laboratory tests (critical tracking task, object movement estimation task) were conducted between 1.5 and 2 h postdrug (0.5 and 1 h postalcohol). Actual driving tests (road tracking test, car-following test) were conducted between 3 and 5 h postdrug (2 and 4 h postalcohol). Subjects completed the addiction research center inventory (ARCI) and rated their driving quality and mental effort during driving. RESULTS: Alcohol alone impaired critical tracking performance, as well as a number of actual driving performance parameters [i.e., standard deviation of lateral position (SDLP), brake reaction time, and coherence]. MDMA alone reduced SDLP and standard deviation of speed. MDMA significantly moderated alcohol induced impairment of road tracking performance but did not affect alcohol impairments of car-following and laboratory task performance. Subjective data seemed to support objective data. CONCLUSION: MDMA moderated the impairing effects of a low dose of alcohol on road tracking performance but it could not overcome alcohol-induced impairment on other aspects of driving behavior or driving related performance."
"['The', 'effects', 'of', 'a', 'sub', '-', 'anaesthetic', 'dose', 'of', 'ketamine', 'on', 'human', 'selective', 'attention.^', '\n', 'Tested', 'the', 'hypothesis', 'that', 'a', 'sub', '-', 'anaesthetic', 'dose', 'of', 'the', 'noncompetitive', 'N', '-', 'methyl', '-', 'D', '-', 'aspartate', '(', 'NMDA', ')', 'antagonist', ',', 'ketamine', ',', 'would', 'induce', 'psychophysiological', 'and', 'selective', 'attention', 'anomalies', 'in', 'healthy', 'Ss', 'that', 'are', 'commonly', 'observed', 'in', 'schizophrenic', 'patients', '.', 'In', 'a', 'double', '-', 'blind', 'randomized', 'placebo', '-', 'controlled', 'design', ',', '18', 'healthy', 'male', '20–28', 'yr', 'olds', 'were', 'challenged', 'with', '0.3', 'mg', '/', 'kg', 'ketamine', '.', 'Ss', 'were', 'then', 'tested', 'in', 'a', 'selective', 'attention', 'task', 'in', 'which', 'standard', '(', '80', '%', ')', 'and', 'deviant', 'tones', '(', '20', '%', ')', 'of', 'either', '1000', 'or', '1100', 'Hz', 'were', 'evenly', 'presented', 'to', 'the', 'left', 'or', 'right', 'ear', '.', 'Stimulus', 'duration', 'was', '50', 'ms', 'and', 'the', 'interstimulus', 'intervals', 'were', 'randomized', 'between', '1750', 'and', '2150', 'ms', '.', 'The', 'S', 'was', 'instructed', 'to', 'push', 'a', 'button', 'as', 'quickly', 'as', 'possible', 'after', 'hearing', 'the', 'deviant', 'tone', 'in', 'a', 'specified', 'ear', '.', 'Ketamine', 'did', 'not', 'alter', 'selective', 'attention', 'task', 'performance', 'of', 'the', 'Ss', ',', 'but', 'did', 'reduce', 'processing', 'negativity', 'and', 'the', 'P300', 'amplitude', '(', 'both', 'in', 'general', 'and', 'to', 'deviant', 'stimuli', 'in', 'particular', ')', ',', 'enhanced', 'the', 'N100', 'amplitude', 'to', 'deviant', 'stimuli', ',', 'and', 'did', 'not', 'effect', 'mismatch', 'negativity', '.', 'Ketamine', 'induces', 'some', 'of', 'the', 'attentional', 'deficits', 'in', 'healthy', 'Ss', 'that', 'are', 'observed', 'in', 'schizophrenics', ',', 'suggesting', 'that', 'reduced', 'glutamatergic', 'activity', 'in', 'the', 'brain', 'may', 'be', 'involved', 'in', 'some', 'of', 'the', 'symptoms', 'of', 'schizophrenia', '.', '(', 'PsycINFO', 'Database', 'Record', '(', 'c', ')', '2016', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6558,"['[CLS]', 'the', 'effects', 'of', 'a', 'sub', '-', 'anaesthe', '##tic', 'dose', 'of', 'ketamine', 'on', 'human', 'selective', 'attention', '.', '^', 'tested', 'the', 'hypothesis', 'that', 'a', 'sub', '-', 'anaesthe', '##tic', 'dose', 'of', 'the', 'non', '##comp', '##eti', '##tive', 'n', '-', 'methyl', '-', 'd', '-', 'aspartate', '(', 'nmda', ')', 'antagonist', ',', 'ketamine', ',', 'would', 'induce', 'psycho', '##phys', '##iol', '##og', '##ical', 'and', 'selective', 'attention', 'anomalies', 'in', 'healthy', 'ss', 'that', 'are', 'commonly', 'observed', 'in', 'schizophren', '##ic', 'patients', '.', 'in', 'a', 'double', '-', 'blind', 'randomized', 'placebo', '-', 'controlled', 'design', ',', '18', 'healthy', 'male', '20', '–', '28', 'yr', 'old', '##s', 'were', 'challenged', 'with', '0', '.', '3', 'mg', '/', 'kg', 'ketamine', '.', 'ss', 'were', 'then', 'tested', 'in', 'a', 'selective', 'attention', 'task', 'in', 'which', 'standard', '(', '80', '%', ')', 'and', 'devi', '##ant', 'tones', '(', '20', '%', ')', 'of', 'either', '1000', 'or', '1100', 'hz', 'were', 'evenly', 'presented', 'to', 'the', 'left', 'or', 'right', 'ear', '.', 'stimulus', 'duration', 'was', '50', 'ms', 'and', 'the', 'intersti', '##mul', '##us', 'intervals', 'were', 'randomized', 'between', '175', '##0', 'and', '215', '##0', 'ms', '.', 'the', 's', 'was', 'instructed', 'to', 'push', 'a', 'button', 'as', 'quickly', 'as', 'possible', 'after', 'hearing', 'the', 'devi', '##ant', 'tone', 'in', 'a', 'specified', 'ear', '.', 'ketamine', 'did', 'not', 'alter', 'selective', 'attention', 'task', 'performance', 'of', 'the', 'ss', ',', 'but', 'did', 'reduce', 'processing', 'neg', '##ativity', 'and', 'the', 'p', '##300', 'amplitude', '(', 'both', 'in', 'general', 'and', 'to', 'devi', '##ant', 'stimuli', 'in', 'particular', ')', ',', 'enhanced', 'the', 'n', '##100', 'amplitude', 'to', 'devi', '##ant', 'stimuli', ',', 'and', 'did', 'not', 'effect', 'mismatch', 'neg', '##ativity', '.', 'ketamine', 'induces', 'some', 'of', 'the', 'attentional', 'deficits', 'in', 'healthy', 'ss', 'that', 'are', 'observed', 'in', 'schizophren', '##ics', ',', 'suggesting', 'that', 'reduced', 'glutamate', '##rg', '##ic', 'activity', 'in', 'the', 'brain', 'may', 'be', 'involved', 'in', 'some', 'of', 'the', 'symptoms', 'of', 'schizophrenia', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '2016', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 6, 7, 8, 9, 10, 11, 12, 13, 13, 13, 15, 16, 17, 18, 19, 20, 21, 22, 22, 23, 24, 25, 26, 26, 26, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 43, 43, 43, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 73, 73, 74, 75, 75, 76, 77, 78, 79, 79, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 131, 131, 132, 133, 134, 135, 136, 136, 137, 138, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 179, 180, 181, 182, 182, 183, 184, 185, 186, 187, 188, 189, 190, 190, 191, 192, 193, 194, 195, 196, 197, 198, 198, 199, 200, 201, 201, 202, 203, 204, 205, 206, 207, 208, 209, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 225, 226, 227, 228, 229, 230, 230, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 247, 247, 248, 249, 250, 251, 252, 253, 254, 254, 255, 256, 257, 258, 259, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","The effects of a sub-anaesthetic dose of ketamine on human selective attention.^
Tested the hypothesis that a sub-anaesthetic dose of the noncompetitive N-methyl-D-aspartate (NMDA) antagonist, ketamine, would induce psychophysiological and selective attention anomalies in healthy Ss that are commonly observed in schizophrenic patients. In a double-blind randomized placebo-controlled design, 18 healthy male 20–28 yr olds were challenged with 0.3 mg/kg ketamine. Ss were then tested in a selective attention task in which standard (80%) and deviant tones (20%) of either 1000 or 1100 Hz were evenly presented to the left or right ear. Stimulus duration was 50 ms and the interstimulus intervals were randomized between 1750 and 2150 ms. The S was instructed to push a button as quickly as possible after hearing the deviant tone in a specified ear. Ketamine did not alter selective attention task performance of the Ss, but did reduce processing negativity and the P300 amplitude (both in general and to deviant stimuli in particular), enhanced the N100 amplitude to deviant stimuli, and did not effect mismatch negativity. Ketamine induces some of the attentional deficits in healthy Ss that are observed in schizophrenics, suggesting that reduced glutamatergic activity in the brain may be involved in some of the symptoms of schizophrenia. (PsycINFO Database Record (c) 2016 APA, all rights reserved)"
"['Efficacy', 'and', 'safety', 'of', 'ketamine', 'in', 'bipolar', 'depression', ':', 'A', 'systematic', 'review.^', '\n', 'The', 'depression', 'is', 'the', 'most', 'prevalent', 'state', 'throughout', 'the', 'life', 'of', 'the', 'bipolar', 'patient', '.', 'Ketamine', 'has', 'been', 'shown', 'to', 'be', 'an', 'effective', 'and', 'rapid', 'treatment', 'for', 'depression', '.', 'The', 'objective', 'of', 'the', 'present', 'work', 'is', 'to', 'perform', 'a', 'systematic', 'review', 'on', 'the', 'efficacy', 'and', 'safety', 'of', 'ketamine', 'as', 'treatment', 'of', 'bipolar', 'depression', ',', 'as', 'well', 'as', 'its', 'different', 'patterns', 'of', 'administration', '.', 'The', 'search', 'found', '10', 'relevant', 'manuscripts', 'that', 'met', 'the', 'inclusion', 'criteria', ':', 'one', 'clinical', 'trial', ',', '5', 'cohort', 'studies', ',', 'and', '4', 'case', 'reports', '.', 'Intravenous', 'infusion', 'was', 'used', 'in', '60', '%', 'of', 'the', 'studies', '.', 'According', 'to', 'data', ',', 'ketamine', 'seems', 'to', 'be', 'an', 'effective', 'and', 'safe', 'treatment', 'for', 'bipolar', 'depression', ',', 'although', 'the', 'length', 'of', 'its', 'effect', 'is', 'short', '.', 'Adverse', 'effects', 'observed', 'generally', 'occurred', 'at', 'the', 'time', 'of', 'infusion', ',', 'and', 'tended', 'to', 'completely', 'disappear', 'within', '1', '-', '2h', '.', 'Therefore', ',', 'more', 'studies', 'are', 'necessary', 'to', 'explore', 'new', 'patterns', 'of', 'administration', ',', 'as', 'well', 'as', 'on', 'its', 'safety', 'and', 'adverse', 'effects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",254,"['[CLS]', 'efficacy', 'and', 'safety', 'of', 'ketamine', 'in', 'bipolar', 'depression', ':', 'a', 'systematic', 'review', '.', '^', 'the', 'depression', 'is', 'the', 'most', 'prevalent', 'state', 'throughout', 'the', 'life', 'of', 'the', 'bipolar', 'patient', '.', 'ketamine', 'has', 'been', 'shown', 'to', 'be', 'an', 'effective', 'and', 'rapid', 'treatment', 'for', 'depression', '.', 'the', 'objective', 'of', 'the', 'present', 'work', 'is', 'to', 'perform', 'a', 'systematic', 'review', 'on', 'the', 'efficacy', 'and', 'safety', 'of', 'ketamine', 'as', 'treatment', 'of', 'bipolar', 'depression', ',', 'as', 'well', 'as', 'its', 'different', 'patterns', 'of', 'administration', '.', 'the', 'search', 'found', '10', 'relevant', 'manuscripts', 'that', 'met', 'the', 'inclusion', 'criteria', ':', 'one', 'clinical', 'trial', ',', '5', 'cohort', 'studies', ',', 'and', '4', 'case', 'reports', '.', 'intravenous', 'infusion', 'was', 'used', 'in', '60', '%', 'of', 'the', 'studies', '.', 'according', 'to', 'data', ',', 'ketamine', 'seems', 'to', 'be', 'an', 'effective', 'and', 'safe', 'treatment', 'for', 'bipolar', 'depression', ',', 'although', 'the', 'length', 'of', 'its', 'effect', 'is', 'short', '.', 'adverse', 'effects', 'observed', 'generally', 'occurred', 'at', 'the', 'time', 'of', 'infusion', ',', 'and', 'tended', 'to', 'completely', 'disappear', 'within', '1', '-', '2', '##h', '.', 'therefore', ',', 'more', 'studies', 'are', 'necessary', 'to', 'explore', 'new', 'patterns', 'of', 'administration', ',', 'as', 'well', 'as', 'on', 'its', 'safety', 'and', 'adverse', 'effects', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Efficacy and safety of ketamine in bipolar depression: A systematic review.^
The depression is the most prevalent state throughout the life of the bipolar patient. Ketamine has been shown to be an effective and rapid treatment for depression. The objective of the present work is to perform a systematic review on the efficacy and safety of ketamine as treatment of bipolar depression, as well as its different patterns of administration. The search found 10 relevant manuscripts that met the inclusion criteria: one clinical trial, 5 cohort studies, and 4 case reports. Intravenous infusion was used in 60% of the studies. According to data, ketamine seems to be an effective and safe treatment for bipolar depression, although the length of its effect is short. Adverse effects observed generally occurred at the time of infusion, and tended to completely disappear within 1-2h. Therefore, more studies are necessary to explore new patterns of administration, as well as on its safety and adverse effects."
"['Sex', 'differences', 'in', 'ketamine', ""'s"", 'therapeutic', 'effects', 'for', 'mood', 'disorders', ':', 'A', 'systematic', 'review.^', '\n', 'Replicated', 'clinical', 'trials', 'have', 'demonstrated', 'rapid', 'and', 'robust', 'antidepressant', 'effects', 'with', 'ketamine', 'in', 'treatment', 'resistant', 'mood', 'disorders', '.', 'Sex', '(', 'biological', ')', 'and', 'gender', 'differences', 'in', 'therapeutic', 'effects', 'for', 'any', 'new', 'intervention', 'is', 'an', 'important', 'consideration', ',', 'however', ',', 'the', 'differential', 'efficacy', ',', 'safety', 'and', 'tolerability', 'of', 'ketamine', 'in', 'males', 'versus', 'females', 'remains', 'underexplored', '.', 'The', 'objective', 'of', 'the', 'present', 'systematic', 'review', 'is', 'to', 'identify', 'and', 'qualitatively', 'synthesize', 'all', 'published', 'clinical', 'studies', 'relevant', 'to', 'the', 'sex', 'differential', 'effects', 'of', 'ketamine', 'for', 'mood', 'disorders', '.', 'A', 'systematic', 'search', 'of', 'PubMed', ',', 'Medline', ',', 'and', 'PsycInfo', 'from', 'inception', 'until', 'January', '20', ',', '2021', ',', 'yielded', '27', 'reports', 'including', '1715', 'patients', '(', '742', 'males', 'and', '973', 'females', ')', 'that', 'met', 'inclusion', 'criteria', '.', 'Results', 'from', 'the', 'vast', 'majority', 'of', 'studies', '(', '88.8', '%', ')', 'do', 'not', 'support', 'significant', 'sex', 'differences', 'in', 'antidepressant', 'response', ',', 'tolerability', 'or', 'safety', 'of', 'ketamine', '.', 'Nine', '(', '33.3', '%', ')', 'of', 'the', 'reports', 'included', 'a', 'bioanalytical', 'component', 'in', 'the', 'analysis', 'and', 'only', 'one', 'reported', 'on', 'sex', 'differences', '.', 'Evidence', 'from', 'the', 'present', 'review', 'does', 'not', 'support', 'clinically', 'or', 'statistically', 'significant', 'sex', 'differences', 'in', 'therapeutic', 'effects', 'with', 'ketamine', '.', 'Nevertheless', ',', 'future', 'studies', 'should', 'continue', 'to', 'consider', 'sex', 'and', 'biological', 'sex', 'differences', 'in', 'study', 'design', 'and', 'data', 'analytic', 'plans', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",751,"['[CLS]', 'sex', 'differences', 'in', 'ketamine', ""'"", 's', 'therapeutic', 'effects', 'for', 'mood', 'disorders', ':', 'a', 'systematic', 'review', '.', '^', 'replicated', 'clinical', 'trials', 'have', 'demonstrated', 'rapid', 'and', 'robust', 'antidepressant', 'effects', 'with', 'ketamine', 'in', 'treatment', 'resistant', 'mood', 'disorders', '.', 'sex', '(', 'biological', ')', 'and', 'gender', 'differences', 'in', 'therapeutic', 'effects', 'for', 'any', 'new', 'intervention', 'is', 'an', 'important', 'consideration', ',', 'however', ',', 'the', 'differential', 'efficacy', ',', 'safety', 'and', 'tolerability', 'of', 'ketamine', 'in', 'males', 'versus', 'females', 'remains', 'under', '##expl', '##ored', '.', 'the', 'objective', 'of', 'the', 'present', 'systematic', 'review', 'is', 'to', 'identify', 'and', 'qualitatively', 'synthesize', 'all', 'published', 'clinical', 'studies', 'relevant', 'to', 'the', 'sex', 'differential', 'effects', 'of', 'ketamine', 'for', 'mood', 'disorders', '.', 'a', 'systematic', 'search', 'of', 'pubmed', ',', 'medline', ',', 'and', 'ps', '##yc', '##info', 'from', 'inc', '##epti', '##on', 'until', 'january', '20', ',', '202', '##1', ',', 'yielded', '27', 'reports', 'including', '171', '##5', 'patients', '(', '74', '##2', 'males', 'and', '97', '##3', 'females', ')', 'that', 'met', 'inclusion', 'criteria', '.', 'results', 'from', 'the', 'vast', 'majority', 'of', 'studies', '(', '88', '.', '8', '%', ')', 'do', 'not', 'support', 'significant', 'sex', 'differences', 'in', 'antidepressant', 'response', ',', 'tolerability', 'or', 'safety', 'of', 'ketamine', '.', 'nine', '(', '33', '.', '3', '%', ')', 'of', 'the', 'reports', 'included', 'a', 'bio', '##analytic', '##al', 'component', 'in', 'the', 'analysis', 'and', 'only', 'one', 'reported', 'on', 'sex', 'differences', '.', 'evidence', 'from', 'the', 'present', 'review', 'does', 'not', 'support', 'clinically', 'or', 'statistically', 'significant', 'sex', 'differences', 'in', 'therapeutic', 'effects', 'with', 'ketamine', '.', 'nevertheless', ',', 'future', 'studies', 'should', 'continue', 'to', 'consider', 'sex', 'and', 'biological', 'sex', 'differences', 'in', 'study', 'design', 'and', 'data', 'analytic', 'plans', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 13, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 68, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 108, 108, 109, 110, 110, 110, 111, 112, 113, 114, 115, 115, 116, 117, 118, 119, 120, 121, 121, 122, 123, 124, 124, 125, 126, 127, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 143, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 164, 164, 165, 166, 167, 168, 169, 170, 171, 172, 172, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review.^
Replicated clinical trials have demonstrated rapid and robust antidepressant effects with ketamine in treatment resistant mood disorders. Sex (biological) and gender differences in therapeutic effects for any new intervention is an important consideration, however, the differential efficacy, safety and tolerability of ketamine in males versus females remains underexplored. The objective of the present systematic review is to identify and qualitatively synthesize all published clinical studies relevant to the sex differential effects of ketamine for mood disorders. A systematic search of PubMed, Medline, and PsycInfo from inception until January 20, 2021, yielded 27 reports including 1715 patients (742 males and 973 females) that met inclusion criteria. Results from the vast majority of studies (88.8%) do not support significant sex differences in antidepressant response, tolerability or safety of ketamine. Nine (33.3%) of the reports included a bioanalytical component in the analysis and only one reported on sex differences. Evidence from the present review does not support clinically or statistically significant sex differences in therapeutic effects with ketamine. Nevertheless, future studies should continue to consider sex and biological sex differences in study design and data analytic plans."
"['Reduced', 'auditory', 'evoked', 'gamma', '-', 'band', 'response', 'and', 'schizophrenia', '-', 'like', 'clinical', 'symptoms', 'under', 'subanesthetic', 'ketamine.^', '\n', 'Abnormal', 'gamma', '-', 'band', 'oscillations', '(', 'GBO', ')', 'have', 'been', 'frequently', 'associated', 'with', 'the', 'pathophysiology', 'of', 'schizophrenia', '.', 'GBO', 'are', 'modulated', 'by', 'glutamate', ',', 'a', 'neurotransmitter', ',', 'which', 'is', 'continuously', 'discussed', 'to', 'shape', 'the', 'complex', 'symptom', 'spectrum', 'in', 'schizophrenia', '.', 'The', 'current', 'study', 'examined', 'the', 'effects', 'of', 'ketamine', ',', 'a', 'glutamate', 'N', '-', 'methyl', '-', 'D', '-', 'aspartate', 'receptor', '(', 'NMDAR', ')', 'antagonist', ',', 'on', 'the', 'auditory', '-', 'evoked', 'gamma', '-', 'band', 'response', '(', 'aeGBR', ')', 'and', 'psychopathological', 'outcomes', 'in', 'healthy', 'volunteers', 'to', 'investigate', 'neuronal', 'mechanisms', 'of', 'psychotic', 'behavior', '.', 'In', 'a', 'placebo', '-', 'controlled', ',', 'randomized', 'crossover', 'design', ',', 'the', 'aeGBR', 'power', ',', 'phase', '-', 'locking', 'factor', '(', 'PLF', ')', 'during', 'a', 'choice', 'reaction', 'task', ',', 'the', 'Positive', 'and', 'Negative', 'Syndrome', 'Scale', '(', 'PANSS', ')', 'and', 'the', 'Altered', 'State', 'of', 'Consciousness', '(', '5D', '-', 'ASC', ')', 'Rating', 'Scale', 'were', 'assessed', 'in', '25', 'healthy', 'subjects', '.', 'Ketamine', 'was', 'applied', 'in', 'a', 'subanaesthetic', 'dose', '.', 'Low', '-', 'resolution', 'brain', 'electromagnetic', 'tomography', 'was', 'used', 'for', 'EEG', 'source', 'localization', '.', 'Significant', 'reductions', 'of', 'the', 'aeGBR', 'power', 'and', 'PLF', 'were', 'identified', 'under', 'ketamine', 'administration', 'compared', 'to', 'placebo', '(', 'p', '<', '0.01', ')', '.', 'Source', '-', 'space', 'analysis', 'of', 'aeGBR', 'generators', 'revealed', 'significantly', 'reduced', 'current', 'source', 'density', '(', 'CSD', ')', 'within', 'the', 'anterior', 'cingulate', 'cortex', 'during', 'ketamine', 'administration', '.', 'Ketamine', 'induced', 'an', 'increase', 'in', 'all', 'PANSS', '(', 'p', '<', '0.001', ')', 'as', 'well', 'as', '5D', '-', 'ASC', 'scores', '(', 'p', '<', '0.01', ')', 'and', 'increased', 'response', 'times', '(', 'p', '<', '0.001', ')', 'and', 'error', 'rates', '(', 'p', '<', '0.01', ')', '.', 'Only', 'negative', 'symptoms', 'were', 'significantly', 'associated', 'with', 'an', 'aeGBR', 'power', 'decrease', '(', 'p', '=', '0.033', ')', 'as', 'revealed', 'by', 'multiple', 'linear', 'regression', '.', 'These', 'findings', 'argue', 'for', 'a', 'substantial', 'role', 'of', 'the', 'glutamate', 'system', 'in', 'the', 'mediation', 'of', 'dysfunctional', 'gamma', 'band', 'responses', 'and', 'negative', 'symptomatology', 'of', 'schizophrenia', 'and', 'are', 'compatible', 'with', 'the', 'NMDAR', 'hypofunction', 'hypothesis', 'of', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1745,"['[CLS]', 'reduced', 'auditory', 'evoked', 'gamma', '-', 'band', 'response', 'and', 'schizophrenia', '-', 'like', 'clinical', 'symptoms', 'under', 'sub', '##anes', '##the', '##tic', 'ketamine', '.', '^', 'abnormal', 'gamma', '-', 'band', 'oscillations', '(', 'gb', '##o', ')', 'have', 'been', 'frequently', 'associated', 'with', 'the', 'pathophysiology', 'of', 'schizophrenia', '.', 'gb', '##o', 'are', 'modulated', 'by', 'glutamate', ',', 'a', 'neurotransmit', '##ter', ',', 'which', 'is', 'continuously', 'discussed', 'to', 'shape', 'the', 'complex', 'symptom', 'spectrum', 'in', 'schizophrenia', '.', 'the', 'current', 'study', 'examined', 'the', 'effects', 'of', 'ketamine', ',', 'a', 'glutamate', 'n', '-', 'methyl', '-', 'd', '-', 'aspartate', 'receptor', '(', 'nmda', '##r', ')', 'antagonist', ',', 'on', 'the', 'auditory', '-', 'evoked', 'gamma', '-', 'band', 'response', '(', 'aeg', '##br', ')', 'and', 'psycho', '##path', '##ological', 'outcomes', 'in', 'healthy', 'volunteers', 'to', 'investigate', 'neuronal', 'mechanisms', 'of', 'psychotic', 'behavior', '.', 'in', 'a', 'placebo', '-', 'controlled', ',', 'randomized', 'crossover', 'design', ',', 'the', 'aeg', '##br', 'power', ',', 'phase', '-', 'locking', 'factor', '(', 'pl', '##f', ')', 'during', 'a', 'choice', 'reaction', 'task', ',', 'the', 'positive', 'and', 'negative', 'syndrome', 'scale', '(', 'pan', '##ss', ')', 'and', 'the', 'altered', 'state', 'of', 'consciousness', '(', '5', '##d', '-', 'asc', ')', 'rating', 'scale', 'were', 'assessed', 'in', '25', 'healthy', 'subjects', '.', 'ketamine', 'was', 'applied', 'in', 'a', 'sub', '##ana', '##esthe', '##tic', 'dose', '.', 'low', '-', 'resolution', 'brain', 'electromagnetic', 'tomography', 'was', 'used', 'for', 'eeg', 'source', 'localization', '.', 'significant', 'reductions', 'of', 'the', 'aeg', '##br', 'power', 'and', 'pl', '##f', 'were', 'identified', 'under', 'ketamine', 'administration', 'compared', 'to', 'placebo', '(', 'p', '<', '0', '.', '01', ')', '.', 'source', '-', 'space', 'analysis', 'of', 'aeg', '##br', 'generators', 'revealed', 'significantly', 'reduced', 'current', 'source', 'density', '(', 'cs', '##d', ')', 'within', 'the', 'anterior', 'cingulate', 'cortex', 'during', 'ketamine', 'administration', '.', 'ketamine', 'induced', 'an', 'increase', 'in', 'all', 'pan', '##ss', '(', 'p', '<', '0', '.', '00', '##1', ')', 'as', 'well', 'as', '5', '##d', '-', 'asc', 'scores', '(', 'p', '<', '0', '.', '01', ')', 'and', 'increased', 'response', 'times', '(', 'p', '<', '0', '.', '00', '##1', ')', 'and', 'error', 'rates', '(', 'p', '<', '0', '.', '01', ')', '.', 'only', 'negative', 'symptoms', 'were', 'significantly', 'associated', 'with', 'an', 'aeg', '##br', 'power', 'decrease', '(', 'p', '=', '0', '.', '03', '##3', ')', 'as', 'revealed', 'by', 'multiple', 'linear', 'regression', '.', 'these', 'findings', 'argue', 'for', 'a', 'substantial', 'role', 'of', 'the', 'glutamate', 'system', 'in', 'the', 'mediation', 'of', 'dysfunction', '##al', 'gamma', 'band', 'responses', 'and', 'negative', 'symptom', '##atology', 'of', 'schizophrenia', 'and', 'are', 'compatible', 'with', 'the', 'nmda', '##r', 'hypo', '##function', 'hypothesis', 'of', 'schizophrenia', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 14, 14, 15, 15, 15, 17, 18, 19, 20, 21, 22, 23, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 35, 36, 37, 38, 39, 40, 41, 42, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 91, 92, 93, 94, 94, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 118, 119, 120, 121, 122, 123, 124, 125, 126, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 168, 168, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 188, 189, 190, 191, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 203, 203, 204, 205, 206, 207, 208, 209, 210, 211, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 237, 238, 239, 240, 241, 241, 241, 241, 242, 243, 244, 245, 246, 246, 247, 248, 249, 250, 251, 252, 253, 253, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 262, 262, 262, 263, 264, 265, 266, 267, 268, 269, 270, 270, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 281, 282, 283, 284, 285, 286, 287, 287, 287, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 311, 312, 313, 314, 315, 316, 317, 317, 318, 319, 320, 321, 322, 323, 324, 325, 325, 326, 326, 327, 328, 329, 330, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Reduced auditory evoked gamma-band response and schizophrenia-like clinical symptoms under subanesthetic ketamine.^
Abnormal gamma-band oscillations (GBO) have been frequently associated with the pathophysiology of schizophrenia. GBO are modulated by glutamate, a neurotransmitter, which is continuously discussed to shape the complex symptom spectrum in schizophrenia. The current study examined the effects of ketamine, a glutamate N-methyl-D-aspartate receptor (NMDAR) antagonist, on the auditory-evoked gamma-band response (aeGBR) and psychopathological outcomes in healthy volunteers to investigate neuronal mechanisms of psychotic behavior. In a placebo-controlled, randomized crossover design, the aeGBR power, phase-locking factor (PLF) during a choice reaction task, the Positive and Negative Syndrome Scale (PANSS) and the Altered State of Consciousness (5D-ASC) Rating Scale were assessed in 25 healthy subjects. Ketamine was applied in a subanaesthetic dose. Low-resolution brain electromagnetic tomography was used for EEG source localization. Significant reductions of the aeGBR power and PLF were identified under ketamine administration compared to placebo (p < 0.01). Source-space analysis of aeGBR generators revealed significantly reduced current source density (CSD) within the anterior cingulate cortex during ketamine administration. Ketamine induced an increase in all PANSS (p < 0.001) as well as 5D-ASC scores (p < 0.01) and increased response times (p < 0.001) and error rates (p < 0.01). Only negative symptoms were significantly associated with an aeGBR power decrease (p = 0.033) as revealed by multiple linear regression. These findings argue for a substantial role of the glutamate system in the mediation of dysfunctional gamma band responses and negative symptomatology of schizophrenia and are compatible with the NMDAR hypofunction hypothesis of schizophrenia."
"['Modulation', 'of', 'simultaneously', 'collected', 'hemodynamic', 'and', 'electrophysiological', 'functional', 'connectivity', 'by', 'ketamine', 'and', 'midazolam.^', '\n', 'The', 'pharmacological', 'modulation', 'of', 'functional', 'connectivity', 'in', 'the', 'brain', 'may', 'underlie', 'therapeutic', 'efficacy', 'for', 'several', 'neurological', 'and', 'psychiatric', 'disorders', '.', 'Functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'provides', 'a', 'noninvasive', 'method', 'of', 'assessing', 'this', 'modulation', ',', 'however', ',', 'the', 'indirect', 'nature', 'of', 'the', 'blood', '-', 'oxygen', 'level', 'dependent', 'signal', 'restricts', 'the', 'discrimination', 'of', 'neural', 'from', 'physiological', 'contributions', '.', 'Here', 'we', 'followed', 'two', 'approaches', 'to', 'assess', 'the', 'validity', 'of', 'fMRI', 'functional', 'connectivity', 'in', 'developing', 'drug', 'biomarkers', ',', 'using', 'simultaneous', 'electroencephalography', '(', 'EEG)/fMRI', 'in', 'a', 'placebo', '-', 'controlled', ',', 'three', '-', 'way', 'crossover', 'design', 'with', 'ketamine', 'and', 'midazolam', '.', 'First', ',', 'we', 'compared', 'seven', 'different', 'preprocessing', 'pipelines', 'to', 'determine', 'their', 'impact', 'on', 'the', 'connectivity', 'of', 'common', 'resting', '-', 'state', 'networks', '.', 'Independent', 'components', 'analysis', '(', 'ICA)-denoising', 'resulted', 'in', 'stronger', 'reductions', 'in', 'connectivity', 'after', 'ketamine', ',', 'and', 'weaker', 'increases', 'after', 'midazolam', ',', 'than', 'pipelines', 'employing', 'physiological', 'noise', 'modelling', 'or', 'averaged', 'signals', 'from', 'cerebrospinal', 'fluid', 'or', 'white', 'matter', '.', 'This', 'suggests', 'that', 'pipeline', 'decisions', 'should', 'reflect', 'a', 'drug', ""'s"", 'unique', 'noise', 'structure', ',', 'and', 'if', 'this', 'is', 'unknown', 'then', 'accepting', 'possible', 'signal', 'loss', 'when', 'choosing', 'extensive', 'ICA', 'denoising', 'pipelines', 'could', 'engender', 'more', 'confidence', 'in', 'the', 'remaining', 'results', '.', 'We', 'then', 'compared', 'the', 'temporal', 'correlation', 'structure', 'of', 'fMRI', 'to', 'that', 'derived', 'from', 'two', 'connectivity', 'metrics', 'of', 'EEG', ',', 'which', 'provides', 'a', 'direct', 'measure', 'of', 'neural', 'activity', '.', 'While', 'electrophysiological', 'estimates', 'based', 'on', 'the', 'power', 'envelope', 'were', 'more', 'closely', 'aligned', 'to', 'BOLD', 'signal', 'connectivity', 'than', 'those', 'based', 'on', 'phase', 'consistency', ',', 'no', 'significant', 'relationship', 'between', 'the', 'change', 'in', 'electrophysiological', 'and', 'hemodynamic', 'correlation', 'structures', 'was', 'found', ',', 'implying', 'caution', 'should', 'be', 'used', 'when', 'making', 'cross', '-', 'modal', 'comparisons', 'of', 'pharmacologically', '-', 'modulated', 'functional', 'connectivity', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",2669,"['[CLS]', 'modulation', 'of', 'simultaneously', 'collected', 'hemodynamic', 'and', 'electroph', '##ysiological', 'functional', 'connectivity', 'by', 'ketamine', 'and', 'mid', '##azol', '##am', '.', '^', 'the', 'pharmacological', 'modulation', 'of', 'functional', 'connectivity', 'in', 'the', 'brain', 'may', 'underlie', 'therapeutic', 'efficacy', 'for', 'several', 'neurological', 'and', 'psychiatric', 'disorders', '.', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fmri', ')', 'provides', 'a', 'noninvasive', 'method', 'of', 'assessing', 'this', 'modulation', ',', 'however', ',', 'the', 'indirect', 'nature', 'of', 'the', 'blood', '-', 'oxygen', 'level', 'dependent', 'signal', 'restricts', 'the', 'discrimination', 'of', 'neural', 'from', 'physiological', 'contributions', '.', 'here', 'we', 'followed', 'two', 'approaches', 'to', 'assess', 'the', 'validity', 'of', 'fmri', 'functional', 'connectivity', 'in', 'developing', 'drug', 'biomarkers', ',', 'using', 'simultaneous', 'electroencephal', '##ography', '(', 'eeg', ')', '/', 'fmri', 'in', 'a', 'placebo', '-', 'controlled', ',', 'three', '-', 'way', 'crossover', 'design', 'with', 'ketamine', 'and', 'mid', '##azol', '##am', '.', 'first', ',', 'we', 'compared', 'seven', 'different', 'preprocessing', 'pipeline', '##s', 'to', 'determine', 'their', 'impact', 'on', 'the', 'connectivity', 'of', 'common', 'resting', '-', 'state', 'networks', '.', 'independent', 'components', 'analysis', '(', 'ica', ')', '-', 'denoising', 'resulted', 'in', 'stronger', 'reductions', 'in', 'connectivity', 'after', 'ketamine', ',', 'and', 'weaker', 'increases', 'after', 'mid', '##azol', '##am', ',', 'than', 'pipeline', '##s', 'employing', 'physiological', 'noise', 'modelling', 'or', 'averaged', 'signals', 'from', 'cerebrospinal', 'fluid', 'or', 'white', 'matter', '.', 'this', 'suggests', 'that', 'pipeline', 'decisions', 'should', 'reflect', 'a', 'drug', ""'"", 's', 'unique', 'noise', 'structure', ',', 'and', 'if', 'this', 'is', 'unknown', 'then', 'accepting', 'possible', 'signal', 'loss', 'when', 'choosing', 'extensive', 'ica', 'denoising', 'pipeline', '##s', 'could', 'eng', '##ender', 'more', 'confidence', 'in', 'the', 'remaining', 'results', '.', 'we', 'then', 'compared', 'the', 'temporal', 'correlation', 'structure', 'of', 'fmri', 'to', 'that', 'derived', 'from', 'two', 'connectivity', 'metrics', 'of', 'eeg', ',', 'which', 'provides', 'a', 'direct', 'measure', 'of', 'neural', 'activity', '.', 'while', 'electroph', '##ysiological', 'estimates', 'based', 'on', 'the', 'power', 'envelope', 'were', 'more', 'closely', 'aligned', 'to', 'bold', 'signal', 'connectivity', 'than', 'those', 'based', 'on', 'phase', 'consistency', ',', 'no', 'significant', 'relationship', 'between', 'the', 'change', 'in', 'electroph', '##ysiological', 'and', 'hemodynamic', 'correlation', 'structures', 'was', 'found', ',', 'implying', 'caution', 'should', 'be', 'used', 'when', 'making', 'cross', '-', 'modal', 'comparisons', 'of', 'pharmacological', '##ly', '-', 'modulated', 'functional', 'connectivity', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 6, 7, 8, 9, 10, 11, 12, 12, 12, 12, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 92, 93, 94, 94, 94, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 137, 137, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 151, 151, 152, 153, 154, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 198, 199, 200, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 286, 287, 288, 289, 290, 291, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Modulation of simultaneously collected hemodynamic and electrophysiological functional connectivity by ketamine and midazolam.^
The pharmacological modulation of functional connectivity in the brain may underlie therapeutic efficacy for several neurological and psychiatric disorders. Functional magnetic resonance imaging (fMRI) provides a noninvasive method of assessing this modulation, however, the indirect nature of the blood-oxygen level dependent signal restricts the discrimination of neural from physiological contributions. Here we followed two approaches to assess the validity of fMRI functional connectivity in developing drug biomarkers, using simultaneous electroencephalography (EEG)/fMRI in a placebo-controlled, three-way crossover design with ketamine and midazolam. First, we compared seven different preprocessing pipelines to determine their impact on the connectivity of common resting-state networks. Independent components analysis (ICA)-denoising resulted in stronger reductions in connectivity after ketamine, and weaker increases after midazolam, than pipelines employing physiological noise modelling or averaged signals from cerebrospinal fluid or white matter. This suggests that pipeline decisions should reflect a drug's unique noise structure, and if this is unknown then accepting possible signal loss when choosing extensive ICA denoising pipelines could engender more confidence in the remaining results. We then compared the temporal correlation structure of fMRI to that derived from two connectivity metrics of EEG, which provides a direct measure of neural activity. While electrophysiological estimates based on the power envelope were more closely aligned to BOLD signal connectivity than those based on phase consistency, no significant relationship between the change in electrophysiological and hemodynamic correlation structures was found, implying caution should be used when making cross-modal comparisons of pharmacologically-modulated functional connectivity."
"['Safety', ',', 'tolerability', ',', 'and', 'efficacy', 'of', 'psilocybin', 'in', '9', 'patients', 'with', 'obsessive', '-', 'compulsive', 'disorder.^', '\n', 'BACKGROUND', ':', 'Anecdotal', 'reports', 'suggest', 'that', 'psychedelic', 'agents', 'may', 'relieve', 'symptoms', 'of', 'obsessive', '-', 'compulsive', 'disorder', '(', 'OCD', ')', '.', 'This', 'modified', 'double', '-', 'blind', 'study', 'investigated', 'the', 'safety', ',', 'tolerability', ',', 'and', 'clinical', 'effects', 'of', 'psilocybin', ',', 'a', 'potent', '5', '-', 'HT(1A', ')', 'and', '5', '-', 'HT(2A/2C', ')', 'agonist', ',', 'in', 'patients', 'with', 'OCD', '.', 'METHOD', ':', 'Nine', 'subjects', 'with', 'DSM', '-', 'IV', '-', 'defined', 'OCD', 'and', 'no', 'other', 'current', 'major', 'psychiatric', 'disorder', 'participated', 'in', 'up', 'to', '4', 'single', '-', 'dose', 'exposures', 'to', 'psilocybin', 'in', 'doses', 'ranging', 'from', 'sub', '-', 'hallucinogenic', 'to', 'frankly', 'hallucinogenic', '.', 'Low', '(', '100', 'microg', '/', 'kg', ')', ',', 'medium', '(', '200', 'microg', '/', 'kg', ')', ',', 'and', 'high', '(', '300', 'microg', '/', 'kg', ')', 'doses', 'were', 'assigned', 'in', 'that', 'order', ',', 'and', 'a', 'very', 'low', 'dose', '(', '25', 'microg', '/', 'kg', ')', 'was', 'inserted', 'randomly', 'and', 'in', 'double', '-', 'blind', 'fashion', 'at', 'any', 'time', 'after', 'the', 'first', 'dose', '.', 'Testing', 'days', 'were', 'separated', 'by', 'at', 'least', '1', 'week', '.', 'Each', 'session', 'was', 'conducted', 'over', 'an', '8', '-', 'hour', 'period', 'in', 'a', 'controlled', 'environment', 'in', 'an', 'outpatient', 'clinic', ';', 'subjects', 'were', 'then', 'transferred', 'to', 'a', 'psychiatric', 'inpatient', 'unit', 'for', 'overnight', 'observation', '.', 'The', 'Yale', '-', 'Brown', 'Obsessive', 'Compulsive', 'Scale', '(', 'YBOCS', ')', 'and', 'a', 'visual', 'analog', 'scale', 'measuring', 'overall', 'obsessive', '-', 'compulsive', 'symptom', 'severity', 'were', 'administered', 'at', '0', ',', '4', ',', '8', ',', 'and', '24', 'hours', 'post', '-', 'ingestion', '.', 'The', 'Hallucinogen', 'Rating', 'Scale', 'was', 'administered', 'at', '8', 'hours', ',', 'and', 'vital', 'signs', 'were', 'recorded', 'at', '0', ',', '1', ',', '4', ',', '8', ',', 'and', '24', 'hours', 'after', 'ingestion', '.', 'The', 'study', 'was', 'conducted', 'from', 'November', '2001', 'to', 'November', '2004', '.', 'RESULTS', ':', 'Nine', 'subjects', 'were', 'administered', 'a', 'total', 'of', '29', 'psilocybin', 'doses', '.', 'One', 'subject', 'experienced', 'transient', 'hypertension', 'without', 'relation', 'to', 'anxiety', 'or', 'somatic', 'symptoms', ',', 'but', 'no', 'other', 'significant', 'adverse', 'effects', 'were', 'observed', '.', 'Marked', 'decreases', 'in', 'OCD', 'symptoms', 'of', 'variable', 'degrees', 'were', 'observed', 'in', 'all', 'subjects', 'during', '1', 'or', 'more', 'of', 'the', 'testing', 'sessions', '(', '23%-100', '%', 'decrease', 'in', 'YBOCS', 'score', ')', '.', 'Repeated', '-', 'measures', 'analysis', 'of', 'variance', 'for', 'all', 'YBOCS', 'values', 'revealed', 'a', 'significant', 'main', 'effect', 'of', 'time', 'on', 'Wilks', 'lambda', '(', 'F', '=', '9.86', ',', 'df', '=', '3,3', ';', 'p', '=', '.046', ')', ',', 'but', 'no', 'significant', 'effect', 'of', 'dose', '(', 'F', '=', '2.25', ',', 'df', '=', '3,3', ';', 'p', '=', '.261', ')', 'or', 'interaction', 'of', 'time', 'and', 'dose', '(', 'F', '=', '0.923', ',', 'df', '=', '9,45', ';', 'p', '=', '.515', ')', '.', 'Improvement', 'generally', 'lasted', 'past', 'the', '24', '-', 'hour', 'timepoint', '.', 'CONCLUSIONS', ':', 'In', 'a', 'controlled', 'clinical', 'environment', ',', 'psilocybin', 'was', 'safely', 'used', 'in', 'subjects', 'with', 'OCD', 'and', 'was', 'associated', 'with', 'acute', 'reductions', 'in', 'core', 'OCD', 'symptoms', 'in', 'several', 'subjects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5789,"['[CLS]', 'safety', ',', 'tolerability', ',', 'and', 'efficacy', 'of', 'psi', '##loc', '##yb', '##in', 'in', '9', 'patients', 'with', 'obs', '##essive', '-', 'comp', '##ulsive', 'disorder', '.', '^', 'background', ':', 'an', '##ecd', '##otal', 'reports', 'suggest', 'that', 'psych', '##ede', '##lic', 'agents', 'may', 'relie', '##ve', 'symptoms', 'of', 'obs', '##essive', '-', 'comp', '##ulsive', 'disorder', '(', 'ocd', ')', '.', 'this', 'modified', 'double', '-', 'blind', 'study', 'investigated', 'the', 'safety', ',', 'tolerability', ',', 'and', 'clinical', 'effects', 'of', 'psi', '##loc', '##yb', '##in', ',', 'a', 'potent', '5', '-', 'ht', '(', '1', '##a', ')', 'and', '5', '-', 'ht', '(', '2', '##a', '/', '2', '##c', ')', 'agonist', ',', 'in', 'patients', 'with', 'ocd', '.', 'method', ':', 'nine', 'subjects', 'with', 'dsm', '-', 'iv', '-', 'defined', 'ocd', 'and', 'no', 'other', 'current', 'major', 'psychiatric', 'disorder', 'participated', 'in', 'up', 'to', '4', 'single', '-', 'dose', 'exposures', 'to', 'psi', '##loc', '##yb', '##in', 'in', 'doses', 'ranging', 'from', 'sub', '-', 'halluc', '##ino', '##genic', 'to', 'frank', '##ly', 'halluc', '##ino', '##genic', '.', 'low', '(', '100', 'microg', '/', 'kg', ')', ',', 'medium', '(', '200', 'microg', '/', 'kg', ')', ',', 'and', 'high', '(', '300', 'microg', '/', 'kg', ')', 'doses', 'were', 'assigned', 'in', 'that', 'order', ',', 'and', 'a', 'very', 'low', 'dose', '(', '25', 'microg', '/', 'kg', ')', 'was', 'inserted', 'randomly', 'and', 'in', 'double', '-', 'blind', 'fashion', 'at', 'any', 'time', 'after', 'the', 'first', 'dose', '.', 'testing', 'days', 'were', 'separated', 'by', 'at', 'least', '1', 'week', '.', 'each', 'session', 'was', 'conducted', 'over', 'an', '8', '-', 'hour', 'period', 'in', 'a', 'controlled', 'environment', 'in', 'an', 'outpatient', 'clinic', ';', 'subjects', 'were', 'then', 'transferred', 'to', 'a', 'psychiatric', 'inpatient', 'unit', 'for', 'overnight', 'observation', '.', 'the', 'yale', '-', 'brown', 'obs', '##essive', 'comp', '##ulsive', 'scale', '(', 'yb', '##ocs', ')', 'and', 'a', 'visual', 'analog', 'scale', 'measuring', 'overall', 'obs', '##essive', '-', 'comp', '##ulsive', 'symptom', 'severity', 'were', 'administered', 'at', '0', ',', '4', ',', '8', ',', 'and', '24', 'hours', 'post', '-', 'ingestion', '.', 'the', 'halluc', '##ino', '##gen', 'rating', 'scale', 'was', 'administered', 'at', '8', 'hours', ',', 'and', 'vital', 'signs', 'were', 'recorded', 'at', '0', ',', '1', ',', '4', ',', '8', ',', 'and', '24', 'hours', 'after', 'ingestion', '.', 'the', 'study', 'was', 'conducted', 'from', 'november', '2001', 'to', 'november', '2004', '.', 'results', ':', 'nine', 'subjects', 'were', 'administered', 'a', 'total', 'of', '29', 'psi', '##loc', '##yb', '##in', 'doses', '.', 'one', 'subject', 'experienced', 'transient', 'hypertension', 'without', 'relation', 'to', 'anxiety', 'or', 'somatic', 'symptoms', ',', 'but', 'no', 'other', 'significant', 'adverse', 'effects', 'were', 'observed', '.', 'marked', 'decreases', 'in', 'ocd', 'symptoms', 'of', 'variable', 'degrees', 'were', 'observed', 'in', 'all', 'subjects', 'during', '1', 'or', 'more', 'of', 'the', 'testing', 'sessions', '(', '23', '%', '-', '100', '%', 'decrease', 'in', 'yb', '##ocs', 'score', ')', '.', 'repeated', '-', 'measures', 'analysis', 'of', 'variance', 'for', 'all', 'yb', '##ocs', 'values', 'revealed', 'a', 'significant', 'main', 'effect', 'of', 'time', 'on', 'wil', '##ks', 'lambda', '(', 'f', '=', '9', '.', '86', ',', 'df', '=', '3', ',', '3', ';', 'p', '=', '.', '04', '##6', ')', ',', 'but', 'no', 'significant', 'effect', 'of', 'dose', '(', 'f', '=', '2', '.', '25', ',', 'df', '=', '3', ',', '3', ';', 'p', '=', '.', '26', '##1', ')', 'or', 'interaction', 'of', 'time', 'and', 'dose', '(', 'f', '=', '0', '.', '92', '##3', ',', 'df', '=', '9', ',', '45', ';', 'p', '=', '.', '51', '##5', ')', '.', 'improvement', 'generally', 'lasted', 'past', 'the', '24', '-', 'hour', 'time', '##point', '.', '[SEP]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 7, 7, 7, 8, 9, 10, 11, 12, 12, 13, 14, 14, 15, 15, 15, 17, 18, 19, 19, 19, 20, 21, 22, 23, 23, 23, 24, 25, 26, 26, 27, 28, 29, 29, 30, 31, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 53, 53, 53, 54, 55, 56, 57, 58, 59, 59, 59, 59, 60, 61, 62, 63, 64, 64, 64, 64, 64, 64, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 101, 101, 101, 102, 103, 104, 105, 106, 107, 108, 108, 108, 109, 110, 110, 111, 111, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 218, 219, 219, 220, 221, 222, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 231, 232, 233, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 253, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 303, 303, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 350, 350, 350, 351, 352, 353, 354, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 376, 377, 378, 379, 380, 381, 381, 381, 382, 383, 384, 385, 385, 385, 386, 387, 388, 389, 389, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 401, 401, 402, 403, 404, 405, 405, 405, 406, 407, 408, 409, 409, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 420, 420, 420, 421, 422, 423, 424, 424, 424, 425, 426, 427, 428, 428, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 439, 440, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 0, 0, 0, 3, 1, 1, 1, 1, 0, 0, 0, 0, 0, 3, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.^
BACKGROUND: Anecdotal reports suggest that psychedelic agents may relieve symptoms of obsessive-compulsive disorder (OCD). This modified double-blind study investigated the safety, tolerability, and clinical effects of psilocybin, a potent 5-HT(1A) and 5-HT(2A/2C) agonist, in patients with OCD. METHOD: Nine subjects with DSM-IV-defined OCD and no other current major psychiatric disorder participated in up to 4 single-dose exposures to psilocybin in doses ranging from sub-hallucinogenic to frankly hallucinogenic. Low (100 microg/kg), medium (200 microg/kg), and high (300 microg/kg) doses were assigned in that order, and a very low dose (25 microg/kg) was inserted randomly and in double-blind fashion at any time after the first dose. Testing days were separated by at least 1 week. Each session was conducted over an 8-hour period in a controlled environment in an outpatient clinic; subjects were then transferred to a psychiatric inpatient unit for overnight observation. The Yale-Brown Obsessive Compulsive Scale (YBOCS) and a visual analog scale measuring overall obsessive-compulsive symptom severity were administered at 0, 4, 8, and 24 hours post-ingestion. The Hallucinogen Rating Scale was administered at 8 hours, and vital signs were recorded at 0, 1, 4, 8, and 24 hours after ingestion. The study was conducted from November 2001 to November 2004. RESULTS: Nine subjects were administered a total of 29 psilocybin doses. One subject experienced transient hypertension without relation to anxiety or somatic symptoms, but no other significant adverse effects were observed. Marked decreases in OCD symptoms of variable degrees were observed in all subjects during 1 or more of the testing sessions (23%-100% decrease in YBOCS score). Repeated-measures analysis of variance for all YBOCS values revealed a significant main effect of time on Wilks lambda (F = 9.86, df = 3,3; p = .046), but no significant effect of dose (F = 2.25, df = 3,3; p = .261) or interaction of time and dose (F = 0.923, df = 9,45; p = .515). Improvement generally lasted past the 24-hour timepoint. CONCLUSIONS: In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects."
"['Investigating', 'the', 'Mechanisms', 'of', 'the', 'Effects', 'of', 'Psilocybin', 'on', 'Visual', 'Perception', 'and', 'Visual', 'Representations', 'in', 'the', 'Brain.^', '\n', 'The', 'long‐term', 'objective', 'of', 'this', 'project', 'is', 'to', 'characterize', 'how', 'psilocybin', 'affects', 'visual', 'perception', 'and', 'the', 'brain', ""'s"", 'representation', 'of', 'the', 'visual', 'environment', '.', 'We', 'know', 'that', 'psilocybin', 'alters', 'aspects', 'of', 'visual', 'perception', ',', 'but', 'the', 'underlying', 'brain', 'mechanisms', 'contributing', 'to', 'these', 'effects', 'are', 'poorly', 'understood', '.', 'The', 'proposed', 'work', 'will', 'address', 'these', 'questions', 'in', 'a', 'large', ',', 'diverse', 'sample', 'of', 'healthy', 'human', 'subjects', 'by', 'using', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'to', 'measure', 'the', 'brain', ""'s"", 'responses', 'to', 'visual', 'stimuli', '.', 'The', 'proposed', 'research', 'will', 'document', 'which', 'brain', 'areas', 'mediate', 'the', 'effects', 'of', 'psilocybin', '.', 'The', 'technique', 'of', 'fMRI', 'will', 'be', 'employed', 'to', 'measure', 'brain', 'activity', 'in', 'different', 'brain', 'areas', 'while', 'subjects', 'are', 'performing', 'a', 'visual', 'perceptual', 'task', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6246,"['[CLS]', 'investigating', 'the', 'mechanisms', 'of', 'the', 'effects', 'of', 'psi', '##loc', '##yb', '##in', 'on', 'visual', 'perception', 'and', 'visual', 'representations', 'in', 'the', 'brain', '.', '^', 'the', 'long', '‐', 'term', 'objective', 'of', 'this', 'project', 'is', 'to', 'characterize', 'how', 'psi', '##loc', '##yb', '##in', 'affects', 'visual', 'perception', 'and', 'the', 'brain', ""'"", 's', 'representation', 'of', 'the', 'visual', 'environment', '.', 'we', 'know', 'that', 'psi', '##loc', '##yb', '##in', 'alters', 'aspects', 'of', 'visual', 'perception', ',', 'but', 'the', 'underlying', 'brain', 'mechanisms', 'contributing', 'to', 'these', 'effects', 'are', 'poorly', 'understood', '.', 'the', 'proposed', 'work', 'will', 'address', 'these', 'questions', 'in', 'a', 'large', ',', 'diverse', 'sample', 'of', 'healthy', 'human', 'subjects', 'by', 'using', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fmri', ')', 'to', 'measure', 'the', 'brain', ""'"", 's', 'responses', 'to', 'visual', 'stimuli', '.', 'the', 'proposed', 'research', 'will', 'document', 'which', 'brain', 'areas', 'mediate', 'the', 'effects', 'of', 'psi', '##loc', '##yb', '##in', '.', 'the', 'technique', 'of', 'fmri', 'will', 'be', 'employed', 'to', 'measure', 'brain', 'activity', 'in', 'different', 'brain', 'areas', 'while', 'subjects', 'are', 'performing', 'a', 'visual', 'perceptual', 'task', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 7, 7, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 16, 16, 18, 19, 19, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 28, 28, 28, 29, 30, 31, 32, 33, 34, 35, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 45, 45, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 113, 113, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain.^
The long‐term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment. We know that psilocybin alters aspects of visual perception, but the underlying brain mechanisms contributing to these effects are poorly understood. The proposed work will address these questions in a large, diverse sample of healthy human subjects by using functional magnetic resonance imaging (fMRI) to measure the brain's responses to visual stimuli. The proposed research will document which brain areas mediate the effects of psilocybin. The technique of fMRI will be employed to measure brain activity in different brain areas while subjects are performing a visual perceptual task."
"['Study', 'protocol', 'for', '""', 'MDMA', '-', 'assisted', 'therapy', 'as', 'a', 'treatment', 'for', 'major', 'depressive', 'disorder', ':', 'A', 'proof', 'of', 'principle', 'study"".^', '\n', 'BACKGROUND', ':', 'Major', 'depressive', 'disorder', '(', 'MDD', ')', 'is', 'a', 'world', '-', 'leading', 'cause', 'of', 'disability', '.', 'The', 'available', 'treatments', 'are', 'not', 'effective', 'in', 'all', 'patients', ',', 'and', 'there', 'is', 'a', 'significant', 'need', 'for', 'more', 'effective', 'treatment', 'options', '.', 'Here', 'we', 'present', 'the', 'protocol', 'for', 'an', 'investigator', '-', 'initiated', 'and', 'publicly', 'funded', 'trial', 'of', 'MDMA', '-', 'assisted', 'therapy', '(', 'MDMA', '-', 'AT', ')', 'for', 'MDD', '.', 'This', 'single', '-', 'site', ',', 'open', '-', 'label', 'study', 'investigates', 'the', 'proof', 'of', 'principle', 'and', 'safety', 'of', 'MDMA', '-', 'AT', 'in', 'participants', 'with', 'MDD', 'and', 'provides', 'an', 'initial', 'impression', 'of', 'treatment', 'effectiveness', '.', 'METHODS', ':', 'A', 'total', 'of', '12', 'participants', '[', '>', '18', 'years', ']', 'with', 'DSM-5', 'diagnosis', 'of', 'MDD', 'will', 'receive', 'a', 'flexible', 'dose', 'of', 'MDMA', 'in', 'a', 'therapeutic', 'setting', 'on', 'two', 'dosing', 'days', 'over', 'a', '4', 'week', 'period', 'preceded', 'by', 'three', 'preparatory', 'sessions', '.', 'Each', 'MDMA', 'dosing', 'session', 'will', 'be', 'followed', 'by', 'three', 'integration', 'sessions', '.', 'The', 'primary', 'outcome', 'is', 'change', 'in', 'MDD', 'symptom', 'severity', ',', 'as', 'measured', 'by', 'the', 'mean', 'change', 'in', 'MADRS', 'scores', 'from', 'Baseline', 'to', '8', 'weeks', 'after', 'the', 'second', 'MDMA', 'session', '.', 'The', 'secondary', 'outcome', 'is', 'change', 'in', 'functional', 'impairment', ',', 'as', 'evaluated', 'by', 'the', 'mean', 'change', 'in', 'Sheehan', 'Disability', 'Scale', 'scores', 'from', 'Baseline', 'to', '8', 'weeks', 'after', 'the', 'second', 'MDMA', 'session', '.', 'Safety', 'measures', 'include', 'vital', 'signs', ',', 'the', 'incidence', 'of', 'Adverse', 'Events', 'and', 'suicidality', 'as', 'measured', 'by', 'the', 'Colombia', '-', 'Suicide', 'Severity', 'Rating', 'Scale', '.', 'DISCUSSION', ':', 'This', 'proof', 'of', 'principle', 'trial', 'will', 'inform', 'the', 'development', 'of', 'fully', 'powered', 'clinical', 'trials', ',', 'optimize', 'the', 'protocol', 'for', 'the', 'administration', 'of', 'MDMA', '-', 'AT', 'in', 'participants', 'with', 'MDD', 'and', 'explore', 'uncertainties', 'including', 'barriers', 'to', 'recruitment', ',', 'retention', 'and', 'acceptability', 'of', 'MDMA', '-', 'AT', 'as', 'a', 'treatment', 'for', 'MDD', '.', 'CLINICAL', 'TRIAL', 'IDENTIFICATION', ':', 'EudraCT', 'number', '2021', '-', '000805', '-', '26', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",4658,"['[CLS]', 'study', 'protocol', 'for', '""', 'mdm', '##a', '-', 'assisted', 'therapy', 'as', 'a', 'treatment', 'for', 'major', 'depressive', 'disorder', ':', 'a', 'proof', 'of', 'principle', 'study', '""', '.', '^', 'background', ':', 'major', 'depressive', 'disorder', '(', 'mdd', ')', 'is', 'a', 'world', '-', 'leading', 'cause', 'of', 'disability', '.', 'the', 'available', 'treatments', 'are', 'not', 'effective', 'in', 'all', 'patients', ',', 'and', 'there', 'is', 'a', 'significant', 'need', 'for', 'more', 'effective', 'treatment', 'options', '.', 'here', 'we', 'present', 'the', 'protocol', 'for', 'an', 'investigator', '-', 'initiated', 'and', 'publicly', 'funded', 'trial', 'of', 'mdm', '##a', '-', 'assisted', 'therapy', '(', 'mdm', '##a', '-', 'at', ')', 'for', 'mdd', '.', 'this', 'single', '-', 'site', ',', 'open', '-', 'label', 'study', 'investigates', 'the', 'proof', 'of', 'principle', 'and', 'safety', 'of', 'mdm', '##a', '-', 'at', 'in', 'participants', 'with', 'mdd', 'and', 'provides', 'an', 'initial', 'impression', 'of', 'treatment', 'effectiveness', '.', 'methods', ':', 'a', 'total', 'of', '12', 'participants', '[', '>', '18', 'years', ']', 'with', 'dsm', '-', '5', 'diagnosis', 'of', 'mdd', 'will', 'receive', 'a', 'flexible', 'dose', 'of', 'mdm', '##a', 'in', 'a', 'therapeutic', 'setting', 'on', 'two', 'dosing', 'days', 'over', 'a', '4', 'week', 'period', 'preceded', 'by', 'three', 'prepar', '##atory', 'sessions', '.', 'each', 'mdm', '##a', 'dosing', 'session', 'will', 'be', 'followed', 'by', 'three', 'integration', 'sessions', '.', 'the', 'primary', 'outcome', 'is', 'change', 'in', 'mdd', 'symptom', 'severity', ',', 'as', 'measured', 'by', 'the', 'mean', 'change', 'in', 'mad', '##rs', 'scores', 'from', 'baseline', 'to', '8', 'weeks', 'after', 'the', 'second', 'mdm', '##a', 'session', '.', 'the', 'secondary', 'outcome', 'is', 'change', 'in', 'functional', 'impairment', ',', 'as', 'evaluated', 'by', 'the', 'mean', 'change', 'in', 'she', '##eh', '##an', 'disability', 'scale', 'scores', 'from', 'baseline', 'to', '8', 'weeks', 'after', 'the', 'second', 'mdm', '##a', 'session', '.', 'safety', 'measures', 'include', 'vital', 'signs', ',', 'the', 'incidence', 'of', 'adverse', 'events', 'and', 'suicidal', '##ity', 'as', 'measured', 'by', 'the', 'colombia', '-', 'suicide', 'severity', 'rating', 'scale', '.', 'discussion', ':', 'this', 'proof', 'of', 'principle', 'trial', 'will', 'inform', 'the', 'development', 'of', 'fully', 'powered', 'clinical', 'trials', ',', 'optimize', 'the', 'protocol', 'for', 'the', 'administration', 'of', 'mdm', '##a', '-', 'at', 'in', 'participants', 'with', 'mdd', 'and', 'explore', 'uncertainties', 'including', 'barriers', 'to', 'recruitment', ',', 'retention', 'and', 'acceptability', 'of', 'mdm', '##a', '-', 'at', 'as', 'a', 'treatment', 'for', 'mdd', '.', 'clinical', 'trial', 'identification', ':', 'eu', '##dr', '##act', 'number', '202', '##1', '-', '000', '##80', '##5', '-', '26', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20, 20, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 76, 77, 78, 79, 80, 81, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 134, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 161, 162, 163, 164, 165, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 222, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 317, 317, 318, 319, 319, 320, 321, 321, 321, 322, 323, 324, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Study protocol for ""MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study"".^
BACKGROUND: Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and there is a significant need for more effective treatment options. Here we present the protocol for an investigator-initiated and publicly funded trial of MDMA-assisted therapy (MDMA-AT) for MDD. This single-site, open-label study investigates the proof of principle and safety of MDMA-AT in participants with MDD and provides an initial impression of treatment effectiveness. METHODS: A total of 12 participants [>18 years] with DSM-5 diagnosis of MDD will receive a flexible dose of MDMA in a therapeutic setting on two dosing days over a 4 week period preceded by three preparatory sessions. Each MDMA dosing session will be followed by three integration sessions. The primary outcome is change in MDD symptom severity, as measured by the mean change in MADRS scores from Baseline to 8 weeks after the second MDMA session. The secondary outcome is change in functional impairment, as evaluated by the mean change in Sheehan Disability Scale scores from Baseline to 8 weeks after the second MDMA session. Safety measures include vital signs, the incidence of Adverse Events and suicidality as measured by the Colombia-Suicide Severity Rating Scale. DISCUSSION: This proof of principle trial will inform the development of fully powered clinical trials, optimize the protocol for the administration of MDMA-AT in participants with MDD and explore uncertainties including barriers to recruitment, retention and acceptability of MDMA-AT as a treatment for MDD. CLINICAL TRIAL IDENTIFICATION: EudraCT number 2021-000805-26."
"['Effects', 'of', 'Low', '-', 'Dose', 'Ketamine', 'on', 'the', 'Antidepressant', 'Efficacy', 'and', 'Suicidal', 'Ideations', 'in', 'Patients', 'Undergoing', 'Electroconvulsive', 'Therapy.^', '\n', 'OBJECTIVES', ':', 'It', 'remains', 'controversial', 'whether', 'a', 'subanesthetic', 'dose', 'of', 'ketamine', 'could', 'modulate', 'the', 'antidepressant', 'effect', 'of', 'electroconvulsive', 'therapy', '(', 'ECT', ')', 'in', 'patients', 'with', 'major', 'depressive', 'disorder', '.', 'We', 'investigated', 'the', 'effect', 'of', 'ketamine', 'on', 'accelerating', 'the', 'antidepressant', 'efficacy', 'of', 'ECT', '.', 'METHODS', ':', 'One', 'hundred', 'twenty', '-', 'seven', 'patients', 'with', 'major', 'depressive', 'disorder', 'were', 'included', 'in', 'this', 'randomized', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', 'study', '.', 'The', 'study', 'group', 'received', '0.3', 'mg', '/', 'kg', 'ketamine', ',', 'and', 'the', 'control', 'group', 'received', 'an', 'isovolumetric', 'dose', 'of', 'normal', 'saline', 'before', 'undergoing', 'ECT', 'under', 'propofol', 'anesthesia', '.', 'The', 'main', 'outcome', 'was', 'the', 'Hamilton', 'Depression', 'Rating', 'Scale', 'score', 'after', 'each', 'ECT', 'session', '.', 'Suicidal', 'ideation', '(', 'SI', ')', 'was', 'also', 'evaluated', 'using', 'the', 'Hamilton', 'Depression', 'Rating', 'Scale', '.', 'The', 'response', ',', 'remission', ',', 'and', 'recurrence', 'rates', 'were', 'analyzed', 'using', 'time', '-', 'to', '-', 'event', 'analysis', '.', 'RESULTS', ':', 'No', 'significant', 'differences', 'were', 'found', 'in', 'the', 'overall', 'response', ',', 'remission', ',', 'and', 'relapse', 'rates', 'between', 'the', 'groups', '(', 'P', '>', '0.05', ')', '.', 'The', 'median', 'number', 'of', 'ECT', 'sessions', 'for', 'achieving', 'response', 'was', '4.0', '±', '0.41', 'in', 'the', 'study', 'group', 'and', '7.0', '±', '0.79', 'in', 'the', 'control', 'group', '(', 'P', '<', '0.05', ')', '.', 'The', 'median', 'number', 'of', 'ECT', 'sessions', 'for', 'achieving', 'remission', 'in', 'the', 'study', 'and', 'control', 'groups', 'was', '8.0', '±', '0.29', 'and', '9.0', '±', '0.48', ',', 'respectively', '(', 'P', '<', '0.05', ')', '.', 'The', 'median', 'number', 'of', 'ECT', 'sessions', 'for', 'achieving', 'SI', 'reduction', 'in', 'the', 'study', 'and', 'control', 'groups', 'was', '3.0', '±', '0.75', 'and', '6.0', '±', '1.19', ',', 'respectively', '(', 'P', '<', '0.05', ')', '.', 'CONCLUSIONS', ':', 'Low', '-', 'dose', 'ketamine', '(', '0.3', 'mg', '/', 'kg', ')', 'could', 'modulate', 'the', 'antidepressant', 'efficacy', 'of', 'ECT', 'via', 'accelerating', 'the', 'onset', 'of', 'its', 'effects', 'and', 'reducing', 'the', 'number', 'of', 'ECT', 'sessions', 'required', 'to', 'obtain', 'response', ',', 'remission', ',', 'and', 'SI', 'reduction', ',', 'without', 'influencing', 'the', 'relapse', 'rates', 'in', 'remitting', 'patients', 'after', 'ECT', 'treatment', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1455,"['[CLS]', 'effects', 'of', 'low', '-', 'dose', 'ketamine', 'on', 'the', 'antidepressant', 'efficacy', 'and', 'suicidal', 'idea', '##tions', 'in', 'patients', 'undergoing', 'electro', '##con', '##v', '##ulsive', 'therapy', '.', '^', 'objectives', ':', 'it', 'remains', 'controversial', 'whether', 'a', 'sub', '##anes', '##the', '##tic', 'dose', 'of', 'ketamine', 'could', 'modulate', 'the', 'antidepressant', 'effect', 'of', 'electro', '##con', '##v', '##ulsive', 'therapy', '(', 'ect', ')', 'in', 'patients', 'with', 'major', 'depressive', 'disorder', '.', 'we', 'investigated', 'the', 'effect', 'of', 'ketamine', 'on', 'accelerating', 'the', 'antidepressant', 'efficacy', 'of', 'ect', '.', 'methods', ':', 'one', 'hundred', 'twenty', '-', 'seven', 'patients', 'with', 'major', 'depressive', 'disorder', 'were', 'included', 'in', 'this', 'randomized', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', 'study', '.', 'the', 'study', 'group', 'received', '0', '.', '3', 'mg', '/', 'kg', 'ketamine', ',', 'and', 'the', 'control', 'group', 'received', 'an', 'iso', '##volume', '##tric', 'dose', 'of', 'normal', 'saline', 'before', 'undergoing', 'ect', 'under', 'propofol', 'anesthesia', '.', 'the', 'main', 'outcome', 'was', 'the', 'hamilton', 'depression', 'rating', 'scale', 'score', 'after', 'each', 'ect', 'session', '.', 'suicidal', 'idea', '##tion', '(', 'si', ')', 'was', 'also', 'evaluated', 'using', 'the', 'hamilton', 'depression', 'rating', 'scale', '.', 'the', 'response', ',', 'remission', ',', 'and', 'recurrence', 'rates', 'were', 'analyzed', 'using', 'time', '-', 'to', '-', 'event', 'analysis', '.', 'results', ':', 'no', 'significant', 'differences', 'were', 'found', 'in', 'the', 'overall', 'response', ',', 'remission', ',', 'and', 'relapse', 'rates', 'between', 'the', 'groups', '(', 'p', '>', '0', '.', '05', ')', '.', 'the', 'median', 'number', 'of', 'ect', 'sessions', 'for', 'achieving', 'response', 'was', '4', '.', '0', '±', '0', '.', '41', 'in', 'the', 'study', 'group', 'and', '7', '.', '0', '±', '0', '.', '79', 'in', 'the', 'control', 'group', '(', 'p', '<', '0', '.', '05', ')', '.', 'the', 'median', 'number', 'of', 'ect', 'sessions', 'for', 'achieving', 'remission', 'in', 'the', 'study', 'and', 'control', 'groups', 'was', '8', '.', '0', '±', '0', '.', '29', 'and', '9', '.', '0', '±', '0', '.', '48', ',', 'respectively', '(', 'p', '<', '0', '.', '05', ')', '.', 'the', 'median', 'number', 'of', 'ect', 'sessions', 'for', 'achieving', 'si', 'reduction', 'in', 'the', 'study', 'and', 'control', 'groups', 'was', '3', '.', '0', '±', '0', '.', '75', 'and', '6', '.', '0', '±', '1', '.', '19', ',', 'respectively', '(', 'p', '<', '0', '.', '05', ')', '.', 'conclusions', ':', 'low', '-', 'dose', 'ketamine', '(', '0', '.', '3', 'mg', '/', 'kg', ')', 'could', 'modulate', 'the', 'antidepressant', 'efficacy', 'of', 'ect', 'via', 'accelerating', 'the', 'onset', 'of', 'its', 'effects', 'and', 'reducing', 'the', 'number', 'of', 'ect', 'sessions', 'required', 'to', 'obtain', 'response', ',', 'remission', ',', 'and', 'si', 'reduction', ',', 'without', 'influencing', 'the', 'relapse', 'rates', 'in', 'rem', '##itting', 'patients', 'after', 'ect', 'treatment', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12, 13, 14, 15, 16, 16, 16, 16, 17, 17, 17, 19, 20, 21, 22, 23, 24, 25, 26, 26, 26, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 36, 36, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 93, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 105, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 188, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 201, 201, 202, 203, 203, 203, 204, 205, 206, 207, 208, 209, 209, 209, 210, 211, 211, 211, 212, 213, 214, 215, 216, 217, 218, 219, 219, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 238, 238, 239, 240, 240, 240, 241, 242, 242, 242, 243, 244, 244, 244, 245, 246, 247, 248, 249, 250, 250, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 270, 270, 271, 272, 272, 272, 273, 274, 274, 274, 275, 276, 276, 276, 277, 278, 279, 280, 281, 282, 282, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 292, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 335, 336, 337, 338, 339, 340, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Effects of Low-Dose Ketamine on the Antidepressant Efficacy and Suicidal Ideations in Patients Undergoing Electroconvulsive Therapy.^
OBJECTIVES: It remains controversial whether a subanesthetic dose of ketamine could modulate the antidepressant effect of electroconvulsive therapy (ECT) in patients with major depressive disorder. We investigated the effect of ketamine on accelerating the antidepressant efficacy of ECT. METHODS: One hundred twenty-seven patients with major depressive disorder were included in this randomized, placebo-controlled, double-blind study. The study group received 0.3 mg/kg ketamine, and the control group received an isovolumetric dose of normal saline before undergoing ECT under propofol anesthesia. The main outcome was the Hamilton Depression Rating Scale score after each ECT session. Suicidal ideation (SI) was also evaluated using the Hamilton Depression Rating Scale. The response, remission, and recurrence rates were analyzed using time-to-event analysis. RESULTS: No significant differences were found in the overall response, remission, and relapse rates between the groups (P > 0.05). The median number of ECT sessions for achieving response was 4.0 ± 0.41 in the study group and 7.0 ± 0.79 in the control group (P < 0.05). The median number of ECT sessions for achieving remission in the study and control groups was 8.0 ± 0.29 and 9.0 ± 0.48, respectively (P < 0.05). The median number of ECT sessions for achieving SI reduction in the study and control groups was 3.0 ± 0.75 and 6.0 ± 1.19, respectively (P < 0.05). CONCLUSIONS: Low-dose ketamine (0.3 mg/kg) could modulate the antidepressant efficacy of ECT via accelerating the onset of its effects and reducing the number of ECT sessions required to obtain response, remission, and SI reduction, without influencing the relapse rates in remitting patients after ECT treatment."
"['Neurocognitive', 'performance', 'of', 'repeated', 'versus', 'single', 'intravenous', 'subanesthetic', 'ketamine', 'in', 'treatment', 'resistant', 'depression.^', '\n', 'BACKGROUND', ':', 'Ketamine', 'demonstrated', 'rapid', 'antidepressant', 'effects', 'in', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', '.', 'However', ',', 'evaluation', 'of', 'ketamine', ""'s"", 'neurocognitive', 'effect', 'in', 'TRD', 'is', 'unclear', '.', 'We', 'aim', 'to', '(', '1', ')', 'characterize', 'baseline', 'neurocognitive', 'performance', 'as', 'a', 'predictor', 'of', 'the', 'change', 'in', 'severity', 'of', 'depressive', 'symptoms', 'over', 'time', ',', 'and', '(', '2', ')', 'investigate', 'the', 'association', 'of', 'six', 'versus', 'single', 'intravenous', '(', 'IV', ')', 'ketamine', 'and', 'neurocognitive', 'changes', 'from', 'baseline', 'to', 'the', 'end', 'of', 'treatment', '.', 'METHODS', ':', 'Subjects', 'with', 'TRD', 'were', 'randomized', 'to', 'receive', 'either', 'five', 'IV', 'midazolam', 'followed', 'by', 'a', 'single', 'IV', 'ketamine', 'or', 'six', 'IV', 'ketamine', 'during', 'a', '12', '-', 'day', 'period', '.', 'Depression', 'symptom', 'assessments', 'occurred', 'prior', 'and', '24', 'h', 'after', 'infusion', 'days', 'using', 'the', 'Montgomery', '-', 'Åsberg', 'Depression', 'Rating', 'Scale', '.', 'Neurocognitive', 'tasks', 'were', 'designed', 'to', 'test', 'attention', ',', 'memory', ',', 'speed', 'of', 'processing', ',', 'and', 'set', 'shifting', 'using', 'the', 'CogState', 'battery', 'at', 'baseline', 'and', 'at', 'the', 'end', 'of', 'treatment', '.', 'RESULTS', ':', 'Better', 'complex', 'working', 'memory', 'at', 'baseline', 'predicted', 'improvement', 'in', 'MADRS', 'scores', 'of', 'ketamine', '(', 'vs', 'midazolam', ')', 'after', '5', 'infusions', '.', 'Most', ',', 'but', 'not', 'all', ',', 'neurocognitive', 'functions', 'remained', 'stable', 'or', 'improved', 'after', 'repeated', 'or', 'single', 'ketamine', '.', 'There', 'was', 'a', 'greater', 'differential', 'effect', 'of', 'treatment', 'on', 'speed', 'of', 'processing', ',', 'set', 'shifting', ',', 'and', 'spatial', 'working', 'memory', 'that', 'favors', 'subjects', 'in', 'the', 'six', 'ketamine', 'group', '.', 'These', 'cognitive', 'improvements', 'from', 'baseline', 'to', 'the', 'end', 'of', 'treatment', 'were', 'robust', 'when', 'controlling', 'for', 'age', 'and', 'changes', 'in', 'depression', 'severity', '.', 'CONCLUSION', ':', 'The', 'study', 'suggests', 'that', 'six', 'IV', 'ketamine', 'compared', 'to', 'single', 'IV', 'ketamine', 'has', 'a', 'mood', 'independent', 'procognitive', 'effect', 'among', 'TRD', 'patients', '.', 'Large', 'scale', 'studies', 'are', 'needed', 'to', 'confirm', 'whether', 'ketamine', 'enhances', 'cognitive', 'function', 'in', 'TRD', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7942,"['[CLS]', 'neuro', '##cognitive', 'performance', 'of', 'repeated', 'versus', 'single', 'intravenous', 'sub', '##anes', '##the', '##tic', 'ketamine', 'in', 'treatment', 'resistant', 'depression', '.', '^', 'background', ':', 'ketamine', 'demonstrated', 'rapid', 'antidepressant', 'effects', 'in', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', '.', 'however', ',', 'evaluation', 'of', 'ketamine', ""'"", 's', 'neuro', '##cognitive', 'effect', 'in', 'tr', '##d', 'is', 'unclear', '.', 'we', 'aim', 'to', '(', '1', ')', 'characterize', 'baseline', 'neuro', '##cognitive', 'performance', 'as', 'a', 'predictor', 'of', 'the', 'change', 'in', 'severity', 'of', 'depressive', 'symptoms', 'over', 'time', ',', 'and', '(', '2', ')', 'investigate', 'the', 'association', 'of', 'six', 'versus', 'single', 'intravenous', '(', 'iv', ')', 'ketamine', 'and', 'neuro', '##cognitive', 'changes', 'from', 'baseline', 'to', 'the', 'end', 'of', 'treatment', '.', 'methods', ':', 'subjects', 'with', 'tr', '##d', 'were', 'randomized', 'to', 'receive', 'either', 'five', 'iv', 'mid', '##azol', '##am', 'followed', 'by', 'a', 'single', 'iv', 'ketamine', 'or', 'six', 'iv', 'ketamine', 'during', 'a', '12', '-', 'day', 'period', '.', 'depression', 'symptom', 'assessments', 'occurred', 'prior', 'and', '24', 'h', 'after', 'infusion', 'days', 'using', 'the', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', '.', 'neuro', '##cognitive', 'tasks', 'were', 'designed', 'to', 'test', 'attention', ',', 'memory', ',', 'speed', 'of', 'processing', ',', 'and', 'set', 'shifting', 'using', 'the', 'cog', '##state', 'battery', 'at', 'baseline', 'and', 'at', 'the', 'end', 'of', 'treatment', '.', 'results', ':', 'better', 'complex', 'working', 'memory', 'at', 'baseline', 'predicted', 'improvement', 'in', 'mad', '##rs', 'scores', 'of', 'ketamine', '(', 'vs', 'mid', '##azol', '##am', ')', 'after', '5', 'infusions', '.', 'most', ',', 'but', 'not', 'all', ',', 'neuro', '##cognitive', 'functions', 'remained', 'stable', 'or', 'improved', 'after', 'repeated', 'or', 'single', 'ketamine', '.', 'there', 'was', 'a', 'greater', 'differential', 'effect', 'of', 'treatment', 'on', 'speed', 'of', 'processing', ',', 'set', 'shifting', ',', 'and', 'spatial', 'working', 'memory', 'that', 'favors', 'subjects', 'in', 'the', 'six', 'ketamine', 'group', '.', 'these', 'cognitive', 'improvements', 'from', 'baseline', 'to', 'the', 'end', 'of', 'treatment', 'were', 'robust', 'when', 'controlling', 'for', 'age', 'and', 'changes', 'in', 'depression', 'severity', '.', 'conclusion', ':', 'the', 'study', 'suggests', 'that', 'six', 'iv', 'ketamine', 'compared', 'to', 'single', 'iv', 'ketamine', 'has', 'a', 'mood', 'independent', 'proc', '##ognitive', 'effect', 'among', 'tr', '##d', 'patients', '.', 'large', 'scale', 'studies', 'are', 'needed', 'to', 'confirm', 'whether', 'ketamine', 'enhances', 'cognitive', 'function', 'in', 'tr', '##d', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 1, 2, 3, 4, 5, 6, 7, 7, 7, 7, 8, 9, 10, 11, 12, 12, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 27, 28, 29, 30, 31, 32, 33, 34, 35, 35, 36, 36, 37, 38, 39, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 98, 99, 100, 101, 102, 103, 104, 105, 106, 106, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 137, 137, 137, 138, 139, 139, 140, 141, 142, 143, 144, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 185, 186, 187, 188, 189, 190, 191, 191, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 284, 285, 286, 287, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 303, 304, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.^
BACKGROUND: Ketamine demonstrated rapid antidepressant effects in treatment-resistant depression (TRD). However, evaluation of ketamine's neurocognitive effect in TRD is unclear. We aim to (1) characterize baseline neurocognitive performance as a predictor of the change in severity of depressive symptoms over time, and (2) investigate the association of six versus single intravenous (IV) ketamine and neurocognitive changes from baseline to the end of treatment. METHODS: Subjects with TRD were randomized to receive either five IV midazolam followed by a single IV ketamine or six IV ketamine during a 12-day period. Depression symptom assessments occurred prior and 24 h after infusion days using the Montgomery-Åsberg Depression Rating Scale. Neurocognitive tasks were designed to test attention, memory, speed of processing, and set shifting using the CogState battery at baseline and at the end of treatment. RESULTS: Better complex working memory at baseline predicted improvement in MADRS scores of ketamine (vs midazolam) after 5 infusions. Most, but not all, neurocognitive functions remained stable or improved after repeated or single ketamine. There was a greater differential effect of treatment on speed of processing, set shifting, and spatial working memory that favors subjects in the six ketamine group. These cognitive improvements from baseline to the end of treatment were robust when controlling for age and changes in depression severity. CONCLUSION: The study suggests that six IV ketamine compared to single IV ketamine has a mood independent procognitive effect among TRD patients. Large scale studies are needed to confirm whether ketamine enhances cognitive function in TRD."
"['6.3', 'CURRENT', 'RESEARCH', 'ON', 'PSILOCYBIN', 'TREATMENT', 'ON', 'END', '-', 'OF', '-', 'LIFE', 'ANXIETY', 'AND', 'MDMA', 'TREATMENT', 'OF', 'SOCIAL', 'ANXIETY', 'IN', 'AUTISM', 'SPECTRUM', 'DISORDER.^', '\n', 'Objectives', ':', 'Over', 'the', 'past', '15', 'years', ',', 'funding', 'and', 'implementation', 'of', 'research', 'projects', 'exploring', 'the', 'range', 'of', 'effects', 'and', 'therapeutic', 'potential', 'of', 'psychedelic', 'drugs', 'have', 'notably', 'increased', '.', 'This', 'presentation', 'will', 'examine', 'the', 'rationale', ',', 'methodology', ',', 'and', 'findings', 'of', '2', 'recent', 'areas', 'of', 'research', 'attention', ',', 'the', 'use', 'of', 'a', 'psilocybin', 'treatment', 'model', 'for', 'existential', 'anxiety', 'reactive', 'to', 'advanced', 'cancer', 'and', 'the', 'use', 'of', 'an', 'MDMA', '(', '3,4‐methylenedioxy‐methamphetamine', ')', 'treatment', 'model', 'for', 'social', 'anxiety', 'in', 'adults', 'with', 'autism', 'spectrum', 'disorder', '.', 'Methods', ':', 'Double‐blind', ',', 'placebo‐controlled', 'methodologies', 'were', 'utilized', 'in', 'both', 'studies', '.', 'The', 'psilocybin', 'study', 'utilized', 'a', 'within‐subject', 'control', 'design', ',', 'with', 'each', 'subject', 'administered', '2', 'blinded', 'treatment', 'sessions', ',', 'one', 'with', 'the', 'experimental', 'drug', 'and', 'the', 'other', 'with', 'the', 'placebo', 'control', '.', 'The', 'MDMA', 'study', 'randomized', 'subjects', 'into', 'either', 'the', 'experimental', 'drug', 'group', 'or', 'the', 'placebo', 'group', ',', 'administering', '2', 'treatment', 'sessions', 'to', 'all', 'subjects', '.', 'Following', 'the', '6‐month', 'data‐collection', 'follow‐up', 'period', ',', 'the', 'blind', 'was', 'broken', 'and', '2', 'open‐label', 'MDMA', 'sessions', 'were', 'offered', 'to', 'each', 'of', 'the', 'subjects', 'who', 'had', 'been', 'randomized', 'to', 'the', 'placebo', 'group', '.', 'Results', ':', 'The', 'psilocybin', 'and', 'MDMA', 'studies', 'each', 'established', 'feasibility', 'as', 'well', 'as', 'effective', 'safety', 'parameters', '.', 'With', 'the', 'psilocybin', 'investigation', ',', 'statistically', 'significant', 'reductions', 'in', 'anxiety', 'were', 'identified', 'at', 'various', 'points', 'over', 'the', '6‐month', 'follow‐up', 'period', ',', 'along', 'with', 'a', 'notable', 'reduction', 'in', 'depression', 'scores', 'at', 'the', '6‐month', 'data', 'point', '.', 'The', 'MDMA', 'study', 'demonstrated', 'a', 'drug', 'effect', 'size', 'of', '1.4', 'for', 'reduction', 'of', 'social', 'anxiety', '.', 'Conclusions', ':', 'Both', 'the', 'psilocybin', 'and', 'MDMA', 'studies', 'demonstrated', 'trends', 'toward', 'therapeutic', 'efficacy', ',', 'with', 'amelioration', 'of', 'identified', 'target', 'symptoms', '.', 'Each', 'of', 'these', 'pilot', 'investigations', 'succeeded', 'in', 'obtaining', 'all', 'necessary', 'regulatory', 'approvals', ',', 'requisite', 'funding', ',', 'and', 'outcome', 'measures', 'consistent', 'with', 'therapeutic', 'outcome', '.', 'Both', 'studies', 'support', 'further', 'clinical', 'explorations', 'of', 'the', 'treatment', 'potential', 'of', 'these', 'novel', 'psychoactive', 'compounds', '.', 'AD', ',', 'ASD', ',', 'PPC']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3192,"['[CLS]', '6', '.', '3', 'current', 'research', 'on', 'psi', '##loc', '##yb', '##in', 'treatment', 'on', 'end', '-', 'of', '-', 'life', 'anxiety', 'and', 'mdm', '##a', 'treatment', 'of', 'social', 'anxiety', 'in', 'autism', 'spectrum', 'disorder', '.', '^', 'objectives', ':', 'over', 'the', 'past', '15', 'years', ',', 'funding', 'and', 'implementation', 'of', 'research', 'projects', 'exploring', 'the', 'range', 'of', 'effects', 'and', 'therapeutic', 'potential', 'of', 'psych', '##ede', '##lic', 'drugs', 'have', 'notably', 'increased', '.', 'this', 'presentation', 'will', 'examine', 'the', 'rationale', ',', 'methodology', ',', 'and', 'findings', 'of', '2', 'recent', 'areas', 'of', 'research', 'attention', ',', 'the', 'use', 'of', 'a', 'psi', '##loc', '##yb', '##in', 'treatment', 'model', 'for', 'existential', 'anxiety', 'reactive', 'to', 'advanced', 'cancer', 'and', 'the', 'use', 'of', 'an', 'mdm', '##a', '(', '3', ',', '4', '‐', 'methylene', '##di', '##oxy', '‐', 'meth', '##amphetamine', ')', 'treatment', 'model', 'for', 'social', 'anxiety', 'in', 'adults', 'with', 'autism', 'spectrum', 'disorder', '.', 'methods', ':', 'double', '‐', 'blind', ',', 'placebo', '‐', 'controlled', 'methodologies', 'were', 'utilized', 'in', 'both', 'studies', '.', 'the', 'psi', '##loc', '##yb', '##in', 'study', 'utilized', 'a', 'within', '‐', 'subject', 'control', 'design', ',', 'with', 'each', 'subject', 'administered', '2', 'blinded', 'treatment', 'sessions', ',', 'one', 'with', 'the', 'experimental', 'drug', 'and', 'the', 'other', 'with', 'the', 'placebo', 'control', '.', 'the', 'mdm', '##a', 'study', 'randomized', 'subjects', 'into', 'either', 'the', 'experimental', 'drug', 'group', 'or', 'the', 'placebo', 'group', ',', 'admin', '##istering', '2', 'treatment', 'sessions', 'to', 'all', 'subjects', '.', 'following', 'the', '6', '‐', 'month', 'data', '‐', 'collection', 'follow', '‐', 'up', 'period', ',', 'the', 'blind', 'was', 'broken', 'and', '2', 'open', '‐', 'label', 'mdm', '##a', 'sessions', 'were', 'offered', 'to', 'each', 'of', 'the', 'subjects', 'who', 'had', 'been', 'randomized', 'to', 'the', 'placebo', 'group', '.', 'results', ':', 'the', 'psi', '##loc', '##yb', '##in', 'and', 'mdm', '##a', 'studies', 'each', 'established', 'feasibility', 'as', 'well', 'as', 'effective', 'safety', 'parameters', '.', 'with', 'the', 'psi', '##loc', '##yb', '##in', 'investigation', ',', 'statistically', 'significant', 'reductions', 'in', 'anxiety', 'were', 'identified', 'at', 'various', 'points', 'over', 'the', '6', '‐', 'month', 'follow', '‐', 'up', 'period', ',', 'along', 'with', 'a', 'notable', 'reduction', 'in', 'depression', 'scores', 'at', 'the', '6', '‐', 'month', 'data', 'point', '.', 'the', 'mdm', '##a', 'study', 'demonstrated', 'a', 'drug', 'effect', 'size', 'of', '1', '.', '4', 'for', 'reduction', 'of', 'social', 'anxiety', '.', 'conclusions', ':', 'both', 'the', 'psi', '##loc', '##yb', '##in', 'and', 'mdm', '##a', 'studies', 'demonstrated', 'trends', 'toward', 'therapeutic', 'efficacy', ',', 'with', 'amelior', '##ation', 'of', 'identified', 'target', 'symptoms', '.', 'each', 'of', 'these', 'pilot', 'investigations', 'succeeded', 'in', 'obtaining', 'all', 'necessary', 'regulatory', 'approval', '##s', ',', 'requi', '##site', 'funding', ',', 'and', 'outcome', 'measures', 'consistent', 'with', 'therapeutic', 'outcome', '.', 'both', 'studies', 'support', 'further', 'clinical', 'exploration', '##s', 'of', 'the', 'treatment', 'potential', 'of', 'these', 'novel', 'psycho', '##active', 'compounds', '.', 'ad', ',', 'asd', ',', 'pp', '##c', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 0, 1, 2, 3, 4, 4, 4, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 15, 16, 17, 18, 19, 20, 21, 22, 22, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 47, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 76, 76, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 91, 92, 93, 93, 93, 93, 93, 93, 93, 93, 93, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 110, 111, 111, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 120, 120, 120, 121, 122, 123, 124, 124, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 176, 176, 177, 177, 177, 178, 178, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 187, 187, 188, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 209, 209, 209, 210, 211, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 225, 225, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 240, 240, 241, 241, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 254, 254, 255, 256, 257, 258, 259, 259, 260, 261, 262, 263, 264, 265, 266, 267, 267, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 278, 278, 278, 279, 280, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 306, 307, 308, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 324, 325, 326, 327, 328, 329, 330, 331, 332, 332, 333, 334, 335, 336, 337, 338, 339, 339, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","6.3 CURRENT RESEARCH ON PSILOCYBIN TREATMENT ON END-OF-LIFE ANXIETY AND MDMA TREATMENT OF SOCIAL ANXIETY IN AUTISM SPECTRUM DISORDER.^
Objectives: Over the past 15 years, funding and implementation of research projects exploring the range of effects and therapeutic potential of psychedelic drugs have notably increased. This presentation will examine the rationale, methodology, and findings of 2 recent areas of research attention, the use of a psilocybin treatment model for existential anxiety reactive to advanced cancer and the use of an MDMA (3,4‐methylenedioxy‐methamphetamine) treatment model for social anxiety in adults with autism spectrum disorder. Methods: Double‐blind, placebo‐controlled methodologies were utilized in both studies. The psilocybin study utilized a within‐subject control design, with each subject administered 2 blinded treatment sessions, one with the experimental drug and the other with the placebo control. The MDMA study randomized subjects into either the experimental drug group or the placebo group, administering 2 treatment sessions to all subjects. Following the 6‐month data‐collection follow‐up period, the blind was broken and 2 open‐label MDMA sessions were offered to each of the subjects who had been randomized to the placebo group. Results: The psilocybin and MDMA studies each established feasibility as well as effective safety parameters. With the psilocybin investigation, statistically significant reductions in anxiety were identified at various points over the 6‐month follow‐up period, along with a notable reduction in depression scores at the 6‐month data point. The MDMA study demonstrated a drug effect size of 1.4 for reduction of social anxiety. Conclusions: Both the psilocybin and MDMA studies demonstrated trends toward therapeutic efficacy, with amelioration of identified target symptoms. Each of these pilot investigations succeeded in obtaining all necessary regulatory approvals, requisite funding, and outcome measures consistent with therapeutic outcome. Both studies support further clinical explorations of the treatment potential of these novel psychoactive compounds. AD, ASD, PPC"
"['Esketamine', 'Nasal', 'Spray', 'Plus', 'Oral', 'Antidepressant', 'in', 'Patients', 'With', 'Treatment', '-', 'Resistant', 'Depression', ':', 'Assessment', 'of', 'Long', '-', 'Term', 'Safety', 'in', 'a', 'Phase', '3', ',', 'Open', '-', 'Label', 'Study', '(', 'SUSTAIN-2).^', '\n', 'OBJECTIVE', ':', 'To', 'evaluate', 'long', '-', 'term', 'safety', 'and', 'efficacy', 'of', 'esketamine', 'nasal', 'spray', 'plus', 'a', 'new', 'oral', 'antidepressant', '(', 'OAD', ')', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', '.', 'METHODS', ':', 'This', 'phase', '3', ',', 'open', '-', 'label', ',', 'multicenter', ',', 'long', '-', 'term', '(', 'up', 'to', '1', 'year', ')', 'study', 'was', 'conducted', 'between', 'October', '2015', 'and', 'October', '2017', '.', 'Patients', '(', '≥', '18', 'years', ')', 'with', 'TRD', '(', 'DSM-5', 'diagnosis', 'of', 'major', 'depressive', 'disorder', 'and', 'nonresponse', 'to', '≥', '2', 'OAD', 'treatments', ')', 'were', 'enrolled', 'directly', 'or', 'transferred', 'from', 'a', 'short', '-', 'term', 'study', '(', 'patients', 'aged', '≥', '65', 'years', ')', '.', 'Esketamine', 'nasal', 'spray', '(', '28', '-', 'mg', ',', '56', '-', 'mg', ',', 'or', '84', '-', 'mg', ')', 'plus', 'new', 'OAD', 'was', 'administered', 'twice', 'a', 'week', 'in', 'a', '4', '-', 'week', 'induction', '(', 'IND', ')', 'phase', 'and', 'weekly', 'or', 'every', '-', 'other', '-', 'week', 'for', 'patients', 'who', 'were', 'responders', 'and', 'entered', 'a', '48', '-', 'week', 'optimization', '/', 'maintenance', '(', 'OP', '/', 'MAINT', ')', 'phase', '.', 'RESULTS', ':', 'Of', '802', 'enrolled', 'patients', ',', '86.2', '%', 'were', 'direct', '-', 'entry', 'and', '13.8', '%', 'were', 'transferred', '-', 'entry', ';', '580', '(', '74.5', '%', ')', 'of', '779', 'patients', 'who', 'entered', 'the', 'IND', 'phase', 'completed', 'the', 'phase', ',', 'and', '150', '(', '24.9', '%', ')', 'of', '603', 'who', 'entered', 'the', 'OP', '/', 'MAINT', 'phase', 'completed', 'the', 'phase', '.', 'Common', 'treatment', '-', 'emergent', 'adverse', 'events', '(', 'TEAEs', ')', 'were', 'dizziness', '(', '32.9', '%', ')', ',', 'dissociation', '(', '27.6', '%', ')', ',', 'nausea', '(', '25.1', '%', ')', ',', 'and', 'headache', '(', '24.9', '%', ')', '.', 'Seventy', '-', 'six', 'patients', '(', '9.5', '%', ')', 'discontinued', 'esketamine', 'due', 'to', 'TEAEs', '.', 'Fifty', '-', 'five', 'patients', '(', '6.9', '%', ')', 'experienced', 'serious', 'TEAEs', '.', 'Most', 'TEAEs', 'occurred', 'on', 'dosing', 'days', ',', 'were', 'mild', 'or', 'moderate', 'in', 'severity', ',', 'and', 'resolved', 'on', 'the', 'same', 'day', '.', 'Two', 'deaths', 'were', 'reported', ';', 'neither', 'was', 'considered', 'related', 'to', 'esketamine', '.', 'Cognitive', 'performance', 'generally', 'either', 'improved', 'or', 'remained', 'stable', 'postbaseline', '.', 'There', 'was', 'no', 'case', 'of', 'interstitial', 'cystitis', 'or', 'respiratory', 'depression', '.', 'Treatment', '-', 'emergent', 'dissociative', 'symptoms', 'were', 'transient', 'and', 'generally', 'resolved', 'within', '1.5', 'hours', 'postdose', '.', 'Montgomery', '-', 'Åsberg', 'Depression', 'Rating', 'Scale', 'total', 'score', 'decreased', 'during', 'the', 'IND', 'phase', ',', 'and', 'this', 'reduction', 'persisted', 'during', 'the', 'OP', '/', 'MAINT', 'phase', '(', 'mean', '[', 'SD', ']', 'change', 'from', 'baseline', 'of', 'respective', 'phase', 'to', 'endpoint', ':', 'IND', ',', '-16.4', '[', '8.76', ']', ';', 'OP', '/', 'MAINT', ',', '0.3', '[', '8.12', ']', ')', '.', 'CONCLUSIONS', ':', 'Long', '-', 'term', 'esketamine', 'nasal', 'spray', 'plus', 'new', 'OAD', 'therapy', 'had', 'a', 'manageable', 'safety', 'profile', ',', 'and', 'improvements', 'in', 'depression', 'appeared', 'to', 'be', 'sustained', 'in', 'patients', 'with', 'TRD', '.', 'TRIAL', 'REGISTRATION', ':', 'ClinicalTrials.gov', 'identifier', ':', 'NCT02497287', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8959,"['[CLS]', 'es', '##ket', '##amine', 'nasal', 'spray', 'plus', 'oral', 'antidepressant', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', ':', 'assessment', 'of', 'long', '-', 'term', 'safety', 'in', 'a', 'phase', '3', ',', 'open', '-', 'label', 'study', '(', 'sustain', '-', '2', ')', '.', '^', 'objective', ':', 'to', 'evaluate', 'long', '-', 'term', 'safety', 'and', 'efficacy', 'of', 'es', '##ket', '##amine', 'nasal', 'spray', 'plus', 'a', 'new', 'oral', 'antidepressant', '(', 'oa', '##d', ')', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', '.', 'methods', ':', 'this', 'phase', '3', ',', 'open', '-', 'label', ',', 'multicenter', ',', 'long', '-', 'term', '(', 'up', 'to', '1', 'year', ')', 'study', 'was', 'conducted', 'between', 'october', '2015', 'and', 'october', '2017', '.', 'patients', '(', '≥', '18', 'years', ')', 'with', 'tr', '##d', '(', 'dsm', '-', '5', 'diagnosis', 'of', 'major', 'depressive', 'disorder', 'and', 'non', '##response', 'to', '≥', '2', 'oa', '##d', 'treatments', ')', 'were', 'enrolled', 'directly', 'or', 'transferred', 'from', 'a', 'short', '-', 'term', 'study', '(', 'patients', 'aged', '≥', '65', 'years', ')', '.', 'es', '##ket', '##amine', 'nasal', 'spray', '(', '28', '-', 'mg', ',', '56', '-', 'mg', ',', 'or', '84', '-', 'mg', ')', 'plus', 'new', 'oa', '##d', 'was', 'administered', 'twice', 'a', 'week', 'in', 'a', '4', '-', 'week', 'induction', '(', 'ind', ')', 'phase', 'and', 'weekly', 'or', 'every', '-', 'other', '-', 'week', 'for', 'patients', 'who', 'were', 'responders', 'and', 'entered', 'a', '48', '-', 'week', 'optimization', '/', 'maintenance', '(', 'op', '/', 'main', '##t', ')', 'phase', '.', 'results', ':', 'of', '802', 'enrolled', 'patients', ',', '86', '.', '2', '%', 'were', 'direct', '-', 'entry', 'and', '13', '.', '8', '%', 'were', 'transferred', '-', 'entry', ';', '58', '##0', '(', '74', '.', '5', '%', ')', 'of', '77', '##9', 'patients', 'who', 'entered', 'the', 'ind', 'phase', 'completed', 'the', 'phase', ',', 'and', '150', '(', '24', '.', '9', '%', ')', 'of', '60', '##3', 'who', 'entered', 'the', 'op', '/', 'main', '##t', 'phase', 'completed', 'the', 'phase', '.', 'common', 'treatment', '-', 'emergent', 'adverse', 'events', '(', 'tea', '##es', ')', 'were', 'di', '##zz', '##iness', '(', '32', '.', '9', '%', ')', ',', 'dissociation', '(', '27', '.', '6', '%', ')', ',', 'nausea', '(', '25', '.', '1', '%', ')', ',', 'and', 'headache', '(', '24', '.', '9', '%', ')', '.', 'seventy', '-', 'six', 'patients', '(', '9', '.', '5', '%', ')', 'discontinued', 'es', '##ket', '##amine', 'due', 'to', 'tea', '##es', '.', 'fifty', '-', 'five', 'patients', '(', '6', '.', '9', '%', ')', 'experienced', 'serious', 'tea', '##es', '.', 'most', 'tea', '##es', 'occurred', 'on', 'dosing', 'days', ',', 'were', 'mild', 'or', 'moderate', 'in', 'severity', ',', 'and', 'resolved', 'on', 'the', 'same', 'day', '.', 'two', 'deaths', 'were', 'reported', ';', 'neither', 'was', 'considered', 'related', 'to', 'es', '##ket', '##amine', '.', 'cognitive', 'performance', 'generally', 'either', 'improved', 'or', 'remained', 'stable', 'post', '##baseline', '.', 'there', 'was', 'no', 'case', 'of', 'interstitial', 'cyst', '##itis', 'or', 'respiratory', 'depression', '.', 'treatment', '-', 'emergent', 'dissoci', '##ative', 'symptoms', 'were', 'transient', 'and', 'generally', 'resolved', 'within', '1', '.', '5', 'hours', 'post', '##dose', '.', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', 'total', 'score', 'decreased', 'during', 'the', 'ind', 'phase', ',', 'and', 'this', 'reduction', 'persisted', 'during', 'the', 'op', '/', 'main', '##t', 'phase', '(', 'mean', '[', 'sd', ']', 'change', 'from', 'baseline', 'of', 'respective', 'phase', 'to', 'endpoint', ':', 'ind', ',', '-', '16', '.', '4', '[', '8', '.', '76', ']', ';', 'op', '/', 'main', '##t', ',', '0', '.', '[SEP]']","[None, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30, 30, 30, 30, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 43, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 103, 104, 105, 105, 105, 106, 107, 108, 109, 110, 111, 112, 112, 113, 114, 115, 116, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 138, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 209, 209, 210, 211, 212, 213, 214, 215, 216, 216, 216, 217, 218, 219, 220, 221, 222, 223, 223, 224, 225, 225, 225, 226, 227, 228, 229, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 243, 243, 244, 245, 246, 247, 247, 248, 249, 250, 251, 252, 253, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 266, 267, 268, 269, 269, 269, 270, 271, 271, 271, 272, 273, 274, 275, 276, 277, 277, 277, 278, 279, 280, 281, 282, 283, 283, 283, 284, 285, 286, 287, 288, 289, 290, 290, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 299, 299, 300, 301, 302, 303, 303, 303, 304, 305, 306, 306, 307, 308, 309, 310, 311, 312, 313, 313, 313, 314, 315, 316, 317, 318, 318, 319, 320, 321, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 351, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 361, 362, 363, 364, 365, 366, 367, 368, 369, 369, 370, 371, 372, 373, 374, 375, 376, 377, 377, 378, 379, 380, 381, 382, 383, 384, 385, 385, 385, 386, 387, 387, 388, 389, 389, 389, 389, 390, 391, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 429, 429, 429, 430, 431, 431, 431, 432, 433, 434, 435, 436, 436, 437, 438, 438, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 0, 3, 1, 1, 0, 0, 3, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).^
OBJECTIVE: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). METHODS: This phase 3, open-label, multicenter, long-term (up to 1 year) study was conducted between October 2015 and October 2017. Patients (≥ 18 years) with TRD (DSM-5 diagnosis of major depressive disorder and nonresponse to ≥ 2 OAD treatments) were enrolled directly or transferred from a short-term study (patients aged ≥ 65 years). Esketamine nasal spray (28-mg, 56-mg, or 84-mg) plus new OAD was administered twice a week in a 4-week induction (IND) phase and weekly or every-other-week for patients who were responders and entered a 48-week optimization/maintenance (OP/MAINT) phase. RESULTS: Of 802 enrolled patients, 86.2% were direct-entry and 13.8% were transferred-entry; 580 (74.5%) of 779 patients who entered the IND phase completed the phase, and 150 (24.9%) of 603 who entered the OP/MAINT phase completed the phase. Common treatment-emergent adverse events (TEAEs) were dizziness (32.9%), dissociation (27.6%), nausea (25.1%), and headache (24.9%). Seventy-six patients (9.5%) discontinued esketamine due to TEAEs. Fifty-five patients (6.9%) experienced serious TEAEs. Most TEAEs occurred on dosing days, were mild or moderate in severity, and resolved on the same day. Two deaths were reported; neither was considered related to esketamine. Cognitive performance generally either improved or remained stable postbaseline. There was no case of interstitial cystitis or respiratory depression. Treatment-emergent dissociative symptoms were transient and generally resolved within 1.5 hours postdose. Montgomery-Åsberg Depression Rating Scale total score decreased during the IND phase, and this reduction persisted during the OP/MAINT phase (mean [SD] change from baseline of respective phase to endpoint: IND, -16.4 [8.76]; OP/MAINT, 0.3 [8.12]). CONCLUSIONS: Long-term esketamine nasal spray plus new OAD therapy had a manageable safety profile, and improvements in depression appeared to be sustained in patients with TRD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02497287."
"['Ketamine', 'normalizes', 'brain', 'activity', 'during', 'emotionally', 'valenced', 'attentional', 'processing', 'in', 'depression.^', '\n', 'BACKGROUND', ':', 'An', 'urgent', 'need', 'exists', 'for', 'faster', '-', 'acting', 'pharmacological', 'treatments', 'in', 'major', 'depressive', 'disorder', '(', 'MDD', ')', '.', 'The', 'glutamatergic', 'modulator', 'ketamine', 'has', 'been', 'shown', 'to', 'have', 'rapid', 'antidepressant', 'effects', ',', 'but', 'much', 'remains', 'unknown', 'about', 'its', 'mechanism', 'of', 'action', '.', 'Functional', 'MRI', '(', 'fMRI', ')', 'can', 'be', 'used', 'to', 'investigate', 'how', 'ketamine', 'impacts', 'brain', 'activity', 'during', 'cognitive', 'and', 'emotional', 'processing', '.', 'METHODS', ':', 'This', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'crossover', 'study', 'of', '33', 'unmedicated', 'participants', 'with', 'MDD', 'and', '26', 'healthy', 'controls', '(', 'HCs', ')', 'examined', 'how', 'ketamine', 'affected', 'fMRI', 'activation', 'during', 'an', 'attentional', 'bias', 'dot', 'probe', 'task', 'with', 'emotional', 'face', 'stimuli', 'across', 'multiple', 'time', 'points', '.', 'A', 'whole', 'brain', 'analysis', 'was', 'conducted', 'to', 'find', 'regions', 'with', 'differential', 'activation', 'associated', 'with', 'group', ',', 'drug', 'session', ',', 'or', 'dot', 'probe', 'task', '-', 'specific', 'factors', '(', 'emotional', 'valence', 'and', 'congruency', 'of', 'stimuli', ')', '.', 'RESULTS', ':', 'A', 'drug', 'session', 'by', 'group', 'interaction', 'was', 'observed', 'in', 'several', 'brain', 'regions', ',', 'such', 'that', 'ketamine', 'had', 'opposite', 'effects', 'on', 'brain', 'activation', 'in', 'MDD', 'versus', 'HC', 'participants', '.', 'Additionally', ',', 'there', 'was', 'a', 'similar', 'finding', 'related', 'to', 'emotional', 'valence', '(', 'a', 'drug', 'session', 'by', 'group', 'by', 'emotion', 'interaction', ')', 'in', 'a', 'large', 'cluster', 'in', 'the', 'anterior', 'cingulate', 'and', 'medial', 'frontal', 'cortex', '.', 'CONCLUSIONS', ':', 'The', 'findings', 'show', 'a', 'pattern', 'of', 'brain', 'activity', 'in', 'MDD', 'participants', 'following', 'ketamine', 'infusion', 'that', 'is', 'similar', 'to', 'activity', 'observed', 'in', 'HCs', 'after', 'placebo', '.', 'This', 'suggests', 'that', 'ketamine', 'may', 'act', 'as', 'an', 'antidepressant', 'by', 'normalizing', 'brain', 'function', 'during', 'emotionally', 'valenced', 'attentional', 'processing', '.', 'CLINICAL', 'TRIAL', ':', 'NCT#00088699', ':', 'https://www.clinicaltrials.gov/ct2/show/NCT00088699', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7224,"['[CLS]', 'ketamine', 'normalize', '##s', 'brain', 'activity', 'during', 'emotional', '##ly', 'valence', '##d', 'attentional', 'processing', 'in', 'depression', '.', '^', 'background', ':', 'an', 'urgent', 'need', 'exists', 'for', 'faster', '-', 'acting', 'pharmacological', 'treatments', 'in', 'major', 'depressive', 'disorder', '(', 'mdd', ')', '.', 'the', 'glutamate', '##rg', '##ic', 'modulator', 'ketamine', 'has', 'been', 'shown', 'to', 'have', 'rapid', 'antidepressant', 'effects', ',', 'but', 'much', 'remains', 'unknown', 'about', 'its', 'mechanism', 'of', 'action', '.', 'functional', 'mri', '(', 'fmri', ')', 'can', 'be', 'used', 'to', 'investigate', 'how', 'ketamine', 'impacts', 'brain', 'activity', 'during', 'cognitive', 'and', 'emotional', 'processing', '.', 'methods', ':', 'this', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'crossover', 'study', 'of', '33', 'un', '##medi', '##cat', '##ed', 'participants', 'with', 'mdd', 'and', '26', 'healthy', 'controls', '(', 'hc', '##s', ')', 'examined', 'how', 'ketamine', 'affected', 'fmri', 'activation', 'during', 'an', 'attentional', 'bias', 'dot', 'probe', 'task', 'with', 'emotional', 'face', 'stimuli', 'across', 'multiple', 'time', 'points', '.', 'a', 'whole', 'brain', 'analysis', 'was', 'conducted', 'to', 'find', 'regions', 'with', 'differential', 'activation', 'associated', 'with', 'group', ',', 'drug', 'session', ',', 'or', 'dot', 'probe', 'task', '-', 'specific', 'factors', '(', 'emotional', 'valence', 'and', 'congru', '##ency', 'of', 'stimuli', ')', '.', 'results', ':', 'a', 'drug', 'session', 'by', 'group', 'interaction', 'was', 'observed', 'in', 'several', 'brain', 'regions', ',', 'such', 'that', 'ketamine', 'had', 'opposite', 'effects', 'on', 'brain', 'activation', 'in', 'mdd', 'versus', 'hc', 'participants', '.', 'additionally', ',', 'there', 'was', 'a', 'similar', 'finding', 'related', 'to', 'emotional', 'valence', '(', 'a', 'drug', 'session', 'by', 'group', 'by', 'emotion', 'interaction', ')', 'in', 'a', 'large', 'cluster', 'in', 'the', 'anterior', 'cingulate', 'and', 'medial', 'frontal', 'cortex', '.', 'conclusions', ':', 'the', 'findings', 'show', 'a', 'pattern', 'of', 'brain', 'activity', 'in', 'mdd', 'participants', 'following', 'ketamine', 'infusion', 'that', 'is', 'similar', 'to', 'activity', 'observed', 'in', 'hc', '##s', 'after', 'placebo', '.', 'this', 'suggests', 'that', 'ketamine', 'may', 'act', 'as', 'an', 'antidepressant', 'by', 'normalizing', 'brain', 'function', 'during', 'emotional', '##ly', 'valence', '##d', 'attentional', 'processing', '.', 'clinical', 'trial', ':', 'nct', '#', '000', '##88', '##69', '##9', ':', 'https', ':', '/', '/', 'www', '.', 'clinical', '##trials', '.', 'go', '##v', '/', 'ct', '##2', '/', 'show', '/', 'nct', '##000', '##88', '##69', '##9', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 1, 2, 3, 4, 5, 5, 6, 6, 7, 8, 9, 10, 10, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 33, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 91, 91, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 264, 265, 265, 266, 267, 268, 269, 270, 271, 272, 272, 272, 272, 272, 272, 273, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 274, 275, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Ketamine normalizes brain activity during emotionally valenced attentional processing in depression.^
BACKGROUND: An urgent need exists for faster-acting pharmacological treatments in major depressive disorder (MDD). The glutamatergic modulator ketamine has been shown to have rapid antidepressant effects, but much remains unknown about its mechanism of action. Functional MRI (fMRI) can be used to investigate how ketamine impacts brain activity during cognitive and emotional processing. METHODS: This double-blind, placebo-controlled, crossover study of 33 unmedicated participants with MDD and 26 healthy controls (HCs) examined how ketamine affected fMRI activation during an attentional bias dot probe task with emotional face stimuli across multiple time points. A whole brain analysis was conducted to find regions with differential activation associated with group, drug session, or dot probe task-specific factors (emotional valence and congruency of stimuli). RESULTS: A drug session by group interaction was observed in several brain regions, such that ketamine had opposite effects on brain activation in MDD versus HC participants. Additionally, there was a similar finding related to emotional valence (a drug session by group by emotion interaction) in a large cluster in the anterior cingulate and medial frontal cortex. CONCLUSIONS: The findings show a pattern of brain activity in MDD participants following ketamine infusion that is similar to activity observed in HCs after placebo. This suggests that ketamine may act as an antidepressant by normalizing brain function during emotionally valenced attentional processing. CLINICAL TRIAL: NCT#00088699: https://www.clinicaltrials.gov/ct2/show/NCT00088699."
"['Pattern', 'of', 'cannabis', 'use', 'in', 'ecstasy', 'polydrug', 'users', ':', 'moderate', 'cannabis', 'use', 'may', 'compensate', 'for', 'self', '-', 'rated', 'aggression', 'and', 'somatic', 'symptoms.^', '\n', 'Cannabis', 'is', 'one', 'of', 'the', 'most', 'common', ""'"", 'co', '-', 'drugs', ""'"", 'for', 'ecstasy', 'users', '.', 'The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'explore', 'self', '-', 'reported', 'psychobiological', 'problems', 'in', 'ecstasy', 'polydrug', 'users', 'in', 'relation', 'to', 'their', 'pattern', 'of', 'cannabis', 'use', '.', 'Two', 'hundred', 'and', 'eighty', 'ecstasy', 'polydrug', 'users', 'were', 'allocated', 'into', 'five', 'cannabis', 'groups', 'according', 'to', 'the', 'frequency', 'of', 'their', 'cannabis', 'use', '.', 'The', 'control', 'group', 'comprised', '121', 'alcohol', '-', 'tobacco', 'users', '.', 'There', 'were', 'no', 'significant', 'group', 'differences', 'with', 'regard', 'to', 'age', ',', 'diagnosed', 'family', 'psychiatric', 'history', 'and', 'level', 'of', 'self', '-', 'rated', 'stress', 'experienced', 'during', '6', 'months', 'prior', 'to', 'the', 'study', '.', 'The', 'present', 'study', 'produced', 'three', 'main', 'findings', ':', '(', 'a', ')', 'Ecstasy', 'users', 'with', 'no', 'concomitant', 'use', 'of', 'cannabis', 'displayed', 'more', 'self', '-', 'rated', 'aggression', 'and', 'somatic', 'symptoms', 'compared', 'with', 'ecstasy', 'users', 'who', 'were', 'smoking', 'cannabis', 'on', 'a', 'monthly', 'or', 'weekly', 'basis', '.', '(', 'b', ')', 'Ecstasy', 'users', 'who', 'reported', 'heavy', 'cannabis', 'use', 'in', 'the', 'past', 'displayed', 'higher', 'paranoid', 'symptoms', 'compared', 'with', 'ecstasy', 'weekly', 'and', 'daily', 'cannabis', 'users', '.', '(', 'c', ')', 'Former', 'heavy', 'cannabis', 'users', 'were', 'the', 'most', 'likely', 'to', 'complain', 'of', 'a', 'variety', 'of', 'ecstasy', 'related', 'long', '-', 'term', 'problems', '.', 'In', 'conclusion', ',', 'moderate', 'cannabis', 'use', 'may', 'help', 'to', 'ameliorate', 'or', 'mask', 'MDMA', '-', 'induced', 'aggressivity', 'and', 'somatic', 'symptoms', '.', 'However', ',', 'this', 'study', 'confirms', 'that', 'heavy', 'cannabis', 'and', 'ecstasy', 'use', 'is', 'associated', 'with', 'several', 'psychobiological', 'problems', ',', 'which', 'may', 'emerge', 'after', 'a', 'period', 'of', 'abstinence', 'from', 'both', 'drugs', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5646,"['[CLS]', 'pattern', 'of', 'cannabis', 'use', 'in', 'ecs', '##tas', '##y', 'poly', '##drug', 'users', ':', 'moderate', 'cannabis', 'use', 'may', 'compensate', 'for', 'self', '-', 'rated', 'aggression', 'and', 'somatic', 'symptoms', '.', '^', 'cannabis', 'is', 'one', 'of', 'the', 'most', 'common', ""'"", 'co', '-', 'drugs', ""'"", 'for', 'ecs', '##tas', '##y', 'users', '.', 'the', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'explore', 'self', '-', 'reported', 'psycho', '##bio', '##log', '##ical', 'problems', 'in', 'ecs', '##tas', '##y', 'poly', '##drug', 'users', 'in', 'relation', 'to', 'their', 'pattern', 'of', 'cannabis', 'use', '.', 'two', 'hundred', 'and', 'eighty', 'ecs', '##tas', '##y', 'poly', '##drug', 'users', 'were', 'allocated', 'into', 'five', 'cannabis', 'groups', 'according', 'to', 'the', 'frequency', 'of', 'their', 'cannabis', 'use', '.', 'the', 'control', 'group', 'comprised', '121', 'alcohol', '-', 'tobacco', 'users', '.', 'there', 'were', 'no', 'significant', 'group', 'differences', 'with', 'regard', 'to', 'age', ',', 'diagnosed', 'family', 'psychiatric', 'history', 'and', 'level', 'of', 'self', '-', 'rated', 'stress', 'experienced', 'during', '6', 'months', 'prior', 'to', 'the', 'study', '.', 'the', 'present', 'study', 'produced', 'three', 'main', 'findings', ':', '(', 'a', ')', 'ecs', '##tas', '##y', 'users', 'with', 'no', 'concomitant', 'use', 'of', 'cannabis', 'displayed', 'more', 'self', '-', 'rated', 'aggression', 'and', 'somatic', 'symptoms', 'compared', 'with', 'ecs', '##tas', '##y', 'users', 'who', 'were', 'smoking', 'cannabis', 'on', 'a', 'monthly', 'or', 'weekly', 'basis', '.', '(', 'b', ')', 'ecs', '##tas', '##y', 'users', 'who', 'reported', 'heavy', 'cannabis', 'use', 'in', 'the', 'past', 'displayed', 'higher', 'paran', '##oid', 'symptoms', 'compared', 'with', 'ecs', '##tas', '##y', 'weekly', 'and', 'daily', 'cannabis', 'users', '.', '(', 'c', ')', 'former', 'heavy', 'cannabis', 'users', 'were', 'the', 'most', 'likely', 'to', 'compl', '##ain', 'of', 'a', 'variety', 'of', 'ecs', '##tas', '##y', 'related', 'long', '-', 'term', 'problems', '.', 'in', 'conclusion', ',', 'moderate', 'cannabis', 'use', 'may', 'help', 'to', 'amelior', '##ate', 'or', 'mask', 'mdm', '##a', '-', 'induced', 'aggres', '##sivity', 'and', 'somatic', 'symptoms', '.', 'however', ',', 'this', 'study', 'confirms', 'that', 'heavy', 'cannabis', 'and', 'ecs', '##tas', '##y', 'use', 'is', 'associated', 'with', 'several', 'psycho', '##bio', '##log', '##ical', 'problems', ',', 'which', 'may', 'emerge', 'after', 'a', 'period', 'of', 'abstinence', 'from', 'both', 'drugs', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 5, 5, 6, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 21, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 36, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 51, 51, 51, 52, 53, 54, 54, 54, 55, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 70, 70, 71, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 140, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 159, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 175, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 187, 188, 189, 190, 191, 191, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 210, 211, 212, 213, 214, 215, 215, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 231, 232, 233, 234, 234, 235, 236, 237, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 251, 251, 252, 253, 254, 255, 256, 257, 257, 257, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms.^
Cannabis is one of the most common 'co-drugs' for ecstasy users. The aim of the present study was to explore self-reported psychobiological problems in ecstasy polydrug users in relation to their pattern of cannabis use. Two hundred and eighty ecstasy polydrug users were allocated into five cannabis groups according to the frequency of their cannabis use. The control group comprised 121 alcohol-tobacco users. There were no significant group differences with regard to age, diagnosed family psychiatric history and level of self-rated stress experienced during 6 months prior to the study. The present study produced three main findings: (a) Ecstasy users with no concomitant use of cannabis displayed more self-rated aggression and somatic symptoms compared with ecstasy users who were smoking cannabis on a monthly or weekly basis. (b) Ecstasy users who reported heavy cannabis use in the past displayed higher paranoid symptoms compared with ecstasy weekly and daily cannabis users. (c) Former heavy cannabis users were the most likely to complain of a variety of ecstasy related long-term problems. In conclusion, moderate cannabis use may help to ameliorate or mask MDMA-induced aggressivity and somatic symptoms. However, this study confirms that heavy cannabis and ecstasy use is associated with several psychobiological problems, which may emerge after a period of abstinence from both drugs."
"['Preliminary', 'evidence', 'of', 'hippocampal', 'dysfunction', 'in', 'adolescent', 'MDMA', '(', '""', 'ecstasy', '""', ')', 'users', ':', 'Possible', 'relationship', 'to', 'neurotoxic', 'effects.^', '\n', 'Rationale', ':', '3,4', '-', 'Methylenedioxymethamphetamine', '(', 'MDMA', 'or', 'ecstasy', ')', 'is', 'a', 'potent', 'and', 'selective', 'serotonin', 'neurotoxin', 'whose', 'use', 'is', 'growing', 'among', 'adolescents', '.', 'Although', 'cognitive', 'deficits', 'among', 'adult', 'MDMA', 'users', 'are', 'well', 'documented', ',', 'little', 'is', 'known', 'of', 'the', 'cognitive', 'and', 'brain', 'functional', 'sequelae', 'of', 'MDMA', 'use', 'during', 'adolescence', '.', 'Objective', ':', 'We', 'tested', 'for', 'evidence', 'of', 'cognitive', 'deficits', 'and', 'changes', 'in', 'brain', 'function', 'in', 'a', 'pilot', 'sample', 'of', 'adolescent', 'MDMA', 'users', ',', 'who', 'were', 'compared', 'with', 'adolescent', 'non', '-', 'users', 'of', 'MDMA', '.', 'Methods', ':', 'Selective', 'and', 'divided', 'attention', 'and', 'verbal', 'working', 'memory', 'were', 'examined', 'in', 'six', 'adolescent', 'MDMA', 'users', 'and', 'six', 'non-', 'users', 'of', 'MDMA', 'who', 'were', 'similar', 'in', 'age', ',', 'gender', ',', 'IQ', ',', 'and', 'other', 'substance', 'use', '.', 'Brain', 'function', 'was', 'assessed', 'during', 'performance', 'of', 'the', 'working', 'memory', 'task', 'using', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', '.', 'Results', ':', 'MDMA', 'users', 'had', 'significantly', 'prolonged', 'reaction', 'times', 'during', 'tests', 'of', 'selective', 'and', 'divided', 'attention', ',', 'and', 'failed', 'to', 'deactivate', 'the', 'left', 'hippocampus', 'normally', 'during', 'high', 'verbal', 'working', 'memory', 'load', '.', 'Conclusions', ':', 'MDMA', 'use', 'in', 'adolescence', 'may', 'be', 'associated', 'with', 'cognitive', 'impairments', 'and', 'dysfunction', 'of', 'inhibitory', 'circuits', 'within', 'the', 'hippocampus', '.', 'Further', 'work', 'is', 'urgently', 'needed', 'to', 'delineate', 'the', 'developmental', 'impact', 'and', 'long', '-', 'term', 'functional', 'and', 'clinical', 'significance', 'of', 'MDMA', 'use', 'during', 'adolescence', '.', '©', 'Springer', '-', 'Verlag', '2003', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3956,"['[CLS]', 'preliminary', 'evidence', 'of', 'hippocampal', 'dysfunction', 'in', 'adolescent', 'mdm', '##a', '(', '""', 'ecs', '##tas', '##y', '""', ')', 'users', ':', 'possible', 'relationship', 'to', 'neurot', '##oxic', 'effects', '.', '^', 'rationale', ':', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', 'or', 'ecs', '##tas', '##y', ')', 'is', 'a', 'potent', 'and', 'selective', 'serotonin', 'neurot', '##oxin', 'whose', 'use', 'is', 'growing', 'among', 'adolescents', '.', 'although', 'cognitive', 'deficits', 'among', 'adult', 'mdm', '##a', 'users', 'are', 'well', 'documented', ',', 'little', 'is', 'known', 'of', 'the', 'cognitive', 'and', 'brain', 'functional', 'sequelae', 'of', 'mdm', '##a', 'use', 'during', 'adolescence', '.', 'objective', ':', 'we', 'tested', 'for', 'evidence', 'of', 'cognitive', 'deficits', 'and', 'changes', 'in', 'brain', 'function', 'in', 'a', 'pilot', 'sample', 'of', 'adolescent', 'mdm', '##a', 'users', ',', 'who', 'were', 'compared', 'with', 'adolescent', 'non', '-', 'users', 'of', 'mdm', '##a', '.', 'methods', ':', 'selective', 'and', 'divided', 'attention', 'and', 'verbal', 'working', 'memory', 'were', 'examined', 'in', 'six', 'adolescent', 'mdm', '##a', 'users', 'and', 'six', 'non', '-', 'users', 'of', 'mdm', '##a', 'who', 'were', 'similar', 'in', 'age', ',', 'gender', ',', 'iq', ',', 'and', 'other', 'substance', 'use', '.', 'brain', 'function', 'was', 'assessed', 'during', 'performance', 'of', 'the', 'working', 'memory', 'task', 'using', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fmri', ')', '.', 'results', ':', 'mdm', '##a', 'users', 'had', 'significantly', 'prolonged', 'reaction', 'times', 'during', 'tests', 'of', 'selective', 'and', 'divided', 'attention', ',', 'and', 'failed', 'to', 'de', '##activate', 'the', 'left', 'hippocampus', 'normally', 'during', 'high', 'verbal', 'working', 'memory', 'load', '.', 'conclusions', ':', 'mdm', '##a', 'use', 'in', 'adolescence', 'may', 'be', 'associated', 'with', 'cognitive', 'impairments', 'and', 'dysfunction', 'of', 'inhibitory', 'circuits', 'within', 'the', 'hippocampus', '.', 'further', 'work', 'is', 'urgent', '##ly', 'needed', 'to', 'delineate', 'the', 'developmental', 'impact', 'and', 'long', '-', 'term', 'functional', 'and', 'clinical', 'significance', 'of', 'mdm', '##a', 'use', 'during', 'adolescence', '.', '©', 'springer', '-', 'verlag', '2003', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 7, 8, 9, 10, 10, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 19, 19, 19, 21, 22, 23, 23, 23, 24, 25, 25, 25, 25, 25, 26, 27, 27, 28, 29, 29, 29, 30, 31, 32, 33, 34, 35, 36, 37, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 121, 122, 123, 124, 125, 125, 126, 127, 128, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Preliminary evidence of hippocampal dysfunction in adolescent MDMA (""ecstasy"") users: Possible relationship to neurotoxic effects.^
Rationale: 3,4-Methylenedioxymethamphetamine (MDMA or ecstasy) is a potent and selective serotonin neurotoxin whose use is growing among adolescents. Although cognitive deficits among adult MDMA users are well documented, little is known of the cognitive and brain functional sequelae of MDMA use during adolescence. Objective: We tested for evidence of cognitive deficits and changes in brain function in a pilot sample of adolescent MDMA users, who were compared with adolescent non-users of MDMA. Methods: Selective and divided attention and verbal working memory were examined in six adolescent MDMA users and six non- users of MDMA who were similar in age, gender, IQ, and other substance use. Brain function was assessed during performance of the working memory task using functional magnetic resonance imaging (fMRI). Results: MDMA users had significantly prolonged reaction times during tests of selective and divided attention, and failed to deactivate the left hippocampus normally during high verbal working memory load. Conclusions: MDMA use in adolescence may be associated with cognitive impairments and dysfunction of inhibitory circuits within the hippocampus. Further work is urgently needed to delineate the developmental impact and long-term functional and clinical significance of MDMA use during adolescence. © Springer-Verlag 2003."
"['Acute', 'Effects', 'of', '3,4', '-', 'methylenedioxymethamphetamine', '(', 'MDMA', ')', 'With', 'and', 'Without', 'a', 'Booster', 'Dose.^', '\n', 'MDMA', 'is', 'a', 'psychoactive', 'substance', 'that', 'primarily', 'enhances', 'serotonergic', 'neurotransmission', 'by', 'releasing', '5‐HT', 'through', 'the', 'SERT', '.', 'It', 'also', 'releases', 'dopamine', 'and', 'norepinephrine', ',', 'although', 'less', 'potently', ',', 'through', 'the', 'dopamine', 'transporter', 'and', 'norepinephrine', 'transporter', ',', 'respectively', '.', 'In', 'addition', 'to', 'its', 'use', 'as', 'a', 'recreational', 'drug', ',', 'MDMA‐assisted', 'psychotherapy', 'has', 'been', 'investigated', 'in', 'several', 'phase', '2', 'trials', 'and', 'one', 'phase', '3', 'trial', 'for', 'PTSD', '.', 'Further', 'indications', 'for', 'MDMA‐assisted', 'therapy', 'being', 'planned', 'or', 'ongoing', 'are', 'eating', 'disorders', ',', 'social', 'anxiety', ',', 'and', 'alcohol', 'use', 'disorder', '.', 'The', 'present', 'study', 'focuses', 'on', 'dosing', 'aspects', 'of', 'MDMA', 'used', 'in', 'clinical', 'studies', 'and', 'recreational', 'settings', ',', 'specifically', 'the', 'benefits', 'of', 'a', 'second', 'administration', '(', 'booster', 'dose', ')', 'given', 'several', 'hours', 'after', 'the', 'initial', 'dose', '.', 'Most', 'published', 'studies', 'of', 'MDMA‐assisted', 'psychotherapy', 'used', 'a', 'booster', 'dose', '.', 'A', 'typical', 'dosing', 'regimen', 'would', 'be', '80‐120', 'mg', 'of', 'MDMA', 'initially', 'followed', 'by', 'half', 'the', 'initial', 'dose', 'after', '1.5‐2.5', 'hours', '.', 'Although', 'previous', 'studies', 'have', 'found', 'that', 'a', 'booster', 'dose', 'could', 'prolong', 'the', 'acute', 'effects', 'of', 'MDMA', ',', 'others', 'have', 'shown', 'an', 'acute', 'tolerance', 'reflected', 'in', 'the', 'finding', 'that', 'acute', 'subjective', 'effects', 'return', 'to', 'baseline', 'within', '4‐5', 'hours', ',', 'while', 'plasma', 'concentrations', 'are', 'still', 'close', 'to', 'peak', 'levels', '.', 'These', 'findings', 'have', 'led', 'to', 'controversy', 'regarding', 'how', 'effective', 'a', 'booster', 'dose', 'would', 'be', 'in', 'prolonging', 'acute', 'effects', ',', 'as', 'it', 'has', 'never', 'been', 'directly', 'compared', 'to', 'placebo', '.', 'Additionally', ',', 'the', 'higher', 'total', 'dose', 'could', 'lead', 'to', 'an', 'increase', 'in', 'side', 'effects', '.', 'Therefore', ',', 'the', 'present', 'phase', '1', 'study', 'intends', 'to', 'compare', 'the', 'acute', 'subjective', ',', 'physiological', ',', 'and', 'endocrine', 'effects', 'of', 'MDMA', '(', '120', 'mg', '+', '60', 'mg', 'after', '2', 'hours', ')', ',', 'MDMA', '(', '120', 'mg', '+', 'placebo', 'after', '2', 'hours', ')', ',', 'and', '(', 'placebo', '+', 'placebo', 'after', '2', 'hours', ')', 'using', 'a', 'double‐blind', ',', 'random‐order', ',', 'crossover', 'design', 'in', 'healthy', 'subjects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6250,"['[CLS]', 'acute', 'effects', 'of', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', ')', 'with', 'and', 'without', 'a', 'boost', '##er', 'dose', '.', '^', 'mdm', '##a', 'is', 'a', 'psycho', '##active', 'substance', 'that', 'primarily', 'enhances', 'serot', '##one', '##rg', '##ic', 'neurotrans', '##mission', 'by', 'releasing', '5', '‐', 'ht', 'through', 'the', 'sert', '.', 'it', 'also', 'releases', 'dopamine', 'and', 'norepinephrine', ',', 'although', 'less', 'potent', '##ly', ',', 'through', 'the', 'dopamine', 'transporter', 'and', 'norepinephrine', 'transporter', ',', 'respectively', '.', 'in', 'addition', 'to', 'its', 'use', 'as', 'a', 'recreational', 'drug', ',', 'mdm', '##a', '‐', 'assisted', 'psychotherapy', 'has', 'been', 'investigated', 'in', 'several', 'phase', '2', 'trials', 'and', 'one', 'phase', '3', 'trial', 'for', 'ptsd', '.', 'further', 'indications', 'for', 'mdm', '##a', '‐', 'assisted', 'therapy', 'being', 'planned', 'or', 'ongoing', 'are', 'eating', 'disorders', ',', 'social', 'anxiety', ',', 'and', 'alcohol', 'use', 'disorder', '.', 'the', 'present', 'study', 'focuses', 'on', 'dosing', 'aspects', 'of', 'mdm', '##a', 'used', 'in', 'clinical', 'studies', 'and', 'recreational', 'settings', ',', 'specifically', 'the', 'benefits', 'of', 'a', 'second', 'administration', '(', 'boost', '##er', 'dose', ')', 'given', 'several', 'hours', 'after', 'the', 'initial', 'dose', '.', 'most', 'published', 'studies', 'of', 'mdm', '##a', '‐', 'assisted', 'psychotherapy', 'used', 'a', 'boost', '##er', 'dose', '.', 'a', 'typical', 'dosing', 'regimen', 'would', 'be', '80', '‐', '120', 'mg', 'of', 'mdm', '##a', 'initially', 'followed', 'by', 'half', 'the', 'initial', 'dose', 'after', '1', '.', '5', '‐', '2', '.', '5', 'hours', '.', 'although', 'previous', 'studies', 'have', 'found', 'that', 'a', 'boost', '##er', 'dose', 'could', 'prolong', 'the', 'acute', 'effects', 'of', 'mdm', '##a', ',', 'others', 'have', 'shown', 'an', 'acute', 'tolerance', 'reflected', 'in', 'the', 'finding', 'that', 'acute', 'subjective', 'effects', 'return', 'to', 'baseline', 'within', '4', '‐', '5', 'hours', ',', 'while', 'plasma', 'concentrations', 'are', 'still', 'close', 'to', 'peak', 'levels', '.', 'these', 'findings', 'have', 'led', 'to', 'controversy', 'regarding', 'how', 'effective', 'a', 'boost', '##er', 'dose', 'would', 'be', 'in', 'prolong', '##ing', 'acute', 'effects', ',', 'as', 'it', 'has', 'never', 'been', 'directly', 'compared', 'to', 'placebo', '.', 'additionally', ',', 'the', 'higher', 'total', 'dose', 'could', 'lead', 'to', 'an', 'increase', 'in', 'side', 'effects', '.', 'therefore', ',', 'the', 'present', 'phase', '1', 'study', 'intend', '##s', 'to', 'compare', 'the', 'acute', 'subjective', ',', 'physiological', ',', 'and', 'endocrine', 'effects', 'of', 'mdm', '##a', '(', '120', 'mg', '+', '60', 'mg', 'after', '2', 'hours', ')', ',', 'mdm', '##a', '(', '120', 'mg', '+', 'placebo', 'after', '2', 'hours', ')', ',', 'and', '(', 'placebo', '+', 'placebo', 'after', '2', 'hours', ')', 'using', 'a', 'double', '‐', 'blind', ',', 'random', '‐', 'order', ',', 'crossover', 'design', 'in', 'healthy', 'subjects', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 4, 5, 5, 5, 5, 5, 6, 7, 7, 8, 9, 10, 11, 12, 13, 13, 14, 14, 14, 16, 16, 17, 18, 19, 19, 20, 21, 22, 23, 24, 24, 24, 24, 25, 25, 26, 27, 28, 28, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 64, 64, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 85, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 143, 143, 143, 144, 145, 146, 147, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 156, 156, 157, 158, 159, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 168, 168, 168, 168, 168, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 178, 179, 180, 181, 182, 183, 184, 185, 186, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 206, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 229, 230, 231, 232, 233, 234, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 317, 317, 318, 319, 319, 319, 320, 321, 322, 323, 324, 325, 326, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose.^
MDMA is a psychoactive substance that primarily enhances serotonergic neurotransmission by releasing 5‐HT through the SERT. It also releases dopamine and norepinephrine, although less potently, through the dopamine transporter and norepinephrine transporter, respectively. In addition to its use as a recreational drug, MDMA‐assisted psychotherapy has been investigated in several phase 2 trials and one phase 3 trial for PTSD. Further indications for MDMA‐assisted therapy being planned or ongoing are eating disorders, social anxiety, and alcohol use disorder. The present study focuses on dosing aspects of MDMA used in clinical studies and recreational settings, specifically the benefits of a second administration (booster dose) given several hours after the initial dose. Most published studies of MDMA‐assisted psychotherapy used a booster dose. A typical dosing regimen would be 80‐120 mg of MDMA initially followed by half the initial dose after 1.5‐2.5 hours. Although previous studies have found that a booster dose could prolong the acute effects of MDMA, others have shown an acute tolerance reflected in the finding that acute subjective effects return to baseline within 4‐5 hours, while plasma concentrations are still close to peak levels. These findings have led to controversy regarding how effective a booster dose would be in prolonging acute effects, as it has never been directly compared to placebo. Additionally, the higher total dose could lead to an increase in side effects. Therefore, the present phase 1 study intends to compare the acute subjective, physiological, and endocrine effects of MDMA (120 mg + 60 mg after 2 hours), MDMA (120 mg + placebo after 2 hours), and (placebo + placebo after 2 hours) using a double‐blind, random‐order, crossover design in healthy subjects."
"['Psilocybin', 'induces', 'aberrant', 'prediction', 'error', 'processing', 'for', 'tactile', 'mismatch', 'responses.^', '\n', 'Background', ':', 'The', 'skin', 'as', 'the', 'body', ""'s"", 'largest', 'organ', 'is', 'our', 'first', 'contact', 'point', 'with', 'the', 'environment', 'encoding', 'information', 'of', 'many', 'different', 'sources', 'as', 'well', 'as', 'providing', 'a', 'sense', 'of', 'boundaries', 'and', 'the', 'Self', '/', 'Non‐Self', 'discrimination', '–', 'thus', 'forming', 'a', 'backdrop', 'of', 'all', 'perceptual', 'experiences', '[', '1', ']', '.', 'Predictive', 'codes', 'integrating', 'bodily', 'states', 'and', 'sensory', 'inputs', 'may', 'give', 'rise', 'to', 'self‐awareness', 'and', 'a', 'sense', 'of', 'agency', '.', 'Distortions', 'in', 'these', 'processes', 'have', 'been', 'linked', 'to', 'psychiatric', 'symptoms', 'like', 'schizophrenic', 'delusions', '[', '2', ']', '.', 'However', ',', 'the', 'relationship', 'between', 'altered', 'tactile', 'prediction', 'error', '(', 'PE', ')', 'processing', 'and', 'distorted', 'self‐experience', 'and', 'its', 'underlying', 'neuropharmacology', 'have', 'never', 'been', 'empirically', 'studied', '.', 'Therefore', ',', 'we', 'investigated', 'the', 'effect', 'of', 'the', 'preferential', '5‐HT2A/1A', 'receptor', 'agonist', 'psilocybin', '(', 'Psi', ')', ',', 'known', 'to', 'induce', 'alterations', 'in', 'self‐experience', ',', 'on', 'the', 'processing', 'of', 'tactile', 'mismatch', 'responses', 'by', 'using', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', '.', 'Methods', ':', 'In', 'this', 'cross‐over', ',', 'double‐blind', ',', 'within‐subject', ',', 'randomized', 'and', 'placebo‐controlled', 'study', ',', 'fifteen', 'healthy', 'participants', '(', '8', 'males', ',', 'and', '7', 'females', ',', 'aged', 'between', '20–40', 'years', ')', 'received', 'a', 'moderate', 'dose', 'of', '0.2', 'mg', '/', 'kg', 'body', 'weight', 'p.', 'o.', 'oral', 'administration', 'of', 'the', '5‐HT2A/1A', 'agonist', 'Psi', '.', 'Participants', 'completed', 'a', 'roving', 'oddball', 'task', 'while', 'undergoing', 'fMRI', '85', 'minutes', 'after', 'Psi', '/', 'Pla', 'administration', 'during', 'peak', 'of', 'subjective', 'Psi', 'effects', '.', 'To', 'induce', 'tactile', 'mismatch', 'responses', ',', 'trains', 'of', 'stimuli', 'switched', 'randomly', 'between', 'high', '(', 'double', 'pulse', ')', 'and', 'low', '(', 'single', 'pulse', ')', 'intensity', 'after', 'a', 'variable', 'number', 'of', '3', 'to', '7', 'repetitions', ',', 'generating', 'an', 'unpredictable', 'sequence', '.', 'The', 'first', 'stimulus', 'of', 'each', 'train', 'was', 'modelled', 'as', 'the', '“', 'Deviant', '(', 'D', ')', '""', 'and', 'the', 'third', 'repetition', 'of', 'each', 'train', 'as', '“', 'Standard', '""', '(', 'S', ')', '.', 'All', 'stimuli', 'were', 'delivered', 'to', 'the', 'median', 'nerve', 'of', 'the', 'left', 'forearm', 'using', 'a', 'MR‐safe', 'electrode', 'and', 'a', 'constant', 'current', 'stimulator', '(', 'Digitimer', ',', 'DS7AH', ')', '.', 'The', 'fMRI', 'images', 'were', 'analyzed', 'using', 'a', 'general', 'linear', 'model', 'implemented', 'in', 'the', 'SPM12', 'software', 'package', '.', 'The', 'dependent', 'variables', 'were', 'the', 'fMRI', 'BOLD', 'contrasts', 'D', '>', 'S.', 'Subjective', 'effects', 'were', 'measured', 'using', 'the', 'Altered', 'State', 'of', 'Consciousness', 'Rating', 'Scale', '(', '5D‐ASC', ')', '.', '5D‐ASC', 'scores', 'were', 'analyzed', 'by', 'using', 'a', 'repeated‐measures', 'ANOVA', 'design', 'with', 'treatment', 'condition', '(', 'Pla', 'and', 'Psi', ')', 'and', 'scale', 'as', 'within‐subject', 'factors', '.', 'Results', ':', 'In', 'response', 'to', 'unpredicted', 'stimuli', 'significant', 'decreases', 'in', 'brain', 'activity', 'after', 'Psi', 'administration', 'were', 'detected', 'for', 'the', 'D', '>', 'S', 'contrast', 'in', 'areas', 'previously', 'implicated', 'in', 'body', 'awareness', 'and', 'tactile', 'deviancy', 'processing', ':', 'thalamus', ',', 'primary', 'somatosensory', 'cortex', ',', 'midcingulate', 'cortex', 'and', 'middle', 'frontal', 'gyrus', '.', 'Further', ',', 'Psi', 'produced', 'robust', 'perceptual', 'alterations', 'of', 'bodily', 'awareness', 'and', 'self‐experience', 'assessed', 'with', 'the', 'rating', 'scale', '5D‐ASC', '.', 'Conclusion', ':', 'This', 'study', 'shows', 'that', 'Psi', 'alters', 'the', 'integration', 'of', 'tactile', 'stimuli', 'through', 'aberrant', 'PE', 'signalling', ',', 'potentially', 'the', 'underlying', 'mechanism', 'of', 'Psi‐induced', 'alterations', 'of', 'self', 'and', 'body‐experience', '.', 'Furthermore', ',', 'it', 'points', 'to', 'the', 'important', 'role', 'of', 'the', '5‐HT2A/1A', 'receptor', 'subtypes', 'in', 'the', 'processes', 'of', 'self‐experience', '.', 'This', 'finding', 'may', 'be', 'relevant', 'for', 'the', 'treatment', 'of', 'psychiatric', 'disorders', 'compromised', 'by', 'distorted', 'self‐experience', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",2245,"['[CLS]', 'psi', '##loc', '##yb', '##in', 'induces', 'aberrant', 'prediction', 'error', 'processing', 'for', 'tactile', 'mismatch', 'responses', '.', '^', 'background', ':', 'the', 'skin', 'as', 'the', 'body', ""'"", 's', 'largest', 'organ', 'is', 'our', 'first', 'contact', 'point', 'with', 'the', 'environment', 'encoding', 'information', 'of', 'many', 'different', 'sources', 'as', 'well', 'as', 'providing', 'a', 'sense', 'of', 'boundaries', 'and', 'the', 'self', '/', 'non', '‐', 'self', 'discrimination', '–', 'thus', 'forming', 'a', 'back', '##drop', 'of', 'all', 'perceptual', 'experiences', '[', '1', ']', '.', 'predictive', 'codes', 'integrating', 'bodily', 'states', 'and', 'sensory', 'inputs', 'may', 'give', 'rise', 'to', 'self', '‐', 'awareness', 'and', 'a', 'sense', 'of', 'agency', '.', 'distortions', 'in', 'these', 'processes', 'have', 'been', 'linked', 'to', 'psychiatric', 'symptoms', 'like', 'schizophren', '##ic', 'del', '##usions', '[', '2', ']', '.', 'however', ',', 'the', 'relationship', 'between', 'altered', 'tactile', 'prediction', 'error', '(', 'pe', ')', 'processing', 'and', 'distorted', 'self', '‐', 'experience', 'and', 'its', 'underlying', 'neuroph', '##armac', '##ology', 'have', 'never', 'been', 'empirically', 'studied', '.', 'therefore', ',', 'we', 'investigated', 'the', 'effect', 'of', 'the', 'preferential', '5', '‐', 'ht', '##2', '##a', '/', '1', '##a', 'receptor', 'agonist', 'psi', '##loc', '##yb', '##in', '(', 'psi', ')', ',', 'known', 'to', 'induce', 'alterations', 'in', 'self', '‐', 'experience', ',', 'on', 'the', 'processing', 'of', 'tactile', 'mismatch', 'responses', 'by', 'using', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fmri', ')', '.', 'methods', ':', 'in', 'this', 'cross', '‐', 'over', ',', 'double', '‐', 'blind', ',', 'within', '‐', 'subject', ',', 'randomized', 'and', 'placebo', '‐', 'controlled', 'study', ',', 'fifteen', 'healthy', 'participants', '(', '8', 'males', ',', 'and', '7', 'females', ',', 'aged', 'between', '20', '–', '40', 'years', ')', 'received', 'a', 'moderate', 'dose', 'of', '0', '.', '2', 'mg', '/', 'kg', 'body', 'weight', 'p', '.', 'o', '.', 'oral', 'administration', 'of', 'the', '5', '‐', 'ht', '##2', '##a', '/', '1', '##a', 'agonist', 'psi', '.', 'participants', 'completed', 'a', 'ro', '##ving', 'odd', '##ball', 'task', 'while', 'undergoing', 'fmri', '85', 'minutes', 'after', 'psi', '/', 'pla', 'administration', 'during', 'peak', 'of', 'subjective', 'psi', 'effects', '.', 'to', 'induce', 'tactile', 'mismatch', 'responses', ',', 'trains', 'of', 'stimuli', 'switched', 'randomly', 'between', 'high', '(', 'double', 'pulse', ')', 'and', 'low', '(', 'single', 'pulse', ')', 'intensity', 'after', 'a', 'variable', 'number', 'of', '3', 'to', '7', 'repetitions', ',', 'generating', 'an', 'unpredictable', 'sequence', '.', 'the', 'first', 'stimulus', 'of', 'each', 'train', 'was', 'modelled', 'as', 'the', '“', 'devi', '##ant', '(', 'd', ')', '""', 'and', 'the', 'third', 'repetition', 'of', 'each', 'train', 'as', '“', 'standard', '""', '(', 's', ')', '.', 'all', 'stimuli', 'were', 'delivered', 'to', 'the', 'median', 'nerve', 'of', 'the', 'left', 'forearm', 'using', 'a', 'mr', '‐', 'safe', 'electrode', 'and', 'a', 'constant', 'current', 'stimul', '##ator', '(', 'digiti', '##mer', ',', 'ds', '##7', '##ah', ')', '.', 'the', 'fmri', 'images', 'were', 'analyzed', 'using', 'a', 'general', 'linear', 'model', 'implemented', 'in', 'the', 'spm', '##12', 'software', 'package', '.', 'the', 'dependent', 'variables', 'were', 'the', 'fmri', 'bold', 'contrasts', 'd', '>', 's', '.', 'subjective', 'effects', 'were', 'measured', 'using', 'the', 'altered', 'state', 'of', 'consciousness', 'rating', 'scale', '(', '5', '##d', '‐', 'asc', ')', '.', '5', '##d', '‐', 'asc', 'scores', 'were', 'analyzed', 'by', 'using', 'a', 'repeated', '‐', 'measures', 'anova', 'design', 'with', 'treatment', 'condition', '(', 'pla', 'and', 'psi', ')', 'and', 'scale', 'as', 'within', '‐', 'subject', 'factors', '.', 'results', ':', 'in', 'response', 'to', 'unpredic', '##ted', 'stimuli', 'significant', 'decreases', 'in', 'brain', 'activity', 'after', 'psi', 'administration', 'were', 'detected', 'for', 'the', 'd', '>', 's', 'contrast', 'in', 'areas', 'previously', 'implicated', 'in', 'body', 'awareness', 'and', 'tactile', 'devi', '##ancy', '[SEP]']","[None, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 9, 9, 11, 12, 13, 14, 15, 16, 17, 18, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 47, 47, 48, 49, 50, 51, 52, 53, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 74, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 92, 93, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 113, 113, 114, 115, 116, 117, 117, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 133, 133, 133, 133, 133, 133, 133, 134, 135, 136, 136, 136, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 146, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 169, 169, 170, 171, 171, 171, 172, 173, 173, 173, 174, 175, 176, 177, 177, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 193, 193, 194, 195, 196, 197, 198, 199, 200, 201, 201, 201, 202, 203, 204, 205, 206, 207, 207, 208, 208, 209, 210, 211, 212, 213, 213, 213, 213, 213, 213, 213, 213, 214, 215, 216, 217, 218, 219, 220, 220, 221, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 324, 324, 325, 326, 327, 328, 329, 330, 330, 331, 332, 332, 333, 334, 334, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 378, 378, 378, 379, 380, 381, 381, 381, 381, 382, 383, 384, 385, 386, 387, 388, 388, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 402, 402, 403, 404, 405, 406, 407, 408, 409, 410, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 437, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","Psilocybin induces aberrant prediction error processing for tactile mismatch responses.^
Background: The skin as the body's largest organ is our first contact point with the environment encoding information of many different sources as well as providing a sense of boundaries and the Self/Non‐Self discrimination – thus forming a backdrop of all perceptual experiences [1]. Predictive codes integrating bodily states and sensory inputs may give rise to self‐awareness and a sense of agency. Distortions in these processes have been linked to psychiatric symptoms like schizophrenic delusions [2]. However, the relationship between altered tactile prediction error (PE) processing and distorted self‐experience and its underlying neuropharmacology have never been empirically studied. Therefore, we investigated the effect of the preferential 5‐HT2A/1A receptor agonist psilocybin (Psi), known to induce alterations in self‐experience, on the processing of tactile mismatch responses by using functional magnetic resonance imaging (fMRI). Methods: In this cross‐over, double‐blind, within‐subject, randomized and placebo‐controlled study, fifteen healthy participants (8 males, and 7 females, aged between 20–40 years) received a moderate dose of 0.2 mg/kg body weight p. o. oral administration of the 5‐HT2A/1A agonist Psi. Participants completed a roving oddball task while undergoing fMRI 85 minutes after Psi/Pla administration during peak of subjective Psi effects. To induce tactile mismatch responses, trains of stimuli switched randomly between high (double pulse) and low (single pulse) intensity after a variable number of 3 to 7 repetitions, generating an unpredictable sequence. The first stimulus of each train was modelled as the “Deviant (D)"" and the third repetition of each train as “Standard"" (S). All stimuli were delivered to the median nerve of the left forearm using a MR‐safe electrode and a constant current stimulator (Digitimer, DS7AH). The fMRI images were analyzed using a general linear model implemented in the SPM12 software package. The dependent variables were the fMRI BOLD contrasts D > S. Subjective effects were measured using the Altered State of Consciousness Rating Scale (5D‐ASC). 5D‐ASC scores were analyzed by using a repeated‐measures ANOVA design with treatment condition (Pla and Psi) and scale as within‐subject factors. Results: In response to unpredicted stimuli significant decreases in brain activity after Psi administration were detected for the D > S contrast in areas previously implicated in body awareness and tactile deviancy processing: thalamus, primary somatosensory cortex, midcingulate cortex and middle frontal gyrus. Further, Psi produced robust perceptual alterations of bodily awareness and self‐experience assessed with the rating scale 5D‐ASC. Conclusion: This study shows that Psi alters the integration of tactile stimuli through aberrant PE signalling, potentially the underlying mechanism of Psi‐induced alterations of self and body‐experience. Furthermore, it points to the important role of the 5‐HT2A/1A receptor subtypes in the processes of self‐experience. This finding may be relevant for the treatment of psychiatric disorders compromised by distorted self‐experience."
"['Patients', '’', 'accounts', 'of', 'increased', ""'"", 'connectedness', ""'"", 'and', ""'"", 'acceptance', ""'"", 'after', 'psilocybin', 'for', 'treatment', '-', 'resistant', 'depression.^', '\n', 'Objective', ':', 'To', 'identify', 'patients', '’', 'perceptions', 'of', 'the', 'value', 'of', 'psilocybin', 'as', 'a', 'treatment', 'for', 'depression', '.', 'Method', ':', 'Twenty', 'patients', 'enrolled', 'in', 'an', 'open', '-', 'label', 'trial', 'of', 'psilocybin', 'for', 'treatment', '-', 'resistant', 'depression', 'participated', 'in', 'a', 'semistructured', 'interview', 'at', '6', '-', 'month', 'follow', '-', 'up', '.', 'Thematic', 'analysis', 'was', 'used', 'to', 'identify', 'patients', '’', 'experiences', 'of', 'the', 'treatment', 'and', 'how', 'it', 'compared', 'with', 'previous', 'treatments', '.', 'Results', ':', 'Two', 'main', 'change', 'processes', 'were', 'identified', 'in', 'relation', 'to', 'the', 'treatment', '.', 'The', 'first', 'concerned', 'change', 'from', 'disconnection', '(', 'from', 'self', ',', 'others', ',', 'and', 'world', ')', 'to', 'connection', ',', 'and', 'the', 'second', 'concerned', 'change', 'from', 'avoidance', '(', 'of', 'emotion', ')', 'to', 'acceptance', '.', 'A', 'third', 'theme', 'concerned', 'comparison', 'between', 'psilocybin', 'and', 'conventional', 'treatments', '.', 'Patients', 'reported', 'that', 'medications', 'and', 'some', 'short', '-', 'term', 'talking', 'therapies', 'tended', 'to', 'reinforce', 'their', 'sense', 'of', 'disconnection', 'and', 'avoidance', ',', 'whereas', 'treatment', 'with', 'psilocybin', 'encouraged', 'connection', 'and', 'acceptance', '.', 'Conclusions', ':', 'These', 'results', 'suggest', 'that', 'psilocybin', 'treatment', 'for', 'depression', 'may', 'work', 'via', 'paradigmatically', 'novel', 'means', ',', 'antithetical', 'to', 'antidepressant', 'medications', ',', 'and', 'some', 'short', '-', 'term', 'talking', 'therapies', '.', '(', 'PsycInfo', 'Database', 'Record', '(', 'c', ')', '2022', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",9055,"['[CLS]', 'patients', '’', 'accounts', 'of', 'increased', ""'"", 'connected', '##ness', ""'"", 'and', ""'"", 'acceptance', ""'"", 'after', 'psi', '##loc', '##yb', '##in', 'for', 'treatment', '-', 'resistant', 'depression', '.', '^', 'objective', ':', 'to', 'identify', 'patients', '’', 'perceptions', 'of', 'the', 'value', 'of', 'psi', '##loc', '##yb', '##in', 'as', 'a', 'treatment', 'for', 'depression', '.', 'method', ':', 'twenty', 'patients', 'enrolled', 'in', 'an', 'open', '-', 'label', 'trial', 'of', 'psi', '##loc', '##yb', '##in', 'for', 'treatment', '-', 'resistant', 'depression', 'participated', 'in', 'a', 'semi', '##structured', 'interview', 'at', '6', '-', 'month', 'follow', '-', 'up', '.', 'thematic', 'analysis', 'was', 'used', 'to', 'identify', 'patients', '’', 'experiences', 'of', 'the', 'treatment', 'and', 'how', 'it', 'compared', 'with', 'previous', 'treatments', '.', 'results', ':', 'two', 'main', 'change', 'processes', 'were', 'identified', 'in', 'relation', 'to', 'the', 'treatment', '.', 'the', 'first', 'concerned', 'change', 'from', 'disconn', '##ection', '(', 'from', 'self', ',', 'others', ',', 'and', 'world', ')', 'to', 'connection', ',', 'and', 'the', 'second', 'concerned', 'change', 'from', 'avoidance', '(', 'of', 'emotion', ')', 'to', 'acceptance', '.', 'a', 'third', 'theme', 'concerned', 'comparison', 'between', 'psi', '##loc', '##yb', '##in', 'and', 'conventional', 'treatments', '.', 'patients', 'reported', 'that', 'medications', 'and', 'some', 'short', '-', 'term', 'talking', 'therapies', 'tended', 'to', 'reinforce', 'their', 'sense', 'of', 'disconn', '##ection', 'and', 'avoidance', ',', 'whereas', 'treatment', 'with', 'psi', '##loc', '##yb', '##in', 'encouraged', 'connection', 'and', 'acceptance', '.', 'conclusions', ':', 'these', 'results', 'suggest', 'that', 'psi', '##loc', '##yb', '##in', 'treatment', 'for', 'depression', 'may', 'work', 'via', 'paradigm', '##atically', 'novel', 'means', ',', 'antit', '##hetic', '##al', 'to', 'antidepressant', 'medications', ',', 'and', 'some', 'short', '-', 'term', 'talking', 'therapies', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '202', '##2', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 6, 7, 8, 9, 10, 11, 12, 13, 13, 13, 13, 14, 15, 16, 17, 18, 18, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 31, 31, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 50, 50, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 141, 141, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 163, 164, 165, 166, 167, 168, 169, 170, 170, 170, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 182, 182, 182, 183, 184, 185, 186, 187, 188, 189, 189, 190, 191, 192, 193, 193, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 207, 207, 208, 209, 210, 211, 212, 213, 213, 214, 214, 215, 216, 217, 218, 219, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Patients’ accounts of increased 'connectedness' and 'acceptance' after psilocybin for treatment-resistant depression.^
Objective: To identify patients’ perceptions of the value of psilocybin as a treatment for depression. Method: Twenty patients enrolled in an open-label trial of psilocybin for treatment-resistant depression participated in a semistructured interview at 6-month follow-up. Thematic analysis was used to identify patients’ experiences of the treatment and how it compared with previous treatments. Results: Two main change processes were identified in relation to the treatment. The first concerned change from disconnection (from self, others, and world) to connection, and the second concerned change from avoidance (of emotion) to acceptance. A third theme concerned comparison between psilocybin and conventional treatments. Patients reported that medications and some short-term talking therapies tended to reinforce their sense of disconnection and avoidance, whereas treatment with psilocybin encouraged connection and acceptance. Conclusions: These results suggest that psilocybin treatment for depression may work via paradigmatically novel means, antithetical to antidepressant medications, and some short-term talking therapies. (PsycInfo Database Record (c) 2022 APA, all rights reserved)"
"['Self', 'reported', 'sleep', 'quality', 'and', 'cognitive', 'performance', 'in', 'ecstasy', 'users.^', '\n', 'Objectives', ':', 'Research', 'suggests', 'that', 'ecstasy', 'users', 'exhibit', 'psychobiological', 'changes', 'relative', 'to', 'nonusers', 'such', 'as', 'altered', 'sleep', 'patterns', 'and', 'cognitive', 'deficits', '.', 'In', 'turn', ',', 'it', 'has', 'been', 'suggested', 'that', 'sleep', 'quality', 'may', 'be', 'a', 'mediator', 'of', 'such', 'cognitive', 'deficits', 'in', 'ecstasy', 'users', '.', 'The', 'present', 'study', 'sought', 'to', 'investigate', 'this', 'proposed', 'relationship', '.', 'Methods', ':', 'Aspects', 'of', 'cognitive', 'functioning', 'in', '104', 'ecstasy', 'users', 'and', '103', 'nonusers', 'obtained', 'from', 'our', 'previous', 'studies', 'were', 'reanalysed', 'to', 'explore', 'the', 'extent', 'to', 'which', 'ecstasy', '-', 'related', 'group', 'differences', 'were', 'attributable', 'to', 'differences', 'in', 'sleep', 'quality', '.', 'Cognitive', 'function', 'was', 'assessed', 'via', 'the', 'computation', 'span', 'test', ',', 'consonant', 'updating', ',', 'paired', 'associate', 'learning', ',', 'syllogistic', 'reasoning', 'and', 'word', 'fluency', '.', 'Sleep', 'quality', 'was', 'measured', 'via', 'the', 'Epworth', 'Sleepiness', 'Scale', '(', 'ESS', ')', ',', 'and', 'the', 'Karolinska', 'Sleepiness', 'Scale', '(', 'KSS', ')', '.', 'Results', ':', 'Ecstasy', 'users', 'performed', 'worse', 'than', 'nonusers', 'on', 'all', 'cognitive', 'measures', '.', 'While', 'no', 'differences', 'were', 'observed', 'on', 'the', 'ESS', ',', 'ecstasy', 'users', 'reported', 'greater', 'tiredness', 'at', 'the', 'beginning', 'of', 'testing', 'than', 'nonusers', '.', 'When', 'the', 'sleep', 'variables', 'were', 'included', 'as', 'covariates', ',', 'the', 'effects', 'of', 'ecstasy', 'on', 'all', 'cognitive', 'measures', 'remained', 'significant', '.', 'Conclusions', ':', 'The', 'results', 'of', 'the', 'present', 'study', 'suggest', 'little', 'evidence', 'for', 'the', 'mediating', 'effects', 'of', 'sleep', 'on', 'cognitive', 'function', 'in', 'ecstasy', 'users', '.', 'Copyright', '©', '2007', 'John', 'Wiley', '&', 'Sons', ',', 'Ltd.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5760,"['[CLS]', 'self', 'reported', 'sleep', 'quality', 'and', 'cognitive', 'performance', 'in', 'ecs', '##tas', '##y', 'users', '.', '^', 'objectives', ':', 'research', 'suggests', 'that', 'ecs', '##tas', '##y', 'users', 'exhibit', 'psycho', '##bio', '##log', '##ical', 'changes', 'relative', 'to', 'non', '##users', 'such', 'as', 'altered', 'sleep', 'patterns', 'and', 'cognitive', 'deficits', '.', 'in', 'turn', ',', 'it', 'has', 'been', 'suggested', 'that', 'sleep', 'quality', 'may', 'be', 'a', 'mediator', 'of', 'such', 'cognitive', 'deficits', 'in', 'ecs', '##tas', '##y', 'users', '.', 'the', 'present', 'study', 'sought', 'to', 'investigate', 'this', 'proposed', 'relationship', '.', 'methods', ':', 'aspects', 'of', 'cognitive', 'functioning', 'in', '104', 'ecs', '##tas', '##y', 'users', 'and', '103', 'non', '##users', 'obtained', 'from', 'our', 'previous', 'studies', 'were', 'rea', '##nal', '##ys', '##ed', 'to', 'explore', 'the', 'extent', 'to', 'which', 'ecs', '##tas', '##y', '-', 'related', 'group', 'differences', 'were', 'attributable', 'to', 'differences', 'in', 'sleep', 'quality', '.', 'cognitive', 'function', 'was', 'assessed', 'via', 'the', 'computation', 'span', 'test', ',', 'consonant', 'updating', ',', 'paired', 'associate', 'learning', ',', 'syll', '##og', '##istic', 'reasoning', 'and', 'word', 'fluency', '.', 'sleep', 'quality', 'was', 'measured', 'via', 'the', 'ep', '##worth', 'sleep', '##iness', 'scale', '(', 'ess', ')', ',', 'and', 'the', 'kar', '##olin', '##ska', 'sleep', '##iness', 'scale', '(', 'ks', '##s', ')', '.', 'results', ':', 'ecs', '##tas', '##y', 'users', 'performed', 'worse', 'than', 'non', '##users', 'on', 'all', 'cognitive', 'measures', '.', 'while', 'no', 'differences', 'were', 'observed', 'on', 'the', 'ess', ',', 'ecs', '##tas', '##y', 'users', 'reported', 'greater', 'tir', '##ed', '##ness', 'at', 'the', 'beginning', 'of', 'testing', 'than', 'non', '##users', '.', 'when', 'the', 'sleep', 'variables', 'were', 'included', 'as', 'covariates', ',', 'the', 'effects', 'of', 'ecs', '##tas', '##y', 'on', 'all', 'cognitive', 'measures', 'remained', 'significant', '.', 'conclusions', ':', 'the', 'results', 'of', 'the', 'present', 'study', 'suggest', 'little', 'evidence', 'for', 'the', 'mediating', 'effects', 'of', 'sleep', 'on', 'cognitive', 'function', 'in', 'ecs', '##tas', '##y', 'users', '.', 'copyright', '©', '2007', 'john', 'wiley', '&', 'sons', ',', 'ltd', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 8, 8, 9, 9, 9, 11, 12, 13, 14, 15, 16, 16, 16, 17, 18, 19, 19, 19, 19, 20, 21, 22, 23, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 52, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 73, 73, 74, 75, 76, 77, 77, 78, 79, 80, 81, 82, 83, 84, 84, 84, 84, 85, 86, 87, 88, 89, 90, 91, 91, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 121, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 133, 134, 134, 135, 136, 137, 138, 139, 140, 141, 142, 142, 142, 143, 143, 144, 145, 146, 146, 147, 148, 149, 150, 151, 151, 151, 152, 153, 154, 155, 156, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 171, 171, 172, 173, 174, 175, 175, 175, 176, 177, 178, 179, 180, 181, 182, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 196, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 225, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 236, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Self reported sleep quality and cognitive performance in ecstasy users.^
Objectives: Research suggests that ecstasy users exhibit psychobiological changes relative to nonusers such as altered sleep patterns and cognitive deficits. In turn, it has been suggested that sleep quality may be a mediator of such cognitive deficits in ecstasy users. The present study sought to investigate this proposed relationship. Methods: Aspects of cognitive functioning in 104 ecstasy users and 103 nonusers obtained from our previous studies were reanalysed to explore the extent to which ecstasy-related group differences were attributable to differences in sleep quality. Cognitive function was assessed via the computation span test, consonant updating, paired associate learning, syllogistic reasoning and word fluency. Sleep quality was measured via the Epworth Sleepiness Scale (ESS), and the Karolinska Sleepiness Scale (KSS). Results: Ecstasy users performed worse than nonusers on all cognitive measures. While no differences were observed on the ESS, ecstasy users reported greater tiredness at the beginning of testing than nonusers. When the sleep variables were included as covariates, the effects of ecstasy on all cognitive measures remained significant. Conclusions: The results of the present study suggest little evidence for the mediating effects of sleep on cognitive function in ecstasy users. Copyright © 2007 John Wiley & Sons, Ltd."
"['Therapeutic', 'mechanisms', 'of', 'psilocybin', ':', 'Changes', 'in', 'amygdala', 'and', 'prefrontal', 'functional', 'connectivity', 'during', 'emotional', 'processing', 'after', 'psilocybin', 'for', 'treatment', '-', 'resistant', 'depression.^', '\n', 'BACKGROUND', ':', 'Psilocybin', 'has', 'shown', 'promise', 'as', 'a', 'treatment', 'for', 'depression', 'but', 'its', 'therapeutic', 'mechanisms', 'are', 'not', 'properly', 'understood', '.', 'In', 'contrast', 'to', 'the', 'presumed', 'actions', 'of', 'antidepressants', ',', 'we', 'recently', 'found', 'increased', 'amygdala', 'responsiveness', 'to', 'fearful', 'faces', 'one', 'day', 'after', 'open', '-', 'label', 'treatment', 'with', 'psilocybin', '(', '25', 'mg', ')', 'in', '19', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', ',', 'which', 'correlated', 'with', 'treatment', 'efficacy', '.', 'AIMS', ':', 'Aiming', 'to', 'further', 'unravel', 'the', 'therapeutic', 'mechanisms', 'of', 'psilocybin', ',', 'the', 'present', 'study', 'extends', 'this', 'basic', 'activation', 'analysis', '.', 'We', 'hypothesised', 'changed', 'amygdala', 'functional', 'connectivity', ',', 'more', 'precisely', 'decreased', 'amygdala', '-', 'ventromedial', 'prefrontal', 'cortex', 'functional', 'connectivity', ',', 'during', 'face', 'processing', 'after', 'treatment', 'with', 'psilocybin', '.', 'METHODS', ':', 'Psychophysiological', 'interaction', 'analyses', 'were', 'conducted', 'on', 'functional', 'magnetic', 'resonance', 'imaging', 'data', 'from', 'a', 'classic', 'face', '/', 'emotion', 'perception', 'task', ',', 'with', 'the', 'bilateral', 'amygdala', 'and', 'ventromedial', 'prefrontal', 'cortex', 'time', '-', 'series', 'as', 'physiological', 'regressors', '.', 'Average', 'parameter', 'estimates', '(', 'beta', 'weights', ')', 'of', 'significant', 'clusters', 'were', 'correlated', 'with', 'clinical', 'outcomes', 'at', 'one', 'week', '.', 'RESULTS', ':', 'Results', 'showed', 'decreased', 'ventromedial', 'prefrontal', 'cortex', '-', 'right', 'amygdala', 'functional', 'connectivity', 'during', 'face', 'processing', 'post-', '(', 'versus', 'pre-', ')', 'treatment', ';', 'this', 'decrease', 'was', 'associated', 'with', 'levels', 'of', 'rumination', 'at', 'one', 'week', '.', 'This', 'effect', 'was', 'driven', 'by', 'connectivity', 'changes', 'in', 'response', 'to', 'fearful', 'and', 'neutral', '(', 'but', 'not', 'happy', ')', 'faces', '.', 'Independent', 'whole', '-', 'brain', 'analyses', 'also', 'revealed', 'a', 'post', '-', 'treatment', 'increase', 'in', 'functional', 'connectivity', 'between', 'the', 'amygdala', 'and', 'ventromedial', 'prefrontal', 'cortex', 'to', 'occipital', '-', 'parietal', 'cortices', 'during', 'face', 'processing', '.', 'CONCLUSION', ':', 'These', 'results', 'are', 'consistent', 'with', 'the', 'idea', 'that', 'psilocybin', 'therapy', 'revives', 'emotional', 'responsiveness', 'on', 'a', 'neural', 'and', 'psychological', 'level', ',', 'which', 'may', 'be', 'a', 'key', 'treatment', 'mechanism', 'for', 'psychedelic', 'therapy', '.', 'Future', 'larger', 'placebo', '-', 'controlled', 'studies', 'are', 'needed', 'to', 'examine', 'the', 'replicability', 'of', 'the', 'current', 'findings', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5597,"['[CLS]', 'therapeutic', 'mechanisms', 'of', 'psi', '##loc', '##yb', '##in', ':', 'changes', 'in', 'amygdala', 'and', 'prefrontal', 'functional', 'connectivity', 'during', 'emotional', 'processing', 'after', 'psi', '##loc', '##yb', '##in', 'for', 'treatment', '-', 'resistant', 'depression', '.', '^', 'background', ':', 'psi', '##loc', '##yb', '##in', 'has', 'shown', 'promise', 'as', 'a', 'treatment', 'for', 'depression', 'but', 'its', 'therapeutic', 'mechanisms', 'are', 'not', 'properly', 'understood', '.', 'in', 'contrast', 'to', 'the', 'presumed', 'actions', 'of', 'antidepressants', ',', 'we', 'recently', 'found', 'increased', 'amygdala', 'responsiveness', 'to', 'fear', '##ful', 'faces', 'one', 'day', 'after', 'open', '-', 'label', 'treatment', 'with', 'psi', '##loc', '##yb', '##in', '(', '25', 'mg', ')', 'in', '19', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', ',', 'which', 'correlated', 'with', 'treatment', 'efficacy', '.', 'aims', ':', 'aiming', 'to', 'further', 'un', '##ra', '##vel', 'the', 'therapeutic', 'mechanisms', 'of', 'psi', '##loc', '##yb', '##in', ',', 'the', 'present', 'study', 'extends', 'this', 'basic', 'activation', 'analysis', '.', 'we', 'hypothesis', '##ed', 'changed', 'amygdala', 'functional', 'connectivity', ',', 'more', 'precisely', 'decreased', 'amygdala', '-', 'vent', '##rome', '##dial', 'prefrontal', 'cortex', 'functional', 'connectivity', ',', 'during', 'face', 'processing', 'after', 'treatment', 'with', 'psi', '##loc', '##yb', '##in', '.', 'methods', ':', 'psycho', '##phys', '##iol', '##og', '##ical', 'interaction', 'analyses', 'were', 'conducted', 'on', 'functional', 'magnetic', 'resonance', 'imaging', 'data', 'from', 'a', 'classic', 'face', '/', 'emotion', 'perception', 'task', ',', 'with', 'the', 'bilateral', 'amygdala', 'and', 'vent', '##rome', '##dial', 'prefrontal', 'cortex', 'time', '-', 'series', 'as', 'physiological', 'regress', '##ors', '.', 'average', 'parameter', 'estimates', '(', 'beta', 'weights', ')', 'of', 'significant', 'clusters', 'were', 'correlated', 'with', 'clinical', 'outcomes', 'at', 'one', 'week', '.', 'results', ':', 'results', 'showed', 'decreased', 'vent', '##rome', '##dial', 'prefrontal', 'cortex', '-', 'right', 'amygdala', 'functional', 'connectivity', 'during', 'face', 'processing', 'post', '-', '(', 'versus', 'pre', '-', ')', 'treatment', ';', 'this', 'decrease', 'was', 'associated', 'with', 'levels', 'of', 'rum', '##ination', 'at', 'one', 'week', '.', 'this', 'effect', 'was', 'driven', 'by', 'connectivity', 'changes', 'in', 'response', 'to', 'fear', '##ful', 'and', 'neutral', '(', 'but', 'not', 'happy', ')', 'faces', '.', 'independent', 'whole', '-', 'brain', 'analyses', 'also', 'revealed', 'a', 'post', '-', 'treatment', 'increase', 'in', 'functional', 'connectivity', 'between', 'the', 'amygdala', 'and', 'vent', '##rome', '##dial', 'prefrontal', 'cortex', 'to', 'occipital', '-', 'parietal', 'cortic', '##es', 'during', 'face', 'processing', '.', 'conclusion', ':', 'these', 'results', 'are', 'consistent', 'with', 'the', 'idea', 'that', 'psi', '##loc', '##yb', '##in', 'therapy', 'rev', '##ives', 'emotional', 'responsiveness', 'on', 'a', 'neural', 'and', 'psychological', 'level', ',', 'which', 'may', 'be', 'a', 'key', 'treatment', 'mechanism', 'for', 'psych', '##ede', '##lic', 'therapy', '.', 'future', 'larger', 'placebo', '-', 'controlled', 'studies', 'are', 'needed', 'to', 'examine', 'the', 'replica', '##bility', 'of', 'the', 'current', 'findings', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 16, 16, 16, 17, 18, 19, 20, 21, 21, 21, 23, 24, 25, 25, 25, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 94, 94, 95, 96, 97, 98, 99, 99, 99, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 122, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 134, 134, 134, 135, 136, 137, 138, 138, 138, 138, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 163, 163, 164, 165, 166, 167, 168, 169, 170, 171, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 197, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 208, 209, 210, 211, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 266, 266, 267, 268, 269, 270, 271, 272, 273, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 288, 288, 288, 289, 290, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 308, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 322, 323, 324, 325, 326, 327, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.^
BACKGROUND: Psilocybin has shown promise as a treatment for depression but its therapeutic mechanisms are not properly understood. In contrast to the presumed actions of antidepressants, we recently found increased amygdala responsiveness to fearful faces one day after open-label treatment with psilocybin (25 mg) in 19 patients with treatment-resistant depression, which correlated with treatment efficacy. AIMS: Aiming to further unravel the therapeutic mechanisms of psilocybin, the present study extends this basic activation analysis. We hypothesised changed amygdala functional connectivity, more precisely decreased amygdala-ventromedial prefrontal cortex functional connectivity, during face processing after treatment with psilocybin. METHODS: Psychophysiological interaction analyses were conducted on functional magnetic resonance imaging data from a classic face/emotion perception task, with the bilateral amygdala and ventromedial prefrontal cortex time-series as physiological regressors. Average parameter estimates (beta weights) of significant clusters were correlated with clinical outcomes at one week. RESULTS: Results showed decreased ventromedial prefrontal cortex-right amygdala functional connectivity during face processing post- (versus pre-) treatment; this decrease was associated with levels of rumination at one week. This effect was driven by connectivity changes in response to fearful and neutral (but not happy) faces. Independent whole-brain analyses also revealed a post-treatment increase in functional connectivity between the amygdala and ventromedial prefrontal cortex to occipital-parietal cortices during face processing. CONCLUSION: These results are consistent with the idea that psilocybin therapy revives emotional responsiveness on a neural and psychological level, which may be a key treatment mechanism for psychedelic therapy. Future larger placebo-controlled studies are needed to examine the replicability of the current findings."
"['The', 'effect', 'of', 'intravenous', 'ketamine', 'on', 'cognitive', 'functions', 'in', 'adults', 'with', 'treatment', '-', 'resistant', 'major', 'depressive', 'or', 'bipolar', 'disorders', ':', 'Results', 'from', 'the', 'Canadian', 'rapid', 'treatment', 'center', 'of', 'excellence', '(', 'CRTCE).^', '\n', 'Ketamine', 'may', 'exert', 'pro', '-', 'cognitive', 'effects', 'on', 'select', 'measures', 'of', 'cognition', 'in', 'adults', 'with', 'mood', 'disorders', '.', 'We', 'evaluated', 'the', 'effectiveness', 'of', 'intravenous', '(', 'IV', ')', 'ketamine', 'on', 'cognition', 'in', '68', 'adult', 'outpatients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', 'at', 'the', 'Canadian', 'Rapid', 'Treatment', 'Center', 'of', 'Excellence', 'between', 'July', '3', ',', '2018', 'and', 'April', '16', ',', '2020', '(', 'NCT04209296', ')', '.', 'Eligibility', 'criteria', 'for', 'the', 'present', 'retrospective', 'study', 'included', ':', 'primary', 'diagnosis', 'of', 'major', 'depressive', 'or', 'bipolar', 'disorder', ';', 'currently', 'depressed', ';', 'and', 'insufficient', 'response', 'to', 'two', 'or', 'more', 'prior', 'treatments', '.', 'Participants', 'received', 'four', 'infusions', 'of', 'ketamine', 'hydrochloride', '(', '0.5', '-', '0.75', 'mg', '/', 'kg', ')', 'over', '1', '-', '2', 'weeks', '.', 'We', 'assessed', 'objective', 'and', 'subjective', 'measures', 'of', 'cognition', 'before', 'and', 'after', 'two', 'infusions', ',', 'i.e.', ',', 'Digit', 'Symbol', 'Substitution', 'Test', '(', 'DSST', ')', ',', 'Trail', 'Making', 'Test', '-', 'B', '(', 'TMT', '-', 'B', ')', ',', 'Patient', 'Deficits', 'Questionnaire', ',', '5', '-', 'item', '(', 'PDQ-5', '-', 'D', ')', '.', 'Ketamine', 'significantly', 'improved', 'DSST', '(', 'effect', 'size', '[', 'ES]=0.60', ')', ',', 'TMT', '-', 'B', '(', 'ES=0.84', ')', ',', 'as', 'well', 'as', 'PDQ-5', '-', 'D', 'scores', '(', 'ES=0.63', ')', ',', 'indicative', 'of', 'a', 'moderate', '-', 'to', '-', 'large', 'effect', 'size', '.', 'Improvements', 'in', 'DSST', 'and', 'PDQ-5', '-', 'D', 'with', 'ketamine', 'were', 'mediated', 'by', 'reductions', 'in', 'depressive', 'symptoms', ',', 'whereas', 'improvements', 'in', 'TMT', '-', 'B', 'were', 'independent', 'of', 'changes', 'in', 'depressive', 'symptoms', '.', 'Our', 'results', 'support', 'the', 'independent', ',', 'rapid', '-', 'onset', ',', 'pro', '-', 'cognitive', 'effects', 'with', 'IV', 'ketamine', 'in', 'adults', 'with', 'TRD', '.', 'Larger', ',', 'randomized', ',', 'controlled', 'trials', 'with', 'ketamine', 'wherein', 'cognition', 'is', 'the', 'primary', 'outcome', 'measure', 'in', 'mood', 'and', 'non', '-', 'mood', 'disorder', 'samples', 'are', 'warranted', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5515,"['[CLS]', 'the', 'effect', 'of', 'intravenous', 'ketamine', 'on', 'cognitive', 'functions', 'in', 'adults', 'with', 'treatment', '-', 'resistant', 'major', 'depressive', 'or', 'bipolar', 'disorders', ':', 'results', 'from', 'the', 'canadian', 'rapid', 'treatment', 'center', 'of', 'excellence', '(', 'crt', '##ce', ')', '.', '^', 'ketamine', 'may', 'exert', 'pro', '-', 'cognitive', 'effects', 'on', 'select', 'measures', 'of', 'cognition', 'in', 'adults', 'with', 'mood', 'disorders', '.', 'we', 'evaluated', 'the', 'effectiveness', 'of', 'intravenous', '(', 'iv', ')', 'ketamine', 'on', 'cognition', 'in', '68', 'adult', 'outpatient', '##s', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', 'at', 'the', 'canadian', 'rapid', 'treatment', 'center', 'of', 'excellence', 'between', 'july', '3', ',', '2018', 'and', 'april', '16', ',', '202', '##0', '(', 'nct', '##04', '##209', '##29', '##6', ')', '.', 'eligibility', 'criteria', 'for', 'the', 'present', 'retrospective', 'study', 'included', ':', 'primary', 'diagnosis', 'of', 'major', 'depressive', 'or', 'bipolar', 'disorder', ';', 'currently', 'depressed', ';', 'and', 'insufficient', 'response', 'to', 'two', 'or', 'more', 'prior', 'treatments', '.', 'participants', 'received', 'four', 'infusions', 'of', 'ketamine', 'hydrochloride', '(', '0', '.', '5', '-', '0', '.', '75', 'mg', '/', 'kg', ')', 'over', '1', '-', '2', 'weeks', '.', 'we', 'assessed', 'objective', 'and', 'subjective', 'measures', 'of', 'cognition', 'before', 'and', 'after', 'two', 'infusions', ',', 'i', '.', 'e', '.', ',', 'digit', 'symbol', 'substitution', 'test', '(', 'dss', '##t', ')', ',', 'trail', 'making', 'test', '-', 'b', '(', 'tm', '##t', '-', 'b', ')', ',', 'patient', 'deficits', 'questionnaire', ',', '5', '-', 'item', '(', 'pd', '##q', '-', '5', '-', 'd', ')', '.', 'ketamine', 'significantly', 'improved', 'dss', '##t', '(', 'effect', 'size', '[', 'es', ']', '=', '0', '.', '60', ')', ',', 'tm', '##t', '-', 'b', '(', 'es', '=', '0', '.', '84', ')', ',', 'as', 'well', 'as', 'pd', '##q', '-', '5', '-', 'd', 'scores', '(', 'es', '=', '0', '.', '63', ')', ',', 'indicative', 'of', 'a', 'moderate', '-', 'to', '-', 'large', 'effect', 'size', '.', 'improvements', 'in', 'dss', '##t', 'and', 'pd', '##q', '-', '5', '-', 'd', 'with', 'ketamine', 'were', 'mediated', 'by', 'reductions', 'in', 'depressive', 'symptoms', ',', 'whereas', 'improvements', 'in', 'tm', '##t', '-', 'b', 'were', 'independent', 'of', 'changes', 'in', 'depressive', 'symptoms', '.', 'our', 'results', 'support', 'the', 'independent', ',', 'rapid', '-', 'onset', ',', 'pro', '-', 'cognitive', 'effects', 'with', 'iv', 'ketamine', 'in', 'adults', 'with', 'tr', '##d', '.', 'larger', ',', 'randomized', ',', 'controlled', 'trials', 'with', 'ketamine', 'wherein', 'cognition', 'is', 'the', 'primary', 'outcome', 'measure', 'in', 'mood', 'and', 'non', '-', 'mood', 'disorder', 'samples', 'are', 'warranted', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30, 30, 30, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 65, 66, 67, 68, 69, 70, 71, 72, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 91, 92, 93, 93, 93, 93, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 135, 135, 136, 137, 137, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 162, 162, 162, 163, 164, 165, 166, 167, 168, 169, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 191, 191, 191, 192, 193, 194, 195, 196, 197, 198, 199, 199, 200, 201, 202, 203, 204, 204, 204, 204, 204, 204, 205, 206, 207, 207, 208, 209, 210, 211, 211, 211, 211, 211, 212, 213, 214, 215, 216, 217, 217, 217, 217, 218, 219, 220, 221, 222, 222, 222, 222, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 238, 239, 240, 240, 240, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).^
Ketamine may exert pro-cognitive effects on select measures of cognition in adults with mood disorders. We evaluated the effectiveness of intravenous (IV) ketamine on cognition in 68 adult outpatients with treatment-resistant depression (TRD) at the Canadian Rapid Treatment Center of Excellence between July 3, 2018 and April 16, 2020 (NCT04209296). Eligibility criteria for the present retrospective study included: primary diagnosis of major depressive or bipolar disorder; currently depressed; and insufficient response to two or more prior treatments. Participants received four infusions of ketamine hydrochloride (0.5-0.75 mg/kg) over 1-2 weeks. We assessed objective and subjective measures of cognition before and after two infusions, i.e., Digit Symbol Substitution Test (DSST), Trail Making Test-B (TMT-B), Patient Deficits Questionnaire, 5-item (PDQ-5-D). Ketamine significantly improved DSST (effect size [ES]=0.60), TMT-B (ES=0.84), as well as PDQ-5-D scores (ES=0.63), indicative of a moderate-to-large effect size. Improvements in DSST and PDQ-5-D with ketamine were mediated by reductions in depressive symptoms, whereas improvements in TMT-B were independent of changes in depressive symptoms. Our results support the independent, rapid-onset, pro-cognitive effects with IV ketamine in adults with TRD. Larger, randomized, controlled trials with ketamine wherein cognition is the primary outcome measure in mood and non-mood disorder samples are warranted."
"['Right', 'dorsolateral', 'prefrontal', 'cortex', 'volumetric', 'reduction', 'is', 'associated', 'with', 'antidepressant', 'effect', 'of', 'low', '-', 'dose', 'ketamine', 'infusion', ':', 'A', 'randomized', ',', 'double', '-', 'blind', ',', 'midazolam', '-', 'controlled', 'PET', '-', 'MRI', 'clinical', 'trial.^', '\n', 'BACKGROUND', ':', 'Evidence', 'has', 'shown', 'a', 'rapid', 'antidepressant', 'and', 'antisuicidal', 'effects', 'of', 'low', '-', 'dose', 'ketamine', 'infusion', 'among', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', 'and', 'prominent', 'suicidal', 'ideation', '(', 'SI', ')', '.', 'The', 'dorsolateral', 'prefrontal', 'cortex', '(', 'DLPFC', ')', 'plays', 'a', 'crucial', 'role', 'in', 'the', 'TRD', 'pathomechanisms', '.', 'OBJECTIVE', ':', 'Whether', 'the', 'structural', 'and', 'functional', 'changes', 'of', 'the', 'DLPFC', ',', 'particularly', 'Brodmann', 'area', '46', ',', 'are', 'associated', 'with', 'the', 'antidepressant', 'and', 'antisuicidal', 'effects', 'of', 'ketamine', 'infusion', 'among', 'such', 'patients', 'is', 'unknown', '.', 'METHODS', ':', 'We', 'randomized', '48', 'patients', 'with', 'TRD', 'and', 'SI', 'into', 'groups', 'receiving', 'a', 'single', 'infusion', 'of', '0.5', 'mg', '/', 'kg', 'ketamine', 'or', '0.045', 'mg', '/', 'kg', 'midazolam', '.', 'The', 'Hamilton', 'Depression', 'Rating', 'Scale', 'and', 'the', 'Montgomery', '-', 'Asberg', 'Depression', 'Rating', 'Scale', 'were', 'used', 'to', 'assess', 'symptoms', '.', 'Positron', 'emission', 'tomography', '(', 'PET)-magnetic', 'resonance', 'imaging', 'was', 'conducted', 'prior', 'to', 'infusion', 'and', 'on', 'Day', '3', 'postinfusion', '.', 'We', 'performed', 'longitudinal', 'voxel', '-', 'based', 'morphometry', '(', 'VBM', ')', 'analysis', 'to', 'evaluate', 'the', 'gray', 'matter', '(', 'GM', ')', 'volume', 'changes', 'of', 'the', 'DLPFC', '.', 'The', 'standardized', 'uptake', 'value', 'ratio', '(', 'SUVr', ')', 'of', '(', '18)F', '-', 'fluorodeoxyglucose', 'PET', 'images', 'was', 'calculated', 'using', 'the', 'SUV', 'of', 'the', 'cerebellum', 'as', 'a', 'reference', 'region', '.', 'RESULTS', ':', 'The', 'VBM', 'analysis', 'revealed', 'a', 'small', 'but', 'significant', 'volumetric', 'reduction', 'in', 'the', 'right', 'DLPFC', 'in', 'the', 'ketamine', 'group', 'compared', 'with', 'that', 'in', 'the', 'midazolam', 'group', '.', 'A', 'greater', 'reduction', 'in', 'depressive', 'symptoms', 'was', 'associated', 'with', 'a', 'smaller', 'decrease', 'in', 'right', 'DLPFC', 'volumes', '(', 'p', '=', '0.025', ')', '.', 'However', ',', 'we', 'found', 'no', 'SUVr', 'changes', 'of', 'the', 'DLPFC', 'between', 'baseline', 'and', 'post', '-', 'Day', '3', 'ketamine', 'infusion', '.', 'DISCUSSION', ':', 'The', 'optimal', 'modulation', 'of', 'the', 'right', 'DLPFC', 'GM', 'volumes', 'may', 'play', 'an', 'essential', 'role', 'in', 'the', 'antidepressant', 'neuromechanisms', 'of', 'low', '-', 'dose', 'ketamine', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",4922,"['[CLS]', 'right', 'dors', '##olateral', 'prefrontal', 'cortex', 'volumetric', 'reduction', 'is', 'associated', 'with', 'antidepressant', 'effect', 'of', 'low', '-', 'dose', 'ketamine', 'infusion', ':', 'a', 'randomized', ',', 'double', '-', 'blind', ',', 'mid', '##azol', '##am', '-', 'controlled', 'pet', '-', 'mri', 'clinical', 'trial', '.', '^', 'background', ':', 'evidence', 'has', 'shown', 'a', 'rapid', 'antidepressant', 'and', 'antis', '##ui', '##cid', '##al', 'effects', 'of', 'low', '-', 'dose', 'ketamine', 'infusion', 'among', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', 'and', 'prominent', 'suicidal', 'idea', '##tion', '(', 'si', ')', '.', 'the', 'dors', '##olateral', 'prefrontal', 'cortex', '(', 'dl', '##pfc', ')', 'plays', 'a', 'crucial', 'role', 'in', 'the', 'tr', '##d', 'path', '##ome', '##chan', '##isms', '.', 'objective', ':', 'whether', 'the', 'structural', 'and', 'functional', 'changes', 'of', 'the', 'dl', '##pfc', ',', 'particularly', 'bro', '##dma', '##nn', 'area', '46', ',', 'are', 'associated', 'with', 'the', 'antidepressant', 'and', 'antis', '##ui', '##cid', '##al', 'effects', 'of', 'ketamine', 'infusion', 'among', 'such', 'patients', 'is', 'unknown', '.', 'methods', ':', 'we', 'randomized', '48', 'patients', 'with', 'tr', '##d', 'and', 'si', 'into', 'groups', 'receiving', 'a', 'single', 'infusion', 'of', '0', '.', '5', 'mg', '/', 'kg', 'ketamine', 'or', '0', '.', '04', '##5', 'mg', '/', 'kg', 'mid', '##azol', '##am', '.', 'the', 'hamilton', 'depression', 'rating', 'scale', 'and', 'the', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', 'were', 'used', 'to', 'assess', 'symptoms', '.', 'positron', 'emission', 'tomography', '(', 'pet', ')', '-', 'magnetic', 'resonance', 'imaging', 'was', 'conducted', 'prior', 'to', 'infusion', 'and', 'on', 'day', '3', 'post', '##inf', '##usion', '.', 'we', 'performed', 'longitudinal', 'voxel', '-', 'based', 'morph', '##ometry', '(', 'vb', '##m', ')', 'analysis', 'to', 'evaluate', 'the', 'gray', 'matter', '(', 'gm', ')', 'volume', 'changes', 'of', 'the', 'dl', '##pfc', '.', 'the', 'standardized', 'uptake', 'value', 'ratio', '(', 'su', '##vr', ')', 'of', '(', '18', ')', 'f', '-', 'fluor', '##ode', '##oxy', '##glucose', 'pet', 'images', 'was', 'calculated', 'using', 'the', 'su', '##v', 'of', 'the', 'cerebellum', 'as', 'a', 'reference', 'region', '.', 'results', ':', 'the', 'vb', '##m', 'analysis', 'revealed', 'a', 'small', 'but', 'significant', 'volumetric', 'reduction', 'in', 'the', 'right', 'dl', '##pfc', 'in', 'the', 'ketamine', 'group', 'compared', 'with', 'that', 'in', 'the', 'mid', '##azol', '##am', 'group', '.', 'a', 'greater', 'reduction', 'in', 'depressive', 'symptoms', 'was', 'associated', 'with', 'a', 'smaller', 'decrease', 'in', 'right', 'dl', '##pfc', 'volumes', '(', 'p', '=', '0', '.', '02', '##5', ')', '.', 'however', ',', 'we', 'found', 'no', 'su', '##vr', 'changes', 'of', 'the', 'dl', '##pfc', 'between', 'baseline', 'and', 'post', '-', 'day', '3', 'ketamine', 'infusion', '.', 'discussion', ':', 'the', 'optimal', 'modulation', 'of', 'the', 'right', 'dl', '##pfc', 'gm', 'volumes', 'may', 'play', 'an', 'essential', 'role', 'in', 'the', 'antidepressant', 'neurom', '##echan', '##isms', 'of', 'low', '-', 'dose', 'ketamine', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 25, 25, 26, 27, 28, 29, 30, 31, 32, 32, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 43, 43, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 59, 60, 61, 62, 63, 64, 64, 65, 66, 67, 68, 69, 70, 70, 71, 72, 73, 74, 74, 75, 76, 77, 78, 79, 80, 81, 82, 82, 83, 83, 83, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 95, 96, 97, 98, 98, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 108, 108, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 136, 136, 137, 138, 139, 140, 141, 142, 142, 142, 142, 143, 144, 145, 146, 146, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 155, 155, 156, 157, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 171, 171, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 183, 183, 184, 185, 186, 187, 188, 189, 190, 191, 191, 192, 193, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 208, 209, 210, 211, 212, 213, 214, 215, 216, 216, 217, 218, 219, 220, 220, 220, 221, 222, 222, 222, 222, 223, 224, 225, 226, 227, 228, 229, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 263, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 280, 281, 282, 283, 284, 285, 285, 285, 285, 286, 287, 288, 289, 290, 291, 292, 293, 293, 294, 295, 296, 297, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 327, 327, 328, 329, 330, 331, 332, 333, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Right dorsolateral prefrontal cortex volumetric reduction is associated with antidepressant effect of low-dose ketamine infusion: A randomized, double-blind, midazolam-controlled PET-MRI clinical trial.^
BACKGROUND: Evidence has shown a rapid antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression (TRD) and prominent suicidal ideation (SI). The dorsolateral prefrontal cortex (DLPFC) plays a crucial role in the TRD pathomechanisms. OBJECTIVE: Whether the structural and functional changes of the DLPFC, particularly Brodmann area 46, are associated with the antidepressant and antisuicidal effects of ketamine infusion among such patients is unknown. METHODS: We randomized 48 patients with TRD and SI into groups receiving a single infusion of 0.5 mg/kg ketamine or 0.045 mg/kg midazolam. The Hamilton Depression Rating Scale and the Montgomery-Asberg Depression Rating Scale were used to assess symptoms. Positron emission tomography (PET)-magnetic resonance imaging was conducted prior to infusion and on Day 3 postinfusion. We performed longitudinal voxel-based morphometry (VBM) analysis to evaluate the gray matter (GM) volume changes of the DLPFC. The standardized uptake value ratio (SUVr) of (18)F-fluorodeoxyglucose PET images was calculated using the SUV of the cerebellum as a reference region. RESULTS: The VBM analysis revealed a small but significant volumetric reduction in the right DLPFC in the ketamine group compared with that in the midazolam group. A greater reduction in depressive symptoms was associated with a smaller decrease in right DLPFC volumes (p = 0.025). However, we found no SUVr changes of the DLPFC between baseline and post-Day 3 ketamine infusion. DISCUSSION: The optimal modulation of the right DLPFC GM volumes may play an essential role in the antidepressant neuromechanisms of low-dose ketamine."
"['Ayahuasca', 'in', 'adolescence', ':', 'a', 'neuropsychological', 'assessment.^', '\n', 'The', 'purpose', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'neuropsychologically', 'adolescents', 'who', 'use', 'ayahuasca', 'in', 'a', 'religious', 'context', '.', 'A', 'battery', 'of', 'neuropsychological', 'tests', 'was', 'administered', 'to', 'adolescents', 'who', 'use', 'ayahuasca', '.', 'These', 'subjects', 'were', 'compared', 'to', 'a', 'matched', 'control', 'group', 'of', 'adolescents', 'who', 'did', 'not', 'use', 'ayahuasca', '.', 'The', 'controls', 'were', 'matched', 'with', 'regards', 'to', 'sex', ',', 'age', ',', 'and', 'education', '.', 'The', 'neuropsychological', 'battery', 'included', 'tests', 'of', 'speeded', 'attention', ',', 'visual', 'search', ',', 'sequencing', ',', 'psychomotor', 'speed', ',', 'verbal', 'and', 'visual', 'abilities', ',', 'memory', ',', 'and', 'mental', 'flexibility', '.', 'The', 'statistical', 'results', 'for', 'subjects', 'from', 'matched', 'controls', 'on', 'neuropsychological', 'measures', 'were', 'computed', 'using', 'independent', 't', '-', 'tests', '.', 'Overall', ',', 'statistical', 'findings', 'suggested', 'that', 'there', 'was', 'no', 'significant', 'difference', 'between', 'the', 'two', 'groups', 'on', 'neuropsychological', 'measures', '.', 'Even', 'though', ',', 'the', 'data', 'overall', 'supports', 'that', 'there', 'was', 'not', 'a', 'difference', 'between', 'ayahuasca', 'users', 'and', 'matched', 'controls', 'on', 'neuropsychological', 'measures', ',', 'further', 'studies', 'are', 'necessary', 'to', 'support', 'these', 'findings', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",2088,"['[CLS]', 'ay', '##ah', '##ua', '##sc', '##a', 'in', 'adolescence', ':', 'a', 'neuropsych', '##ological', 'assessment', '.', '^', 'the', 'purpose', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'neuropsych', '##ologically', 'adolescents', 'who', 'use', 'ay', '##ah', '##ua', '##sc', '##a', 'in', 'a', 'religious', 'context', '.', 'a', 'battery', 'of', 'neuropsych', '##ological', 'tests', 'was', 'administered', 'to', 'adolescents', 'who', 'use', 'ay', '##ah', '##ua', '##sc', '##a', '.', 'these', 'subjects', 'were', 'compared', 'to', 'a', 'matched', 'control', 'group', 'of', 'adolescents', 'who', 'did', 'not', 'use', 'ay', '##ah', '##ua', '##sc', '##a', '.', 'the', 'controls', 'were', 'matched', 'with', 'regards', 'to', 'sex', ',', 'age', ',', 'and', 'education', '.', 'the', 'neuropsych', '##ological', 'battery', 'included', 'tests', 'of', 'speed', '##ed', 'attention', ',', 'visual', 'search', ',', 'sequencing', ',', 'psycho', '##motor', 'speed', ',', 'verbal', 'and', 'visual', 'abilities', ',', 'memory', ',', 'and', 'mental', 'flexibility', '.', 'the', 'statistical', 'results', 'for', 'subjects', 'from', 'matched', 'controls', 'on', 'neuropsych', '##ological', 'measures', 'were', 'computed', 'using', 'independent', 't', '-', 'tests', '.', 'overall', ',', 'statistical', 'findings', 'suggested', 'that', 'there', 'was', 'no', 'significant', 'difference', 'between', 'the', 'two', 'groups', 'on', 'neuropsych', '##ological', 'measures', '.', 'even', 'though', ',', 'the', 'data', 'overall', 'supports', 'that', 'there', 'was', 'not', 'a', 'difference', 'between', 'ay', '##ah', '##ua', '##sc', '##a', 'users', 'and', 'matched', 'controls', 'on', 'neuropsych', '##ological', 'measures', ',', 'further', 'studies', 'are', 'necessary', 'to', 'support', 'these', 'findings', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 5, 6, 6, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 16, 17, 18, 19, 20, 20, 20, 20, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 29, 30, 31, 32, 33, 34, 35, 36, 37, 37, 37, 37, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 54, 54, 54, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 71, 72, 73, 74, 75, 76, 76, 77, 78, 79, 80, 81, 82, 83, 84, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 150, 150, 150, 150, 151, 152, 153, 154, 155, 156, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Ayahuasca in adolescence: a neuropsychological assessment.^
The purpose of the study was to evaluate neuropsychologically adolescents who use ayahuasca in a religious context. A battery of neuropsychological tests was administered to adolescents who use ayahuasca. These subjects were compared to a matched control group of adolescents who did not use ayahuasca. The controls were matched with regards to sex, age, and education. The neuropsychological battery included tests of speeded attention, visual search, sequencing, psychomotor speed, verbal and visual abilities, memory, and mental flexibility. The statistical results for subjects from matched controls on neuropsychological measures were computed using independent t-tests. Overall, statistical findings suggested that there was no significant difference between the two groups on neuropsychological measures. Even though, the data overall supports that there was not a difference between ayahuasca users and matched controls on neuropsychological measures, further studies are necessary to support these findings."
"['Single', 'i.v', '.', 'ketamine', 'augmentation', 'of', 'newly', 'initiated', 'escitalopram', 'for', 'major', 'depression', ':', 'results', 'from', 'a', 'randomized', ',', 'placebo', '-', 'controlled', '4', '-', 'week', 'study.^', '\n', 'BACKGROUND', ':', 'While', 'oral', 'antidepressants', 'reach', 'efficacy', 'after', 'weeks', ',', 'single', '-', 'dose', 'intravenous', '(', 'i.v', '.', ')', 'ketamine', 'has', 'rapid', ',', 'yet', 'time', '-', 'limited', 'antidepressant', 'effects', '.', 'We', 'aimed', 'to', 'determine', 'the', 'efficacy', 'and', 'safety', 'of', 'single', '-', 'dose', 'i.v', '.', 'ketamine', 'augmentation', 'of', 'escitalopram', 'in', 'major', 'depressive', 'disorder', '(', 'MDD', ')', '.', 'METHOD', ':', 'Thirty', 'outpatients', 'with', 'severe', 'MDD', '(', '17', '-', 'item', 'Hamilton', 'Rating', 'Scale', 'for', 'Depression', 'total', 'score', '⩾', '24', ')', 'were', 'randomized', 'to', '4', 'weeks', 'double', '-', 'blind', 'treatment', 'with', 'escitalopram', '10', 'mg', '/', 'day+single', '-', 'dose', 'i.v', '.', 'ketamine', '(', '0.5', 'mg', '/', 'kg', 'over', '40', 'min', ')', 'or', 'escitalopram', '10', 'mg', '/', 'day', '+', 'placebo', '(', '0.9', '%', 'i.v', '.', 'saline', ')', '.', 'Depressive', 'symptoms', 'were', 'measured', 'using', 'the', 'Montgomery', '-', 'Asberg', 'Depression', 'Rating', 'Scale', '(', 'MADRS', ')', 'and', 'the', 'Quick', 'Inventory', 'of', 'Depressive', 'Symptomatology', '-', 'Self', '-', 'Report', '(', 'QIDS', '-', 'SR', ')', '.', 'Suicidal', 'ideation', 'was', 'evaluated', 'with', 'the', 'QIDS', '-', 'SR', 'item', '12', '.', 'Adverse', 'psychopathological', 'effects', 'were', 'measured', 'with', 'the', 'Brief', 'Psychiatric', 'Rating', 'Scale', '(', 'BPRS)-positive', 'symptoms', ',', 'Young', 'Mania', 'Rating', 'Scale', '(', 'YMRS', ')', 'and', 'Clinician', 'Administered', 'Dissociative', 'States', 'Scale', '(', 'CADSS', ')', '.', 'Patients', 'were', 'assessed', 'at', 'baseline', ',', '1', ',', '2', ',', '4', ',', '24', 'and', '72', 'h', 'and', '7', ',', '14', ',', '21', 'and', '28', 'days', '.', 'Time', 'to', 'response', '(', '⩾', '50', '%', 'MADRS', 'score', 'reduction', ')', 'was', 'the', 'primary', 'outcome', '.', 'RESULTS', ':', 'By', '4', 'weeks', ',', 'more', 'escitalopram', '+', 'ketamine', '-', 'treated', 'than', 'escitalopram', '+', 'placebo', '-', 'treated', 'patients', 'responded', '(', '92.3', '%', 'v.', '57.1', '%', ',', 'p', '=', '0.04', ')', 'and', 'remitted', '(', '76.9', '%', 'v.', '14.3', '%', ',', 'p', '=', '0.001', ')', ',', 'with', 'significantly', 'shorter', 'time', 'to', 'response', '[', 'hazard', 'ratio', '(', 'HR', ')', '0.04', ',', '95', '%', 'confidence', 'interval', '(', 'CI', ')', '0.01', '-', '0.22', ',', 'p', '<', '0.001', ']', 'and', 'remission', '(', 'HR', '0.11', ',', '95', '%', 'CI', '0.02', '-', '0.63', ',', 'p', '=', '0.01', ')', '.', 'Compared', 'to', 'escitalopram', '+', 'placebo', ',', 'escitalopram', '+', 'ketamine', 'was', 'associated', 'with', 'significantly', 'lower', 'MADRS', 'scores', 'from', '2', 'h', 'to', '2', 'weeks', '[', '(', 'peak', '=', '3', 'days-2', 'weeks', ';', 'effect', 'size', '(', 'ES', ')', '=', '1.08', '-', '1.18', ')', ']', ',', 'QIDS', '-', 'SR', 'scores', 'from', '2', 'h', 'to', '2', 'weeks', '(', 'maximum', 'ES', '=', '1.27', ')', ',', 'and', 'QIDS', '-', 'SR', 'suicidality', 'from', '2', 'to', '72', 'h', '(', 'maximum', 'ES', '=', '2.24', ')', '.', 'Only', 'YMRS', 'scores', 'increased', 'significantly', 'with', 'ketamine', 'augmentation', '(', '1', 'and', '2', 'h', ')', ',', 'without', 'significant', 'BPRS', 'or', 'CADSS', 'elevation', '.', 'CONCLUSIONS', ':', 'Single', '-', 'dose', 'i.v', '.', 'ketamine', 'augmentation', 'of', 'escitalopram', 'was', 'safe', 'and', 'effective', 'in', 'severe', 'MDD', ',', 'holding', 'promise', 'for', 'speeding', 'up', 'early', 'oral', 'antidepressant', 'efficacy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3704,"['[CLS]', 'single', 'i', '.', 'v', '.', 'ketamine', 'augmentation', 'of', 'newly', 'initiated', 'esc', '##ital', '##opr', '##am', 'for', 'major', 'depression', ':', 'results', 'from', 'a', 'randomized', ',', 'placebo', '-', 'controlled', '4', '-', 'week', 'study', '.', '^', 'background', ':', 'while', 'oral', 'antidepressants', 'reach', 'efficacy', 'after', 'weeks', ',', 'single', '-', 'dose', 'intravenous', '(', 'i', '.', 'v', '.', ')', 'ketamine', 'has', 'rapid', ',', 'yet', 'time', '-', 'limited', 'antidepressant', 'effects', '.', 'we', 'aimed', 'to', 'determine', 'the', 'efficacy', 'and', 'safety', 'of', 'single', '-', 'dose', 'i', '.', 'v', '.', 'ketamine', 'augmentation', 'of', 'esc', '##ital', '##opr', '##am', 'in', 'major', 'depressive', 'disorder', '(', 'mdd', ')', '.', 'method', ':', 'thirty', 'outpatient', '##s', 'with', 'severe', 'mdd', '(', '17', '-', 'item', 'hamilton', 'rating', 'scale', 'for', 'depression', 'total', 'score', '[UNK]', '24', ')', 'were', 'randomized', 'to', '4', 'weeks', 'double', '-', 'blind', 'treatment', 'with', 'esc', '##ital', '##opr', '##am', '10', 'mg', '/', 'day', '+', 'single', '-', 'dose', 'i', '.', 'v', '.', 'ketamine', '(', '0', '.', '5', 'mg', '/', 'kg', 'over', '40', 'min', ')', 'or', 'esc', '##ital', '##opr', '##am', '10', 'mg', '/', 'day', '+', 'placebo', '(', '0', '.', '9', '%', 'i', '.', 'v', '.', 'saline', ')', '.', 'depressive', 'symptoms', 'were', 'measured', 'using', 'the', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', '(', 'mad', '##rs', ')', 'and', 'the', 'quick', 'inventory', 'of', 'depressive', 'symptom', '##atology', '-', 'self', '-', 'report', '(', 'qi', '##ds', '-', 'sr', ')', '.', 'suicidal', 'idea', '##tion', 'was', 'evaluated', 'with', 'the', 'qi', '##ds', '-', 'sr', 'item', '12', '.', 'adverse', 'psycho', '##path', '##ological', 'effects', 'were', 'measured', 'with', 'the', 'brief', 'psychiatric', 'rating', 'scale', '(', 'bp', '##rs', ')', '-', 'positive', 'symptoms', ',', 'young', 'man', '##ia', 'rating', 'scale', '(', 'ym', '##rs', ')', 'and', 'clinician', 'administered', 'dissoci', '##ative', 'states', 'scale', '(', 'cad', '##ss', ')', '.', 'patients', 'were', 'assessed', 'at', 'baseline', ',', '1', ',', '2', ',', '4', ',', '24', 'and', '72', 'h', 'and', '7', ',', '14', ',', '21', 'and', '28', 'days', '.', 'time', 'to', 'response', '(', '[UNK]', '50', '%', 'mad', '##rs', 'score', 'reduction', ')', 'was', 'the', 'primary', 'outcome', '.', 'results', ':', 'by', '4', 'weeks', ',', 'more', 'esc', '##ital', '##opr', '##am', '+', 'ketamine', '-', 'treated', 'than', 'esc', '##ital', '##opr', '##am', '+', 'placebo', '-', 'treated', 'patients', 'responded', '(', '92', '.', '3', '%', 'v', '.', '57', '.', '1', '%', ',', 'p', '=', '0', '.', '04', ')', 'and', 'rem', '##itt', '##ed', '(', '76', '.', '9', '%', 'v', '.', '14', '.', '3', '%', ',', 'p', '=', '0', '.', '00', '##1', ')', ',', 'with', 'significantly', 'shorter', 'time', 'to', 'response', '[', 'hazard', 'ratio', '(', 'hr', ')', '0', '.', '04', ',', '95', '%', 'confidence', 'interval', '(', 'ci', ')', '0', '.', '01', '-', '0', '.', '22', ',', 'p', '<', '0', '.', '00', '##1', ']', 'and', 'remission', '(', 'hr', '0', '.', '11', ',', '95', '%', 'ci', '0', '.', '02', '-', '0', '.', '63', ',', 'p', '=', '0', '.', '01', ')', '.', 'compared', 'to', 'esc', '##ital', '##opr', '##am', '+', 'placebo', ',', 'esc', '##ital', '##opr', '##am', '+', 'ketamine', 'was', 'associated', 'with', 'significantly', 'lower', 'mad', '##rs', 'scores', 'from', '2', 'h', 'to', '2', 'weeks', '[', '(', 'peak', '=', '3', 'days', '-', '2', 'weeks', ';', 'effect', 'size', '(', 'es', ')', '=', '1', '.', '08', '-', '1', '.', '18', ')', ']', ',', 'qi', '##ds', '-', 'sr', 'scores', 'from', '2', 'h', '[SEP]']","[None, 0, 1, 1, 1, 2, 3, 4, 5, 6, 7, 8, 8, 8, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 24, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 41, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 67, 67, 68, 69, 70, 71, 72, 72, 72, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 112, 112, 112, 113, 114, 115, 116, 116, 116, 117, 118, 119, 119, 119, 120, 121, 122, 123, 123, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 132, 132, 132, 133, 134, 135, 136, 137, 138, 139, 140, 140, 140, 141, 142, 142, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 153, 153, 153, 154, 155, 155, 156, 157, 158, 159, 160, 160, 161, 162, 163, 164, 165, 166, 167, 168, 168, 169, 170, 171, 172, 173, 174, 174, 175, 176, 177, 178, 179, 180, 180, 181, 182, 183, 184, 185, 185, 186, 187, 188, 189, 190, 191, 192, 192, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 203, 203, 203, 203, 204, 205, 206, 207, 207, 208, 209, 210, 211, 211, 212, 213, 214, 215, 216, 216, 217, 218, 219, 220, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 272, 272, 272, 273, 274, 275, 276, 277, 278, 278, 278, 278, 279, 280, 281, 282, 283, 284, 285, 286, 286, 286, 287, 288, 288, 289, 289, 289, 290, 291, 292, 293, 294, 294, 294, 295, 296, 297, 297, 297, 298, 299, 299, 299, 300, 301, 301, 302, 302, 302, 303, 304, 305, 306, 307, 307, 307, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 322, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 331, 331, 332, 333, 333, 333, 334, 335, 336, 337, 337, 337, 337, 338, 339, 340, 341, 342, 343, 343, 343, 344, 345, 346, 347, 348, 348, 348, 349, 350, 350, 350, 351, 352, 353, 354, 354, 354, 355, 356, 357, 358, 359, 359, 359, 359, 360, 361, 362, 363, 363, 363, 363, 364, 365, 366, 367, 368, 369, 370, 371, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 384, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 393, 393, 394, 395, 395, 395, 396, 397, 398, 399, 399, 400, 401, 402, 403, 404, 405, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.^
BACKGROUND: While oral antidepressants reach efficacy after weeks, single-dose intravenous (i.v.) ketamine has rapid, yet time-limited antidepressant effects. We aimed to determine the efficacy and safety of single-dose i.v. ketamine augmentation of escitalopram in major depressive disorder (MDD). METHOD: Thirty outpatients with severe MDD (17-item Hamilton Rating Scale for Depression total score ⩾ 24) were randomized to 4 weeks double-blind treatment with escitalopram 10 mg/day+single-dose i.v. ketamine (0.5 mg/kg over 40 min) or escitalopram 10 mg/day + placebo (0.9% i.v. saline). Depressive symptoms were measured using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR). Suicidal ideation was evaluated with the QIDS-SR item 12. Adverse psychopathological effects were measured with the Brief Psychiatric Rating Scale (BPRS)-positive symptoms, Young Mania Rating Scale (YMRS) and Clinician Administered Dissociative States Scale (CADSS). Patients were assessed at baseline, 1, 2, 4, 24 and 72 h and 7, 14, 21 and 28 days. Time to response (⩾ 50% MADRS score reduction) was the primary outcome. RESULTS: By 4 weeks, more escitalopram + ketamine-treated than escitalopram + placebo-treated patients responded (92.3% v. 57.1%, p = 0.04) and remitted (76.9% v. 14.3%, p = 0.001), with significantly shorter time to response [hazard ratio (HR) 0.04, 95% confidence interval (CI) 0.01-0.22, p < 0.001] and remission (HR 0.11, 95% CI 0.02-0.63, p = 0.01). Compared to escitalopram + placebo, escitalopram + ketamine was associated with significantly lower MADRS scores from 2 h to 2 weeks [(peak = 3 days-2 weeks; effect size (ES) = 1.08-1.18)], QIDS-SR scores from 2 h to 2 weeks (maximum ES = 1.27), and QIDS-SR suicidality from 2 to 72 h (maximum ES = 2.24). Only YMRS scores increased significantly with ketamine augmentation (1 and 2 h), without significant BPRS or CADSS elevation. CONCLUSIONS: Single-dose i.v. ketamine augmentation of escitalopram was safe and effective in severe MDD, holding promise for speeding up early oral antidepressant efficacy."
"['Neuropsychological', 'and', 'mood', 'effects', 'of', 'ketamine', 'in', 'electroconvulsive', 'therapy', ':', 'a', 'randomised', 'controlled', 'trial.^', '\n', 'BACKGROUND', ':', 'Preliminary', 'evidence', 'suggests', 'that', 'the', 'use', 'of', 'ketamine', 'during', 'electroconvulsive', 'therapy', '(', 'ECT', ')', 'may', 'be', 'neuroprotective', 'against', 'cognitive', 'impairment', 'and', 'have', 'synergistic', 'antidepressant', 'effects', '.', 'This', 'study', 'tested', 'whether', 'the', 'addition', 'of', 'ketamine', 'reduced', 'cognitive', 'impairment', 'and', 'enhanced', 'efficacy', 'over', 'a', 'course', 'of', 'ECT', ',', 'in', 'a', 'randomised', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', 'study', '.', 'METHODS', ':', 'Fifty', '-', 'one', 'depressed', 'patients', 'treated', 'with', 'ultrabrief', 'pulse', '-', 'width', 'right', 'unilateral', 'ECT', 'were', 'randomised', 'to', 'receive', 'either', 'ketamine', '(', '0.5mg', '/', 'kg', ')', 'or', 'placebo', '(', 'saline', ')', 'in', 'addition', 'to', 'thiopentone', 'during', 'anaesthesia', 'for', 'ECT', '.', 'Neuropsychological', 'outcomes', '(', 'measured', 'before', 'ECT', ',', 'after', 'six', 'treatments', ',', 'and', 'after', 'the', 'final', 'ECT', 'treatment', ')', 'and', 'mood', 'outcomes', '(', 'measured', 'before', 'ECT', ',', 'and', 'weekly', 'after', 'every', 'three', 'ECT', 'treatments', ')', 'were', 'measured', 'by', 'a', 'rater', 'blinded', 'to', 'treatment', 'condition', '.', 'RESULTS', ':', 'Neuropsychological', 'outcomes', 'did', 'not', 'differ', 'between', 'groups', '.', 'The', 'ECT', '-', 'ketamine', 'group', 'had', 'a', 'slightly', 'greater', 'improvement', 'in', 'depressive', 'symptoms', 'over', 'the', 'first', 'week', 'of', 'treatment', 'and', 'at', 'one', '-', 'week', 'follow', 'up', ',', 'though', 'there', 'was', 'no', 'overall', 'difference', 'in', 'efficacy', 'at', 'the', 'end', 'of', 'the', 'ECT', 'course', '.', 'No', 'psychomimetic', 'effects', 'were', 'detected', '.', 'LIMITATIONS', ':', 'The', 'study', 'was', 'conducted', 'in', 'a', 'clinical', 'setting', ',', 'so', 'not', 'all', 'aspects', 'of', 'ECT', 'treatment', 'were', 'fully', 'controlled', '.', 'Thiopentone', 'doses', 'differed', 'slightly', 'between', 'groups', ',', 'in', 'order', 'to', 'accommodate', 'the', 'addition', 'of', 'ketamine', 'to', 'the', 'anaesthetic', '.', 'CONCLUSIONS', ':', 'The', 'addition', 'of', 'ketamine', 'did', 'not', 'decrease', 'cognitive', 'impairment', 'in', 'patients', 'having', 'ultrabrief', 'pulse', '-', 'width', 'right', 'unilateral', 'ECT', ',', 'but', 'was', 'safe', 'and', 'slightly', 'improved', 'efficacy', 'in', 'the', 'first', 'week', 'of', 'treatment', 'and', 'at', 'one', '-', 'week', 'follow', 'up', '.', 'CLINICAL', 'TRIALS', 'REGISTRATION', ':', 'Clinicaltrials.gov', 'ID', ':', 'NCT00680433', '.', 'Ketamine', 'as', 'an', 'anaesthetic', 'agent', 'in', 'electroconvulsive', 'therapy', '(', 'ECT', ')', '.', 'www.clinicaltrials.gov', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5082,"['[CLS]', 'neuropsych', '##ological', 'and', 'mood', 'effects', 'of', 'ketamine', 'in', 'electro', '##con', '##v', '##ulsive', 'therapy', ':', 'a', 'randomised', 'controlled', 'trial', '.', '^', 'background', ':', 'preliminary', 'evidence', 'suggests', 'that', 'the', 'use', 'of', 'ketamine', 'during', 'electro', '##con', '##v', '##ulsive', 'therapy', '(', 'ect', ')', 'may', 'be', 'neuroprotective', 'against', 'cognitive', 'impairment', 'and', 'have', 'synergistic', 'antidepressant', 'effects', '.', 'this', 'study', 'tested', 'whether', 'the', 'addition', 'of', 'ketamine', 'reduced', 'cognitive', 'impairment', 'and', 'enhanced', 'efficacy', 'over', 'a', 'course', 'of', 'ect', ',', 'in', 'a', 'randomised', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', 'study', '.', 'methods', ':', 'fifty', '-', 'one', 'depressed', 'patients', 'treated', 'with', 'ultra', '##bri', '##ef', 'pulse', '-', 'width', 'right', 'unilateral', 'ect', 'were', 'randomised', 'to', 'receive', 'either', 'ketamine', '(', '0', '.', '5', '##mg', '/', 'kg', ')', 'or', 'placebo', '(', 'saline', ')', 'in', 'addition', 'to', 'thio', '##pent', '##one', 'during', 'anaesthesia', 'for', 'ect', '.', 'neuropsych', '##ological', 'outcomes', '(', 'measured', 'before', 'ect', ',', 'after', 'six', 'treatments', ',', 'and', 'after', 'the', 'final', 'ect', 'treatment', ')', 'and', 'mood', 'outcomes', '(', 'measured', 'before', 'ect', ',', 'and', 'weekly', 'after', 'every', 'three', 'ect', 'treatments', ')', 'were', 'measured', 'by', 'a', 'rate', '##r', 'blinded', 'to', 'treatment', 'condition', '.', 'results', ':', 'neuropsych', '##ological', 'outcomes', 'did', 'not', 'differ', 'between', 'groups', '.', 'the', 'ect', '-', 'ketamine', 'group', 'had', 'a', 'slightly', 'greater', 'improvement', 'in', 'depressive', 'symptoms', 'over', 'the', 'first', 'week', 'of', 'treatment', 'and', 'at', 'one', '-', 'week', 'follow', 'up', ',', 'though', 'there', 'was', 'no', 'overall', 'difference', 'in', 'efficacy', 'at', 'the', 'end', 'of', 'the', 'ect', 'course', '.', 'no', 'psycho', '##mim', '##etic', 'effects', 'were', 'detected', '.', 'limitations', ':', 'the', 'study', 'was', 'conducted', 'in', 'a', 'clinical', 'setting', ',', 'so', 'not', 'all', 'aspects', 'of', 'ect', 'treatment', 'were', 'fully', 'controlled', '.', 'thio', '##pent', '##one', 'doses', 'differed', 'slightly', 'between', 'groups', ',', 'in', 'order', 'to', 'accommodate', 'the', 'addition', 'of', 'ketamine', 'to', 'the', 'anaesthe', '##tic', '.', 'conclusions', ':', 'the', 'addition', 'of', 'ketamine', 'did', 'not', 'decrease', 'cognitive', 'impairment', 'in', 'patients', 'having', 'ultra', '##bri', '##ef', 'pulse', '-', 'width', 'right', 'unilateral', 'ect', ',', 'but', 'was', 'safe', 'and', 'slightly', 'improved', 'efficacy', 'in', 'the', 'first', 'week', 'of', 'treatment', 'and', 'at', 'one', '-', 'week', 'follow', 'up', '.', 'clinical', 'trials', 'registration', ':', 'clinical', '##trials', '.', 'go', '##v', 'id', ':', 'nct', '##006', '##80', '##43', '##3', '.', 'ketamine', 'as', 'an', 'anaesthe', '##tic', 'agent', 'in', 'electro', '##con', '##v', '##ulsive', 'therapy', '(', 'ect', ')', '.', 'www', '.', 'clinical', '##trials', '.', 'go', '##v', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 1, 2, 3, 4, 5, 6, 7, 7, 7, 7, 8, 9, 10, 11, 12, 13, 13, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 26, 26, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99, 99, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 111, 111, 112, 113, 114, 115, 116, 117, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 156, 157, 158, 159, 160, 161, 162, 163, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 215, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 242, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 275, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 308, 308, 308, 308, 309, 310, 311, 311, 311, 311, 311, 312, 313, 314, 315, 316, 316, 317, 318, 319, 319, 319, 319, 320, 321, 322, 323, 324, 325, 325, 325, 325, 325, 325, 325, 326, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.^
BACKGROUND: Preliminary evidence suggests that the use of ketamine during electroconvulsive therapy (ECT) may be neuroprotective against cognitive impairment and have synergistic antidepressant effects. This study tested whether the addition of ketamine reduced cognitive impairment and enhanced efficacy over a course of ECT, in a randomised, placebo-controlled, double-blind study. METHODS: Fifty-one depressed patients treated with ultrabrief pulse-width right unilateral ECT were randomised to receive either ketamine (0.5mg/kg) or placebo (saline) in addition to thiopentone during anaesthesia for ECT. Neuropsychological outcomes (measured before ECT, after six treatments, and after the final ECT treatment) and mood outcomes (measured before ECT, and weekly after every three ECT treatments) were measured by a rater blinded to treatment condition. RESULTS: Neuropsychological outcomes did not differ between groups. The ECT-ketamine group had a slightly greater improvement in depressive symptoms over the first week of treatment and at one-week follow up, though there was no overall difference in efficacy at the end of the ECT course. No psychomimetic effects were detected. LIMITATIONS: The study was conducted in a clinical setting, so not all aspects of ECT treatment were fully controlled. Thiopentone doses differed slightly between groups, in order to accommodate the addition of ketamine to the anaesthetic. CONCLUSIONS: The addition of ketamine did not decrease cognitive impairment in patients having ultrabrief pulse-width right unilateral ECT, but was safe and slightly improved efficacy in the first week of treatment and at one-week follow up. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov ID: NCT00680433. Ketamine as an anaesthetic agent in electroconvulsive therapy (ECT). www.clinicaltrials.gov."
"['Differential', 'ketamine', 'effects', 'on', 'clinical', ',', 'behavioral', 'and', 'brain', 'function', 'outcome', 'measures', ':', 'a', 'simultaneous', 'fmri', '/', 'eeg', 'study.^', '\n', 'Background', ':', 'Various', 'ketamine', 'models', 'of', 'schizophrenia', 'are', 'used', 'for', 'testing', 'novel', 'compounds', '.', 'Questions', 'remain', 'whether', 'electrophysiological', 'and', 'functional', 'imaging', 'outcome', 'measures', 'offer', 'any', 'advantages', 'compared', 'to', 'clinical', 'and', 'behavioral', 'measures', 'in', 'the', 'context', 'of', 'drug', 'trials', '.', 'Here', 'we', 'tested', 'whether', 'a', 'possible', 'confounder', 'of', 'ketamine', 'action', ',', 'the', 'physiological', 'stress', 'response', ',', 'differentially', 'affects', 'these', 'outcome', 'measures', '.', 'Methods', ':', 'Randomized', ',', 'cross‐over', ',', 'placebo‐controlled', 'pharmaimaging', 'study', 'in', '24', 'male', 'volunteers', '.', 'Low‐dose', 'S‐ketamine', '(', 'bolus', 'prior', 'to', 'functional', 'imaging', ':', '0.1', 'mg', '/', 'kg', 'during', '5', 'min', ',', 'thereafter', 'continuous', 'infusion', ':', '0.0156', 'mg', '/', 'kg', '/', 'min', 'reduced', 'by', '10', '%', 'every', 'ten', 'minutes', ')', 'or', 'placebo', 'was', 'administered', 'while', 'performing', 'a', 'visual', 'oddball', 'reaction', 'time', 'task', 'during', 'fMRI', 'with', 'simultaneous', 'recording', 'of', 'event‐related', 'potentials', '(', 'P300', ')', 'and', 'surrogate', 'endpoint', 'measures', 'of', 'the', 'physiological', 'stress', 'response', ':', 'electrodermal', 'activity', '(', 'EDA', ')', 'and', 'heart', 'rate', '.', 'Pre‐post', 'imaging', 'psychopathological', 'status', 'was', 'assessed', 'using', 'the', 'PANSS', 'scale', '.', 'Results', ':', 'Comparable', 'separation', 'of', 'drug', 'conditions', 'was', 'achieved', 'with', 'area', 'under', 'the', 'curve', '(', 'AUC', ')', 'values', 'of', '0.8‐1.0', 'in', 'the', 'clinical', '(', 'PANSS', ')', ',', 'behavioral', '(', 'reaction', 'hit', 'and', 'false', 'alarm', 'rate', ')', ',', 'peripheral', 'physiological', '(', 'EDA', ',', 'heart', 'rate', ')', ',', 'electrophyiological', '(', 'P300', ')', 'and', 'fMRI', '(', 'ROIs', ')', 'domains', '.', 'Analysis', 'of', 'multivariate', 'covariance', 'structure', 'revealed', 'that', 'clinical', '/', 'behavioral', 'but', 'not', 'EEG', '/', 'fMRI', 'AUC', 'residuals', 'are', 'dramatically', 'affected', 'by', 'stress', 'parameters', '(', 'heart', 'rate', ',', 'EDA', ')', '.', 'Conclusions', ':', 'Our', 'ketamine', 'experiment', 'provides', 'an', 'instructive', 'example', 'how', 'functional', 'imaging', 'and', 'electrophysiology', 'can', 'aid', 'the', 'dissection', 'of', 'partial', 'drug', 'effects', '.', 'These', 'partial', 'effects', 'can', 'be', 'confounders', 'leading', 'to', 'wrong', 'decisions', 'in', 'the', 'process', 'of', 'drug', 'development', 'when', 'exclusively', 'relying', 'on', 'clinical', '/', 'behavioral', 'outcome', 'measures', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",9225,"['[CLS]', 'differential', 'ketamine', 'effects', 'on', 'clinical', ',', 'behavioral', 'and', 'brain', 'function', 'outcome', 'measures', ':', 'a', 'simultaneous', 'fmri', '/', 'eeg', 'study', '.', '^', 'background', ':', 'various', 'ketamine', 'models', 'of', 'schizophrenia', 'are', 'used', 'for', 'testing', 'novel', 'compounds', '.', 'questions', 'remain', 'whether', 'electroph', '##ysiological', 'and', 'functional', 'imaging', 'outcome', 'measures', 'offer', 'any', 'advantages', 'compared', 'to', 'clinical', 'and', 'behavioral', 'measures', 'in', 'the', 'context', 'of', 'drug', 'trials', '.', 'here', 'we', 'tested', 'whether', 'a', 'possible', 'confound', '##er', 'of', 'ketamine', 'action', ',', 'the', 'physiological', 'stress', 'response', ',', 'differentially', 'affects', 'these', 'outcome', 'measures', '.', 'methods', ':', 'randomized', ',', 'cross', '‐', 'over', ',', 'placebo', '‐', 'controlled', 'pharma', '##imaging', 'study', 'in', '24', 'male', 'volunteers', '.', 'low', '‐', 'dose', 's', '‐', 'ketamine', '(', 'bolus', 'prior', 'to', 'functional', 'imaging', ':', '0', '.', '1', 'mg', '/', 'kg', 'during', '5', 'min', ',', 'thereafter', 'continuous', 'infusion', ':', '0', '.', '01', '##56', 'mg', '/', 'kg', '/', 'min', 'reduced', 'by', '10', '%', 'every', 'ten', 'minutes', ')', 'or', 'placebo', 'was', 'administered', 'while', 'performing', 'a', 'visual', 'odd', '##ball', 'reaction', 'time', 'task', 'during', 'fmri', 'with', 'simultaneous', 'recording', 'of', 'event', '‐', 'related', 'potentials', '(', 'p', '##300', ')', 'and', 'surrogate', 'endpoint', 'measures', 'of', 'the', 'physiological', 'stress', 'response', ':', 'electrode', '##rm', '##al', 'activity', '(', 'ed', '##a', ')', 'and', 'heart', 'rate', '.', 'pre', '‐', 'post', 'imaging', 'psycho', '##path', '##ological', 'status', 'was', 'assessed', 'using', 'the', 'pan', '##ss', 'scale', '.', 'results', ':', 'comparable', 'separation', 'of', 'drug', 'conditions', 'was', 'achieved', 'with', 'area', 'under', 'the', 'curve', '(', 'auc', ')', 'values', 'of', '0', '.', '8', '‐', '1', '.', '0', 'in', 'the', 'clinical', '(', 'pan', '##ss', ')', ',', 'behavioral', '(', 'reaction', 'hit', 'and', 'false', 'alarm', 'rate', ')', ',', 'peripheral', 'physiological', '(', 'ed', '##a', ',', 'heart', 'rate', ')', ',', 'electroph', '##yi', '##ological', '(', 'p', '##300', ')', 'and', 'fmri', '(', 'rois', ')', 'domains', '.', 'analysis', 'of', 'multivariate', 'covariance', 'structure', 'revealed', 'that', 'clinical', '/', 'behavioral', 'but', 'not', 'eeg', '/', 'fmri', 'auc', 'residuals', 'are', 'dramatically', 'affected', 'by', 'stress', 'parameters', '(', 'heart', 'rate', ',', 'ed', '##a', ')', '.', 'conclusions', ':', 'our', 'ketamine', 'experiment', 'provides', 'an', 'instruc', '##tive', 'example', 'how', 'functional', 'imaging', 'and', 'electroph', '##ysiology', 'can', 'aid', 'the', 'dissection', 'of', 'partial', 'drug', 'effects', '.', 'these', 'partial', 'effects', 'can', 'be', 'confounders', 'leading', 'to', 'wrong', 'decisions', 'in', 'the', 'process', 'of', 'drug', 'development', 'when', 'exclusively', 'relying', 'on', 'clinical', '/', 'behavioral', 'outcome', 'measures', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 85, 86, 87, 87, 87, 88, 88, 89, 90, 91, 92, 93, 94, 95, 95, 95, 96, 96, 96, 97, 98, 99, 100, 101, 102, 103, 104, 104, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 116, 116, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 148, 148, 149, 150, 151, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 163, 163, 164, 165, 166, 166, 167, 168, 169, 170, 171, 172, 172, 172, 173, 174, 174, 174, 175, 176, 177, 178, 179, 180, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 202, 202, 202, 202, 202, 202, 203, 204, 205, 206, 207, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 223, 224, 225, 226, 227, 228, 229, 229, 229, 230, 231, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 277, 278, 279, 280, 281, 282, 283, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Differential ketamine effects on clinical, behavioral and brain function outcome measures: a simultaneous fmri/eeg study.^
Background: Various ketamine models of schizophrenia are used for testing novel compounds. Questions remain whether electrophysiological and functional imaging outcome measures offer any advantages compared to clinical and behavioral measures in the context of drug trials. Here we tested whether a possible confounder of ketamine action, the physiological stress response, differentially affects these outcome measures. Methods: Randomized, cross‐over, placebo‐controlled pharmaimaging study in 24 male volunteers. Low‐dose S‐ketamine (bolus prior to functional imaging: 0.1 mg/kg during 5 min, thereafter continuous infusion: 0.0156 mg/kg/min reduced by 10% every ten minutes) or placebo was administered while performing a visual oddball reaction time task during fMRI with simultaneous recording of event‐related potentials (P300) and surrogate endpoint measures of the physiological stress response: electrodermal activity (EDA) and heart rate. Pre‐post imaging psychopathological status was assessed using the PANSS scale. Results: Comparable separation of drug conditions was achieved with area under the curve (AUC) values of 0.8‐1.0 in the clinical (PANSS), behavioral (reaction hit and false alarm rate), peripheral physiological (EDA, heart rate), electrophyiological (P300) and fMRI (ROIs) domains. Analysis of multivariate covariance structure revealed that clinical/behavioral but not EEG/fMRI AUC residuals are dramatically affected by stress parameters (heart rate, EDA). Conclusions: Our ketamine experiment provides an instructive example how functional imaging and electrophysiology can aid the dissection of partial drug effects. These partial effects can be confounders leading to wrong decisions in the process of drug development when exclusively relying on clinical/behavioral outcome measures."
"['Happiness', 'During', 'Low', '-', 'Dose', 'Ketamine', 'Infusion', 'Predicts', 'Treatment', 'Response', ':', 'Reexploring', 'the', 'Adjunctive', 'Ketamine', 'Study', 'of', 'Taiwanese', 'Patients', 'With', 'Treatment', '-', 'Resistant', 'Depression.^', '\n', 'BACKGROUND', ':', 'Studies', 'have', 'reported', 'that', 'ketamine', 'potentially', 'increases', 'subjective', 'happiness', 'in', 'healthy', 'volunteers', '.', 'However', ',', 'whether', 'ketamine', '-', 'induced', 'happiness', 'can', 'predict', 'the', 'treatment', 'response', 'of', 'ketamine', 'infusion', 'among', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', 'remains', 'unknown', '.', 'METHODS', ':', 'Between', '2012', 'and', '2015', ',', '71', 'adult', 'patients', 'with', 'TRD', '(', 'based', 'on', 'DSM', '-', 'IV', '-', 'TR', 'criteria', ')', 'were', 'enrolled', 'and', 'randomly', 'assigned', 'to', 'receive', 'a', '40', '-', 'minute', 'ketamine', '(', '0.5', 'mg', '/', 'kg', 'or', '0.2', 'mg', '/', 'kg', ')', 'or', 'normal', 'saline', 'placebo', 'infusion', '.', 'Depressive', 'symptoms', 'were', 'measured', 'using', 'the', '17', '-', 'item', 'Hamilton', 'Depression', 'Rating', 'Scale', '.', 'Measurements', 'were', 'conducted', 'prior', 'to', 'infusion', ',', 'at', '40', 'and', '240', 'minutes', 'postinfusion', ',', 'and', ',', 'sequentially', ',', 'on', 'days', '2', 'to', '7', 'and', '14', 'postinfusion', '.', 'The', 'visual', 'analog', 'scale', 'for', 'happiness', '(', 'VASH', ')', 'was', 'used', 'to', 'assess', 'happiness', 'during', 'infusion', '.', 'The', 'positive', 'symptoms', 'subscale', 'of', 'the', 'Brief', 'Psychiatric', 'Rating', 'Scale', '(', 'BPRS', '-', 'P', ')', 'was', 'used', 'to', 'measure', 'the', 'potential', 'psychotomimetic', 'effects', 'of', 'ketamine', '.', 'RESULTS', ':', 'For', 'both', 'the', '2', '-', 'factor', '(', 'ketamine', 'vs', 'placebo', ')', 'and', '3', '-', 'factor', '(', 'ketamine', '0.5', 'mg', '/', 'kg', 'vs', '0.2', 'mg', '/', 'kg', 'vs', 'placebo', ')', 'models', ',', 'a', 'generalized', 'estimating', 'equation', 'model', 'indicated', 'that', 'infusion', 'response', 'type', '(', 'happiness', 'vs', 'nonhappiness', ')', 'significantly', '(', 'P', '=', '.008', 'vs', 'P', '=', '.002', ')', 'predicted', 'the', 'trajectory', 'of', 'depressive', 'symptoms', 'after', 'infusion', '.', 'Changes', 'in', 'VASH', 'and', 'BPRS', '-', 'P', 'measures', 'were', 'not', 'associated', 'with', 'each', 'other', '.', 'CONCLUSIONS', ':', 'Subjective', 'happiness', 'during', 'ketamine', 'infusion', 'predicted', 'the', 'antidepressant', 'effect', 'of', 'both', '0.5', 'mg', '/', 'kg', 'and', '0.2', 'mg', '/', 'kg', 'ketamine', 'infusion', 'over', 'time', '.', 'Happiness', 'during', 'ketamine', 'infusion', ',', 'which', 'was', 'not', 'related', 'to', 'the', 'psychotomimetic', 'effect', 'of', 'ketamine', ',', 'may', 'be', 'associated', 'with', 'the', 'reduction', 'of', 'depressive', 'symptoms', 'during', 'the', 'follow', '-', 'up', '.', 'TRIAL', 'REGISTRATION', ':', 'UMIN', 'Clinical', 'Trials', 'Registry', 'registration', 'number', ':', 'UMIN000016985', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1443,"['[CLS]', 'happiness', 'during', 'low', '-', 'dose', 'ketamine', 'infusion', 'predicts', 'treatment', 'response', ':', 'ree', '##xp', '##lor', '##ing', 'the', 'adjunct', '##ive', 'ketamine', 'study', 'of', 'taiwan', '##ese', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '.', '^', 'background', ':', 'studies', 'have', 'reported', 'that', 'ketamine', 'potentially', 'increases', 'subjective', 'happiness', 'in', 'healthy', 'volunteers', '.', 'however', ',', 'whether', 'ketamine', '-', 'induced', 'happiness', 'can', 'predict', 'the', 'treatment', 'response', 'of', 'ketamine', 'infusion', 'among', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', 'remains', 'unknown', '.', 'methods', ':', 'between', '2012', 'and', '2015', ',', '71', 'adult', 'patients', 'with', 'tr', '##d', '(', 'based', 'on', 'dsm', '-', 'iv', '-', 'tr', 'criteria', ')', 'were', 'enrolled', 'and', 'randomly', 'assigned', 'to', 'receive', 'a', '40', '-', 'minute', 'ketamine', '(', '0', '.', '5', 'mg', '/', 'kg', 'or', '0', '.', '2', 'mg', '/', 'kg', ')', 'or', 'normal', 'saline', 'placebo', 'infusion', '.', 'depressive', 'symptoms', 'were', 'measured', 'using', 'the', '17', '-', 'item', 'hamilton', 'depression', 'rating', 'scale', '.', 'measurements', 'were', 'conducted', 'prior', 'to', 'infusion', ',', 'at', '40', 'and', '240', 'minutes', 'post', '##inf', '##usion', ',', 'and', ',', 'sequentially', ',', 'on', 'days', '2', 'to', '7', 'and', '14', 'post', '##inf', '##usion', '.', 'the', 'visual', 'analog', 'scale', 'for', 'happiness', '(', 'vas', '##h', ')', 'was', 'used', 'to', 'assess', 'happiness', 'during', 'infusion', '.', 'the', 'positive', 'symptoms', 'subscale', 'of', 'the', 'brief', 'psychiatric', 'rating', 'scale', '(', 'bp', '##rs', '-', 'p', ')', 'was', 'used', 'to', 'measure', 'the', 'potential', 'psycho', '##tom', '##ime', '##tic', 'effects', 'of', 'ketamine', '.', 'results', ':', 'for', 'both', 'the', '2', '-', 'factor', '(', 'ketamine', 'vs', 'placebo', ')', 'and', '3', '-', 'factor', '(', 'ketamine', '0', '.', '5', 'mg', '/', 'kg', 'vs', '0', '.', '2', 'mg', '/', 'kg', 'vs', 'placebo', ')', 'models', ',', 'a', 'generalized', 'estimating', 'equation', 'model', 'indicated', 'that', 'infusion', 'response', 'type', '(', 'happiness', 'vs', 'non', '##ha', '##ppi', '##ness', ')', 'significantly', '(', 'p', '=', '.', '00', '##8', 'vs', 'p', '=', '.', '00', '##2', ')', 'predicted', 'the', 'trajectory', 'of', 'depressive', 'symptoms', 'after', 'infusion', '.', 'changes', 'in', 'vas', '##h', 'and', 'bp', '##rs', '-', 'p', 'measures', 'were', 'not', 'associated', 'with', 'each', 'other', '.', 'conclusions', ':', 'subjective', 'happiness', 'during', 'ketamine', 'infusion', 'predicted', 'the', 'antidepressant', 'effect', 'of', 'both', '0', '.', '5', 'mg', '/', 'kg', 'and', '0', '.', '2', 'mg', '/', 'kg', 'ketamine', 'infusion', 'over', 'time', '.', 'happiness', 'during', 'ketamine', 'infusion', ',', 'which', 'was', 'not', 'related', 'to', 'the', 'psycho', '##tom', '##ime', '##tic', 'effect', 'of', 'ketamine', ',', 'may', 'be', 'associated', 'with', 'the', 'reduction', 'of', 'depressive', 'symptoms', 'during', 'the', 'follow', '-', 'up', '.', 'trial', 'registration', ':', 'um', '##in', 'clinical', 'trials', 'registry', 'registration', 'number', ':', 'um', '##in', '##0000', '##169', '##85', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11, 11, 11, 12, 13, 13, 14, 15, 16, 17, 17, 18, 19, 20, 21, 22, 23, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 103, 103, 104, 105, 106, 107, 108, 108, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 145, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 158, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 198, 198, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 222, 222, 223, 224, 225, 226, 227, 227, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 249, 249, 249, 250, 251, 252, 253, 254, 255, 255, 255, 256, 257, 258, 259, 259, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 272, 273, 274, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 298, 298, 299, 300, 301, 302, 303, 303, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 323, 323, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 346, 347, 348, 349, 350, 351, 352, 353, 353, 353, 353, 353, 354, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Happiness During Low-Dose Ketamine Infusion Predicts Treatment Response: Reexploring the Adjunctive Ketamine Study of Taiwanese Patients With Treatment-Resistant Depression.^
BACKGROUND: Studies have reported that ketamine potentially increases subjective happiness in healthy volunteers. However, whether ketamine-induced happiness can predict the treatment response of ketamine infusion among patients with treatment-resistant depression (TRD) remains unknown. METHODS: Between 2012 and 2015, 71 adult patients with TRD (based on DSM-IV-TR criteria) were enrolled and randomly assigned to receive a 40-minute ketamine (0.5 mg/kg or 0.2 mg/kg) or normal saline placebo infusion. Depressive symptoms were measured using the 17-item Hamilton Depression Rating Scale. Measurements were conducted prior to infusion, at 40 and 240 minutes postinfusion, and, sequentially, on days 2 to 7 and 14 postinfusion. The visual analog scale for happiness (VASH) was used to assess happiness during infusion. The positive symptoms subscale of the Brief Psychiatric Rating Scale (BPRS-P) was used to measure the potential psychotomimetic effects of ketamine. RESULTS: For both the 2-factor (ketamine vs placebo) and 3-factor (ketamine 0.5 mg/kg vs 0.2 mg/kg vs placebo) models, a generalized estimating equation model indicated that infusion response type (happiness vs nonhappiness) significantly (P = .008 vs P = .002) predicted the trajectory of depressive symptoms after infusion. Changes in VASH and BPRS-P measures were not associated with each other. CONCLUSIONS: Subjective happiness during ketamine infusion predicted the antidepressant effect of both 0.5 mg/kg and 0.2 mg/kg ketamine infusion over time. Happiness during ketamine infusion, which was not related to the psychotomimetic effect of ketamine, may be associated with the reduction of depressive symptoms during the follow-up. TRIAL REGISTRATION: UMIN Clinical Trials Registry registration number: UMIN000016985."
"['Potential', 'advantages', 'of', 'ketamine', 'over', 'electroconvulsive', 'therapy', 'in', 'the', 'treatment', 'of', 'nonrefractory', 'severe', 'depression', 'in', 'older', 'patients', 'with', 'multiple', 'medical', 'comorbidities.^', '\n', 'Depression', 'in', 'older', 'adults', 'with', 'multiple', 'medical', 'comorbidities', 'can', 'contribute', 'to', 'clinical', 'deterioration', ',', 'and', 'increased', 'mortality', '.', 'Electroconvulsive', 'therapy', '(', 'ECT', ')', 'is', 'the', 'first', '-', 'line', 'treatment', 'for', 'these', 'patients', '.', 'This', 'study', 'aimed', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'safety', 'of', 'subcutaneous', '(', 'SC', ')', 'ketamine', 'as', 'an', 'alternative', 'to', 'ECT', '.', 'We', 'reviewed', 'the', 'medical', 'records', 'of', 'all', 'consecutive', 'older', 'inpatients', 'with', 'severe', 'depression', 'and', 'multiple', 'medical', 'comorbidities', 'who', 'were', 'referred', 'for', 'ECT', 'but', 'treated', 'with', 'SC', 'ketamine', 'over', '1', 'year', 'in', 'our', 'institution', '.', 'Demographic', 'data', ',', 'DSM-5', 'diagnosis', ',', 'MÅDRS', 'score', ',', 'and', 'CGI', 'score', 'were', 'analyzed', '.', 'Twelve', 'patients', 'aged', '67', '-', '94', 'years', 'were', 'included', '.', 'All', 'patients', 'were', 'rated', 'as', 'severely', 'ill', ',', '83', '%', 'were', 'women', ',', 'with', 'a', 'mean', 'of', '12.6', '(', 'SD', ',', '1.4', ')', 'medical', 'comorbidities', '.', 'Remission', 'was', 'achieved', 'in', '75', '%', 'of', 'the', 'intention', '-', 'to', '-', 'treat', 'population', 'and', '100', '%', 'of', 'treatment', 'completers', '.', 'The', 'number', 'of', 'sessions', 'ranged', 'from', '1', 'to', '6', ',', 'and', 'days', 'until', 'remission', 'from', '1', 'to', '16', '.', 'Patients', 'remained', 'without', 'relapse', 'for', '8', '-', '28', 'months', '.', 'SC', 'ketamine', 'was', 'safe', 'and', 'well', 'tolerated', ',', 'and', 'most', 'adverse', 'events', 'were', 'mild', 'and', 'transient', '.', 'Although', 'limited', 'by', 'the', 'retrospective', 'open', '-', 'label', 'design', 'of', 'the', 'study', 'and', 'small', 'sample', 'size', ',', 'our', 'findings', 'provide', 'a', 'potential', 'new', 'indication', 'for', 'ketamine', ':', 'treatment', 'of', 'severe', 'depression', ',', 'not', 'necessarily', 'resistant', 'to', 'antidepressants', ',', 'in', 'older', 'patients', 'with', 'multiple', 'medical', 'comorbidities', ',', 'at', 'risk', 'of', 'clinical', 'deterioration', ',', 'and', 'referral', 'for', 'ECT', '.', 'SC', 'ketamine', 'was', 'highly', 'effective', 'in', 'this', 'population', ',', 'with', 'no', 'relapse', 'and', 'good', 'tolerance', '.', 'Randomized', 'controlled', 'trials', 'are', 'needed', 'to', 'adequately', 'test', 'the', 'use', 'of', 'ketamine', 'in', 'this', 'specific', 'group', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7378,"['[CLS]', 'potential', 'advantages', 'of', 'ketamine', 'over', 'electro', '##con', '##v', '##ulsive', 'therapy', 'in', 'the', 'treatment', 'of', 'non', '##ref', '##rac', '##tory', 'severe', 'depression', 'in', 'older', 'patients', 'with', 'multiple', 'medical', 'comorbidities', '.', '^', 'depression', 'in', 'older', 'adults', 'with', 'multiple', 'medical', 'comorbidities', 'can', 'contribute', 'to', 'clinical', 'deterioration', ',', 'and', 'increased', 'mortality', '.', 'electro', '##con', '##v', '##ulsive', 'therapy', '(', 'ect', ')', 'is', 'the', 'first', '-', 'line', 'treatment', 'for', 'these', 'patients', '.', 'this', 'study', 'aimed', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'safety', 'of', 'subcutaneous', '(', 'sc', ')', 'ketamine', 'as', 'an', 'alternative', 'to', 'ect', '.', 'we', 'reviewed', 'the', 'medical', 'records', 'of', 'all', 'consecutive', 'older', 'inpatient', '##s', 'with', 'severe', 'depression', 'and', 'multiple', 'medical', 'comorbidities', 'who', 'were', 'referred', 'for', 'ect', 'but', 'treated', 'with', 'sc', 'ketamine', 'over', '1', 'year', 'in', 'our', 'institution', '.', 'demographic', 'data', ',', 'dsm', '-', '5', 'diagnosis', ',', 'mad', '##rs', 'score', ',', 'and', 'cg', '##i', 'score', 'were', 'analyzed', '.', 'twelve', 'patients', 'aged', '67', '-', '94', 'years', 'were', 'included', '.', 'all', 'patients', 'were', 'rated', 'as', 'severely', 'ill', ',', '83', '%', 'were', 'women', ',', 'with', 'a', 'mean', 'of', '12', '.', '6', '(', 'sd', ',', '1', '.', '4', ')', 'medical', 'comorbidities', '.', 'remission', 'was', 'achieved', 'in', '75', '%', 'of', 'the', 'intention', '-', 'to', '-', 'treat', 'population', 'and', '100', '%', 'of', 'treatment', 'complete', '##rs', '.', 'the', 'number', 'of', 'sessions', 'ranged', 'from', '1', 'to', '6', ',', 'and', 'days', 'until', 'remission', 'from', '1', 'to', '16', '.', 'patients', 'remained', 'without', 'relapse', 'for', '8', '-', '28', 'months', '.', 'sc', 'ketamine', 'was', 'safe', 'and', 'well', 'tolerated', ',', 'and', 'most', 'adverse', 'events', 'were', 'mild', 'and', 'transient', '.', 'although', 'limited', 'by', 'the', 'retrospective', 'open', '-', 'label', 'design', 'of', 'the', 'study', 'and', 'small', 'sample', 'size', ',', 'our', 'findings', 'provide', 'a', 'potential', 'new', 'indication', 'for', 'ketamine', ':', 'treatment', 'of', 'severe', 'depression', ',', 'not', 'necessarily', 'resistant', 'to', 'antidepressants', ',', 'in', 'older', 'patients', 'with', 'multiple', 'medical', 'comorbidities', ',', 'at', 'risk', 'of', 'clinical', 'deterioration', ',', 'and', 'referral', 'for', 'ect', '.', 'sc', 'ketamine', 'was', 'highly', 'effective', 'in', 'this', 'population', ',', 'with', 'no', 'relapse', 'and', 'good', 'tolerance', '.', 'randomized', 'controlled', 'trials', 'are', 'needed', 'to', 'adequately', 'test', 'the', 'use', 'of', 'ketamine', 'in', 'this', 'specific', 'group', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 5, 5, 5, 6, 7, 8, 9, 10, 11, 11, 11, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 40, 40, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 113, 113, 114, 115, 116, 116, 117, 118, 119, 120, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 152, 152, 153, 154, 155, 156, 156, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities.^
Depression in older adults with multiple medical comorbidities can contribute to clinical deterioration, and increased mortality. Electroconvulsive therapy (ECT) is the first-line treatment for these patients. This study aimed to evaluate the effectiveness and safety of subcutaneous (SC) ketamine as an alternative to ECT. We reviewed the medical records of all consecutive older inpatients with severe depression and multiple medical comorbidities who were referred for ECT but treated with SC ketamine over 1 year in our institution. Demographic data, DSM-5 diagnosis, MÅDRS score, and CGI score were analyzed. Twelve patients aged 67-94 years were included. All patients were rated as severely ill, 83% were women, with a mean of 12.6 (SD, 1.4) medical comorbidities. Remission was achieved in 75% of the intention-to-treat population and 100% of treatment completers. The number of sessions ranged from 1 to 6, and days until remission from 1 to 16. Patients remained without relapse for 8-28 months. SC ketamine was safe and well tolerated, and most adverse events were mild and transient. Although limited by the retrospective open-label design of the study and small sample size, our findings provide a potential new indication for ketamine: treatment of severe depression, not necessarily resistant to antidepressants, in older patients with multiple medical comorbidities, at risk of clinical deterioration, and referral for ECT. SC ketamine was highly effective in this population, with no relapse and good tolerance. Randomized controlled trials are needed to adequately test the use of ketamine in this specific group."
"['Clinical', 'predictors', 'of', 'ketamine', 'response', 'in', 'treatment', '-', 'resistant', 'major', 'depression.^', '\n', 'OBJECTIVE', ':', 'The', 'N', '-', 'methyl', '-', 'D', '-', 'aspartate', 'receptor', 'antagonist', 'ketamine', 'has', 'rapid', 'antidepressant', 'effects', 'in', 'treatment', '-', 'resistant', 'major', 'depressive', 'disorder', '(', 'MDD', ')', 'and', 'bipolar', 'depression', '.', 'Clinical', 'predictors', 'may', 'identify', 'those', 'more', 'likely', 'to', 'benefit', 'from', 'ketamine', 'within', 'clinically', 'heterogeneous', 'populations', '.', 'METHOD', ':', 'Data', 'were', 'analyzed', 'from', '4', 'studies', 'of', 'treatment', '-', 'resistant', 'inpatients', 'with', 'DSM', '-', 'IV', '-', 'TR', '-', 'diagnosed', 'MDD', 'or', 'bipolar', 'I', 'or', 'II', 'depression', '.', 'Patients', 'who', 'were', 'currently', 'experiencing', 'a', 'moderate', '-', 'to', '-', 'severe', 'major', 'depressive', 'episode', 'were', 'enrolled', 'between', 'November', '2004', 'and', 'March', '2013', '.', 'All', 'subjects', 'received', 'a', 'single', 'subanesthetic', '(', '0.5', 'mg', '/', 'kg', ')', 'ketamine', 'infusion', 'over', '40', 'minutes', '.', 'Patients', 'were', 'analyzed', 'at', 'the', '230', '-', 'minute', 'postinfusion', 'time', 'point', '(', 'n', '=', '108', ')', ',', 'at', 'day', '1', '(', 'n', '=', '82', ')', ',', 'and', 'at', 'day', '7', '(', 'n', '=', '71', ')', '.', 'Univariate', 'Pearson', 'correlations', 'were', 'performed', 'for', 'each', 'variable', 'with', 'percent', 'change', 'from', 'baseline', 'in', 'the', '17', '-', 'item', 'Hamilton', 'Depression', 'Rating', 'Scale', '(', 'HDRS', ')', '.', 'Multivariate', 'linear', 'regression', 'was', 'then', 'conducted', 'for', 'statistically', 'significant', 'predictors', '(', 'P', '≤', '.05', ',', '2', '-', 'tailed', ')', '.', 'RESULTS', ':', 'Higher', 'body', 'mass', 'index', 'correlated', 'with', 'greater', 'HDRS', 'improvement', 'at', '230', 'minutes', '(', 'standardized', 'β', '=', '-0.30', ',', 'P', '=', '.004', ')', 'and', 'at', 'day', '1', '(', 'standardized', 'β', '=', '-0.37', ',', 'P', '=', '.001', ')', ',', 'but', 'not', 'at', 'day', '7', '(', 'standardized', 'β', '=', '-0.18', ',', 'P', '=', '.10', ')', '.', 'Family', 'history', 'of', 'an', 'alcohol', 'use', 'disorder', 'in', 'a', 'first', '-', 'degree', 'relative', 'was', 'associated', 'with', 'greater', 'HDRS', 'improvement', 'at', 'day', '1', '(', 'standardized', 'β', '=', '-0.27', ',', 'P', '=', '.014', ')', 'and', 'day', '7', '(', 'standardized', 'β', '=', '-0.41', ',', 'P', '<', '.001', ')', '.', 'No', 'prior', 'history', 'of', 'suicide', 'attempt(s', ')', 'was', 'associated', 'with', 'greater', 'improvement', 'only', 'at', 'day', '7', '(', 'standardized', 'β', '=', '0.28', ',', 'P', '=', '.01', ')', '.', 'The', 'overall', 'statistical', 'model', 'explained', '13', '%', ',', '23', '%', ',', 'and', '36', '%', 'of', 'HDRS', 'percent', 'change', 'variance', 'at', '230', 'minutes', ',', 'day', '1', ',', 'and', 'day', '7', ',', 'respectively', '.', 'CONCLUSIONS', ':', 'Despite', 'its', 'post', 'hoc', 'nature', ',', 'this', 'study', 'identified', 'several', 'clinical', 'correlates', 'of', 'ketamine', ""'s"", 'rapid', 'and', 'durable', 'antidepressant', 'effects', '.', 'Further', 'investigation', 'of', 'these', 'relationships', 'is', 'critical', 'for', 'individualized', 'treatment', 'of', 'depression', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6361,"['[CLS]', 'clinical', 'predictors', 'of', 'ketamine', 'response', 'in', 'treatment', '-', 'resistant', 'major', 'depression', '.', '^', 'objective', ':', 'the', 'n', '-', 'methyl', '-', 'd', '-', 'aspartate', 'receptor', 'antagonist', 'ketamine', 'has', 'rapid', 'antidepressant', 'effects', 'in', 'treatment', '-', 'resistant', 'major', 'depressive', 'disorder', '(', 'mdd', ')', 'and', 'bipolar', 'depression', '.', 'clinical', 'predictors', 'may', 'identify', 'those', 'more', 'likely', 'to', 'benefit', 'from', 'ketamine', 'within', 'clinically', 'heterogeneous', 'populations', '.', 'method', ':', 'data', 'were', 'analyzed', 'from', '4', 'studies', 'of', 'treatment', '-', 'resistant', 'inpatient', '##s', 'with', 'dsm', '-', 'iv', '-', 'tr', '-', 'diagnosed', 'mdd', 'or', 'bipolar', 'i', 'or', 'ii', 'depression', '.', 'patients', 'who', 'were', 'currently', 'experiencing', 'a', 'moderate', '-', 'to', '-', 'severe', 'major', 'depressive', 'episode', 'were', 'enrolled', 'between', 'november', '2004', 'and', 'march', '2013', '.', 'all', 'subjects', 'received', 'a', 'single', 'sub', '##anes', '##the', '##tic', '(', '0', '.', '5', 'mg', '/', 'kg', ')', 'ketamine', 'infusion', 'over', '40', 'minutes', '.', 'patients', 'were', 'analyzed', 'at', 'the', '230', '-', 'minute', 'post', '##inf', '##usion', 'time', 'point', '(', 'n', '=', '108', ')', ',', 'at', 'day', '1', '(', 'n', '=', '82', ')', ',', 'and', 'at', 'day', '7', '(', 'n', '=', '71', ')', '.', 'univariate', 'pearson', 'correlations', 'were', 'performed', 'for', 'each', 'variable', 'with', 'percent', 'change', 'from', 'baseline', 'in', 'the', '17', '-', 'item', 'hamilton', 'depression', 'rating', 'scale', '(', 'hd', '##rs', ')', '.', 'multivariate', 'linear', 'regression', 'was', 'then', 'conducted', 'for', 'statistically', 'significant', 'predictors', '(', 'p', '≤', '.', '05', ',', '2', '-', 'tail', '##ed', ')', '.', 'results', ':', 'higher', 'body', 'mass', 'index', 'correlated', 'with', 'greater', 'hd', '##rs', 'improvement', 'at', '230', 'minutes', '(', 'standardized', 'β', '=', '-', '0', '.', '30', ',', 'p', '=', '.', '00', '##4', ')', 'and', 'at', 'day', '1', '(', 'standardized', 'β', '=', '-', '0', '.', '37', ',', 'p', '=', '.', '00', '##1', ')', ',', 'but', 'not', 'at', 'day', '7', '(', 'standardized', 'β', '=', '-', '0', '.', '18', ',', 'p', '=', '.', '10', ')', '.', 'family', 'history', 'of', 'an', 'alcohol', 'use', 'disorder', 'in', 'a', 'first', '-', 'degree', 'relative', 'was', 'associated', 'with', 'greater', 'hd', '##rs', 'improvement', 'at', 'day', '1', '(', 'standardized', 'β', '=', '-', '0', '.', '27', ',', 'p', '=', '.', '01', '##4', ')', 'and', 'day', '7', '(', 'standardized', 'β', '=', '-', '0', '.', '41', ',', 'p', '<', '.', '00', '##1', ')', '.', 'no', 'prior', 'history', 'of', 'suicide', 'attempt', '(', 's', ')', 'was', 'associated', 'with', 'greater', 'improvement', 'only', 'at', 'day', '7', '(', 'standardized', 'β', '=', '0', '.', '28', ',', 'p', '=', '.', '01', ')', '.', 'the', 'overall', 'statistical', 'model', 'explained', '13', '%', ',', '23', '%', ',', 'and', '36', '%', 'of', 'hd', '##rs', 'percent', 'change', 'variance', 'at', '230', 'minutes', ',', 'day', '1', ',', 'and', 'day', '7', ',', 'respectively', '.', 'conclusions', ':', 'despite', 'its', 'post', 'hoc', 'nature', ',', 'this', 'study', 'identified', 'several', 'clinical', 'correlates', 'of', 'ketamine', ""'"", 's', 'rapid', 'and', 'durable', 'antidepressant', 'effects', '.', 'further', 'investigation', 'of', 'these', 'relationships', 'is', 'critical', 'for', 'individualized', 'treatment', 'of', 'depression', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 116, 116, 116, 117, 118, 118, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 137, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 204, 205, 206, 207, 208, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 229, 229, 229, 230, 231, 232, 233, 233, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 243, 243, 243, 244, 245, 246, 247, 247, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 259, 259, 259, 260, 261, 262, 263, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 292, 292, 292, 293, 294, 295, 296, 296, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 305, 305, 305, 306, 307, 308, 309, 309, 309, 310, 311, 312, 313, 314, 315, 316, 317, 317, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 332, 332, 333, 334, 335, 336, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 4, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Clinical predictors of ketamine response in treatment-resistant major depression.^
OBJECTIVE: The N-methyl-D-aspartate receptor antagonist ketamine has rapid antidepressant effects in treatment-resistant major depressive disorder (MDD) and bipolar depression. Clinical predictors may identify those more likely to benefit from ketamine within clinically heterogeneous populations. METHOD: Data were analyzed from 4 studies of treatment-resistant inpatients with DSM-IV-TR-diagnosed MDD or bipolar I or II depression. Patients who were currently experiencing a moderate-to-severe major depressive episode were enrolled between November 2004 and March 2013. All subjects received a single subanesthetic (0.5 mg/kg) ketamine infusion over 40 minutes. Patients were analyzed at the 230-minute postinfusion time point (n = 108), at day 1 (n = 82), and at day 7 (n = 71). Univariate Pearson correlations were performed for each variable with percent change from baseline in the 17-item Hamilton Depression Rating Scale (HDRS). Multivariate linear regression was then conducted for statistically significant predictors (P ≤ .05, 2-tailed). RESULTS: Higher body mass index correlated with greater HDRS improvement at 230 minutes (standardized β = -0.30, P = .004) and at day 1 (standardized β = -0.37, P = .001), but not at day 7 (standardized β = -0.18, P = .10). Family history of an alcohol use disorder in a first-degree relative was associated with greater HDRS improvement at day 1 (standardized β = -0.27, P = .014) and day 7 (standardized β = -0.41, P < .001). No prior history of suicide attempt(s) was associated with greater improvement only at day 7 (standardized β = 0.28, P = .01). The overall statistical model explained 13%, 23%, and 36% of HDRS percent change variance at 230 minutes, day 1, and day 7, respectively. CONCLUSIONS: Despite its post hoc nature, this study identified several clinical correlates of ketamine's rapid and durable antidepressant effects. Further investigation of these relationships is critical for individualized treatment of depression."
"['Increase', 'in', 'PAS', '-', 'induced', 'neuroplasticity', 'after', 'a', 'treatment', 'course', 'of', 'intranasal', 'ketamine', 'for', 'depression', '.', 'Report', 'of', 'three', 'cases', 'from', 'a', 'placebo', '-', 'controlled', 'trial.^', '\n', 'BACKGROUND', ':', 'Animal', 'studies', 'suggest', 'that', 'neural', 'plasticity', 'may', 'play', 'a', 'role', 'in', 'the', 'antidepressant', 'effects', 'of', 'a', 'single', 'ketamine', 'dose', '.', 'However', ',', 'the', 'potential', 'effects', 'of', 'repeated', 'ketamine', 'treatments', 'on', 'human', 'neuroplasticity', 'are', 'unknown', '.', 'METHODS', ':', 'This', 'pilot', 'RCT', 'study', 'measured', 'plasticity', '-', 'induced', 'changes', 'before', 'and', 'after', 'a', 'ketamine', 'course', ',', 'in', 'three', 'treatment', '-', 'resistant', 'depressed', 'subjects', ',', 'who', 'were', 'randomized', 'to', 'receive', '8', 'intranasal', 'treatments', 'of', '100', 'mg', 'ketamine', 'or', '4.5', 'mg', 'midazolam', '.', 'Mood', 'ratings', 'were', 'performed', 'by', 'a', 'trained', 'blinded', 'rater', 'at', 'baseline', 'and', '24h-48h', 'after', 'the', 'ketamine', 'course', ',', 'using', 'the', 'Montgomery', 'Asberg', 'Depression', 'Rating', 'Scale', '(', 'MADRS', ')', '.', 'Neuroplasticity', 'was', 'assessed', 'in', 'the', 'motor', 'cortex', 'using', 'a', 'paired', 'associative', 'stimulation', '(', 'PAS', ')', 'paradigm', 'at', 'baseline', 'and', '24h-48h', 'after', 'the', 'treatment', 'course', '.', 'No', 'changes', 'in', 'current', 'psychotropic', 'medication', 'or', 'dosage', 'were', 'permitted', 'for', '4weeks', 'prior', 'to', 'trial', 'entry', 'and', 'throughout', 'the', 'trial', '.', 'RESULTS', ':', 'The', 'subject', 'receiving', 'ketamine', ',', 'but', 'not', 'those', 'receiving', 'midazolam', ',', 'presented', 'a', 'marked', 'increase', 'in', 'neural', 'plasticity', 'after', 'the', 'treatment', 'course', '.', 'However', ',', 'mood', 'changes', 'were', 'not', 'associated', 'with', 'changes', 'in', 'neural', 'plasticity', '.', 'LIMITATIONS', ':', 'Pilot', 'study', 'with', 'small', 'sample', 'size', '.', 'Concomitant', 'antidepressant', 'medications', 'taken', '.', 'Plasticity', 'was', 'tested', 'in', 'the', 'motor', 'cortex', 'only', ',', 'thus', 'the', 'generalizability', 'of', 'these', 'findings', 'to', 'other', 'brain', 'areas', 'can', 'not', 'be', 'assumed', '.', 'CONCLUSIONS', ':', 'These', 'results', 'suggest', 'that', 'a', 'course', 'of', 'intranasal', 'ketamine', 'may', 'enhance', 'synaptic', 'plasticity', 'in', 'subjects', 'with', 'depression', ',', 'but', 'this', 'was', 'not', 'associated', 'with', 'antidepressant', 'effects', '.', 'Further', 'research', 'on', 'this', 'topic', 'is', 'warranted', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",2822,"['[CLS]', 'increase', 'in', 'pas', '-', 'induced', 'neurop', '##last', '##icity', 'after', 'a', 'treatment', 'course', 'of', 'intran', '##asal', 'ketamine', 'for', 'depression', '.', 'report', 'of', 'three', 'cases', 'from', 'a', 'placebo', '-', 'controlled', 'trial', '.', '^', 'background', ':', 'animal', 'studies', 'suggest', 'that', 'neural', 'plasticity', 'may', 'play', 'a', 'role', 'in', 'the', 'antidepressant', 'effects', 'of', 'a', 'single', 'ketamine', 'dose', '.', 'however', ',', 'the', 'potential', 'effects', 'of', 'repeated', 'ketamine', 'treatments', 'on', 'human', 'neurop', '##last', '##icity', 'are', 'unknown', '.', 'methods', ':', 'this', 'pilot', 'rct', 'study', 'measured', 'plasticity', '-', 'induced', 'changes', 'before', 'and', 'after', 'a', 'ketamine', 'course', ',', 'in', 'three', 'treatment', '-', 'resistant', 'depressed', 'subjects', ',', 'who', 'were', 'randomized', 'to', 'receive', '8', 'intran', '##asal', 'treatments', 'of', '100', 'mg', 'ketamine', 'or', '4', '.', '5', 'mg', 'mid', '##azol', '##am', '.', 'mood', 'ratings', 'were', 'performed', 'by', 'a', 'trained', 'blinded', 'rate', '##r', 'at', 'baseline', 'and', '24', '##h', '-', '48', '##h', 'after', 'the', 'ketamine', 'course', ',', 'using', 'the', 'mont', '##go', '##mer', '##y', 'as', '##berg', 'depression', 'rating', 'scale', '(', 'mad', '##rs', ')', '.', 'neurop', '##last', '##icity', 'was', 'assessed', 'in', 'the', 'motor', 'cortex', 'using', 'a', 'paired', 'associative', 'stimulation', '(', 'pas', ')', 'paradigm', 'at', 'baseline', 'and', '24', '##h', '-', '48', '##h', 'after', 'the', 'treatment', 'course', '.', 'no', 'changes', 'in', 'current', 'psycho', '##tro', '##pic', 'medication', 'or', 'dosage', 'were', 'permitted', 'for', '4', '##week', '##s', 'prior', 'to', 'trial', 'entry', 'and', 'throughout', 'the', 'trial', '.', 'results', ':', 'the', 'subject', 'receiving', 'ketamine', ',', 'but', 'not', 'those', 'receiving', 'mid', '##azol', '##am', ',', 'presented', 'a', 'marked', 'increase', 'in', 'neural', 'plasticity', 'after', 'the', 'treatment', 'course', '.', 'however', ',', 'mood', 'changes', 'were', 'not', 'associated', 'with', 'changes', 'in', 'neural', 'plasticity', '.', 'limitations', ':', 'pilot', 'study', 'with', 'small', 'sample', 'size', '.', 'concomitant', 'antidepressant', 'medications', 'taken', '.', 'plasticity', 'was', 'tested', 'in', 'the', 'motor', 'cortex', 'only', ',', 'thus', 'the', 'general', '##izability', 'of', 'these', 'findings', 'to', 'other', 'brain', 'areas', 'can', 'not', 'be', 'assumed', '.', 'conclusions', ':', 'these', 'results', 'suggest', 'that', 'a', 'course', 'of', 'intran', '##asal', 'ketamine', 'may', 'enhance', 'synaptic', 'plasticity', 'in', 'subjects', 'with', 'depression', ',', 'but', 'this', 'was', 'not', 'associated', 'with', 'antidepressant', 'effects', '.', 'further', 'research', 'on', 'this', 'topic', 'is', 'warranted', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 5, 5, 6, 7, 8, 9, 10, 11, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 25, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 60, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 96, 97, 98, 99, 100, 101, 102, 103, 103, 103, 104, 105, 105, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 115, 116, 117, 118, 119, 119, 119, 119, 119, 120, 121, 122, 123, 124, 125, 126, 127, 127, 127, 127, 128, 128, 129, 130, 131, 132, 133, 133, 134, 135, 136, 136, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 155, 155, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 165, 165, 166, 167, 168, 169, 170, 171, 172, 172, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 193, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial.^
BACKGROUND: Animal studies suggest that neural plasticity may play a role in the antidepressant effects of a single ketamine dose. However, the potential effects of repeated ketamine treatments on human neuroplasticity are unknown. METHODS: This pilot RCT study measured plasticity-induced changes before and after a ketamine course, in three treatment-resistant depressed subjects, who were randomized to receive 8 intranasal treatments of 100mg ketamine or 4.5mg midazolam. Mood ratings were performed by a trained blinded rater at baseline and 24h-48h after the ketamine course, using the Montgomery Asberg Depression Rating Scale (MADRS). Neuroplasticity was assessed in the motor cortex using a paired associative stimulation (PAS) paradigm at baseline and 24h-48h after the treatment course. No changes in current psychotropic medication or dosage were permitted for 4weeks prior to trial entry and throughout the trial. RESULTS: The subject receiving ketamine, but not those receiving midazolam, presented a marked increase in neural plasticity after the treatment course. However, mood changes were not associated with changes in neural plasticity. LIMITATIONS: Pilot study with small sample size. Concomitant antidepressant medications taken. Plasticity was tested in the motor cortex only, thus the generalizability of these findings to other brain areas cannot be assumed. CONCLUSIONS: These results suggest that a course of intranasal ketamine may enhance synaptic plasticity in subjects with depression, but this was not associated with antidepressant effects. Further research on this topic is warranted."
"['Influence', 'of', 'low', '-', 'dose', 'esketamine', 'on', 'postoperative', 'depressive', 'symptoms', 'in', 'patients', 'with', 'breast', 'cancer', '(', 'EASE', '):', 'study', 'protocol', 'for', 'a', 'randomised', 'controlled', 'trial.^', '\n', 'Introduction', 'Depressive', 'symptoms', 'have', 'surfaced', 'as', 'the', 'principal', 'mental', 'health', 'concern', 'among', 'patients', 'with', 'breast', 'cancer', ',', 'with', 'surgical', 'interventions', 'potentially', 'exacerbating', 'these', 'symptoms', 'and', 'adversely', 'influencing', 'clinical', 'outcomes', '.', 'This', 'study', 'protocol', 'is', 'designed', 'to', 'investigate', 'the', 'efficacy', 'of', 'low‐dose', 'esketamine', 'administered', 'perioperatively', 'on', 'depressive', 'symptoms', 'in', 'patients', 'with', 'breast', 'cancer', '.', 'It', 'also', 'aims', 'to', 'illuminate', 'the', 'potential', 'neurobiological', 'underpinnings', 'of', 'this', 'effect', '.', 'Methods', 'and', 'analysis', 'This', 'research', 'represents', 'a', 'single‐centre', ',', 'prospective', ',', 'randomised', ',', 'double‐blind', ',', 'placebo‐controlled', 'study', '.', 'The', 'trial', 'anticipates', 'enrolling', '108', 'female', 'patients', 'exhibiting', 'mild‐to‐severe', 'depressive', 'symptoms', 'who', 'are', 'slated', 'for', 'radical', 'mastectomy', '.', 'Through', 'stratified', 'randomisation', ',', 'eligible', 'patients', 'will', 'be', 'systematically', 'assigned', 'to', 'either', 'the', 'esketamine', 'group', '(', '0.25', 'mg', '/', 'kg', ')', 'or', 'placebo', 'group', '(', '0.9', '%', 'saline', ')', 'in', 'a', '1:1', 'ratio', '.', 'The', 'primary', 'outcome', 'is', 'the', 'response', 'rate', 'at', 'the', 'third', 'postoperative', 'day', '.', 'Secondary', 'outcomes', 'encompass', 'the', 'remission', 'rate', ',', 'depression‐related', 'scores', ',', 'depression', 'severity', 'and', 'safety‐related', 'endpoints', '.', 'Tertiary', '(', 'exploratory', ')', 'outcomes', 'involve', 'alterations', 'in', 'brain‐derived', 'neurotrophic', 'factor', 'and', 'resting‐state', 'functional', 'brain', 'connectivity', '.', 'Ethics', 'and', 'dissemination', 'The', 'Clinical', 'Trial', 'Ethics', 'Committee', 'at', 'The', 'First', 'Affiliated', 'Hospital', 'of', 'Anhui', 'Medical', 'University', 'has', 'conferred', 'ethical', 'approvals', 'for', 'this', 'trial', '(', 'approval', 'number', ':', 'PJ2023‐05‐25', ')', '.', 'Results', 'from', 'this', 'trial', 'will', 'be', 'disseminated', 'in', 'peer‐reviewed', 'journals', 'and', 'presented', 'at', 'professional', 'symposiums', '.', 'Trial', 'registration', 'number', 'Chinese', 'Clinical', 'Trials', 'Registry', '(', 'ChiCTR2300071062', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",9071,"['[CLS]', 'influence', 'of', 'low', '-', 'dose', 'es', '##ket', '##amine', 'on', 'postoperative', 'depressive', 'symptoms', 'in', 'patients', 'with', 'breast', 'cancer', '(', 'ease', ')', ':', 'study', 'protocol', 'for', 'a', 'randomised', 'controlled', 'trial', '.', '^', 'introduction', 'depressive', 'symptoms', 'have', 'surface', '##d', 'as', 'the', 'principal', 'mental', 'health', 'concern', 'among', 'patients', 'with', 'breast', 'cancer', ',', 'with', 'surgical', 'interventions', 'potentially', 'exacerb', '##ating', 'these', 'symptoms', 'and', 'adversely', 'influencing', 'clinical', 'outcomes', '.', 'this', 'study', 'protocol', 'is', 'designed', 'to', 'investigate', 'the', 'efficacy', 'of', 'low', '‐', 'dose', 'es', '##ket', '##amine', 'administered', 'perioperative', '##ly', 'on', 'depressive', 'symptoms', 'in', 'patients', 'with', 'breast', 'cancer', '.', 'it', 'also', 'aims', 'to', 'illumina', '##te', 'the', 'potential', 'neurobi', '##ological', 'underpin', '##nings', 'of', 'this', 'effect', '.', 'methods', 'and', 'analysis', 'this', 'research', 'represents', 'a', 'single', '‐', 'centre', ',', 'prospective', ',', 'randomised', ',', 'double', '‐', 'blind', ',', 'placebo', '‐', 'controlled', 'study', '.', 'the', 'trial', 'anticipate', '##s', 'enroll', '##ing', '108', 'female', 'patients', 'exhibiting', 'mild', '‐', 'to', '‐', 'severe', 'depressive', 'symptoms', 'who', 'are', 'sla', '##ted', 'for', 'radical', 'mast', '##ectomy', '.', 'through', 'stratified', 'random', '##isation', ',', 'eligible', 'patients', 'will', 'be', 'systematically', 'assigned', 'to', 'either', 'the', 'es', '##ket', '##amine', 'group', '(', '0', '.', '25', 'mg', '/', 'kg', ')', 'or', 'placebo', 'group', '(', '0', '.', '9', '%', 'saline', ')', 'in', 'a', '1', ':', '1', 'ratio', '.', 'the', 'primary', 'outcome', 'is', 'the', 'response', 'rate', 'at', 'the', 'third', 'postoperative', 'day', '.', 'secondary', 'outcomes', 'encompass', 'the', 'remission', 'rate', ',', 'depression', '‐', 'related', 'scores', ',', 'depression', 'severity', 'and', 'safety', '‐', 'related', 'endpoints', '.', 'tertiary', '(', 'exploratory', ')', 'outcomes', 'involve', 'alterations', 'in', 'brain', '‐', 'derived', 'neurotrophic', 'factor', 'and', 'resting', '‐', 'state', 'functional', 'brain', 'connectivity', '.', 'ethics', 'and', 'dissemination', 'the', 'clinical', 'trial', 'ethics', 'committee', 'at', 'the', 'first', 'affiliated', 'hospital', 'of', 'an', '##hu', '##i', 'medical', 'university', 'has', 'conferred', 'ethical', 'approval', '##s', 'for', 'this', 'trial', '(', 'approval', 'number', ':', 'pj', '##202', '##3', '‐', '05', '‐', '25', ')', '.', 'results', 'from', 'this', 'trial', 'will', 'be', 'disseminated', 'in', 'peer', '‐', 'reviewed', 'journals', 'and', 'presented', 'at', 'professional', 'symposium', '##s', '.', 'trial', 'registration', 'number', 'chinese', 'clinical', 'trials', 'registry', '(', 'chic', '##tr', '##23', '##000', '##71', '##06', '##2', ')', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 17, 18, 19, 20, 21, 22, 23, 24, 24, 24, 26, 27, 28, 29, 30, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 66, 66, 67, 67, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 83, 84, 85, 86, 86, 87, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99, 99, 100, 101, 102, 103, 104, 105, 105, 105, 106, 107, 107, 107, 108, 109, 110, 111, 112, 112, 113, 113, 114, 115, 116, 117, 118, 118, 118, 118, 118, 119, 120, 121, 122, 123, 123, 124, 125, 126, 126, 127, 128, 129, 130, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 141, 141, 142, 143, 144, 144, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 153, 153, 154, 155, 156, 157, 158, 159, 159, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 182, 182, 183, 184, 185, 186, 187, 188, 188, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 199, 199, 200, 201, 202, 203, 203, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 222, 222, 223, 224, 225, 226, 227, 228, 228, 229, 230, 231, 232, 233, 234, 235, 236, 236, 236, 236, 236, 236, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 247, 247, 248, 249, 250, 251, 252, 253, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 263, 263, 263, 263, 263, 263, 264, 265, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Influence of low-dose esketamine on postoperative depressive symptoms in patients with breast cancer (EASE): study protocol for a randomised controlled trial.^
Introduction Depressive symptoms have surfaced as the principal mental health concern among patients with breast cancer, with surgical interventions potentially exacerbating these symptoms and adversely influencing clinical outcomes. This study protocol is designed to investigate the efficacy of low‐dose esketamine administered perioperatively on depressive symptoms in patients with breast cancer. It also aims to illuminate the potential neurobiological underpinnings of this effect. Methods and analysis This research represents a single‐centre, prospective, randomised, double‐blind, placebo‐controlled study. The trial anticipates enrolling 108 female patients exhibiting mild‐to‐severe depressive symptoms who are slated for radical mastectomy. Through stratified randomisation, eligible patients will be systematically assigned to either the esketamine group (0.25 mg/kg) or placebo group (0.9% saline) in a 1:1 ratio. The primary outcome is the response rate at the third postoperative day. Secondary outcomes encompass the remission rate, depression‐related scores, depression severity and safety‐related endpoints. Tertiary (exploratory) outcomes involve alterations in brain‐derived neurotrophic factor and resting‐state functional brain connectivity. Ethics and dissemination The Clinical Trial Ethics Committee at The First Affiliated Hospital of Anhui Medical University has conferred ethical approvals for this trial (approval number: PJ2023‐05‐25). Results from this trial will be disseminated in peer‐reviewed journals and presented at professional symposiums. Trial registration number Chinese Clinical Trials Registry (ChiCTR2300071062)."
"['Intravenous', 'ketamine', 'relieves', 'pain', 'and', 'depression', 'after', 'traumatic', 'suicide', 'attempts', ':', 'A', 'case', 'series.^', '\n', 'The', 'letter', 'presents', 'a', 'series', 'of', 'cases', 'where', ',', 'after', 'traumatic', 'suicide', 'attempts', ',', 'authors', 'administered', 'intravenous', 'doses', 'of', 'ketamine', 'to', 'decrease', 'pain', 'and', 'acute', 'suicidal', 'thoughts', '.', 'The', 'first', 'case', 'is', 'an', '81', '-', 'year', '-', 'old', 'man', 'who', 'presented', 'with', 'a', 'suicide', 'attempt', 'involving', 'self', '-', 'inflicted', 'neck', 'laceration', 'and', 'left', 'wrist', 'laceration', '.', 'On', 'initial', 'psychiatric', 'consultation', ',', 'it', 'was', 'discovered', 'that', 'the', 'patient', 'had', 'been', 'holding', 'a', 'delusional', 'belief', 'that', 'he', 'and', 'his', 'wife', 'were', 'developing', 'dementia', '.', 'After', 'discussion', 'with', 'the', 'patient', ',', 'family', ',', 'and', 'surgical', 'specialists', ',', 'it', 'was', 'decided', 'that', 'the', 'patient', 'was', 'not', 'medically', 'stable', 'for', 'electroconvulsive', 'therapy', '(', 'ECT', ')', 'and', 'pharmacotherapy', 'was', 'initiated', 'to', 'target', 'symptoms', 'of', 'depression', 'and', 'psychosis', 'using', 'venlafaxine', ',', 'mirtazapine', ',', 'and', 'aripiprazole', 'on', 'hospital', 'day', '3', '.', 'The', 'second', 'case', 'is', 'also', 'an', 'elderly', 'man', 'who', 'presented', 'with', 'a', 'suicide', 'attempt', 'involving', 'self', '-', 'inflicted', 'bilateral', 'orbit', 'trauma', '.', 'The', 'treatment', 'team', 'decided', 'to', 'start', 'him', 'on', 'venlafaxine', 'and', 'mirtazapine', 'with', 'a', 'rapid', 'titration', 'to', 'doses', 'of', '225', 'mg', 'and', '30', 'mg', ',', 'respectively', '.', 'In', 'this', 'set', 'of', '2', 'cases', ',', 'we', 'have', 'provided', 'strong', 'evidence', 'of', 'the', 'utility', 'of', 'intravenous', 'ketamine', 'for', 'treatment', 'of', 'comorbid', 'pain', ',', 'depression', ',', 'and', 'suicidal', 'ideation', 'after', 'traumatic', 'suicide', 'attempts', '.', 'This', 'combines', 'the', 'traditional', 'use', 'of', 'ketamine', 'as', 'an', 'anesthetic', 'with', 'newly', 'discovered', 'antidepressant', 'and', 'antisuicidal', 'properties', '.', 'In', 'these', '2', 'cases', ',', 'symptom', 'relief', 'was', 'the', 'desired', 'outcome', 'of', 'treatment', ',', 'and', 'by', 'this', 'metric', ',', 'the', 'use', 'of', 'ketamine', 'was', 'a', 'success', 'in', 'these', 'patients', 'in', 'terms', 'of', 'management', 'of', 'pain', ',', 'depression', ',', 'and', 'suicidality', '.', 'Of', 'note', ',', 'both', 'patients', 'in', 'this', 'series', 'were', 'elderly', 'and', 'diagnosed', 'as', 'having', 'MDD', 'with', 'psychotic', 'features', '.', 'These', 'patients', 'did', 'not', 'have', 'any', 'exacerbation', 'of', 'psychosis', 'and', 'rather', 'appeared', 'to', 'lessen', 'these', 'symptoms', ',', 'possibly', 'by', 'exerting', 'treatment', 'of', 'their', 'underlying', 'depression', '.', 'These', 'treatments', 'were', 'given', 'in', 'the', 'clinical', 'setting', ',', 'and', 'outcomes', 'were', 'measured', 'by', 'clinicians', 'and', 'thus', 'not', 'subject', 'to', 'rigorous', 'scientific', 'scrutiny', 'one', 'would', 'see', 'in', 'the', 'setting', 'of', 'a', 'clinical', 'trial', '.', 'This', 'case', 'series', 'bolsters', 'the', 'ongoing', 'discussion', 'of', 'how', 'to', 'best', 'use', 'intravenous', 'administration', 'of', 'ketamine', 'to', 'treat', 'psychiatric', 'disorders', ',', 'particularly', 'when', 'comorbid', 'pain', 'is', 'present', 'and/or', 'ECT', 'is', 'unavailable', '.', '(', 'PsycINFO', 'Database', 'Record', '(', 'c', ')', '2018', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5680,"['[CLS]', 'intravenous', 'ketamine', 'relie', '##ves', 'pain', 'and', 'depression', 'after', 'traumatic', 'suicide', 'attempts', ':', 'a', 'case', 'series', '.', '^', 'the', 'letter', 'presents', 'a', 'series', 'of', 'cases', 'where', ',', 'after', 'traumatic', 'suicide', 'attempts', ',', 'authors', 'administered', 'intravenous', 'doses', 'of', 'ketamine', 'to', 'decrease', 'pain', 'and', 'acute', 'suicidal', 'thoughts', '.', 'the', 'first', 'case', 'is', 'an', '81', '-', 'year', '-', 'old', 'man', 'who', 'presented', 'with', 'a', 'suicide', 'attempt', 'involving', 'self', '-', 'infl', '##icted', 'neck', 'lac', '##eration', 'and', 'left', 'wrist', 'lac', '##eration', '.', 'on', 'initial', 'psychiatric', 'consultation', ',', 'it', 'was', 'discovered', 'that', 'the', 'patient', 'had', 'been', 'holding', 'a', 'del', '##usion', '##al', 'belief', 'that', 'he', 'and', 'his', 'wife', 'were', 'developing', 'dementia', '.', 'after', 'discussion', 'with', 'the', 'patient', ',', 'family', ',', 'and', 'surgical', 'specialists', ',', 'it', 'was', 'decided', 'that', 'the', 'patient', 'was', 'not', 'medically', 'stable', 'for', 'electro', '##con', '##v', '##ulsive', 'therapy', '(', 'ect', ')', 'and', 'pharmac', '##otherapy', 'was', 'initiated', 'to', 'target', 'symptoms', 'of', 'depression', 'and', 'psychosis', 'using', 'ven', '##la', '##fa', '##xin', '##e', ',', 'mir', '##ta', '##za', '##pine', ',', 'and', 'ari', '##pip', '##ra', '##zol', '##e', 'on', 'hospital', 'day', '3', '.', 'the', 'second', 'case', 'is', 'also', 'an', 'elderly', 'man', 'who', 'presented', 'with', 'a', 'suicide', 'attempt', 'involving', 'self', '-', 'infl', '##icted', 'bilateral', 'orbit', 'trauma', '.', 'the', 'treatment', 'team', 'decided', 'to', 'start', 'him', 'on', 'ven', '##la', '##fa', '##xin', '##e', 'and', 'mir', '##ta', '##za', '##pine', 'with', 'a', 'rapid', 'titration', 'to', 'doses', 'of', '225', 'mg', 'and', '30', 'mg', ',', 'respectively', '.', 'in', 'this', 'set', 'of', '2', 'cases', ',', 'we', 'have', 'provided', 'strong', 'evidence', 'of', 'the', 'utility', 'of', 'intravenous', 'ketamine', 'for', 'treatment', 'of', 'comorbid', 'pain', ',', 'depression', ',', 'and', 'suicidal', 'idea', '##tion', 'after', 'traumatic', 'suicide', 'attempts', '.', 'this', 'combines', 'the', 'traditional', 'use', 'of', 'ketamine', 'as', 'an', 'anesthetic', 'with', 'newly', 'discovered', 'antidepressant', 'and', 'antis', '##ui', '##cid', '##al', 'properties', '.', 'in', 'these', '2', 'cases', ',', 'symptom', 'relief', 'was', 'the', 'desired', 'outcome', 'of', 'treatment', ',', 'and', 'by', 'this', 'metric', ',', 'the', 'use', 'of', 'ketamine', 'was', 'a', 'success', 'in', 'these', 'patients', 'in', 'terms', 'of', 'management', 'of', 'pain', ',', 'depression', ',', 'and', 'suicidal', '##ity', '.', 'of', 'note', ',', 'both', 'patients', 'in', 'this', 'series', 'were', 'elderly', 'and', 'diagnosed', 'as', 'having', 'mdd', 'with', 'psychotic', 'features', '.', 'these', 'patients', 'did', 'not', 'have', 'any', 'exacerbation', 'of', 'psychosis', 'and', 'rather', 'appeared', 'to', 'less', '##en', 'these', 'symptoms', ',', 'possibly', 'by', 'exert', '##ing', 'treatment', 'of', 'their', 'underlying', 'depression', '.', 'these', 'treatments', 'were', 'given', 'in', 'the', 'clinical', 'setting', ',', 'and', 'outcomes', 'were', 'measured', 'by', 'clinicians', 'and', 'thus', 'not', 'subject', 'to', 'rigorous', 'scientific', 'scrutin', '##y', 'one', 'would', 'see', 'in', 'the', 'setting', 'of', 'a', 'clinical', 'trial', '.', 'this', 'case', 'series', 'bol', '##sters', 'the', 'ongoing', 'discussion', 'of', 'how', 'to', 'best', 'use', 'intravenous', 'administration', 'of', 'ketamine', 'to', 'treat', 'psychiatric', 'disorders', ',', 'particularly', 'when', 'comorbid', 'pain', 'is', 'present', 'and', '/', 'or', 'ect', 'is', 'unavailable', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '2018', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 13, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 63, 64, 65, 65, 66, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 86, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 120, 120, 120, 121, 122, 123, 124, 125, 126, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 137, 137, 137, 137, 138, 139, 139, 139, 139, 140, 141, 142, 142, 142, 142, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 178, 178, 178, 178, 179, 180, 180, 180, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 245, 245, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 321, 322, 323, 324, 325, 326, 327, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 395, 395, 396, 397, 398, 399, 400, 401, 401, 401, 402, 403, 404, 405, 406, 407, 408, 408, 409, 410, 411, 412, 413, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Intravenous ketamine relieves pain and depression after traumatic suicide attempts: A case series.^
The letter presents a series of cases where, after traumatic suicide attempts, authors administered intravenous doses of ketamine to decrease pain and acute suicidal thoughts. The first case is an 81-year-old man who presented with a suicide attempt involving self-inflicted neck laceration and left wrist laceration. On initial psychiatric consultation, it was discovered that the patient had been holding a delusional belief that he and his wife were developing dementia. After discussion with the patient, family, and surgical specialists, it was decided that the patient was not medically stable for electroconvulsive therapy (ECT) and pharmacotherapy was initiated to target symptoms of depression and psychosis using venlafaxine, mirtazapine, and aripiprazole on hospital day 3. The second case is also an elderly man who presented with a suicide attempt involving self-inflicted bilateral orbit trauma. The treatment team decided to start him on venlafaxine and mirtazapine with a rapid titration to doses of 225 mg and 30 mg, respectively. In this set of 2 cases, we have provided strong evidence of the utility of intravenous ketamine for treatment of comorbid pain, depression, and suicidal ideation after traumatic suicide attempts. This combines the traditional use of ketamine as an anesthetic with newly discovered antidepressant and antisuicidal properties. In these 2 cases, symptom relief was the desired outcome of treatment, and by this metric, the use of ketamine was a success in these patients in terms of management of pain, depression, and suicidality. Of note, both patients in this series were elderly and diagnosed as having MDD with psychotic features. These patients did not have any exacerbation of psychosis and rather appeared to lessen these symptoms, possibly by exerting treatment of their underlying depression. These treatments were given in the clinical setting, and outcomes were measured by clinicians and thus not subject to rigorous scientific scrutiny one would see in the setting of a clinical trial. This case series bolsters the ongoing discussion of how to best use intravenous administration of ketamine to treat psychiatric disorders, particularly when comorbid pain is present and/or ECT is unavailable. (PsycINFO Database Record (c) 2018 APA, all rights reserved)"
"['The', 'adverse', 'events', 'of', 'ibogaine', 'in', 'humans', ':', 'an', 'updated', 'systematic', 'review', 'of', 'the', 'literature', '(', '2015', '-', '2020).^', '\n', 'CONTEXT', ':', 'Ibogaine', 'is', 'the', 'main', 'alkaloid', 'of', 'the', 'African', 'shrub', 'Tabernanthe', 'iboga', '.', 'It', 'produces', 'hallucinogenic', 'and', 'psychostimulant', 'effects', ',', 'but', 'it', 'is', 'currently', 'known', 'for', 'the', 'anti', '-', 'addictive', 'properties', '.', 'Despite', 'the', 'potential', 'therapeutic', 'effects', ',', 'several', 'cases', 'of', 'fatalities', 'and', 'serious', 'adverse', 'events', 'related', 'to', 'ibogaine', '/', 'noribogaine', 'use', 'can', 'be', 'found', 'in', 'the', 'literature', '.', 'Most', 'studies', 'consist', 'in', 'case', 'reports', 'or', 'were', 'conducted', 'under', 'non', '-', 'controlled', 'settings', ',', 'so', 'causation', 'can', 'not', 'be', 'clearly', 'established', '.', 'OBJECTIVES', ':', 'To', 'update', '(', '2015', '-', '2020', ')', 'the', 'literature', 'on', 'the', 'adverse', 'events', 'and', 'fatalities', 'associated', 'with', 'ibogaine', '/', 'noribogaine', 'administration', '.', 'METHODS', ':', 'Systematic', 'review', 'following', 'the', 'Preferred', 'Reporting', 'Items', 'for', 'Systematic', 'Reviews', 'and', 'Meta', '-', 'Analyses', '(', 'PRISMA', ')', '.', 'RESULTS', ':', 'Eighteen', 'studies', 'were', 'included', 'in', 'the', 'final', 'selection', '.', 'Highly', 'heterogeneous', 'results', 'were', 'found', 'in', 'terms', 'of', 'kind', 'of', 'product', 'used', 'or', 'the', 'known', 'dosages', '.', 'The', 'adverse', 'events', 'were', 'classified', 'in', 'acute', 'effects', '(', '<', '24', 'h', ')', ',', 'mainly', 'cardiac', '(', 'the', 'most', 'common', 'was', 'QTc', 'prolongation', ')', ',', 'gastrointestinal', ',', 'neurological', ',', 'and', 'clinical', 'alterations', ',', 'and', 'long', '-', 'lasting', 'effects', '(', '>', '24', 'h', ')', ',', 'mainly', 'persistent', 'cardiac', 'alterations', ',', 'psychiatric', ',', 'and', 'neurological', 'signs', '.', 'CONCLUSIONS', ':', 'There', 'is', 'a', 'high', 'need', 'of', 'phase', 'I', 'clinical', 'trials', 'that', 'can', 'describe', 'the', 'safety', 'of', 'different', 'dosages', 'of', 'ibogaine', 'with', 'standardized', 'products', '.', 'Further', 'research', 'should', 'perform', 'clinical', 'profiling', 'of', 'vulnerable', 'populations', ',', 'and', 'design', 'effective', 'screening', 'methods', 'and', 'clinical', 'procedures', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6540,"['[CLS]', 'the', 'adverse', 'events', 'of', 'ib', '##oga', '##ine', 'in', 'humans', ':', 'an', 'updated', 'systematic', 'review', 'of', 'the', 'literature', '(', '2015', '-', '202', '##0', ')', '.', '^', 'context', ':', 'ib', '##oga', '##ine', 'is', 'the', 'main', 'alkal', '##oid', 'of', 'the', 'african', 'shr', '##ub', 'tab', '##ern', '##anth', '##e', 'ib', '##oga', '.', 'it', 'produces', 'halluc', '##ino', '##genic', 'and', 'psychos', '##tim', '##ulant', 'effects', ',', 'but', 'it', 'is', 'currently', 'known', 'for', 'the', 'anti', '-', 'addic', '##tive', 'properties', '.', 'despite', 'the', 'potential', 'therapeutic', 'effects', ',', 'several', 'cases', 'of', 'fatal', '##ities', 'and', 'serious', 'adverse', 'events', 'related', 'to', 'ib', '##oga', '##ine', '/', 'nor', '##ib', '##oga', '##ine', 'use', 'can', 'be', 'found', 'in', 'the', 'literature', '.', 'most', 'studies', 'consist', 'in', 'case', 'reports', 'or', 'were', 'conducted', 'under', 'non', '-', 'controlled', 'settings', ',', 'so', 'causation', 'can', 'not', 'be', 'clearly', 'established', '.', 'objectives', ':', 'to', 'update', '(', '2015', '-', '202', '##0', ')', 'the', 'literature', 'on', 'the', 'adverse', 'events', 'and', 'fatal', '##ities', 'associated', 'with', 'ib', '##oga', '##ine', '/', 'nor', '##ib', '##oga', '##ine', 'administration', '.', 'methods', ':', 'systematic', 'review', 'following', 'the', 'preferred', 'reporting', 'items', 'for', 'systematic', 'reviews', 'and', 'meta', '-', 'analyses', '(', 'prism', '##a', ')', '.', 'results', ':', 'eighteen', 'studies', 'were', 'included', 'in', 'the', 'final', 'selection', '.', 'highly', 'heterogeneous', 'results', 'were', 'found', 'in', 'terms', 'of', 'kind', 'of', 'product', 'used', 'or', 'the', 'known', 'dosages', '.', 'the', 'adverse', 'events', 'were', 'classified', 'in', 'acute', 'effects', '(', '<', '24', 'h', ')', ',', 'mainly', 'cardiac', '(', 'the', 'most', 'common', 'was', 'qt', '##c', 'prolongation', ')', ',', 'gastro', '##intestinal', ',', 'neurological', ',', 'and', 'clinical', 'alterations', ',', 'and', 'long', '-', 'lasting', 'effects', '(', '>', '24', 'h', ')', ',', 'mainly', 'persistent', 'cardiac', 'alterations', ',', 'psychiatric', ',', 'and', 'neurological', 'signs', '.', 'conclusions', ':', 'there', 'is', 'a', 'high', 'need', 'of', 'phase', 'i', 'clinical', 'trials', 'that', 'can', 'describe', 'the', 'safety', 'of', 'different', 'dosages', 'of', 'ib', '##oga', '##ine', 'with', 'standardized', 'products', '.', 'further', 'research', 'should', 'perform', 'clinical', 'profiling', 'of', 'vulnerable', 'populations', ',', 'and', 'design', 'effective', 'screening', 'methods', 'and', 'clinical', 'procedures', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 4, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 18, 18, 18, 20, 21, 22, 22, 22, 23, 24, 25, 26, 26, 27, 28, 29, 30, 30, 31, 31, 31, 31, 32, 32, 33, 34, 35, 36, 36, 36, 37, 38, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 62, 63, 64, 65, 66, 67, 68, 69, 69, 69, 70, 71, 71, 71, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 119, 120, 121, 122, 122, 122, 123, 124, 124, 124, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 196, 197, 198, 199, 200, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 251, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).^
CONTEXT: Ibogaine is the main alkaloid of the African shrub Tabernanthe iboga. It produces hallucinogenic and psychostimulant effects, but it is currently known for the anti-addictive properties. Despite the potential therapeutic effects, several cases of fatalities and serious adverse events related to ibogaine/noribogaine use can be found in the literature. Most studies consist in case reports or were conducted under non-controlled settings, so causation cannot be clearly established. OBJECTIVES: To update (2015-2020) the literature on the adverse events and fatalities associated with ibogaine/noribogaine administration. METHODS: Systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). RESULTS: Eighteen studies were included in the final selection. Highly heterogeneous results were found in terms of kind of product used or the known dosages. The adverse events were classified in acute effects (< 24 h), mainly cardiac (the most common was QTc prolongation), gastrointestinal, neurological, and clinical alterations, and long-lasting effects (> 24 h), mainly persistent cardiac alterations, psychiatric, and neurological signs. CONCLUSIONS: There is a high need of phase I clinical trials that can describe the safety of different dosages of ibogaine with standardized products. Further research should perform clinical profiling of vulnerable populations, and design effective screening methods and clinical procedures."
"['Repeated', 'intranasal', 'ketamine', 'for', 'treatment', '-', 'resistant', 'depression', '-', 'the', 'way', 'to', 'go', '?', 'Results', 'from', 'a', 'pilot', 'randomised', 'controlled', 'trial.^', '\n', 'BACKGROUND', ':', 'Ketamine', 'research', 'in', 'depression', 'has', 'mostly', 'used', 'intravenous', ',', 'weight', '-', 'based', 'approaches', ',', 'which', 'are', 'difficult', 'to', 'translate', 'clinically', '.', 'Intranasal', '(', 'IN', ')', 'ketamine', 'is', 'a', 'promising', 'alternative', 'but', 'no', 'controlled', 'data', 'has', 'been', 'published', 'on', 'the', 'feasibility', ',', 'safety', 'and', 'potential', 'efficacy', 'of', 'repeated', 'IN', 'ketamine', 'treatments', '.', 'METHODS', ':', 'This', 'randomised', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'pilot', 'study', 'compared', 'a', '4', '-', 'week', 'course', 'of', 'eight', 'treatments', 'of', '100', 'mg', 'ketamine', 'or', '4.5', 'mg', 'midazolam', '.', 'Each', 'treatment', 'was', 'given', 'as', '10', 'separate', 'IN', 'sprays', ',', 'self', '-', 'administered', '5', 'min', 'apart', '.', 'The', 'study', 'was', 'stopped', 'early', 'due', 'to', 'poor', 'tolerability', 'after', 'five', 'treatment', '-', 'resistant', 'depressed', 'participants', 'were', 'included', '.', 'Feasibility', ',', 'safety', '(', 'acute', 'and', 'cumulative', ')', ',', 'cognitive', 'and', 'efficacy', 'outcomes', 'were', 'assessed', '.', 'Plasma', 'ketamine', 'and', 'norketamine', 'concentrations', 'were', 'assayed', 'after', 'the', 'first', 'treatment', '.', 'RESULTS', ':', 'Significant', 'acute', 'cardiovascular', ',', 'psychotomimetic', 'and', 'neurological', 'side', 'effects', 'occurred', 'at', 'doses', '<', '100', 'mg', 'ketamine', '.', 'No', 'participants', 'were', 'able', 'to', 'self', '-', 'administer', 'all', '10', 'ketamine', 'sprays', 'due', 'to', 'incoordination', ';', 'treatment', 'time', 'occasionally', 'had', 'to', 'be', 'extended', '(', '>', '45', 'min', ')', 'due', 'to', 'acute', 'side', 'effects', '.', 'No', 'hepatic', ',', 'cognitive', 'or', 'urinary', 'changes', 'were', 'observed', 'after', 'the', 'treatment', 'course', 'in', 'either', 'group', '.', 'There', 'was', 'an', 'approximately', 'two', '-', 'fold', 'variation', 'in', 'ketamine', 'and', 'norketamine', 'plasma', 'concentrations', 'between', 'ketamine', 'participants', '.', 'At', 'course', 'end', ',', 'one', 'participant', 'had', 'remitted', 'in', 'each', 'of', 'the', 'ketamine', 'and', 'midazolam', 'groups', '.', 'CONCLUSIONS', ':', 'IN', 'ketamine', ',', 'with', 'the', 'drug', 'formulation', 'and', 'delivery', 'device', 'used', ',', 'was', 'not', 'a', 'useful', 'treatment', 'approach', 'in', 'this', 'study', '.', 'Absorption', 'was', 'variable', 'between', 'individuals', 'and', 'acute', 'tolerability', 'was', 'poor', ',', 'requiring', 'prolonged', 'treatment', 'administration', 'time', 'in', 'some', 'individuals', '.', 'The', 'drug', 'formulation', ',', 'the', 'delivery', 'device', ',', 'the', 'insufflation', 'technique', 'and', 'individual', 'patient', 'factors', 'play', 'an', 'important', 'role', 'in', 'tolerability', 'and', 'efficacy', 'when', 'using', 'IN', 'ketamine', 'for', 'TRD', '.']","['O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O']",2820,"['[CLS]', 'repeated', 'intran', '##asal', 'ketamine', 'for', 'treatment', '-', 'resistant', 'depression', '-', 'the', 'way', 'to', 'go', '?', 'results', 'from', 'a', 'pilot', 'randomised', 'controlled', 'trial', '.', '^', 'background', ':', 'ketamine', 'research', 'in', 'depression', 'has', 'mostly', 'used', 'intravenous', ',', 'weight', '-', 'based', 'approaches', ',', 'which', 'are', 'difficult', 'to', 'translate', 'clinically', '.', 'intran', '##asal', '(', 'in', ')', 'ketamine', 'is', 'a', 'promising', 'alternative', 'but', 'no', 'controlled', 'data', 'has', 'been', 'published', 'on', 'the', 'feasibility', ',', 'safety', 'and', 'potential', 'efficacy', 'of', 'repeated', 'in', 'ketamine', 'treatments', '.', 'methods', ':', 'this', 'randomised', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'pilot', 'study', 'compared', 'a', '4', '-', 'week', 'course', 'of', 'eight', 'treatments', 'of', '100', 'mg', 'ketamine', 'or', '4', '.', '5', 'mg', 'mid', '##azol', '##am', '.', 'each', 'treatment', 'was', 'given', 'as', '10', 'separate', 'in', 'spray', '##s', ',', 'self', '-', 'administered', '5', 'min', 'apart', '.', 'the', 'study', 'was', 'stopped', 'early', 'due', 'to', 'poor', 'tolerability', 'after', 'five', 'treatment', '-', 'resistant', 'depressed', 'participants', 'were', 'included', '.', 'feasibility', ',', 'safety', '(', 'acute', 'and', 'cumulative', ')', ',', 'cognitive', 'and', 'efficacy', 'outcomes', 'were', 'assessed', '.', 'plasma', 'ketamine', 'and', 'nor', '##ket', '##amine', 'concentrations', 'were', 'assayed', 'after', 'the', 'first', 'treatment', '.', 'results', ':', 'significant', 'acute', 'cardiovascular', ',', 'psycho', '##tom', '##ime', '##tic', 'and', 'neurological', 'side', 'effects', 'occurred', 'at', 'doses', '<', '100', 'mg', 'ketamine', '.', 'no', 'participants', 'were', 'able', 'to', 'self', '-', 'admin', '##ister', 'all', '10', 'ketamine', 'spray', '##s', 'due', 'to', 'inco', '##ord', '##ination', ';', 'treatment', 'time', 'occasionally', 'had', 'to', 'be', 'extended', '(', '>', '45', 'min', ')', 'due', 'to', 'acute', 'side', 'effects', '.', 'no', 'hepatic', ',', 'cognitive', 'or', 'urinary', 'changes', 'were', 'observed', 'after', 'the', 'treatment', 'course', 'in', 'either', 'group', '.', 'there', 'was', 'an', 'approximately', 'two', '-', 'fold', 'variation', 'in', 'ketamine', 'and', 'nor', '##ket', '##amine', 'plasma', 'concentrations', 'between', 'ketamine', 'participants', '.', 'at', 'course', 'end', ',', 'one', 'participant', 'had', 'rem', '##itt', '##ed', 'in', 'each', 'of', 'the', 'ketamine', 'and', 'mid', '##azol', '##am', 'groups', '.', 'conclusions', ':', 'in', 'ketamine', ',', 'with', 'the', 'drug', 'formulation', 'and', 'delivery', 'device', 'used', ',', 'was', 'not', 'a', 'useful', 'treatment', 'approach', 'in', 'this', 'study', '.', 'absorption', 'was', 'variable', 'between', 'individuals', 'and', 'acute', 'tolerability', 'was', 'poor', ',', 'requiring', 'prolonged', 'treatment', 'administration', 'time', 'in', 'some', 'individuals', '.', 'the', 'drug', 'formulation', ',', 'the', 'delivery', 'device', ',', 'the', 'insuff', '##lation', 'technique', 'and', 'individual', 'patient', 'factors', 'play', 'an', 'important', 'role', 'in', 'tolerability', 'and', 'efficacy', 'when', 'using', 'in', 'ketamine', 'for', 'tr', '##d', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 103, 103, 104, 105, 105, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 162, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 177, 177, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 197, 198, 199, 200, 201, 201, 202, 203, 204, 204, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 252, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 266, 266, 267, 268, 269, 270, 271, 272, 273, 273, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 348, 349, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.^
BACKGROUND: Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. METHODS: This randomised, double-blind, placebo-controlled pilot study compared a 4-week course of eight treatments of 100 mg ketamine or 4.5 mg midazolam. Each treatment was given as 10 separate IN sprays, self-administered 5 min apart. The study was stopped early due to poor tolerability after five treatment-resistant depressed participants were included. Feasibility, safety (acute and cumulative), cognitive and efficacy outcomes were assessed. Plasma ketamine and norketamine concentrations were assayed after the first treatment. RESULTS: Significant acute cardiovascular, psychotomimetic and neurological side effects occurred at doses < 100 mg ketamine. No participants were able to self-administer all 10 ketamine sprays due to incoordination; treatment time occasionally had to be extended (>45 min) due to acute side effects. No hepatic, cognitive or urinary changes were observed after the treatment course in either group. There was an approximately two-fold variation in ketamine and norketamine plasma concentrations between ketamine participants. At course end, one participant had remitted in each of the ketamine and midazolam groups. CONCLUSIONS: IN ketamine, with the drug formulation and delivery device used, was not a useful treatment approach in this study. Absorption was variable between individuals and acute tolerability was poor, requiring prolonged treatment administration time in some individuals. The drug formulation, the delivery device, the insufflation technique and individual patient factors play an important role in tolerability and efficacy when using IN ketamine for TRD."
"['Neuronal', 'correlates', 'of', 'visual', 'and', 'auditory', 'alertness', 'in', 'the', 'DMT', 'and', 'ketamine', 'model', 'of', 'psychosis.^', '\n', 'Deficits', 'in', 'attentional', 'functions', 'belong', 'to', 'the', 'core', 'cognitive', 'symptoms', 'in', 'schizophrenic', 'patients', '.', 'Alertness', 'is', 'a', 'nonselective', 'attention', 'component', 'that', 'refers', 'to', 'a', 'state', 'of', 'general', 'readiness', 'that', 'improves', 'stimulus', 'processing', 'and', 'response', 'initiation', '.', 'The', 'main', 'goal', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'cerebral', 'correlates', 'of', 'alertness', 'in', 'the', 'human', '5HT(2A', ')', 'agonist', 'and', 'N', '-', 'methyl', '-', 'D', '-', 'aspartic', 'acid', '(', 'NMDA', ')', 'antagonist', 'model', 'of', 'psychosis', '.', 'Fourteen', 'healthy', 'volunteers', 'participated', 'in', 'a', 'randomized', 'double', '-', 'blind', ',', 'cross', '-', 'over', 'event', '-', 'related', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'study', 'with', 'dimethyltryptamine', '(', 'DMT', ')', 'and', 'S', '-', 'ketamine', '.', 'A', 'target', 'detection', 'task', 'with', 'cued', 'and', 'uncued', 'trials', 'in', 'both', 'the', 'visual', 'and', 'the', 'auditory', 'modality', 'was', 'used', '.', 'Administration', 'of', 'DMT', 'led', 'to', 'decreased', 'blood', 'oxygenation', 'level', '-', 'dependent', 'response', 'during', 'performance', 'of', 'an', 'alertness', 'task', ',', 'particularly', 'in', 'extrastriate', 'regions', 'during', 'visual', 'alerting', 'and', 'in', 'temporal', 'regions', 'during', 'auditory', 'alerting', '.', 'In', 'general', ',', 'the', 'effects', 'for', 'the', 'visual', 'modality', 'were', 'more', 'pronounced', '.', 'In', 'contrast', ',', 'administration', 'of', 'S', '-', 'ketamine', 'led', 'to', 'increased', 'cortical', 'activation', 'in', 'the', 'left', 'insula', 'and', 'precentral', 'gyrus', 'in', 'the', 'auditory', 'modality', '.', 'The', 'results', 'of', 'the', 'present', 'study', 'might', 'deliver', 'more', 'insight', 'into', 'potential', 'differences', 'and', 'overlapping', 'pathomechanisms', 'in', 'schizophrenia', '.', 'These', 'conclusions', 'must', 'remain', 'preliminary', 'and', 'should', 'be', 'explored', 'by', 'further', 'fMRI', 'studies', 'with', 'schizophrenic', 'patients', 'performing', 'modality', '-', 'specific', 'alertness', 'tasks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1850,"['[CLS]', 'neuronal', 'correlates', 'of', 'visual', 'and', 'auditory', 'alert', '##ness', 'in', 'the', 'dm', '##t', 'and', 'ketamine', 'model', 'of', 'psychosis', '.', '^', 'deficits', 'in', 'attentional', 'functions', 'belong', 'to', 'the', 'core', 'cognitive', 'symptoms', 'in', 'schizophren', '##ic', 'patients', '.', 'alert', '##ness', 'is', 'a', 'nons', '##elec', '##tive', 'attention', 'component', 'that', 'refers', 'to', 'a', 'state', 'of', 'general', 'readiness', 'that', 'improves', 'stimulus', 'processing', 'and', 'response', 'initiation', '.', 'the', 'main', 'goal', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'cerebral', 'correlates', 'of', 'alert', '##ness', 'in', 'the', 'human', '5', '##ht', '(', '2', '##a', ')', 'agonist', 'and', 'n', '-', 'methyl', '-', 'd', '-', 'aspart', '##ic', 'acid', '(', 'nmda', ')', 'antagonist', 'model', 'of', 'psychosis', '.', 'fourteen', 'healthy', 'volunteers', 'participated', 'in', 'a', 'randomized', 'double', '-', 'blind', ',', 'cross', '-', 'over', 'event', '-', 'related', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fmri', ')', 'study', 'with', 'dimethyl', '##try', '##pt', '##amine', '(', 'dm', '##t', ')', 'and', 's', '-', 'ketamine', '.', 'a', 'target', 'detection', 'task', 'with', 'cue', '##d', 'and', 'unc', '##ued', 'trials', 'in', 'both', 'the', 'visual', 'and', 'the', 'auditory', 'modality', 'was', 'used', '.', 'administration', 'of', 'dm', '##t', 'led', 'to', 'decreased', 'blood', 'oxygenation', 'level', '-', 'dependent', 'response', 'during', 'performance', 'of', 'an', 'alert', '##ness', 'task', ',', 'particularly', 'in', 'extra', '##stri', '##ate', 'regions', 'during', 'visual', 'alert', '##ing', 'and', 'in', 'temporal', 'regions', 'during', 'auditory', 'alert', '##ing', '.', 'in', 'general', ',', 'the', 'effects', 'for', 'the', 'visual', 'modality', 'were', 'more', 'pronounced', '.', 'in', 'contrast', ',', 'administration', 'of', 's', '-', 'ketamine', 'led', 'to', 'increased', 'cortical', 'activation', 'in', 'the', 'left', 'ins', '##ula', 'and', 'prec', '##entral', 'gyrus', 'in', 'the', 'auditory', 'modality', '.', 'the', 'results', 'of', 'the', 'present', 'study', 'might', 'deliver', 'more', 'insight', 'into', 'potential', 'differences', 'and', 'overlapping', 'path', '##ome', '##chan', '##isms', 'in', 'schizophrenia', '.', 'these', 'conclusions', 'must', 'remain', 'preliminary', 'and', 'should', 'be', 'explored', 'by', 'further', 'fmri', 'studies', 'with', 'schizophren', '##ic', 'patients', 'performing', 'modality', '-', 'specific', 'alert', '##ness', 'tasks', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 6, 7, 8, 9, 9, 10, 11, 12, 13, 14, 14, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 27, 28, 29, 30, 30, 31, 32, 33, 33, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 65, 66, 67, 68, 69, 69, 69, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 115, 115, 115, 116, 117, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 129, 130, 131, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 160, 161, 162, 163, 164, 165, 165, 165, 166, 167, 168, 169, 169, 170, 171, 172, 173, 174, 175, 176, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 207, 208, 209, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 231, 231, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 249, 250, 251, 252, 253, 254, 255, 255, 256, 257, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis.^
Deficits in attentional functions belong to the core cognitive symptoms in schizophrenic patients. Alertness is a nonselective attention component that refers to a state of general readiness that improves stimulus processing and response initiation. The main goal of the present study was to investigate cerebral correlates of alertness in the human 5HT(2A) agonist and N-methyl-D-aspartic acid (NMDA) antagonist model of psychosis. Fourteen healthy volunteers participated in a randomized double-blind, cross-over event-related functional magnetic resonance imaging (fMRI) study with dimethyltryptamine (DMT) and S-ketamine. A target detection task with cued and uncued trials in both the visual and the auditory modality was used. Administration of DMT led to decreased blood oxygenation level-dependent response during performance of an alertness task, particularly in extrastriate regions during visual alerting and in temporal regions during auditory alerting. In general, the effects for the visual modality were more pronounced. In contrast, administration of S-ketamine led to increased cortical activation in the left insula and precentral gyrus in the auditory modality. The results of the present study might deliver more insight into potential differences and overlapping pathomechanisms in schizophrenia. These conclusions must remain preliminary and should be explored by further fMRI studies with schizophrenic patients performing modality-specific alertness tasks."
"['Co', '-', 'use', 'of', 'MDMA', 'with', 'psilocybin', '/', 'LSD', 'may', 'buffer', 'against', 'challenging', 'experiences', 'and', 'enhance', 'positive', 'experiences.^', '\n', 'Psilocybin', 'and', 'lysergic', 'acid', 'diethylamide', '(', 'LSD', ')', 'experiences', 'can', 'range', 'from', 'very', 'positive', 'to', 'highly', 'challenging', '(', 'e.g.', ',', 'fear', ',', 'grief', ',', 'and', 'paranoia', ')', '.', 'These', 'challenging', 'experiences', 'contribute', 'to', 'hesitancy', 'toward', 'psychedelic', '-', 'assisted', 'psychotherapy', 'among', 'health', 'care', 'providers', 'and', 'patients', '.', 'Co', '-', 'use', 'of', '3,4', '-', 'Methylenedioxy', 'methamphetamine', '(', 'MDMA', ')', 'with', 'psilocybin', '/', 'LSD', 'anecdotally', 'reduces', 'challenging', 'experiences', 'and', 'enhances', 'positive', 'experiences', 'associated', 'with', 'psilocybin', '/', 'LSD', '.', 'However', ',', 'limited', 'research', 'has', 'investigated', 'the', 'acute', 'effects', 'of', 'co', '-', 'use', 'of', 'MDMA', 'and', 'psilocybin', '/', 'LSD', '.', 'In', 'a', 'prospective', 'convenience', 'sample', '(', 'N', '=', '698', ')', 'of', 'individuals', 'with', 'plans', 'to', 'use', 'psilocybin', '/', 'LSD', ',', 'we', 'examined', 'whether', 'co', '-', 'use', 'of', 'MDMA', 'with', 'psilocybin', '/', 'LSD', '(', 'n', '=', '27', ')', 'is', 'associated', 'with', 'differences', 'in', 'challenging', 'or', 'positive', 'experiences', '.', 'Challenging', 'experiences', 'were', 'measured', 'using', 'the', 'Challenging', 'Experiences', 'Questionnaire', 'and', 'positive', 'experiences', 'were', 'measured', 'using', 'the', 'Mystical', 'Experience', 'Questionnaire', 'and', 'single', '-', 'item', 'measures', 'of', 'self', '-', 'compassion', ',', 'compassion', ',', 'love', ',', 'and', 'gratitude', '.', 'Potentially', 'confounding', 'variables', 'were', 'identified', 'and', 'included', 'as', 'covariates', '.', 'Relative', 'to', 'psilocybin', '/', 'LSD', 'alone', ',', 'co', '-', 'use', 'of', 'psilocybin', '/', 'LSD', 'with', 'a', 'self', '-', 'reported', 'low', '(', 'but', 'not', 'medium', '-', 'high', ')', 'dose', 'of', 'MDMA', 'was', 'associated', 'with', 'significantly', 'less', 'intense', 'total', 'challenging', 'experiences', ',', 'grief', ',', 'and', 'fear', ',', 'as', 'well', 'as', 'increased', 'self', '-', 'compassion', ',', 'love', 'and', 'gratitude', '.', 'Co', '-', 'use', 'of', 'psilocybin', '/', 'LSD', 'and', 'MDMA', 'was', 'not', 'associated', 'with', 'differences', 'in', 'mystical', '-', 'type', 'experiences', 'or', 'compassion', '.', 'Findings', 'suggest', 'co', '-', 'use', 'of', 'MDMA', 'with', 'psilocybin', '/', 'LSD', 'may', 'buffer', 'against', 'some', 'aspects', 'of', 'challenging', 'experiences', 'and', 'enhance', 'certain', 'positive', 'experiences', '.', 'Limitations', 'include', 'use', 'of', 'a', 'convenience', 'sample', ',', 'small', 'sample', 'size', ',', 'and', 'non', '-', 'experimental', 'design', '.', 'Additional', 'studies', '(', 'including', 'controlled', 'dose', '-', 'response', 'studies', ')', 'that', 'examine', 'the', 'effects', 'and', 'safety', 'of', 'co', '-', 'administering', 'MDMA', 'with', 'psilocybin', '/', 'LSD', '(', 'in', 'healthy', 'controls', 'and', 'clinical', 'samples', ')', 'are', 'warranted', 'and', 'may', 'assist', 'the', 'development', 'of', 'personalized', 'treatments', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",9503,"['[CLS]', 'co', '-', 'use', 'of', 'mdm', '##a', 'with', 'psi', '##loc', '##yb', '##in', '/', 'lsd', 'may', 'buffer', 'against', 'challenging', 'experiences', 'and', 'enhance', 'positive', 'experiences', '.', '^', 'psi', '##loc', '##yb', '##in', 'and', 'lys', '##ergic', 'acid', 'diethyl', '##amide', '(', 'lsd', ')', 'experiences', 'can', 'range', 'from', 'very', 'positive', 'to', 'highly', 'challenging', '(', 'e', '.', 'g', '.', ',', 'fear', ',', 'gri', '##ef', ',', 'and', 'paran', '##oi', '##a', ')', '.', 'these', 'challenging', 'experiences', 'contribute', 'to', 'hes', '##itan', '##cy', 'toward', 'psych', '##ede', '##lic', '-', 'assisted', 'psychotherapy', 'among', 'health', 'care', 'providers', 'and', 'patients', '.', 'co', '-', 'use', 'of', '3', ',', '4', '-', 'methylene', '##di', '##oxy', 'meth', '##amphetamine', '(', 'mdm', '##a', ')', 'with', 'psi', '##loc', '##yb', '##in', '/', 'lsd', 'an', '##ecd', '##otal', '##ly', 'reduces', 'challenging', 'experiences', 'and', 'enhances', 'positive', 'experiences', 'associated', 'with', 'psi', '##loc', '##yb', '##in', '/', 'lsd', '.', 'however', ',', 'limited', 'research', 'has', 'investigated', 'the', 'acute', 'effects', 'of', 'co', '-', 'use', 'of', 'mdm', '##a', 'and', 'psi', '##loc', '##yb', '##in', '/', 'lsd', '.', 'in', 'a', 'prospective', 'convenience', 'sample', '(', 'n', '=', '69', '##8', ')', 'of', 'individuals', 'with', 'plans', 'to', 'use', 'psi', '##loc', '##yb', '##in', '/', 'lsd', ',', 'we', 'examined', 'whether', 'co', '-', 'use', 'of', 'mdm', '##a', 'with', 'psi', '##loc', '##yb', '##in', '/', 'lsd', '(', 'n', '=', '27', ')', 'is', 'associated', 'with', 'differences', 'in', 'challenging', 'or', 'positive', 'experiences', '.', 'challenging', 'experiences', 'were', 'measured', 'using', 'the', 'challenging', 'experiences', 'questionnaire', 'and', 'positive', 'experiences', 'were', 'measured', 'using', 'the', 'mys', '##tical', 'experience', 'questionnaire', 'and', 'single', '-', 'item', 'measures', 'of', 'self', '-', 'comp', '##assion', ',', 'comp', '##assion', ',', 'love', ',', 'and', 'gratitude', '.', 'potentially', 'confounding', 'variables', 'were', 'identified', 'and', 'included', 'as', 'covariates', '.', 'relative', 'to', 'psi', '##loc', '##yb', '##in', '/', 'lsd', 'alone', ',', 'co', '-', 'use', 'of', 'psi', '##loc', '##yb', '##in', '/', 'lsd', 'with', 'a', 'self', '-', 'reported', 'low', '(', 'but', 'not', 'medium', '-', 'high', ')', 'dose', 'of', 'mdm', '##a', 'was', 'associated', 'with', 'significantly', 'less', 'intense', 'total', 'challenging', 'experiences', ',', 'gri', '##ef', ',', 'and', 'fear', ',', 'as', 'well', 'as', 'increased', 'self', '-', 'comp', '##assion', ',', 'love', 'and', 'gratitude', '.', 'co', '-', 'use', 'of', 'psi', '##loc', '##yb', '##in', '/', 'lsd', 'and', 'mdm', '##a', 'was', 'not', 'associated', 'with', 'differences', 'in', 'mys', '##tical', '-', 'type', 'experiences', 'or', 'comp', '##assion', '.', 'findings', 'suggest', 'co', '-', 'use', 'of', 'mdm', '##a', 'with', 'psi', '##loc', '##yb', '##in', '/', 'lsd', 'may', 'buffer', 'against', 'some', 'aspects', 'of', 'challenging', 'experiences', 'and', 'enhance', 'certain', 'positive', 'experiences', '.', 'limitations', 'include', 'use', 'of', 'a', 'convenience', 'sample', ',', 'small', 'sample', 'size', ',', 'and', 'non', '-', 'experimental', 'design', '.', 'additional', 'studies', '(', 'including', 'controlled', 'dose', '-', 'response', 'studies', ')', 'that', 'examine', 'the', 'effects', 'and', 'safety', 'of', 'co', '-', 'admin', '##istering', 'mdm', '##a', 'with', 'psi', '##loc', '##yb', '##in', '/', 'lsd', '(', 'in', 'healthy', 'controls', 'and', 'clinical', 'samples', ')', 'are', 'warranted', 'and', 'may', 'assist', 'the', 'development', 'of', 'personalized', 'treatments', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 4, 5, 6, 6, 6, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 17, 17, 19, 19, 19, 19, 20, 21, 21, 22, 23, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 37, 37, 37, 38, 39, 40, 41, 41, 42, 43, 44, 44, 44, 45, 46, 47, 48, 49, 50, 51, 52, 52, 52, 53, 54, 54, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 69, 70, 71, 71, 71, 72, 72, 73, 74, 74, 75, 76, 77, 77, 77, 77, 78, 79, 80, 80, 80, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 90, 90, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 108, 109, 110, 110, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 122, 123, 124, 125, 126, 127, 128, 129, 130, 130, 130, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 141, 142, 143, 143, 143, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 188, 189, 190, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 209, 209, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 218, 218, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 268, 268, 268, 269, 270, 271, 272, 272, 273, 274, 275, 276, 277, 278, 279, 279, 280, 281, 282, 283, 284, 284, 285, 286, 287, 288, 289, 290, 291, 292, 292, 293, 294, 294, 294, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 348, 349, 349, 350, 351, 351, 351, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.^
Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health care providers and patients. Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin/LSD anecdotally reduces challenging experiences and enhances positive experiences associated with psilocybin/LSD. However, limited research has investigated the acute effects of co-use of MDMA and psilocybin/LSD. In a prospective convenience sample (N = 698) of individuals with plans to use psilocybin/LSD, we examined whether co-use of MDMA with psilocybin/LSD (n = 27) is associated with differences in challenging or positive experiences. Challenging experiences were measured using the Challenging Experiences Questionnaire and positive experiences were measured using the Mystical Experience Questionnaire and single-item measures of self-compassion, compassion, love, and gratitude. Potentially confounding variables were identified and included as covariates. Relative to psilocybin/LSD alone, co-use of psilocybin/LSD with a self-reported low (but not medium-high) dose of MDMA was associated with significantly less intense total challenging experiences, grief, and fear, as well as increased self-compassion, love and gratitude. Co-use of psilocybin/LSD and MDMA was not associated with differences in mystical-type experiences or compassion. Findings suggest co-use of MDMA with psilocybin/LSD may buffer against some aspects of challenging experiences and enhance certain positive experiences. Limitations include use of a convenience sample, small sample size, and non-experimental design. Additional studies (including controlled dose-response studies) that examine the effects and safety of co-administering MDMA with psilocybin/LSD (in healthy controls and clinical samples) are warranted and may assist the development of personalized treatments."
"['Comparative', 'Effects', 'of', 'Methylphenidate', ',', 'Modafinil', ',', 'and', 'MDMA', 'on', 'Response', 'Inhibition', 'Neural', 'Networks', 'in', 'Healthy', 'Subjects.^', '\n', 'BACKGROUND', ':', 'Psychostimulants', 'such', 'as', 'methylphenidate', 'and', 'modafinil', 'are', 'increasingly', 'used', 'by', 'healthy', 'people', 'for', 'cognitive', 'enhancement', 'purposes', ',', 'whereas', 'the', 'acute', 'effect', 'of', '3,4', '-', 'methylenedioxymethamphetamine', '(', 'ecstasy', ')', 'on', 'cognitive', 'functioning', 'in', 'healthy', 'subjects', 'remains', 'unclear', '.', 'This', 'study', 'directly', 'compared', 'the', 'acute', 'effects', 'of', 'methylphenidate', ',', 'modafinil', ',', 'and', '3,4', '-', 'methylenedioxymethamphetamine', 'on', 'the', 'neural', 'mechanisms', 'underlying', 'response', 'inhibition', 'in', 'healthy', 'subjects', '.', 'METHODS', ':', 'Using', 'a', 'double', '-', 'blind', ',', 'within', '-', 'subject', ',', 'placebo', '-', 'controlled', ',', 'cross', '-', 'over', 'design', ',', 'methylphenidate', ',', 'modafinil', ',', 'and', '3,4', '-', 'methylenedioxymethamphetamine', 'were', 'administrated', 'to', '21', 'healthy', 'subjects', 'while', 'performing', 'a', 'go', '/', 'no', '-', 'go', 'event', '-', 'related', 'functional', 'magnetic', 'resonance', 'imaging', 'task', 'to', 'assess', 'brain', 'activation', 'during', 'motor', 'response', 'inhibition', '.', 'RESULTS', ':', 'Relative', 'to', 'placebo', ',', 'methylphenidate', 'and', 'modafinil', 'but', 'not', '3,4', '-', 'methylenedioxymethamphetamine', 'improved', 'inhibitory', 'performance', '.', 'Methylphenidate', 'significantly', 'increased', 'activation', 'in', 'the', 'right', 'middle', 'frontal', 'gyrus', ',', 'middle', '/', 'superior', 'temporal', 'gyrus', ',', 'inferior', 'parietal', 'lobule', ',', 'presupplementary', 'motor', 'area', ',', 'and', 'anterior', 'cingulate', 'cortex', 'compared', 'with', 'placebo', '.', 'Methylphenidate', 'also', 'induced', 'significantly', 'higher', 'activation', 'in', 'the', 'anterior', 'cingulate', 'cortex', 'and', 'presupplementary', 'motor', 'area', 'and', 'relative', 'to', 'modafinil', '.', 'Relative', 'to', 'placebo', ',', 'modafinil', 'significantly', 'increased', 'activation', 'in', 'the', 'right', 'middle', 'frontal', 'gyrus', 'and', 'superior', '/', 'inferior', 'parietal', 'lobule', ',', 'while', '3,4', '-', 'methylenedioxymethamphetamine', 'significantly', 'increased', 'activation', 'in', 'the', 'right', 'middle', '/', 'inferior', 'frontal', 'gyrus', 'and', 'superior', 'parietal', 'lobule', '.', 'CONCLUSIONS', ':', 'Direct', 'comparison', 'of', 'methylphenidate', ',', 'modafinil', ',', 'and', '3,4', '-', 'methylenedioxymethamphetamine', 'revealed', 'broad', 'recruitment', 'of', 'fronto', '-', 'parietal', 'regions', 'but', 'specific', 'effects', 'of', 'methylphenidate', 'on', 'middle', '/', 'superior', 'temporal', 'gyrus', ',', 'anterior', 'cingulate', 'cortex', ',', 'and', 'presupplementary', 'motor', 'area', 'activation', ',', 'suggesting', 'dissociable', 'modulations', 'of', 'response', 'inhibition', 'networks', 'and', 'potentially', 'the', 'superiority', 'of', 'methylphenidate', 'in', 'the', 'enhancement', 'of', 'cognitive', 'performance', 'in', 'healthy', 'subjects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7752,"['[CLS]', 'comparative', 'effects', 'of', 'methyl', '##phen', '##idate', ',', 'mod', '##af', '##ini', '##l', ',', 'and', 'mdm', '##a', 'on', 'response', 'inhibition', 'neural', 'networks', 'in', 'healthy', 'subjects', '.', '^', 'background', ':', 'psychos', '##tim', '##ulant', '##s', 'such', 'as', 'methyl', '##phen', '##idate', 'and', 'mod', '##af', '##ini', '##l', 'are', 'increasingly', 'used', 'by', 'healthy', 'people', 'for', 'cognitive', 'enhancement', 'purposes', ',', 'whereas', 'the', 'acute', 'effect', 'of', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'ecs', '##tas', '##y', ')', 'on', 'cognitive', 'functioning', 'in', 'healthy', 'subjects', 'remains', 'unclear', '.', 'this', 'study', 'directly', 'compared', 'the', 'acute', 'effects', 'of', 'methyl', '##phen', '##idate', ',', 'mod', '##af', '##ini', '##l', ',', 'and', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', 'on', 'the', 'neural', 'mechanisms', 'underlying', 'response', 'inhibition', 'in', 'healthy', 'subjects', '.', 'methods', ':', 'using', 'a', 'double', '-', 'blind', ',', 'within', '-', 'subject', ',', 'placebo', '-', 'controlled', ',', 'cross', '-', 'over', 'design', ',', 'methyl', '##phen', '##idate', ',', 'mod', '##af', '##ini', '##l', ',', 'and', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', 'were', 'administr', '##ated', 'to', '21', 'healthy', 'subjects', 'while', 'performing', 'a', 'go', '/', 'no', '-', 'go', 'event', '-', 'related', 'functional', 'magnetic', 'resonance', 'imaging', 'task', 'to', 'assess', 'brain', 'activation', 'during', 'motor', 'response', 'inhibition', '.', 'results', ':', 'relative', 'to', 'placebo', ',', 'methyl', '##phen', '##idate', 'and', 'mod', '##af', '##ini', '##l', 'but', 'not', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', 'improved', 'inhibitory', 'performance', '.', 'methyl', '##phen', '##idate', 'significantly', 'increased', 'activation', 'in', 'the', 'right', 'middle', 'frontal', 'gyrus', ',', 'middle', '/', 'superior', 'temporal', 'gyrus', ',', 'inferior', 'parietal', 'lob', '##ule', ',', 'presup', '##plement', '##ary', 'motor', 'area', ',', 'and', 'anterior', 'cingulate', 'cortex', 'compared', 'with', 'placebo', '.', 'methyl', '##phen', '##idate', 'also', 'induced', 'significantly', 'higher', 'activation', 'in', 'the', 'anterior', 'cingulate', 'cortex', 'and', 'presup', '##plement', '##ary', 'motor', 'area', 'and', 'relative', 'to', 'mod', '##af', '##ini', '##l', '.', 'relative', 'to', 'placebo', ',', 'mod', '##af', '##ini', '##l', 'significantly', 'increased', 'activation', 'in', 'the', 'right', 'middle', 'frontal', 'gyrus', 'and', 'superior', '/', 'inferior', 'parietal', 'lob', '##ule', ',', 'while', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', 'significantly', 'increased', 'activation', 'in', 'the', 'right', 'middle', '/', 'inferior', 'frontal', 'gyrus', 'and', 'superior', 'parietal', 'lob', '##ule', '.', 'conclusions', ':', 'direct', 'comparison', 'of', 'methyl', '##phen', '##idate', ',', 'mod', '##af', '##ini', '##l', ',', 'and', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', 'revealed', 'broad', 'recruitment', 'of', 'front', '##o', '-', 'parietal', 'regions', 'but', 'specific', 'effects', 'of', 'methyl', '##phen', '##idate', 'on', 'middle', '/', 'superior', 'temporal', 'gyrus', ',', 'anterior', 'cingulate', 'cortex', ',', 'and', 'presup', '##plement', '##ary', 'motor', 'area', 'activation', ',', 'suggesting', 'dissoci', '##able', 'modulation', '##s', 'of', 'response', 'inhibition', 'networks', 'and', 'potentially', 'the', 'superiority', 'of', 'methyl', '##phen', '##idate', 'in', 'the', 'enhancement', 'of', 'cognitive', 'performance', 'in', 'healthy', 'subjects', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 4, 5, 5, 5, 5, 6, 7, 8, 8, 9, 10, 11, 12, 13, 14, 15, 16, 16, 16, 18, 19, 20, 20, 20, 20, 21, 22, 23, 23, 23, 24, 25, 25, 25, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 42, 42, 43, 44, 44, 44, 44, 44, 45, 46, 46, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 65, 65, 66, 67, 67, 67, 67, 68, 69, 70, 70, 70, 71, 72, 72, 72, 72, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 105, 105, 106, 107, 107, 107, 107, 108, 109, 110, 110, 110, 111, 112, 112, 112, 112, 112, 113, 114, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 150, 150, 151, 152, 152, 152, 152, 153, 154, 155, 155, 155, 156, 157, 157, 157, 157, 157, 158, 159, 160, 161, 162, 162, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 181, 182, 183, 183, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 207, 207, 208, 209, 210, 211, 212, 213, 213, 213, 213, 214, 215, 216, 217, 218, 219, 219, 219, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 234, 235, 236, 237, 237, 237, 238, 239, 239, 239, 239, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 254, 255, 256, 257, 258, 259, 260, 261, 261, 261, 262, 263, 263, 263, 263, 264, 265, 266, 266, 266, 267, 268, 268, 268, 268, 268, 269, 270, 271, 272, 273, 273, 274, 275, 276, 277, 278, 279, 280, 281, 281, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 294, 294, 295, 296, 297, 298, 299, 300, 300, 301, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 311, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Comparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects.^
BACKGROUND: Psychostimulants such as methylphenidate and modafinil are increasingly used by healthy people for cognitive enhancement purposes, whereas the acute effect of 3,4-methylenedioxymethamphetamine (ecstasy) on cognitive functioning in healthy subjects remains unclear. This study directly compared the acute effects of methylphenidate, modafinil, and 3,4-methylenedioxymethamphetamine on the neural mechanisms underlying response inhibition in healthy subjects. METHODS: Using a double-blind, within-subject, placebo-controlled, cross-over design, methylphenidate, modafinil, and 3,4-methylenedioxymethamphetamine were administrated to 21 healthy subjects while performing a go/no-go event-related functional magnetic resonance imaging task to assess brain activation during motor response inhibition. RESULTS: Relative to placebo, methylphenidate and modafinil but not 3,4-methylenedioxymethamphetamine improved inhibitory performance. Methylphenidate significantly increased activation in the right middle frontal gyrus, middle/superior temporal gyrus, inferior parietal lobule, presupplementary motor area, and anterior cingulate cortex compared with placebo. Methylphenidate also induced significantly higher activation in the anterior cingulate cortex and presupplementary motor area and relative to modafinil. Relative to placebo, modafinil significantly increased activation in the right middle frontal gyrus and superior/inferior parietal lobule, while 3,4-methylenedioxymethamphetamine significantly increased activation in the right middle/inferior frontal gyrus and superior parietal lobule. CONCLUSIONS: Direct comparison of methylphenidate, modafinil, and 3,4-methylenedioxymethamphetamine revealed broad recruitment of fronto-parietal regions but specific effects of methylphenidate on middle/superior temporal gyrus, anterior cingulate cortex, and presupplementary motor area activation, suggesting dissociable modulations of response inhibition networks and potentially the superiority of methylphenidate in the enhancement of cognitive performance in healthy subjects."
"['Ayahuasca', 'improves', 'emotion', 'dysregulation', 'in', 'a', 'community', 'sample', 'and', 'in', 'individuals', 'with', 'borderline', '-', 'like', 'traits.^', '\n', 'BACKGROUND', ':', 'Research', 'suggests', 'that', 'mindfulness', '-', 'based', 'interventions', 'may', 'improve', 'mindfulness', '-', 'related', 'capacities', '(', 'e.g.', ',', 'decentering', ',', 'non', '-', 'judging', ',', 'and', 'non', '-', 'reacting', ')', 'and', 'emotion', 'regulation', '.', 'Previously', ',', 'our', 'group', 'reported', 'that', 'ayahuasca', 'could', 'be', 'a', 'potential', 'analogue', 'of', 'mindfulness', 'practice', '.', 'The', 'main', 'aim', 'of', 'the', 'current', 'study', 'was', 'to', 'examine', 'the', 'effects', 'of', 'ayahuasca', 'on', 'emotional', 'regulation', 'and', 'mindfulness', '-', 'related', 'capacities', '.', 'Secondarily', ',', 'we', 'sought', 'to', 'explore', 'the', 'effects', 'of', 'ayahuasca', 'on', 'individuals', 'with', 'borderline', 'personality', 'disorder', '(', 'BPD', ')', 'traits', '.', 'METHOD', ':', 'This', 'is', 'an', 'observational', 'study', 'of', '45', 'volunteers', 'who', 'participated', 'in', 'an', 'ayahuasca', 'session', '.', 'The', 'volunteers', 'completed', 'various', 'self', '-', 'report', 'instruments', 'designed', 'to', 'measure', 'emotional', 'dysregulation', '(', 'Difficulties', 'in', 'Emotion', 'Regulation', 'Scale', '(', 'DERS', ')', ')', 'and', 'mindfulness', 'traits', '(', 'Five', 'Facet', 'Mindfulness', 'Questionnaire', '(', 'FFMQ)-Short', 'Form', 'and', 'Experiences', 'Questionnaire', '(', 'EQ', ')', ')', 'prior', 'to', 'and', '24', 'h', 'after', 'the', 'ayahuasca', 'session', '.', 'The', 'volunteers', 'were', 'divided', 'into', 'two', 'subgroups', 'based', 'on', 'their', 'score', 'on', 'the', 'McLean', 'Screening', 'Instrument', 'for', 'BPD', '(', 'MSI', '-', 'BPD', ')', '.', 'Twelve', 'participants', 'were', 'grouped', 'into', 'the', 'BPD', '-', 'like', 'traits', 'subgroup', 'while', 'the', 'rest', 'of', 'them', 'were', 'included', 'in', 'the', 'non', '-', 'BPD', '-', 'like', 'subgroup', '.', 'We', 'performed', 'within', '-', 'subjects', 'and', 'between', '-', 'group', 'analyses', '.', 'RESULTS', ':', 'Overall', ',', 'the', 'participants', 'showed', 'significant', 'improvements', 'on', 'the', 'FFMQ', 'subscales', 'observing', ',', 'acting', 'with', 'awareness', ',', 'non', '-', 'judging', ',', 'and', 'non', '-', 'reacting', 'and', 'also', 'significantly', 'improved', 'on', 'decentering', '(', 'EQ', 'scale', ')', 'and', 'on', 'the', 'DERS', 'subscales', 'emotional', 'non', '-', 'acceptance', ',', 'emotional', 'interference', ',', 'and', 'lack', 'of', 'control', '.', 'The', 'BPD', '-', 'like', 'subgroup', 'also', 'showed', 'significant', 'improvements', 'on', 'the', 'DERS', 'subscales', 'emotional', 'interference', 'and', 'lack', 'of', 'control', 'but', 'not', 'in', 'mindfulness', 'capacities', '.', 'CONCLUSIONS', ':', 'These', 'findings', 'suggest', 'a', 'potential', 'therapeutic', 'effect', 'for', 'ayahuasca', 'in', 'emotion', 'regulation', 'and', 'mindfulness', 'capacities', '(', 'including', 'decentering', ',', 'acceptance', ',', 'awareness', ',', 'and', 'sensitivity', 'to', 'meditation', 'practice', ')', '.', 'Based', 'on', 'these', 'results', ',', 'we', 'believe', 'that', 'ayahuasca', 'therapy', 'could', 'be', 'of', 'value', 'in', 'clinical', 'populations', ',', 'such', 'as', 'individuals', 'with', 'BPD', ',', 'affected', 'by', 'emotion', 'dysregulation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",2117,"['[CLS]', 'ay', '##ah', '##ua', '##sc', '##a', 'improves', 'emotion', 'dysregulation', 'in', 'a', 'community', 'sample', 'and', 'in', 'individuals', 'with', 'borderline', '-', 'like', 'traits', '.', '^', 'background', ':', 'research', 'suggests', 'that', 'mind', '##fulness', '-', 'based', 'interventions', 'may', 'improve', 'mind', '##fulness', '-', 'related', 'capacities', '(', 'e', '.', 'g', '.', ',', 'dece', '##nt', '##ering', ',', 'non', '-', 'judg', '##ing', ',', 'and', 'non', '-', 'reacting', ')', 'and', 'emotion', 'regulation', '.', 'previously', ',', 'our', 'group', 'reported', 'that', 'ay', '##ah', '##ua', '##sc', '##a', 'could', 'be', 'a', 'potential', 'analogue', 'of', 'mind', '##fulness', 'practice', '.', 'the', 'main', 'aim', 'of', 'the', 'current', 'study', 'was', 'to', 'examine', 'the', 'effects', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'on', 'emotional', 'regulation', 'and', 'mind', '##fulness', '-', 'related', 'capacities', '.', 'second', '##arily', ',', 'we', 'sought', 'to', 'explore', 'the', 'effects', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'on', 'individuals', 'with', 'borderline', 'personality', 'disorder', '(', 'bpd', ')', 'traits', '.', 'method', ':', 'this', 'is', 'an', 'observational', 'study', 'of', '45', 'volunteers', 'who', 'participated', 'in', 'an', 'ay', '##ah', '##ua', '##sc', '##a', 'session', '.', 'the', 'volunteers', 'completed', 'various', 'self', '-', 'report', 'instruments', 'designed', 'to', 'measure', 'emotional', 'dysregulation', '(', 'difficulties', 'in', 'emotion', 'regulation', 'scale', '(', 'ders', ')', ')', 'and', 'mind', '##fulness', 'traits', '(', 'five', 'facet', 'mind', '##fulness', 'questionnaire', '(', 'ff', '##m', '##q', ')', '-', 'short', 'form', 'and', 'experiences', 'questionnaire', '(', 'eq', ')', ')', 'prior', 'to', 'and', '24', 'h', 'after', 'the', 'ay', '##ah', '##ua', '##sc', '##a', 'session', '.', 'the', 'volunteers', 'were', 'divided', 'into', 'two', 'subgroups', 'based', 'on', 'their', 'score', 'on', 'the', 'mcl', '##ea', '##n', 'screening', 'instrument', 'for', 'bpd', '(', 'ms', '##i', '-', 'bpd', ')', '.', 'twelve', 'participants', 'were', 'grouped', 'into', 'the', 'bpd', '-', 'like', 'traits', 'subgroup', 'while', 'the', 'rest', 'of', 'them', 'were', 'included', 'in', 'the', 'non', '-', 'bpd', '-', 'like', 'subgroup', '.', 'we', 'performed', 'within', '-', 'subjects', 'and', 'between', '-', 'group', 'analyses', '.', 'results', ':', 'overall', ',', 'the', 'participants', 'showed', 'significant', 'improvements', 'on', 'the', 'ff', '##m', '##q', 'subscales', 'observing', ',', 'acting', 'with', 'awareness', ',', 'non', '-', 'judg', '##ing', ',', 'and', 'non', '-', 'reacting', 'and', 'also', 'significantly', 'improved', 'on', 'dece', '##nt', '##ering', '(', 'eq', 'scale', ')', 'and', 'on', 'the', 'ders', 'subscales', 'emotional', 'non', '-', 'acceptance', ',', 'emotional', 'interference', ',', 'and', 'lack', 'of', 'control', '.', 'the', 'bpd', '-', 'like', 'subgroup', 'also', 'showed', 'significant', 'improvements', 'on', 'the', 'ders', 'subscales', 'emotional', 'interference', 'and', 'lack', 'of', 'control', 'but', 'not', 'in', 'mind', '##fulness', 'capacities', '.', 'conclusions', ':', 'these', 'findings', 'suggest', 'a', 'potential', 'therapeutic', 'effect', 'for', 'ay', '##ah', '##ua', '##sc', '##a', 'in', 'emotion', 'regulation', 'and', 'mind', '##fulness', 'capacities', '(', 'including', 'dece', '##nt', '##ering', ',', 'acceptance', ',', 'awareness', ',', 'and', 'sensitivity', 'to', 'medi', '##tation', 'practice', ')', '.', 'based', 'on', 'these', 'results', ',', 'we', 'believe', 'that', 'ay', '##ah', '##ua', '##sc', '##a', 'therapy', 'could', 'be', 'of', 'value', 'in', 'clinical', 'populations', ',', 'such', 'as', 'individuals', 'with', 'bpd', ',', 'affected', 'by', 'emotion', 'dysregulation', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 15, 15, 17, 18, 19, 20, 21, 22, 22, 23, 24, 25, 26, 27, 28, 28, 29, 30, 31, 32, 33, 33, 33, 33, 34, 35, 35, 35, 36, 37, 38, 39, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 56, 56, 56, 56, 57, 58, 59, 60, 61, 62, 63, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 79, 79, 79, 79, 80, 81, 82, 83, 84, 84, 85, 86, 87, 88, 89, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 98, 98, 98, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 124, 124, 124, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 151, 152, 153, 154, 155, 156, 156, 157, 158, 159, 159, 159, 159, 159, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 175, 175, 175, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 191, 191, 192, 193, 194, 195, 196, 197, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 251, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 272, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 330, 330, 330, 330, 331, 332, 333, 334, 335, 335, 336, 337, 338, 339, 339, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 360, 360, 360, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits.^
BACKGROUND: Research suggests that mindfulness-based interventions may improve mindfulness-related capacities (e.g., decentering, non-judging, and non-reacting) and emotion regulation. Previously, our group reported that ayahuasca could be a potential analogue of mindfulness practice. The main aim of the current study was to examine the effects of ayahuasca on emotional regulation and mindfulness-related capacities. Secondarily, we sought to explore the effects of ayahuasca on individuals with borderline personality disorder (BPD) traits. METHOD: This is an observational study of 45 volunteers who participated in an ayahuasca session. The volunteers completed various self-report instruments designed to measure emotional dysregulation (Difficulties in Emotion Regulation Scale (DERS)) and mindfulness traits (Five Facet Mindfulness Questionnaire (FFMQ)-Short Form and Experiences Questionnaire (EQ)) prior to and 24 h after the ayahuasca session. The volunteers were divided into two subgroups based on their score on the McLean Screening Instrument for BPD (MSI-BPD). Twelve participants were grouped into the BPD-like traits subgroup while the rest of them were included in the non-BPD-like subgroup. We performed within-subjects and between-group analyses. RESULTS: Overall, the participants showed significant improvements on the FFMQ subscales observing, acting with awareness, non-judging, and non-reacting and also significantly improved on decentering (EQ scale) and on the DERS subscales emotional non-acceptance, emotional interference, and lack of control. The BPD-like subgroup also showed significant improvements on the DERS subscales emotional interference and lack of control but not in mindfulness capacities. CONCLUSIONS: These findings suggest a potential therapeutic effect for ayahuasca in emotion regulation and mindfulness capacities (including decentering, acceptance, awareness, and sensitivity to meditation practice). Based on these results, we believe that ayahuasca therapy could be of value in clinical populations, such as individuals with BPD, affected by emotion dysregulation."
"['Acute', 'psychological', 'and', 'physiological', 'effects', 'of', 'MDMA', '(', '""', 'Ecstasy', '""', ')', 'after', 'haloperidol', 'pretreatment', 'in', 'healthy', 'humans.^', '\n', '3,4', '-', 'Methylenedioxymethamphetamine', '(', 'MDMA', ',', '""', 'Ecstasy', '""', ')', 'releases', 'serotonin', 'and', 'dopamine', '.', 'The', 'role', 'for', 'dopamine', 'in', 'mediating', 'the', 'effects', 'of', 'MDMA', 'has', 'not', 'yet', 'been', 'examined', 'in', 'humans', '.', 'We', 'investigated', 'the', 'effect', 'of', 'pretreatment', 'with', 'the', 'dopamine', 'D(2', ')', 'antagonist', 'haloperidol', '(', '1.4', 'mg', 'i.v', '.', ')', 'on', 'psychological', 'and', 'physiological', 'responses', 'to', 'MDMA', '(', '1.5', 'mg', '/', 'kg', 'p.o', '.', ')', 'in', '14', 'healthy', 'volunteers', 'using', 'a', 'double', '-', 'blind', 'placebo', '-', 'controlled', 'within', '-', 'subject', 'design', '.', 'Subjective', 'peak', 'effects', 'were', 'rated', 'using', 'standardised', 'scales', '.', 'The', 'physiological', 'effects', 'measured', 'were', 'blood', 'pressure', ',', 'heart', 'rate', 'and', 'body', 'temperature', '.', 'Side', 'effects', 'were', 'assessed', 'during', 'the', 'session', ',', 'and', 'after', '1', 'and', '3', 'days', '.', 'Haloperidol', 'attenuated', 'MDMA', '-', 'induced', 'positive', 'and', 'mania', '-', 'like', 'mood', 'but', 'had', 'no', 'reducing', 'effect', 'on', 'other', 'subjective', 'changes', 'or', 'on', 'cardiovascular', 'effects', '.', 'Results', 'are', 'consistent', 'with', 'a', 'partial', 'dopaminergic', 'mediation', 'of', 'the', 'euphoriant', 'effects', 'of', 'MDMA', '.', 'In', 'contrast', ',', 'dopamine', 'does', 'not', 'seem', 'to', 'contribute', 'to', 'the', 'physiological', 'effects', 'of', 'MDMA', ',', 'indicating', 'a', 'role', 'for', 'serotonin', 'and', 'norepinephrine', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",4970,"['[CLS]', 'acute', 'psychological', 'and', 'physiological', 'effects', 'of', 'mdm', '##a', '(', '""', 'ecs', '##tas', '##y', '""', ')', 'after', 'halo', '##per', '##idol', 'pretreatment', 'in', 'healthy', 'humans', '.', '^', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', ',', '""', 'ecs', '##tas', '##y', '""', ')', 'releases', 'serotonin', 'and', 'dopamine', '.', 'the', 'role', 'for', 'dopamine', 'in', 'mediating', 'the', 'effects', 'of', 'mdm', '##a', 'has', 'not', 'yet', 'been', 'examined', 'in', 'humans', '.', 'we', 'investigated', 'the', 'effect', 'of', 'pretreatment', 'with', 'the', 'dopamine', 'd', '(', '2', ')', 'antagonist', 'halo', '##per', '##idol', '(', '1', '.', '4', 'mg', 'i', '.', 'v', '.', ')', 'on', 'psychological', 'and', 'physiological', 'responses', 'to', 'mdm', '##a', '(', '1', '.', '5', 'mg', '/', 'kg', 'p', '.', 'o', '.', ')', 'in', '14', 'healthy', 'volunteers', 'using', 'a', 'double', '-', 'blind', 'placebo', '-', 'controlled', 'within', '-', 'subject', 'design', '.', 'subjective', 'peak', 'effects', 'were', 'rated', 'using', 'standardised', 'scales', '.', 'the', 'physiological', 'effects', 'measured', 'were', 'blood', 'pressure', ',', 'heart', 'rate', 'and', 'body', 'temperature', '.', 'side', 'effects', 'were', 'assessed', 'during', 'the', 'session', ',', 'and', 'after', '1', 'and', '3', 'days', '.', 'halo', '##per', '##idol', 'attenuated', 'mdm', '##a', '-', 'induced', 'positive', 'and', 'man', '##ia', '-', 'like', 'mood', 'but', 'had', 'no', 'reducing', 'effect', 'on', 'other', 'subjective', 'changes', 'or', 'on', 'cardiovascular', 'effects', '.', 'results', 'are', 'consistent', 'with', 'a', 'partial', 'dopaminergic', 'mediation', 'of', 'the', 'eup', '##hor', '##iant', 'effects', 'of', 'mdm', '##a', '.', 'in', 'contrast', ',', 'dopamine', 'does', 'not', 'seem', 'to', 'contribute', 'to', 'the', 'physiological', 'effects', 'of', 'mdm', '##a', ',', 'indicating', 'a', 'role', 'for', 'serotonin', 'and', 'norepinephrine', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 6, 7, 8, 9, 9, 9, 10, 11, 12, 13, 13, 13, 14, 15, 16, 17, 17, 17, 19, 19, 19, 20, 21, 21, 21, 21, 21, 22, 23, 23, 24, 25, 26, 26, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 61, 61, 62, 63, 64, 64, 64, 65, 66, 66, 66, 67, 68, 68, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 77, 78, 79, 79, 79, 80, 81, 82, 83, 83, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 141, 141, 142, 143, 143, 144, 145, 146, 147, 148, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 176, 176, 177, 178, 179, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Acute psychological and physiological effects of MDMA (""Ecstasy"") after haloperidol pretreatment in healthy humans.^
3,4-Methylenedioxymethamphetamine (MDMA, ""Ecstasy"") releases serotonin and dopamine. The role for dopamine in mediating the effects of MDMA has not yet been examined in humans. We investigated the effect of pretreatment with the dopamine D(2) antagonist haloperidol (1.4 mg i.v.) on psychological and physiological responses to MDMA (1.5 mg/kg p.o.) in 14 healthy volunteers using a double-blind placebo-controlled within-subject design. Subjective peak effects were rated using standardised scales. The physiological effects measured were blood pressure, heart rate and body temperature. Side effects were assessed during the session, and after 1 and 3 days. Haloperidol attenuated MDMA-induced positive and mania-like mood but had no reducing effect on other subjective changes or on cardiovascular effects. Results are consistent with a partial dopaminergic mediation of the euphoriant effects of MDMA. In contrast, dopamine does not seem to contribute to the physiological effects of MDMA, indicating a role for serotonin and norepinephrine."
"['Group', 'format', 'psychedelic', '-', 'assisted', 'therapy', 'interventions', ':', 'Observations', 'and', 'impressions', 'from', 'the', 'HOPE', 'trial.^', '\n', 'Background', ':', 'Psilocybin', '-', 'assisted', 'psychotherapy', 'has', 'demonstrated', 'significant', 'promise', 'as', 'a', 'treatment', 'for', 'depression', ',', 'anxiety', ',', 'and', 'existential', 'distress', 'associated', 'with', 'serious', 'medical', 'illness', 'and', 'has', 'generally', 'been', 'employed', 'on', 'an', 'individual', 'basis', ',', 'which', 'presents', 'challenges', 'for', 'scaling', 'and', 'resource', 'availability', '.', 'There', 'are', 'also', 'compelling', 'theoretical', 'reasons', 'to', 'suggest', 'that', 'group', '-', 'based', 'formats', '-', 'if', 'utilized', 'in', 'a', 'thoughtful', 'fashion', '-', 'might', 'offer', 'unique', 'or', 'enhanced', 'therapeutic', 'benefits', 'for', 'certain', 'conditions', 'or', 'populations', '.', 'The', 'HOPE', 'trial', 'is', 'an', 'IRB', '-', 'approved', 'open', '-', 'label', 'feasibility', 'and', 'safety', 'pilot', 'study', 'of', 'psi', '-', 'locybin', 'enhanced', 'group', 'therapy', 'in', 'patients', 'with', 'a', 'DSM-5', 'depressive', 'disorder', 'associated', 'with', 'a', 'cancer', 'diagnosis', 'completed', 'at', 'the', 'Huntsman', 'Cancer', 'Institute', '(', 'HCI', ')', 'in', 'Salt', 'Lake', 'City', ',', 'Utah', '(', 'HOPE', ':', 'A', 'Pilot', 'Study', 'of', 'Psilocybin', 'Enhanced', 'Group', 'Psychotherapy', 'in', 'Patients', 'with', 'Cancer', ')', '.', 'We', 'report', 'here', 'quali', '-', 'tative', 'survey', '-', 'based', 'data', ',', 'impressions', ',', 'and', 'suggestions', 'for', 'group', '-', 'based', 'psychedelic', '-', 'assisted', 'therapy', 'interventions', 'based', 'on', 'our', 'observations', 'to', 'inform', 'future', 'studies', '.', 'Methods', ':', 'Patients', 'with', 'a', 'DSM-5', 'depressive', 'disorder', 'with', 'an', 'underlying', 'cancer', 'diagnosis', 'were', 'recruited', 'from', 'HCI', 'by', 'referral', 'from', 'oncology', 'providers', ',', 'palliative', 'care', ',', 'and', 'social', 'work', '.', 'Following', 'screening', 'and', 'consenting', ',', '4', '-', '6', 'partici', '-', 'pants', 'per', 'cohort', '(', 'with', 'three', 'total', 'cohorts', ')', 'were', 'enrolled', 'in', 'a', 'protocol', 'involving', '3', '120', 'min', 'group', 'preparatory', 'sessions', ',', 'a', 'single', 'high', '-', 'dose', '(', '25', 'mg', ')', 'group', 'psilocybin', 'session', ',', 'and', '3', 'subsequent', 'group', 'integration', 'sessions', '.', 'Primary', 'clinical', 'outcomes', 'are', 'still', 'in', 'process', 'of', 'data', 'collection', 'and', 'analysis', '.', 'Qualitative', 'data', 'was', 'gathered', 'from', 'patient', 'written', 'reports', 'and', 'a', 'survey', 'administered', 'at', '2', 'weeks', 'post', 'intervention', '.', 'Qualitative', 'reports', 'were', 'also', 'gathered', 'from', 'the', 'therapist', 'team', 'at', 'a', 'post', '-', 'study', 'group', 'process', 'session', '.', 'Findings', ':', 'We', 'report', 'here', 'results', 'from', 'a', 'qualitative', 'survey', 'of', 'participant', 'experiences', 'with', 'group', 'format', 'study', 'design', ',', 'as', 'well', 'as', 'impressions', 'and', 'guidelines', 'for', 'group', 'format', 'and', 'group', 'psychotherapeutic', 'process', 'to', 'inform', 'other', 'studies', 'pursuing', 'group', '-', 'based', 'interventions', 'in', 'psychedelic', 'therapy', '.', 'Suggestions', 'are', 'provided', 'for', 'protocol', 'design', ',', 'screening', 'processes', ',', 'space', 'considerations', ',', 'therapist', 'team', 'structure', ',', 'group', 'process', ',', 'music', ',', 'timeline', ',', 'as', 'well', 'as', 'potential', 'issues', 'and', 'challenges', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",4884,"['[CLS]', 'group', 'format', 'psych', '##ede', '##lic', '-', 'assisted', 'therapy', 'interventions', ':', 'observations', 'and', 'impression', '##s', 'from', 'the', 'hope', 'trial', '.', '^', 'background', ':', 'psi', '##loc', '##yb', '##in', '-', 'assisted', 'psychotherapy', 'has', 'demonstrated', 'significant', 'promise', 'as', 'a', 'treatment', 'for', 'depression', ',', 'anxiety', ',', 'and', 'existential', 'distress', 'associated', 'with', 'serious', 'medical', 'illness', 'and', 'has', 'generally', 'been', 'employed', 'on', 'an', 'individual', 'basis', ',', 'which', 'presents', 'challenges', 'for', 'scaling', 'and', 'resource', 'availability', '.', 'there', 'are', 'also', 'compelling', 'theoretical', 'reasons', 'to', 'suggest', 'that', 'group', '-', 'based', 'formats', '-', 'if', 'utilized', 'in', 'a', 'thought', '##ful', 'fashion', '-', 'might', 'offer', 'unique', 'or', 'enhanced', 'therapeutic', 'benefits', 'for', 'certain', 'conditions', 'or', 'populations', '.', 'the', 'hope', 'trial', 'is', 'an', 'ir', '##b', '-', 'approved', 'open', '-', 'label', 'feasibility', 'and', 'safety', 'pilot', 'study', 'of', 'psi', '-', 'loc', '##yb', '##in', 'enhanced', 'group', 'therapy', 'in', 'patients', 'with', 'a', 'dsm', '-', '5', 'depressive', 'disorder', 'associated', 'with', 'a', 'cancer', 'diagnosis', 'completed', 'at', 'the', 'hunt', '##sma', '##n', 'cancer', 'institute', '(', 'hci', ')', 'in', 'salt', 'lake', 'city', ',', 'utah', '(', 'hope', ':', 'a', 'pilot', 'study', 'of', 'psi', '##loc', '##yb', '##in', 'enhanced', 'group', 'psychotherapy', 'in', 'patients', 'with', 'cancer', ')', '.', 'we', 'report', 'here', 'qual', '##i', '-', 'tat', '##ive', 'survey', '-', 'based', 'data', ',', 'impression', '##s', ',', 'and', 'suggestions', 'for', 'group', '-', 'based', 'psych', '##ede', '##lic', '-', 'assisted', 'therapy', 'interventions', 'based', 'on', 'our', 'observations', 'to', 'inform', 'future', 'studies', '.', 'methods', ':', 'patients', 'with', 'a', 'dsm', '-', '5', 'depressive', 'disorder', 'with', 'an', 'underlying', 'cancer', 'diagnosis', 'were', 'recruited', 'from', 'hci', 'by', 'referral', 'from', 'oncology', 'providers', ',', 'palliative', 'care', ',', 'and', 'social', 'work', '.', 'following', 'screening', 'and', 'consent', '##ing', ',', '4', '-', '6', 'partic', '##i', '-', 'pant', '##s', 'per', 'cohort', '(', 'with', 'three', 'total', 'cohorts', ')', 'were', 'enrolled', 'in', 'a', 'protocol', 'involving', '3', '120', 'min', 'group', 'prepar', '##atory', 'sessions', ',', 'a', 'single', 'high', '-', 'dose', '(', '25', 'mg', ')', 'group', 'psi', '##loc', '##yb', '##in', 'session', ',', 'and', '3', 'subsequent', 'group', 'integration', 'sessions', '.', 'primary', 'clinical', 'outcomes', 'are', 'still', 'in', 'process', 'of', 'data', 'collection', 'and', 'analysis', '.', 'qualitative', 'data', 'was', 'gathered', 'from', 'patient', 'written', 'reports', 'and', 'a', 'survey', 'administered', 'at', '2', 'weeks', 'post', 'intervention', '.', 'qualitative', 'reports', 'were', 'also', 'gathered', 'from', 'the', 'therapist', 'team', 'at', 'a', 'post', '-', 'study', 'group', 'process', 'session', '.', 'findings', ':', 'we', 'report', 'here', 'results', 'from', 'a', 'qualitative', 'survey', 'of', 'participant', 'experiences', 'with', 'group', 'format', 'study', 'design', ',', 'as', 'well', 'as', 'impression', '##s', 'and', 'guidelines', 'for', 'group', 'format', 'and', 'group', 'psycho', '##ther', '##apeutic', 'process', 'to', 'inform', 'other', 'studies', 'pursuing', 'group', '-', 'based', 'interventions', 'in', 'psych', '##ede', '##lic', 'therapy', '.', 'suggestions', 'are', 'provided', 'for', 'protocol', 'design', ',', 'screening', 'processes', ',', 'space', 'considerations', ',', 'therapist', 'team', 'structure', ',', 'group', 'process', ',', 'music', ',', 'time', '##line', ',', 'as', 'well', 'as', 'potential', 'issues', 'and', 'challenges', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10, 11, 12, 13, 14, 14, 14, 16, 17, 18, 18, 18, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 114, 114, 115, 116, 117, 118, 119, 120, 121, 122, 122, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 133, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 152, 152, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 165, 166, 167, 167, 168, 169, 170, 171, 172, 173, 173, 174, 175, 176, 177, 178, 179, 180, 181, 181, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 200, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 228, 229, 230, 231, 232, 233, 233, 234, 235, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 267, 267, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 348, 349, 350, 351, 352, 353, 354, 355, 356, 356, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 368, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial.^
Background: Psilocybin-assisted psychotherapy has demonstrated significant promise as a treatment for depression, anxiety, and existential distress associated with serious medical illness and has generally been employed on an individual basis, which presents challenges for scaling and resource availability. There are also compelling theoretical reasons to suggest that group-based formats-if utilized in a thoughtful fashion-might offer unique or enhanced therapeutic benefits for certain conditions or populations. The HOPE trial is an IRB-approved open-label feasibility and safety pilot study of psi-locybin enhanced group therapy in patients with a DSM-5 depressive disorder associated with a cancer diagnosis completed at the Huntsman Cancer Institute (HCI) in Salt Lake City, Utah (HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer). We report here quali-tative survey-based data, impressions, and suggestions for group-based psychedelic-assisted therapy interventions based on our observations to inform future studies. Methods: Patients with a DSM-5 depressive disorder with an underlying cancer diagnosis were recruited from HCI by referral from oncology providers, palliative care, and social work. Following screening and consenting, 4-6 partici-pants per cohort (with three total cohorts) were enrolled in a protocol involving 3 120 min group preparatory sessions, a single high-dose (25 mg) group psilocybin session, and 3 subsequent group integration sessions. Primary clinical outcomes are still in process of data collection and analysis. Qualitative data was gathered from patient written reports and a survey administered at 2 weeks post intervention. Qualitative reports were also gathered from the therapist team at a post-study group process session. Findings: We report here results from a qualitative survey of participant experiences with group format study design, as well as impressions and guidelines for group format and group psychotherapeutic process to inform other studies pursuing group-based interventions in psychedelic therapy. Suggestions are provided for protocol design, screening processes, space considerations, therapist team structure, group process, music, timeline, as well as potential issues and challenges."
"['An', 'evaluation', 'of', 'a', 'brief', 'intervention', 'model', 'for', 'use', 'with', 'young', 'non', '-', 'injecting', 'stimulant', 'users.^', '\n', 'This', 'report', 'describes', 'the', 'rationale', ',', 'implementation', ',', 'and', 'efficacy', 'evaluation', 'of', 'a', 'brief', ',', 'motivational', 'intervention', 'for', 'young', 'users', 'of', 'cocaine', ',', 'crack', 'cocaine', ',', 'and', 'ecstasy', 'not', 'in', 'contact', 'with', 'treatment', 'services', '.', 'The', 'intervention', 'was', 'developed', 'so', 'it', 'could', 'be', 'used', 'by', 'peer', 'and', 'other', 'drug', 'workers', '.', 'The', 'evaluation', 'was', 'a', 'two', '-', 'condition', ',', 'multi', '-', 'site', ',', 'randomized', 'controlled', 'trial', 'with', 'a', 'single', '6', '-', 'month', 'follow', '-', 'up', '.', 'Participants', 'were', '16', '-', '22', 'years', 'old', '.', 'They', 'identified', 'themselves', 'to', 'be', 'primary', 'users', 'of', 'cocaine', 'hydrochloride', ',', 'crack', 'cocaine', ',', 'or', 'ecstasy', 'and', 'were', 'subsequently', 'assigned', 'to', 'these', 'primary', 'stimulant', 'groups', 'for', 'analysis', '.', 'No', 'participant', 'had', 'been', 'in', 'treatment', 'during', 'the', 'previous', '12', 'months', 'and', 'none', 'had', 'a', 'treatment', 'history', 'for', 'opiate', 'dependence', 'or', 'injecting', '.', 'Trial', 'participants', 'were', 'recruited', 'in', '11', 'sites', 'in', 'Greater', 'London', 'and', 'Kent', 'using', 'detached', 'outreach', ',', 'specific', 'advertising', 'campaigns', ',', 'and', 'by', 'participant', '-', 'driven', 'snowball', '-', 'sampling', 'methods', '.', 'Six', '-', 'month', 'follow', '-', 'up', 'interviews', 'were', 'successfully', 'conducted', 'with', '299', 'participants', '.', 'The', 'participant', 'recruitment', 'methodology', 'used', 'in', 'the', 'trial', 'was', 'successful', ',', 'showing', 'that', 'longitudinal', ',', 'experimental', 'studies', 'with', 'young', 'out', '-', 'of', '-', 'treatment', 'drug', 'users', 'are', 'quite', 'feasible', '.', 'There', 'were', 'a', 'range', 'of', 'positive', 'changes', 'reported', 'by', 'participants', 'in', 'both', 'the', 'experimental', 'and', 'control', 'conditions', '.', '(', 'PsycINFO', 'Database', 'Record', '(', 'c', ')', '2016', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5317,"['[CLS]', 'an', 'evaluation', 'of', 'a', 'brief', 'intervention', 'model', 'for', 'use', 'with', 'young', 'non', '-', 'injecting', 'stimul', '##ant', 'users', '.', '^', 'this', 'report', 'describes', 'the', 'rationale', ',', 'implementation', ',', 'and', 'efficacy', 'evaluation', 'of', 'a', 'brief', ',', 'motivational', 'intervention', 'for', 'young', 'users', 'of', 'cocaine', ',', 'crack', 'cocaine', ',', 'and', 'ecs', '##tas', '##y', 'not', 'in', 'contact', 'with', 'treatment', 'services', '.', 'the', 'intervention', 'was', 'developed', 'so', 'it', 'could', 'be', 'used', 'by', 'peer', 'and', 'other', 'drug', 'workers', '.', 'the', 'evaluation', 'was', 'a', 'two', '-', 'condition', ',', 'multi', '-', 'site', ',', 'randomized', 'controlled', 'trial', 'with', 'a', 'single', '6', '-', 'month', 'follow', '-', 'up', '.', 'participants', 'were', '16', '-', '22', 'years', 'old', '.', 'they', 'identified', 'themselves', 'to', 'be', 'primary', 'users', 'of', 'cocaine', 'hydrochloride', ',', 'crack', 'cocaine', ',', 'or', 'ecs', '##tas', '##y', 'and', 'were', 'subsequently', 'assigned', 'to', 'these', 'primary', 'stimul', '##ant', 'groups', 'for', 'analysis', '.', 'no', 'participant', 'had', 'been', 'in', 'treatment', 'during', 'the', 'previous', '12', 'months', 'and', 'none', 'had', 'a', 'treatment', 'history', 'for', 'opi', '##ate', 'dependence', 'or', 'injecting', '.', 'trial', 'participants', 'were', 'recruited', 'in', '11', 'sites', 'in', 'greater', 'london', 'and', 'kent', 'using', 'detached', 'out', '##reach', ',', 'specific', 'advertising', 'campaigns', ',', 'and', 'by', 'participant', '-', 'driven', 'snow', '##ball', '-', 'sampling', 'methods', '.', 'six', '-', 'month', 'follow', '-', 'up', 'interviews', 'were', 'successfully', 'conducted', 'with', '299', 'participants', '.', 'the', 'participant', 'recruitment', 'methodology', 'used', 'in', 'the', 'trial', 'was', 'successful', ',', 'showing', 'that', 'longitudinal', ',', 'experimental', 'studies', 'with', 'young', 'out', '-', 'of', '-', 'treatment', 'drug', 'users', 'are', 'quite', 'feasible', '.', 'there', 'were', 'a', 'range', 'of', 'positive', 'changes', 'reported', 'by', 'participants', 'in', 'both', 'the', 'experimental', 'and', 'control', 'conditions', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '2016', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 15, 15, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 44, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 116, 116, 117, 118, 119, 120, 121, 122, 123, 124, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 245, 245, 246, 247, 248, 249, 250, 251, 252, 252, 253, 254, 255, 256, 257, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","An evaluation of a brief intervention model for use with young non-injecting stimulant users.^
This report describes the rationale, implementation, and efficacy evaluation of a brief, motivational intervention for young users of cocaine, crack cocaine, and ecstasy not in contact with treatment services. The intervention was developed so it could be used by peer and other drug workers. The evaluation was a two-condition, multi-site, randomized controlled trial with a single 6-month follow-up. Participants were 16-22 years old. They identified themselves to be primary users of cocaine hydrochloride, crack cocaine, or ecstasy and were subsequently assigned to these primary stimulant groups for analysis. No participant had been in treatment during the previous 12 months and none had a treatment history for opiate dependence or injecting. Trial participants were recruited in 11 sites in Greater London and Kent using detached outreach, specific advertising campaigns, and by participant-driven snowball-sampling methods. Six-month follow-up interviews were successfully conducted with 299 participants. The participant recruitment methodology used in the trial was successful, showing that longitudinal, experimental studies with young out-of-treatment drug users are quite feasible. There were a range of positive changes reported by participants in both the experimental and control conditions. (PsycINFO Database Record (c) 2016 APA, all rights reserved)"
"['Synaptic', 'potentiation', 'is', 'critical', 'for', 'rapid', 'antidepressant', 'response', 'to', 'ketamine', 'in', 'treatment', '-', 'resistant', 'major', 'depression.^', '\n', 'BACKGROUND', ':', 'Clinical', 'evidence', 'that', 'ketamine', ',', 'a', 'nonselective', 'N', '-', 'methyl', '-', 'D', '-', 'aspartate', 'receptor', '(', 'NMDAR', ')', 'antagonist', ',', 'has', 'therapeutic', 'effects', 'within', 'hours', 'in', 'people', 'suffering', 'from', 'depression', 'suggests', 'that', 'modulating', 'glutamatergic', 'neurotransmission', 'is', 'a', 'fundamental', 'step', 'in', 'alleviating', 'the', 'debilitating', 'symptoms', 'of', 'mood', 'disorders', '.', 'Acutely', ',', 'ketamine', 'increases', 'extracellular', 'glutamate', 'levels', ',', 'neuronal', 'excitability', ',', 'and', 'spontaneous', 'γ', 'oscillations', ',', 'but', 'it', 'is', 'unknown', 'whether', 'these', 'effects', 'are', 'key', 'to', 'the', 'mechanism', 'of', 'antidepressant', 'action', 'of', 'ketamine', '.', 'METHODS', ':', 'Twenty', 'drug', '-', 'free', 'major', 'depressive', 'disorder', 'patients', 'received', 'a', 'single', ',', 'open', '-', 'label', 'intravenous', 'infusion', 'of', 'ketamine', 'hydrochloride', '(', '.5', 'mg', '/', 'kg', ')', '.', 'Magnetoencephalographic', 'recordings', 'were', 'made', 'approximately', '3', 'days', 'before', 'and', 'approximately', '6.5', 'hours', 'after', 'the', 'infusion', ',', 'whereas', 'patients', 'passively', 'received', 'tactile', 'stimulation', 'to', 'the', 'right', 'and', 'left', 'index', 'fingers', 'and', 'also', 'while', 'they', 'rested', '(', 'eyes', '-', 'closed', ')', '.', 'Antidepressant', 'response', 'was', 'assessed', 'by', 'percentage', 'change', 'in', 'Montgomery', '-', 'Åsberg', 'Depression', 'Rating', 'Scale', 'scores', '.', 'RESULTS', ':', 'Patients', 'with', 'robust', 'improvements', 'in', 'depressive', 'symptoms', '230', 'min', 'after', 'infusion', '(', 'responders', ')', 'exhibited', 'increased', 'cortical', 'excitability', 'within', 'this', 'antidepressant', 'response', 'window', '.', 'Specifically', ',', 'we', 'found', 'that', 'stimulus', '-', 'evoked', 'somatosensory', 'cortical', 'responses', 'increase', 'after', 'infusion', ',', 'relative', 'to', 'pretreatment', 'responses', 'in', 'responders', 'but', 'not', 'in', 'treatment', 'nonresponders', '.', 'Spontaneous', 'somatosensory', 'cortical', 'γ', '-', 'band', 'activity', 'during', 'rest', 'did', 'not', 'change', 'within', 'the', 'same', 'timeframe', 'after', 'ketamine', 'in', 'either', 'responders', 'or', 'nonresponders', '.', 'CONCLUSIONS', ':', 'These', 'findings', 'suggest', 'NMDAR', 'antagonism', 'does', 'not', 'lead', 'directly', 'to', 'increased', 'cortical', 'excitability', 'hours', 'later', 'and', 'thus', 'might', 'not', 'be', 'sufficient', 'for', 'therapeutic', 'effects', 'of', 'ketamine', 'to', 'take', 'hold', '.', 'Rather', ',', 'increased', 'cortical', 'excitability', 'as', 'depressive', 'symptoms', 'improve', 'is', 'consistent', 'with', 'the', 'hypothesis', 'that', 'enhanced', 'non', '-', 'NMDAR', '-', 'mediated', 'glutamatergic', 'neurotransmission', 'via', 'synaptic', 'potentiation', 'is', 'central', 'to', 'the', 'antidepressant', 'effect', 'of', 'ketamine', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1647,"['[CLS]', 'synaptic', 'potentiation', 'is', 'critical', 'for', 'rapid', 'antidepressant', 'response', 'to', 'ketamine', 'in', 'treatment', '-', 'resistant', 'major', 'depression', '.', '^', 'background', ':', 'clinical', 'evidence', 'that', 'ketamine', ',', 'a', 'nons', '##elec', '##tive', 'n', '-', 'methyl', '-', 'd', '-', 'aspartate', 'receptor', '(', 'nmda', '##r', ')', 'antagonist', ',', 'has', 'therapeutic', 'effects', 'within', 'hours', 'in', 'people', 'suffering', 'from', 'depression', 'suggests', 'that', 'modulating', 'glutamate', '##rg', '##ic', 'neurotrans', '##mission', 'is', 'a', 'fundamental', 'step', 'in', 'allevi', '##ating', 'the', 'deb', '##ili', '##ta', '##ting', 'symptoms', 'of', 'mood', 'disorders', '.', 'acutely', ',', 'ketamine', 'increases', 'extracellular', 'glutamate', 'levels', ',', 'neuronal', 'excitability', ',', 'and', 'spontaneous', 'γ', 'oscillations', ',', 'but', 'it', 'is', 'unknown', 'whether', 'these', 'effects', 'are', 'key', 'to', 'the', 'mechanism', 'of', 'antidepressant', 'action', 'of', 'ketamine', '.', 'methods', ':', 'twenty', 'drug', '-', 'free', 'major', 'depressive', 'disorder', 'patients', 'received', 'a', 'single', ',', 'open', '-', 'label', 'intravenous', 'infusion', 'of', 'ketamine', 'hydrochloride', '(', '.', '5', 'mg', '/', 'kg', ')', '.', 'magnet', '##oen', '##cephal', '##ographic', 'recordings', 'were', 'made', 'approximately', '3', 'days', 'before', 'and', 'approximately', '6', '.', '5', 'hours', 'after', 'the', 'infusion', ',', 'whereas', 'patients', 'passive', '##ly', 'received', 'tactile', 'stimulation', 'to', 'the', 'right', 'and', 'left', 'index', 'fingers', 'and', 'also', 'while', 'they', 'rest', '##ed', '(', 'eyes', '-', 'closed', ')', '.', 'antidepressant', 'response', 'was', 'assessed', 'by', 'percentage', 'change', 'in', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', 'scores', '.', 'results', ':', 'patients', 'with', 'robust', 'improvements', 'in', 'depressive', 'symptoms', '230', 'min', 'after', 'infusion', '(', 'responders', ')', 'exhibited', 'increased', 'cortical', 'excitability', 'within', 'this', 'antidepressant', 'response', 'window', '.', 'specifically', ',', 'we', 'found', 'that', 'stimulus', '-', 'evoked', 'somatosensory', 'cortical', 'responses', 'increase', 'after', 'infusion', ',', 'relative', 'to', 'pretreatment', 'responses', 'in', 'responders', 'but', 'not', 'in', 'treatment', 'non', '##respond', '##ers', '.', 'spontaneous', 'somatosensory', 'cortical', 'γ', '-', 'band', 'activity', 'during', 'rest', 'did', 'not', 'change', 'within', 'the', 'same', 'time', '##frame', 'after', 'ketamine', 'in', 'either', 'responders', 'or', 'non', '##respond', '##ers', '.', 'conclusions', ':', 'these', 'findings', 'suggest', 'nmda', '##r', 'antagonism', 'does', 'not', 'lead', 'directly', 'to', 'increased', 'cortical', 'excitability', 'hours', 'later', 'and', 'thus', 'might', 'not', 'be', 'sufficient', 'for', 'therapeutic', 'effects', 'of', 'ketamine', 'to', 'take', 'hold', '.', 'rather', ',', 'increased', 'cortical', 'excitability', 'as', 'depressive', 'symptoms', 'improve', 'is', 'consistent', 'with', 'the', 'hypothesis', 'that', 'enhanced', 'non', '-', 'nmda', '##r', '-', 'mediated', 'glutamate', '##rg', '##ic', 'neurotrans', '##mission', 'via', 'synaptic', 'potentiation', 'is', 'central', 'to', 'the', 'antidepressant', 'effect', 'of', 'ketamine', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 15, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 25, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 52, 52, 53, 53, 54, 55, 56, 57, 58, 59, 59, 60, 61, 61, 61, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 124, 125, 126, 127, 128, 129, 130, 130, 130, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 140, 140, 141, 142, 143, 144, 145, 146, 147, 148, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 178, 178, 178, 179, 180, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 237, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 254, 255, 256, 257, 258, 259, 260, 261, 261, 261, 262, 263, 264, 265, 266, 267, 268, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 313, 314, 315, 316, 316, 316, 317, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.^
BACKGROUND: Clinical evidence that ketamine, a nonselective N-methyl-D-aspartate receptor (NMDAR) antagonist, has therapeutic effects within hours in people suffering from depression suggests that modulating glutamatergic neurotransmission is a fundamental step in alleviating the debilitating symptoms of mood disorders. Acutely, ketamine increases extracellular glutamate levels, neuronal excitability, and spontaneous γ oscillations, but it is unknown whether these effects are key to the mechanism of antidepressant action of ketamine. METHODS: Twenty drug-free major depressive disorder patients received a single, open-label intravenous infusion of ketamine hydrochloride (.5 mg/kg). Magnetoencephalographic recordings were made approximately 3 days before and approximately 6.5 hours after the infusion, whereas patients passively received tactile stimulation to the right and left index fingers and also while they rested (eyes-closed). Antidepressant response was assessed by percentage change in Montgomery-Åsberg Depression Rating Scale scores. RESULTS: Patients with robust improvements in depressive symptoms 230 min after infusion (responders) exhibited increased cortical excitability within this antidepressant response window. Specifically, we found that stimulus-evoked somatosensory cortical responses increase after infusion, relative to pretreatment responses in responders but not in treatment nonresponders. Spontaneous somatosensory cortical γ-band activity during rest did not change within the same timeframe after ketamine in either responders or nonresponders. CONCLUSIONS: These findings suggest NMDAR antagonism does not lead directly to increased cortical excitability hours later and thus might not be sufficient for therapeutic effects of ketamine to take hold. Rather, increased cortical excitability as depressive symptoms improve is consistent with the hypothesis that enhanced non-NMDAR-mediated glutamatergic neurotransmission via synaptic potentiation is central to the antidepressant effect of ketamine."
"['Effects', 'of', 'cannabis', 'use', 'on', 'antidepressant', 'treatment', 'response', 'to', 'repetitive', 'transcranial', 'magnetic', 'stimulation', 'and', 'ketamine.^', '\n', 'The', 'present', 'letter', 'presents', 'a', 'retrospective', 'analysis', 'of', 'Veterans', 'treated', 'with', 'these', 'modalities', 'at', 'the', 'VA', 'San', 'Diego', 'Medical', 'Center', 'between', '2017', 'and', '2023', 'and', 'analyzed', 'whether', 'cannabis', 'moderated', 'the', 'antidepressant', 'effects', '.', 'We', 'found', 'a', 'group', 'difference', 'only', 'in', 'age', 'for', 'the', 'rTMS', 'and', 'ketamine', 'groups', '(', 'cannabis', 'users', 'were', 'on', 'average', 'younger', '(', 'p', '<', '0.05', ')', ')', '.', 'We', 'next', 'examined', 'whether', 'cannabis', 'use', 'affected', 'changes', 'in', 'PHQ-9', 'scores', 'during', 'ketamine', 'treatments', ',', 'revealing', 'a', 'main', 'effect', 'of', 'treatment', '(', 'F', '(', '4', ',', '510', ')', '=', '21.6', ',', 'p', '<', '0.0001', ')', ',', 'with', 'a', 'mean', 'reduction', 'of', '4.4', 'points', 'on', 'the', 'PHQ-9', '(', 'CI', '2.7–6.1', ')', '.', 'There', 'was', 'no', 'main', 'effect', 'of', 'cannabis', 'use', '(', 'F', '(', '1', ',', '118', ')', '=', '0.58', ',', 'p', '=', '0.45', ')', 'nor', 'a', 'significant', 'group', 'x', 'time', 'interaction', '(', 'F', '(', '7', ',', '759', ')', '=', '0.36', ',', 'p', '=', '0.93', ')', '.', 'Non', '-', 'cannabis', 'users', 'showed', 'a', '4.5', 'point', 'reduction', '(', 'CI', '2.539–6.407', ')', 'while', 'cannabis', 'users', 'showed', 'a', '4.3', 'point', 'reduction', '(', 'CI', '0.7802–7.917', ')', '.', 'Our', 'study', 'limitations', 'include', 'a', 'modest', 'sample', ',', 'a', 'unique', 'population', 'of', 'Veterans', 'that', 'may', 'not', 'generalize', ',', 'and', 'a', 'non', '-', 'randomized', 'uncontrolled', 'analysis', '.', 'Our', 'study', 'strengths', 'include', 'results', 'that', 'generalize', 'across', 'two', 'treatments', '(', 'ketamine', 'and', 'rTMS', ')', ',', 'and', 'a', 'naturalistic', 'design', 'without', 'obvious', 'bias', '.', 'Finally', ',', 'this', 'is', 'currently', 'the', 'largest', 'data', 'on', 'the', 'effects', 'of', 'cannabis', 'on', 'treatment', 'outcomes', 'of', 'ketamine', 'and', 'rTMS', '.', '(', 'PsycInfo', 'Database', 'Record', '(', 'c', ')', '2023', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7914,"['[CLS]', 'effects', 'of', 'cannabis', 'use', 'on', 'antidepressant', 'treatment', 'response', 'to', 'repetitive', 'transc', '##ran', '##ial', 'magnetic', 'stimulation', 'and', 'ketamine', '.', '^', 'the', 'present', 'letter', 'presents', 'a', 'retrospective', 'analysis', 'of', 'veterans', 'treated', 'with', 'these', 'modalities', 'at', 'the', 'va', 'san', 'diego', 'medical', 'center', 'between', '2017', 'and', '202', '##3', 'and', 'analyzed', 'whether', 'cannabis', 'moderate', '##d', 'the', 'antidepressant', 'effects', '.', 'we', 'found', 'a', 'group', 'difference', 'only', 'in', 'age', 'for', 'the', 'rt', '##ms', 'and', 'ketamine', 'groups', '(', 'cannabis', 'users', 'were', 'on', 'average', 'younger', '(', 'p', '<', '0', '.', '05', ')', ')', '.', 'we', 'next', 'examined', 'whether', 'cannabis', 'use', 'affected', 'changes', 'in', 'ph', '##q', '-', '9', 'scores', 'during', 'ketamine', 'treatments', ',', 'revealing', 'a', 'main', 'effect', 'of', 'treatment', '(', 'f', '(', '4', ',', '510', ')', '=', '21', '.', '6', ',', 'p', '<', '0', '.', '000', '##1', ')', ',', 'with', 'a', 'mean', 'reduction', 'of', '4', '.', '4', 'points', 'on', 'the', 'ph', '##q', '-', '9', '(', 'ci', '2', '.', '7', '–', '6', '.', '1', ')', '.', 'there', 'was', 'no', 'main', 'effect', 'of', 'cannabis', 'use', '(', 'f', '(', '1', ',', '118', ')', '=', '0', '.', '58', ',', 'p', '=', '0', '.', '45', ')', 'nor', 'a', 'significant', 'group', 'x', 'time', 'interaction', '(', 'f', '(', '7', ',', '75', '##9', ')', '=', '0', '.', '36', ',', 'p', '=', '0', '.', '93', ')', '.', 'non', '-', 'cannabis', 'users', 'showed', 'a', '4', '.', '5', 'point', 'reduction', '(', 'ci', '2', '.', '53', '##9', '–', '6', '.', '40', '##7', ')', 'while', 'cannabis', 'users', 'showed', 'a', '4', '.', '3', 'point', 'reduction', '(', 'ci', '0', '.', '78', '##02', '–', '7', '.', '91', '##7', ')', '.', 'our', 'study', 'limitations', 'include', 'a', 'modest', 'sample', ',', 'a', 'unique', 'population', 'of', 'veterans', 'that', 'may', 'not', 'generalize', ',', 'and', 'a', 'non', '-', 'randomized', 'uncontrolled', 'analysis', '.', 'our', 'study', 'strengths', 'include', 'results', 'that', 'generalize', 'across', 'two', 'treatments', '(', 'ketamine', 'and', 'rt', '##ms', ')', ',', 'and', 'a', 'natural', '##istic', 'design', 'without', 'obvious', 'bias', '.', 'finally', ',', 'this', 'is', 'currently', 'the', 'largest', 'data', 'on', 'the', 'effects', 'of', 'cannabis', 'on', 'treatment', 'outcomes', 'of', 'ketamine', 'and', 'rt', '##ms', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '202', '##3', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10, 10, 11, 12, 13, 14, 14, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 39, 40, 41, 42, 43, 44, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 73, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 86, 86, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 106, 106, 107, 108, 109, 110, 110, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 118, 118, 119, 120, 121, 122, 122, 122, 122, 123, 124, 125, 125, 125, 125, 125, 125, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 144, 144, 145, 146, 147, 148, 148, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 162, 163, 164, 165, 165, 165, 166, 167, 168, 169, 169, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 178, 178, 179, 180, 181, 182, 183, 183, 183, 183, 183, 183, 183, 183, 183, 184, 185, 186, 187, 188, 189, 190, 190, 190, 191, 192, 193, 194, 195, 195, 195, 195, 195, 195, 195, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 237, 238, 239, 240, 241, 242, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 267, 268, 269, 270, 270, 270, 271, 272, 273, 274, 275, 276, 276, 277, 277, 278, 279, 280, 281, 282, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Effects of cannabis use on antidepressant treatment response to repetitive transcranial magnetic stimulation and ketamine.^
The present letter presents a retrospective analysis of Veterans treated with these modalities at the VA San Diego Medical Center between 2017 and 2023 and analyzed whether cannabis moderated the antidepressant effects. We found a group difference only in age for the rTMS and ketamine groups (cannabis users were on average younger (p < 0.05)). We next examined whether cannabis use affected changes in PHQ-9 scores during ketamine treatments, revealing a main effect of treatment (F (4, 510) = 21.6, p < 0.0001), with a mean reduction of 4.4 points on the PHQ-9 (CI 2.7–6.1). There was no main effect of cannabis use (F (1, 118) = 0.58, p = 0.45) nor a significant group x time interaction (F (7, 759) = 0.36, p = 0.93). Non-cannabis users showed a 4.5 point reduction (CI 2.539–6.407) while cannabis users showed a 4.3 point reduction (CI 0.7802–7.917). Our study limitations include a modest sample, a unique population of Veterans that may not generalize, and a non-randomized uncontrolled analysis. Our study strengths include results that generalize across two treatments (ketamine and rTMS), and a naturalistic design without obvious bias. Finally, this is currently the largest data on the effects of cannabis on treatment outcomes of ketamine and rTMS. (PsycInfo Database Record (c) 2023 APA, all rights reserved)"
"['Evidence', 'for', 'a', 'hallucinogen', 'dependence', 'syndrome', 'developing', 'soon', 'after', 'onset', 'of', 'hallucinogen', 'use', 'during', 'adolescence.^', '\n', 'This', 'study', 'uses', 'latent', 'class', 'methods', 'and', 'multiple', 'regression', 'to', 'shed', 'light', 'on', 'hypothesized', 'hallucinogen', 'dependence', 'syndromes', 'experienced', 'by', 'young', 'people', 'who', 'have', 'recently', 'initiated', 'hallucinogen', 'use', '.', 'It', 'explores', 'possible', 'variation', 'in', 'risk', '.', 'The', 'study', 'sample', ',', 'identified', 'within', 'public', '-', 'use', 'data', 'files', 'of', 'the', '1999', 'National', 'Household', 'Survey', 'on', 'Drug', 'Abuse', '(', 'NHSDA', ')', ',', 'consists', 'of', '1186', 'recent', '-', 'onset', 'hallucinogen', 'users', ',', 'defined', 'as', 'having', 'initiated', 'hallucinogen', 'use', 'within', '24', 'months', 'of', 'assessment', '(', 'median', 'elapsed', 'time', 'since', 'onset', 'of', 'use', '∼12', 'to', '13', 'months', ')', '.', 'The', 'recent', '-', 'onset', 'users', 'in', 'this', 'sample', 'were', 'age', '12', 'to', '21', 'at', 'the', 'time', 'of', 'assessment', 'and', 'were', 'between', 'the', 'ages', 'of', '10', 'and', '21', 'at', 'the', 'time', 'of', 'their', 'first', 'hallucinogen', 'use', '.', 'The', 'NHSDA', 'included', 'items', 'to', 'assess', 'seven', 'clinical', 'features', 'often', 'associated', 'with', 'hallucinogen', 'dependence', ',', 'which', 'were', 'used', 'in', 'latent', 'class', 'modelling', '.', 'Latent', 'class', 'analysis', ',', 'in', 'conjunction', 'with', 'prior', 'theory', ',', 'supports', 'a', 'three', '-', 'class', 'solution', ',', 'with', '2', '%', 'of', 'recent', '-', 'onset', 'users', 'in', 'a', 'class', 'that', 'resembles', 'a', 'hallucinogen', 'dependence', 'syndrome', ',', 'whereas', '88', '%', 'expressed', 'few', 'or', 'no', 'clinical', 'features', 'of', 'dependence', '.', 'The', 'remaining', '10', '%', 'may', 'reflect', 'users', 'who', 'are', 'at', 'risk', 'for', 'dependence', 'or', 'in', 'an', 'early', 'stage', 'of', 'dependence', '.', 'Results', 'from', 'latent', 'class', 'regressions', 'indicate', 'that', 'susceptibility', 'to', 'rapid', 'transition', 'from', 'first', 'hallucinogen', 'use', 'to', 'onset', 'of', 'this', 'hallucinogen', 'dependence', 'syndrome', 'might', 'be', 'influenced', 'by', 'hallucinogenic', 'compounds', 'taken', '(', 'for', 'example', ',', 'estimated', 'relative', 'risk', ',', 'RR', '=', '2.4', ',', '95', '%', 'CI', '=', '1.6', ',', '7.6', 'for', 'users', 'of', 'MDMA', 'versus', 'users', 'of', 'LSD', ')', '.', 'Excess', 'risk', 'of', 'rapid', 'transition', 'did', 'not', 'appear', 'to', 'depend', 'upon', 'age', ',', 'sex', ',', 'or', 'race', '/', 'ethnicity', '.', 'Copyright', '©', '2006', 'John', 'Wiley', '&', 'Sons', ',', 'Ltd.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8294,"['[CLS]', 'evidence', 'for', 'a', 'halluc', '##ino', '##gen', 'dependence', 'syndrome', 'developing', 'soon', 'after', 'onset', 'of', 'halluc', '##ino', '##gen', 'use', 'during', 'adolescence', '.', '^', 'this', 'study', 'uses', 'latent', 'class', 'methods', 'and', 'multiple', 'regression', 'to', 'shed', 'light', 'on', 'hypothesized', 'halluc', '##ino', '##gen', 'dependence', 'syndromes', 'experienced', 'by', 'young', 'people', 'who', 'have', 'recently', 'initiated', 'halluc', '##ino', '##gen', 'use', '.', 'it', 'explores', 'possible', 'variation', 'in', 'risk', '.', 'the', 'study', 'sample', ',', 'identified', 'within', 'public', '-', 'use', 'data', 'files', 'of', 'the', '1999', 'national', 'household', 'survey', 'on', 'drug', 'abuse', '(', 'nhs', '##da', ')', ',', 'consists', 'of', '118', '##6', 'recent', '-', 'onset', 'halluc', '##ino', '##gen', 'users', ',', 'defined', 'as', 'having', 'initiated', 'halluc', '##ino', '##gen', 'use', 'within', '24', 'months', 'of', 'assessment', '(', 'median', 'elapsed', 'time', 'since', 'onset', 'of', 'use', '∼', '##12', 'to', '13', 'months', ')', '.', 'the', 'recent', '-', 'onset', 'users', 'in', 'this', 'sample', 'were', 'age', '12', 'to', '21', 'at', 'the', 'time', 'of', 'assessment', 'and', 'were', 'between', 'the', 'ages', 'of', '10', 'and', '21', 'at', 'the', 'time', 'of', 'their', 'first', 'halluc', '##ino', '##gen', 'use', '.', 'the', 'nhs', '##da', 'included', 'items', 'to', 'assess', 'seven', 'clinical', 'features', 'often', 'associated', 'with', 'halluc', '##ino', '##gen', 'dependence', ',', 'which', 'were', 'used', 'in', 'latent', 'class', 'modelling', '.', 'latent', 'class', 'analysis', ',', 'in', 'conjunction', 'with', 'prior', 'theory', ',', 'supports', 'a', 'three', '-', 'class', 'solution', ',', 'with', '2', '%', 'of', 'recent', '-', 'onset', 'users', 'in', 'a', 'class', 'that', 'resembles', 'a', 'halluc', '##ino', '##gen', 'dependence', 'syndrome', ',', 'whereas', '88', '%', 'expressed', 'few', 'or', 'no', 'clinical', 'features', 'of', 'dependence', '.', 'the', 'remaining', '10', '%', 'may', 'reflect', 'users', 'who', 'are', 'at', 'risk', 'for', 'dependence', 'or', 'in', 'an', 'early', 'stage', 'of', 'dependence', '.', 'results', 'from', 'latent', 'class', 'regressions', 'indicate', 'that', 'susceptibility', 'to', 'rapid', 'transition', 'from', 'first', 'halluc', '##ino', '##gen', 'use', 'to', 'onset', 'of', 'this', 'halluc', '##ino', '##gen', 'dependence', 'syndrome', 'might', 'be', 'influenced', 'by', 'halluc', '##ino', '##genic', 'compounds', 'taken', '(', 'for', 'example', ',', 'estimated', 'relative', 'risk', ',', 'rr', '=', '2', '.', '4', ',', '95', '%', 'ci', '=', '1', '.', '6', ',', '7', '.', '6', 'for', 'users', 'of', 'mdm', '##a', 'versus', 'users', 'of', 'lsd', ')', '.', 'excess', 'risk', 'of', 'rapid', 'transition', 'did', 'not', 'appear', 'to', 'depend', 'upon', 'age', ',', 'sex', ',', 'or', 'race', '/', 'ethnicity', '.', 'copyright', '©', '2006', 'john', 'wiley', '&', 'sons', ',', 'ltd', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11, 11, 12, 13, 14, 14, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 41, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 72, 73, 74, 75, 76, 77, 77, 78, 79, 80, 81, 81, 81, 82, 83, 84, 85, 86, 87, 88, 88, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 142, 142, 143, 144, 145, 146, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 157, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 199, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 249, 249, 250, 251, 252, 253, 254, 255, 255, 255, 256, 257, 258, 259, 260, 261, 262, 262, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 275, 275, 276, 277, 278, 279, 280, 281, 281, 281, 282, 283, 283, 283, 284, 285, 286, 287, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 322, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence.^
This study uses latent class methods and multiple regression to shed light on hypothesized hallucinogen dependence syndromes experienced by young people who have recently initiated hallucinogen use. It explores possible variation in risk. The study sample, identified within public-use data files of the 1999 National Household Survey on Drug Abuse (NHSDA), consists of 1186 recent-onset hallucinogen users, defined as having initiated hallucinogen use within 24 months of assessment (median elapsed time since onset of use ∼12 to 13 months). The recent-onset users in this sample were age 12 to 21 at the time of assessment and were between the ages of 10 and 21 at the time of their first hallucinogen use. The NHSDA included items to assess seven clinical features often associated with hallucinogen dependence, which were used in latent class modelling. Latent class analysis, in conjunction with prior theory, supports a three-class solution, with 2% of recent-onset users in a class that resembles a hallucinogen dependence syndrome, whereas 88% expressed few or no clinical features of dependence. The remaining 10% may reflect users who are at risk for dependence or in an early stage of dependence. Results from latent class regressions indicate that susceptibility to rapid transition from first hallucinogen use to onset of this hallucinogen dependence syndrome might be influenced by hallucinogenic compounds taken (for example, estimated relative risk, RR = 2.4, 95% CI = 1.6, 7.6 for users of MDMA versus users of LSD). Excess risk of rapid transition did not appear to depend upon age, sex, or race/ethnicity. Copyright © 2006 John Wiley & Sons, Ltd."
"['Efficacy', 'and', 'Safety', 'of', 'a', 'Rapid', 'Intravenous', 'Injection', 'of', 'Ketamine', '0.5', 'mg', '/', 'kg', 'in', 'Treatment', '-', 'Resistant', 'Major', 'Depression', ':', 'An', 'Open', '4', '-', 'Week', 'Longitudinal', 'Study.^', '\n', 'BACKGROUND', ':', 'Ketamine', 'has', 'been', 'documented', 'for', 'its', 'rapid', 'antidepressant', 'effects', '.', 'However', ',', 'optimal', 'dose', 'and', 'delivery', 'route', 'have', 'not', 'yet', 'been', 'thoroughly', 'investigated', '.', 'The', 'objectives', 'of', 'this', 'study', 'were', 'to', 'document', 'the', 'safety', 'and', 'test', 'the', 'antidepressant', 'and', 'antisuicidal', 'effects', 'of', 'a', 'single', 'rapid', '1', '-', 'minute', 'injection', 'of', 'ketamine', '0.5', 'mg', '/', 'kg', 'in', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', '.', 'METHODS', ':', 'Ten', 'patients', 'with', 'TRD', 'were', 'included', 'in', 'an', 'open', ',', 'noncontrolled', '4', '-', 'week', 'study', 'and', 'received', 'a', 'rapid', 'intravenous', 'dose', 'of', 'ketamine', '0.5', 'mg', '/', 'kg', '.', 'Main', 'outcome', 'measure', 'was', 'the', 'Montgomery', '-', 'Åsberg', 'Depression', 'Rating', 'Scale', 'and', 'suicidality', 'was', 'assessed', 'using', 'the', 'Scale', 'for', 'Suicide', 'Ideation', '.', 'RESULTS', ':', 'Rapid', 'injection', 'of', 'ketamine', 'elicited', 'transient', 'increase', 'of', 'blood', 'pressure', 'and', 'altered', 'states', 'of', 'consciousness', 'in', 'all', 'patients', 'and', 'mild', 'psychotomimetic', 'effects', 'in', '4', 'patients', ',', 'which', 'all', 'resolved', 'without', 'any', 'intervention', '.', 'Decrease', 'of', 'depression', 'severity', 'was', 'observed', 'from', '40', '-', 'minute', 'postinjection', 'until', 'day', '15', '.', 'Eight', 'patients', 'became', 'responders', 'within', '1', 'day', 'and', 'all', 'were', 'nonresponders', 'after', '4', 'weeks', '.', 'The', 'decrease', 'of', 'suicidal', 'ideation', 'was', 'significant', 'until', 'day', '7', '.', 'Analysis', 'indicated', 'that', 'higher', 'severity', 'of', 'depression', 'and', 'anxiety', 'at', 'baseline', 'predicted', 'a', 'larger', 'Montgomery', '-', 'Åsberg', 'Depression', 'Rating', 'Scale', 'decrease', 'after', '4', 'weeks', '.', 'CONCLUSIONS', ':', 'This', 'study', 'suggests', 'that', 'in', 'well', '-', 'controlled', 'medical', 'settings', 'with', 'adequate', 'monitoring', ',', 'a', 'single', 'rapid', '1', '-', 'minute', 'injection', 'of', 'ketamine', '0.5', 'mg', '/', 'kg', 'can', 'be', 'well', 'tolerated', 'and', 'is', 'efficacious', 'in', 'rapidly', 'reducing', 'depression', 'symptoms', 'and', 'suicidal', 'thoughts', 'in', 'outpatients', 'with', 'TRD', '.', 'These', 'findings', 'are', 'relevant', 'to', 'the', 'practice', 'of', 'general', 'clinical', 'psychiatry', 'and', 'emergency', 'departments', 'were', 'ketamine', 'can', 'have', 'a', 'place', 'in', 'acute', 'management', 'of', 'TRD', '.', 'Larger', 'studies', 'are', 'necessary', 'to', 'confirm', 'these', 'results', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8836,"['[CLS]', 'efficacy', 'and', 'safety', 'of', 'a', 'rapid', 'intravenous', 'injection', 'of', 'ketamine', '0', '.', '5', 'mg', '/', 'kg', 'in', 'treatment', '-', 'resistant', 'major', 'depression', ':', 'an', 'open', '4', '-', 'week', 'longitudinal', 'study', '.', '^', 'background', ':', 'ketamine', 'has', 'been', 'documented', 'for', 'its', 'rapid', 'antidepressant', 'effects', '.', 'however', ',', 'optimal', 'dose', 'and', 'delivery', 'route', 'have', 'not', 'yet', 'been', 'thoroughly', 'investigated', '.', 'the', 'objectives', 'of', 'this', 'study', 'were', 'to', 'document', 'the', 'safety', 'and', 'test', 'the', 'antidepressant', 'and', 'antis', '##ui', '##cid', '##al', 'effects', 'of', 'a', 'single', 'rapid', '1', '-', 'minute', 'injection', 'of', 'ketamine', '0', '.', '5', 'mg', '/', 'kg', 'in', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', '.', 'methods', ':', 'ten', 'patients', 'with', 'tr', '##d', 'were', 'included', 'in', 'an', 'open', ',', 'non', '##controlled', '4', '-', 'week', 'study', 'and', 'received', 'a', 'rapid', 'intravenous', 'dose', 'of', 'ketamine', '0', '.', '5', 'mg', '/', 'kg', '.', 'main', 'outcome', 'measure', 'was', 'the', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', 'and', 'suicidal', '##ity', 'was', 'assessed', 'using', 'the', 'scale', 'for', 'suicide', 'idea', '##tion', '.', 'results', ':', 'rapid', 'injection', 'of', 'ketamine', 'elicited', 'transient', 'increase', 'of', 'blood', 'pressure', 'and', 'altered', 'states', 'of', 'consciousness', 'in', 'all', 'patients', 'and', 'mild', 'psycho', '##tom', '##ime', '##tic', 'effects', 'in', '4', 'patients', ',', 'which', 'all', 'resolved', 'without', 'any', 'intervention', '.', 'decrease', 'of', 'depression', 'severity', 'was', 'observed', 'from', '40', '-', 'minute', 'post', '##injection', 'until', 'day', '15', '.', 'eight', 'patients', 'became', 'responders', 'within', '1', 'day', 'and', 'all', 'were', 'non', '##respond', '##ers', 'after', '4', 'weeks', '.', 'the', 'decrease', 'of', 'suicidal', 'idea', '##tion', 'was', 'significant', 'until', 'day', '7', '.', 'analysis', 'indicated', 'that', 'higher', 'severity', 'of', 'depression', 'and', 'anxiety', 'at', 'baseline', 'predicted', 'a', 'larger', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', 'decrease', 'after', '4', 'weeks', '.', 'conclusions', ':', 'this', 'study', 'suggests', 'that', 'in', 'well', '-', 'controlled', 'medical', 'settings', 'with', 'adequate', 'monitoring', ',', 'a', 'single', 'rapid', '1', '-', 'minute', 'injection', 'of', 'ketamine', '0', '.', '5', 'mg', '/', 'kg', 'can', 'be', 'well', 'tolerated', 'and', 'is', 'efficacious', 'in', 'rapidly', 'reducing', 'depression', 'symptoms', 'and', 'suicidal', 'thoughts', 'in', 'outpatient', '##s', 'with', 'tr', '##d', '.', 'these', 'findings', 'are', 'relevant', 'to', 'the', 'practice', 'of', 'general', 'clinical', 'psychiatry', 'and', 'emergency', 'departments', 'were', 'ketamine', 'can', 'have', 'a', 'place', 'in', 'acute', 'management', 'of', 'tr', '##d', '.', 'larger', 'studies', 'are', 'necessary', 'to', 'confirm', 'these', 'results', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 27, 27, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 70, 70, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 82, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 92, 93, 94, 95, 96, 97, 98, 99, 100, 100, 101, 102, 103, 104, 105, 106, 107, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 120, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 130, 130, 130, 131, 132, 132, 133, 134, 135, 136, 137, 137, 138, 139, 140, 141, 142, 143, 144, 145, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 169, 169, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 207, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 237, 237, 237, 238, 239, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 273, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 293, 294, 295, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.^
BACKGROUND: Ketamine has been documented for its rapid antidepressant effects. However, optimal dose and delivery route have not yet been thoroughly investigated. The objectives of this study were to document the safety and test the antidepressant and antisuicidal effects of a single rapid 1-minute injection of ketamine 0.5 mg/kg in treatment-resistant depression (TRD). METHODS: Ten patients with TRD were included in an open, noncontrolled 4-week study and received a rapid intravenous dose of ketamine 0.5 mg/kg. Main outcome measure was the Montgomery-Åsberg Depression Rating Scale and suicidality was assessed using the Scale for Suicide Ideation. RESULTS: Rapid injection of ketamine elicited transient increase of blood pressure and altered states of consciousness in all patients and mild psychotomimetic effects in 4 patients, which all resolved without any intervention. Decrease of depression severity was observed from 40-minute postinjection until day 15. Eight patients became responders within 1 day and all were nonresponders after 4 weeks. The decrease of suicidal ideation was significant until day 7. Analysis indicated that higher severity of depression and anxiety at baseline predicted a larger Montgomery-Åsberg Depression Rating Scale decrease after 4 weeks. CONCLUSIONS: This study suggests that in well-controlled medical settings with adequate monitoring, a single rapid 1-minute injection of ketamine 0.5 mg/kg can be well tolerated and is efficacious in rapidly reducing depression symptoms and suicidal thoughts in outpatients with TRD. These findings are relevant to the practice of general clinical psychiatry and emergency departments were ketamine can have a place in acute management of TRD. Larger studies are necessary to confirm these results."
"['Acute', 'effects', 'of', 'intravenous', 'sub', '-', 'anesthetic', 'doses', 'of', 'ketamine', 'and', 'intranasal', 'inhaled', 'esketamine', 'on', 'suicidal', 'ideation', ':', 'A', 'systematic', 'review', 'and', 'meta', '-', 'analysis.^', '\n', 'Purpose', ':', 'Suicide', 'is', 'a', 'major', 'public', 'health', 'concern', 'with', 'currently', 'no', 'validated', 'and', 'efficacious', 'treatments', 'approved', '.', 'Preliminary', 'evidence', 'suggests', 'that', 'intravenous', 'ketamine', 'has', 'rapid', 'and', 'sustained', 'antidepressant', 'effects', ',', 'making', 'it', 'a', 'candidate', 'with', 'therapeutic', 'potential', 'for', 'depressed', 'patients', 'at', 'risk', 'for', 'suicide', '.', 'We', 'conducted', 'a', 'meta', '-', 'analysis', 'to', 'evaluate', 'the', 'efficacy', 'of', 'ketamine', 'and', 'esketamine', 'in', 'reducing', 'suicidal', 'ideation', '(', 'SI', ')', ',', 'as', 'well', 'as', 'their', 'respective', 'onset', 'and', 'duration', 'of', 'action', '.', 'Data', 'Sources', ':', 'We', 'searched', 'PubMed', ',', 'Embase', ',', 'Ovid', ',', 'Cochrane', ',', 'and', 'Web', 'of', 'Science', 'databases', 'for', 'studies', 'published', 'from', 'inception', 'to', 'September', '29', ',', '2022', '.', 'Study', 'Eligibility', 'Criteria', ':', 'We', 'conducted', 'a', 'systematic', 'review', 'of', 'all', 'parallel', 'randomized', 'controlled', 'trials', '(', 'RCTs', ')', 'examining', 'the', 'effect', 'and', 'duration', 'of', 'ketamine', 'or', 'esketamine', 'on', 'SI', '.', 'Our', 'primary', 'outcome', 'measure', 'was', 'the', 'Suicide', 'Scale', 'score', ',', 'which', 'was', 'measured', 'using', 'the', 'Scale', 'for', 'Suicidal', 'Ideation', '(', 'SSI', ')', ',', 'Beck', 'Scale', 'for', 'Suicide', 'Ideation', '(', 'BSS', ')', ',', 'Beck', 'Depression', 'Inventory', '(', 'BDI', ')', ',', 'or', 'Modified', 'Scale', 'for', 'Suicidal', 'Ideation', '(', 'MSSI', ')', '.', 'To', 'obtain', 'effect', 'sizes', '(', 'Cohen', '’s', 'd', ')', ',', 'we', 'calculated', 'the', 'difference', 'in', 'Suicide', 'Scale', 'scores', 'before', 'and', 'after', 'administration', 'in', 'each', 'group', '.', 'Results', ':', 'Our', 'study', 'showed', 'that', 'intravenous', 'sub', '-', 'anesthetic', 'doses', 'of', 'ketamine', 'and', 'intranasal', 'inhaled', 'esketamine', 'had', 'a', 'significant', 'anti', '-', 'SI', 'effect', '.', 'Specifically', ',', 'ketamine', 'produced', 'a', 'large', 'degree', 'of', 'anti', '-', 'SI', 'effect', 'within', 'the', '4–6', 'hours', '(', 'Cohen', '’s', 'd', '=', '1.16', ',', '95', '%', 'CI', ':', '0.50', ',', '1.81', ')', 'and', 'a', 'medium', '-', 'large', 'degree', 'in', 'the', '24', 'hours', '(', 'Cohen', '’s', 'd', '=', '0.95', ',', '95', '%', 'CI', ':', '0.48', ',', '1.41', ')', '.', 'Esketamine', ',', 'on', 'the', 'other', 'hand', ',', 'produced', 'a', 'small', '-', 'medium', 'degree', 'of', 'anti', '-', 'SI', 'effect', 'within', 'the', '4–6', 'hours', 'timeframe', '(', 'Cohen', '’s', 'd', '=', '0.26', ',', '95', '%', 'CI', ':', '0.09', ',', '0.44', ')', 'and', 'the', '24', 'hours', '(', 'Cohen', '’s', 'd', '=', '0.30', ',', '95', '%', 'CI', ':', '0.17', ',', '0.47', ')', '.', 'Conclusion', ':', 'Intravenous', 'sub', '-', 'anesthetic', 'doses', 'of', 'ketamine', 'and', 'intranasal', 'inhaled', 'esketamine', 'could', 'reduce', 'SI', 'within', '4', 'hours', 'and', 'last', 'for', '24', 'hours', '.', '(', 'PsycInfo', 'Database', 'Record', '(', 'c', ')', '2023', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1418,"['[CLS]', 'acute', 'effects', 'of', 'intravenous', 'sub', '-', 'anesthetic', 'doses', 'of', 'ketamine', 'and', 'intran', '##asal', 'inhaled', 'es', '##ket', '##amine', 'on', 'suicidal', 'idea', '##tion', ':', 'a', 'systematic', 'review', 'and', 'meta', '-', 'analysis', '.', '^', 'purpose', ':', 'suicide', 'is', 'a', 'major', 'public', 'health', 'concern', 'with', 'currently', 'no', 'validated', 'and', 'efficacious', 'treatments', 'approved', '.', 'preliminary', 'evidence', 'suggests', 'that', 'intravenous', 'ketamine', 'has', 'rapid', 'and', 'sustained', 'antidepressant', 'effects', ',', 'making', 'it', 'a', 'candidate', 'with', 'therapeutic', 'potential', 'for', 'depressed', 'patients', 'at', 'risk', 'for', 'suicide', '.', 'we', 'conducted', 'a', 'meta', '-', 'analysis', 'to', 'evaluate', 'the', 'efficacy', 'of', 'ketamine', 'and', 'es', '##ket', '##amine', 'in', 'reducing', 'suicidal', 'idea', '##tion', '(', 'si', ')', ',', 'as', 'well', 'as', 'their', 'respective', 'onset', 'and', 'duration', 'of', 'action', '.', 'data', 'sources', ':', 'we', 'searched', 'pubmed', ',', 'emb', '##ase', ',', 'ov', '##id', ',', 'cochrane', ',', 'and', 'web', 'of', 'science', 'databases', 'for', 'studies', 'published', 'from', 'inc', '##epti', '##on', 'to', 'september', '29', ',', '202', '##2', '.', 'study', 'eligibility', 'criteria', ':', 'we', 'conducted', 'a', 'systematic', 'review', 'of', 'all', 'parallel', 'randomized', 'controlled', 'trials', '(', 'rcts', ')', 'examining', 'the', 'effect', 'and', 'duration', 'of', 'ketamine', 'or', 'es', '##ket', '##amine', 'on', 'si', '.', 'our', 'primary', 'outcome', 'measure', 'was', 'the', 'suicide', 'scale', 'score', ',', 'which', 'was', 'measured', 'using', 'the', 'scale', 'for', 'suicidal', 'idea', '##tion', '(', 'ss', '##i', ')', ',', 'beck', 'scale', 'for', 'suicide', 'idea', '##tion', '(', 'bss', ')', ',', 'beck', 'depression', 'inventory', '(', 'bd', '##i', ')', ',', 'or', 'modified', 'scale', 'for', 'suicidal', 'idea', '##tion', '(', 'mss', '##i', ')', '.', 'to', 'obtain', 'effect', 'sizes', '(', 'cohen', '’', 's', 'd', ')', ',', 'we', 'calculated', 'the', 'difference', 'in', 'suicide', 'scale', 'scores', 'before', 'and', 'after', 'administration', 'in', 'each', 'group', '.', 'results', ':', 'our', 'study', 'showed', 'that', 'intravenous', 'sub', '-', 'anesthetic', 'doses', 'of', 'ketamine', 'and', 'intran', '##asal', 'inhaled', 'es', '##ket', '##amine', 'had', 'a', 'significant', 'anti', '-', 'si', 'effect', '.', 'specifically', ',', 'ketamine', 'produced', 'a', 'large', 'degree', 'of', 'anti', '-', 'si', 'effect', 'within', 'the', '4', '–', '6', 'hours', '(', 'cohen', '’', 's', 'd', '=', '1', '.', '16', ',', '95', '%', 'ci', ':', '0', '.', '50', ',', '1', '.', '81', ')', 'and', 'a', 'medium', '-', 'large', 'degree', 'in', 'the', '24', 'hours', '(', 'cohen', '’', 's', 'd', '=', '0', '.', '95', ',', '95', '%', 'ci', ':', '0', '.', '48', ',', '1', '.', '41', ')', '.', 'es', '##ket', '##amine', ',', 'on', 'the', 'other', 'hand', ',', 'produced', 'a', 'small', '-', 'medium', 'degree', 'of', 'anti', '-', 'si', 'effect', 'within', 'the', '4', '–', '6', 'hours', 'time', '##frame', '(', 'cohen', '’', 's', 'd', '=', '0', '.', '26', ',', '95', '%', 'ci', ':', '0', '.', '09', ',', '0', '.', '44', ')', 'and', 'the', '24', 'hours', '(', 'cohen', '’', 's', 'd', '=', '0', '.', '30', ',', '95', '%', 'ci', ':', '0', '.', '17', ',', '0', '.', '47', ')', '.', 'conclusion', ':', 'intravenous', 'sub', '-', 'anesthetic', 'doses', 'of', 'ketamine', 'and', 'intran', '##asal', 'inhaled', 'es', '##ket', '##amine', 'could', 'reduce', 'si', 'within', '4', 'hours', 'and', 'last', 'for', '24', 'hours', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '202', '##3', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11, 12, 13, 13, 13, 14, 15, 16, 16, 17, 18, 19, 20, 21, 22, 23, 24, 24, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 85, 86, 87, 88, 89, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 112, 113, 114, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 127, 127, 128, 129, 130, 131, 132, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 160, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 182, 183, 184, 184, 185, 186, 187, 188, 189, 190, 191, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 200, 201, 202, 203, 204, 205, 206, 207, 208, 208, 209, 210, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 253, 254, 255, 255, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 278, 278, 279, 280, 281, 282, 282, 283, 284, 285, 285, 285, 286, 287, 288, 289, 290, 291, 291, 291, 292, 293, 293, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 307, 308, 309, 310, 310, 310, 311, 312, 313, 314, 315, 316, 316, 316, 317, 318, 318, 318, 319, 320, 321, 321, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 341, 341, 342, 343, 343, 344, 345, 346, 346, 347, 348, 349, 349, 349, 350, 351, 352, 353, 354, 355, 355, 355, 356, 357, 357, 357, 358, 359, 360, 361, 362, 363, 364, 365, 365, 366, 367, 368, 368, 368, 369, 370, 371, 372, 373, 374, 374, 374, 375, 376, 376, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 389, 390, 391, 391, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 405, 405, 406, 407, 408, 409, 410, 411, 411, 412, 412, 413, 414, 415, 416, 417, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine on suicidal ideation: A systematic review and meta-analysis.^
Purpose: Suicide is a major public health concern with currently no validated and efficacious treatments approved. Preliminary evidence suggests that intravenous ketamine has rapid and sustained antidepressant effects, making it a candidate with therapeutic potential for depressed patients at risk for suicide. We conducted a meta-analysis to evaluate the efficacy of ketamine and esketamine in reducing suicidal ideation (SI), as well as their respective onset and duration of action. Data Sources: We searched PubMed, Embase, Ovid, Cochrane, and Web of Science databases for studies published from inception to September 29, 2022. Study Eligibility Criteria: We conducted a systematic review of all parallel randomized controlled trials (RCTs) examining the effect and duration of ketamine or esketamine on SI. Our primary outcome measure was the Suicide Scale score, which was measured using the Scale for Suicidal Ideation (SSI), Beck Scale for Suicide Ideation (BSS), Beck Depression Inventory (BDI), or Modified Scale for Suicidal Ideation (MSSI). To obtain effect sizes (Cohen’s d), we calculated the difference in Suicide Scale scores before and after administration in each group. Results: Our study showed that intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine had a significant anti-SI effect. Specifically, ketamine produced a large degree of anti-SI effect within the 4–6 hours (Cohen’s d = 1.16, 95% CI: 0.50, 1.81) and a medium-large degree in the 24 hours (Cohen’s d = 0.95, 95% CI: 0.48, 1.41). Esketamine, on the other hand, produced a small-medium degree of anti-SI effect within the 4–6 hours timeframe (Cohen’s d = 0.26, 95% CI: 0.09, 0.44) and the 24 hours (Cohen’s d = 0.30, 95% CI: 0.17, 0.47). Conclusion: Intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine could reduce SI within 4 hours and last for 24 hours. (PsycInfo Database Record (c) 2023 APA, all rights reserved)"
"['The', 'effects', 'of', 'ketamine', 'on', 'the', 'mismatch', 'negativity', '(', 'MMN', ')', 'in', 'humans', '—', 'A', 'meta', '-', 'analysis.^', '\n', 'Objective', ':', 'To', 'investigate', 'whether', 'effects', 'of', 'the', 'glutamatergic', 'N', '-', 'methyl', '-', 'D', '-', 'aspartate', '(', 'NMDA', ')', 'receptor', 'antagonist', 'ketamine', 'on', 'the', 'mismatch', 'negativity', '(', 'MMN', ')', 'vary', 'between', 'duration', 'and', 'frequency', 'deviants', ',', 'as', 'suggested', 'by', 'clinical', 'studies', 'on', 'schizophrenia', 'patients', '.', 'Methods', ':', 'Our', 'meta', '-', 'analysis', 'included', 'previous', 'studies', 'that', 'used', 'ketamine', 'in', 'order', 'to', 'induce', 'psychotic', 'experiences', 'in', 'healthy', 'participants', 'and', 'that', 'recorded', 'the', 'MMN', 'either', 'by', 'electroencephalography', 'or', 'magnetoencephalography', '.', 'Results', ':', 'The', 'analysis', 'revealed', 'systematic', 'MMN', 'amplitude', 'decreases', 'and', ',', 'with', 'a', 'lower', 'effect', 'size', ',', 'latency', 'increases', 'after', 'ketamine', 'administration', '.', 'However', ',', 'the', 'observed', 'amplitude', 'and', 'latency', 'effects', 'did', 'not', 'vary', 'between', 'duration', 'and', 'frequency', 'deviants', '.', 'Conclusion', ':', 'Across', 'studies', ',', 'there', 'is', 'no', 'evidence', 'that', 'ketamine', 'effects', 'on', 'the', 'MMN', 'are', 'larger', 'for', 'duration', 'than', 'frequency', 'deviants', '.', 'Significance', ':', 'Our', 'findings', 'tentatively', 'suggest', 'that', ',', 'in', 'addition', 'to', 'an', 'NMDA', 'receptor', 'hypofunction', ',', 'other', 'factors', 'might', 'contribute', 'to', 'the', 'sometimes', 'observed', 'pattern', 'of', 'impaired', 'MMN', 'responses', 'to', 'duration', 'deviants', ',', 'but', 'unimpaired', 'MMN', 'responses', 'to', 'frequency', 'deviants', 'in', 'schizophrenia', '.', '(', 'PsycINFO', 'Database', 'Record', '(', 'c', ')', '2016', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7451,"['[CLS]', 'the', 'effects', 'of', 'ketamine', 'on', 'the', 'mismatch', 'neg', '##ativity', '(', 'mm', '##n', ')', 'in', 'humans', '—', 'a', 'meta', '-', 'analysis', '.', '^', 'objective', ':', 'to', 'investigate', 'whether', 'effects', 'of', 'the', 'glutamate', '##rg', '##ic', 'n', '-', 'methyl', '-', 'd', '-', 'aspartate', '(', 'nmda', ')', 'receptor', 'antagonist', 'ketamine', 'on', 'the', 'mismatch', 'neg', '##ativity', '(', 'mm', '##n', ')', 'vary', 'between', 'duration', 'and', 'frequency', 'devi', '##ants', ',', 'as', 'suggested', 'by', 'clinical', 'studies', 'on', 'schizophrenia', 'patients', '.', 'methods', ':', 'our', 'meta', '-', 'analysis', 'included', 'previous', 'studies', 'that', 'used', 'ketamine', 'in', 'order', 'to', 'induce', 'psychotic', 'experiences', 'in', 'healthy', 'participants', 'and', 'that', 'recorded', 'the', 'mm', '##n', 'either', 'by', 'electroencephal', '##ography', 'or', 'magnet', '##oen', '##cephal', '##ography', '.', 'results', ':', 'the', 'analysis', 'revealed', 'systematic', 'mm', '##n', 'amplitude', 'decreases', 'and', ',', 'with', 'a', 'lower', 'effect', 'size', ',', 'latency', 'increases', 'after', 'ketamine', 'administration', '.', 'however', ',', 'the', 'observed', 'amplitude', 'and', 'latency', 'effects', 'did', 'not', 'vary', 'between', 'duration', 'and', 'frequency', 'devi', '##ants', '.', 'conclusion', ':', 'across', 'studies', ',', 'there', 'is', 'no', 'evidence', 'that', 'ketamine', 'effects', 'on', 'the', 'mm', '##n', 'are', 'larger', 'for', 'duration', 'than', 'frequency', 'devi', '##ants', '.', 'significance', ':', 'our', 'findings', 'tent', '##atively', 'suggest', 'that', ',', 'in', 'addition', 'to', 'an', 'nmda', 'receptor', 'hypo', '##function', ',', 'other', 'factors', 'might', 'contribute', 'to', 'the', 'sometimes', 'observed', 'pattern', 'of', 'impaired', 'mm', '##n', 'responses', 'to', 'duration', 'devi', '##ants', ',', 'but', 'unim', '##paired', 'mm', '##n', 'responses', 'to', 'frequency', 'devi', '##ants', 'in', 'schizophrenia', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '2016', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 7, 8, 9, 9, 10, 11, 12, 13, 14, 15, 16, 17, 17, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 27, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 44, 45, 46, 46, 47, 48, 49, 50, 51, 52, 53, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 89, 90, 91, 92, 92, 93, 94, 94, 94, 94, 95, 96, 97, 98, 99, 100, 101, 102, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 150, 151, 152, 153, 154, 155, 156, 157, 157, 158, 159, 160, 161, 162, 163, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 186, 187, 188, 189, 190, 190, 191, 192, 193, 193, 194, 194, 195, 196, 197, 198, 198, 199, 200, 201, 202, 203, 203, 203, 204, 205, 206, 207, 208, 209, 210, 210, 211, 212, 213, 214, 215, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","The effects of ketamine on the mismatch negativity (MMN) in humans—A meta-analysis.^
Objective: To investigate whether effects of the glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist ketamine on the mismatch negativity (MMN) vary between duration and frequency deviants, as suggested by clinical studies on schizophrenia patients. Methods: Our meta-analysis included previous studies that used ketamine in order to induce psychotic experiences in healthy participants and that recorded the MMN either by electroencephalography or magnetoencephalography. Results: The analysis revealed systematic MMN amplitude decreases and, with a lower effect size, latency increases after ketamine administration. However, the observed amplitude and latency effects did not vary between duration and frequency deviants. Conclusion: Across studies, there is no evidence that ketamine effects on the MMN are larger for duration than frequency deviants. Significance: Our findings tentatively suggest that, in addition to an NMDA receptor hypofunction, other factors might contribute to the sometimes observed pattern of impaired MMN responses to duration deviants, but unimpaired MMN responses to frequency deviants in schizophrenia. (PsycINFO Database Record (c) 2016 APA, all rights reserved)"
"['Ketamine', '-', 'Associated', 'Intraoperative', 'Electroencephalographic', 'Signatures', 'of', 'Elderly', 'Patients', 'With', 'and', 'Without', 'Preoperative', 'Cognitive', 'Impairment.^', '\n', 'BACKGROUND', ':', 'Ketamine', 'is', 'typically', 'used', 'by', 'anesthesiologists', 'as', 'an', 'adjunct', 'for', 'general', 'anesthesia', 'and', 'as', 'a', 'nonopioid', 'analgesic', '.', 'It', 'has', 'been', 'explored', 'for', 'prevention', 'of', 'postoperative', 'delirium', ',', 'although', 'results', 'have', 'been', 'contradictory', '.', 'In', 'this', 'study', ',', 'we', 'investigated', 'the', 'association', 'of', 'ketamine', 'with', 'postoperative', 'delirium', 'and', 'specific', 'encephalographic', 'signatures', '.', 'Furthermore', ',', 'we', 'examined', 'these', 'associations', 'in', 'the', 'context', 'of', 'baseline', 'neurocognition', 'as', 'measured', 'by', 'a', 'validated', 'assessment', '.', 'METHODS', ':', 'We', 'conducted', 'a', 'prospective', 'observational', 'study', 'from', 'January', '2019', 'to', 'December', '2020', '.', 'Ninety', '-', 'eight', 'patients', 'aged', '≥65', 'years', 'and', 'undergoing', 'spine', 'surgery', 'scheduled', 'for', '≥3', 'hours', 'were', 'included', 'in', 'the', 'study', '.', 'All', 'participants', 'who', 'completed', 'the', 'University', 'of', 'California', 'San', 'Francisco', '(', 'UCSF', ')', 'Brain', 'Health', 'Assessment', 'preoperatively', 'and', 'postoperatively', 'were', 'assessed', 'with', 'the', 'confusion', 'assessment', 'method', 'for', 'intensive', 'care', 'unit', '(', 'CAM', '-', 'ICU', ')', 'and/or', 'the', 'Nursing', 'Delirium', 'Screening', 'Scale', '(', 'NuDESC', ')', '.', 'Patients', 'had', 'frontal', 'electroencephalogram', '(', 'EEG', ')', 'recordings', '(', 'SedLine', 'Root', ',', 'Masimo', ',', 'Corp', ')', 'quantitatively', 'analyzed', '.', 'We', 'used', '60', 'seconds', 'of', 'artifact', '-', 'free', 'EEG', '(', 'without', 'burst', 'suppression', ')', 'extracted', 'from', 'the', 'middle', 'of', 'the', 'maintenance', 'period', 'to', 'calculate', 'the', 'normalized', 'power', 'spectral', 'density', '(', 'PSD', ')', '.', 'Comparisons', 'were', 'made', 'between', 'those', 'who', 'did', 'or', 'did', 'not', 'receive', 'ketamine', 'and', 'according', 'to', 'results', 'from', 'neurocognitive', 'assessments', '.', 'RESULTS', ':', 'Ninety', '-', 'eight', 'patients', '(', 'of', 'a', 'total', 'of', '155', ',', 'enrolled', 'and', 'consented', ')', 'had', 'EEG', 'of', 'sufficient', 'quality', 'for', 'analysis', '(', '42', 'women', ')', '.', 'Overall', ',', 'we', 'found', 'a', 'significant', 'increase', 'in', 'the', 'EEG', 'power', 'in', 'the', 'moderate', 'frequency', 'range', '(', '10', '-', '20', 'Hz', ')', 'in', 'patients', 'that', 'received', 'ketamine', '.', 'When', 'the', 'patients', 'were', 'divided', 'by', 'their', 'preoperative', 'cognitive', 'status', ',', 'this', 'result', 'in', 'the', 'ketamine', 'group', 'only', 'held', 'true', 'for', 'the', 'cognitively', 'normal', 'patients', '.', 'Patients', 'that', 'were', 'cognitively', 'impaired', 'at', 'baseline', 'did', 'not', 'demonstrate', 'a', 'significant', 'change', 'in', 'EEG', 'characteristics', 'based', 'on', 'ketamine', 'administration', ',', 'but', 'impaired', 'patients', 'that', 'received', 'ketamine', 'had', 'a', 'significantly', 'higher', 'rate', 'of', 'postoperative', 'delirium', '(', '52', '%', 'ketamine', 'versus', '20', '%', 'no', 'ketamine', ')', '(', 'odds', 'ratio', '[', 'OR', ']', ',', '4.36', ';', 'confidence', 'interval', '[', 'CI', ']', ',', '1.02', '-', '18.22', ';', 'P', '=', '.048', ')', '.', 'In', 'patients', 'determined', 'to', 'be', 'preoperatively', 'cognitively', 'normal', ',', 'the', 'incidence', 'of', 'postoperative', 'delirium', 'was', 'not', 'significantly', 'associated', 'with', 'ketamine', 'administration', '(', '19', '%', 'ketamine', 'versus', '17', '%', 'no', 'ketamine', ')', '(', 'OR', ',', '1.10', ';', 'CI', ',', '0.30', '-', '4.04', ';', 'P', '=', '.5833', ')', '.', 'CONCLUSIONS', ':', 'Ketamine', '-', 'related', 'changes', 'in', 'EEG', 'are', 'observed', 'in', 'a', 'heterogeneous', 'group', 'of', 'patients', 'receiving', 'spine', 'surgery', '.', 'This', 'result', 'was', 'driven', 'primarily', 'by', 'the', 'effect', 'of', 'ketamine', 'on', 'cognitively', 'normal', 'patients', 'and', 'not', 'observed', 'in', 'patients', 'that', 'were', 'cognitively', 'impaired', 'at', 'baseline', '.', 'Furthermore', ',', 'patients', 'who', 'were', 'cognitively', 'impaired', 'at', 'baseline', 'and', 'who', 'had', 'received', 'ketamine', 'were', 'more', 'likely', 'to', 'develop', 'postoperative', 'delirium', ',', 'suggesting', 'that', 'cognitive', 'vulnerability', 'might', 'be', 'predicted', 'by', 'the', 'lack', 'of', 'a', 'neurophysiologic', 'response', 'to', 'ketamine', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",633,"['[CLS]', 'ketamine', '-', 'associated', 'intraoperative', 'electroencephal', '##ographic', 'signatures', 'of', 'elderly', 'patients', 'with', 'and', 'without', 'preoperative', 'cognitive', 'impairment', '.', '^', 'background', ':', 'ketamine', 'is', 'typically', 'used', 'by', 'anesthesi', '##ologists', 'as', 'an', 'adjunct', 'for', 'general', 'anesthesia', 'and', 'as', 'a', 'non', '##op', '##ioid', 'analgesic', '.', 'it', 'has', 'been', 'explored', 'for', 'prevention', 'of', 'postoperative', 'delirium', ',', 'although', 'results', 'have', 'been', 'contradictory', '.', 'in', 'this', 'study', ',', 'we', 'investigated', 'the', 'association', 'of', 'ketamine', 'with', 'postoperative', 'delirium', 'and', 'specific', 'encephal', '##ographic', 'signatures', '.', 'furthermore', ',', 'we', 'examined', 'these', 'associations', 'in', 'the', 'context', 'of', 'baseline', 'neuro', '##co', '##gn', '##ition', 'as', 'measured', 'by', 'a', 'validated', 'assessment', '.', 'methods', ':', 'we', 'conducted', 'a', 'prospective', 'observational', 'study', 'from', 'january', '201', '##9', 'to', 'december', '202', '##0', '.', 'ninety', '-', 'eight', 'patients', 'aged', '≥', '##65', 'years', 'and', 'undergoing', 'spine', 'surgery', 'scheduled', 'for', '≥', '##3', 'hours', 'were', 'included', 'in', 'the', 'study', '.', 'all', 'participants', 'who', 'completed', 'the', 'university', 'of', 'california', 'san', 'francisco', '(', 'uc', '##sf', ')', 'brain', 'health', 'assessment', 'preoperatively', 'and', 'postoperatively', 'were', 'assessed', 'with', 'the', 'confusion', 'assessment', 'method', 'for', 'intensive', 'care', 'unit', '(', 'cam', '-', 'icu', ')', 'and', '/', 'or', 'the', 'nursing', 'delirium', 'screening', 'scale', '(', 'nude', '##sc', ')', '.', 'patients', 'had', 'frontal', 'electroencephal', '##ogram', '(', 'eeg', ')', 'recordings', '(', 'sed', '##line', 'root', ',', 'mas', '##imo', ',', 'corp', ')', 'quantitatively', 'analyzed', '.', 'we', 'used', '60', 'seconds', 'of', 'artifact', '-', 'free', 'eeg', '(', 'without', 'burst', 'suppression', ')', 'extracted', 'from', 'the', 'middle', 'of', 'the', 'maintenance', 'period', 'to', 'calculate', 'the', 'normalized', 'power', 'spectral', 'density', '(', 'psd', ')', '.', 'comparisons', 'were', 'made', 'between', 'those', 'who', 'did', 'or', 'did', 'not', 'receive', 'ketamine', 'and', 'according', 'to', 'results', 'from', 'neuro', '##cognitive', 'assessments', '.', 'results', ':', 'ninety', '-', 'eight', 'patients', '(', 'of', 'a', 'total', 'of', '155', ',', 'enrolled', 'and', 'consent', '##ed', ')', 'had', 'eeg', 'of', 'sufficient', 'quality', 'for', 'analysis', '(', '42', 'women', ')', '.', 'overall', ',', 'we', 'found', 'a', 'significant', 'increase', 'in', 'the', 'eeg', 'power', 'in', 'the', 'moderate', 'frequency', 'range', '(', '10', '-', '20', 'hz', ')', 'in', 'patients', 'that', 'received', 'ketamine', '.', 'when', 'the', 'patients', 'were', 'divided', 'by', 'their', 'preoperative', 'cognitive', 'status', ',', 'this', 'result', 'in', 'the', 'ketamine', 'group', 'only', 'held', 'true', 'for', 'the', 'cognitive', '##ly', 'normal', 'patients', '.', 'patients', 'that', 'were', 'cognitive', '##ly', 'impaired', 'at', 'baseline', 'did', 'not', 'demonstrate', 'a', 'significant', 'change', 'in', 'eeg', 'characteristics', 'based', 'on', 'ketamine', 'administration', ',', 'but', 'impaired', 'patients', 'that', 'received', 'ketamine', 'had', 'a', 'significantly', 'higher', 'rate', 'of', 'postoperative', 'delirium', '(', '52', '%', 'ketamine', 'versus', '20', '%', 'no', 'ketamine', ')', '(', 'odds', 'ratio', '[', 'or', ']', ',', '4', '.', '36', ';', 'confidence', 'interval', '[', 'ci', ']', ',', '1', '.', '02', '-', '18', '.', '22', ';', 'p', '=', '.', '04', '##8', ')', '.', 'in', 'patients', 'determined', 'to', 'be', 'preoperatively', 'cognitive', '##ly', 'normal', ',', 'the', 'incidence', 'of', 'postoperative', 'delirium', 'was', 'not', 'significantly', 'associated', 'with', 'ketamine', 'administration', '(', '19', '%', 'ketamine', 'versus', '17', '%', 'no', 'ketamine', ')', '(', 'or', ',', '1', '.', '10', ';', 'ci', ',', '0', '.', '30', '-', '4', '.', '04', ';', 'p', '=', '.', '58', '##33', ')', '.', 'conclusions', ':', 'ketamine', '-', 'related', 'changes', 'in', 'eeg', 'are', 'observed', 'in', 'a', 'heterogeneous', 'group', 'of', 'patients', 'receiving', 'spine', 'surgery', '.', 'this', 'result', 'was', 'driven', 'primarily', 'by', 'the', 'effect', '[SEP]']","[None, 0, 1, 2, 3, 4, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 14, 16, 17, 18, 19, 20, 21, 22, 23, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 33, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 81, 81, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99, 100, 101, 102, 102, 103, 104, 105, 106, 107, 108, 109, 109, 110, 111, 112, 113, 114, 115, 116, 117, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 160, 160, 161, 162, 163, 164, 165, 166, 167, 167, 168, 169, 170, 171, 172, 173, 173, 174, 175, 176, 177, 178, 179, 179, 180, 181, 182, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 321, 322, 323, 324, 325, 326, 327, 328, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 377, 377, 378, 379, 380, 381, 382, 383, 384, 385, 385, 385, 386, 387, 387, 387, 388, 389, 390, 391, 391, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 428, 428, 429, 430, 431, 432, 432, 432, 433, 434, 434, 434, 435, 436, 437, 438, 438, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","Ketamine-Associated Intraoperative Electroencephalographic Signatures of Elderly Patients With and Without Preoperative Cognitive Impairment.^
BACKGROUND: Ketamine is typically used by anesthesiologists as an adjunct for general anesthesia and as a nonopioid analgesic. It has been explored for prevention of postoperative delirium, although results have been contradictory. In this study, we investigated the association of ketamine with postoperative delirium and specific encephalographic signatures. Furthermore, we examined these associations in the context of baseline neurocognition as measured by a validated assessment. METHODS: We conducted a prospective observational study from January 2019 to December 2020. Ninety-eight patients aged ≥65 years and undergoing spine surgery scheduled for ≥3 hours were included in the study. All participants who completed the University of California San Francisco (UCSF) Brain Health Assessment preoperatively and postoperatively were assessed with the confusion assessment method for intensive care unit (CAM-ICU) and/or the Nursing Delirium Screening Scale (NuDESC). Patients had frontal electroencephalogram (EEG) recordings (SedLine Root, Masimo, Corp) quantitatively analyzed. We used 60 seconds of artifact-free EEG (without burst suppression) extracted from the middle of the maintenance period to calculate the normalized power spectral density (PSD). Comparisons were made between those who did or did not receive ketamine and according to results from neurocognitive assessments. RESULTS: Ninety-eight patients (of a total of 155, enrolled and consented) had EEG of sufficient quality for analysis (42 women). Overall, we found a significant increase in the EEG power in the moderate frequency range (10-20 Hz) in patients that received ketamine. When the patients were divided by their preoperative cognitive status, this result in the ketamine group only held true for the cognitively normal patients. Patients that were cognitively impaired at baseline did not demonstrate a significant change in EEG characteristics based on ketamine administration, but impaired patients that received ketamine had a significantly higher rate of postoperative delirium (52% ketamine versus 20% no ketamine) (odds ratio [OR], 4.36; confidence interval [CI], 1.02-18.22; P = .048). In patients determined to be preoperatively cognitively normal, the incidence of postoperative delirium was not significantly associated with ketamine administration (19% ketamine versus 17% no ketamine) (OR, 1.10; CI, 0.30-4.04; P = .5833). CONCLUSIONS: Ketamine-related changes in EEG are observed in a heterogeneous group of patients receiving spine surgery. This result was driven primarily by the effect of ketamine on cognitively normal patients and not observed in patients that were cognitively impaired at baseline. Furthermore, patients who were cognitively impaired at baseline and who had received ketamine were more likely to develop postoperative delirium, suggesting that cognitive vulnerability might be predicted by the lack of a neurophysiologic response to ketamine."
"['Impulsivity', ',', 'inhibition', 'and', 'negative', 'priming', 'in', 'ecstasy', 'users.^', '\n', 'A', 'modified', 'Stroop', 'color', '-', 'word', 'interference', 'paradigm', 'was', 'used', 'to', 'investigate', 'the', 'effects', 'of', 'recreational', 'ecstasy', '(', 'MDMA', ')', 'use', 'on', 'central', 'executive', 'inhibitory', 'processes', '.', 'Ecstasy', 'users', 'who', 'also', 'used', 'cannabis', 'were', 'compared', 'with', 'non', '-', 'users', 'matched', 'for', 'cannabis', 'consumption', 'and', 'with', 'non', '-', 'drug', 'users', 'on', 'a', 'Stroop', 'task', 'in', 'which', 'standard', 'color', '-', 'word', 'interference', 'trials', 'were', 'interspersed', 'with', 'trials', 'in', 'which', 'the', 'target', 'color', 'was', 'the', 'same', 'as', 'the', 'distractor', 'word', 'on', 'the', 'immediately', 'preceding', 'trial', '.', 'Ecstasy', ""'s"", 'effects', 'on', 'standard', 'inhibition', '(', 'conscious', 'suppression', 'of', 'a', 'prepotent', 'response', 'pattern', '-', 'responsible', 'for', 'Stroop', 'interference', ')', 'could', 'thus', 'be', 'contrasted', 'with', 'its', 'effect', 'on', 'the', 'short', '-', 'term', ',', 'unconscious', ',', 'inhibitory', 'process', 'responsible', 'for', 'suppression', 'of', 'the', 'preceding', 'distractor', 'word', '(', 'negative', 'priming', ')', '.', 'Neither', 'drug', 'group', 'differed', 'from', 'the', 'non', '-', 'drug', 'users', 'in', 'level', 'of', 'Stroop', 'interference', 'but', 'ecstasy', 'users', 'showed', 'reduced', 'negative', 'priming', 'compared', 'to', 'the', 'cannabis', 'users', 'and', 'non', '-', 'drug', 'users', '.', 'The', 'loss', 'of', 'inhibition', 'in', 'the', 'ecstasy', 'users', 'was', 'not', 'related', 'to', 'impulsivity', 'assessed', 'by', 'two', 'standard', 'scales', 'since', 'these', 'were', 'similar', 'in', 'both', 'drug', '-', 'user', 'groups', 'and', 'raised', 'relative', 'to', 'the', 'non', '-', 'drug', 'users', '.', 'It', 'is', 'argued', 'that', 'previous', 'failures', 'to', 'demonstrate', 'loss', 'of', 'inhibition', 'could', 'be', 'partly', 'due', 'to', 'the', 'fact', 'that', 'standard', 'executive', 'function', 'tests', ',', 'such', 'as', 'the', 'Stroop', ',', 'are', 'unable', 'to', 'differentiate', 'between', 'sub', '-', 'types', 'of', 'inhibition', ',', 'only', 'some', 'of', 'which', 'may', 'be', 'affected', 'by', 'ecstasy', 'use', '.', '©', '2005', 'Elsevier', 'Ltd.', 'All', 'rights', 'reserved', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1791,"['[CLS]', 'impul', '##sivity', ',', 'inhibition', 'and', 'negative', 'priming', 'in', 'ecs', '##tas', '##y', 'users', '.', '^', 'a', 'modified', 'stro', '##op', 'color', '-', 'word', 'interference', 'paradigm', 'was', 'used', 'to', 'investigate', 'the', 'effects', 'of', 'recreational', 'ecs', '##tas', '##y', '(', 'mdm', '##a', ')', 'use', 'on', 'central', 'executive', 'inhibitory', 'processes', '.', 'ecs', '##tas', '##y', 'users', 'who', 'also', 'used', 'cannabis', 'were', 'compared', 'with', 'non', '-', 'users', 'matched', 'for', 'cannabis', 'consumption', 'and', 'with', 'non', '-', 'drug', 'users', 'on', 'a', 'stro', '##op', 'task', 'in', 'which', 'standard', 'color', '-', 'word', 'interference', 'trials', 'were', 'inters', '##pers', '##ed', 'with', 'trials', 'in', 'which', 'the', 'target', 'color', 'was', 'the', 'same', 'as', 'the', 'distr', '##actor', 'word', 'on', 'the', 'immediately', 'preceding', 'trial', '.', 'ecs', '##tas', '##y', ""'"", 's', 'effects', 'on', 'standard', 'inhibition', '(', 'conscious', 'suppression', 'of', 'a', 'prep', '##ote', '##nt', 'response', 'pattern', '-', 'responsible', 'for', 'stro', '##op', 'interference', ')', 'could', 'thus', 'be', 'contrasted', 'with', 'its', 'effect', 'on', 'the', 'short', '-', 'term', ',', 'unconscious', ',', 'inhibitory', 'process', 'responsible', 'for', 'suppression', 'of', 'the', 'preceding', 'distr', '##actor', 'word', '(', 'negative', 'priming', ')', '.', 'neither', 'drug', 'group', 'differed', 'from', 'the', 'non', '-', 'drug', 'users', 'in', 'level', 'of', 'stro', '##op', 'interference', 'but', 'ecs', '##tas', '##y', 'users', 'showed', 'reduced', 'negative', 'priming', 'compared', 'to', 'the', 'cannabis', 'users', 'and', 'non', '-', 'drug', 'users', '.', 'the', 'loss', 'of', 'inhibition', 'in', 'the', 'ecs', '##tas', '##y', 'users', 'was', 'not', 'related', 'to', 'impul', '##sivity', 'assessed', 'by', 'two', 'standard', 'scales', 'since', 'these', 'were', 'similar', 'in', 'both', 'drug', '-', 'user', 'groups', 'and', 'raised', 'relative', 'to', 'the', 'non', '-', 'drug', 'users', '.', 'it', 'is', 'argued', 'that', 'previous', 'failures', 'to', 'demonstrate', 'loss', 'of', 'inhibition', 'could', 'be', 'partly', 'due', 'to', 'the', 'fact', 'that', 'standard', 'executive', 'function', 'tests', ',', 'such', 'as', 'the', 'stro', '##op', ',', 'are', 'unable', 'to', 'differentiate', 'between', 'sub', '-', 'types', 'of', 'inhibition', ',', 'only', 'some', 'of', 'which', 'may', 'be', 'affected', 'by', 'ecs', '##tas', '##y', 'use', '.', '©', '2005', 'elsevier', 'ltd', '.', 'all', 'rights', 'reserved', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 1, 2, 3, 4, 5, 6, 7, 7, 7, 8, 8, 8, 10, 11, 12, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 26, 26, 27, 28, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 37, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 72, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 86, 87, 88, 89, 90, 91, 92, 93, 93, 93, 94, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 104, 104, 105, 106, 107, 108, 109, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 156, 157, 158, 159, 159, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 182, 182, 183, 184, 185, 186, 187, 188, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 262, 262, 263, 264, 265, 266, 267, 268, 268, 269, 270, 271, 272, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Impulsivity, inhibition and negative priming in ecstasy users.^
A modified Stroop color-word interference paradigm was used to investigate the effects of recreational ecstasy (MDMA) use on central executive inhibitory processes. Ecstasy users who also used cannabis were compared with non-users matched for cannabis consumption and with non-drug users on a Stroop task in which standard color-word interference trials were interspersed with trials in which the target color was the same as the distractor word on the immediately preceding trial. Ecstasy's effects on standard inhibition (conscious suppression of a prepotent response pattern-responsible for Stroop interference) could thus be contrasted with its effect on the short-term, unconscious, inhibitory process responsible for suppression of the preceding distractor word (negative priming). Neither drug group differed from the non-drug users in level of Stroop interference but ecstasy users showed reduced negative priming compared to the cannabis users and non-drug users. The loss of inhibition in the ecstasy users was not related to impulsivity assessed by two standard scales since these were similar in both drug-user groups and raised relative to the non-drug users. It is argued that previous failures to demonstrate loss of inhibition could be partly due to the fact that standard executive function tests, such as the Stroop, are unable to differentiate between sub-types of inhibition, only some of which may be affected by ecstasy use. © 2005 Elsevier Ltd. All rights reserved."
"['Efficacy', 'of', 'ketamine', 'in', 'the', 'rapid', 'treatment', 'of', 'major', 'depressive', 'disorder', ':', 'A', 'meta', '-', 'analysis', 'of', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'studies.^', '\n', 'Background', ':', 'An', 'increasing', 'number', 'of', 'studies', 'are', 'reporting', 'that', 'ketamine', 'could', 'be', 'treated', 'as', 'a', 'novel', 'antidepressant', 'for', 'major', 'depressive', 'disorder', '(', 'MDD', ')', '.', 'Therefore', ',', 'we', 'performed', 'this', 'meta', '-', 'analysis', 'to', 'comprehensively', 'and', 'systematically', 'assess', 'the', 'efficacy', 'of', 'ketamine', 'for', 'treating', 'patients', 'with', 'MDD', '.', 'Method', ':', 'Randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'studies', 'on', 'ketamine', 'versus', 'placebo', 'for', 'treating', 'MDD', 'were', 'searched', 'up', 'to', 'April', '2016', 'in', 'medical', 'databases', '(', 'PubMed', ',', 'CCTR', ',', 'Web', 'of', 'Science', ',', 'Embase', ',', 'CBM', '-', 'disc', ',', 'and', 'CNKI', ')', '.', 'Three', 'treatment', 'time', 'points', '(', '24', 'and', '72', 'h', ',', 'and', 'day', '7', ')', 'were', 'chosen', '.', 'Response', 'and', 'remission', 'rates', 'were', 'the', 'main', 'outcomes', '.', 'The', 'random', 'effects', 'model', 'was', 'used', '.', 'An', 'intention', '-', 'to', '-', 'treat', 'analysis', 'was', 'conducted', '.', 'Results', ':', 'Nine', 'high', '-', 'quality', 'studies', 'that', 'included', '368', 'patients', 'were', 'selected', 'to', 'compare', 'the', 'efficacy', 'of', 'ketamine', 'to', 'placebo', '.', 'The', 'therapeutic', 'effects', 'of', 'ketamine', 'at', '24', 'and', '72', 'h', ',', 'and', 'day', '7', 'were', 'found', 'to', 'be', 'significantly', 'better', 'than', 'placebo', '.', 'Response', 'and', 'remission', 'rates', 'in', 'the', 'ketamine', 'group', 'at', '24', 'and', '72', 'h', ',', 'and', 'day', '7', 'were', '52.2', '%', 'and', '20.6', '%', ';', '47.9', '%', 'and', '23.8', '%', ';', 'and', '39.8', '%', 'and', '26.2', '%', ',', 'respectively', '.', 'No', 'significant', 'heterogeneity', 'existed', ',', 'and', 'the', 'Egger', '’s', 'test', 'showed', 'no', 'publication', 'bias', '.', 'Conclusion', ':', 'These', 'results', 'indicated', 'that', 'ketamine', 'could', 'yield', 'a', 'good', 'efficacy', 'in', 'the', 'rapid', 'treatment', 'of', 'MDD', '.', 'Future', 'large', '-', 'scale', 'clinical', 'studies', 'are', 'needed', 'to', 'confirm', 'our', 'results', 'and', 'investigate', 'the', 'mid-', 'and', 'long', '-', 'term', 'efficacy', 'of', 'ketamine', 'in', 'treating', 'MDD', '.', '(', 'PsycInfo', 'Database', 'Record', '(', 'c', ')', '2021', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3353,"['[CLS]', 'efficacy', 'of', 'ketamine', 'in', 'the', 'rapid', 'treatment', 'of', 'major', 'depressive', 'disorder', ':', 'a', 'meta', '-', 'analysis', 'of', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'studies', '.', '^', 'background', ':', 'an', 'increasing', 'number', 'of', 'studies', 'are', 'reporting', 'that', 'ketamine', 'could', 'be', 'treated', 'as', 'a', 'novel', 'antidepressant', 'for', 'major', 'depressive', 'disorder', '(', 'mdd', ')', '.', 'therefore', ',', 'we', 'performed', 'this', 'meta', '-', 'analysis', 'to', 'comprehensive', '##ly', 'and', 'systematically', 'assess', 'the', 'efficacy', 'of', 'ketamine', 'for', 'treating', 'patients', 'with', 'mdd', '.', 'method', ':', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'studies', 'on', 'ketamine', 'versus', 'placebo', 'for', 'treating', 'mdd', 'were', 'searched', 'up', 'to', 'april', '2016', 'in', 'medical', 'databases', '(', 'pubmed', ',', 'cct', '##r', ',', 'web', 'of', 'science', ',', 'emb', '##ase', ',', 'cb', '##m', '-', 'disc', ',', 'and', 'cn', '##ki', ')', '.', 'three', 'treatment', 'time', 'points', '(', '24', 'and', '72', 'h', ',', 'and', 'day', '7', ')', 'were', 'chosen', '.', 'response', 'and', 'remission', 'rates', 'were', 'the', 'main', 'outcomes', '.', 'the', 'random', 'effects', 'model', 'was', 'used', '.', 'an', 'intention', '-', 'to', '-', 'treat', 'analysis', 'was', 'conducted', '.', 'results', ':', 'nine', 'high', '-', 'quality', 'studies', 'that', 'included', '36', '##8', 'patients', 'were', 'selected', 'to', 'compare', 'the', 'efficacy', 'of', 'ketamine', 'to', 'placebo', '.', 'the', 'therapeutic', 'effects', 'of', 'ketamine', 'at', '24', 'and', '72', 'h', ',', 'and', 'day', '7', 'were', 'found', 'to', 'be', 'significantly', 'better', 'than', 'placebo', '.', 'response', 'and', 'remission', 'rates', 'in', 'the', 'ketamine', 'group', 'at', '24', 'and', '72', 'h', ',', 'and', 'day', '7', 'were', '52', '.', '2', '%', 'and', '20', '.', '6', '%', ';', '47', '.', '9', '%', 'and', '23', '.', '8', '%', ';', 'and', '39', '.', '8', '%', 'and', '26', '.', '2', '%', ',', 'respectively', '.', 'no', 'significant', 'heterogeneity', 'existed', ',', 'and', 'the', 'egg', '##er', '’', 's', 'test', 'showed', 'no', 'publication', 'bias', '.', 'conclusion', ':', 'these', 'results', 'indicated', 'that', 'ketamine', 'could', 'yield', 'a', 'good', 'efficacy', 'in', 'the', 'rapid', 'treatment', 'of', 'mdd', '.', 'future', 'large', '-', 'scale', 'clinical', 'studies', 'are', 'needed', 'to', 'confirm', 'our', 'results', 'and', 'investigate', 'the', 'mid', '-', 'and', 'long', '-', 'term', 'efficacy', 'of', 'ketamine', 'in', 'treating', 'mdd', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '202', '##1', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 26, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 108, 109, 110, 111, 112, 113, 114, 114, 115, 116, 116, 117, 118, 119, 120, 121, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 230, 230, 231, 232, 233, 233, 233, 234, 235, 236, 236, 236, 237, 238, 239, 239, 239, 240, 241, 242, 243, 243, 243, 244, 245, 246, 246, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 258, 259, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 313, 313, 314, 315, 316, 317, 318, 319, 319, 320, 320, 321, 322, 323, 324, 325, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Efficacy of ketamine in the rapid treatment of major depressive disorder: A meta-analysis of randomized, double-blind, placebo-controlled studies.^
Background: An increasing number of studies are reporting that ketamine could be treated as a novel antidepressant for major depressive disorder (MDD). Therefore, we performed this meta-analysis to comprehensively and systematically assess the efficacy of ketamine for treating patients with MDD. Method: Randomized, double-blind, placebo-controlled studies on ketamine versus placebo for treating MDD were searched up to April 2016 in medical databases (PubMed, CCTR, Web of Science, Embase, CBM-disc, and CNKI). Three treatment time points (24 and 72 h, and day 7) were chosen. Response and remission rates were the main outcomes. The random effects model was used. An intention-to-treat analysis was conducted. Results: Nine high-quality studies that included 368 patients were selected to compare the efficacy of ketamine to placebo. The therapeutic effects of ketamine at 24 and 72 h, and day 7 were found to be significantly better than placebo. Response and remission rates in the ketamine group at 24 and 72 h, and day 7 were 52.2% and 20.6%; 47.9% and 23.8%; and 39.8% and 26.2%, respectively. No significant heterogeneity existed, and the Egger’s test showed no publication bias. Conclusion: These results indicated that ketamine could yield a good efficacy in the rapid treatment of MDD. Future large-scale clinical studies are needed to confirm our results and investigate the mid- and long-term efficacy of ketamine in treating MDD. (PsycInfo Database Record (c) 2021 APA, all rights reserved)"
"['Ketamine', 'for', 'acute', 'suicidality', 'in', 'the', 'emergency', 'department', ':', 'A', 'systematic', 'review.^', '\n', 'INTRODUCTION', ':', 'There', 'are', 'no', 'emergent', 'pharmaceutical', 'interventions', 'for', 'acute', 'suicidal', 'ideation', ',', 'a', 'common', 'presenting', 'complaint', 'in', 'the', 'ED', '.', 'Ketamine', 'is', 'a', 'NMDA', 'agonist', 'frequently', 'used', 'by', 'ED', 'physicians', 'for', 'sedation', 'and', 'analgesia', '.', 'Prior', 'evidence', 'from', 'studies', 'conducted', 'in', 'inpatient', 'psychiatry', 'units', 'suggests', 'that', 'ketamine', 'may', 'have', 'a', 'role', 'in', 'alleviating', 'treatment', '-', 'resistant', 'depression', 'as', 'well', 'as', 'suicidal', 'ideation', '.', 'METHODS', ':', 'PubMed', ',', 'MEDLINE', ',', 'and', 'Cochrane', 'reviews', 'were', 'queried', 'for', 'articles', 'related', 'to', 'keywords', 'ketamine', ',', 'suicidality', ',', 'suicidal', 'ideation', ',', 'and', 'emergency', 'department', '/', 'room', '.', 'Relevant', 'articles', 'were', 'selected', 'and', 'reviewed', 'by', 'two', 'separate', 'authors', '.', 'RESULTS', ':', 'Three', 'relevant', ',', 'prospective', 'studies', 'were', 'identified', 'with', 'a', 'mean', 'sample', 'size', 'of', '25.7', '.', 'Each', 'was', 'performed', 'using', '0.2', 'mg', '/', 'kg', 'ketamine', 'for', 'individuals', 'receiving', 'active', 'treatment', '.', 'Each', 'study', 'reported', 'a', 'decrease', 'in', 'depressive', 'symptoms', 'among', 'those', 'receiving', 'ketamine', '.', 'One', 'study', 'reported', 'a', 'significant', 'reduction', 'in', 'SI', 'when', 'compared', 'to', 'placebo', 'at', '90', 'min', 'that', 'became', 'non', '-', 'significant', 'by', '230', 'min', '.', 'No', 'significant', 'adverse', 'events', 'were', 'reported', 'in', 'any', 'study', '.', 'CONCLUSION', ':', 'Current', 'evidence', 'suggests', 'that', 'ketamine', 'is', 'a', 'promising', ',', 'safe', 'potential', 'intervention', 'for', 'acute', 'suicidality', 'in', 'the', 'ED', '.', 'Convincing', 'evidence', 'for', 'efficacy', 'of', 'ketamine', 'for', 'acute', 'suicidal', 'ideation', 'remains', 'lacking', ',', 'and', 'this', 'promising', 'potential', 'intervention', 'should', 'be', 'further', 'investigated', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5213,"['[CLS]', 'ketamine', 'for', 'acute', 'suicidal', '##ity', 'in', 'the', 'emergency', 'department', ':', 'a', 'systematic', 'review', '.', '^', 'introduction', ':', 'there', 'are', 'no', 'emergent', 'pharmaceutical', 'interventions', 'for', 'acute', 'suicidal', 'idea', '##tion', ',', 'a', 'common', 'presenting', 'complaint', 'in', 'the', 'ed', '.', 'ketamine', 'is', 'a', 'nmda', 'agonist', 'frequently', 'used', 'by', 'ed', 'physicians', 'for', 'sedation', 'and', 'analgesia', '.', 'prior', 'evidence', 'from', 'studies', 'conducted', 'in', 'inpatient', 'psychiatry', 'units', 'suggests', 'that', 'ketamine', 'may', 'have', 'a', 'role', 'in', 'allevi', '##ating', 'treatment', '-', 'resistant', 'depression', 'as', 'well', 'as', 'suicidal', 'idea', '##tion', '.', 'methods', ':', 'pubmed', ',', 'medline', ',', 'and', 'cochrane', 'reviews', 'were', 'quer', '##ied', 'for', 'articles', 'related', 'to', 'keywords', 'ketamine', ',', 'suicidal', '##ity', ',', 'suicidal', 'idea', '##tion', ',', 'and', 'emergency', 'department', '/', 'room', '.', 'relevant', 'articles', 'were', 'selected', 'and', 'reviewed', 'by', 'two', 'separate', 'authors', '.', 'results', ':', 'three', 'relevant', ',', 'prospective', 'studies', 'were', 'identified', 'with', 'a', 'mean', 'sample', 'size', 'of', '25', '.', '7', '.', 'each', 'was', 'performed', 'using', '0', '.', '2', 'mg', '/', 'kg', 'ketamine', 'for', 'individuals', 'receiving', 'active', 'treatment', '.', 'each', 'study', 'reported', 'a', 'decrease', 'in', 'depressive', 'symptoms', 'among', 'those', 'receiving', 'ketamine', '.', 'one', 'study', 'reported', 'a', 'significant', 'reduction', 'in', 'si', 'when', 'compared', 'to', 'placebo', 'at', '90', 'min', 'that', 'became', 'non', '-', 'significant', 'by', '230', 'min', '.', 'no', 'significant', 'adverse', 'events', 'were', 'reported', 'in', 'any', 'study', '.', 'conclusion', ':', 'current', 'evidence', 'suggests', 'that', 'ketamine', 'is', 'a', 'promising', ',', 'safe', 'potential', 'intervention', 'for', 'acute', 'suicidal', '##ity', 'in', 'the', 'ed', '.', 'convincing', 'evidence', 'for', 'efficacy', 'of', 'ketamine', 'for', 'acute', 'suicidal', 'idea', '##tion', 'remains', 'lacking', ',', 'and', 'this', 'promising', 'potential', 'intervention', 'should', 'be', 'further', 'investigated', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 87, 88, 89, 90, 91, 92, 93, 94, 95, 95, 96, 97, 98, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 132, 132, 133, 134, 135, 136, 137, 138, 138, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Ketamine for acute suicidality in the emergency department: A systematic review.^
INTRODUCTION: There are no emergent pharmaceutical interventions for acute suicidal ideation, a common presenting complaint in the ED. Ketamine is a NMDA agonist frequently used by ED physicians for sedation and analgesia. Prior evidence from studies conducted in inpatient psychiatry units suggests that ketamine may have a role in alleviating treatment-resistant depression as well as suicidal ideation. METHODS: PubMed, MEDLINE, and Cochrane reviews were queried for articles related to keywords ketamine, suicidality, suicidal ideation, and emergency department/room. Relevant articles were selected and reviewed by two separate authors. RESULTS: Three relevant, prospective studies were identified with a mean sample size of 25.7. Each was performed using 0.2 mg/kg ketamine for individuals receiving active treatment. Each study reported a decrease in depressive symptoms among those receiving ketamine. One study reported a significant reduction in SI when compared to placebo at 90 min that became non-significant by 230 min. No significant adverse events were reported in any study. CONCLUSION: Current evidence suggests that ketamine is a promising, safe potential intervention for acute suicidality in the ED. Convincing evidence for efficacy of ketamine for acute suicidal ideation remains lacking, and this promising potential intervention should be further investigated."
"['Influence', 'of', 'formulation', 'and', 'route', 'of', 'administration', 'on', 'ketamine', ""'s"", 'safety', 'and', 'tolerability', ':', 'systematic', 'review.^', '\n', 'PURPOSE', ':', 'Ketamine', 'has', 'rapid', '-', 'onset', 'antidepressant', 'effects', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '.', 'Common', 'side', 'effects', 'include', 'dissociation', '(', 'a', 'sense', 'of', 'detachment', 'from', 'reality', ')', 'and', 'increases', 'in', 'systolic', 'and', 'diastolic', 'blood', 'pressure', '.', 'The', 'objective', 'of', 'this', 'structured', 'review', 'was', 'to', 'examine', 'the', 'effect', 'of', 'ketamine', 'formulation', 'and', 'route', 'of', 'administration', 'on', 'its', 'pharmacokinetics', ',', 'safety', 'and', 'tolerability', ',', 'to', 'identify', 'formulation', 'characteristics', 'and', 'routes', 'of', 'administration', 'that', 'might', 'minimise', 'side', 'effects', '.', 'METHODS', ':', 'This', 'was', 'a', 'structured', 'review', 'of', 'published', 'ketamine', 'pharmacokinetics', ',', 'safety', 'and', 'tolerability', 'data', 'for', 'any', 'ketamine', 'formulation', '.', 'The', 'ratio', 'of', 'ketamine', ':', 'norketamine', 'was', 'calculated', 'from', 'reported', 'C(max', ')', 'values', ',', 'as', 'a', 'measure', 'of', 'first', 'pass', 'metabolism', '.', 'The', 'effect', 'of', 'formulation', 'and', 'route', 'of', 'administration', 'on', 'safety', 'was', 'evaluated', 'by', 'measuring', 'mean', 'changes', 'in', 'systolic', 'blood', 'pressure', 'and', 'tolerability', 'by', 'changes', 'in', 'dissociation', 'ratings', '.', 'Data', 'were', 'correlated', 'using', 'Spearman', ""'s"", 'method', '.', 'RESULTS', ':', 'A', 'total', 'of', '41', 'treatment', 'arms', 'were', 'identified', 'from', '21', 'publications', ',', 'and', 'included', 'formulation', 'development', 'studies', 'in', 'healthy', 'volunteers', ',', 'and', 'studies', 'in', 'clinical', 'populations', '(', 'patients', 'undergoing', 'anaesthesia', ',', 'or', 'being', 'treated', 'for', 'pain', 'or', 'depression', ')', '.', 'Ketamine', ':', 'norketamine', 'ratios', 'were', 'strongly', 'positively', 'correlated', 'with', 'change', 'in', 'dissociation', 'ratings', '(', 'r', '=', '0.89', ')', 'and', 'change', 'in', 'blood', 'pressure', '(', 'r', '=', '0.96', ')', ',', 'and', 'strongly', 'negatively', 'correlated', 'with', 'ketamine', 'T(max', ')', '(', 'r', '=', '-', '0.87', ';', 'p', '<', '0.00001', 'for', 'all', ')', '.', 'Ketamine', 'T(max', ')', 'strongly', 'positively', 'correlated', 'with', 'a', 'change', 'in', 'dissociation', 'ratings', '(', 'r', '=', '-', '0.96', ')', 'and', 'change', 'in', 'blood', 'pressure', '(', 'r', '=', '-', '0.99', ';', 'p', '<', '0.00001', 'for', 'all', ')', '.', 'CONCLUSION', ':', 'Ketamine', 'formulations', 'that', 'maximize', 'first', 'pass', 'metabolism', 'and', 'delay', 'T(max', ')', 'will', 'be', 'better', 'tolerated', 'and', 'safer', 'than', 'formulations', 'which', 'lack', 'those', 'characteristics', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3002,"['[CLS]', 'influence', 'of', 'formulation', 'and', 'route', 'of', 'administration', 'on', 'ketamine', ""'"", 's', 'safety', 'and', 'tolerability', ':', 'systematic', 'review', '.', '^', 'purpose', ':', 'ketamine', 'has', 'rapid', '-', 'onset', 'antidepressant', 'effects', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '.', 'common', 'side', 'effects', 'include', 'dissociation', '(', 'a', 'sense', 'of', 'detachment', 'from', 'reality', ')', 'and', 'increases', 'in', 'systolic', 'and', 'diastolic', 'blood', 'pressure', '.', 'the', 'objective', 'of', 'this', 'structured', 'review', 'was', 'to', 'examine', 'the', 'effect', 'of', 'ketamine', 'formulation', 'and', 'route', 'of', 'administration', 'on', 'its', 'pharmacokinetic', '##s', ',', 'safety', 'and', 'tolerability', ',', 'to', 'identify', 'formulation', 'characteristics', 'and', 'routes', 'of', 'administration', 'that', 'might', 'minimise', 'side', 'effects', '.', 'methods', ':', 'this', 'was', 'a', 'structured', 'review', 'of', 'published', 'ketamine', 'pharmacokinetic', '##s', ',', 'safety', 'and', 'tolerability', 'data', 'for', 'any', 'ketamine', 'formulation', '.', 'the', 'ratio', 'of', 'ketamine', ':', 'nor', '##ket', '##amine', 'was', 'calculated', 'from', 'reported', 'c', '(', 'max', ')', 'values', ',', 'as', 'a', 'measure', 'of', 'first', 'pass', 'metabolism', '.', 'the', 'effect', 'of', 'formulation', 'and', 'route', 'of', 'administration', 'on', 'safety', 'was', 'evaluated', 'by', 'measuring', 'mean', 'changes', 'in', 'systolic', 'blood', 'pressure', 'and', 'tolerability', 'by', 'changes', 'in', 'dissociation', 'ratings', '.', 'data', 'were', 'correlated', 'using', 'spearman', ""'"", 's', 'method', '.', 'results', ':', 'a', 'total', 'of', '41', 'treatment', 'arms', 'were', 'identified', 'from', '21', 'publications', ',', 'and', 'included', 'formulation', 'development', 'studies', 'in', 'healthy', 'volunteers', ',', 'and', 'studies', 'in', 'clinical', 'populations', '(', 'patients', 'undergoing', 'anaesthesia', ',', 'or', 'being', 'treated', 'for', 'pain', 'or', 'depression', ')', '.', 'ketamine', ':', 'nor', '##ket', '##amine', 'ratios', 'were', 'strongly', 'positively', 'correlated', 'with', 'change', 'in', 'dissociation', 'ratings', '(', 'r', '=', '0', '.', '89', ')', 'and', 'change', 'in', 'blood', 'pressure', '(', 'r', '=', '0', '.', '96', ')', ',', 'and', 'strongly', 'negatively', 'correlated', 'with', 'ketamine', 't', '(', 'max', ')', '(', 'r', '=', '-', '0', '.', '87', ';', 'p', '<', '0', '.', '0000', '##1', 'for', 'all', ')', '.', 'ketamine', 't', '(', 'max', ')', 'strongly', 'positively', 'correlated', 'with', 'a', 'change', 'in', 'dissociation', 'ratings', '(', 'r', '=', '-', '0', '.', '96', ')', 'and', 'change', 'in', 'blood', 'pressure', '(', 'r', '=', '-', '0', '.', '99', ';', 'p', '<', '0', '.', '0000', '##1', 'for', 'all', ')', '.', 'conclusion', ':', 'ketamine', 'formulations', 'that', 'maximize', 'first', 'pass', 'metabolism', 'and', 'delay', 't', '(', 'max', ')', 'will', 'be', 'better', 'tolerated', 'and', 'safer', 'than', 'formulations', 'which', 'lack', 'those', 'characteristics', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 9, 10, 11, 12, 13, 14, 15, 15, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 122, 122, 123, 124, 125, 126, 127, 127, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 219, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 233, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 243, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 252, 252, 253, 254, 255, 256, 257, 258, 258, 258, 259, 260, 261, 262, 262, 262, 262, 263, 264, 265, 266, 267, 268, 268, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 283, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 294, 294, 295, 296, 297, 298, 298, 298, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 314, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review.^
PURPOSE: Ketamine has rapid-onset antidepressant effects in patients with treatment-resistant depression. Common side effects include dissociation (a sense of detachment from reality) and increases in systolic and diastolic blood pressure. The objective of this structured review was to examine the effect of ketamine formulation and route of administration on its pharmacokinetics, safety and tolerability, to identify formulation characteristics and routes of administration that might minimise side effects. METHODS: This was a structured review of published ketamine pharmacokinetics, safety and tolerability data for any ketamine formulation. The ratio of ketamine:norketamine was calculated from reported C(max) values, as a measure of first pass metabolism. The effect of formulation and route of administration on safety was evaluated by measuring mean changes in systolic blood pressure and tolerability by changes in dissociation ratings. Data were correlated using Spearman's method. RESULTS: A total of 41 treatment arms were identified from 21 publications, and included formulation development studies in healthy volunteers, and studies in clinical populations (patients undergoing anaesthesia, or being treated for pain or depression). Ketamine:norketamine ratios were strongly positively correlated with change in dissociation ratings (r = 0.89) and change in blood pressure (r = 0.96), and strongly negatively correlated with ketamine T(max) (r = - 0.87; p < 0.00001 for all). Ketamine T(max) strongly positively correlated with a change in dissociation ratings (r = - 0.96) and change in blood pressure (r = - 0.99; p < 0.00001 for all). CONCLUSION: Ketamine formulations that maximize first pass metabolism and delay T(max) will be better tolerated and safer than formulations which lack those characteristics."
"['Ketamine', 'and', 'other', 'glutamate', 'receptor', 'modulators', 'for', 'depression', 'in', 'adults', 'with', 'bipolar', 'disorder.^', '\n', 'BACKGROUND', ':', 'Glutamergic', 'system', 'dysfunction', 'has', 'been', 'implicated', 'in', 'the', 'pathophysiology', 'of', 'bipolar', 'depression', '.', 'This', 'is', 'an', 'update', 'of', 'the', '2015', 'Cochrane', 'Review', 'for', 'the', 'use', 'of', 'glutamate', 'receptor', 'modulators', 'for', 'depression', 'in', 'bipolar', 'disorder', '.', 'OBJECTIVES', ':', '1', '.', 'To', 'assess', 'the', 'effects', 'of', 'ketamine', 'and', 'other', 'glutamate', 'receptor', 'modulators', 'in', 'alleviating', 'the', 'acute', 'symptoms', 'of', 'depression', 'in', 'people', 'with', 'bipolar', 'disorder', '.', '2', '.', 'To', 'review', 'the', 'acceptability', 'of', 'ketamine', 'and', 'other', 'glutamate', 'receptor', 'modulators', 'in', 'people', 'with', 'bipolar', 'disorder', 'who', 'are', 'experiencing', 'depressive', 'symptoms', '.', 'SEARCH', 'METHODS', ':', 'We', 'searched', 'the', 'Cochrane', 'Central', 'Register', 'of', 'Controlled', 'Trials', '(', 'CENTRAL', ')', ',', 'Ovid', 'MEDLINE', ',', 'Embase', 'and', 'PsycINFO', 'all', 'years', 'to', 'July', '2020', '.', 'We', 'did', 'not', 'apply', 'any', 'restrictions', 'to', 'date', ',', 'language', 'or', 'publication', 'status', '.', 'SELECTION', 'CRITERIA', ':', 'RCTs', 'comparing', 'ketamine', 'or', 'other', 'glutamate', 'receptor', 'modulators', 'with', 'other', 'active', 'psychotropic', 'drugs', 'or', 'saline', 'placebo', 'in', 'adults', 'with', 'bipolar', 'depression', '.', 'DATA', 'COLLECTION', 'AND', 'ANALYSIS', ':', 'Two', 'review', 'authors', 'independently', 'selected', 'studies', 'for', 'inclusion', ',', 'assessed', 'trial', 'quality', 'and', 'extracted', 'data', '.', 'Primary', 'outcomes', 'were', 'response', 'rate', 'and', 'adverse', 'events', '.', 'Secondary', 'outcomes', 'included', 'remission', 'rate', ',', 'depression', 'severity', 'change', 'scores', ',', 'suicidality', ',', 'cognition', ',', 'quality', 'of', 'life', ',', 'and', 'dropout', 'rate', '.', 'The', 'GRADE', 'framework', 'was', 'used', 'to', 'assess', 'the', 'certainty', 'of', 'the', 'evidence', '.', 'MAIN', 'RESULTS', ':', 'Ten', 'studies', '(', '647', 'participants', ')', 'were', 'included', 'in', 'this', 'review', '(', 'an', 'additional', 'five', 'studies', 'compared', 'to', 'the', '2015', 'review', ')', '.', 'There', 'were', 'no', 'additional', 'studies', 'added', 'to', 'the', 'comparisons', 'identified', 'in', 'the', '2015', 'Cochrane', 'review', 'on', 'ketamine', ',', 'memantine', 'and', 'cytidine', 'versus', 'placebo', '.', 'However', ',', 'three', 'new', 'comparisons', 'were', 'found', ':', 'ketamine', 'versus', 'midazolam', ',', 'N', '-', 'acetylcysteine', 'versus', 'placebo', ',', 'and', 'riluzole', 'versus', 'placebo', '.', 'The', 'glutamate', 'receptor', 'modulators', 'studied', 'were', 'ketamine', '(', 'three', 'trials', ')', ',', 'memantine', '(', 'two', ')', ',', 'cytidine', '(', 'one', ')', ',', 'N', '-', 'acetylcysteine', '(', 'three', ')', ',', 'and', 'riluzole', '(', 'one', ')', '.', 'Eight', 'of', 'these', 'studies', 'were', 'placebo', '-', 'controlled', 'and', 'two', '-', 'armed', '.', 'In', 'seven', 'trials', 'the', 'glutamate', 'receptor', 'modulators', 'had', 'been', 'used', 'as', 'add', '-', 'on', 'drugs', 'to', 'mood', 'stabilisers', '.', 'Only', 'one', 'trial', 'compared', 'ketamine', 'with', 'an', 'active', 'comparator', ',', 'midazolam', '.', 'The', 'treatment', 'period', 'ranged', 'from', 'a', 'single', 'intravenous', 'administration', '(', 'all', 'ketamine', 'studies', ')', ',', 'to', 'repeated', 'administration', 'for', 'riluzole', ',', 'memantine', ',', 'cytidine', ',', 'and', 'N', '-', 'acetylcysteine', '(', 'with', 'a', 'follow', '-', 'up', 'of', 'eight', 'weeks', ',', '8', 'to', '12', 'weeks', ',', '12', 'weeks', ',', 'and', '16', 'to', '20', 'weeks', ',', 'respectively', ')', '.', 'Six', 'of', 'the', 'studies', 'included', 'sites', 'in', 'the', 'USA', ',', 'one', 'in', 'Taiwan', ',', 'one', 'in', 'Denmark', ',', 'one', 'in', 'Australia', ',', 'and', 'in', 'one', 'study', 'the', 'location', 'was', 'unclear', '.', 'All', 'participants', 'had', 'a', 'primary', 'diagnosis', 'of', 'bipolar', 'disorder', 'and', 'were', 'experiencing', 'an', 'acute', 'bipolar', 'depressive', 'episode', ',', 'diagnosed', 'according', 'to', 'the', 'Diagnostic', 'and', 'Statistical', 'Manual', 'of', 'Mental', 'Disorders', 'fourth', 'edition', '(', 'IV', ')', 'or', 'fourth', 'edition', 'text', 'revision', '(', 'IV', '-', 'TR', ')', '.', 'Among', 'all', 'glutamate', 'receptor', 'modulators', 'included', 'in', 'this', 'review', ',', 'only', 'ketamine', 'appeared', 'to', 'be', 'more', 'efficacious', 'than', 'placebo', '24', 'hours', 'after', 'infusion', 'for', 'response', 'rate', '(', 'odds', 'ratio', '(', 'OR', ')', '11.61', ',', '95', '%', 'confidence', 'interval', '(', 'CI', ')', '1.25', 'to', '107.74', ';', 'P', '=', '0.03', ';', 'participants', '=', '33', ';', 'studies', '=', '2', ';', 'I²', '=', '0', '%', ',', 'low', '-', 'certainty', 'evidence', ')', '.', 'Ketamine', 'seemed', 'to', 'be', 'more', 'effective', 'in', 'reducing', 'depression', 'rating', 'scale', 'scores', '(', 'MD', '-11.81', ',', '95', '%', 'CI', '-20.01', 'to', '-3.61', ';', 'P', '=', '0.005', ';', 'participants', '=', '32', ';', 'studies', '=', '2', ';', 'I(2', ')', '=', '0', '%', ',', 'very', 'low', '-', 'certainty', 'evidence', ')', '.', 'There', 'was', 'no', 'evidence', 'of', 'ketamine', ""'s"", 'efficacy', 'in', 'producing', 'remission', 'over', 'placebo', 'at', '24', 'hours', '(', 'OR', '5.16', ',', '95', '%', 'CI', '0.51', 'to', '52.30', ';', 'P', '=', '0.72', ';', 'participants', '=', '33', ';', 'studies', '=', '2', ';', 'I(2', ')', '=', '0', '%', ',', 'very', 'low', '-', 'certainty', 'evidence', ')', '.', 'Evidence', 'on', 'response', ',', 'remission', 'or', 'depression', 'rating', 'scale', 'scores', 'between', 'ketamine', 'and', 'midazolam', 'was', 'uncertain', 'at', '24', 'hours', 'due', 'to', 'very', 'low', '-', 'certainty', 'evidence', '(', 'OR', '3.20', ',', '95', '%', 'CI', '0.23', 'to', '45.19', ')', '.', 'In', 'the', 'one', 'trial', 'assessing', 'ketamine', 'and', 'midazolam', ',', 'there', 'were', 'no', 'dropouts', 'due', 'to', 'adverse', 'effects', 'or', 'for', 'any', 'reason', '(', 'very', 'low', '-', 'certainty', 'evidence', ')', '.', 'Placebo', 'may', 'have', 'been', 'more', 'effective', 'than', 'N', '-', 'acetylcysteine', 'in', 'reducing', 'depression', 'rating', 'scale', 'scores', 'at', 'three', 'months', ',', 'although', 'this', 'was', 'based', 'on', 'very', 'low', '-', 'certainty', 'evidence', '(', 'MD', '1.28', ',', '95', '%', 'CI', '0.24', 'to', '2.31', ';', 'participants', '=', '58', ';', 'studies', '=', '2', ')', '.', 'Very', 'uncertain', 'evidence', 'found', 'no', 'difference', 'in', 'response', 'at', 'three', 'months', '(', 'OR', '0.82', ',', '95', '%', 'CI', '0.32', 'to', '2.14', ';', 'participants', '=', '69', ';', 'studies', '=', '2', ';', 'very', 'low', '-', 'certainty', 'evidence', ')', '.', 'No', 'data', 'were', 'available', 'for', 'remission', 'or', 'acceptability', '.', 'Extremely', 'limited', 'data', 'were', 'available', 'for', 'riluzole', 'vs', 'placebo', ',', 'finding', 'only', 'very', '-', 'low', 'certainty', 'evidence', 'of', 'no', 'difference', 'in', 'dropout', 'rates', '(', 'OR', '2.00', ',', '95', '%', 'CI', '0.31', 'to', '12.84', ';', 'P', '=', '0.46', ';', 'participants', '=', '19', ';', 'studies', '=', '1', ';', 'I(2', ')', '=', '0', '%', ')', '.', 'AUTHORS', ""'"", 'CONCLUSIONS', ':', 'It', 'is', 'difficult', 'to', 'draw', 'reliable', 'conclusions', 'from', 'this', 'review', 'due', 'to', 'the', 'certainty', 'of', 'the', 'evidence', 'being', 'low', 'to', 'very', 'low', ',', 'and', 'the', 'relatively', 'small', 'amount', 'of', 'data', 'usable', 'for', 'analysis', 'in', 'bipolar', 'disorder', ',', 'which', 'is', 'considerably', 'less', 'than', 'the', 'information', 'available', 'for', 'unipolar', 'depression', '.', 'Nevertheless', ',', 'we', 'found', 'uncertain', 'evidence', 'in', 'favour', 'of', 'a', 'single', 'intravenous', 'dose', 'of', 'ketamine', '(', 'as', 'add', '-', 'on', 'therapy', 'to', 'mood', 'stabilisers', ')', 'over', 'placebo', 'in', 'terms', 'of', 'response', 'rate', 'up', 'to', '24', 'hours', ',', 'however', 'ketamine', 'did', 'not', 'show', 'any', 'better', 'efficacy', 'for', 'remission', 'in', 'bipolar', 'depression', '.', 'Even', 'though', 'ketamine', 'has', 'the', 'potential', 'to', 'have', 'a', 'rapid', 'and', 'transient', 'antidepressant', 'effect', ',', 'the', 'efficacy', 'of', 'a', 'single', 'intravenous', 'dose', 'may', 'be', 'limited', '.', 'We', 'did', 'not', 'find', 'conclusive', 'evidence', 'on', 'adverse', 'events', 'with', 'ketamine', ',', 'and', 'there', 'was', 'insufficient', 'evidence', 'to', 'draw', 'meaningful', 'conclusions', 'for', 'the', 'remaining', 'glutamate', 'receptor', 'modulators', '.', 'However', ',', 'ketamine', ""'s"", 'psychotomimetic', 'effects', '(', 'such', 'as', 'delusions', 'or', 'delirium', ')', 'may', 'have', 'compromised', 'study', 'blinding', 'in', 'some', 'studies', ',', 'and', 'so', 'we', 'can', 'not', 'rule', 'out', 'the', 'potential', 'bias', 'introduced', 'by', 'inadequate', 'blinding', 'procedures', '.', 'To', 'draw', 'more', 'robust', 'conclusions', ',', 'further', 'methodologically', 'sound', 'RCTs', '(', 'with', 'adequate', 'blinding', ')', 'are', 'needed', 'to', 'explore', 'different', 'modes', 'of', 'administration', 'of', 'ketamine', ',', 'and', 'to', 'study', 'different', 'methods', 'of', 'sustaining', 'antidepressant', 'response', ',', 'such', 'as', 'repeated', 'administrations', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1964,"['[CLS]', 'ketamine', 'and', 'other', 'glutamate', 'receptor', 'modulators', 'for', 'depression', 'in', 'adults', 'with', 'bipolar', 'disorder', '.', '^', 'background', ':', 'glutam', '##ergic', 'system', 'dysfunction', 'has', 'been', 'implicated', 'in', 'the', 'pathophysiology', 'of', 'bipolar', 'depression', '.', 'this', 'is', 'an', 'update', 'of', 'the', '2015', 'cochrane', 'review', 'for', 'the', 'use', 'of', 'glutamate', 'receptor', 'modulators', 'for', 'depression', 'in', 'bipolar', 'disorder', '.', 'objectives', ':', '1', '.', 'to', 'assess', 'the', 'effects', 'of', 'ketamine', 'and', 'other', 'glutamate', 'receptor', 'modulators', 'in', 'allevi', '##ating', 'the', 'acute', 'symptoms', 'of', 'depression', 'in', 'people', 'with', 'bipolar', 'disorder', '.', '2', '.', 'to', 'review', 'the', 'acceptability', 'of', 'ketamine', 'and', 'other', 'glutamate', 'receptor', 'modulators', 'in', 'people', 'with', 'bipolar', 'disorder', 'who', 'are', 'experiencing', 'depressive', 'symptoms', '.', 'search', 'methods', ':', 'we', 'searched', 'the', 'cochrane', 'central', 'register', 'of', 'controlled', 'trials', '(', 'central', ')', ',', 'ov', '##id', 'medline', ',', 'emb', '##ase', 'and', 'ps', '##yc', '##info', 'all', 'years', 'to', 'july', '202', '##0', '.', 'we', 'did', 'not', 'apply', 'any', 'restrictions', 'to', 'date', ',', 'language', 'or', 'publication', 'status', '.', 'selection', 'criteria', ':', 'rcts', 'comparing', 'ketamine', 'or', 'other', 'glutamate', 'receptor', 'modulators', 'with', 'other', 'active', 'psycho', '##tro', '##pic', 'drugs', 'or', 'saline', 'placebo', 'in', 'adults', 'with', 'bipolar', 'depression', '.', 'data', 'collection', 'and', 'analysis', ':', 'two', 'review', 'authors', 'independently', 'selected', 'studies', 'for', 'inclusion', ',', 'assessed', 'trial', 'quality', 'and', 'extracted', 'data', '.', 'primary', 'outcomes', 'were', 'response', 'rate', 'and', 'adverse', 'events', '.', 'secondary', 'outcomes', 'included', 'remission', 'rate', ',', 'depression', 'severity', 'change', 'scores', ',', 'suicidal', '##ity', ',', 'cognition', ',', 'quality', 'of', 'life', ',', 'and', 'dropout', 'rate', '.', 'the', 'grade', 'framework', 'was', 'used', 'to', 'assess', 'the', 'certainty', 'of', 'the', 'evidence', '.', 'main', 'results', ':', 'ten', 'studies', '(', '64', '##7', 'participants', ')', 'were', 'included', 'in', 'this', 'review', '(', 'an', 'additional', 'five', 'studies', 'compared', 'to', 'the', '2015', 'review', ')', '.', 'there', 'were', 'no', 'additional', 'studies', 'added', 'to', 'the', 'comparisons', 'identified', 'in', 'the', '2015', 'cochrane', 'review', 'on', 'ketamine', ',', 'mem', '##anti', '##ne', 'and', 'cyt', '##idine', 'versus', 'placebo', '.', 'however', ',', 'three', 'new', 'comparisons', 'were', 'found', ':', 'ketamine', 'versus', 'mid', '##azol', '##am', ',', 'n', '-', 'acetyl', '##cys', '##tein', '##e', 'versus', 'placebo', ',', 'and', 'ri', '##lu', '##zol', '##e', 'versus', 'placebo', '.', 'the', 'glutamate', 'receptor', 'modulators', 'studied', 'were', 'ketamine', '(', 'three', 'trials', ')', ',', 'mem', '##anti', '##ne', '(', 'two', ')', ',', 'cyt', '##idine', '(', 'one', ')', ',', 'n', '-', 'acetyl', '##cys', '##tein', '##e', '(', 'three', ')', ',', 'and', 'ri', '##lu', '##zol', '##e', '(', 'one', ')', '.', 'eight', 'of', 'these', 'studies', 'were', 'placebo', '-', 'controlled', 'and', 'two', '-', 'armed', '.', 'in', 'seven', 'trials', 'the', 'glutamate', 'receptor', 'modulators', 'had', 'been', 'used', 'as', 'add', '-', 'on', 'drugs', 'to', 'mood', 'stabil', '##iser', '##s', '.', 'only', 'one', 'trial', 'compared', 'ketamine', 'with', 'an', 'active', 'comparator', ',', 'mid', '##azol', '##am', '.', 'the', 'treatment', 'period', 'ranged', 'from', 'a', 'single', 'intravenous', 'administration', '(', 'all', 'ketamine', 'studies', ')', ',', 'to', 'repeated', 'administration', 'for', 'ri', '##lu', '##zol', '##e', ',', 'mem', '##anti', '##ne', ',', 'cyt', '##idine', ',', 'and', 'n', '-', 'acetyl', '##cys', '##tein', '##e', '(', 'with', 'a', 'follow', '-', 'up', 'of', 'eight', 'weeks', ',', '8', 'to', '12', 'weeks', ',', '12', 'weeks', ',', 'and', '16', 'to', '20', 'weeks', ',', 'respectively', ')', '.', 'six', 'of', 'the', 'studies', 'included', 'sites', 'in', 'the', 'usa', ',', 'one', 'in', 'taiwan', ',', 'one', 'in', 'denmark', ',', 'one', 'in', 'australia', '[SEP]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12, 12, 14, 15, 16, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 119, 120, 121, 122, 122, 123, 124, 124, 124, 125, 126, 127, 128, 129, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 159, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 280, 280, 281, 282, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 296, 296, 297, 298, 299, 300, 300, 300, 300, 301, 302, 303, 304, 305, 305, 305, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 321, 321, 322, 323, 324, 325, 326, 326, 327, 328, 329, 330, 331, 332, 333, 333, 333, 333, 334, 335, 336, 337, 338, 339, 339, 339, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 374, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 386, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 407, 407, 407, 408, 409, 409, 409, 410, 411, 411, 412, 413, 414, 415, 416, 416, 416, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.^
BACKGROUND: Glutamergic system dysfunction has been implicated in the pathophysiology of bipolar depression. This is an update of the 2015 Cochrane Review for the use of glutamate receptor modulators for depression in bipolar disorder. OBJECTIVES: 1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder. 2. To review the acceptability of ketamine and other glutamate receptor modulators in people with bipolar disorder who are experiencing depressive symptoms. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase and PsycINFO all years to July 2020.  We did not apply any restrictions to date, language or publication status. SELECTION CRITERIA: RCTs comparing ketamine or other glutamate receptor modulators with other active psychotropic drugs or saline placebo in adults with bipolar depression. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, assessed trial quality and extracted data. Primary outcomes were response rate and adverse events. Secondary outcomes included remission rate, depression severity change scores, suicidality, cognition, quality of life, and dropout rate. The GRADE framework was used to assess the certainty of the evidence. MAIN RESULTS: Ten studies (647 participants) were included in this review (an additional five studies compared to the 2015 review). There were no additional studies added to the comparisons identified in the 2015 Cochrane review on ketamine, memantine and cytidine versus placebo. However, three new comparisons were found: ketamine versus midazolam, N-acetylcysteine versus placebo, and riluzole versus placebo. The glutamate receptor modulators studied were ketamine (three trials), memantine (two), cytidine (one), N-acetylcysteine (three), and riluzole (one). Eight of these studies were placebo-controlled and two-armed. In seven trials the glutamate receptor modulators had been used as add-on drugs to mood stabilisers. Only one trial compared ketamine with an active comparator, midazolam. The treatment period ranged from a single intravenous administration (all ketamine studies), to repeated administration for riluzole, memantine, cytidine, and N-acetylcysteine (with a follow-up of eight weeks, 8 to 12 weeks, 12 weeks, and 16 to 20 weeks, respectively). Six of the studies included sites in the USA, one in Taiwan, one in Denmark, one in Australia, and in one study the location was unclear. All participants had a primary diagnosis of bipolar disorder and were experiencing an acute bipolar depressive episode, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders fourth edition (IV) or fourth edition text revision (IV-TR). Among all glutamate receptor modulators included in this review, only ketamine appeared to be more efficacious than placebo 24 hours after infusion for response rate (odds ratio (OR) 11.61, 95% confidence interval (CI) 1.25 to 107.74; P = 0.03; participants = 33; studies = 2; I² = 0%, low-certainty evidence). Ketamine seemed to be more effective in reducing depression rating scale scores (MD -11.81, 95% CI -20.01 to -3.61; P = 0.005; participants = 32; studies = 2; I(2) = 0%, very low-certainty evidence). There was no evidence of ketamine's efficacy in producing remission over placebo at 24 hours (OR 5.16, 95% CI 0.51 to 52.30; P = 0.72; participants = 33; studies = 2; I(2) = 0%, very low-certainty evidence). Evidence on response, remission or depression rating scale scores between ketamine and midazolam was uncertain at 24 hours due to very low-certainty evidence (OR 3.20, 95% CI 0.23 to 45.19). In the one trial assessing ketamine and midazolam, there were no dropouts due to adverse effects or for any reason (very low-certainty evidence). Placebo may have been more effective than N-acetylcysteine in reducing depression rating scale scores at three months, although this was based on very low-certainty evidence (MD 1.28, 95% CI 0.24 to 2.31; participants = 58; studies = 2). Very uncertain evidence found no difference in response at three months (OR 0.82, 95% CI 0.32 to 2.14; participants = 69; studies = 2; very low-certainty evidence). No data were available for remission or acceptability. Extremely limited data were available for riluzole vs placebo, finding only very-low certainty evidence of no difference in dropout rates (OR 2.00, 95% CI 0.31 to 12.84; P = 0.46; participants = 19; studies = 1; I(2) = 0%). AUTHORS' CONCLUSIONS: It is difficult to draw reliable conclusions from this review due to the certainty of the evidence being low to very low, and the relatively small amount of data usable for analysis in bipolar disorder, which is considerably less than the information available for unipolar depression. Nevertheless, we found uncertain evidence in favour of a single intravenous dose of ketamine (as add-on therapy to mood stabilisers) over placebo in terms of response rate up to 24 hours, however ketamine did not show any better efficacy for remission in bipolar depression. Even though ketamine has the potential to have a rapid and transient antidepressant effect, the efficacy of a single intravenous dose may be limited. We did not find conclusive evidence on adverse events with ketamine, and there was insufficient evidence to draw meaningful conclusions for the remaining glutamate receptor modulators. However, ketamine's psychotomimetic effects (such as delusions or delirium) may have compromised study blinding in some studies, and so we cannot rule out the potential bias introduced by inadequate blinding procedures. To draw more robust conclusions, further methodologically sound RCTs (with adequate blinding) are needed to explore different modes of administration of ketamine, and to study different methods of sustaining antidepressant response, such as repeated administrations."
"['A', 'Research', 'Domain', 'Criteria', '(', 'RDoC)-Guided', 'Dashboard', 'to', 'Review', 'Psilocybin', 'Target', 'Domains', ':', 'A', 'Systematic', 'Review.^', '\n', 'BACKGROUND', ':', 'Preliminary', 'results', 'from', 'randomized', 'controlled', 'studies', 'as', 'well', 'as', 'identified', 'molecular', ',', 'cellular', ',', 'and', 'circuit', 'targets', 'of', 'select', 'psychedelics', '(', 'e.g.', ',', 'psilocybin', ')', 'suggest', 'that', 'their', 'effects', 'are', 'transdiagnostic', '.', 'In', 'this', 'review', ',', 'we', 'exploit', 'the', 'Research', 'Domain', 'Criteria', '(', 'RDoC', ')', 'transdiagnostic', 'framework', ',', 'to', 'synthesize', 'extant', 'literature', 'on', 'psilocybin', '.', 'OBJECTIVE', ':', 'We', 'aimed', 'to', 'identify', 'RDoC', '-', 'based', 'effects', 'of', 'psilocybin', 'and', 'vistas', 'for', 'future', 'mechanistic', 'and', 'interventional', 'research', '.', 'METHODS', ':', 'A', 'systematic', 'search', 'in', 'electronic', 'databases', '(', 'i.e.', ',', 'PubMed', ',', 'Scopus', ',', 'PsycINFO', ',', 'and', 'Web', 'of', 'Science', ')', 'performed', 'in', 'January', 'and', 'February', '2021', 'identified', 'English', 'articles', 'published', 'between', '1990', 'and', '2020', 'reporting', 'the', 'effects', 'of', 'psilocybin', 'on', 'mental', 'health', 'measures', '.', 'Data', 'from', 'included', 'articles', 'were', 'retrieved', 'and', 'organized', 'according', 'to', 'the', 'RDoC', 'bio', '-', 'behavioral', 'matrix', 'and', 'its', 'constituent', 'six', 'main', 'domains', ',', 'namely', ':', 'positive', 'valence', 'systems', ',', 'negative', 'valence', 'systems', ',', 'cognitive', 'systems', ',', 'social', 'processes', ',', 'sensorimotor', 'systems', ',', 'and', 'arousal', 'and', 'regulatory', 'systems', '.', 'RESULTS', ':', 'The', 'preponderance', 'of', 'research', 'with', 'psilocybin', 'has', 'differentially', 'reported', 'beneficial', 'effects', 'on', 'positive', 'valence', 'systems', ',', 'negative', 'valence', 'system', ',', 'and', 'social', 'process', 'domains', '.', 'The', 'data', 'from', 'the', 'included', 'studies', 'support', 'both', 'short', '-', 'term', '(', '23', 'assessments', ')', 'and', 'long', '-', 'term', '(', '15', 'assessments', ')', 'beneficial', 'effects', 'of', 'psilocybin', 'on', 'the', 'positive', 'valence', 'systems', '.', 'While', '12', 'of', 'the', 'extracted', 'outcome', 'measures', 'suggest', 'that', 'psilocybin', 'use', 'is', 'associated', 'with', 'increases', 'in', 'the', '""', 'fear', '""', 'construct', 'of', 'the', 'negative', 'valence', 'systems', 'domain', ',', '19', 'findings', 'show', 'no', 'significant', 'effects', 'on', 'this', 'construct', ',', 'and', 'seven', 'parameters', 'show', 'lowered', 'levels', 'of', 'the', '""', 'sustained', 'threat', '""', 'construct', 'in', 'the', 'long', 'term', '.', 'Thirty', '-', 'four', 'outcome', 'measures', 'revealed', 'short', '-', 'term', 'alterations', 'in', 'the', 'social', 'systems', ""'"", 'construct', 'namely', ',', '""', 'perception', 'and', 'understanding', 'of', 'self', ',', '""', 'and', '""', 'social', 'communications', '""', 'as', 'well', 'as', 'enhancements', 'in', '""', 'perception', 'and', 'understanding', 'of', 'others', '""', 'and', '""', 'affiliation', 'and', 'attachment', '""', '.', 'The', 'majority', 'of', 'findings', 'related', 'to', 'the', 'cognitive', 'systems', ""'"", 'domain', 'reported', 'dyscognitive', 'effects', '.', 'There', 'have', 'been', 'relatively', 'few', 'studies', 'reporting', 'outcomes', 'of', 'psilocybin', 'on', 'the', 'remaining', 'RDoC', 'domains', '.', 'Moreover', ',', 'seven', 'of', 'the', 'included', 'studies', 'suggest', 'the', 'transdiagnostic', 'effects', 'of', 'psilocybin', '.', 'The', 'dashboard', 'characterization', 'of', 'RDoC', 'outcomes', 'with', 'psilocybin', 'suggests', 'beneficial', 'effects', 'in', 'the', 'measures', 'of', 'reward', ',', 'threat', ',', 'and', 'arousal', ',', 'as', 'well', 'as', 'general', 'social', 'systems', '.', 'CONCLUSIONS', ':', 'Psilocybin', 'possesses', 'a', 'multi', '-', 'domain', 'effectiveness', '.', 'The', 'field', 'would', 'benefit', 'from', 'highly', 'rigorous', 'proof', '-', 'of', '-', 'mechanism', 'research', 'to', 'assess', 'the', 'effects', 'of', 'psilocybin', 'using', 'the', 'RDoC', 'framework', '.', 'The', 'combined', 'effect', 'of', 'psilocybin', 'with', 'psychosocial', 'interventions', 'with', 'RDoC', '-', 'based', 'outcomes', 'is', 'a', 'priority', 'therapeutic', 'vista', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7035,"['[CLS]', 'a', 'research', 'domain', 'criteria', '(', 'rd', '##oc', ')', '-', 'guided', 'dash', '##board', 'to', 'review', 'psi', '##loc', '##yb', '##in', 'target', 'domains', ':', 'a', 'systematic', 'review', '.', '^', 'background', ':', 'preliminary', 'results', 'from', 'randomized', 'controlled', 'studies', 'as', 'well', 'as', 'identified', 'molecular', ',', 'cellular', ',', 'and', 'circuit', 'targets', 'of', 'select', 'psych', '##ede', '##lic', '##s', '(', 'e', '.', 'g', '.', ',', 'psi', '##loc', '##yb', '##in', ')', 'suggest', 'that', 'their', 'effects', 'are', 'trans', '##diagn', '##ostic', '.', 'in', 'this', 'review', ',', 'we', 'exploit', 'the', 'research', 'domain', 'criteria', '(', 'rd', '##oc', ')', 'trans', '##diagn', '##ostic', 'framework', ',', 'to', 'synthesize', 'extant', 'literature', 'on', 'psi', '##loc', '##yb', '##in', '.', 'objective', ':', 'we', 'aimed', 'to', 'identify', 'rd', '##oc', '-', 'based', 'effects', 'of', 'psi', '##loc', '##yb', '##in', 'and', 'vis', '##tas', 'for', 'future', 'mechanistic', 'and', 'interventional', 'research', '.', 'methods', ':', 'a', 'systematic', 'search', 'in', 'electronic', 'databases', '(', 'i', '.', 'e', '.', ',', 'pubmed', ',', 'sc', '##opus', ',', 'ps', '##yc', '##info', ',', 'and', 'web', 'of', 'science', ')', 'performed', 'in', 'january', 'and', 'february', '202', '##1', 'identified', 'english', 'articles', 'published', 'between', '1990', 'and', '202', '##0', 'reporting', 'the', 'effects', 'of', 'psi', '##loc', '##yb', '##in', 'on', 'mental', 'health', 'measures', '.', 'data', 'from', 'included', 'articles', 'were', 'retrieved', 'and', 'organized', 'according', 'to', 'the', 'rd', '##oc', 'bio', '-', 'behavioral', 'matrix', 'and', 'its', 'constituent', 'six', 'main', 'domains', ',', 'namely', ':', 'positive', 'valence', 'systems', ',', 'negative', 'valence', 'systems', ',', 'cognitive', 'systems', ',', 'social', 'processes', ',', 'sensorimotor', 'systems', ',', 'and', 'arousal', 'and', 'regulatory', 'systems', '.', 'results', ':', 'the', 'prep', '##onder', '##ance', 'of', 'research', 'with', 'psi', '##loc', '##yb', '##in', 'has', 'differentially', 'reported', 'beneficial', 'effects', 'on', 'positive', 'valence', 'systems', ',', 'negative', 'valence', 'system', ',', 'and', 'social', 'process', 'domains', '.', 'the', 'data', 'from', 'the', 'included', 'studies', 'support', 'both', 'short', '-', 'term', '(', '23', 'assessments', ')', 'and', 'long', '-', 'term', '(', '15', 'assessments', ')', 'beneficial', 'effects', 'of', 'psi', '##loc', '##yb', '##in', 'on', 'the', 'positive', 'valence', 'systems', '.', 'while', '12', 'of', 'the', 'extracted', 'outcome', 'measures', 'suggest', 'that', 'psi', '##loc', '##yb', '##in', 'use', 'is', 'associated', 'with', 'increases', 'in', 'the', '""', 'fear', '""', 'construct', 'of', 'the', 'negative', 'valence', 'systems', 'domain', ',', '19', 'findings', 'show', 'no', 'significant', 'effects', 'on', 'this', 'construct', ',', 'and', 'seven', 'parameters', 'show', 'lowered', 'levels', 'of', 'the', '""', 'sustained', 'threat', '""', 'construct', 'in', 'the', 'long', 'term', '.', 'thirty', '-', 'four', 'outcome', 'measures', 'revealed', 'short', '-', 'term', 'alterations', 'in', 'the', 'social', 'systems', ""'"", 'construct', 'namely', ',', '""', 'perception', 'and', 'understanding', 'of', 'self', ',', '""', 'and', '""', 'social', 'communications', '""', 'as', 'well', 'as', 'enhancements', 'in', '""', 'perception', 'and', 'understanding', 'of', 'others', '""', 'and', '""', 'affiliation', 'and', 'attachment', '""', '.', 'the', 'majority', 'of', 'findings', 'related', 'to', 'the', 'cognitive', 'systems', ""'"", 'domain', 'reported', 'dys', '##cognitive', 'effects', '.', 'there', 'have', 'been', 'relatively', 'few', 'studies', 'reporting', 'outcomes', 'of', 'psi', '##loc', '##yb', '##in', 'on', 'the', 'remaining', 'rd', '##oc', 'domains', '.', 'moreover', ',', 'seven', 'of', 'the', 'included', 'studies', 'suggest', 'the', 'trans', '##diagn', '##ostic', 'effects', 'of', 'psi', '##loc', '##yb', '##in', '.', 'the', 'dash', '##board', 'character', '##ization', 'of', 'rd', '##oc', 'outcomes', 'with', 'psi', '##loc', '##yb', '##in', 'suggests', 'beneficial', 'effects', 'in', 'the', 'measures', 'of', 'reward', ',', 'threat', ',', 'and', 'arousal', ',', 'as', 'well', 'as', 'general', 'social', 'systems', '.', 'conclusions', ':', 'psi', '##loc', '##yb', '##in', 'possesses', 'a', 'multi', '-', 'domain', '[SEP]']","[None, 0, 1, 2, 3, 4, 5, 5, 5, 5, 5, 6, 6, 7, 8, 9, 9, 9, 9, 10, 11, 12, 13, 14, 15, 15, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 38, 38, 38, 39, 40, 40, 40, 40, 41, 42, 42, 42, 42, 43, 44, 45, 46, 47, 48, 49, 49, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 62, 63, 64, 64, 64, 65, 66, 67, 68, 69, 70, 71, 72, 72, 72, 72, 73, 74, 75, 76, 77, 78, 79, 80, 80, 81, 82, 83, 84, 85, 85, 85, 85, 86, 87, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 104, 104, 104, 105, 106, 107, 108, 108, 109, 110, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 122, 123, 124, 125, 126, 127, 128, 129, 130, 130, 131, 132, 133, 134, 135, 135, 135, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 192, 192, 193, 194, 195, 196, 196, 196, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 242, 242, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 258, 258, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 379, 379, 379, 380, 381, 382, 383, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 395, 395, 396, 397, 398, 398, 398, 398, 399, 400, 401, 401, 402, 402, 403, 404, 404, 405, 406, 407, 407, 407, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 431, 431, 431, 432, 433, 434, 435, 436, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.^
BACKGROUND: Preliminary results from randomized controlled studies as well as identified molecular, cellular, and circuit targets of select psychedelics (e.g., psilocybin) suggest that their effects are transdiagnostic. In this review, we exploit the Research Domain Criteria (RDoC) transdiagnostic framework, to synthesize extant literature on psilocybin. OBJECTIVE: We aimed to identify RDoC-based effects of psilocybin and vistas for future mechanistic and interventional research. METHODS: A systematic search in electronic databases (i.e., PubMed, Scopus, PsycINFO, and Web of Science) performed in January and February 2021 identified English articles published between 1990 and 2020 reporting the effects of psilocybin on mental health measures. Data from included articles were retrieved and organized according to the RDoC bio-behavioral matrix and its constituent six main domains, namely: positive valence systems, negative valence systems, cognitive systems, social processes, sensorimotor systems, and arousal and regulatory systems. RESULTS: The preponderance of research with psilocybin has differentially reported beneficial effects on positive valence systems, negative valence system, and social process domains. The data from the included studies support both short-term (23 assessments) and long-term (15 assessments) beneficial effects of psilocybin on the positive valence systems. While 12 of the extracted outcome measures suggest that psilocybin use is associated with increases in the ""fear"" construct of the negative valence systems domain, 19 findings show no significant effects on this construct, and seven parameters show lowered levels of the ""sustained threat"" construct in the long term. Thirty-four outcome measures revealed short-term alterations in the social systems' construct namely, ""perception and understanding of self,"" and ""social communications"" as well as enhancements in ""perception and understanding of others"" and ""affiliation and attachment"". The majority of findings related to the cognitive systems' domain reported dyscognitive effects. There have been relatively few studies reporting outcomes of psilocybin on the remaining RDoC domains. Moreover, seven of the included studies suggest the transdiagnostic effects of psilocybin. The dashboard characterization of RDoC outcomes with psilocybin suggests beneficial effects in the measures of reward, threat, and arousal, as well as general social systems. CONCLUSIONS: Psilocybin possesses a multi-domain effectiveness. The field would benefit from highly rigorous proof-of-mechanism research to assess the effects of psilocybin using the RDoC framework. The combined effect of psilocybin with psychosocial interventions with RDoC-based outcomes is a priority therapeutic vista."
"['Increased', 'global', 'integration', 'in', 'the', 'brain', 'after', 'psilocybin', 'therapy', 'for', 'depression.^', '\n', 'Psilocybin', 'therapy', 'shows', 'antidepressant', 'potential', ',', 'but', 'its', 'therapeutic', 'actions', 'are', 'not', 'well', 'understood', '.', 'We', 'assessed', 'the', 'subacute', 'impact', 'of', 'psilocybin', 'on', 'brain', 'function', 'in', 'two', 'clinical', 'trials', 'of', 'depression', '.', 'The', 'first', 'was', 'an', 'open', '-', 'label', 'trial', 'of', 'orally', 'administered', 'psilocybin', '(', '10', 'mg', 'and', '25', 'mg', ',', '7', 'd', 'apart', ')', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '.', 'Functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'was', 'recorded', 'at', 'baseline', 'and', '1', 'd', 'after', 'the', '25', '-', 'mg', 'dose', '.', 'Beck', ""'s"", 'depression', 'inventory', 'was', 'the', 'primary', 'outcome', 'measure', '(', 'MR', '/', 'J00460X/1', ')', '.', 'The', 'second', 'trial', 'was', 'a', 'double', '-', 'blind', 'phase', 'II', 'randomized', 'controlled', 'trial', 'comparing', 'psilocybin', 'therapy', 'with', 'escitalopram', '.', 'Patients', 'with', 'major', 'depressive', 'disorder', 'received', 'either', '2', '×', '25', 'mg', 'oral', 'psilocybin', ',', '3', 'weeks', 'apart', ',', 'plus', '6', 'weeks', 'of', 'daily', 'placebo', '(', ""'"", 'psilocybin', 'arm', ""'"", ')', 'or', '2', '×', '1', 'mg', 'oral', 'psilocybin', ',', '3', 'weeks', 'apart', ',', 'plus', '6', 'weeks', 'of', 'daily', 'escitalopram', '(', '10', '-', '20', 'mg', ')', '(', ""'"", 'escitalopram', 'arm', ""'"", ')', '.', 'fMRI', 'was', 'recorded', 'at', 'baseline', 'and', '3', 'weeks', 'after', 'the', 'second', 'psilocybin', 'dose', '(', 'NCT03429075', ')', '.', 'In', 'both', 'trials', ',', 'the', 'antidepressant', 'response', 'to', 'psilocybin', 'was', 'rapid', ',', 'sustained', 'and', 'correlated', 'with', 'decreases', 'in', 'fMRI', 'brain', 'network', 'modularity', ',', 'implying', 'that', 'psilocybin', ""'s"", 'antidepressant', 'action', 'may', 'depend', 'on', 'a', 'global', 'increase', 'in', 'brain', 'network', 'integration', '.', 'Network', 'cartography', 'analyses', 'indicated', 'that', '5', '-', 'HT2A', 'receptor', '-', 'rich', 'higher', '-', 'order', 'functional', 'networks', 'became', 'more', 'functionally', 'interconnected', 'and', 'flexible', 'after', 'psilocybin', 'treatment', '.', 'The', 'antidepressant', 'response', 'to', 'escitalopram', 'was', 'milder', 'and', 'no', 'changes', 'in', 'brain', 'network', 'organization', 'were', 'observed', '.', 'Consistent', 'efficacy', '-', 'related', 'brain', 'changes', ',', 'correlating', 'with', 'robust', 'antidepressant', 'effects', 'across', 'two', 'studies', ',', 'suggest', 'an', 'antidepressant', 'mechanism', 'for', 'psilocybin', 'therapy', ':', 'global', 'increases', 'in', 'brain', 'network', 'integration', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1884,"['[CLS]', 'increased', 'global', 'integration', 'in', 'the', 'brain', 'after', 'psi', '##loc', '##yb', '##in', 'therapy', 'for', 'depression', '.', '^', 'psi', '##loc', '##yb', '##in', 'therapy', 'shows', 'antidepressant', 'potential', ',', 'but', 'its', 'therapeutic', 'actions', 'are', 'not', 'well', 'understood', '.', 'we', 'assessed', 'the', 'sub', '##acute', 'impact', 'of', 'psi', '##loc', '##yb', '##in', 'on', 'brain', 'function', 'in', 'two', 'clinical', 'trials', 'of', 'depression', '.', 'the', 'first', 'was', 'an', 'open', '-', 'label', 'trial', 'of', 'orally', 'administered', 'psi', '##loc', '##yb', '##in', '(', '10', 'mg', 'and', '25', 'mg', ',', '7', 'd', 'apart', ')', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '.', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fmri', ')', 'was', 'recorded', 'at', 'baseline', 'and', '1', 'd', 'after', 'the', '25', '-', 'mg', 'dose', '.', 'beck', ""'"", 's', 'depression', 'inventory', 'was', 'the', 'primary', 'outcome', 'measure', '(', 'mr', '/', 'j', '##004', '##60', '##x', '/', '1', ')', '.', 'the', 'second', 'trial', 'was', 'a', 'double', '-', 'blind', 'phase', 'ii', 'randomized', 'controlled', 'trial', 'comparing', 'psi', '##loc', '##yb', '##in', 'therapy', 'with', 'esc', '##ital', '##opr', '##am', '.', 'patients', 'with', 'major', 'depressive', 'disorder', 'received', 'either', '2', '×', '25', 'mg', 'oral', 'psi', '##loc', '##yb', '##in', ',', '3', 'weeks', 'apart', ',', 'plus', '6', 'weeks', 'of', 'daily', 'placebo', '(', ""'"", 'psi', '##loc', '##yb', '##in', 'arm', ""'"", ')', 'or', '2', '×', '1', 'mg', 'oral', 'psi', '##loc', '##yb', '##in', ',', '3', 'weeks', 'apart', ',', 'plus', '6', 'weeks', 'of', 'daily', 'esc', '##ital', '##opr', '##am', '(', '10', '-', '20', 'mg', ')', '(', ""'"", 'esc', '##ital', '##opr', '##am', 'arm', ""'"", ')', '.', 'fmri', 'was', 'recorded', 'at', 'baseline', 'and', '3', 'weeks', 'after', 'the', 'second', 'psi', '##loc', '##yb', '##in', 'dose', '(', 'nct', '##03', '##42', '##90', '##75', ')', '.', 'in', 'both', 'trials', ',', 'the', 'antidepressant', 'response', 'to', 'psi', '##loc', '##yb', '##in', 'was', 'rapid', ',', 'sustained', 'and', 'correlated', 'with', 'decreases', 'in', 'fmri', 'brain', 'network', 'modularity', ',', 'implying', 'that', 'psi', '##loc', '##yb', '##in', ""'"", 's', 'antidepressant', 'action', 'may', 'depend', 'on', 'a', 'global', 'increase', 'in', 'brain', 'network', 'integration', '.', 'network', 'cart', '##ography', 'analyses', 'indicated', 'that', '5', '-', 'ht', '##2', '##a', 'receptor', '-', 'rich', 'higher', '-', 'order', 'functional', 'networks', 'became', 'more', 'functionally', 'interconnected', 'and', 'flexible', 'after', 'psi', '##loc', '##yb', '##in', 'treatment', '.', 'the', 'antidepressant', 'response', 'to', 'esc', '##ital', '##opr', '##am', 'was', 'mild', '##er', 'and', 'no', 'changes', 'in', 'brain', 'network', 'organization', 'were', 'observed', '.', 'consistent', 'efficacy', '-', 'related', 'brain', 'changes', ',', 'correlating', 'with', 'robust', 'antidepressant', 'effects', 'across', 'two', 'studies', ',', 'suggest', 'an', 'antidepressant', 'mechanism', 'for', 'psi', '##loc', '##yb', '##in', 'therapy', ':', 'global', 'increases', 'in', 'brain', 'network', 'integration', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 7, 7, 7, 8, 9, 10, 10, 10, 12, 12, 12, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30, 31, 32, 33, 33, 33, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 55, 55, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 108, 108, 108, 108, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 125, 125, 125, 126, 127, 128, 128, 128, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 142, 142, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 156, 156, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 166, 166, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 177, 177, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 186, 186, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 202, 202, 202, 203, 204, 205, 205, 205, 205, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 216, 216, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 233, 233, 233, 234, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 249, 250, 251, 252, 253, 254, 255, 255, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 271, 271, 271, 272, 273, 274, 275, 276, 277, 278, 278, 278, 278, 279, 280, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 312, 312, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Increased global integration in the brain after psilocybin therapy for depression.^
Psilocybin therapy shows antidepressant potential, but its therapeutic actions are not well understood. We assessed the subacute impact of psilocybin on brain function in two clinical trials of depression. The first was an open-label trial of orally administered psilocybin (10 mg and 25 mg, 7 d apart) in patients with treatment-resistant depression. Functional magnetic resonance imaging (fMRI) was recorded at baseline and 1 d after the 25-mg dose. Beck's depression inventory was the primary outcome measure ( MR/J00460X/1 ). The second trial was a double-blind phase II randomized controlled trial comparing psilocybin therapy with escitalopram. Patients with major depressive disorder received either 2 × 25 mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily placebo ('psilocybin arm') or 2 × 1 mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily escitalopram (10-20 mg) ('escitalopram arm'). fMRI was recorded at baseline and 3 weeks after the second psilocybin dose ( NCT03429075 ). In both trials, the antidepressant response to psilocybin was rapid, sustained and correlated with decreases in fMRI brain network modularity, implying that psilocybin's antidepressant action may depend on a global increase in brain network integration. Network cartography analyses indicated that 5-HT2A receptor-rich higher-order functional networks became more functionally interconnected and flexible after psilocybin treatment. The antidepressant response to escitalopram was milder and no changes in brain network organization were observed. Consistent efficacy-related brain changes, correlating with robust antidepressant effects across two studies, suggest an antidepressant mechanism for psilocybin therapy: global increases in brain network integration."
"['Electrophysiological', 'evidence', 'of', 'serotonergic', 'impairment', 'in', 'long', '-', 'term', 'MDMA', '(', '""', 'Ecstasy', '""', ')', 'users.^', '\n', 'Objective', ':', '""', 'Ecstasy', ',', '""', 'or', '3,4', '-', 'methylenedioxymethamphetamine', '(', 'MDMA', ')', ',', 'causes', 'long', '-', 'term', 'impairment', 'to', 'the', 'serotonin', '(', '5', '-', 'HT', ')', 'system', 'in', 'rats', ',', 'dogs', ',', 'and', 'nonhuman', 'primates', '.', '5', '-', 'HT', 'dysfunction', 'has', 'also', 'been', 'observed', 'in', 'human', 'recreational', 'users', 'of', 'the', 'drug', ',', 'but', 'whether', '5', '-', 'HT', 'dysfunction', 'in', 'humans', 'is', 'caused', 'by', 'MDMA', 'has', 'not', 'been', 'established', ',', 'since', 'dysfunction', 'may', 'have', 'preceded', 'MDMA', 'exposure', '.', 'This', 'ambiguity', 'about', 'causation', 'is', 'particularly', 'important', 'in', 'MDMA', 'research', ',', 'because', '5', '-', 'HT', 'deficiency', 'is', 'a', 'predictor', 'of', 'risky', 'behavior', '.', 'Method', ':', 'The', '5', '-', 'HT', 'function', 'of', '22', 'long', '-', 'term', 'MDMA', 'users', 'was', 'compared', 'to', 'that', 'of', '20', 'drug', '-', 'naive', 'comparison', 'subjects', 'and', '19', 'cannabis', 'users', '.', '5', '-', 'HT', 'function', 'was', 'assessed', 'with', 'the', 'intensity', 'dependence', 'paradigm', ',', 'a', 'tool', 'that', 'measures', '5', '-', 'HT', '-', 'related', 'attenuation', 'of', 'neural', 'response', 'to', 'auditory', 'stimuli', '(', 'measured', 'with', 'EEG', ')', '.', 'Results', ':', 'Long', '-', 'term', 'MDMA', 'users', 'exhibited', '5', '-', 'HT', 'dysfunction', ',', 'relative', 'to', 'both', 'cannabis', 'users', 'and', 'drug', '-', 'naive', 'comparison', 'subjects', '.', 'This', 'dysfunction', 'was', 'related', 'to', 'total', 'MDMA', 'consumption', '(', 'after', 'removing', 'the', 'effect', 'of', 'frequency', 'of', 'use', ')', 'but', 'not', 'to', 'frequency', 'of', 'use', '(', 'after', 'removing', 'the', 'effect', 'of', 'total', 'consumption', ')', '.', 'Conclusions', ':', 'These', 'data', 'show', 'that', '5', '-', 'HT', 'dysfunction', 'occurs', 'in', 'MDMA', 'users', ',', 'is', 'related', 'to', 'users', ""'"", 'MDMA', 'consumption', ',', 'and', 'is', 'independent', 'of', 'cannabis', 'use', '.', 'The', 'results', 'do', 'not', 'suggest', 'that', 'self', '-', 'medication', 'explains', 'this', 'relationship', ',', 'because', 'the', 'deficit', 'was', 'related', 'to', 'total', 'MDMA', 'consumption', 'but', 'not', 'frequency', 'of', 'consumption', '.', 'The', 'results', 'are', 'thus', 'consistent', 'with', 'the', 'thesis', 'that', 'MDMA', 'consumption', 'causes', '5', '-', 'HT', 'impairment', 'in', 'humans', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1710,"['[CLS]', 'electroph', '##ysiological', 'evidence', 'of', 'serot', '##one', '##rg', '##ic', 'impairment', 'in', 'long', '-', 'term', 'mdm', '##a', '(', '""', 'ecs', '##tas', '##y', '""', ')', 'users', '.', '^', 'objective', ':', '""', 'ecs', '##tas', '##y', ',', '""', 'or', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', ')', ',', 'causes', 'long', '-', 'term', 'impairment', 'to', 'the', 'serotonin', '(', '5', '-', 'ht', ')', 'system', 'in', 'rats', ',', 'dogs', ',', 'and', 'non', '##human', 'primates', '.', '5', '-', 'ht', 'dysfunction', 'has', 'also', 'been', 'observed', 'in', 'human', 'recreational', 'users', 'of', 'the', 'drug', ',', 'but', 'whether', '5', '-', 'ht', 'dysfunction', 'in', 'humans', 'is', 'caused', 'by', 'mdm', '##a', 'has', 'not', 'been', 'established', ',', 'since', 'dysfunction', 'may', 'have', 'preceded', 'mdm', '##a', 'exposure', '.', 'this', 'ambiguity', 'about', 'causation', 'is', 'particularly', 'important', 'in', 'mdm', '##a', 'research', ',', 'because', '5', '-', 'ht', 'deficiency', 'is', 'a', 'predictor', 'of', 'risky', 'behavior', '.', 'method', ':', 'the', '5', '-', 'ht', 'function', 'of', '22', 'long', '-', 'term', 'mdm', '##a', 'users', 'was', 'compared', 'to', 'that', 'of', '20', 'drug', '-', 'naive', 'comparison', 'subjects', 'and', '19', 'cannabis', 'users', '.', '5', '-', 'ht', 'function', 'was', 'assessed', 'with', 'the', 'intensity', 'dependence', 'paradigm', ',', 'a', 'tool', 'that', 'measures', '5', '-', 'ht', '-', 'related', 'attenuation', 'of', 'neural', 'response', 'to', 'auditory', 'stimuli', '(', 'measured', 'with', 'eeg', ')', '.', 'results', ':', 'long', '-', 'term', 'mdm', '##a', 'users', 'exhibited', '5', '-', 'ht', 'dysfunction', ',', 'relative', 'to', 'both', 'cannabis', 'users', 'and', 'drug', '-', 'naive', 'comparison', 'subjects', '.', 'this', 'dysfunction', 'was', 'related', 'to', 'total', 'mdm', '##a', 'consumption', '(', 'after', 'removing', 'the', 'effect', 'of', 'frequency', 'of', 'use', ')', 'but', 'not', 'to', 'frequency', 'of', 'use', '(', 'after', 'removing', 'the', 'effect', 'of', 'total', 'consumption', ')', '.', 'conclusions', ':', 'these', 'data', 'show', 'that', '5', '-', 'ht', 'dysfunction', 'occurs', 'in', 'mdm', '##a', 'users', ',', 'is', 'related', 'to', 'users', ""'"", 'mdm', '##a', 'consumption', ',', 'and', 'is', 'independent', 'of', 'cannabis', 'use', '.', 'the', 'results', 'do', 'not', 'suggest', 'that', 'self', '-', 'medication', 'explains', 'this', 'relationship', ',', 'because', 'the', 'deficit', 'was', 'related', 'to', 'total', 'mdm', '##a', 'consumption', 'but', 'not', 'frequency', 'of', 'consumption', '.', 'the', 'results', 'are', 'thus', 'consistent', 'with', 'the', 'thesis', 'that', 'mdm', '##a', 'consumption', 'causes', '5', '-', 'ht', 'impairment', 'in', 'humans', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 1, 2, 3, 3, 3, 3, 4, 5, 6, 7, 8, 9, 9, 10, 11, 12, 12, 12, 13, 14, 15, 15, 15, 17, 18, 19, 20, 20, 20, 21, 22, 23, 24, 24, 24, 25, 26, 26, 26, 26, 26, 27, 28, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 253, 254, 255, 256, 257, 258, 259, 260, 261, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Electrophysiological evidence of serotonergic impairment in long-term MDMA (""Ecstasy"") users.^
Objective: ""Ecstasy,"" or 3,4-methylenedioxymethamphetamine (MDMA), causes long-term impairment to the serotonin (5-HT) system in rats, dogs, and nonhuman primates. 5-HT dysfunction has also been observed in human recreational users of the drug, but whether 5-HT dysfunction in humans is caused by MDMA has not been established, since dysfunction may have preceded MDMA exposure. This ambiguity about causation is particularly important in MDMA research, because 5-HT deficiency is a predictor of risky behavior. Method: The 5-HT function of 22 long-term MDMA users was compared to that of 20 drug-naive comparison subjects and 19 cannabis users. 5-HT function was assessed with the intensity dependence paradigm, a tool that measures 5-HT-related attenuation of neural response to auditory stimuli (measured with EEG). Results: Long-term MDMA users exhibited 5-HT dysfunction, relative to both cannabis users and drug-naive comparison subjects. This dysfunction was related to total MDMA consumption (after removing the effect of frequency of use) but not to frequency of use (after removing the effect of total consumption). Conclusions: These data show that 5-HT dysfunction occurs in MDMA users, is related to users' MDMA consumption, and is independent of cannabis use. The results do not suggest that self-medication explains this relationship, because the deficit was related to total MDMA consumption but not frequency of consumption. The results are thus consistent with the thesis that MDMA consumption causes 5-HT impairment in humans."
"['Reduced', 'N', '-', 'acetylaspartate', 'levels', 'in', 'the', 'frontal', 'cortex', 'of', '3,4', '-', 'methylenedioxymethamphetamine', '(', 'ecstasy', ')', 'users', ':', 'Preliminary', 'results.^', '\n', 'BACKGROUND', 'AND', 'PURPOSE', ':', 'The', 'perceived', 'safety', 'of', 'the', 'recreational', 'drug', 'methylenedioxymethamphetamine', '(', 'MDMA', ')', ',', 'or', 'Ecstasy', ',', 'conflicts', 'with', 'animal', 'evidence', 'indicating', 'that', 'MDMA', 'damages', 'cortical', 'serotonin', '(', '5', '-', 'HT', ')', 'neurons', 'at', 'doses', 'similar', 'to', 'those', 'used', 'by', 'humans', '.', 'Few', 'data', 'are', 'available', 'about', 'the', 'effects', 'of', 'MDMA', 'on', 'the', 'human', 'brain', '.', 'This', 'study', 'was', 'designed', 'to', 'evaluate', 'MDMA', '-', 'related', 'alterations', 'in', 'metabolite', 'ratios', 'with', 'single', '-', 'voxel', 'proton', '(', '1H', ')', 'MR', 'spectroscopy', '.', 'METHODS', ':', 'Fifteen', 'male', 'MDMA', 'users', '(', 'mean', 'lifetime', 'exposure', ',', '723', 'tablets', ';', 'mean', 'time', 'since', 'last', 'tablet', ',', '12.0', 'weeks', ')', 'and', '12', 'age', '-', 'matched', 'control', 'subjects', 'underwent', 'single', '-', 'voxel', '1H', 'MR', 'spectroscopy', '.', 'N', '-', 'Acetylaspartate', '(', 'NAA)/creatine', '(', 'Cr', ')', ',', 'NAA', '/', 'Choline', '(', 'Cho', ')', ',', 'and', 'myoinositol', '(', 'MI)/Cr', 'ratios', 'were', 'measured', 'in', 'midfrontal', 'gray', 'matter', ',', 'midoccipital', 'gray', 'matter', ',', 'and', 'right', 'parietal', 'white', 'matter', '.', 'Data', 'were', 'analyzed', 'with', 'linear', 'model', '-', 'based', 'multivariate', 'analysis', 'of', 'variance', '.', 'RESULTS', ':', 'NAA', '/', 'Cr', '(', 'P', '=', '.04', ')', 'and', 'NAA', '/', 'Cho', '(', 'P', '=', '.03', ')', 'ratios', ',', 'markers', 'associated', 'with', 'neuronal', 'loss', 'or', 'dysfunction', ',', 'were', 'reduced', 'in', 'the', 'frontal', 'cortex', 'of', 'MDMA', 'users', '.', 'Neither', 'NAA', '/', 'Cr', '(', 'P', '=', '.72', ')', 'nor', 'NAA', '/', 'Cho', '(', 'P', '=', '.12', ')', 'ratios', 'were', 'different', 'between', 'both', 'groups', 'in', 'occipital', 'gray', 'matter', 'and', 'parietal', 'white', 'matter', '(', 'P', '=', '.18', ')', '.', 'Extent', 'of', 'previous', 'MDMA', 'use', 'and', 'frontal', 'cortical', 'NAA', '/', 'Cr', '(', 'ρ', '=', '-.50', ',', 'P', '=', '.012', ')', 'or', 'NAA', '/', 'Cho', '(', 'ρ', '=', '-.550', ',', 'P', '<', '.01', ')', 'ratios', 'were', 'significantly', 'associated', '.', 'CONCLUSION', ':', 'Reduced', 'NAA', '/', 'Cr', 'and', 'NAA', '/', 'Cho', 'ratios', 'at', '1H', 'MR', 'spectroscopy', 'provide', 'evidence', 'for', 'neuronal', 'abnormality', 'in', 'the', 'frontal', 'cortex', 'of', 'MDMA', 'users', ';', 'these', 'are', 'correlated', 'with', 'the', 'degree', 'of', 'MDMA', 'exposure', '.', 'These', 'data', 'suggest', 'that', 'MDMA', 'may', 'be', 'a', 'neurotoxin', 'in', 'humans', ',', 'as', 'it', 'is', 'in', 'animals', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7278,"['[CLS]', 'reduced', 'n', '-', 'acetyl', '##asp', '##art', '##ate', 'levels', 'in', 'the', 'frontal', 'cortex', 'of', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'ecs', '##tas', '##y', ')', 'users', ':', 'preliminary', 'results', '.', '^', 'background', 'and', 'purpose', ':', 'the', 'perceived', 'safety', 'of', 'the', 'recreational', 'drug', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', ')', ',', 'or', 'ecs', '##tas', '##y', ',', 'conflicts', 'with', 'animal', 'evidence', 'indicating', 'that', 'mdm', '##a', 'damages', 'cortical', 'serotonin', '(', '5', '-', 'ht', ')', 'neurons', 'at', 'doses', 'similar', 'to', 'those', 'used', 'by', 'humans', '.', 'few', 'data', 'are', 'available', 'about', 'the', 'effects', 'of', 'mdm', '##a', 'on', 'the', 'human', 'brain', '.', 'this', 'study', 'was', 'designed', 'to', 'evaluate', 'mdm', '##a', '-', 'related', 'alterations', 'in', 'metabolite', 'ratios', 'with', 'single', '-', 'voxel', 'proton', '(', '1', '##h', ')', 'mr', 'spectroscopy', '.', 'methods', ':', 'fifteen', 'male', 'mdm', '##a', 'users', '(', 'mean', 'lifetime', 'exposure', ',', '72', '##3', 'tablets', ';', 'mean', 'time', 'since', 'last', 'tablet', ',', '12', '.', '0', 'weeks', ')', 'and', '12', 'age', '-', 'matched', 'control', 'subjects', 'underwent', 'single', '-', 'voxel', '1', '##h', 'mr', 'spectroscopy', '.', 'n', '-', 'acetyl', '##asp', '##art', '##ate', '(', 'na', '##a', ')', '/', 'creatine', '(', 'cr', ')', ',', 'na', '##a', '/', 'choline', '(', 'cho', ')', ',', 'and', 'myo', '##inositol', '(', 'mi', ')', '/', 'cr', 'ratios', 'were', 'measured', 'in', 'mid', '##front', '##al', 'gray', 'matter', ',', 'mid', '##occ', '##ipital', 'gray', 'matter', ',', 'and', 'right', 'parietal', 'white', 'matter', '.', 'data', 'were', 'analyzed', 'with', 'linear', 'model', '-', 'based', 'multivariate', 'analysis', 'of', 'variance', '.', 'results', ':', 'na', '##a', '/', 'cr', '(', 'p', '=', '.', '04', ')', 'and', 'na', '##a', '/', 'cho', '(', 'p', '=', '.', '03', ')', 'ratios', ',', 'markers', 'associated', 'with', 'neuronal', 'loss', 'or', 'dysfunction', ',', 'were', 'reduced', 'in', 'the', 'frontal', 'cortex', 'of', 'mdm', '##a', 'users', '.', 'neither', 'na', '##a', '/', 'cr', '(', 'p', '=', '.', '72', ')', 'nor', 'na', '##a', '/', 'cho', '(', 'p', '=', '.', '12', ')', 'ratios', 'were', 'different', 'between', 'both', 'groups', 'in', 'occipital', 'gray', 'matter', 'and', 'parietal', 'white', 'matter', '(', 'p', '=', '.', '18', ')', '.', 'extent', 'of', 'previous', 'mdm', '##a', 'use', 'and', 'frontal', 'cortical', 'na', '##a', '/', 'cr', '(', 'ρ', '=', '-', '.', '50', ',', 'p', '=', '.', '01', '##2', ')', 'or', 'na', '##a', '/', 'cho', '(', 'ρ', '=', '-', '.', '550', ',', 'p', '<', '.', '01', ')', 'ratios', 'were', 'significantly', 'associated', '.', 'conclusion', ':', 'reduced', 'na', '##a', '/', 'cr', 'and', 'na', '##a', '/', 'cho', 'ratios', 'at', '1', '##h', 'mr', 'spectroscopy', 'provide', 'evidence', 'for', 'neuronal', 'abnormality', 'in', 'the', 'frontal', 'cortex', 'of', 'mdm', '##a', 'users', ';', 'these', 'are', 'correlated', 'with', 'the', 'degree', 'of', 'mdm', '##a', 'exposure', '.', 'these', 'data', 'suggest', 'that', 'mdm', '##a', 'may', 'be', 'a', 'neurot', '##oxin', 'in', 'humans', ',', 'as', 'it', 'is', 'in', 'animals', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 3, 4, 5, 6, 7, 8, 9, 10, 10, 10, 11, 12, 12, 12, 12, 12, 13, 14, 14, 14, 15, 16, 17, 18, 19, 19, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 32, 32, 32, 32, 33, 34, 34, 35, 36, 37, 38, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 107, 108, 109, 110, 111, 112, 113, 114, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 123, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 137, 138, 139, 140, 141, 142, 143, 143, 143, 143, 144, 145, 145, 145, 145, 145, 146, 147, 148, 149, 150, 150, 151, 152, 153, 154, 155, 156, 157, 158, 158, 159, 160, 160, 160, 160, 161, 162, 163, 164, 165, 165, 165, 166, 167, 168, 169, 169, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 194, 195, 196, 197, 198, 199, 200, 200, 201, 202, 203, 203, 204, 205, 206, 207, 208, 209, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 228, 229, 230, 231, 232, 232, 233, 234, 235, 236, 237, 238, 238, 239, 240, 241, 241, 242, 243, 244, 245, 246, 247, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 266, 267, 268, 269, 270, 271, 272, 272, 273, 274, 275, 276, 277, 277, 278, 279, 280, 281, 282, 283, 283, 283, 284, 285, 286, 287, 287, 287, 288, 289, 290, 290, 291, 292, 293, 294, 295, 296, 296, 296, 297, 298, 299, 300, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 310, 311, 312, 313, 314, 314, 315, 316, 317, 318, 319, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 342, 343, 344, 345, 346, 347, 348, 349, 349, 350, 351, 352, 353, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (ecstasy) users: Preliminary results.^
BACKGROUND AND PURPOSE: The perceived safety of the recreational drug methylenedioxymethamphetamine (MDMA), or Ecstasy, conflicts with animal evidence indicating that MDMA damages cortical serotonin (5-HT) neurons at doses similar to those used by humans. Few data are available about the effects of MDMA on the human brain. This study was designed to evaluate MDMA-related alterations in metabolite ratios with single-voxel proton (1H) MR spectroscopy. METHODS: Fifteen male MDMA users (mean lifetime exposure, 723 tablets; mean time since last tablet, 12.0 weeks) and 12 age-matched control subjects underwent single-voxel 1H MR spectroscopy. N-Acetylaspartate (NAA)/creatine (Cr), NAA/Choline (Cho), and myoinositol (MI)/Cr ratios were measured in midfrontal gray matter, midoccipital gray matter, and right parietal white matter. Data were analyzed with linear model-based multivariate analysis of variance. RESULTS: NAA/Cr (P = .04) and NAA/Cho (P = .03) ratios, markers associated with neuronal loss or dysfunction, were reduced in the frontal cortex of MDMA users. Neither NAA/Cr (P = .72) nor NAA/Cho (P = .12) ratios were different between both groups in occipital gray matter and parietal white matter (P = .18). Extent of previous MDMA use and frontal cortical NAA/Cr (ρ = -.50, P = .012) or NAA/Cho (ρ = -.550, P < .01) ratios were significantly associated. CONCLUSION: Reduced NAA/Cr and NAA/Cho ratios at 1H MR spectroscopy provide evidence for neuronal abnormality in the frontal cortex of MDMA users; these are correlated with the degree of MDMA exposure. These data suggest that MDMA may be a neurotoxin in humans, as it is in animals."
"['Potentiation', 'of', 'low', 'dose', 'ketamine', 'effects', 'by', 'naltrexone', ':', 'potential', 'implications', 'for', 'the', 'pharmacotherapy', 'of', 'alcoholism.^', '\n', 'The', 'interplay', 'of', 'opiate', 'and', 'NMDA', 'glutamate', 'receptors', 'may', 'contribute', 'to', 'psychosis', ',', 'cognitive', 'function', ',', 'alcoholism', ',', 'and', 'substance', 'dependence', '.', 'Ketamine', 'and', 'ethanol', 'block', 'the', 'NMDA', 'glutamate', 'receptor', '.', 'The', 'purpose', 'of', 'this', 'randomized', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'human', 'laboratory', 'study', 'was', 'to', 'evaluate', 'whether', 'the', 'interactive', 'effects', 'of', 'drugs', 'acting', 'at', 'opiate', 'and', 'NMDA', 'glutamate', 'receptors', 'might', 'partially', 'explain', 'the', 'efficacy', 'of', 'naltrexone', 'for', 'the', 'treatment', 'of', 'alcoholism', ',', 'that', 'is', ',', 'whether', 'naltrexone', '25', 'mg', 'pretreatment', 'would', 'modulate', 'ketamine', 'effects', 'in', 'healthy', 'human', 'subjects', '.', 'Two', 'groups', 'of', 'healthy', 'subjects', 'were', 'studied', '.', 'An', 'initial', 'group', '(', 'n=31', ')', 'received', 'a', 'perception', '-', 'altering', 'subanesthetic', 'dose', 'of', 'ketamine', '(', 'bolus', 'of', '0.23', 'mg', '/', 'kg', 'over', '1', 'min', 'followed', 'by', 'a', '60', '-', 'min', 'infusion', 'of', '0.58', 'mg', '/', 'kg', 'or', 'saline', 'bolus', 'and', 'infusion', ')', '.', 'A', 'second', 'group', '(', 'n=24', ')', 'completed', 'the', 'same', 'testing', 'procedures', ',', 'but', 'received', 'a', 'subperceptual', 'ketamine', 'dose', '(', 'bolus', '0.081', 'mg', '/', 'kg', 'over', '10', 'min', 'followed', 'by', 'an', 'infusion', 'of', '0.4', 'mg', '/', 'kg', '/', 'h', ')', '.', 'Ketamine', 'produced', 'positive', 'symptoms', ',', 'negative', 'symptoms', ',', 'emotional', 'discomfort', ',', 'and', 'cognitive', 'effects', 'as', 'measured', 'by', 'the', 'Positive', 'and', 'Negative', 'Syndrome', 'Scale', '(', 'PANSS', ')', 'in', 'a', 'dose', '-', 'related', 'fashion', '.', 'The', 'lower', 'ketamine', 'dose', 'produced', 'subjective', 'effects', 'similar', 'to', 'two', 'standard', 'ethanol', 'drinks', ',', 'whereas', 'the', 'higher', 'ketamine', 'dose', 'produced', 'effects', 'similar', 'to', 'five', 'standard', 'drinks', '.', 'Although', 'naltrexone', 'produced', 'no', 'significant', 'behavioral', 'effects', ',', 'it', 'significantly', 'magnified', 'the', 'increase', 'in', 'the', 'total', 'PANSS', 'score', 'produced', 'by', 'the', 'lower', 'subperceptual', 'dose', 'of', 'ketamine', ',', 'but', 'not', 'the', 'higher', 'perception', '-', 'altering', 'dose', 'of', 'ketamine', '.', 'These', 'data', 'suggest', 'that', 'the', 'interplay', 'of', 'opiate', 'receptor', 'antagonism', 'and', 'NMDA', 'receptor', 'antagonism', 'may', 'be', 'relevant', 'to', 'the', 'protective', 'effects', 'of', 'naltrexone', 'on', 'alcohol', 'consumption', 'via', 'potentiation', 'of', 'dysphoric', 'effects', 'associated', 'with', 'the', 'NMDA', 'receptor', 'antagonist', 'effects', 'of', 'ethanol', '.', 'However', ',', 'these', 'data', 'suggest', 'that', 'at', 'levels', 'of', 'NMDA', 'receptor', 'antagonism', 'associated', 'with', 'heavy', 'drinking', ',', 'this', 'protective', 'effect', 'of', 'naltrexone', 'on', 'drinking', 'is', 'no', 'longer', 'present', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",4581,"['[CLS]', 'potentiation', 'of', 'low', 'dose', 'ketamine', 'effects', 'by', 'nal', '##tre', '##xo', '##ne', ':', 'potential', 'implications', 'for', 'the', 'pharmac', '##otherapy', 'of', 'alcohol', '##ism', '.', '^', 'the', 'interplay', 'of', 'opi', '##ate', 'and', 'nmda', 'glutamate', 'receptors', 'may', 'contribute', 'to', 'psychosis', ',', 'cognitive', 'function', ',', 'alcohol', '##ism', ',', 'and', 'substance', 'dependence', '.', 'ketamine', 'and', 'ethanol', 'block', 'the', 'nmda', 'glutamate', 'receptor', '.', 'the', 'purpose', 'of', 'this', 'randomized', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'human', 'laboratory', 'study', 'was', 'to', 'evaluate', 'whether', 'the', 'interactive', 'effects', 'of', 'drugs', 'acting', 'at', 'opi', '##ate', 'and', 'nmda', 'glutamate', 'receptors', 'might', 'partially', 'explain', 'the', 'efficacy', 'of', 'nal', '##tre', '##xo', '##ne', 'for', 'the', 'treatment', 'of', 'alcohol', '##ism', ',', 'that', 'is', ',', 'whether', 'nal', '##tre', '##xo', '##ne', '25', 'mg', 'pretreatment', 'would', 'modulate', 'ketamine', 'effects', 'in', 'healthy', 'human', 'subjects', '.', 'two', 'groups', 'of', 'healthy', 'subjects', 'were', 'studied', '.', 'an', 'initial', 'group', '(', 'n', '=', '31', ')', 'received', 'a', 'perception', '-', 'altering', 'sub', '##anes', '##the', '##tic', 'dose', 'of', 'ketamine', '(', 'bolus', 'of', '0', '.', '23', 'mg', '/', 'kg', 'over', '1', 'min', 'followed', 'by', 'a', '60', '-', 'min', 'infusion', 'of', '0', '.', '58', 'mg', '/', 'kg', 'or', 'saline', 'bolus', 'and', 'infusion', ')', '.', 'a', 'second', 'group', '(', 'n', '=', '24', ')', 'completed', 'the', 'same', 'testing', 'procedures', ',', 'but', 'received', 'a', 'sub', '##per', '##cept', '##ual', 'ketamine', 'dose', '(', 'bolus', '0', '.', '08', '##1', 'mg', '/', 'kg', 'over', '10', 'min', 'followed', 'by', 'an', 'infusion', 'of', '0', '.', '4', 'mg', '/', 'kg', '/', 'h', ')', '.', 'ketamine', 'produced', 'positive', 'symptoms', ',', 'negative', 'symptoms', ',', 'emotional', 'discomfort', ',', 'and', 'cognitive', 'effects', 'as', 'measured', 'by', 'the', 'positive', 'and', 'negative', 'syndrome', 'scale', '(', 'pan', '##ss', ')', 'in', 'a', 'dose', '-', 'related', 'fashion', '.', 'the', 'lower', 'ketamine', 'dose', 'produced', 'subjective', 'effects', 'similar', 'to', 'two', 'standard', 'ethanol', 'drinks', ',', 'whereas', 'the', 'higher', 'ketamine', 'dose', 'produced', 'effects', 'similar', 'to', 'five', 'standard', 'drinks', '.', 'although', 'nal', '##tre', '##xo', '##ne', 'produced', 'no', 'significant', 'behavioral', 'effects', ',', 'it', 'significantly', 'magn', '##ified', 'the', 'increase', 'in', 'the', 'total', 'pan', '##ss', 'score', 'produced', 'by', 'the', 'lower', 'sub', '##per', '##cept', '##ual', 'dose', 'of', 'ketamine', ',', 'but', 'not', 'the', 'higher', 'perception', '-', 'altering', 'dose', 'of', 'ketamine', '.', 'these', 'data', 'suggest', 'that', 'the', 'interplay', 'of', 'opi', '##ate', 'receptor', 'antagonism', 'and', 'nmda', 'receptor', 'antagonism', 'may', 'be', 'relevant', 'to', 'the', 'protective', 'effects', 'of', 'nal', '##tre', '##xo', '##ne', 'on', 'alcohol', 'consumption', 'via', 'potentiation', 'of', 'dysph', '##oric', 'effects', 'associated', 'with', 'the', 'nmda', 'receptor', 'antagonist', 'effects', 'of', 'ethanol', '.', 'however', ',', 'these', 'data', 'suggest', 'that', 'at', 'levels', 'of', 'nmda', 'receptor', 'antagonism', 'associated', 'with', 'heavy', 'drinking', ',', 'this', 'protective', 'effect', 'of', 'nal', '##tre', '##xo', '##ne', 'on', 'drinking', 'is', 'no', 'longer', 'present', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 7, 7, 7, 8, 9, 10, 11, 12, 13, 13, 14, 15, 15, 15, 15, 17, 18, 19, 20, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 85, 85, 86, 87, 88, 89, 90, 90, 91, 92, 93, 94, 95, 96, 96, 96, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 121, 121, 122, 123, 124, 125, 126, 127, 128, 128, 128, 128, 129, 130, 131, 132, 133, 134, 135, 135, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 150, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 165, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 176, 176, 176, 177, 178, 179, 180, 181, 181, 181, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 193, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 262, 262, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 271, 272, 273, 274, 275, 276, 277, 277, 278, 279, 280, 281, 282, 283, 283, 283, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 321, 321, 321, 322, 323, 324, 325, 326, 327, 328, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 361, 361, 361, 362, 363, 364, 365, 366, 367, 368, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism.^
The interplay of opiate and NMDA glutamate receptors may contribute to psychosis, cognitive function, alcoholism, and substance dependence. Ketamine and ethanol block the NMDA glutamate receptor. The purpose of this randomized double-blind, placebo-controlled human laboratory study was to evaluate whether the interactive effects of drugs acting at opiate and NMDA glutamate receptors might partially explain the efficacy of naltrexone for the treatment of alcoholism, that is, whether naltrexone 25 mg pretreatment would modulate ketamine effects in healthy human subjects. Two groups of healthy subjects were studied. An initial group (n=31) received a perception-altering subanesthetic dose of ketamine (bolus of 0.23 mg/kg over 1 min followed by a 60-min infusion of 0.58 mg/kg or saline bolus and infusion). A second group (n=24) completed the same testing procedures, but received a subperceptual ketamine dose (bolus 0.081 mg/kg over 10 min followed by an infusion of 0.4 mg/kg/h). Ketamine produced positive symptoms, negative symptoms, emotional discomfort, and cognitive effects as measured by the Positive and Negative Syndrome Scale (PANSS) in a dose-related fashion. The lower ketamine dose produced subjective effects similar to two standard ethanol drinks, whereas the higher ketamine dose produced effects similar to five standard drinks. Although naltrexone produced no significant behavioral effects, it significantly magnified the increase in the total PANSS score produced by the lower subperceptual dose of ketamine, but not the higher perception-altering dose of ketamine. These data suggest that the interplay of opiate receptor antagonism and NMDA receptor antagonism may be relevant to the protective effects of naltrexone on alcohol consumption via potentiation of dysphoric effects associated with the NMDA receptor antagonist effects of ethanol. However, these data suggest that at levels of NMDA receptor antagonism associated with heavy drinking, this protective effect of naltrexone on drinking is no longer present."
"['Individual', 'differences', 'in', 'distress', ',', 'impulsivity', ',', 'and', 'coping', 'motives', 'for', 'use', 'as', 'predictors', 'of', 'problematic', 'ecstasy', 'use.^', '\n', 'Background', ':', 'Ecstasy', 'users', 'who', 'report', 'problematic', 'use', 'of', 'ecstasy', 'experience', 'adverse', 'social', ',', 'psychological', ',', 'and', 'health', '-', 'related', 'consequences', 'not', 'reported', 'by', 'non', '-', 'problem', 'users', '.', 'Relatively', 'little', 'is', 'known', 'about', 'the', 'risk', 'factors', 'for', 'the', 'development', 'of', 'problematic', 'ecstasy', 'use', '.', 'Such', 'information', 'would', 'be', 'valuable', 'for', 'targeted', 'intervention', ',', 'prevention', ',', 'and', 'education', 'Aims', ':', 'The', 'current', 'study', 'aimed', 'to', 'fill', 'this', 'gap', 'by', 'investigating', 'several', 'hypothesised', 'risk', 'factors', 'for', 'problematic', 'use', 'and', 'the', 'relationships', 'between', 'them', '.', 'Methods', ':', 'Self', '-', 'reported', 'impulsivity', ',', 'psychological', 'distress', ',', 'sex', ',', 'and', 'coping', 'motives', 'for', 'ecstasy', 'use', 'were', 'investigated', 'as', 'predictors', 'of', 'problematic', 'ecstasy', 'use', 'in', 'a', 'cross', '-', 'sectional', 'online', 'survey', '.', 'Results', ':', 'The', 'sample', 'consisted', 'of', '483', 'individuals', '(', '60.5', '%', 'male', ',', '38.3', '%', 'female', ',', '1.2', '%', 'other', ')', 'aged', '18–62', 'years', ',', 'reporting', 'ecstasy', 'use', 'on', 'an', 'average', 'of', '59.7', 'occasions', '(', 'SD', '=', '167.8', ')', '.', 'Both', 'higher', 'self', '-', 'reported', 'impulsivity', 'and', 'psychological', 'distress', 'predicted', 'problem', 'ecstasy', 'use', ',', 'and', 'both', 'these', 'relationships', 'were', 'partially', 'mediated', 'by', 'coping', 'motives', '.', 'When', 'these', 'variables', 'were', 'examined', 'in', 'a', 'combined', 'mediation', 'model', 'accounting', 'for', 'their', 'covariance', ',', 'psychological', 'distress', 'still', 'predicted', 'problematic', 'use', 'partially', 'via', 'an', 'effect', 'on', 'coping', 'motives', ',', 'while', 'impulsivity', 'showed', 'only', 'a', 'direct', 'effect', 'on', 'problem', 'use', '.', 'No', 'sex', 'differences', 'in', 'problem', 'ecstasy', 'use', 'were', 'observed', '.', 'Conclusions', ':', 'Increased', 'trait', 'impulsivity', 'and', 'psychological', 'distress', 'appear', 'to', 'confer', 'greater', 'risk', 'of', 'problematic', 'ecstasy', 'use', '.', 'Targeting', 'these', 'factors', ',', 'as', 'well', 'as', 'coping', 'motives', 'for', 'ecstasy', 'use', ',', 'may', 'be', 'useful', 'in', 'efforts', 'to', 'prevent', 'and', 'reduce', 'problematic', 'ecstasy', 'use', 'among', 'those', 'who', 'use', 'the', 'drug', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5556,"['[CLS]', 'individual', 'differences', 'in', 'distress', ',', 'impul', '##sivity', ',', 'and', 'coping', 'motives', 'for', 'use', 'as', 'predictors', 'of', 'problematic', 'ecs', '##tas', '##y', 'use', '.', '^', 'background', ':', 'ecs', '##tas', '##y', 'users', 'who', 'report', 'problematic', 'use', 'of', 'ecs', '##tas', '##y', 'experience', 'adverse', 'social', ',', 'psychological', ',', 'and', 'health', '-', 'related', 'consequences', 'not', 'reported', 'by', 'non', '-', 'problem', 'users', '.', 'relatively', 'little', 'is', 'known', 'about', 'the', 'risk', 'factors', 'for', 'the', 'development', 'of', 'problematic', 'ecs', '##tas', '##y', 'use', '.', 'such', 'information', 'would', 'be', 'valuable', 'for', 'targeted', 'intervention', ',', 'prevention', ',', 'and', 'education', 'aims', ':', 'the', 'current', 'study', 'aimed', 'to', 'fill', 'this', 'gap', 'by', 'investigating', 'several', 'hypothesis', '##ed', 'risk', 'factors', 'for', 'problematic', 'use', 'and', 'the', 'relationships', 'between', 'them', '.', 'methods', ':', 'self', '-', 'reported', 'impul', '##sivity', ',', 'psychological', 'distress', ',', 'sex', ',', 'and', 'coping', 'motives', 'for', 'ecs', '##tas', '##y', 'use', 'were', 'investigated', 'as', 'predictors', 'of', 'problematic', 'ecs', '##tas', '##y', 'use', 'in', 'a', 'cross', '-', 'sectional', 'online', 'survey', '.', 'results', ':', 'the', 'sample', 'consisted', 'of', '48', '##3', 'individuals', '(', '60', '.', '5', '%', 'male', ',', '38', '.', '3', '%', 'female', ',', '1', '.', '2', '%', 'other', ')', 'aged', '18', '–', '62', 'years', ',', 'reporting', 'ecs', '##tas', '##y', 'use', 'on', 'an', 'average', 'of', '59', '.', '7', 'occasions', '(', 'sd', '=', '167', '.', '8', ')', '.', 'both', 'higher', 'self', '-', 'reported', 'impul', '##sivity', 'and', 'psychological', 'distress', 'predicted', 'problem', 'ecs', '##tas', '##y', 'use', ',', 'and', 'both', 'these', 'relationships', 'were', 'partially', 'mediated', 'by', 'coping', 'motives', '.', 'when', 'these', 'variables', 'were', 'examined', 'in', 'a', 'combined', 'mediation', 'model', 'accounting', 'for', 'their', 'covariance', ',', 'psychological', 'distress', 'still', 'predicted', 'problematic', 'use', 'partially', 'via', 'an', 'effect', 'on', 'coping', 'motives', ',', 'while', 'impul', '##sivity', 'showed', 'only', 'a', 'direct', 'effect', 'on', 'problem', 'use', '.', 'no', 'sex', 'differences', 'in', 'problem', 'ecs', '##tas', '##y', 'use', 'were', 'observed', '.', 'conclusions', ':', 'increased', 'trait', 'impul', '##sivity', 'and', 'psychological', 'distress', 'appear', 'to', 'confer', 'greater', 'risk', 'of', 'problematic', 'ecs', '##tas', '##y', 'use', '.', 'targeting', 'these', 'factors', ',', 'as', 'well', 'as', 'coping', 'motives', 'for', 'ecs', '##tas', '##y', 'use', ',', 'may', 'be', 'useful', 'in', 'efforts', 'to', 'prevent', 'and', 'reduce', 'problematic', 'ecs', '##tas', '##y', 'use', 'among', 'those', 'who', 'use', 'the', 'drug', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 16, 16, 17, 17, 17, 19, 20, 21, 21, 21, 22, 23, 24, 25, 26, 27, 28, 28, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 61, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 118, 118, 119, 120, 121, 122, 123, 124, 125, 126, 126, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 142, 143, 144, 145, 145, 145, 146, 147, 148, 149, 149, 149, 150, 151, 152, 153, 153, 153, 154, 155, 156, 157, 158, 158, 158, 159, 160, 161, 162, 162, 162, 163, 164, 165, 166, 167, 168, 168, 168, 169, 170, 171, 172, 173, 173, 173, 174, 175, 176, 177, 178, 179, 180, 181, 181, 182, 183, 184, 185, 186, 187, 187, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 246, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 266, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 279, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 292, 292, 293, 294, 295, 296, 297, 298, 299, 300, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Individual differences in distress, impulsivity, and coping motives for use as predictors of problematic ecstasy use.^
Background: Ecstasy users who report problematic use of ecstasy experience adverse social, psychological, and health-related consequences not reported by non-problem users. Relatively little is known about the risk factors for the development of problematic ecstasy use. Such information would be valuable for targeted intervention, prevention, and education Aims: The current study aimed to fill this gap by investigating several hypothesised risk factors for problematic use and the relationships between them. Methods: Self-reported impulsivity, psychological distress, sex, and coping motives for ecstasy use were investigated as predictors of problematic ecstasy use in a cross-sectional online survey. Results: The sample consisted of 483 individuals (60.5% male, 38.3% female, 1.2% other) aged 18–62 years, reporting ecstasy use on an average of 59.7 occasions (SD = 167.8). Both higher self-reported impulsivity and psychological distress predicted problem ecstasy use, and both these relationships were partially mediated by coping motives. When these variables were examined in a combined mediation model accounting for their covariance, psychological distress still predicted problematic use partially via an effect on coping motives, while impulsivity showed only a direct effect on problem use. No sex differences in problem ecstasy use were observed. Conclusions: Increased trait impulsivity and psychological distress appear to confer greater risk of problematic ecstasy use. Targeting these factors, as well as coping motives for ecstasy use, may be useful in efforts to prevent and reduce problematic ecstasy use among those who use the drug."
"['Longitudinal', 'Course', 'of', 'Adverse', 'Events', 'With', 'Esketamine', 'Nasal', 'Spray', ':', 'A', 'Post', 'Hoc', 'Analysis', 'of', 'Pooled', 'Data', 'From', 'Phase', '3', 'Trials', 'in', 'Patients', 'With', 'Treatment', '-', 'Resistant', 'Depression.^', '\n', 'Objective', ':', 'To', 'describe', 'the', 'tolerability', 'of', 'esketamine', 'nasal', 'spray', 'based', 'on', 'the', 'adverse', 'event', 'profile', 'observed', 'during', 'treatment', 'sessions', 'occurring', 'early', 'and', 'later', 'over', 'the', 'course', 'of', 'treatment', '.', 'Methods', ':', 'In', '2', 'long', '-', 'term', ',', 'phase', '3', 'studies', '(', 'NCT02493868', ',', 'October', '1', ',', '2015', '-', 'February', '16', ',', '2018', ';', 'NCT02497287', ',', 'September', '30', ',', '2015', '-', 'October', '28', ',', '2017', ')', ',', 'patients', 'with', 'treatment', '-', 'resistant', 'major', 'depressive', 'disorder', '(', 'per', 'DSM-5', ')', 'and', 'nonresponse', 'to', '≥', '2', 'oral', 'antidepressants', 'received', 'esketamine', 'nasal', 'spray', '(', '56', 'or', '84', 'mg', ')', 'twice', 'weekly', 'during', 'a', '4', '-', 'week', 'induction', 'phase', ',', 'weekly', 'for', 'weeks', '5', '-', '8', ',', 'and', 'weekly', 'or', 'every', '2', 'weeks', 'thereafter', 'as', 'maintenance', 'treatment', ',', 'in', 'conjunction', 'with', 'a', 'new', 'oral', 'antidepressant', '.', 'A', 'post', 'hoc', 'analysis', 'using', 'descriptive', 'statistics', 'evaluated', 'occurrence', '(', 'incidence', ',', 'frequency', ',', 'severity', ')', 'and', 'recurrence', '(', 'incidence', 'and', 'severity', ')', 'of', 'events', 'of', 'specific', 'interest', '.', 'Results', ':', 'In', 'patients', 'treated', 'with', 'esketamine', 'nasal', 'spray', 'plus', 'a', 'newly', 'initiated', 'oral', 'antidepressant', '(', 'n', '=', '928', ')', ',', 'spontaneously', 'reported', 'adverse', 'events', 'of', 'dizziness', ',', 'nausea', ',', 'sedation', ',', 'vertigo', ',', 'and', 'increased', 'blood', 'pressure', 'were', 'more', 'likely', 'to', 'recur', 'after', 'the', 'first', 'week', 'of', 'treatment', 'if', 'they', 'occurred', 'more', 'frequently', '(', 'twice', '>', 'once', '>', 'none', ')', 'during', 'the', 'first', 'week', '.', 'The', 'same', 'pattern', 'was', 'observed', 'when', 'these', 'events', 'were', 'assessed', 'by', 'structured', 'instruments', '.', 'Incidences', 'of', 'dizziness', ',', 'dissociation', ',', 'increased', 'blood', 'pressure', ',', 'nausea', ',', 'vertigo', ',', 'and', 'sedation', 'were', 'highest', 'in', 'week', '1', 'of', 'treatment', '(', '20.6', '%', ',', '16.7', '%', ',', '4.3', '%', ',', '14.0', '%', ',', '12.1', '%', ',', 'and', '3.8', '%', ',', 'respectively', ')', 'and', 'decreased', 'thereafter', '.', 'Initial', 'occurrences', 'and', 'subsequent', 'recurrences', 'of', 'events', 'were', 'mostly', 'mild', 'or', 'moderate', 'in', 'severity', '.', 'Conclusions', ':', 'Adverse', 'events', 'during', 'treatment', 'with', 'esketamine', 'nasal', 'spray', 'plus', 'an', 'oral', 'antidepressant', 'generally', 'become', 'less', 'frequent', 'with', 'ongoing', 'treatment', ',', 'and', 'the', 'majority', 'are', 'mild', 'or', 'moderate', 'in', 'severity', '.', 'Trial', 'Registration', ':', 'ClinicalTrials.gov', 'identifiers', ':', 'NCT02493868', ';', 'NCT02497287', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",9198,"['[CLS]', 'longitudinal', 'course', 'of', 'adverse', 'events', 'with', 'es', '##ket', '##amine', 'nasal', 'spray', ':', 'a', 'post', 'hoc', 'analysis', 'of', 'pooled', 'data', 'from', 'phase', '3', 'trials', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '.', '^', 'objective', ':', 'to', 'describe', 'the', 'tolerability', 'of', 'es', '##ket', '##amine', 'nasal', 'spray', 'based', 'on', 'the', 'adverse', 'event', 'profile', 'observed', 'during', 'treatment', 'sessions', 'occurring', 'early', 'and', 'later', 'over', 'the', 'course', 'of', 'treatment', '.', 'methods', ':', 'in', '2', 'long', '-', 'term', ',', 'phase', '3', 'studies', '(', 'nct', '##02', '##49', '##386', '##8', ',', 'october', '1', ',', '2015', '-', 'february', '16', ',', '2018', ';', 'nct', '##02', '##49', '##72', '##87', ',', 'september', '30', ',', '2015', '-', 'october', '28', ',', '2017', ')', ',', 'patients', 'with', 'treatment', '-', 'resistant', 'major', 'depressive', 'disorder', '(', 'per', 'dsm', '-', '5', ')', 'and', 'non', '##response', 'to', '≥', '2', 'oral', 'antidepressants', 'received', 'es', '##ket', '##amine', 'nasal', 'spray', '(', '56', 'or', '84', 'mg', ')', 'twice', 'weekly', 'during', 'a', '4', '-', 'week', 'induction', 'phase', ',', 'weekly', 'for', 'weeks', '5', '-', '8', ',', 'and', 'weekly', 'or', 'every', '2', 'weeks', 'thereafter', 'as', 'maintenance', 'treatment', ',', 'in', 'conjunction', 'with', 'a', 'new', 'oral', 'antidepressant', '.', 'a', 'post', 'hoc', 'analysis', 'using', 'descriptive', 'statistics', 'evaluated', 'occurrence', '(', 'incidence', ',', 'frequency', ',', 'severity', ')', 'and', 'recurrence', '(', 'incidence', 'and', 'severity', ')', 'of', 'events', 'of', 'specific', 'interest', '.', 'results', ':', 'in', 'patients', 'treated', 'with', 'es', '##ket', '##amine', 'nasal', 'spray', 'plus', 'a', 'newly', 'initiated', 'oral', 'antidepressant', '(', 'n', '=', '92', '##8', ')', ',', 'spontaneously', 'reported', 'adverse', 'events', 'of', 'di', '##zz', '##iness', ',', 'nausea', ',', 'sedation', ',', 'ver', '##tig', '##o', ',', 'and', 'increased', 'blood', 'pressure', 'were', 'more', 'likely', 'to', 'recur', 'after', 'the', 'first', 'week', 'of', 'treatment', 'if', 'they', 'occurred', 'more', 'frequently', '(', 'twice', '>', 'once', '>', 'none', ')', 'during', 'the', 'first', 'week', '.', 'the', 'same', 'pattern', 'was', 'observed', 'when', 'these', 'events', 'were', 'assessed', 'by', 'structured', 'instruments', '.', 'incidence', '##s', 'of', 'di', '##zz', '##iness', ',', 'dissociation', ',', 'increased', 'blood', 'pressure', ',', 'nausea', ',', 'ver', '##tig', '##o', ',', 'and', 'sedation', 'were', 'highest', 'in', 'week', '1', 'of', 'treatment', '(', '20', '.', '6', '%', ',', '16', '.', '7', '%', ',', '4', '.', '3', '%', ',', '14', '.', '0', '%', ',', '12', '.', '1', '%', ',', 'and', '3', '.', '8', '%', ',', 'respectively', ')', 'and', 'decreased', 'thereafter', '.', 'initial', 'occurrences', 'and', 'subsequent', 'recurrences', 'of', 'events', 'were', 'mostly', 'mild', 'or', 'moderate', 'in', 'severity', '.', 'conclusions', ':', 'adverse', 'events', 'during', 'treatment', 'with', 'es', '##ket', '##amine', 'nasal', 'spray', 'plus', 'an', 'oral', 'antidepressant', 'generally', 'become', 'less', 'frequent', 'with', 'ongoing', 'treatment', ',', 'and', 'the', 'majority', 'are', 'mild', 'or', 'moderate', 'in', 'severity', '.', 'trial', 'registration', ':', 'clinical', '##trials', '.', 'go', '##v', 'identifiers', ':', 'nct', '##02', '##49', '##386', '##8', ';', 'nct', '##02', '##49', '##72', '##87', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 6, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 27, 27, 29, 30, 31, 32, 33, 34, 35, 36, 36, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 71, 71, 71, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 83, 83, 83, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 106, 106, 107, 108, 109, 109, 110, 111, 112, 113, 114, 115, 116, 116, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 196, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 208, 209, 210, 211, 212, 213, 214, 215, 216, 216, 216, 217, 218, 219, 220, 221, 222, 222, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 270, 271, 272, 272, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 282, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 294, 294, 295, 296, 297, 297, 297, 298, 299, 300, 300, 300, 301, 302, 303, 303, 303, 304, 305, 306, 306, 306, 307, 308, 309, 310, 310, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 341, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 369, 369, 369, 369, 370, 371, 372, 372, 372, 372, 372, 373, 374, 374, 374, 374, 374, 375, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.^
Objective: To describe the tolerability of esketamine nasal spray based on the adverse event profile observed during treatment sessions occurring early and later over the course of treatment. Methods: In 2 long-term, phase 3 studies (NCT02493868, October 1, 2015-February 16, 2018; NCT02497287, September 30, 2015-October 28, 2017), patients with treatment-resistant major depressive disorder (per DSM-5) and nonresponse to ≥ 2 oral antidepressants received esketamine nasal spray (56 or 84 mg) twice weekly during a 4-week induction phase, weekly for weeks 5-8, and weekly or every 2 weeks thereafter as maintenance treatment, in conjunction with a new oral antidepressant. A post hoc analysis using descriptive statistics evaluated occurrence (incidence, frequency, severity) and recurrence (incidence and severity) of events of specific interest. Results: In patients treated with esketamine nasal spray plus a newly initiated oral antidepressant (n = 928), spontaneously reported adverse events of dizziness, nausea, sedation, vertigo, and increased blood pressure were more likely to recur after the first week of treatment if they occurred more frequently (twice > once > none) during the first week. The same pattern was observed when these events were assessed by structured instruments. Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment (20.6%, 16.7%, 4.3%, 14.0%, 12.1%, and 3.8%, respectively) and decreased thereafter. Initial occurrences and subsequent recurrences of events were mostly mild or moderate in severity. Conclusions: Adverse events during treatment with esketamine nasal spray plus an oral antidepressant generally become less frequent with ongoing treatment, and the majority are mild or moderate in severity. Trial Registration: ClinicalTrials.gov identifiers: NCT02493868; NCT02497287."
"['Effects', 'of', 'ayahuasca', 'on', 'the', 'endocannabinoid', 'system', 'of', 'healthy', 'volunteers', 'and', 'in', 'volunteers', 'with', 'social', 'anxiety', 'disorder', ':', 'Results', 'from', 'two', 'pilot', ',', 'proof', '-', 'of', '-', 'concept', ',', 'randomized', ',', 'placebo', '-', 'controlled', 'trials.^', '\n', 'OBJECTIVE', ':', 'To', 'assess', 'endocannabinoid', '(', 'anandamide', ',', 'AEA', ';', '2', '-', 'arachidonoylglycerol', ',', '2', '-', 'AG', ')', 'plasma', 'levels', 'in', 'healthy', 'volunteers', 'and', 'in', 'volunteers', 'with', 'social', 'anxiety', 'disorder', '(', 'SAD', ')', 'after', 'a', 'single', 'oral', 'dose', 'of', 'ayahuasca', 'or', 'placebo', '.', 'METHODS', ':', 'Post', 'hoc', 'analysis', 'of', 'endocannabinoid', 'plasma', 'levels', '(', 'baseline', ',', '90', 'and', '240', 'min', 'after', 'drug', 'intake', ')', 'from', 'two', 'parallel', '-', 'group', ',', 'randomized', ',', 'placebo', '-', 'controlled', 'trials', '.', 'In', 'Study', '1', ',', '20', 'healthy', 'volunteers', 'ingested', 'ayahuasca', '(', 'average', '1.58', 'mg', '/', 'ml', 'dimethyltryptamine', '(', 'DMT', ')', ')', 'or', 'placebo', ',', 'and', 'in', 'Study', '2', ',', '17', 'volunteers', 'with', 'SAD', 'received', 'ayahuasca', '(', 'average', '0.680', 'mg', '/', 'ml', 'DMT', ')', 'or', 'placebo', '.', 'RESULTS', ':', 'A', 'significant', 'difference', 'was', 'observed', 'in', 'AEA', 'concentrations', 'in', 'Study', '2', 'after', 'ayahuasca', 'intake', '(', 'Χ(2', ')', '(', '2', ')', '=', '6.5', ',', 'p', '=', '0.03', ',', 'Friedman', 'test', ')', ',', 'and', 'near', 'significant', 'differences', '(', 'increases', ')', 'were', 'observed', 'between', 'baseline', 'and', '90', '(', 'Z', '=', '0', ',', 'p', '=', '0.06', ',', 'Wilcoxon', 'test', ')', 'and', '240', '(', 'Z', '=', '10', ',', 'p', '=', '0.06', ')', 'minutes', 'after', 'ayahuasca', 'intake', '.', 'CONCLUSIONS', ':', 'Although', 'our', 'findings', 'suggest', 'that', 'ayahuasca', 'could', 'modulate', 'AEA', 'levels', 'in', 'SAD', 'patients', ',', 'the', 'high', 'interindividual', 'variability', 'in', 'both', 'trials', 'and', 'the', 'small', 'samples', 'preclude', 'definitive', 'conclusions', '.', 'More', 'research', 'with', 'larger', 'samples', 'is', 'needed', 'to', 'better', 'understand', 'the', 'effects', 'of', 'ayahuasca', 'and', 'other', 'hallucinogens', 'in', 'the', 'endocannabinoid', 'system', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",2153,"['[CLS]', 'effects', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'on', 'the', 'endo', '##can', '##na', '##bin', '##oid', 'system', 'of', 'healthy', 'volunteers', 'and', 'in', 'volunteers', 'with', 'social', 'anxiety', 'disorder', ':', 'results', 'from', 'two', 'pilot', ',', 'proof', '-', 'of', '-', 'concept', ',', 'randomized', ',', 'placebo', '-', 'controlled', 'trials', '.', '^', 'objective', ':', 'to', 'assess', 'endo', '##can', '##na', '##bin', '##oid', '(', 'ana', '##nd', '##amide', ',', 'ae', '##a', ';', '2', '-', 'arachid', '##ono', '##yl', '##glycerol', ',', '2', '-', 'ag', ')', 'plasma', 'levels', 'in', 'healthy', 'volunteers', 'and', 'in', 'volunteers', 'with', 'social', 'anxiety', 'disorder', '(', 'sad', ')', 'after', 'a', 'single', 'oral', 'dose', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'or', 'placebo', '.', 'methods', ':', 'post', 'hoc', 'analysis', 'of', 'endo', '##can', '##na', '##bin', '##oid', 'plasma', 'levels', '(', 'baseline', ',', '90', 'and', '240', 'min', 'after', 'drug', 'intake', ')', 'from', 'two', 'parallel', '-', 'group', ',', 'randomized', ',', 'placebo', '-', 'controlled', 'trials', '.', 'in', 'study', '1', ',', '20', 'healthy', 'volunteers', 'ingested', 'ay', '##ah', '##ua', '##sc', '##a', '(', 'average', '1', '.', '58', 'mg', '/', 'ml', 'dimethyl', '##try', '##pt', '##amine', '(', 'dm', '##t', ')', ')', 'or', 'placebo', ',', 'and', 'in', 'study', '2', ',', '17', 'volunteers', 'with', 'sad', 'received', 'ay', '##ah', '##ua', '##sc', '##a', '(', 'average', '0', '.', '68', '##0', 'mg', '/', 'ml', 'dm', '##t', ')', 'or', 'placebo', '.', 'results', ':', 'a', 'significant', 'difference', 'was', 'observed', 'in', 'ae', '##a', 'concentrations', 'in', 'study', '2', 'after', 'ay', '##ah', '##ua', '##sc', '##a', 'intake', '(', 'χ', '(', '2', ')', '(', '2', ')', '=', '6', '.', '5', ',', 'p', '=', '0', '.', '03', ',', 'friedman', 'test', ')', ',', 'and', 'near', 'significant', 'differences', '(', 'increases', ')', 'were', 'observed', 'between', 'baseline', 'and', '90', '(', 'z', '=', '0', ',', 'p', '=', '0', '.', '06', ',', 'wilcoxon', 'test', ')', 'and', '240', '(', 'z', '=', '10', ',', 'p', '=', '0', '.', '06', ')', 'minutes', 'after', 'ay', '##ah', '##ua', '##sc', '##a', 'intake', '.', 'conclusions', ':', 'although', 'our', 'findings', 'suggest', 'that', 'ay', '##ah', '##ua', '##sc', '##a', 'could', 'modulate', 'ae', '##a', 'levels', 'in', 'sad', 'patients', ',', 'the', 'high', 'inter', '##individual', 'variability', 'in', 'both', 'trials', 'and', 'the', 'small', 'samples', 'preclude', 'definitive', 'conclusions', '.', 'more', 'research', 'with', 'larger', 'samples', 'is', 'needed', 'to', 'better', 'understand', 'the', 'effects', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'and', 'other', 'halluc', '##ino', '##gens', 'in', 'the', 'endo', '##can', '##na', '##bin', '##oid', 'system', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 2, 2, 2, 2, 3, 4, 5, 5, 5, 5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 34, 34, 36, 37, 38, 39, 40, 40, 40, 40, 40, 41, 42, 42, 42, 43, 44, 44, 45, 46, 47, 48, 48, 48, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 75, 75, 75, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 85, 85, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 120, 120, 120, 120, 121, 122, 123, 123, 123, 124, 125, 126, 127, 127, 127, 127, 128, 129, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 145, 145, 145, 145, 146, 147, 148, 148, 148, 148, 149, 150, 151, 152, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 165, 166, 167, 168, 169, 170, 171, 171, 171, 171, 171, 172, 173, 174, 174, 174, 175, 176, 177, 178, 179, 180, 180, 180, 181, 182, 183, 184, 184, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 210, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 224, 224, 225, 226, 227, 228, 228, 228, 228, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 238, 238, 238, 238, 239, 240, 241, 241, 242, 243, 244, 245, 246, 247, 248, 249, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 275, 275, 275, 275, 276, 277, 278, 278, 278, 279, 280, 281, 281, 281, 281, 281, 282, 283, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials.^
OBJECTIVE: To assess endocannabinoid (anandamide, AEA; 2-arachidonoylglycerol, 2-AG) plasma levels in healthy volunteers and in volunteers with social anxiety disorder (SAD) after a single oral dose of ayahuasca or placebo. METHODS: Post hoc analysis of endocannabinoid plasma levels (baseline, 90 and 240 min after drug intake) from two parallel-group, randomized, placebo-controlled trials. In Study 1, 20 healthy volunteers ingested ayahuasca (average 1.58 mg/ml dimethyltryptamine (DMT)) or placebo, and in Study 2, 17 volunteers with SAD received ayahuasca (average 0.680 mg/ml DMT) or placebo. RESULTS: A significant difference was observed in AEA concentrations in Study 2 after ayahuasca intake (Χ(2) (2) = 6.5, p = 0.03, Friedman test), and near significant differences (increases) were observed between baseline and 90 (Z = 0, p = 0.06, Wilcoxon test) and 240 (Z = 10, p = 0.06) minutes after ayahuasca intake. CONCLUSIONS: Although our findings suggest that ayahuasca could modulate AEA levels in SAD patients, the high interindividual variability in both trials and the small samples preclude definitive conclusions. More research with larger samples is needed to better understand the effects of ayahuasca and other hallucinogens in the endocannabinoid system."
"['Gray', 'matter', 'volume', 'of', 'rostral', 'anterior', 'cingulate', 'cortex', 'predicts', 'rapid', 'antidepressant', 'response', 'to', 'ketamine.^', '\n', 'Ketamine', 'was', 'recently', 'approved', 'for', 'treatment', 'resistant', 'depression', '.', 'However', ',', 'despite', 'its', 'therapeutic', 'potential', ',', 'about', '50', '%', 'of', 'patients', 'do', 'not', 'show', 'improvement', 'under', 'this', 'therapy', '.', 'In', 'this', 'prospective', 'two', '-', 'site', 'study', ',', 'we', 'investigated', 'baseline', 'brain', 'structural', 'predictors', 'for', 'rapid', 'symptom', 'improvement', 'after', 'a', 'single', 'subanesthetic', 'ketamine', 'infusion', '.', 'Furthermore', ',', 'given', 'the', 'preclinical', 'evidence', 'and', 'findings', 'from', 'a', 'pilot', 'study', 'in', 'a', 'clinical', 'population', 'that', 'ketamine', 'induces', 'rapid', 'neuroplasticity', ',', 'we', 'performed', 'an', 'exploratory', 'investigation', 'of', 'macroscopic', 'changes', '24', 'h', 'post', '-', 'treatment', '.', 'T1', '-', 'weighted', 'MRI', 'brain', 'images', 'from', '33', 'depressed', 'patients', 'were', 'acquired', 'before', 'and', '24', 'h', 'after', 'a', 'single', 'ketamine', 'infusion', 'and', 'analyzed', 'using', 'voxel', '-', 'based', 'morphometry', '(', 'VBM', ')', '.', 'Additionally', ',', 'we', 'performed', 'a', 'region', 'of', 'interest', '(', 'ROI)-based', 'analysis', 'of', 'structures', 'that', 'have', 'previously', 'been', 'shown', 'to', 'play', 'a', 'role', 'in', 'the', 'antidepressant', 'effects', 'of', 'ketamine', ':', 'bilateral', 'hippocampus', ',', 'nucleus', 'accumbens', ',', 'anterior', 'cingulate', 'cortex', ',', 'and', 'thalamus', '.', 'A', 'whole', '-', 'brain', 'regression', 'analysis', 'showed', 'that', 'greater', 'baseline', 'volume', 'of', 'the', 'bilateral', 'rostral', 'anterior', 'cingulate', 'cortex', '(', 'rACC', ')', 'significantly', 'predicts', 'rapid', 'symptom', 'reduction', '.', 'The', 'right', 'ACC', 'showed', 'the', 'same', 'association', 'in', 'the', 'ROI', 'analysis', ',', 'while', 'the', 'other', 'regions', 'yielded', 'no', 'significant', 'results', '.', 'Exploratory', 'follow', '-', 'up', 'analyses', 'revealed', 'no', 'volumetric', 'changes', '24', 'h', 'after', 'treatment', '.', 'This', 'is', 'the', 'first', 'study', 'reporting', 'an', 'association', 'between', 'pretreatment', 'gray', 'matter', 'volume', 'of', 'the', 'bilateral', 'rACC', 'and', 'the', 'rapid', 'antidepressant', 'effects', 'of', 'ketamine', '.', 'Results', 'are', 'in', 'line', 'with', 'previous', 'investigations', ',', 'which', 'highlighted', 'the', 'potential', 'of', 'the', 'rACC', 'as', 'a', 'biomarker', 'for', 'response', 'prediction', 'to', 'different', 'antidepressant', 'treatments', '.', 'Ketamine', '-', 'induced', 'volumetric', 'changes', 'may', 'be', 'seen', 'at', 'later', 'time', 'points', '.', '(', 'PsycInfo', 'Database', 'Record', '(', 'c', ')', '2021', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3537,"['[CLS]', 'gray', 'matter', 'volume', 'of', 'rostral', 'anterior', 'cingulate', 'cortex', 'predicts', 'rapid', 'antidepressant', 'response', 'to', 'ketamine', '.', '^', 'ketamine', 'was', 'recently', 'approved', 'for', 'treatment', 'resistant', 'depression', '.', 'however', ',', 'despite', 'its', 'therapeutic', 'potential', ',', 'about', '50', '%', 'of', 'patients', 'do', 'not', 'show', 'improvement', 'under', 'this', 'therapy', '.', 'in', 'this', 'prospective', 'two', '-', 'site', 'study', ',', 'we', 'investigated', 'baseline', 'brain', 'structural', 'predictors', 'for', 'rapid', 'symptom', 'improvement', 'after', 'a', 'single', 'sub', '##anes', '##the', '##tic', 'ketamine', 'infusion', '.', 'furthermore', ',', 'given', 'the', 'preclinical', 'evidence', 'and', 'findings', 'from', 'a', 'pilot', 'study', 'in', 'a', 'clinical', 'population', 'that', 'ketamine', 'induces', 'rapid', 'neurop', '##last', '##icity', ',', 'we', 'performed', 'an', 'exploratory', 'investigation', 'of', 'macroscopic', 'changes', '24', 'h', 'post', '-', 'treatment', '.', 't', '##1', '-', 'weighted', 'mri', 'brain', 'images', 'from', '33', 'depressed', 'patients', 'were', 'acquired', 'before', 'and', '24', 'h', 'after', 'a', 'single', 'ketamine', 'infusion', 'and', 'analyzed', 'using', 'voxel', '-', 'based', 'morph', '##ometry', '(', 'vb', '##m', ')', '.', 'additionally', ',', 'we', 'performed', 'a', 'region', 'of', 'interest', '(', 'roi', ')', '-', 'based', 'analysis', 'of', 'structures', 'that', 'have', 'previously', 'been', 'shown', 'to', 'play', 'a', 'role', 'in', 'the', 'antidepressant', 'effects', 'of', 'ketamine', ':', 'bilateral', 'hippocampus', ',', 'nucleus', 'accum', '##bens', ',', 'anterior', 'cingulate', 'cortex', ',', 'and', 'thalamus', '.', 'a', 'whole', '-', 'brain', 'regression', 'analysis', 'showed', 'that', 'greater', 'baseline', 'volume', 'of', 'the', 'bilateral', 'rostral', 'anterior', 'cingulate', 'cortex', '(', 'rac', '##c', ')', 'significantly', 'predicts', 'rapid', 'symptom', 'reduction', '.', 'the', 'right', 'acc', 'showed', 'the', 'same', 'association', 'in', 'the', 'roi', 'analysis', ',', 'while', 'the', 'other', 'regions', 'yielded', 'no', 'significant', 'results', '.', 'exploratory', 'follow', '-', 'up', 'analyses', 'revealed', 'no', 'volumetric', 'changes', '24', 'h', 'after', 'treatment', '.', 'this', 'is', 'the', 'first', 'study', 'reporting', 'an', 'association', 'between', 'pretreatment', 'gray', 'matter', 'volume', 'of', 'the', 'bilateral', 'rac', '##c', 'and', 'the', 'rapid', 'antidepressant', 'effects', 'of', 'ketamine', '.', 'results', 'are', 'in', 'line', 'with', 'previous', 'investigations', ',', 'which', 'highlighted', 'the', 'potential', 'of', 'the', 'rac', '##c', 'as', 'a', 'biomarker', 'for', 'response', 'prediction', 'to', 'different', 'antidepressant', 'treatments', '.', 'ketamine', '-', 'induced', 'volumetric', 'changes', 'may', 'be', 'seen', 'at', 'later', 'time', 'points', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '202', '##1', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 13, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 65, 65, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 89, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 132, 133, 134, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 146, 146, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 306, 306, 307, 308, 309, 310, 311, 312, 312, 313, 313, 314, 315, 316, 317, 318, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Gray matter volume of rostral anterior cingulate cortex predicts rapid antidepressant response to ketamine.^
Ketamine was recently approved for treatment resistant depression. However, despite its therapeutic potential, about 50% of patients do not show improvement under this therapy. In this prospective two-site study, we investigated baseline brain structural predictors for rapid symptom improvement after a single subanesthetic ketamine infusion. Furthermore, given the preclinical evidence and findings from a pilot study in a clinical population that ketamine induces rapid neuroplasticity, we performed an exploratory investigation of macroscopic changes 24 h post-treatment. T1-weighted MRI brain images from 33 depressed patients were acquired before and 24 h after a single ketamine infusion and analyzed using voxel-based morphometry (VBM). Additionally, we performed a region of interest (ROI)-based analysis of structures that have previously been shown to play a role in the antidepressant effects of ketamine: bilateral hippocampus, nucleus accumbens, anterior cingulate cortex, and thalamus. A whole-brain regression analysis showed that greater baseline volume of the bilateral rostral anterior cingulate cortex (rACC) significantly predicts rapid symptom reduction. The right ACC showed the same association in the ROI analysis, while the other regions yielded no significant results. Exploratory follow-up analyses revealed no volumetric changes 24 h after treatment. This is the first study reporting an association between pretreatment gray matter volume of the bilateral rACC and the rapid antidepressant effects of ketamine. Results are in line with previous investigations, which highlighted the potential of the rACC as a biomarker for response prediction to different antidepressant treatments. Ketamine-induced volumetric changes may be seen at later time points. (PsycInfo Database Record (c) 2021 APA, all rights reserved)"
"['Sub', '-', 'acute', 'and', 'long', '-', 'term', 'effects', 'of', 'ayahuasca', 'on', 'affect', 'and', 'cognitive', 'thinking', 'style', 'and', 'their', 'association', 'with', 'ego', 'dissolution.^', '\n', 'RATIONALE', ':', 'Ayahuasca', 'is', 'a', 'psychotropic', 'plant', 'tea', 'from', 'South', 'America', 'used', 'for', 'religious', 'purposes', 'by', 'indigenous', 'people', 'of', 'the', 'Amazon', '.', 'Increasing', 'evidence', 'indicates', 'that', 'ayahuasca', 'may', 'have', 'therapeutic', 'potential', 'in', 'the', 'treatment', 'of', 'mental', 'health', 'disorders', 'and', 'can', 'enhance', 'mindfulness', '-', 'related', 'capacities', '.', 'Most', 'research', 'so', 'far', 'has', 'focused', 'on', 'acute', 'and', 'sub', '-', 'acute', 'effects', 'of', 'ayahuasca', 'on', 'mental', 'health', '-', 'related', 'parameters', 'and', 'less', 'on', 'long', '-', 'term', 'effects', '.', 'OBJECTIVES', ':', 'The', 'present', 'study', 'aimed', 'to', 'assess', 'sub', '-', 'acute', 'and', 'long', '-', 'term', 'effects', 'of', 'ayahuasca', 'on', 'well', '-', 'being', 'and', 'cognitive', 'thinking', 'style', '.', 'The', 'second', 'objective', 'was', 'to', 'assess', 'whether', 'sub', '-', 'acute', 'and', 'long', '-', 'term', 'effects', 'of', 'ayahuasca', 'depend', 'on', 'the', 'degree', 'of', 'ego', 'dissolution', 'that', 'was', 'experienced', 'after', 'consumption', 'of', 'ayahuasca', '.', 'RESULTS', ':', 'Ayahuasca', 'ceremony', 'attendants', '(', 'N', '=', '57', ')', 'in', 'the', 'Netherlands', 'and', 'Colombia', 'were', 'assessed', 'before', ',', 'the', 'day', 'after', ',', 'and', '4', 'weeks', 'following', 'the', 'ritual', '.', 'Relative', 'to', 'baseline', ',', 'ratings', 'of', 'depression', 'and', 'stress', 'significantly', 'decreased', 'after', 'the', 'ayahuasca', 'ceremony', 'and', 'these', 'changes', 'persisted', 'for', '4', 'weeks', '.', 'Likewise', ',', 'convergent', 'thinking', 'improved', 'post', '-', 'ayahuasca', 'ceremony', 'up', 'until', 'the', '4', 'weeks', 'follow', '-', 'up', '.', 'Satisfaction', 'with', 'life', 'and', 'several', 'aspects', 'of', 'mindfulness', 'increased', 'the', 'day', 'after', 'the', 'ceremony', ',', 'but', 'these', 'changes', 'failed', 'to', 'reach', 'significance', '4', 'weeks', 'after', '.', 'Changes', 'in', 'affect', ',', 'satisfaction', 'with', 'life', ',', 'and', 'mindfulness', 'were', 'significantly', 'correlated', 'to', 'the', 'level', 'of', 'ego', 'dissolution', 'experienced', 'during', 'the', 'ayahuasca', 'ceremony', 'and', 'were', 'unrelated', 'to', 'previous', 'experience', 'with', 'ayahuasca', '.', 'CONCLUSION', ':', 'It', 'is', 'concluded', 'that', 'ayahuasca', 'produces', 'sub', '-', 'acute', 'and', 'long', '-', 'term', 'improvements', 'in', 'affect', 'and', 'cognitive', 'thinking', 'style', 'in', 'non', '-', 'pathological', 'users', '.', 'These', 'data', 'highlight', 'the', 'therapeutic', 'potential', 'of', 'ayahuasca', 'in', 'the', 'treatment', 'of', 'mental', 'health', 'disorders', ',', 'such', 'as', 'depression', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8682,"['[CLS]', 'sub', '-', 'acute', 'and', 'long', '-', 'term', 'effects', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'on', 'affect', 'and', 'cognitive', 'thinking', 'style', 'and', 'their', 'association', 'with', 'ego', 'dissolution', '.', '^', 'rationale', ':', 'ay', '##ah', '##ua', '##sc', '##a', 'is', 'a', 'psycho', '##tro', '##pic', 'plant', 'tea', 'from', 'south', 'america', 'used', 'for', 'religious', 'purposes', 'by', 'indigenous', 'people', 'of', 'the', 'amazon', '.', 'increasing', 'evidence', 'indicates', 'that', 'ay', '##ah', '##ua', '##sc', '##a', 'may', 'have', 'therapeutic', 'potential', 'in', 'the', 'treatment', 'of', 'mental', 'health', 'disorders', 'and', 'can', 'enhance', 'mind', '##fulness', '-', 'related', 'capacities', '.', 'most', 'research', 'so', 'far', 'has', 'focused', 'on', 'acute', 'and', 'sub', '-', 'acute', 'effects', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'on', 'mental', 'health', '-', 'related', 'parameters', 'and', 'less', 'on', 'long', '-', 'term', 'effects', '.', 'objectives', ':', 'the', 'present', 'study', 'aimed', 'to', 'assess', 'sub', '-', 'acute', 'and', 'long', '-', 'term', 'effects', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'on', 'well', '-', 'being', 'and', 'cognitive', 'thinking', 'style', '.', 'the', 'second', 'objective', 'was', 'to', 'assess', 'whether', 'sub', '-', 'acute', 'and', 'long', '-', 'term', 'effects', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'depend', 'on', 'the', 'degree', 'of', 'ego', 'dissolution', 'that', 'was', 'experienced', 'after', 'consumption', 'of', 'ay', '##ah', '##ua', '##sc', '##a', '.', 'results', ':', 'ay', '##ah', '##ua', '##sc', '##a', 'cere', '##mon', '##y', 'attend', '##ants', '(', 'n', '=', '57', ')', 'in', 'the', 'netherlands', 'and', 'colombia', 'were', 'assessed', 'before', ',', 'the', 'day', 'after', ',', 'and', '4', 'weeks', 'following', 'the', 'rit', '##ual', '.', 'relative', 'to', 'baseline', ',', 'ratings', 'of', 'depression', 'and', 'stress', 'significantly', 'decreased', 'after', 'the', 'ay', '##ah', '##ua', '##sc', '##a', 'cere', '##mon', '##y', 'and', 'these', 'changes', 'persisted', 'for', '4', 'weeks', '.', 'likewise', ',', 'convergent', 'thinking', 'improved', 'post', '-', 'ay', '##ah', '##ua', '##sc', '##a', 'cere', '##mon', '##y', 'up', 'until', 'the', '4', 'weeks', 'follow', '-', 'up', '.', 'satisfaction', 'with', 'life', 'and', 'several', 'aspects', 'of', 'mind', '##fulness', 'increased', 'the', 'day', 'after', 'the', 'cere', '##mon', '##y', ',', 'but', 'these', 'changes', 'failed', 'to', 'reach', 'significance', '4', 'weeks', 'after', '.', 'changes', 'in', 'affect', ',', 'satisfaction', 'with', 'life', ',', 'and', 'mind', '##fulness', 'were', 'significantly', 'correlated', 'to', 'the', 'level', 'of', 'ego', 'dissolution', 'experienced', 'during', 'the', 'ay', '##ah', '##ua', '##sc', '##a', 'cere', '##mon', '##y', 'and', 'were', 'unrelated', 'to', 'previous', 'experience', 'with', 'ay', '##ah', '##ua', '##sc', '##a', '.', 'conclusion', ':', 'it', 'is', 'concluded', 'that', 'ay', '##ah', '##ua', '##sc', '##a', 'produces', 'sub', '-', 'acute', 'and', 'long', '-', 'term', 'improvements', 'in', 'affect', 'and', 'cognitive', 'thinking', 'style', 'in', 'non', '-', 'pathological', 'users', '.', 'these', 'data', 'highlight', 'the', 'therapeutic', 'potential', 'of', 'ay', '##ah', '##ua', '##sc', '##a', 'in', 'the', 'treatment', 'of', 'mental', 'health', 'disorders', ',', 'such', 'as', 'depression', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 9, 9, 9, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 21, 21, 23, 24, 25, 25, 25, 25, 25, 26, 27, 28, 28, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 49, 49, 49, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 83, 83, 83, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 115, 115, 115, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 141, 141, 141, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 155, 155, 155, 156, 157, 158, 159, 159, 159, 159, 159, 160, 160, 160, 161, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 200, 200, 200, 200, 201, 201, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 217, 217, 217, 217, 218, 218, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 235, 236, 237, 238, 239, 240, 241, 241, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 276, 276, 276, 276, 277, 277, 277, 278, 279, 280, 281, 282, 283, 284, 285, 285, 285, 285, 285, 286, 287, 288, 289, 290, 291, 292, 293, 293, 293, 293, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 322, 322, 322, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution.^
RATIONALE: Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on mental health-related parameters and less on long-term effects. OBJECTIVES: The present study aimed to assess sub-acute and long-term effects of ayahuasca on well-being and cognitive thinking style. The second objective was to assess whether sub-acute and long-term effects of ayahuasca depend on the degree of ego dissolution that was experienced after consumption of ayahuasca. RESULTS: Ayahuasca ceremony attendants (N = 57) in the Netherlands and Colombia were assessed before, the day after, and 4 weeks following the ritual. Relative to baseline, ratings of depression and stress significantly decreased after the ayahuasca ceremony and these changes persisted for 4 weeks. Likewise, convergent thinking improved post-ayahuasca ceremony up until the 4 weeks follow-up. Satisfaction with life and several aspects of mindfulness increased the day after the ceremony, but these changes failed to reach significance 4 weeks after. Changes in affect, satisfaction with life, and mindfulness were significantly correlated to the level of ego dissolution experienced during the ayahuasca ceremony and were unrelated to previous experience with ayahuasca. CONCLUSION: It is concluded that ayahuasca produces sub-acute and long-term improvements in affect and cognitive thinking style in non-pathological users. These data highlight the therapeutic potential of ayahuasca in the treatment of mental health disorders, such as depression."
"['Evidence', 'that', 'subanesthetic', 'doses', 'of', 'ketamine', 'cause', 'sustained', 'disruptions', 'of', 'NMDA', 'and', 'AMPA', '-', 'mediated', 'frontoparietal', 'connectivity', 'in', 'humans.^', '\n', 'Following', 'the', 'discovery', 'of', 'the', 'antidepressant', 'properties', 'of', 'ketamine', ',', 'there', 'has', 'been', 'a', 'recent', 'resurgence', 'in', 'the', 'interest', 'in', 'this', 'NMDA', 'receptor', 'antagonist', '.', 'Although', 'detailed', 'animal', 'models', 'of', 'the', 'molecular', 'mechanisms', 'underlying', 'ketamine', '’s', 'effects', 'have', 'emerged', ',', 'there', 'are', 'few', 'MEG', '/', 'EEG', 'studies', 'examining', 'the', 'acute', 'subanesthetic', 'effects', 'of', 'ketamine', 'infusion', 'in', 'man', '.', 'We', 'recorded', '275', 'channel', 'MEG', 'in', 'two', 'experiments', '(', 'n', '=', '25', 'human', 'males', ')', 'examining', 'the', 'effects', 'of', 'subanesthetic', 'ketamine', 'infusion', '.', 'MEG', 'power', 'spectra', 'revealed', 'a', 'rich', 'set', 'of', 'significant', 'oscillatory', 'changes', 'compared', 'with', 'placebo', 'sessions', ',', 'including', 'decreases', 'in', 'occipital', ',', 'parietal', ',', 'and', 'anterior', 'cingulate', 'alpha', 'power', ',', 'increases', 'in', 'medial', 'frontal', 'theta', 'power', ',', 'and', 'increases', 'in', 'parietal', 'and', 'cingulate', 'cortex', 'high', 'gamma', 'power', '.', 'Each', 'of', 'these', 'spectral', 'effects', 'demonstrated', 'their', 'own', 'set', 'of', 'temporal', 'dynamics', '.', 'Dynamic', 'causal', 'modeling', 'of', 'frontoparietal', 'connectivity', 'changes', 'with', 'ketamine', 'indicated', 'a', 'decrease', 'in', 'NMDA', 'and', 'AMPA', '-', 'mediated', 'frontal', '-', 'to', '-', 'parietal', 'connectivity', '.', 'AMPA', '-', 'mediated', 'connectivity', 'changes', 'were', 'sustained', 'for', 'up', 'to', '50', 'min', 'after', 'ketamine', 'infusion', 'had', 'ceased', ',', 'by', 'which', 'time', 'perceptual', 'distortions', 'were', 'absent', '.', 'The', 'results', 'also', 'indicated', 'a', 'decrease', 'in', 'gain', 'of', 'parietal', 'pyramidal', 'cells', ',', 'which', 'was', 'correlated', 'with', 'participants', '’', 'self', '-', 'reports', 'of', 'blissful', 'state', '.', 'Based', 'on', 'these', 'results', ',', 'we', 'suggest', 'that', 'the', 'antidepressant', 'effects', 'of', 'ketamine', 'may', 'depend', 'on', 'its', 'ability', 'to', 'change', 'the', 'balance', 'of', 'frontoparietal', 'connectivity', 'patterns', '.', '(', 'PsycINFO', 'Database', 'Record', '(', 'c', ')', '2016', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5928,"['[CLS]', 'evidence', 'that', 'sub', '##anes', '##the', '##tic', 'doses', 'of', 'ketamine', 'cause', 'sustained', 'disruption', '##s', 'of', 'nmda', 'and', 'ampa', '-', 'mediated', 'front', '##opa', '##rie', '##tal', 'connectivity', 'in', 'humans', '.', '^', 'following', 'the', 'discovery', 'of', 'the', 'antidepressant', 'properties', 'of', 'ketamine', ',', 'there', 'has', 'been', 'a', 'recent', 'res', '##urg', '##ence', 'in', 'the', 'interest', 'in', 'this', 'nmda', 'receptor', 'antagonist', '.', 'although', 'detailed', 'animal', 'models', 'of', 'the', 'molecular', 'mechanisms', 'underlying', 'ketamine', '’', 's', 'effects', 'have', 'emerged', ',', 'there', 'are', 'few', 'meg', '/', 'eeg', 'studies', 'examining', 'the', 'acute', 'sub', '##anes', '##the', '##tic', 'effects', 'of', 'ketamine', 'infusion', 'in', 'man', '.', 'we', 'recorded', '275', 'channel', 'meg', 'in', 'two', 'experiments', '(', 'n', '=', '25', 'human', 'males', ')', 'examining', 'the', 'effects', 'of', 'sub', '##anes', '##the', '##tic', 'ketamine', 'infusion', '.', 'meg', 'power', 'spectra', 'revealed', 'a', 'rich', 'set', 'of', 'significant', 'oscillatory', 'changes', 'compared', 'with', 'placebo', 'sessions', ',', 'including', 'decreases', 'in', 'occipital', ',', 'parietal', ',', 'and', 'anterior', 'cingulate', 'alpha', 'power', ',', 'increases', 'in', 'medial', 'frontal', 'theta', 'power', ',', 'and', 'increases', 'in', 'parietal', 'and', 'cingulate', 'cortex', 'high', 'gamma', 'power', '.', 'each', 'of', 'these', 'spectral', 'effects', 'demonstrated', 'their', 'own', 'set', 'of', 'temporal', 'dynamics', '.', 'dynamic', 'causal', 'modeling', 'of', 'front', '##opa', '##rie', '##tal', 'connectivity', 'changes', 'with', 'ketamine', 'indicated', 'a', 'decrease', 'in', 'nmda', 'and', 'ampa', '-', 'mediated', 'frontal', '-', 'to', '-', 'parietal', 'connectivity', '.', 'ampa', '-', 'mediated', 'connectivity', 'changes', 'were', 'sustained', 'for', 'up', 'to', '50', 'min', 'after', 'ketamine', 'infusion', 'had', 'cea', '##sed', ',', 'by', 'which', 'time', 'perceptual', 'distortions', 'were', 'absent', '.', 'the', 'results', 'also', 'indicated', 'a', 'decrease', 'in', 'gain', 'of', 'parietal', 'pyramidal', 'cells', ',', 'which', 'was', 'correlated', 'with', 'participants', '’', 'self', '-', 'reports', 'of', 'bl', '##iss', '##ful', 'state', '.', 'based', 'on', 'these', 'results', ',', 'we', 'suggest', 'that', 'the', 'antidepressant', 'effects', 'of', 'ketamine', 'may', 'depend', 'on', 'its', 'ability', 'to', 'change', 'the', 'balance', 'of', 'front', '##opa', '##rie', '##tal', 'connectivity', 'patterns', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '2016', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 2, 2, 2, 3, 4, 5, 6, 7, 8, 8, 9, 10, 11, 12, 13, 14, 15, 15, 15, 15, 16, 17, 18, 18, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 35, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 70, 70, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 97, 97, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 165, 165, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 235, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 261, 261, 261, 262, 263, 264, 265, 266, 266, 266, 267, 268, 269, 270, 271, 272, 273, 273, 274, 275, 276, 277, 278, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Evidence that subanesthetic doses of ketamine cause sustained disruptions of NMDA and AMPA-mediated frontoparietal connectivity in humans.^
Following the discovery of the antidepressant properties of ketamine, there has been a recent resurgence in the interest in this NMDA receptor antagonist. Although detailed animal models of the molecular mechanisms underlying ketamine’s effects have emerged, there are few MEG/EEG studies examining the acute subanesthetic effects of ketamine infusion in man. We recorded 275 channel MEG in two experiments (n = 25 human males) examining the effects of subanesthetic ketamine infusion. MEG power spectra revealed a rich set of significant oscillatory changes compared with placebo sessions, including decreases in occipital, parietal, and anterior cingulate alpha power, increases in medial frontal theta power, and increases in parietal and cingulate cortex high gamma power. Each of these spectral effects demonstrated their own set of temporal dynamics. Dynamic causal modeling of frontoparietal connectivity changes with ketamine indicated a decrease in NMDA and AMPA-mediated frontal-to-parietal connectivity. AMPA-mediated connectivity changes were sustained for up to 50 min after ketamine infusion had ceased, by which time perceptual distortions were absent. The results also indicated a decrease in gain of parietal pyramidal cells, which was correlated with participants’ self-reports of blissful state. Based on these results, we suggest that the antidepressant effects of ketamine may depend on its ability to change the balance of frontoparietal connectivity patterns. (PsycINFO Database Record (c) 2016 APA, all rights reserved)"
"['Ketamine', 'augmentation', 'rapidly', 'improves', 'depression', 'scores', 'in', 'inpatients', 'with', 'treatment', '-', 'resistant', 'bipolar', 'depression.^', '\n', 'OBJECTIVE', ':', 'To', 'study', 'the', 'clinical', 'effect', 'of', 'a', 'single', 'ketamine', 'infusion', ',', '0.5', 'mg', '/', 'kg', 'body', 'weight', ',', 'in', 'bipolar', 'depressive', 'patients', 'receiving', 'mood', '-', 'stabilising', 'drugs', ',', 'not', 'improving', 'on', 'antidepressants', '.', 'Previously', ',', 'in', 'such', 'patients', ',', 'we', 'had', 'found', 'a', 'correlation', 'between', 'clinical', 'efficacy', ',', 'serum', 'brain', '-', 'derived', 'neurotrophic', 'factor', 'and', 'vitamin', 'B12', 'levels', 'and', 'a', 'rapid', 'improvement', 'in', 'neurocognitive', 'performance', '.', 'METHODS', ':', 'The', 'study', 'included', '53', 'patients', '(', '13', 'men', ',', '40', 'women', ')', ',', 'aged', '22', '-', '81', 'years', ',', 'receiving', '≥1', 'mood', '-', 'stabilising', 'medications', 'of', 'the', 'first', 'and/or', 'second', 'generation', '.', 'Pre', '-', 'infusion', 'depression', 'intensity', 'on', 'the', 'Hamilton', 'Depression', 'Rating', 'Scale', '(', 'HDRS', ')', 'was', '23.4', '±', '4.6', 'points', 'and', 'the', 'assumed', 'criterion', 'for', 'response', 'was', 'a', 'reduction', 'of', '≥50', '%', 'in', 'the', 'HDRS', 'score', 'after', '7', 'days', '.', 'RESULTS', ':', 'Twenty', '-', 'seven', 'subjects', '(', '51', '%', ')', 'met', 'a', 'criterion', 'for', 'response', ',', 'more', 'frequently', 'males', '(', '77', '%', ')', 'than', 'females', '(', '43', '%', ')', '.', 'Responders', 'did', 'not', 'differ', 'from', 'non', '-', 'responders', 'as', 'to', 'age', ',', 'illness', 'onset', ',', 'duration', 'of', 'depressive', 'episode', ',', 'type', 'of', 'bipolar', 'illness', ',', 'family', 'history', 'of', 'psychiatric', 'illness', ',', 'personal', '/', 'family', 'history', 'of', 'alcoholism', 'or', 'using', 'lithium', ',', 'quetiapine', 'or', 'a', 'combination', 'of', 'these', 'mood', 'stabilisers', '.', 'CONCLUSIONS', ':', 'The', 'results', 'confirm', 'a', 'rapid', 'antidepressant', 'effect', 'of', 'ketamine', 'infusion', 'in', 'a', 'considerable', 'proportion', 'of', 'those', 'patients', 'with', 'bipolar', 'depression', 'receiving', 'mood', '-', 'stabilising', 'drugs', '.', 'Apart', 'from', 'male', 'gender', ',', 'no', 'other', 'clinical', 'factors', 'were', 'predictors', 'of', 'response', '.']","['O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7554,"['[CLS]', 'ketamine', 'augmentation', 'rapidly', 'improves', 'depression', 'scores', 'in', 'inpatient', '##s', 'with', 'treatment', '-', 'resistant', 'bipolar', 'depression', '.', '^', 'objective', ':', 'to', 'study', 'the', 'clinical', 'effect', 'of', 'a', 'single', 'ketamine', 'infusion', ',', '0', '.', '5', 'mg', '/', 'kg', 'body', 'weight', ',', 'in', 'bipolar', 'depressive', 'patients', 'receiving', 'mood', '-', 'stabil', '##ising', 'drugs', ',', 'not', 'improving', 'on', 'antidepressants', '.', 'previously', ',', 'in', 'such', 'patients', ',', 'we', 'had', 'found', 'a', 'correlation', 'between', 'clinical', 'efficacy', ',', 'serum', 'brain', '-', 'derived', 'neurotrophic', 'factor', 'and', 'vitamin', 'b', '##12', 'levels', 'and', 'a', 'rapid', 'improvement', 'in', 'neuro', '##cognitive', 'performance', '.', 'methods', ':', 'the', 'study', 'included', '53', 'patients', '(', '13', 'men', ',', '40', 'women', ')', ',', 'aged', '22', '-', '81', 'years', ',', 'receiving', '≥', '##1', 'mood', '-', 'stabil', '##ising', 'medications', 'of', 'the', 'first', 'and', '/', 'or', 'second', 'generation', '.', 'pre', '-', 'infusion', 'depression', 'intensity', 'on', 'the', 'hamilton', 'depression', 'rating', 'scale', '(', 'hd', '##rs', ')', 'was', '23', '.', '4', '±', '4', '.', '6', 'points', 'and', 'the', 'assumed', 'criterion', 'for', 'response', 'was', 'a', 'reduction', 'of', '≥', '##50', '%', 'in', 'the', 'hd', '##rs', 'score', 'after', '7', 'days', '.', 'results', ':', 'twenty', '-', 'seven', 'subjects', '(', '51', '%', ')', 'met', 'a', 'criterion', 'for', 'response', ',', 'more', 'frequently', 'males', '(', '77', '%', ')', 'than', 'females', '(', '43', '%', ')', '.', 'responders', 'did', 'not', 'differ', 'from', 'non', '-', 'responders', 'as', 'to', 'age', ',', 'illness', 'onset', ',', 'duration', 'of', 'depressive', 'episode', ',', 'type', 'of', 'bipolar', 'illness', ',', 'family', 'history', 'of', 'psychiatric', 'illness', ',', 'personal', '/', 'family', 'history', 'of', 'alcohol', '##ism', 'or', 'using', 'lithium', ',', 'que', '##tia', '##pine', 'or', 'a', 'combination', 'of', 'these', 'mood', 'stabil', '##iser', '##s', '.', 'conclusions', ':', 'the', 'results', 'confirm', 'a', 'rapid', 'antidepressant', 'effect', 'of', 'ketamine', 'infusion', 'in', 'a', 'considerable', 'proportion', 'of', 'those', 'patients', 'with', 'bipolar', 'depression', 'receiving', 'mood', '-', 'stabil', '##ising', 'drugs', '.', 'apart', 'from', 'male', 'gender', ',', 'no', 'other', 'clinical', 'factors', 'were', 'predictors', 'of', 'response', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 7, 8, 9, 10, 11, 12, 13, 13, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 28, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 73, 74, 75, 76, 77, 78, 79, 80, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 105, 106, 107, 108, 108, 109, 110, 111, 112, 113, 113, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 129, 130, 131, 132, 132, 132, 133, 134, 134, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 146, 147, 148, 149, 150, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 222, 223, 224, 225, 226, 227, 227, 227, 228, 229, 230, 231, 232, 233, 234, 234, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression.^
OBJECTIVE: To study the clinical effect of a single ketamine infusion, 0.5 mg/kg body weight, in bipolar depressive patients receiving mood-stabilising drugs, not improving on antidepressants. Previously, in such patients, we had found a correlation between clinical efficacy, serum brain-derived neurotrophic factor and vitamin B12 levels and a rapid improvement in neurocognitive performance. METHODS: The study included 53 patients (13 men, 40 women), aged 22-81 years, receiving ≥1 mood-stabilising medications of the first and/or second generation. Pre-infusion depression intensity on the Hamilton Depression Rating Scale (HDRS) was 23.4 ± 4.6 points and the assumed criterion for response was a reduction of ≥50% in the HDRS score after 7 days. RESULTS: Twenty-seven subjects (51%) met a criterion for response, more frequently males (77%) than females (43%). Responders did not differ from non-responders as to age, illness onset, duration of depressive episode, type of bipolar illness, family history of psychiatric illness, personal/family history of alcoholism or using lithium, quetiapine or a combination of these mood stabilisers. CONCLUSIONS: The results confirm a rapid antidepressant effect of ketamine infusion in a considerable proportion of those patients with bipolar depression receiving mood-stabilising drugs. Apart from male gender, no other clinical factors were predictors of response."
"['Quality', 'of', 'Acute', 'Psychedelic', 'Experience', 'Predicts', 'Therapeutic', 'Efficacy', 'of', 'Psilocybin', 'for', 'Treatment', '-', 'Resistant', 'Depression.^', '\n', 'Introduction', ':', 'It', 'is', 'a', 'basic', 'principle', 'of', 'the', '""', 'psychedelic', '""', 'treatment', 'model', 'that', 'the', 'quality', 'of', 'the', 'acute', 'experience', 'mediates', 'long', '-', 'term', 'improvements', 'in', 'mental', 'health', '.', 'In', 'the', 'present', 'paper', 'we', 'sought', 'to', 'test', 'this', 'using', 'data', 'from', 'a', 'clinical', 'trial', 'assessing', 'psilocybin', 'for', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', '.', 'In', 'line', 'with', 'previous', 'reports', ',', 'we', 'hypothesized', 'that', 'the', 'occurrence', 'and', 'magnitude', 'of', 'Oceanic', 'Boundlessness', '(', 'OBN', ')', '(', 'sharing', 'features', 'with', 'mystical', '-', 'type', 'experience', ')', 'and', 'Dread', 'of', 'Ego', 'Dissolution', '(', 'DED', ')', '(', 'similar', 'to', 'anxiety', ')', 'would', 'predict', 'long', '-', 'term', 'positive', 'outcomes', ',', 'whereas', 'sensory', 'perceptual', 'effects', 'would', 'have', 'negligible', 'predictive', 'value', '.', 'Materials', 'and', 'Methods', ':', 'Twenty', 'patients', 'with', 'treatment', 'resistant', 'depression', 'underwent', 'treatment', 'with', 'psilocybin', '(', 'two', 'separate', 'sessions', ':', '10', 'and', '25', 'mg', 'psilocybin', ')', '.', 'The', 'Altered', 'States', 'of', 'Consciousness', '(', 'ASC', ')', 'questionnaire', 'was', 'used', 'to', 'assess', 'the', 'quality', 'of', 'experiences', 'in', 'the', '25', 'mg', 'psilocybin', 'session', '.', 'From', 'the', 'ASC', ',', 'the', 'dimensions', 'OBN', 'and', 'DED', 'were', 'used', 'to', 'measure', 'the', 'mystical', '-', 'type', 'and', 'challenging', 'experiences', ',', 'respectively', '.', 'The', 'Self', '-', 'Reported', 'Quick', 'Inventory', 'of', 'Depressive', 'Symptoms', '(', 'QIDS', '-', 'SR', ')', 'at', '5', 'weeks', 'served', 'as', 'the', 'endpoint', 'clinical', 'outcome', 'measure', ',', 'as', 'in', 'later', 'time', 'points', 'some', 'of', 'the', 'subjects', 'had', 'gone', 'on', 'to', 'receive', 'new', 'treatments', ',', 'thus', 'confounding', 'inferences', '.', 'In', 'a', 'repeated', 'measure', 'ANOVA', ',', 'Time', 'was', 'the', 'within', '-', 'subject', 'factor', '(', 'independent', 'variable', ')', ',', 'with', 'QIDS', '-', 'SR', 'as', 'the', 'within', '-', 'subject', 'dependent', 'variable', 'in', 'baseline', ',', '1', '-', 'day', ',', '1', '-', 'week', ',', '5', '-', 'weeks', '.', 'OBN', 'and', 'DED', 'were', 'independent', 'variables', '.', 'OBN', '-', 'by', '-', 'Time', 'and', 'DED', '-', 'by', '-', 'Time', 'interactions', 'were', 'the', 'primary', 'outcomes', 'of', 'interest', '.', 'Results', ':', 'For', 'the', 'interaction', 'of', 'OBN', 'and', 'DED', 'with', 'Time', '(', 'QIDS', '-', 'SR', 'as', 'dependent', 'variable', ')', ',', 'the', 'main', 'effect', 'and', 'the', 'effects', 'at', 'each', 'time', 'point', 'compared', 'to', 'baseline', 'were', 'all', 'significant', '(', 'p', '=', '0.002', 'and', 'p', '=', '0.003', ',', 'respectively', ',', 'for', 'main', 'effects', ')', ',', 'confirming', 'our', 'main', 'hypothesis', '.', 'Furthermore', ',', 'Pearson', ""'s"", 'correlation', 'of', 'OBN', 'with', 'QIDS', '-', 'SR', '(', '5', 'weeks', ')', 'was', 'specific', 'compared', 'to', 'perceptual', 'dimensions', 'of', 'the', 'ASC', '(', 'p', '<', '0.05', ')', '.', 'Discussion', ':', 'This', 'report', 'further', 'bolsters', 'the', 'view', 'that', 'the', 'quality', 'of', 'the', 'acute', 'psychedelic', 'experience', 'is', 'a', 'key', 'mediator', 'of', 'long', '-', 'term', 'changes', 'in', 'mental', 'health', '.', 'Future', 'therapeutic', 'work', 'with', 'psychedelics', 'should', 'recognize', 'the', 'essential', 'importance', 'of', 'quality', 'of', 'experience', 'in', 'determining', 'treatment', 'efficacy', 'and', 'consider', 'ways', 'of', 'enhancing', 'mystical', '-', 'type', 'experiences', 'and', 'reducing', 'anxiety', '.', 'Trial', 'Registration', ':', 'ISRCTN', ',', 'number', 'ISRCTN14426797', ',', 'http://www.isrctn.com/ISRCTN14426797', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7456,"['[CLS]', 'quality', 'of', 'acute', 'psych', '##ede', '##lic', 'experience', 'predicts', 'therapeutic', 'efficacy', 'of', 'psi', '##loc', '##yb', '##in', 'for', 'treatment', '-', 'resistant', 'depression', '.', '^', 'introduction', ':', 'it', 'is', 'a', 'basic', 'principle', 'of', 'the', '""', 'psych', '##ede', '##lic', '""', 'treatment', 'model', 'that', 'the', 'quality', 'of', 'the', 'acute', 'experience', 'mediates', 'long', '-', 'term', 'improvements', 'in', 'mental', 'health', '.', 'in', 'the', 'present', 'paper', 'we', 'sought', 'to', 'test', 'this', 'using', 'data', 'from', 'a', 'clinical', 'trial', 'assessing', 'psi', '##loc', '##yb', '##in', 'for', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', '.', 'in', 'line', 'with', 'previous', 'reports', ',', 'we', 'hypothesized', 'that', 'the', 'occurrence', 'and', 'magnitude', 'of', 'oceanic', 'bound', '##lessness', '(', 'ob', '##n', ')', '(', 'sharing', 'features', 'with', 'mys', '##tical', '-', 'type', 'experience', ')', 'and', 'dre', '##ad', 'of', 'ego', 'dissolution', '(', 'ded', ')', '(', 'similar', 'to', 'anxiety', ')', 'would', 'predict', 'long', '-', 'term', 'positive', 'outcomes', ',', 'whereas', 'sensory', 'perceptual', 'effects', 'would', 'have', 'negligible', 'predictive', 'value', '.', 'materials', 'and', 'methods', ':', 'twenty', 'patients', 'with', 'treatment', 'resistant', 'depression', 'underwent', 'treatment', 'with', 'psi', '##loc', '##yb', '##in', '(', 'two', 'separate', 'sessions', ':', '10', 'and', '25', 'mg', 'psi', '##loc', '##yb', '##in', ')', '.', 'the', 'altered', 'states', 'of', 'consciousness', '(', 'asc', ')', 'questionnaire', 'was', 'used', 'to', 'assess', 'the', 'quality', 'of', 'experiences', 'in', 'the', '25', 'mg', 'psi', '##loc', '##yb', '##in', 'session', '.', 'from', 'the', 'asc', ',', 'the', 'dimensions', 'ob', '##n', 'and', 'ded', 'were', 'used', 'to', 'measure', 'the', 'mys', '##tical', '-', 'type', 'and', 'challenging', 'experiences', ',', 'respectively', '.', 'the', 'self', '-', 'reported', 'quick', 'inventory', 'of', 'depressive', 'symptoms', '(', 'qi', '##ds', '-', 'sr', ')', 'at', '5', 'weeks', 'served', 'as', 'the', 'endpoint', 'clinical', 'outcome', 'measure', ',', 'as', 'in', 'later', 'time', 'points', 'some', 'of', 'the', 'subjects', 'had', 'gone', 'on', 'to', 'receive', 'new', 'treatments', ',', 'thus', 'confounding', 'inferences', '.', 'in', 'a', 'repeated', 'measure', 'anova', ',', 'time', 'was', 'the', 'within', '-', 'subject', 'factor', '(', 'independent', 'variable', ')', ',', 'with', 'qi', '##ds', '-', 'sr', 'as', 'the', 'within', '-', 'subject', 'dependent', 'variable', 'in', 'baseline', ',', '1', '-', 'day', ',', '1', '-', 'week', ',', '5', '-', 'weeks', '.', 'ob', '##n', 'and', 'ded', 'were', 'independent', 'variables', '.', 'ob', '##n', '-', 'by', '-', 'time', 'and', 'ded', '-', 'by', '-', 'time', 'interactions', 'were', 'the', 'primary', 'outcomes', 'of', 'interest', '.', 'results', ':', 'for', 'the', 'interaction', 'of', 'ob', '##n', 'and', 'ded', 'with', 'time', '(', 'qi', '##ds', '-', 'sr', 'as', 'dependent', 'variable', ')', ',', 'the', 'main', 'effect', 'and', 'the', 'effects', 'at', 'each', 'time', 'point', 'compared', 'to', 'baseline', 'were', 'all', 'significant', '(', 'p', '=', '0', '.', '00', '##2', 'and', 'p', '=', '0', '.', '00', '##3', ',', 'respectively', ',', 'for', 'main', 'effects', ')', ',', 'confirming', 'our', 'main', 'hypothesis', '.', 'furthermore', ',', 'pearson', ""'"", 's', 'correlation', 'of', 'ob', '##n', 'with', 'qi', '##ds', '-', 'sr', '(', '5', 'weeks', ')', 'was', 'specific', 'compared', 'to', 'perceptual', 'dimensions', 'of', 'the', 'asc', '(', 'p', '<', '0', '.', '05', ')', '.', 'discussion', ':', 'this', 'report', 'further', 'bol', '##sters', 'the', 'view', 'that', 'the', 'quality', 'of', 'the', 'acute', 'psych', '##ede', '##lic', 'experience', 'is', 'a', 'key', 'mediator', 'of', 'long', '-', 'term', 'changes', 'in', 'mental', 'health', '.', 'future', 'therapeutic', 'work', 'with', 'psych', '##ede', '##lic', '##s', 'should', 'recognize', 'the', 'essential', 'importance', 'of', 'quality', 'of', 'experience', 'in', 'determining', 'treatment', 'efficacy', 'and', 'consider', 'ways', 'of', 'enhancing', 'mys', '[SEP]']","[None, 0, 1, 2, 3, 3, 3, 4, 5, 6, 7, 8, 9, 9, 9, 9, 10, 11, 12, 13, 14, 14, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 26, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 62, 62, 62, 63, 64, 65, 66, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 87, 88, 89, 89, 90, 91, 92, 93, 94, 95, 95, 96, 97, 98, 99, 100, 101, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 144, 144, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 154, 154, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 178, 178, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 187, 188, 189, 190, 191, 192, 193, 194, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 294, 295, 296, 297, 298, 299, 300, 301, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 326, 327, 328, 329, 330, 331, 332, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 359, 359, 359, 360, 361, 362, 363, 363, 363, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 380, 381, 382, 383, 383, 384, 385, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 404, 404, 405, 406, 407, 408, 409, 410, 411, 412, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 421, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 440, 440, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.^
Introduction: It is a basic principle of the ""psychedelic"" treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) (sharing features with mystical-type experience) and Dread of Ego Dissolution (DED) (similar to anxiety) would predict long-term positive outcomes, whereas sensory perceptual effects would have negligible predictive value. Materials and Methods: Twenty patients with treatment resistant depression underwent treatment with psilocybin (two separate sessions: 10 and 25 mg psilocybin). The Altered States of Consciousness (ASC) questionnaire was used to assess the quality of experiences in the 25 mg psilocybin session. From the ASC, the dimensions OBN and DED were used to measure the mystical-type and challenging experiences, respectively. The Self-Reported Quick Inventory of Depressive Symptoms (QIDS-SR) at 5 weeks served as the endpoint clinical outcome measure, as in later time points some of the subjects had gone on to receive new treatments, thus confounding inferences. In a repeated measure ANOVA, Time was the within-subject factor (independent variable), with QIDS-SR as the within-subject dependent variable in baseline, 1-day, 1-week, 5-weeks. OBN and DED were independent variables. OBN-by-Time and DED-by-Time interactions were the primary outcomes of interest. Results: For the interaction of OBN and DED with Time (QIDS-SR as dependent variable), the main effect and the effects at each time point compared to baseline were all significant (p = 0.002 and p = 0.003, respectively, for main effects), confirming our main hypothesis. Furthermore, Pearson's correlation of OBN with QIDS-SR (5 weeks) was specific compared to perceptual dimensions of the ASC (p < 0.05). Discussion: This report further bolsters the view that the quality of the acute psychedelic experience is a key mediator of long-term changes in mental health. Future therapeutic work with psychedelics should recognize the essential importance of quality of experience in determining treatment efficacy and consider ways of enhancing mystical-type experiences and reducing anxiety. Trial Registration: ISRCTN, number ISRCTN14426797, http://www.isrctn.com/ISRCTN14426797."
"['Change', 'in', 'frequency', 'of', 'acute', 'and', 'subacute', 'effects', 'of', 'ecstasy', 'in', 'a', 'group', 'of', 'novice', 'users', 'after', '6', 'months', 'of', 'regular', 'use.^', '\n', 'Background', ':', 'Recent', 'research', 'trends', 'are', 'to', 'specify', 'the', 'relation', 'between', 'patterns', 'of', 'ecstasy', 'use', 'and', 'side', 'effects', ',', 'possibility', 'of', 'dependency', ',', 'tolerance', 'and', 'long', 'term', 'neurocognitive', 'damage', '.', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', 'assess', 'the', 'impact', 'of', 'regular', 'ecstasy', 'use', 'on', 'its', 'acute', 'and', 'subacute', 'effects', '.', 'Subjects', 'and', 'methods', ':', 'At', 'the', 'first', 'stage', ',', 'we', 'recruited', '120', 'subjects', '.', 'If', 'participants', 'continued', 'regular', 'use', 'of', 'ecstasy', 'in', 'this', 'period', ',', 'they', 'were', 'asked', 'to', 'participate', 'in', 'the', 'second', 'stage', 'of', 'the', 'research', '6', 'months', 'later', '.', 'Thirty', '-', 'five', 'subjects', 'attended', 'the', 'second', 'stage', 'of', 'the', 'study', ',', '5', 'of', 'which', 'were', 'excluded', 'because', 'they', 'had', 'less', 'than', '5', 'drug', 'experiences', 'during', 'the', 'last', '6', 'months', '.', 'At', 'last', ',', 'we', 'recruited', '30', 'novice', 'ecstasy', 'users', 'by', 'means', 'of', 'the', 'snowball', 'technique', 'in', 'Tehran', ',', 'Iran', '.', 'The', 'pattern', 'of', 'use', 'and', 'experienced', 'effects', 'of', 'ecstasy', 'was', 'documented', 'at', 'the', 'beginning', 'and', 'after', '6', 'months', 'of', 'regular', 'consumption', 'with', 'a', 'self', 'administered', 'questionnaire', '.', 'Results', ':', 'Little', 'or', 'no', 'change', 'was', 'observed', 'in', 'acute', 'effects', '.', 'Those', 'subacute', 'effects', 'that', 'had', 'considerable', 'increase', 'in', 'frequency', 'were', 'anxiety', ',', 'depression', ',', 'aggression', ',', 'memory', 'impairment', ',', 'poor', 'concentration', 'and', 'learning', 'problems', '.', 'Conclusion', ':', 'Small', 'change', 'in', 'acute', 'effects', 'suggests', 'low', 'possibility', 'of', 'tolerance', 'after', 'at', 'least', '6', 'months', 'of', 'regular', 'use', '.', 'Our', 'results', 'support', 'long', 'term', 'neurocognitive', 'damage', 'and', 'mood', 'impairment', 'with', 'ecstasy', 'use', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7210,"['[CLS]', 'change', 'in', 'frequency', 'of', 'acute', 'and', 'sub', '##acute', 'effects', 'of', 'ecs', '##tas', '##y', 'in', 'a', 'group', 'of', 'nov', '##ice', 'users', 'after', '6', 'months', 'of', 'regular', 'use', '.', '^', 'background', ':', 'recent', 'research', 'trends', 'are', 'to', 'specify', 'the', 'relation', 'between', 'patterns', 'of', 'ecs', '##tas', '##y', 'use', 'and', 'side', 'effects', ',', 'possibility', 'of', 'dependency', ',', 'tolerance', 'and', 'long', 'term', 'neuro', '##cognitive', 'damage', '.', 'the', 'objective', 'of', 'this', 'study', 'was', 'to', 'assess', 'the', 'impact', 'of', 'regular', 'ecs', '##tas', '##y', 'use', 'on', 'its', 'acute', 'and', 'sub', '##acute', 'effects', '.', 'subjects', 'and', 'methods', ':', 'at', 'the', 'first', 'stage', ',', 'we', 'recruited', '120', 'subjects', '.', 'if', 'participants', 'continued', 'regular', 'use', 'of', 'ecs', '##tas', '##y', 'in', 'this', 'period', ',', 'they', 'were', 'asked', 'to', 'participate', 'in', 'the', 'second', 'stage', 'of', 'the', 'research', '6', 'months', 'later', '.', 'thirty', '-', 'five', 'subjects', 'attended', 'the', 'second', 'stage', 'of', 'the', 'study', ',', '5', 'of', 'which', 'were', 'excluded', 'because', 'they', 'had', 'less', 'than', '5', 'drug', 'experiences', 'during', 'the', 'last', '6', 'months', '.', 'at', 'last', ',', 'we', 'recruited', '30', 'nov', '##ice', 'ecs', '##tas', '##y', 'users', 'by', 'means', 'of', 'the', 'snow', '##ball', 'technique', 'in', 'tehran', ',', 'iran', '.', 'the', 'pattern', 'of', 'use', 'and', 'experienced', 'effects', 'of', 'ecs', '##tas', '##y', 'was', 'documented', 'at', 'the', 'beginning', 'and', 'after', '6', 'months', 'of', 'regular', 'consumption', 'with', 'a', 'self', 'administered', 'questionnaire', '.', 'results', ':', 'little', 'or', 'no', 'change', 'was', 'observed', 'in', 'acute', 'effects', '.', 'those', 'sub', '##acute', 'effects', 'that', 'had', 'considerable', 'increase', 'in', 'frequency', 'were', 'anxiety', ',', 'depression', ',', 'aggression', ',', 'memory', 'impairment', ',', 'poor', 'concentration', 'and', 'learning', 'problems', '.', 'conclusion', ':', 'small', 'change', 'in', 'acute', 'effects', 'suggests', 'low', 'possibility', 'of', 'tolerance', 'after', 'at', 'least', '6', 'months', 'of', 'regular', 'use', '.', 'our', 'results', 'support', 'long', 'term', 'neuro', '##cognitive', 'damage', 'and', 'mood', 'impairment', 'with', 'ecs', '##tas', '##y', 'use', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 6, 7, 8, 9, 9, 9, 10, 11, 12, 13, 14, 14, 15, 16, 17, 18, 19, 20, 21, 21, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 36, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 65, 65, 66, 67, 68, 69, 70, 71, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 94, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 152, 153, 153, 153, 154, 155, 156, 157, 158, 159, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 174, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 256, 257, 258, 259, 260, 261, 262, 262, 262, 263, 264, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Change in frequency of acute and subacute effects of ecstasy in a group of novice users after 6 months of regular use.^
Background: Recent research trends are to specify the relation between patterns of ecstasy use and side effects, possibility of dependency, tolerance and long term neurocognitive damage. The objective of this study was to assess the impact of regular ecstasy use on its acute and subacute effects. Subjects and methods: At the first stage, we recruited 120 subjects. If participants continued regular use of ecstasy in this period, they were asked to participate in the second stage of the research 6 months later. Thirty-five subjects attended the second stage of the study, 5 of which were excluded because they had less than 5 drug experiences during the last 6 months. At last, we recruited 30 novice ecstasy users by means of the snowball technique in Tehran, Iran. The pattern of use and experienced effects of ecstasy was documented at the beginning and after 6 months of regular consumption with a self administered questionnaire. Results: Little or no change was observed in acute effects. Those subacute effects that had considerable increase in frequency were anxiety, depression, aggression, memory impairment, poor concentration and learning problems. Conclusion: Small change in acute effects suggests low possibility of tolerance after at least 6 months of regular use. Our results support long term neurocognitive damage and mood impairment with ecstasy use."
"['Relationship', 'between', 'cognitive', 'impairment', 'and', 'depressive', 'symptoms', 'in', 'current', 'ketamine', 'users.^', '\n', 'Objective', ':', 'Both', 'cognitive', 'impairment', 'and', 'depressive', 'symptoms', 'have', 'been', 'reported', 'in', 'ketamine', 'users', '.', 'However', ',', 'no', 'previous', 'study', 'has', 'examined', 'the', 'relationship', 'between', 'them', '.', 'This', 'study', 'aimed', 'to', 'examine', 'cognitive', 'functions', 'and', 'depressive', 'symptoms', 'and', 'their', 'relationship', 'in', 'young', 'ketamine', 'users', 'in', 'Hong', 'Kong', '.', 'Method', ':', 'Fifty', '-', 'one', 'current', 'ketamine', 'users', ',', '49', 'ex', '-', 'ketamine', 'users', ',', 'and', '100', 'healthy', 'controls', 'were', 'recruited', 'from', 'counseling', 'and', 'youth', 'centers', 'in', 'Hong', 'Kong', 'in', 'this', 'cross', '-', 'sectional', 'study', '.', 'Cognitive', 'assessment', 'included', 'mental', 'and', 'motor', 'speed', ';', 'working', ',', 'verbal', ',', 'and', 'visual', 'memory', ';', 'and', 'executive', 'functions', '.', 'Depressive', 'symptoms', 'were', 'measured', 'using', 'the', 'Beck', 'Depression', 'Inventory', '.', 'One', '-', 'way', 'analyses', 'of', 'covariance', '(', 'ANCOVA', ')', 'and', 'chi', '-', 'square', 'tests', 'were', 'used', 'to', 'analyze', 'participants', '’', 'demographic', 'data', ',', 'patterns', 'of', 'drug', 'use', ',', 'Beck', 'Depression', 'Inventory', 'score', ',', 'and', 'performance', 'in', 'a', 'cognitive', 'battery', '.', 'Cognitive', 'functions', 'were', 'adjusted', 'for', 'age', ',', 'gender', ',', 'and', 'education', 'using', 'ANCOVA', '.', 'Correlations', 'between', 'the', 'Beck', 'Depression', 'Inventory', 'score', 'and', 'cognitive', 'functions', 'were', 'examined', 'using', 'Pearson', '’s', 'correlation', 'coefficient', '.', 'Results', ':', 'Cognitive', 'impairment', 'was', 'found', 'only', 'in', 'current', 'ketamine', 'users', 'in', 'the', 'domains', 'of', 'mental', 'and', 'motor', 'speed', '(', 'p', '<', '.001', ')', ',', 'visual', 'and', 'verbal', 'memory', '(', 'p', '<', '.001', ')', ',', 'and', 'executive', 'functions', '(', 'p', '<', '.001', ')', '.', 'Depressive', 'symptoms', 'were', 'also', 'more', 'frequently', 'found', 'in', 'current', 'ketamine', 'users', '(', 'p', '<', '.001', ')', '.', 'Correlations', 'between', 'depressive', 'symptoms', 'and', 'certain', 'cognitive', 'scores', 'were', 'statistically', 'significant', 'but', 'modest', '.', 'Conclusions', ':', 'Current', 'ketamine', 'use', 'is', 'associated', 'with', 'cognitive', 'impairment', '.', 'Illicit', 'substance', 'treatment', 'and', 'rehabilitation', 'services', 'should', 'pay', 'attention', 'to', 'ketamine', '’s', 'cognitive', 'effects', 'and', 'motivate', 'their', 'clients', 'to', 'quit', 'using', 'ketamine', 'and', 'stay', 'abstinent', '.', '(', 'PsycINFO', 'Database', 'Record', '(', 'c', ')', '2016', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8466,"['[CLS]', 'relationship', 'between', 'cognitive', 'impairment', 'and', 'depressive', 'symptoms', 'in', 'current', 'ketamine', 'users', '.', '^', 'objective', ':', 'both', 'cognitive', 'impairment', 'and', 'depressive', 'symptoms', 'have', 'been', 'reported', 'in', 'ketamine', 'users', '.', 'however', ',', 'no', 'previous', 'study', 'has', 'examined', 'the', 'relationship', 'between', 'them', '.', 'this', 'study', 'aimed', 'to', 'examine', 'cognitive', 'functions', 'and', 'depressive', 'symptoms', 'and', 'their', 'relationship', 'in', 'young', 'ketamine', 'users', 'in', 'hong', 'kong', '.', 'method', ':', 'fifty', '-', 'one', 'current', 'ketamine', 'users', ',', '49', 'ex', '-', 'ketamine', 'users', ',', 'and', '100', 'healthy', 'controls', 'were', 'recruited', 'from', 'counseling', 'and', 'youth', 'centers', 'in', 'hong', 'kong', 'in', 'this', 'cross', '-', 'sectional', 'study', '.', 'cognitive', 'assessment', 'included', 'mental', 'and', 'motor', 'speed', ';', 'working', ',', 'verbal', ',', 'and', 'visual', 'memory', ';', 'and', 'executive', 'functions', '.', 'depressive', 'symptoms', 'were', 'measured', 'using', 'the', 'beck', 'depression', 'inventory', '.', 'one', '-', 'way', 'analyses', 'of', 'covariance', '(', 'anc', '##ova', ')', 'and', 'chi', '-', 'square', 'tests', 'were', 'used', 'to', 'analyze', 'participants', '’', 'demographic', 'data', ',', 'patterns', 'of', 'drug', 'use', ',', 'beck', 'depression', 'inventory', 'score', ',', 'and', 'performance', 'in', 'a', 'cognitive', 'battery', '.', 'cognitive', 'functions', 'were', 'adjusted', 'for', 'age', ',', 'gender', ',', 'and', 'education', 'using', 'anc', '##ova', '.', 'correlations', 'between', 'the', 'beck', 'depression', 'inventory', 'score', 'and', 'cognitive', 'functions', 'were', 'examined', 'using', 'pearson', '’', 's', 'correlation', 'coefficient', '.', 'results', ':', 'cognitive', 'impairment', 'was', 'found', 'only', 'in', 'current', 'ketamine', 'users', 'in', 'the', 'domains', 'of', 'mental', 'and', 'motor', 'speed', '(', 'p', '<', '.', '00', '##1', ')', ',', 'visual', 'and', 'verbal', 'memory', '(', 'p', '<', '.', '00', '##1', ')', ',', 'and', 'executive', 'functions', '(', 'p', '<', '.', '00', '##1', ')', '.', 'depressive', 'symptoms', 'were', 'also', 'more', 'frequently', 'found', 'in', 'current', 'ketamine', 'users', '(', 'p', '<', '.', '00', '##1', ')', '.', 'correlations', 'between', 'depressive', 'symptoms', 'and', 'certain', 'cognitive', 'scores', 'were', 'statistically', 'significant', 'but', 'modest', '.', 'conclusions', ':', 'current', 'ketamine', 'use', 'is', 'associated', 'with', 'cognitive', 'impairment', '.', 'ill', '##icit', 'substance', 'treatment', 'and', 'rehabilitation', 'services', 'should', 'pay', 'attention', 'to', 'ketamine', '’', 's', 'cognitive', 'effects', 'and', 'motivate', 'their', 'clients', 'to', 'quit', 'using', 'ketamine', 'and', 'stay', 'abst', '##inent', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '2016', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 220, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 230, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 239, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 256, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 308, 309, 310, 311, 311, 311, 312, 313, 314, 315, 316, 317, 318, 318, 319, 320, 321, 322, 323, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Relationship between cognitive impairment and depressive symptoms in current ketamine users.^
Objective: Both cognitive impairment and depressive symptoms have been reported in ketamine users. However, no previous study has examined the relationship between them. This study aimed to examine cognitive functions and depressive symptoms and their relationship in young ketamine users in Hong Kong. Method: Fifty-one current ketamine users, 49 ex-ketamine users, and 100 healthy controls were recruited from counseling and youth centers in Hong Kong in this cross-sectional study. Cognitive assessment included mental and motor speed; working, verbal, and visual memory; and executive functions. Depressive symptoms were measured using the Beck Depression Inventory. One-way analyses of covariance (ANCOVA) and chi-square tests were used to analyze participants’ demographic data, patterns of drug use, Beck Depression Inventory score, and performance in a cognitive battery. Cognitive functions were adjusted for age, gender, and education using ANCOVA. Correlations between the Beck Depression Inventory score and cognitive functions were examined using Pearson’s correlation coefficient. Results: Cognitive impairment was found only in current ketamine users in the domains of mental and motor speed (p < .001), visual and verbal memory (p < .001), and executive functions (p < .001). Depressive symptoms were also more frequently found in current ketamine users (p < .001). Correlations between depressive symptoms and certain cognitive scores were statistically significant but modest. Conclusions: Current ketamine use is associated with cognitive impairment. Illicit substance treatment and rehabilitation services should pay attention to ketamine’s cognitive effects and motivate their clients to quit using ketamine and stay abstinent. (PsycINFO Database Record (c) 2016 APA, all rights reserved)"
"['Effect', 'of', 'baseline', 'anxious', 'depression', 'on', 'initial', 'and', 'sustained', 'antidepressant', 'response', 'to', 'ketamine.^', '\n', 'OBJECTIVE', ':', 'Patients', 'with', 'anxious', 'depression', 'are', 'typically', 'more', 'difficult', 'to', 'treat', 'with', 'monoaminergic', 'antidepressants', 'compared', 'to', 'those', 'with', 'nonanxious', 'depression', '.', 'Although', 'novel', 'research', 'has', 'shown', 'that', 'the', 'N', '-', 'methyl', '-', 'D', '-', 'aspartate', '(', 'NMDA', ')', 'receptor', 'antagonist', 'ketamine', 'has', 'rapidly', 'acting', ',', 'relatively', 'sustained', 'effects', 'in', 'treating', 'depression', ',', 'we', 'predicted', 'that', ',', 'consistent', 'with', 'the', 'existent', 'literature', 'on', 'traditional', 'antidepressants', ',', 'patients', 'with', 'anxious', 'depression', 'would', 'have', 'a', 'poorer', 'antidepressant', 'response', '.', 'METHOD', ':', 'Twenty', '-', 'six', 'inpatients', 'with', 'treatment', '-', 'resistant', 'major', 'depressive', 'disorder', '(', 'MDD', ')', '(', 'DSM', '-', 'IV', 'criteria', ')', 'received', 'a', 'single', 'infusion', 'of', 'ketamine', '(', '0.5', 'mg', '/', 'kg', 'over', '40', 'minutes', ')', 'from', 'January', '2006', '-', 'March', '2013', 'and', 'were', 'followed', 'for', '28', 'days', '.', 'A', 'post', 'hoc', 'analysis', 'compared', 'treatment', 'response', 'and', 'relapse', 'using', 'the', 'Montgomery', '-', 'Asberg', 'Depression', 'Rating', 'Scale', '(', 'MADRS', ')', 'in', 'patients', 'with', 'anxious', 'versus', 'nonanxious', 'depression', '.', 'Anxious', 'depression', 'was', 'defined', 'as', 'MDD', 'plus', 'a', 'Hamilton', 'Depression', 'Rating', 'Scale', 'anxiety', '/', 'somatization', 'factor', 'score', '≥', '7', '.', 'RESULTS', ':', 'Both', 'anxious', 'and', 'nonanxious', 'depressed', 'patients', 'responded', 'positively', 'to', 'ketamine', '.', 'A', 'linear', 'mixed', 'model', 'controlling', 'for', 'baseline', 'with', 'the', 'MADRS', 'revealed', 'a', 'significant', 'group', 'main', 'effect', '(', 'P', '=', '.03', ')', 'and', 'group', '-', 'by', '-', 'time', 'interaction', '(', 'P', '=', '.01', ')', '.', 'Post', 'hoc', 'tests', 'indicated', 'that', 'patients', 'with', 'anxious', 'depression', 'had', 'significantly', 'fewer', 'depression', 'symptoms', 'compared', 'to', 'those', 'with', 'nonanxious', 'depression', 'at', 'days', '1', 'through', '5', ',', '9', 'through', '12', ',', '15', 'through', '17', ',', 'and', '25', ',', 'with', 'no', 'significant', 'group', 'differences', 'in', 'dissociative', '(', 'P', '=', '.62', ')', 'or', 'psychotic', '(', 'P', '=', '.41', ')', 'side', 'effects', '.', 'Regarding', 'responders', ',', 'patients', 'with', 'anxious', 'depression', 'relapsed', 'significantly', 'later', 'than', 'those', 'with', 'nonanxious', 'depression', '(', 'median', '±', 'SE', '=', '19.0', '±', '17.9', 'vs', '1.0', '±', '0.0', 'days', 'to', 'relapse', ',', 'respectively', ';', 'χ²', '=', '9.30', ';', 'P', '=', '.002', ')', '.', 'CONCLUSIONS', ':', 'Unexpectedly', ',', 'patients', 'with', 'anxious', 'depression', 'responded', 'better', 'to', 'ketamine', 'than', 'those', 'with', 'nonanxious', 'depression', ',', 'with', 'longer', 'time', 'to', 'relapse', 'and', 'no', 'side', 'effect', 'differences', '.', 'This', 'finding', 'gives', 'promise', 'for', 'the', 'role', 'of', 'novel', 'glutamatergic', 'medications', 'for', 'the', 'treatment', 'of', 'those', 'with', 'anxious', 'depression', ',', 'a', 'traditionally', 'difficult', '-', 'to', '-', 'treat', 'subgroup', 'of', 'depressed', 'patients', '.', 'TRIAL', 'REGISTRATION', ':', 'ClinicalTrials.gov', 'identifier', ':', 'NCT00088699', '.']","['O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3820,"['[CLS]', 'effect', 'of', 'baseline', 'anxious', 'depression', 'on', 'initial', 'and', 'sustained', 'antidepressant', 'response', 'to', 'ketamine', '.', '^', 'objective', ':', 'patients', 'with', 'anxious', 'depression', 'are', 'typically', 'more', 'difficult', 'to', 'treat', 'with', 'mono', '##aminergic', 'antidepressants', 'compared', 'to', 'those', 'with', 'non', '##an', '##xi', '##ous', 'depression', '.', 'although', 'novel', 'research', 'has', 'shown', 'that', 'the', 'n', '-', 'methyl', '-', 'd', '-', 'aspartate', '(', 'nmda', ')', 'receptor', 'antagonist', 'ketamine', 'has', 'rapidly', 'acting', ',', 'relatively', 'sustained', 'effects', 'in', 'treating', 'depression', ',', 'we', 'predicted', 'that', ',', 'consistent', 'with', 'the', 'exist', '##ent', 'literature', 'on', 'traditional', 'antidepressants', ',', 'patients', 'with', 'anxious', 'depression', 'would', 'have', 'a', 'poorer', 'antidepressant', 'response', '.', 'method', ':', 'twenty', '-', 'six', 'inpatient', '##s', 'with', 'treatment', '-', 'resistant', 'major', 'depressive', 'disorder', '(', 'mdd', ')', '(', 'dsm', '-', 'iv', 'criteria', ')', 'received', 'a', 'single', 'infusion', 'of', 'ketamine', '(', '0', '.', '5', 'mg', '/', 'kg', 'over', '40', 'minutes', ')', 'from', 'january', '2006', '-', 'march', '2013', 'and', 'were', 'followed', 'for', '28', 'days', '.', 'a', 'post', 'hoc', 'analysis', 'compared', 'treatment', 'response', 'and', 'relapse', 'using', 'the', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', '(', 'mad', '##rs', ')', 'in', 'patients', 'with', 'anxious', 'versus', 'non', '##an', '##xi', '##ous', 'depression', '.', 'anxious', 'depression', 'was', 'defined', 'as', 'mdd', 'plus', 'a', 'hamilton', 'depression', 'rating', 'scale', 'anxiety', '/', 'somat', '##ization', 'factor', 'score', '≥', '7', '.', 'results', ':', 'both', 'anxious', 'and', 'non', '##an', '##xi', '##ous', 'depressed', 'patients', 'responded', 'positively', 'to', 'ketamine', '.', 'a', 'linear', 'mixed', 'model', 'controlling', 'for', 'baseline', 'with', 'the', 'mad', '##rs', 'revealed', 'a', 'significant', 'group', 'main', 'effect', '(', 'p', '=', '.', '03', ')', 'and', 'group', '-', 'by', '-', 'time', 'interaction', '(', 'p', '=', '.', '01', ')', '.', 'post', 'hoc', 'tests', 'indicated', 'that', 'patients', 'with', 'anxious', 'depression', 'had', 'significantly', 'fewer', 'depression', 'symptoms', 'compared', 'to', 'those', 'with', 'non', '##an', '##xi', '##ous', 'depression', 'at', 'days', '1', 'through', '5', ',', '9', 'through', '12', ',', '15', 'through', '17', ',', 'and', '25', ',', 'with', 'no', 'significant', 'group', 'differences', 'in', 'dissoci', '##ative', '(', 'p', '=', '.', '62', ')', 'or', 'psychotic', '(', 'p', '=', '.', '41', ')', 'side', 'effects', '.', 'regarding', 'responders', ',', 'patients', 'with', 'anxious', 'depression', 'relapse', '##d', 'significantly', 'later', 'than', 'those', 'with', 'non', '##an', '##xi', '##ous', 'depression', '(', 'median', '±', 'se', '=', '19', '.', '0', '±', '17', '.', '9', 'vs', '1', '.', '0', '±', '0', '.', '0', 'days', 'to', 'relapse', ',', 'respectively', ';', '[UNK]', '=', '9', '.', '30', ';', 'p', '=', '.', '00', '##2', ')', '.', 'conclusions', ':', 'unexpectedly', ',', 'patients', 'with', 'anxious', 'depression', 'responded', 'better', 'to', 'ketamine', 'than', 'those', 'with', 'non', '##an', '##xi', '##ous', 'depression', ',', 'with', 'longer', 'time', 'to', 'relapse', 'and', 'no', 'side', 'effect', 'differences', '.', 'this', 'finding', 'gives', 'promise', 'for', 'the', 'role', 'of', 'novel', 'glutamate', '##rg', '##ic', 'medications', 'for', 'the', 'treatment', 'of', 'those', 'with', 'anxious', 'depression', ',', 'a', 'traditionally', 'difficult', '-', 'to', '-', 'treat', 'subgroup', 'of', 'depressed', 'patients', '.', 'trial', 'registration', ':', 'clinical', '##trials', '.', 'go', '##v', 'identifier', ':', 'nct', '##000', '##88', '##69', '##9', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 27, 28, 29, 30, 31, 32, 33, 33, 33, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 120, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 152, 152, 152, 153, 154, 154, 155, 156, 157, 158, 159, 159, 160, 161, 162, 163, 164, 165, 166, 166, 166, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 194, 194, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 254, 254, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 279, 280, 281, 282, 283, 283, 284, 285, 286, 287, 288, 289, 290, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 302, 303, 304, 305, 306, 307, 308, 308, 308, 308, 309, 310, 311, 312, 313, 314, 315, 315, 315, 316, 317, 317, 317, 318, 319, 319, 319, 320, 321, 321, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 330, 330, 331, 332, 333, 334, 334, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 352, 352, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 375, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 401, 401, 401, 401, 402, 403, 404, 404, 404, 404, 404, 405, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.^
OBJECTIVE: Patients with anxious depression are typically more difficult to treat with monoaminergic antidepressants compared to those with nonanxious depression. Although novel research has shown that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapidly acting, relatively sustained effects in treating depression, we predicted that, consistent with the existent literature on traditional antidepressants, patients with anxious depression would have a poorer antidepressant response. METHOD: Twenty-six inpatients with treatment-resistant major depressive disorder (MDD) (DSM-IV criteria) received a single infusion of ketamine (0.5 mg/kg over 40 minutes) from January 2006-March 2013 and were followed for 28 days. A post hoc analysis compared treatment response and relapse using the Montgomery-Asberg Depression Rating Scale (MADRS) in patients with anxious versus nonanxious depression. Anxious depression was defined as MDD plus a Hamilton Depression Rating Scale anxiety/somatization factor score ≥ 7. RESULTS: Both anxious and nonanxious depressed patients responded positively to ketamine. A linear mixed model controlling for baseline with the MADRS revealed a significant group main effect (P = .03) and group-by-time interaction (P = .01). Post hoc tests indicated that patients with anxious depression had significantly fewer depression symptoms compared to those with nonanxious depression at days 1 through 5, 9 through 12, 15 through 17, and 25, with no significant group differences in dissociative (P = .62) or psychotic (P = .41) side effects. Regarding responders, patients with anxious depression relapsed significantly later than those with nonanxious depression (median ± SE = 19.0 ± 17.9 vs 1.0 ± 0.0 days to relapse, respectively; χ² = 9.30; P = .002). CONCLUSIONS: Unexpectedly, patients with anxious depression responded better to ketamine than those with nonanxious depression, with longer time to relapse and no side effect differences. This finding gives promise for the role of novel glutamatergic medications for the treatment of those with anxious depression, a traditionally difficult-to-treat subgroup of depressed patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00088699."
"['Efficacy', 'of', 'repeated', 'intravenous', 'esketamine', 'in', 'adolescents', 'with', 'anxious', 'versus', 'non', '-', 'anxious', 'depression.^', '\n', 'BACKGROUND', ':', 'Patients', 'with', 'anxious', 'major', 'depressive', 'disorder', '(', 'MDD', ')', 'are', 'more', 'likely', 'to', 'have', 'poorer', 'outcomes', 'than', 'those', 'with', 'non', '-', 'anxious', 'MDD', '.', 'However', ',', 'the', 'effect', 'of', 'esketamine', 'on', 'adolescents', 'with', 'anxious', 'versus', 'non', '-', 'anxious', 'MDD', 'has', 'remained', 'unknown', '.', 'AIMS', ':', 'We', 'compared', 'the', 'efficacy', 'of', 'esketamine', 'in', 'adolescents', 'with', 'MDD', 'and', 'suicidal', 'ideation', ',', 'both', 'anxious', 'and', 'non', '-', 'anxious', '.', 'METHODS', ':', 'Fifty', '-', 'four', 'adolescents', 'with', 'anxious', '(', 'n=33', ')', 'and', 'non', '-', 'anxious', '(', 'n=21', ')', 'MDD', 'received', 'three', 'infusions', 'of', 'esketamine', '0.25', 'mg', '/', 'kg', 'or', 'active', '-', 'placebo', '(', 'midazolam', '0.045', 'mg', '/', 'kg', ')', 'over', '5', 'days', ',', 'with', 'routine', 'inpatient', 'care', 'and', 'treatment', '.', 'Suicidal', 'ideation', 'and', 'depressive', 'symptoms', 'were', 'assessed', 'using', 'the', 'Columbia', 'Suicide', 'Severity', 'Rating', 'Scale', 'and', 'the', 'Montgomery', '-', 'Åsberg', 'Depression', 'Rating', 'Scale', '.', 'Multiple', '-', 'sample', 'proportional', 'tests', 'were', 'used', 'to', 'compare', 'the', 'differences', 'between', 'groups', 'on', 'treatment', 'outcomes', '24', 'hours', 'after', 'the', 'final', 'infusion', '(', 'day', '6', ',', 'primacy', 'efficacy', 'endpoint', ')', 'and', 'throughout', 'the', '4', '-', 'week', 'post', '-', 'treatment', '(', 'days', '12', ',', '19', 'and', '33', ')', '.', 'RESULTS', ':', 'In', 'subjects', 'who', 'received', 'esketamine', ',', 'a', 'greater', 'number', 'of', 'patients', 'in', 'the', 'non', '-', 'anxious', 'group', 'than', 'the', 'anxious', 'group', 'achieved', 'antisuicidal', 'remission', 'on', 'day', '6', '(', '72.7', '%', 'vs', '18.8', '%', ',', 'p=0.015', ')', 'and', 'day', '12', '(', '90.9', '%', 'vs', '43.8', '%', ',', 'p=0.013', ')', ',', 'and', 'the', 'non', '-', 'anxious', 'group', 'had', 'a', 'higher', 'antidepressant', 'remission', 'rate', 'compared', 'with', 'the', 'anxious', 'group', 'on', 'day', '33', '(', '72.7', '%', 'vs', '26.7', '%', ',', 'p=0.045', ')', '.', 'No', 'significant', 'differences', 'in', 'treatment', 'outcomes', 'were', 'observed', 'between', 'the', 'anxious', 'and', 'non', '-', 'anxious', 'groups', 'at', 'other', 'time', 'points', '.', 'CONCLUSIONS', ':', 'Three', 'infusions', 'of', 'esketamine', 'as', 'an', 'adjunct', 'to', 'routine', 'inpatient', 'care', 'and', 'treatment', 'had', 'a', 'greater', 'immediate', 'post', '-', 'treatment', 'antisuicidal', 'effect', 'in', 'adolescents', 'with', 'non', '-', 'anxious', 'MDD', 'than', 'in', 'those', 'with', 'anxious', 'MDD', ';', 'however', ',', 'this', 'benefit', 'was', 'temporary', 'and', 'was', 'not', 'maintained', 'over', 'time', '.', 'TRIAL', 'REGISTRATION', 'NUMBER', ':', 'ChiCTR2000041232', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",4708,"['[CLS]', 'efficacy', 'of', 'repeated', 'intravenous', 'es', '##ket', '##amine', 'in', 'adolescents', 'with', 'anxious', 'versus', 'non', '-', 'anxious', 'depression', '.', '^', 'background', ':', 'patients', 'with', 'anxious', 'major', 'depressive', 'disorder', '(', 'mdd', ')', 'are', 'more', 'likely', 'to', 'have', 'poorer', 'outcomes', 'than', 'those', 'with', 'non', '-', 'anxious', 'mdd', '.', 'however', ',', 'the', 'effect', 'of', 'es', '##ket', '##amine', 'on', 'adolescents', 'with', 'anxious', 'versus', 'non', '-', 'anxious', 'mdd', 'has', 'remained', 'unknown', '.', 'aims', ':', 'we', 'compared', 'the', 'efficacy', 'of', 'es', '##ket', '##amine', 'in', 'adolescents', 'with', 'mdd', 'and', 'suicidal', 'idea', '##tion', ',', 'both', 'anxious', 'and', 'non', '-', 'anxious', '.', 'methods', ':', 'fifty', '-', 'four', 'adolescents', 'with', 'anxious', '(', 'n', '=', '33', ')', 'and', 'non', '-', 'anxious', '(', 'n', '=', '21', ')', 'mdd', 'received', 'three', 'infusions', 'of', 'es', '##ket', '##amine', '0', '.', '25', 'mg', '/', 'kg', 'or', 'active', '-', 'placebo', '(', 'mid', '##azol', '##am', '0', '.', '04', '##5', 'mg', '/', 'kg', ')', 'over', '5', 'days', ',', 'with', 'routine', 'inpatient', 'care', 'and', 'treatment', '.', 'suicidal', 'idea', '##tion', 'and', 'depressive', 'symptoms', 'were', 'assessed', 'using', 'the', 'columbia', 'suicide', 'severity', 'rating', 'scale', 'and', 'the', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', '.', 'multiple', '-', 'sample', 'proportional', 'tests', 'were', 'used', 'to', 'compare', 'the', 'differences', 'between', 'groups', 'on', 'treatment', 'outcomes', '24', 'hours', 'after', 'the', 'final', 'infusion', '(', 'day', '6', ',', 'prim', '##acy', 'efficacy', 'endpoint', ')', 'and', 'throughout', 'the', '4', '-', 'week', 'post', '-', 'treatment', '(', 'days', '12', ',', '19', 'and', '33', ')', '.', 'results', ':', 'in', 'subjects', 'who', 'received', 'es', '##ket', '##amine', ',', 'a', 'greater', 'number', 'of', 'patients', 'in', 'the', 'non', '-', 'anxious', 'group', 'than', 'the', 'anxious', 'group', 'achieved', 'antis', '##ui', '##cid', '##al', 'remission', 'on', 'day', '6', '(', '72', '.', '7', '%', 'vs', '18', '.', '8', '%', ',', 'p', '=', '0', '.', '01', '##5', ')', 'and', 'day', '12', '(', '90', '.', '9', '%', 'vs', '43', '.', '8', '%', ',', 'p', '=', '0', '.', '01', '##3', ')', ',', 'and', 'the', 'non', '-', 'anxious', 'group', 'had', 'a', 'higher', 'antidepressant', 'remission', 'rate', 'compared', 'with', 'the', 'anxious', 'group', 'on', 'day', '33', '(', '72', '.', '7', '%', 'vs', '26', '.', '7', '%', ',', 'p', '=', '0', '.', '04', '##5', ')', '.', 'no', 'significant', 'differences', 'in', 'treatment', 'outcomes', 'were', 'observed', 'between', 'the', 'anxious', 'and', 'non', '-', 'anxious', 'groups', 'at', 'other', 'time', 'points', '.', 'conclusions', ':', 'three', 'infusions', 'of', 'es', '##ket', '##amine', 'as', 'an', 'adjunct', 'to', 'routine', 'inpatient', 'care', 'and', 'treatment', 'had', 'a', 'greater', 'immediate', 'post', '-', 'treatment', 'antis', '##ui', '##cid', '##al', 'effect', 'in', 'adolescents', 'with', 'non', '-', 'anxious', 'mdd', 'than', 'in', 'those', 'with', 'anxious', 'mdd', ';', 'however', ',', 'this', 'benefit', 'was', 'temporary', 'and', 'was', 'not', 'maintained', 'over', 'time', '.', 'trial', 'registration', 'number', ':', 'chic', '##tr', '##2000', '##04', '##123', '##2', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 4, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 13, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 46, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 67, 67, 68, 69, 70, 71, 72, 73, 74, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 92, 92, 93, 94, 95, 96, 97, 98, 99, 99, 99, 100, 101, 102, 103, 104, 105, 106, 106, 106, 107, 107, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 116, 116, 117, 117, 117, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 149, 149, 149, 150, 151, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 210, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 228, 228, 228, 229, 230, 231, 232, 233, 234, 234, 234, 235, 236, 237, 237, 237, 238, 239, 240, 240, 240, 240, 240, 240, 241, 242, 243, 244, 245, 246, 246, 246, 247, 248, 249, 249, 249, 250, 251, 252, 252, 252, 252, 252, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 276, 276, 277, 278, 279, 279, 279, 280, 281, 282, 282, 282, 282, 282, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 311, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 328, 328, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 361, 361, 361, 361, 361, 362, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression.^
BACKGROUND: Patients with anxious major depressive disorder (MDD) are more likely to have poorer outcomes than those with non-anxious MDD. However, the effect of esketamine on adolescents with anxious versus non-anxious MDD has remained unknown. AIMS: We compared the efficacy of esketamine in adolescents with MDD and suicidal ideation, both anxious and non-anxious. METHODS: Fifty-four adolescents with anxious (n=33) and non-anxious (n=21) MDD received three infusions of esketamine 0.25 mg/kg or active-placebo (midazolam 0.045 mg/kg) over 5 days, with routine inpatient care and treatment. Suicidal ideation and depressive symptoms were assessed using the Columbia Suicide Severity Rating Scale and the Montgomery-Åsberg Depression Rating Scale. Multiple-sample proportional tests were used to compare the differences between groups on treatment outcomes 24 hours after the final infusion (day 6, primacy efficacy endpoint) and throughout the 4-week post-treatment (days 12, 19 and 33). RESULTS: In subjects who received esketamine, a greater number of patients in the non-anxious group than the anxious group achieved antisuicidal remission on day 6 (72.7% vs 18.8%, p=0.015) and day 12 (90.9% vs 43.8%, p=0.013), and the non-anxious group had a higher antidepressant remission rate compared with the anxious group on day 33 (72.7% vs 26.7%, p=0.045). No significant differences in treatment outcomes were observed between the anxious and non-anxious groups at other time points. CONCLUSIONS: Three infusions of esketamine as an adjunct to routine inpatient care and treatment had a greater immediate post-treatment antisuicidal effect in adolescents with non-anxious MDD than in those with anxious MDD; however, this benefit was temporary and was not maintained over time. TRIAL REGISTRATION NUMBER: ChiCTR2000041232."
"['Comparability', 'of', 'blinded', 'remote', 'and', 'site', '-', 'based', 'assessments', 'of', 'response', 'to', 'adjunctive', 'esketamine', 'or', 'placebo', 'nasal', 'spray', 'in', 'patients', 'with', 'treatment', 'resistant', 'depression.^', '\n', 'Functional', 'unblinding', 'due', 'to', 'treatment', 'emergent', 'adverse', 'events', '(', 'TEAEs', ')', 'may', 'occur', 'with', 'any', 'investigational', 'drug', 'and', 'poses', 'a', 'challenge', 'for', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'studies', '.', 'This', 'pilot', 'study', 'compared', 'site', '-', 'based', 'Montgomery', '-', 'Asberg', 'Depression', 'Rating', 'Scale', '(', 'MADRS', ')', 'scores', 'to', 'remote', ',', 'site', '-', 'independent', 'scores', 'by', 'blinded', 'raters', '.', 'Audio', '-', 'digital', 'recordings', 'of', 'site', '-', 'based', 'MADRS', 'interviews', 'were', 'obtained', 'from', 'a', 'subset', 'of', 'patients', 'during', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'study', 'of', 'esketamine', 'nasal', 'spray', 'or', 'placebo', 'spray', 'in', 'treatment', 'resistant', 'depression', '(', 'Clinical', 'Trials', 'Registration', ':', 'NCT01998958', ')', '.', 'Fourteen', 'of', '67', 'patients', '(', '21', '%', ')', 'in', 'the', 'ITT', 'population', 'were', 'randomly', 'selected', 'from', '3', 'clinical', 'trial', 'sites', '.', 'The', 'site', '-', 'based', 'MADRS', 'interviews', 'were', 'recorded', 'at', 'the', 'baseline', 'and', '2', 'h', 'post', '-', 'dose', 'assessments', 'on', 'the', 'first', 'intranasal', 'dosing', 'day', '.', 'Site', '-', 'independent', 'raters', 'scored', 'the', 'recordings', 'and', 'were', 'blinded', 'to', 'treatment', 'and', 'all', 'reported', 'TEAEs', ',', 'including', 'any', 'transient', 'dissociative', '/', 'perceptual', 'symptoms', '.', 'None', 'of', 'the', '7', 'placebo', '-', 'assigned', 'patients', 'achieved', 'a', 'treatment', 'response', 'or', 'remission', 'at', 'the', '2', '-', 'h', 'post', '-', 'dose', 'assessment', '.', 'Four', 'of', 'the', '7', 'esketamine', '-', 'assigned', 'patients', '(', '57.1', '%', ')', 'achieved', 'a', 'treatment', 'response', 'at', '2', '-', 'h', 'post', '-', 'dose', ',', 'and', '3', 'patients', '(', '42.9', '%', ')', 'achieved', 'remission', '.', 'Three', 'esketamine', '-', 'treated', 'patients', 'experienced', 'transient', 'dissociative', 'symptoms', '.', 'The', 'remote', 'site', '-', 'independent', 'raters', 'essentially', 'replicated', 'the', 'site', '-', 'based', 'MADRS', 'scores', 'and', 'yielded', 'a', '92.9', '%', 'predictive', 'value', 'for', 'matching', 'treatment', 'response', 'and', 'remission', 'rates', '.', 'This', 'small', 'pilot', 'study', 'affirms', 'that', 'blinded', 'remote', 'ratings', '(', 'without', 'the', 'likelihood', 'of', 'functional', 'unblinding', ')', 'are', 'comparable', 'to', 'site', '-', 'based', 'ratings', 'of', 'efficacy', 'of', 'esketamine', 'nasal', 'spray', '.', 'The', 'audio', '-', 'digital', 'recording', 'method', 'offers', 'a', 'reasonable', 'strategy', 'for', 'other', 'studies', 'that', 'may', 'also', 'be', 'vulnerable', 'to', 'functional', 'unblinding', 'due', 'to', 'distinctive', 'TEAEs', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8470,"['[CLS]', 'compar', '##ability', 'of', 'blinded', 'remote', 'and', 'site', '-', 'based', 'assessments', 'of', 'response', 'to', 'adjunct', '##ive', 'es', '##ket', '##amine', 'or', 'placebo', 'nasal', 'spray', 'in', 'patients', 'with', 'treatment', 'resistant', 'depression', '.', '^', 'functional', 'un', '##blind', '##ing', 'due', 'to', 'treatment', 'emergent', 'adverse', 'events', '(', 'tea', '##es', ')', 'may', 'occur', 'with', 'any', 'investigation', '##al', 'drug', 'and', 'poses', 'a', 'challenge', 'for', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'studies', '.', 'this', 'pilot', 'study', 'compared', 'site', '-', 'based', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', '(', 'mad', '##rs', ')', 'scores', 'to', 'remote', ',', 'site', '-', 'independent', 'scores', 'by', 'blinded', 'rate', '##rs', '.', 'audio', '-', 'digital', 'recordings', 'of', 'site', '-', 'based', 'mad', '##rs', 'interviews', 'were', 'obtained', 'from', 'a', 'subset', 'of', 'patients', 'during', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'study', 'of', 'es', '##ket', '##amine', 'nasal', 'spray', 'or', 'placebo', 'spray', 'in', 'treatment', 'resistant', 'depression', '(', 'clinical', 'trials', 'registration', ':', 'nct', '##019', '##98', '##95', '##8', ')', '.', 'fourteen', 'of', '67', 'patients', '(', '21', '%', ')', 'in', 'the', 'it', '##t', 'population', 'were', 'randomly', 'selected', 'from', '3', 'clinical', 'trial', 'sites', '.', 'the', 'site', '-', 'based', 'mad', '##rs', 'interviews', 'were', 'recorded', 'at', 'the', 'baseline', 'and', '2', 'h', 'post', '-', 'dose', 'assessments', 'on', 'the', 'first', 'intran', '##asal', 'dosing', 'day', '.', 'site', '-', 'independent', 'rate', '##rs', 'scored', 'the', 'recordings', 'and', 'were', 'blinded', 'to', 'treatment', 'and', 'all', 'reported', 'tea', '##es', ',', 'including', 'any', 'transient', 'dissoci', '##ative', '/', 'perceptual', 'symptoms', '.', 'none', 'of', 'the', '7', 'placebo', '-', 'assigned', 'patients', 'achieved', 'a', 'treatment', 'response', 'or', 'remission', 'at', 'the', '2', '-', 'h', 'post', '-', 'dose', 'assessment', '.', 'four', 'of', 'the', '7', 'es', '##ket', '##amine', '-', 'assigned', 'patients', '(', '57', '.', '1', '%', ')', 'achieved', 'a', 'treatment', 'response', 'at', '2', '-', 'h', 'post', '-', 'dose', ',', 'and', '3', 'patients', '(', '42', '.', '9', '%', ')', 'achieved', 'remission', '.', 'three', 'es', '##ket', '##amine', '-', 'treated', 'patients', 'experienced', 'transient', 'dissoci', '##ative', 'symptoms', '.', 'the', 'remote', 'site', '-', 'independent', 'rate', '##rs', 'essentially', 'replicated', 'the', 'site', '-', 'based', 'mad', '##rs', 'scores', 'and', 'yielded', 'a', '92', '.', '9', '%', 'predictive', 'value', 'for', 'matching', 'treatment', 'response', 'and', 'remission', 'rates', '.', 'this', 'small', 'pilot', 'study', 'affirm', '##s', 'that', 'blinded', 'remote', 'ratings', '(', 'without', 'the', 'likelihood', 'of', 'functional', 'un', '##blind', '##ing', ')', 'are', 'comparable', 'to', 'site', '-', 'based', 'ratings', 'of', 'efficacy', 'of', 'es', '##ket', '##amine', 'nasal', 'spray', '.', 'the', 'audio', '-', 'digital', 'recording', 'method', 'offers', 'a', 'reasonable', 'strategy', 'for', 'other', 'studies', 'that', 'may', 'also', 'be', 'vulnerable', 'to', 'functional', 'un', '##blind', '##ing', 'due', 'to', 'distinctive', 'tea', '##es', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12, 13, 13, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 23, 25, 26, 26, 26, 27, 28, 29, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 63, 63, 63, 64, 65, 65, 66, 67, 68, 69, 70, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 112, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 127, 127, 127, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 172, 173, 174, 175, 176, 177, 178, 179, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 191, 192, 193, 194, 195, 196, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 229, 229, 230, 231, 232, 233, 234, 234, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 253, 253, 254, 255, 256, 257, 258, 259, 260, 260, 260, 261, 262, 263, 264, 265, 266, 266, 267, 268, 269, 270, 271, 272, 273, 274, 274, 275, 276, 277, 278, 279, 280, 281, 281, 282, 283, 284, 285, 286, 286, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 313, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 325, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 349, 349, 350, 351, 352, 353, 353, 354, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression.^
Functional unblinding due to treatment emergent adverse events (TEAEs) may occur with any investigational drug and poses a challenge for double-blind, placebo-controlled studies. This pilot study compared site-based Montgomery-Asberg Depression Rating Scale (MADRS) scores to remote, site-independent scores by blinded raters. Audio-digital recordings of site-based MADRS interviews were obtained from a subset of patients during a double-blind, placebo-controlled study of esketamine nasal spray or placebo spray in treatment resistant depression (Clinical Trials Registration: NCT01998958). Fourteen of 67 patients (21%) in the ITT population were randomly selected from 3 clinical trial sites. The site-based MADRS interviews were recorded at the baseline and 2 h post-dose assessments on the first intranasal dosing day. Site-independent raters scored the recordings and were blinded to treatment and all reported TEAEs, including any transient dissociative/perceptual symptoms. None of the 7 placebo-assigned patients achieved a treatment response or remission at the 2-h post-dose assessment. Four of the 7 esketamine-assigned patients (57.1%) achieved a treatment response at 2-h post-dose, and 3 patients (42.9%) achieved remission. Three esketamine-treated patients experienced transient dissociative symptoms. The remote site-independent raters essentially replicated the site-based MADRS scores and yielded a 92.9% predictive value for matching treatment response and remission rates. This small pilot study affirms that blinded remote ratings (without the likelihood of functional unblinding) are comparable to site-based ratings of efficacy of esketamine nasal spray. The audio-digital recording method offers a reasonable strategy for other studies that may also be vulnerable to functional unblinding due to distinctive TEAEs."
"['Safety', ',', 'tolerability', ',', 'pharmacokinetics', ',', 'and', 'pharmacodynamics', 'of', 'low', 'dose', 'lysergic', 'acid', 'diethylamide', '(', 'LSD', ')', 'in', 'healthy', 'older', 'volunteers.^', '\n', 'Research', 'has', 'shown', 'that', 'psychedelics', ',', 'such', 'as', 'lysergic', 'acid', 'diethylamide', '(', 'LSD', ')', ',', 'have', 'profound', 'anti', '-', 'inflammatory', 'properties', 'mediated', 'by', '5', '-', 'HT(2A', ')', 'receptor', 'signaling', ',', 'supporting', 'their', 'evaluation', 'as', 'a', 'therapeutic', 'for', 'neuroinflammation', 'associated', 'with', 'neurodegenerative', 'disease', '.', 'OBJECTIVE', ':', 'This', 'study', 'evaluated', 'the', 'safety', ',', 'tolerability', ',', 'pharmacokinetics', ',', 'and', 'pharmacodynamics', 'of', 'orally', 'repeated', 'administration', 'of', '5', 'μg', ',', '10', 'μg', ',', 'and', '20', 'μg', 'LSD', 'in', 'older', 'healthy', 'individuals', '.', 'In', 'the', 'current', 'paper', ',', 'we', 'present', 'safety', ',', 'tolerability', ',', 'pharmacokinetics', ',', 'and', 'pharmacodynamic', 'measures', 'that', 'relate', 'to', 'safety', ',', 'tolerability', ',', 'and', 'dose', 'response', '.', 'METHODS', ':', 'This', 'was', 'a', 'phase', '1', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'randomized', 'study', '.', 'Volunteers', 'were', 'randomly', 'assigned', 'to', '1', 'of', '4', 'dose', 'groups', '(', '5', 'μg', ',', '10', 'μg', ',', '20', 'μg', 'LSD', ',', 'and', 'placebo', ')', ',', 'and', 'received', 'their', 'assigned', 'dose', 'on', 'six', 'occasions', '(', 'i.e.', ',', 'every', '4', 'days', ')', '.', 'RESULTS', ':', 'Forty', '-', 'eight', 'older', 'healthy', 'volunteers', '(', 'mean', 'age', '=', '62.9', 'years', ')', 'received', 'placebo', '(', 'n', '=', '12', ')', ',', '5', 'μg', '(', 'n', '=', '12', ')', ',', '10', 'μg', '(', 'n', '=', '12', ')', ',', 'or', '20', 'μg', '(', 'n', '=', '12', ')', 'LSD', '.', 'LSD', 'plasma', 'levels', 'were', 'undetectable', 'for', 'the', '5', 'μg', 'group', 'and', 'peak', 'blood', 'plasma', 'levels', 'for', 'the', '10', 'μg', 'and', '20', 'μg', 'groups', 'occurred', 'at', '30', 'min', '.', 'LSD', 'was', 'well', 'tolerated', ',', 'and', 'the', 'frequency', 'of', 'adverse', 'events', 'was', 'no', 'higher', 'than', 'for', 'placebo', '.', 'Assessments', 'of', 'cognition', ',', 'balance', ',', 'and', 'proprioception', 'revealed', 'no', 'impairment', '.', 'CONCLUSIONS', ':', 'Our', 'results', 'suggest', 'safety', 'and', 'tolerability', 'of', 'orally', 'administered', '5', 'μg', ',', '10', 'μg', ',', 'and', '20', 'μg', 'LSD', 'every', 'fourth', 'day', 'over', 'a', '21', '-', 'day', 'period', 'and', 'support', 'further', 'clinical', 'development', 'of', 'LSD', 'for', 'the', 'treatment', 'and', 'prevention', 'of', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'O', 'B-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",2482,"['[CLS]', 'safety', ',', 'tolerability', ',', 'pharmacokinetic', '##s', ',', 'and', 'pharmac', '##odynamics', 'of', 'low', 'dose', 'lys', '##ergic', 'acid', 'diethyl', '##amide', '(', 'lsd', ')', 'in', 'healthy', 'older', 'volunteers', '.', '^', 'research', 'has', 'shown', 'that', 'psych', '##ede', '##lic', '##s', ',', 'such', 'as', 'lys', '##ergic', 'acid', 'diethyl', '##amide', '(', 'lsd', ')', ',', 'have', 'profound', 'anti', '-', 'inflammatory', 'properties', 'mediated', 'by', '5', '-', 'ht', '(', '2', '##a', ')', 'receptor', 'signaling', ',', 'supporting', 'their', 'evaluation', 'as', 'a', 'therapeutic', 'for', 'neuro', '##inflamm', '##ation', 'associated', 'with', 'neurode', '##generative', 'disease', '.', 'objective', ':', 'this', 'study', 'evaluated', 'the', 'safety', ',', 'tolerability', ',', 'pharmacokinetic', '##s', ',', 'and', 'pharmac', '##odynamics', 'of', 'orally', 'repeated', 'administration', 'of', '5', 'μ', '##g', ',', '10', 'μ', '##g', ',', 'and', '20', 'μ', '##g', 'lsd', 'in', 'older', 'healthy', 'individuals', '.', 'in', 'the', 'current', 'paper', ',', 'we', 'present', 'safety', ',', 'tolerability', ',', 'pharmacokinetic', '##s', ',', 'and', 'pharmac', '##odynamic', 'measures', 'that', 'relate', 'to', 'safety', ',', 'tolerability', ',', 'and', 'dose', 'response', '.', 'methods', ':', 'this', 'was', 'a', 'phase', '1', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'randomized', 'study', '.', 'volunteers', 'were', 'randomly', 'assigned', 'to', '1', 'of', '4', 'dose', 'groups', '(', '5', 'μ', '##g', ',', '10', 'μ', '##g', ',', '20', 'μ', '##g', 'lsd', ',', 'and', 'placebo', ')', ',', 'and', 'received', 'their', 'assigned', 'dose', 'on', 'six', 'occasions', '(', 'i', '.', 'e', '.', ',', 'every', '4', 'days', ')', '.', 'results', ':', 'forty', '-', 'eight', 'older', 'healthy', 'volunteers', '(', 'mean', 'age', '=', '62', '.', '9', 'years', ')', 'received', 'placebo', '(', 'n', '=', '12', ')', ',', '5', 'μ', '##g', '(', 'n', '=', '12', ')', ',', '10', 'μ', '##g', '(', 'n', '=', '12', ')', ',', 'or', '20', 'μ', '##g', '(', 'n', '=', '12', ')', 'lsd', '.', 'lsd', 'plasma', 'levels', 'were', 'undetectable', 'for', 'the', '5', 'μ', '##g', 'group', 'and', 'peak', 'blood', 'plasma', 'levels', 'for', 'the', '10', 'μ', '##g', 'and', '20', 'μ', '##g', 'groups', 'occurred', 'at', '30', 'min', '.', 'lsd', 'was', 'well', 'tolerated', ',', 'and', 'the', 'frequency', 'of', 'adverse', 'events', 'was', 'no', 'higher', 'than', 'for', 'placebo', '.', 'assessments', 'of', 'cognition', ',', 'balance', ',', 'and', 'propri', '##oce', '##ption', 'revealed', 'no', 'impairment', '.', 'conclusions', ':', 'our', 'results', 'suggest', 'safety', 'and', 'tolerability', 'of', 'orally', 'administered', '5', 'μ', '##g', ',', '10', 'μ', '##g', ',', 'and', '20', 'μ', '##g', 'lsd', 'every', 'fourth', 'day', 'over', 'a', '21', '-', 'day', 'period', 'and', 'support', 'further', 'clinical', 'development', 'of', 'lsd', 'for', 'the', 'treatment', 'and', 'prevention', 'of', 'alzheimer', ""'"", 's', 'disease', '(', 'ad', ')', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 4, 5, 6, 7, 7, 8, 9, 10, 11, 11, 12, 13, 13, 14, 15, 16, 17, 18, 19, 20, 20, 20, 22, 23, 24, 25, 26, 26, 26, 26, 27, 28, 29, 30, 30, 31, 32, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 47, 47, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 59, 59, 60, 61, 62, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 75, 76, 77, 78, 78, 79, 80, 81, 82, 83, 84, 85, 85, 86, 87, 88, 88, 89, 90, 91, 92, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 110, 111, 112, 113, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 156, 157, 158, 159, 159, 160, 161, 162, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 178, 178, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 197, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 209, 210, 211, 212, 213, 214, 215, 216, 217, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 252, 253, 254, 255, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 287, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 304, 305, 306, 307, 307, 308, 309, 310, 311, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 336, 337, 338, 339, 340, 341, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 0, 3, 1, 1, 0, 0, 3, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 0, 3, 1, 1, 0, 3, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 0, 0, 0, 0, 0, 0, 3, 1, 1, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 0, 3, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.^
Research has shown that psychedelics, such as lysergic acid diethylamide (LSD), have profound anti-inflammatory properties mediated by 5-HT(2A) receptor signaling, supporting their evaluation as a therapeutic for neuroinflammation associated with neurodegenerative disease. OBJECTIVE: This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally repeated administration of 5 μg, 10 μg, and 20 μg LSD in older healthy individuals. In the current paper, we present safety, tolerability, pharmacokinetics, and pharmacodynamic measures that relate to safety, tolerability, and dose response. METHODS: This was a phase 1 double-blind, placebo-controlled, randomized study. Volunteers were randomly assigned to 1 of 4 dose groups (5 μg, 10 μg, 20 μg LSD, and placebo), and received their assigned dose on six occasions (i.e., every 4 days). RESULTS: Forty-eight older healthy volunteers (mean age = 62.9 years) received placebo (n = 12), 5 μg (n = 12), 10 μg (n = 12), or 20 μg (n = 12) LSD. LSD plasma levels were undetectable for the 5 μg group and peak blood plasma levels for the 10 μg and 20 μg groups occurred at 30 min. LSD was well tolerated, and the frequency of adverse events was no higher than for placebo. Assessments of cognition, balance, and proprioception revealed no impairment. CONCLUSIONS: Our results suggest safety and tolerability of orally administered 5 μg, 10 μg, and 20 μg LSD every fourth day over a 21-day period and support further clinical development of LSD for the treatment and prevention of Alzheimer's disease (AD)."
"['Intranasal', 'ketamine', 'and', 'cognitive', '-', 'behavioral', 'therapy', 'for', 'treatment', '-', 'refractory', 'obsessive', '-', 'compulsive', 'disorder.^', '\n', 'The', 'letter', 'presents', 'a', 'case', 'report', 'of', 'A.', 'L.', 'a', 'white', 'man', 'in', 'his', 'late', 'twenties', 'with', 'Refractory', 'obsessive', '-', 'compulsive', 'disorder', '(', 'OCD', ')', ',', 'comorbid', 'major', 'depressive', 'disorder', '(', 'MDD', ')', 'with', 'chronic', 'suicidal', 'ideation', ',', 'social', 'anxiety', 'disorder', ',', 'and', 'a', 'history', 'of', 'bulimia', 'nervosa', '.', 'A.L.', 'was', 'treated', 'for', '8', 'weeks', 'on', 'an', 'inpatient', 'psychiatric', 'unit', 'and', 'for', '8', 'weeks', 'as', 'an', 'outpatient', '.', 'To', 'the', 'authors', 'knowledge', ',', 'this', 'this', 'is', 'the', 'first', 'report', 'of', 'an', 'OCD', 'patient', 'being', 'treated', 'with', 'intranasal', 'ketamine', ',', 'the', 'first', 'treated', 'with', 'multiple', 'ketamine', 'administrations', ',', 'and', 'the', 'first', 'treated', 'with', 'intensive', 'ERP', 'and', 'repeated', 'ketamine', 'administrations', '.', 'It', 'is', 'of', 'course', 'impossible', ',', 'in', 'examination', 'of', 'this', 'single', 'case', ',', 'to', 'determine', 'whether', 'ketamine', 'and', 'intensive', 'CBT', 'synergized', 'to', 'produce', 'clinical', 'benefit', '.', 'It', 'is', 'possible', 'that', 'the', 'patient', 'benefited', 'solely', 'from', 'inpatient', 'CBT', '.', 'Indeed', ',', 'improvements', 'in', 'OCD', 'symptoms', 'were', 'seen', 'after', '2', 'weeks', 'of', 'CBT', 'and', 'before', 'ketamine', 'was', 'administered', '.', 'These', 'improvements', 'may', 'have', 'also', 'resulted', 'from', 'the', 'lack', 'of', 'pertinent', 'obsessive', '-', 'compulsive', 'triggers', 'on', 'the', 'inpatient', 'unit', '.', 'Nonetheless', ',', 'there', 'are', 'several', 'reasons', 'to', 'believe', 'that', 'the', 'patient', 'benefited', 'from', 'ketamine', ':', 'He', 'reported', 'additional', 'symptom', 'reductions', 'following', 'the', 'initiation', 'of', 'ketamine', 'treatments', '(', 'this', 'may', 'have', 'also', 'been', 'due', 'to', 'continued', 'CBT', ')', '.', 'Compliance', 'with', 'response', 'prevention', 'drastically', 'improved', 'shortly', 'after', 'beginning', 'ketamine', ',', 'suggesting', 'that', 'ketamine', 'may', 'augment', 'the', 'process', 'of', 'ERP', 'for', 'OCD', ',', 'and', 'the', 'patient', 'reported', 'rapid', 'and', 'drastic', 'reductions', 'in', 'suicidal', 'ideation', 'following', 'the', 'first', 'week', 'of', 'ketamine', 'treatments', '.', 'Further', 'examination', 'of', 'the', 'concurrent', 'use', 'of', 'ketamine', 'and', 'extinction', '-', 'based', 'ERP', 'for', 'OCD', 'is', 'warranted', '.', 'Component', '-', 'controlled', 'trials', 'will', 'be', 'necessary', 'to', 'establish', 'if', 'ketamine', 'and', 'ERP', 'have', 'synergistic', 'effects', 'on', 'OCD', 'symptoms', '.', '(', 'PsycINFO', 'Database', 'Record', '(', 'c', ')', '2017', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",176,"['[CLS]', 'intran', '##asal', 'ketamine', 'and', 'cognitive', '-', 'behavioral', 'therapy', 'for', 'treatment', '-', 'refractory', 'obs', '##essive', '-', 'comp', '##ulsive', 'disorder', '.', '^', 'the', 'letter', 'presents', 'a', 'case', 'report', 'of', 'a', '.', 'l', '.', 'a', 'white', 'man', 'in', 'his', 'late', 'twe', '##nt', '##ies', 'with', 'refractory', 'obs', '##essive', '-', 'comp', '##ulsive', 'disorder', '(', 'ocd', ')', ',', 'comorbid', 'major', 'depressive', 'disorder', '(', 'mdd', ')', 'with', 'chronic', 'suicidal', 'idea', '##tion', ',', 'social', 'anxiety', 'disorder', ',', 'and', 'a', 'history', 'of', 'bul', '##imi', '##a', 'nerv', '##osa', '.', 'a', '.', 'l', '.', 'was', 'treated', 'for', '8', 'weeks', 'on', 'an', 'inpatient', 'psychiatric', 'unit', 'and', 'for', '8', 'weeks', 'as', 'an', 'outpatient', '.', 'to', 'the', 'authors', 'knowledge', ',', 'this', 'this', 'is', 'the', 'first', 'report', 'of', 'an', 'ocd', 'patient', 'being', 'treated', 'with', 'intran', '##asal', 'ketamine', ',', 'the', 'first', 'treated', 'with', 'multiple', 'ketamine', 'administration', '##s', ',', 'and', 'the', 'first', 'treated', 'with', 'intensive', 'erp', 'and', 'repeated', 'ketamine', 'administration', '##s', '.', 'it', 'is', 'of', 'course', 'impossible', ',', 'in', 'examination', 'of', 'this', 'single', 'case', ',', 'to', 'determine', 'whether', 'ketamine', 'and', 'intensive', 'cbt', 'synerg', '##ized', 'to', 'produce', 'clinical', 'benefit', '.', 'it', 'is', 'possible', 'that', 'the', 'patient', 'benefit', '##ed', 'solely', 'from', 'inpatient', 'cbt', '.', 'indeed', ',', 'improvements', 'in', 'ocd', 'symptoms', 'were', 'seen', 'after', '2', 'weeks', 'of', 'cbt', 'and', 'before', 'ketamine', 'was', 'administered', '.', 'these', 'improvements', 'may', 'have', 'also', 'resulted', 'from', 'the', 'lack', 'of', 'pertinent', 'obs', '##essive', '-', 'comp', '##ulsive', 'triggers', 'on', 'the', 'inpatient', 'unit', '.', 'nonetheless', ',', 'there', 'are', 'several', 'reasons', 'to', 'believe', 'that', 'the', 'patient', 'benefit', '##ed', 'from', 'ketamine', ':', 'he', 'reported', 'additional', 'symptom', 'reductions', 'following', 'the', 'initiation', 'of', 'ketamine', 'treatments', '(', 'this', 'may', 'have', 'also', 'been', 'due', 'to', 'continued', 'cbt', ')', '.', 'compliance', 'with', 'response', 'prevention', 'drastically', 'improved', 'shortly', 'after', 'beginning', 'ketamine', ',', 'suggesting', 'that', 'ketamine', 'may', 'augment', 'the', 'process', 'of', 'erp', 'for', 'ocd', ',', 'and', 'the', 'patient', 'reported', 'rapid', 'and', 'drastic', 'reductions', 'in', 'suicidal', 'idea', '##tion', 'following', 'the', 'first', 'week', 'of', 'ketamine', 'treatments', '.', 'further', 'examination', 'of', 'the', 'concurrent', 'use', 'of', 'ketamine', 'and', 'extinction', '-', 'based', 'erp', 'for', 'ocd', 'is', 'warranted', '.', 'component', '-', 'controlled', 'trials', 'will', 'be', 'necessary', 'to', 'establish', 'if', 'ketamine', 'and', 'erp', 'have', 'synergistic', 'effects', 'on', 'ocd', 'symptoms', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '2017', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11, 12, 13, 13, 14, 14, 14, 16, 17, 18, 19, 20, 21, 22, 23, 23, 24, 24, 25, 26, 27, 28, 29, 30, 31, 31, 31, 32, 33, 34, 34, 35, 36, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 62, 62, 63, 63, 64, 65, 65, 65, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 193, 194, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 321, 321, 322, 323, 324, 325, 326, 327, 328, 328, 329, 330, 331, 332, 333, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Intranasal ketamine and cognitive-behavioral therapy for treatment-refractory obsessive-compulsive disorder.^
The letter presents a case report of A. L. a white man in his late twenties with Refractory obsessive-compulsive disorder (OCD), comorbid major depressive disorder (MDD) with chronic suicidal ideation, social anxiety disorder, and a history of bulimia nervosa. A.L. was treated for 8 weeks on an inpatient psychiatric unit and for 8 weeks as an outpatient. To the authors knowledge, this this is the first report of an OCD patient being treated with intranasal ketamine, the first treated with multiple ketamine administrations, and the first treated with intensive ERP and repeated ketamine administrations. It is of course impossible, in examination of this single case, to determine whether ketamine and intensive CBT synergized to produce clinical benefit. It is possible that the patient benefited solely from inpatient CBT. Indeed, improvements in OCD symptoms were seen after 2 weeks of CBT and before ketamine was administered. These improvements may have also resulted from the lack of pertinent obsessive-compulsive triggers on the inpatient unit. Nonetheless, there are several reasons to believe that the patient benefited from ketamine: He reported additional symptom reductions following the initiation of ketamine treatments (this may have also been due to continued CBT). Compliance with response prevention drastically improved shortly after beginning ketamine, suggesting that ketamine may augment the process of ERP for OCD, and the patient reported rapid and drastic reductions in suicidal ideation following the first week of ketamine treatments. Further examination of the concurrent use of ketamine and extinction-based ERP for OCD is warranted. Component-controlled trials will be necessary to establish if ketamine and ERP have synergistic effects on OCD symptoms. (PsycINFO Database Record (c) 2017 APA, all rights reserved)"
"['Efficacy', 'and', 'safety', 'of', 'racemic', 'ketamine', 'and', 'esketamine', 'for', 'depression', ':', 'a', 'systematic', 'review', 'and', 'meta', '-', 'analysis.^', '\n', 'BACKGROUND', ':', 'Racemic', 'ketamine', 'and', 'esketamine', 'have', 'demonstrated', 'rapid', 'antidepressant', 'effects', '.', 'We', 'aimed', 'to', 'review', 'the', 'efficacy', 'and', 'safety', 'of', 'racemic', 'and', 'esketamine', 'for', 'depression', '.', 'RESEARCH', 'DESIGN', 'AND', 'METHODS', ':', 'We', 'conducted', 'a', 'PRISMA', '-', 'guided', 'review', 'for', 'relevant', 'randomized', 'controlled', 'trials', 'of', 'racemic', 'or', 'esketamine', 'for', 'unipolar', 'or', 'bipolar', 'major', 'depression', 'from', 'database', 'inception', 'through', '2021', '.', 'We', 'conducted', 'random', '-', 'effects', 'meta', '-', 'analyses', 'using', 'pooled', 'rate', 'ratios', '(', 'RRs', ')', 'and', 'Cohen', ""'s"", 'standardized', 'mean', 'differences', '(', 'd', ')', 'with', 'their', '95', '%', 'confidence', 'intervals', '(', 'CI', ')', '.', 'RESULTS', ':', 'We', 'found', '36', 'studies', '(', '2903', 'participants', ',', '57', '%', 'female', ',', '45.1', '+', '/-', '7.0', 'years', ')', '.', 'Nine', 'trials', 'used', 'esketamine', ',', 'while', 'the', 'rest', 'used', 'racemic', 'ketamine', '.', 'The', 'overall', 'study', 'quality', 'was', 'high', '.', 'Treatment', 'with', 'any', 'form', 'of', 'ketamine', 'was', 'associated', 'with', 'improved', 'response', '(', 'RR=2.14', ';', '95', '%', 'CI', ',', '1.72', '-', '2.66', ';', 'I2=65', '%', ')', ',', 'remission', '(', 'RR=1.64', ';', '95', '%', 'CI', ',', '1.33', '-', '2.02', ';', 'I2=39', '%', ')', ',', 'and', 'depression', 'severity', '(', 'd=-0.63', ';', '95', '%', 'CI', ',', '-0.80', 'to', '-0.45', ';', 'I2=78', '%', ')', 'against', 'placebo', '.', 'Overall', ',', 'there', 'was', 'no', 'association', 'between', 'treatment', 'with', 'any', 'form', 'of', 'ketamine', 'and', 'retention', 'in', 'treatment', '(', 'RR=1.00', ';', '95', '%', 'CI', ',', '0.99', '-', '1.01', ';', 'I2<1', '%', ')', ',', 'dropouts', 'due', 'to', 'adverse', 'events', '(', 'RR=1.56', ';', '95', '%', 'CI', ',', '1.00', '-', '2.45', ';', 'I2<1', '%', ')', ',', 'or', 'the', 'overall', 'number', 'of', 'adverse', 'events', 'reported', 'per', 'participant', '(', 'OR=2.14', ';', '95', '%', 'CI', ',', '0.82', '-', '5.60', ';', 'I2=62', '%', ')', 'against', 'placebo', '.', 'CONCLUSIONS', ':', 'Ketamine', 'and', 'esketamine', 'are', 'effective', ',', 'safe', ',', 'and', 'acceptable', 'treatments', 'for', 'individuals', 'living', 'with', 'depression', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",531,"['[CLS]', 'efficacy', 'and', 'safety', 'of', 'race', '##mic', 'ketamine', 'and', 'es', '##ket', '##amine', 'for', 'depression', ':', 'a', 'systematic', 'review', 'and', 'meta', '-', 'analysis', '.', '^', 'background', ':', 'race', '##mic', 'ketamine', 'and', 'es', '##ket', '##amine', 'have', 'demonstrated', 'rapid', 'antidepressant', 'effects', '.', 'we', 'aimed', 'to', 'review', 'the', 'efficacy', 'and', 'safety', 'of', 'race', '##mic', 'and', 'es', '##ket', '##amine', 'for', 'depression', '.', 'research', 'design', 'and', 'methods', ':', 'we', 'conducted', 'a', 'prism', '##a', '-', 'guided', 'review', 'for', 'relevant', 'randomized', 'controlled', 'trials', 'of', 'race', '##mic', 'or', 'es', '##ket', '##amine', 'for', 'unip', '##olar', 'or', 'bipolar', 'major', 'depression', 'from', 'database', 'inc', '##epti', '##on', 'through', '202', '##1', '.', 'we', 'conducted', 'random', '-', 'effects', 'meta', '-', 'analyses', 'using', 'pooled', 'rate', 'ratios', '(', 'rr', '##s', ')', 'and', 'cohen', ""'"", 's', 'standardized', 'mean', 'differences', '(', 'd', ')', 'with', 'their', '95', '%', 'confidence', 'intervals', '(', 'ci', ')', '.', 'results', ':', 'we', 'found', '36', 'studies', '(', '290', '##3', 'participants', ',', '57', '%', 'female', ',', '45', '.', '1', '+', '/', '-', '7', '.', '0', 'years', ')', '.', 'nine', 'trials', 'used', 'es', '##ket', '##amine', ',', 'while', 'the', 'rest', 'used', 'race', '##mic', 'ketamine', '.', 'the', 'overall', 'study', 'quality', 'was', 'high', '.', 'treatment', 'with', 'any', 'form', 'of', 'ketamine', 'was', 'associated', 'with', 'improved', 'response', '(', 'rr', '=', '2', '.', '14', ';', '95', '%', 'ci', ',', '1', '.', '72', '-', '2', '.', '66', ';', 'i', '##2', '=', '65', '%', ')', ',', 'remission', '(', 'rr', '=', '1', '.', '64', ';', '95', '%', 'ci', ',', '1', '.', '33', '-', '2', '.', '02', ';', 'i', '##2', '=', '39', '%', ')', ',', 'and', 'depression', 'severity', '(', 'd', '=', '-', '0', '.', '63', ';', '95', '%', 'ci', ',', '-', '0', '.', '80', 'to', '-', '0', '.', '45', ';', 'i', '##2', '=', '78', '%', ')', 'against', 'placebo', '.', 'overall', ',', 'there', 'was', 'no', 'association', 'between', 'treatment', 'with', 'any', 'form', 'of', 'ketamine', 'and', 'retention', 'in', 'treatment', '(', 'rr', '=', '1', '.', '00', ';', '95', '%', 'ci', ',', '0', '.', '99', '-', '1', '.', '01', ';', 'i', '##2', '<', '1', '%', ')', ',', 'dropout', '##s', 'due', 'to', 'adverse', 'events', '(', 'rr', '=', '1', '.', '56', ';', '95', '%', 'ci', ',', '1', '.', '00', '-', '2', '.', '45', ';', 'i', '##2', '<', '1', '%', ')', ',', 'or', 'the', 'overall', 'number', 'of', 'adverse', 'events', 'reported', 'per', 'participant', '(', 'or', '=', '2', '.', '14', ';', '95', '%', 'ci', ',', '0', '.', '82', '-', '5', '.', '60', ';', 'i', '##2', '=', '62', '%', ')', 'against', 'placebo', '.', 'conclusions', ':', 'ketamine', 'and', 'es', '##ket', '##amine', 'are', 'effective', ',', 'safe', ',', 'and', 'acceptable', 'treatments', 'for', 'individuals', 'living', 'with', 'depression', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 4, 5, 6, 7, 7, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 17, 17, 19, 20, 21, 21, 22, 23, 24, 24, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 40, 41, 42, 42, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 64, 65, 66, 66, 66, 67, 68, 68, 69, 70, 71, 72, 73, 74, 75, 75, 75, 76, 77, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 92, 93, 94, 95, 96, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 120, 121, 122, 123, 124, 125, 126, 127, 127, 127, 128, 129, 129, 130, 130, 130, 131, 132, 133, 134, 135, 136, 137, 137, 137, 138, 139, 140, 141, 142, 143, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 165, 165, 165, 165, 166, 167, 168, 169, 170, 171, 171, 171, 172, 173, 173, 173, 174, 175, 175, 175, 175, 176, 177, 178, 179, 180, 181, 181, 181, 181, 181, 182, 183, 184, 185, 186, 187, 187, 187, 188, 189, 189, 189, 190, 191, 191, 191, 191, 192, 193, 194, 195, 196, 197, 198, 199, 199, 199, 199, 199, 199, 200, 201, 202, 203, 204, 205, 205, 205, 205, 206, 207, 207, 207, 207, 208, 209, 209, 209, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 233, 233, 233, 233, 234, 235, 236, 237, 238, 239, 239, 239, 240, 241, 241, 241, 242, 243, 243, 243, 243, 244, 245, 246, 247, 247, 248, 249, 250, 251, 252, 253, 253, 253, 253, 253, 254, 255, 256, 257, 258, 259, 259, 259, 260, 261, 261, 261, 262, 263, 263, 263, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 278, 278, 278, 278, 279, 280, 281, 282, 283, 284, 284, 284, 285, 286, 286, 286, 287, 288, 288, 288, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 298, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.^
BACKGROUND: Racemic ketamine and esketamine have demonstrated rapid antidepressant effects. We aimed to review the efficacy and safety of racemic and esketamine for depression. RESEARCH DESIGN AND METHODS: We conducted a PRISMA-guided review for relevant randomized controlled trials of racemic or esketamine for unipolar or bipolar major depression from database inception through 2021. We conducted random-effects meta-analyses using pooled rate ratios (RRs) and Cohen's standardized mean differences (d) with their 95% confidence intervals (CI). RESULTS: We found 36 studies (2903 participants, 57% female, 45.1 +/- 7.0 years). Nine trials used esketamine, while the rest used racemic ketamine. The overall study quality was high. Treatment with any form of ketamine was associated with improved response (RR=2.14; 95% CI, 1.72-2.66; I2=65%), remission (RR=1.64; 95% CI, 1.33-2.02; I2=39%), and depression severity (d=-0.63; 95% CI, -0.80 to -0.45; I2=78%) against placebo. Overall, there was no association between treatment with any form of ketamine and retention in treatment (RR=1.00; 95% CI, 0.99-1.01; I2<1%), dropouts due to adverse events (RR=1.56; 95% CI, 1.00-2.45; I2<1%), or the overall number of adverse events reported per participant (OR=2.14; 95% CI, 0.82-5.60; I2=62%) against placebo. CONCLUSIONS: Ketamine and esketamine are effective, safe, and acceptable treatments for individuals living with depression."
"['Analysis', 'of', 'recreational', 'psychedelic', 'substance', 'use', 'experiences', 'classified', 'by', 'substance.^', '\n', 'RATIONALE', 'AND', 'OBJECTIVES', ':', 'Differences', 'among', 'psychedelic', 'substances', 'regarding', 'their', 'subjective', 'experiences', 'are', 'clinically', 'and', 'scientifically', 'interesting', '.', 'Quantitative', 'linguistic', 'analysis', 'is', 'a', 'powerful', 'tool', 'to', 'examine', 'such', 'differences', '.', 'This', 'study', 'compared', 'five', 'psychedelic', 'substance', 'report', 'groups', 'and', 'a', 'non', '-', 'psychedelic', 'report', 'group', 'on', 'quantitative', 'linguistic', 'markers', 'of', 'psychological', 'states', 'and', 'processes', 'derived', 'from', 'recreational', 'use', '-', 'based', 'online', 'experience', 'reports', '.', 'METHODS', ':', 'Using', '2947', 'publicly', 'available', 'online', 'reports', ',', 'we', 'compared', 'Ayahuasca', 'and', 'N', ',', 'N', '-', 'dimethyltryptamine', '(', 'DMT', ',', 'analyzed', 'together', ')', ',', 'ketamine', ',', 'lysergic', 'acid', 'diethylamide', '(', 'LSD', ')', ',', '3,4', '-', 'methylenedioxymethamphetamine', '(', 'MDMA', ')', ',', 'psilocybin', '(', 'mushroom', ')', ',', 'and', 'antidepressant', 'drug', 'use', 'experiences', '.', 'We', 'examined', 'word', 'frequencies', 'related', 'to', 'various', 'psychological', 'states', 'and', 'processes', 'and', 'semantic', 'proximity', 'to', 'psychedelic', 'and', 'mystical', 'experience', 'scales', '.', 'RESULTS', ':', 'Linguistic', 'markers', 'of', 'psychological', 'function', 'indicated', 'distinct', 'effect', 'profiles', '.', 'For', 'example', ',', 'MDMA', 'experience', 'reports', 'featured', 'an', 'emotionally', 'intensifying', 'profile', 'accompanied', 'by', 'many', 'cognitive', 'process', 'words', 'and', 'dynamic', '-', 'personal', 'language', '.', 'In', 'contrast', ',', 'Ayahuasca', 'and', 'DMT', 'experience', 'reports', 'involved', 'relatively', 'little', 'emotional', 'language', ',', 'few', 'cognitive', 'process', 'words', ',', 'increased', 'analytical', 'thinking', '-', 'associated', 'language', ',', 'and', 'the', 'most', 'semantic', 'similarity', 'with', 'psychedelic', 'and', 'mystical', 'experience', 'descriptions', '.', 'LSD', ',', 'psilocybin', 'mushroom', ',', 'and', 'ketamine', 'reports', 'showed', 'only', 'small', 'differences', 'on', 'the', 'emotion-', ',', 'analytical', 'thinking-', ',', 'psychedelic', ',', 'and', 'mystical', 'experience', '-', 'related', 'language', 'outcomes', '.', 'Antidepressant', 'reports', 'featured', 'more', 'negative', 'emotional', 'and', 'cognitive', 'process', '-', 'related', 'words', ',', 'fewer', 'positive', 'emotional', 'and', 'analytical', 'thinking', '-', 'related', 'words', ',', 'and', 'were', 'generally', 'not', 'similar', 'to', 'mystical', 'and', 'psychedelic', 'language', '.', 'CONCLUSION', ':', 'This', 'article', 'addresses', 'an', 'existing', 'research', 'gap', 'regarding', 'the', 'comparison', 'of', 'different', 'psychedelic', 'drugs', 'on', 'linguistic', 'profiles', 'of', 'psychological', 'states', ',', 'processes', ',', 'and', 'experiences', '.', 'The', 'large', 'sample', 'of', 'experience', 'reports', 'involving', 'multiple', 'psychedelic', 'drugs', 'provides', 'valuable', 'information', 'that', 'would', 'otherwise', 'be', 'difficult', 'to', 'obtain', '.', 'The', 'results', 'could', 'inform', 'experimental', 'research', 'into', 'psychedelic', 'drug', 'effects', 'in', 'healthy', 'populations', 'and', 'clinical', 'trials', 'for', 'psychedelic', 'treatments', 'of', 'psychiatric', 'problems', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3410,"['[CLS]', 'analysis', 'of', 'recreational', 'psych', '##ede', '##lic', 'substance', 'use', 'experiences', 'classified', 'by', 'substance', '.', '^', 'rationale', 'and', 'objectives', ':', 'differences', 'among', 'psych', '##ede', '##lic', 'substances', 'regarding', 'their', 'subjective', 'experiences', 'are', 'clinically', 'and', 'scientific', '##ally', 'interesting', '.', 'quantitative', 'linguistic', 'analysis', 'is', 'a', 'powerful', 'tool', 'to', 'examine', 'such', 'differences', '.', 'this', 'study', 'compared', 'five', 'psych', '##ede', '##lic', 'substance', 'report', 'groups', 'and', 'a', 'non', '-', 'psych', '##ede', '##lic', 'report', 'group', 'on', 'quantitative', 'linguistic', 'markers', 'of', 'psychological', 'states', 'and', 'processes', 'derived', 'from', 'recreational', 'use', '-', 'based', 'online', 'experience', 'reports', '.', 'methods', ':', 'using', '294', '##7', 'publicly', 'available', 'online', 'reports', ',', 'we', 'compared', 'ay', '##ah', '##ua', '##sc', '##a', 'and', 'n', ',', 'n', '-', 'dimethyl', '##try', '##pt', '##amine', '(', 'dm', '##t', ',', 'analyzed', 'together', ')', ',', 'ketamine', ',', 'lys', '##ergic', 'acid', 'diethyl', '##amide', '(', 'lsd', ')', ',', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', ')', ',', 'psi', '##loc', '##yb', '##in', '(', 'mush', '##room', ')', ',', 'and', 'antidepressant', 'drug', 'use', 'experiences', '.', 'we', 'examined', 'word', 'frequencies', 'related', 'to', 'various', 'psychological', 'states', 'and', 'processes', 'and', 'semantic', 'proximity', 'to', 'psych', '##ede', '##lic', 'and', 'mys', '##tical', 'experience', 'scales', '.', 'results', ':', 'linguistic', 'markers', 'of', 'psychological', 'function', 'indicated', 'distinct', 'effect', 'profiles', '.', 'for', 'example', ',', 'mdm', '##a', 'experience', 'reports', 'feature', '##d', 'an', 'emotional', '##ly', 'intens', '##ifying', 'profile', 'accompanied', 'by', 'many', 'cognitive', 'process', 'words', 'and', 'dynamic', '-', 'personal', 'language', '.', 'in', 'contrast', ',', 'ay', '##ah', '##ua', '##sc', '##a', 'and', 'dm', '##t', 'experience', 'reports', 'involved', 'relatively', 'little', 'emotional', 'language', ',', 'few', 'cognitive', 'process', 'words', ',', 'increased', 'analytical', 'thinking', '-', 'associated', 'language', ',', 'and', 'the', 'most', 'semantic', 'similarity', 'with', 'psych', '##ede', '##lic', 'and', 'mys', '##tical', 'experience', 'descriptions', '.', 'lsd', ',', 'psi', '##loc', '##yb', '##in', 'mush', '##room', ',', 'and', 'ketamine', 'reports', 'showed', 'only', 'small', 'differences', 'on', 'the', 'emotion', '-', ',', 'analytical', 'thinking', '-', ',', 'psych', '##ede', '##lic', ',', 'and', 'mys', '##tical', 'experience', '-', 'related', 'language', 'outcomes', '.', 'antidepressant', 'reports', 'feature', '##d', 'more', 'negative', 'emotional', 'and', 'cognitive', 'process', '-', 'related', 'words', ',', 'fewer', 'positive', 'emotional', 'and', 'analytical', 'thinking', '-', 'related', 'words', ',', 'and', 'were', 'generally', 'not', 'similar', 'to', 'mys', '##tical', 'and', 'psych', '##ede', '##lic', 'language', '.', 'conclusion', ':', 'this', 'article', 'addresses', 'an', 'existing', 'research', 'gap', 'regarding', 'the', 'comparison', 'of', 'different', 'psych', '##ede', '##lic', 'drugs', 'on', 'linguistic', 'profiles', 'of', 'psychological', 'states', ',', 'processes', ',', 'and', 'experiences', '.', 'the', 'large', 'sample', 'of', 'experience', 'reports', 'involving', 'multiple', 'psych', '##ede', '##lic', 'drugs', 'provides', 'valuable', 'information', 'that', 'would', 'otherwise', 'be', 'difficult', 'to', 'obtain', '.', 'the', 'results', 'could', 'inform', 'experimental', 'research', 'into', 'psych', '##ede', '##lic', 'drug', 'effects', 'in', 'healthy', 'populations', 'and', 'clinical', 'trials', 'for', 'psych', '##ede', '##lic', 'treatments', 'of', 'psychiatric', 'problems', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 4, 5, 6, 7, 8, 9, 9, 9, 11, 12, 13, 14, 15, 16, 17, 17, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 45, 45, 46, 47, 48, 49, 50, 51, 52, 53, 53, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 78, 79, 80, 81, 82, 83, 84, 85, 86, 86, 86, 86, 86, 87, 88, 89, 90, 91, 92, 92, 92, 92, 93, 94, 94, 95, 96, 97, 98, 99, 100, 101, 102, 102, 103, 104, 104, 105, 106, 107, 108, 109, 109, 109, 110, 111, 111, 111, 111, 111, 112, 113, 113, 114, 115, 116, 116, 116, 116, 117, 118, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 142, 142, 143, 144, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 163, 164, 165, 166, 166, 167, 168, 168, 169, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 186, 186, 186, 186, 187, 188, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 215, 215, 216, 217, 217, 218, 219, 220, 221, 222, 223, 223, 223, 223, 224, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 235, 236, 237, 238, 238, 239, 240, 240, 240, 241, 242, 243, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 279, 280, 281, 281, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 298, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 320, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 340, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 350, 350, 351, 352, 353, 354, 355, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Analysis of recreational psychedelic substance use experiences classified by substance.^
RATIONALE AND OBJECTIVES: Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers of psychological states and processes derived from recreational use-based online experience reports. METHODS: Using 2947 publicly available online reports, we compared Ayahuasca and N,N-dimethyltryptamine (DMT, analyzed together), ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin (mushroom), and antidepressant drug use experiences. We examined word frequencies related to various psychological states and processes and semantic proximity to psychedelic and mystical experience scales. RESULTS: Linguistic markers of psychological function indicated distinct effect profiles. For example, MDMA experience reports featured an emotionally intensifying profile accompanied by many cognitive process words and dynamic-personal language. In contrast, Ayahuasca and DMT experience reports involved relatively little emotional language, few cognitive process words, increased analytical thinking-associated language, and the most semantic similarity with psychedelic and mystical experience descriptions. LSD, psilocybin mushroom, and ketamine reports showed only small differences on the emotion-, analytical thinking-, psychedelic, and mystical experience-related language outcomes. Antidepressant reports featured more negative emotional and cognitive process-related words, fewer positive emotional and analytical thinking-related words, and were generally not similar to mystical and psychedelic language. CONCLUSION: This article addresses an existing research gap regarding the comparison of different psychedelic drugs on linguistic profiles of psychological states, processes, and experiences. The large sample of experience reports involving multiple psychedelic drugs provides valuable information that would otherwise be difficult to obtain. The results could inform experimental research into psychedelic drug effects in healthy populations and clinical trials for psychedelic treatments of psychiatric problems."
"['Effects', 'of', 'low', '-', 'dose', 'intranasal', '(', 'S)-ketamine', 'in', 'patients', 'with', 'neuropathic', 'pain.^', '\n', 'Background', ':', 'NMDA', 'receptors', 'are', 'involved', 'in', 'the', 'development', 'and', 'maintenance', 'of', 'neuropathic', 'pain', '.', 'We', 'evaluated', 'the', 'efficacy', 'and', 'safety', 'of', 'intranasal', '(', 'S)-ketamine', ',', 'one', 'of', 'the', 'most', 'potent', 'clinically', 'available', 'NMDA', 'receptor', 'antagonists', '.', 'Methods', ':', 'Sixteen', 'patients', 'with', 'neuropathic', 'pain', 'of', 'various', 'origins', 'were', 'randomized', 'into', 'two', 'treatment', 'groups', ':', '(', 'S)-ketamine', '0.2', 'mg', '/', 'kg', '(', 'group', '1', ')', ';', '(', 'S)-ketamine', '0.4', 'mg', '/', 'kg', '(', 'group', '2', ')', '.', 'Plasma', 'concentrations', 'of', '(', 'S)-ketamine', 'and', '(', 'S)-norketamine', 'were', 'measured', 'over', '6', 'h', 'by', 'High', 'Performance', 'Liquid', 'Chromatography', 'combined', 'with', 'mass', 'spectrometry', '.', 'Quantitative', 'sensory', 'testing', '(', 'QST', ')', 'was', 'conducted', 'before', ',', 'during', 'and', 'after', 'treatment', '.', 'Side', 'effects', 'and', 'amount', 'of', 'pain', 'reduction', 'were', 'recorded', '.', 'Results', ':', 'Intranasal', '(', 'S)-ketamine', 'administration', 'lead', 'to', 'peak', 'plasma', 'concentrations', 'of', '27.7', '±', '5.9', 'ng', '/', 'ml', 'at', '10', '±', '6.3', 'min', '(', 'group', '1', ')', 'and', '34.3', '±', '22.2', 'ng', '/', 'ml', 'at', '13.8', '±', '4.8', 'min', 'after', 'application', '(', 'group', '2', ')', '.', 'Maximal', 'plasma', 'concentrations', 'of', '(', 'S)-norketamine', 'were', '18.3', '±', '14.9', 'ng', '/', 'ml', 'at', '81', '±', '59', 'min', '(', 'group', '1', ')', 'and', '34.3', '±', '5.5', 'ng', '/', 'ml', 'at', '75', '±', '40', 'min', '(', 'group', '2', ')', '.', 'Pain', 'scores', 'decreased', 'significantly', 'in', 'both', 'groups', 'with', 'minimal', 'pain', 'at', '60', 'min', 'after', 'drug', 'administration', '(', '70', '±', '10', '%', 'and', '61', '±', '13', '%', 'of', 'initial', 'pain', 'in', 'groups', '1', 'and', '2', ')', '.', 'The', 'time', 'course', 'of', 'pain', 'decrease', 'was', 'significantly', 'correlated', 'with', 'plasma', 'concentrations', 'of', '(', 'S)-ketamine', 'and', '(', 'S)-norketamine', '(', 'partial', 'correlations', ':', '(', 'S)-norketamine', ':', '-0.90', 'and', '-0.86', ';', '(', 'S)-ketamine', ':', '-0.72', 'and', '-0.71', 'for', 'group', '1', 'and', 'group', '2', ',', 'respectively', ')', '.', 'Higher', 'dosing', 'elicited', 'significantly', 'more', 'side', 'effects', '.', 'Intranasal', '(', 'S)-ketamine', 'had', 'no', 'significant', 'impact', 'on', 'thermal', 'or', 'mechanical', 'detection', 'and', 'pain', 'thresholds', 'in', 'normal', 'or', 'symptomatic', 'skin', 'areas', '.', 'Conclusions', ':', 'Intranasal', 'administration', 'of', 'low', 'dose', '(', 'S)-ketamine', 'rapidly', 'induces', 'adequate', 'plasma', 'concentrations', 'of', '(', 'S)-ketamine', 'and', 'subsequently', 'of', 'its', 'metabolite', '(', 'S)-norketamine', '.', 'The', 'time', 'course', 'of', 'analgesia', 'correlated', 'with', 'plasma', 'concentrations', '.', '(', 'PsycINFO', 'Database', 'Record', '(', 'c', ')', '2016', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3728,"['[CLS]', 'effects', 'of', 'low', '-', 'dose', 'intran', '##asal', '(', 's', ')', '-', 'ketamine', 'in', 'patients', 'with', 'neuropathic', 'pain', '.', '^', 'background', ':', 'nmda', 'receptors', 'are', 'involved', 'in', 'the', 'development', 'and', 'maintenance', 'of', 'neuropathic', 'pain', '.', 'we', 'evaluated', 'the', 'efficacy', 'and', 'safety', 'of', 'intran', '##asal', '(', 's', ')', '-', 'ketamine', ',', 'one', 'of', 'the', 'most', 'potent', 'clinically', 'available', 'nmda', 'receptor', 'antagonists', '.', 'methods', ':', 'sixteen', 'patients', 'with', 'neuropathic', 'pain', 'of', 'various', 'origins', 'were', 'randomized', 'into', 'two', 'treatment', 'groups', ':', '(', 's', ')', '-', 'ketamine', '0', '.', '2', 'mg', '/', 'kg', '(', 'group', '1', ')', ';', '(', 's', ')', '-', 'ketamine', '0', '.', '4', 'mg', '/', 'kg', '(', 'group', '2', ')', '.', 'plasma', 'concentrations', 'of', '(', 's', ')', '-', 'ketamine', 'and', '(', 's', ')', '-', 'nor', '##ket', '##amine', 'were', 'measured', 'over', '6', 'h', 'by', 'high', 'performance', 'liquid', 'chromatography', 'combined', 'with', 'mass', 'spectrometry', '.', 'quantitative', 'sensory', 'testing', '(', 'qs', '##t', ')', 'was', 'conducted', 'before', ',', 'during', 'and', 'after', 'treatment', '.', 'side', 'effects', 'and', 'amount', 'of', 'pain', 'reduction', 'were', 'recorded', '.', 'results', ':', 'intran', '##asal', '(', 's', ')', '-', 'ketamine', 'administration', 'lead', 'to', 'peak', 'plasma', 'concentrations', 'of', '27', '.', '7', '±', '5', '.', '9', 'ng', '/', 'ml', 'at', '10', '±', '6', '.', '3', 'min', '(', 'group', '1', ')', 'and', '34', '.', '3', '±', '22', '.', '2', 'ng', '/', 'ml', 'at', '13', '.', '8', '±', '4', '.', '8', 'min', 'after', 'application', '(', 'group', '2', ')', '.', 'maximal', 'plasma', 'concentrations', 'of', '(', 's', ')', '-', 'nor', '##ket', '##amine', 'were', '18', '.', '3', '±', '14', '.', '9', 'ng', '/', 'ml', 'at', '81', '±', '59', 'min', '(', 'group', '1', ')', 'and', '34', '.', '3', '±', '5', '.', '5', 'ng', '/', 'ml', 'at', '75', '±', '40', 'min', '(', 'group', '2', ')', '.', 'pain', 'scores', 'decreased', 'significantly', 'in', 'both', 'groups', 'with', 'minimal', 'pain', 'at', '60', 'min', 'after', 'drug', 'administration', '(', '70', '±', '10', '%', 'and', '61', '±', '13', '%', 'of', 'initial', 'pain', 'in', 'groups', '1', 'and', '2', ')', '.', 'the', 'time', 'course', 'of', 'pain', 'decrease', 'was', 'significantly', 'correlated', 'with', 'plasma', 'concentrations', 'of', '(', 's', ')', '-', 'ketamine', 'and', '(', 's', ')', '-', 'nor', '##ket', '##amine', '(', 'partial', 'correlations', ':', '(', 's', ')', '-', 'nor', '##ket', '##amine', ':', '-', '0', '.', '90', 'and', '-', '0', '.', '86', ';', '(', 's', ')', '-', 'ketamine', ':', '-', '0', '.', '72', 'and', '-', '0', '.', '71', 'for', 'group', '1', 'and', 'group', '2', ',', 'respectively', ')', '.', 'higher', 'dosing', 'elicited', 'significantly', 'more', 'side', 'effects', '.', 'intran', '##asal', '(', 's', ')', '-', 'ketamine', 'had', 'no', 'significant', 'impact', 'on', 'thermal', 'or', 'mechanical', 'detection', 'and', 'pain', 'thresholds', 'in', 'normal', 'or', 'symptomatic', 'skin', 'areas', '.', 'conclusions', ':', 'intran', '##asal', 'administration', 'of', 'low', 'dose', '(', 's', ')', '-', 'ketamine', 'rapidly', 'induces', 'adequate', 'plasma', 'concentrations', 'of', '(', 's', ')', '-', 'ketamine', 'and', 'subsequently', 'of', 'its', 'metabolite', '(', 's', ')', '-', 'nor', '##ket', '##amine', '.', 'the', 'time', 'course', 'of', 'analgesia', 'correlated', 'with', 'plasma', 'concentrations', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '2016', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 5, 6, 7, 7, 7, 7, 8, 9, 10, 11, 12, 12, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 36, 37, 38, 38, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 69, 69, 70, 70, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 80, 80, 80, 81, 81, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 94, 94, 94, 95, 96, 97, 97, 97, 97, 97, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 140, 141, 142, 142, 142, 142, 143, 144, 145, 146, 147, 148, 149, 150, 150, 150, 151, 152, 152, 152, 153, 154, 155, 156, 157, 158, 159, 159, 159, 160, 161, 162, 163, 164, 165, 166, 166, 166, 167, 168, 168, 168, 169, 170, 171, 172, 173, 173, 173, 174, 175, 175, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 189, 189, 189, 189, 189, 190, 191, 191, 191, 192, 193, 193, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 207, 207, 208, 209, 209, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 273, 273, 273, 274, 275, 276, 276, 276, 276, 276, 276, 277, 278, 279, 280, 281, 282, 282, 282, 282, 282, 282, 283, 284, 284, 284, 284, 285, 286, 286, 286, 286, 287, 288, 289, 289, 289, 289, 290, 291, 291, 291, 291, 292, 293, 293, 293, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 312, 313, 314, 314, 314, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 336, 337, 338, 339, 340, 341, 342, 342, 342, 342, 343, 344, 345, 346, 347, 348, 349, 350, 350, 350, 350, 351, 352, 353, 354, 355, 356, 357, 357, 357, 357, 357, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 370, 370, 371, 372, 373, 374, 375, 376, 377, 377, 378, 379, 380, 381, 382, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain.^
Background: NMDA receptors are involved in the development and maintenance of neuropathic pain. We evaluated the efficacy and safety of intranasal (S)-ketamine, one of the most potent clinically available NMDA receptor antagonists. Methods: Sixteen patients with neuropathic pain of various origins were randomized into two treatment groups: (S)-ketamine 0.2 mg/kg (group 1); (S)-ketamine 0.4 mg/kg (group 2). Plasma concentrations of (S)-ketamine and (S)-norketamine were measured over 6 h by High Performance Liquid Chromatography combined with mass spectrometry. Quantitative sensory testing (QST) was conducted before, during and after treatment. Side effects and amount of pain reduction were recorded. Results: Intranasal (S)-ketamine administration lead to peak plasma concentrations of 27.7 ± 5.9 ng/ml at 10 ± 6.3 min (group 1) and 34.3 ± 22.2 ng/ml at 13.8 ± 4.8 min after application (group 2). Maximal plasma concentrations of (S)-norketamine were 18.3 ± 14.9 ng/ml at 81 ± 59 min (group 1) and 34.3 ± 5.5 ng/ml at 75 ± 40 min (group 2). Pain scores decreased significantly in both groups with minimal pain at 60 min after drug administration (70 ± 10% and 61 ± 13% of initial pain in groups 1 and 2). The time course of pain decrease was significantly correlated with plasma concentrations of (S)-ketamine and (S)-norketamine (partial correlations: (S)-norketamine: -0.90 and -0.86; (S)-ketamine: -0.72 and -0.71 for group 1 and group 2, respectively). Higher dosing elicited significantly more side effects. Intranasal (S)-ketamine had no significant impact on thermal or mechanical detection and pain thresholds in normal or symptomatic skin areas. Conclusions: Intranasal administration of low dose (S)-ketamine rapidly induces adequate plasma concentrations of (S)-ketamine and subsequently of its metabolite (S)-norketamine. The time course of analgesia correlated with plasma concentrations. (PsycINFO Database Record (c) 2016 APA, all rights reserved)"
"['Pharmacological', 'Interaction', 'Between', 'Doxazosin', 'and', 'Methylenedioxymethamphetamine', '(', 'MDMA).^', '\n', '3,4‐methylenedioxymethamphetamine', '(', 'MDMA', ',', '""', 'ecstasy', '""', ')', 'is', 'widely', 'used', 'by', 'young', 'people', 'for', 'its', 'euphoric', 'effects', '.', 'MDMA', 'releases', 'serotonin', '(', '5‐HT', ')', ',', 'dopamine', ',', 'and', 'norepinephrine', '(', 'NE', ')', '.', 'NE', 'release', 'is', 'thought', 'to', 'mediate', 'the', 'cardiovascular', 'effects', 'of', 'MDMA', 'and', 'may', 'also', 'contribute', 'to', 'its', 'psychostimulant', 'effects', '.', 'However', ',', 'the', 'functional', 'role', 'of', 'adrenergic', 'postsynaptic', 'receptors', 'in', 'the', 'cardiovascular', 'and', 'subjective', 'effects', 'of', 'MDMA', 'in', 'humans', 'is', 'largely', 'unclear', '.', 'To', 'determine', 'the', 'role', 'of', 'alpha‐adrenergic', 'receptors', 'in', 'the', 'response', 'to', 'MDMA', 'in', 'humans', 'the', 'investigators', 'test', 'the', 'effects', 'of', 'the', 'alpha1‐receptor', 'blocker', 'doxazosin', 'on', 'the', 'physiological', 'and', 'subjective', 'effects', 'of', 'MDMA', '.', 'The', 'investigators', 'use', 'a', 'randomized', 'double‐blind', 'placebo‐controlled', 'cross‐over', 'design', 'with', 'four', 'experimental', 'sessions', '.', 'doxazosin', 'or', 'placebo', 'will', 'be', 'administered', 'before', 'MDMA', 'or', 'placebo', 'to', '16', 'healthy', 'volunteers', '.', 'Subjective', 'and', 'cardiovascular', 'responses', 'will', 'be', 'repeatedly', 'assessed', 'throughout', 'the', 'experiments', 'and', 'plasma', 'samples', 'are', 'collected', 'for', 'pharmacokinetics', '.', 'The', 'primary', 'hypothesis', 'is', 'that', 'doxazosin', 'will', 'significantly', 'reduce', 'the', 'blood', 'pressure', 'response', 'to', 'MDMA', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6028,"['[CLS]', 'pharmacological', 'interaction', 'between', 'dox', '##azo', '##sin', 'and', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', ')', '.', '^', '3', ',', '4', '‐', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', ',', '""', 'ecs', '##tas', '##y', '""', ')', 'is', 'widely', 'used', 'by', 'young', 'people', 'for', 'its', 'eup', '##hor', '##ic', 'effects', '.', 'mdm', '##a', 'releases', 'serotonin', '(', '5', '‐', 'ht', ')', ',', 'dopamine', ',', 'and', 'norepinephrine', '(', 'ne', ')', '.', 'ne', 'release', 'is', 'thought', 'to', 'mediate', 'the', 'cardiovascular', 'effects', 'of', 'mdm', '##a', 'and', 'may', 'also', 'contribute', 'to', 'its', 'psychos', '##tim', '##ulant', 'effects', '.', 'however', ',', 'the', 'functional', 'role', 'of', 'adren', '##ergic', 'postsynaptic', 'receptors', 'in', 'the', 'cardiovascular', 'and', 'subjective', 'effects', 'of', 'mdm', '##a', 'in', 'humans', 'is', 'largely', 'unclear', '.', 'to', 'determine', 'the', 'role', 'of', 'alpha', '‐', 'adren', '##ergic', 'receptors', 'in', 'the', 'response', 'to', 'mdm', '##a', 'in', 'humans', 'the', 'investigators', 'test', 'the', 'effects', 'of', 'the', 'alpha', '##1', '‐', 'receptor', 'blocker', 'dox', '##azo', '##sin', 'on', 'the', 'physiological', 'and', 'subjective', 'effects', 'of', 'mdm', '##a', '.', 'the', 'investigators', 'use', 'a', 'randomized', 'double', '‐', 'blind', 'placebo', '‐', 'controlled', 'cross', '‐', 'over', 'design', 'with', 'four', 'experimental', 'sessions', '.', 'dox', '##azo', '##sin', 'or', 'placebo', 'will', 'be', 'administered', 'before', 'mdm', '##a', 'or', 'placebo', 'to', '16', 'healthy', 'volunteers', '.', 'subjective', 'and', 'cardiovascular', 'responses', 'will', 'be', 'repeatedly', 'assessed', 'throughout', 'the', 'experiments', 'and', 'plasma', 'samples', 'are', 'collected', 'for', 'pharmacokinetic', '##s', '.', 'the', 'primary', 'hypothesis', 'is', 'that', 'dox', '##azo', '##sin', 'will', 'significantly', 'reduce', 'the', 'blood', 'pressure', 'response', 'to', 'mdm', '##a', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 4, 5, 5, 5, 5, 5, 6, 7, 7, 7, 7, 7, 9, 9, 9, 9, 9, 9, 9, 9, 9, 10, 11, 11, 12, 13, 14, 14, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 25, 25, 26, 27, 28, 28, 29, 30, 31, 32, 32, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 53, 54, 55, 56, 57, 58, 59, 60, 60, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 91, 91, 91, 92, 93, 94, 95, 96, 97, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 107, 107, 107, 108, 109, 109, 109, 110, 111, 112, 113, 114, 115, 116, 117, 117, 118, 119, 120, 121, 122, 123, 124, 124, 124, 125, 125, 125, 126, 126, 126, 127, 128, 129, 130, 131, 132, 133, 133, 133, 134, 135, 136, 137, 138, 139, 140, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 165, 166, 167, 168, 169, 170, 171, 172, 172, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 181, 182, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA).^
3,4‐methylenedioxymethamphetamine (MDMA, ""ecstasy"") is widely used by young people for its euphoric effects. MDMA releases serotonin (5‐HT), dopamine, and norepinephrine (NE). NE release is thought to mediate the cardiovascular effects of MDMA and may also contribute to its psychostimulant effects. However, the functional role of adrenergic postsynaptic receptors in the cardiovascular and subjective effects of MDMA in humans is largely unclear. To determine the role of alpha‐adrenergic receptors in the response to MDMA in humans the investigators test the effects of the alpha1‐receptor blocker doxazosin on the physiological and subjective effects of MDMA. The investigators use a randomized double‐blind placebo‐controlled cross‐over design with four experimental sessions. doxazosin or placebo will be administered before MDMA or placebo to 16 healthy volunteers. Subjective and cardiovascular responses will be repeatedly assessed throughout the experiments and plasma samples are collected for pharmacokinetics. The primary hypothesis is that doxazosin will significantly reduce the blood pressure response to MDMA."
"['Ketamine', 'monotherapy', 'versus', 'adjunctive', 'ketamine', 'in', 'adults', 'with', 'treatment', '-', 'resistant', 'depression', ':', 'Results', 'from', 'the', 'Canadian', 'Rapid', 'Treatment', 'Centre', 'of', 'Excellence.^', '\n', 'A', 'proportion', 'of', 'individuals', 'with', 'major', 'depressive', 'disorder', '(', 'MDD', ')', 'do', 'not', 'receive', 'adequate', 'therapeutic', 'benefit', 'from', 'conventional', 'monoaminergic', 'antidepressant', 'drugs', ',', 'leading', 'to', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', '.', 'Ketamine', 'has', 'been', 'shown', 'to', 'provide', 'rapid', 'and', 'significant', 'efficacy', 'in', 'treating', 'patients', 'with', 'TRD', '.', 'The', 'majority', 'of', 'published', 'studies', 'have', 'investigated', 'the', 'adjunctive', 'efficacy', 'of', 'ketamine', 'with', 'one', 'or', 'more', 'monoaminergic', 'antidepressants', '.', 'There', 'remains', 'a', 'clinical', 'need', 'to', 'ascertain', 'the', 'relative', 'effectiveness', 'of', 'ketamine', 'monotherapy', 'versus', 'adjunctive', 'ketamine', 'treatment', 'in', 'adults', 'with', 'TRD', '.', 'In', 'this', 'retrospective', 'study', ',', 'we', 'investigate', 'multidimensional', ',', 'self', '-', 'reported', 'outcomes', '(', 'i.e.', ',', 'antidepressant', ',', 'anti', '-', 'suicidality', ',', 'antianxiety', ',', 'and', 'anti', '-', 'functional', 'impairment', ')', 'of', '220', 'patients', 'to', 'compare', 'monotherapy', '(', 'n', '=', '39', ')', 'and', 'adjunctive', '(', 'n', '=', '181', ')', 'ketamine', 'treatment', 'for', 'TRD', 'at', 'a', 'community', '-', 'based', 'clinic', '.', 'Both', 'groups', 'had', 'clinically', 'and', 'statistically', 'significant', 'antidepressant', 'effects', '(', 'p', '<', '0.05', ')', '.', 'Individuals', 'receiving', 'ketamine', 'monotherapy', 'exhibited', 'a', 'significantly', 'greater', 'reduction', 'on', 'the', 'suicidal', 'ideation', '(', 'SI', ')', 'item', 'of', 'the', 'Quick', 'Inventory', 'for', 'Depressive', 'Symptomatology', '-', 'Self', 'Report', '16', '-', 'Item', '(', 'QIDS', '-', 'SR(16', ')', ')', 'than', 'the', 'adjunctive', 'group', ',', 'with', 'a', 'small', 'effect', 'size', '[', 'F', '(', '1', ',', '265', ')', '=', '4.73', ';', 'p', '=', '0.03', '*', ';', 'partial', 'η(2', ')', '=', '0.02', ']', ',', 'and', 'a', 'significantly', 'higher', 'proportion', 'of', 'partial', 'responders', 'at', 'post', '-', 'infusion', '4', '(', 'p', '=', '0.034', '*', ')', '.', 'No', 'other', 'between', '-', 'group', 'differences', 'were', 'significant', '.', 'Limitations', 'include', 'the', 'small', 'sample', ',', 'single', '-', 'centred', ',', 'open', '-', 'label', ',', 'non', '-', 'randomized', ',', 'uncontrolled', ',', 'retrospective', 'nature', 'of', 'this', 'study', 'and', 'indication', 'bias', '.', 'Our', 'real', '-', 'world', 'evidence', 'suggests', 'that', 'ketamine', 'may', 'be', 'effective', 'as', 'monotherapy', 'or', 'adjunct', 'to', 'monoamine', '-', 'based', 'treatments', '.', 'A', 'priority', 'research', 'and', 'clinical', 'vista', 'is', 'to', 'identify', 'subsets', 'of', 'individuals', 'with', 'TRD', 'who', 'are', 'most', 'likely', 'to', 'have', 'a', 'desired', 'therapeutic', 'outcome', 'with', 'monotherapy', 'versus', 'adjunctive', 'ketamine', 'treatment', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",2033,"['[CLS]', 'ketamine', 'monotherapy', 'versus', 'adjunct', '##ive', 'ketamine', 'in', 'adults', 'with', 'treatment', '-', 'resistant', 'depression', ':', 'results', 'from', 'the', 'canadian', 'rapid', 'treatment', 'centre', 'of', 'excellence', '.', '^', 'a', 'proportion', 'of', 'individuals', 'with', 'major', 'depressive', 'disorder', '(', 'mdd', ')', 'do', 'not', 'receive', 'adequate', 'therapeutic', 'benefit', 'from', 'conventional', 'mono', '##aminergic', 'antidepressant', 'drugs', ',', 'leading', 'to', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', '.', 'ketamine', 'has', 'been', 'shown', 'to', 'provide', 'rapid', 'and', 'significant', 'efficacy', 'in', 'treating', 'patients', 'with', 'tr', '##d', '.', 'the', 'majority', 'of', 'published', 'studies', 'have', 'investigated', 'the', 'adjunct', '##ive', 'efficacy', 'of', 'ketamine', 'with', 'one', 'or', 'more', 'mono', '##aminergic', 'antidepressants', '.', 'there', 'remains', 'a', 'clinical', 'need', 'to', 'ascertain', 'the', 'relative', 'effectiveness', 'of', 'ketamine', 'monotherapy', 'versus', 'adjunct', '##ive', 'ketamine', 'treatment', 'in', 'adults', 'with', 'tr', '##d', '.', 'in', 'this', 'retrospective', 'study', ',', 'we', 'investigate', 'multi', '##dimensional', ',', 'self', '-', 'reported', 'outcomes', '(', 'i', '.', 'e', '.', ',', 'antidepressant', ',', 'anti', '-', 'suicidal', '##ity', ',', 'anti', '##an', '##xi', '##ety', ',', 'and', 'anti', '-', 'functional', 'impairment', ')', 'of', '220', 'patients', 'to', 'compare', 'monotherapy', '(', 'n', '=', '39', ')', 'and', 'adjunct', '##ive', '(', 'n', '=', '181', ')', 'ketamine', 'treatment', 'for', 'tr', '##d', 'at', 'a', 'community', '-', 'based', 'clinic', '.', 'both', 'groups', 'had', 'clinically', 'and', 'statistically', 'significant', 'antidepressant', 'effects', '(', 'p', '<', '0', '.', '05', ')', '.', 'individuals', 'receiving', 'ketamine', 'monotherapy', 'exhibited', 'a', 'significantly', 'greater', 'reduction', 'on', 'the', 'suicidal', 'idea', '##tion', '(', 'si', ')', 'item', 'of', 'the', 'quick', 'inventory', 'for', 'depressive', 'symptom', '##atology', '-', 'self', 'report', '16', '-', 'item', '(', 'qi', '##ds', '-', 'sr', '(', '16', ')', ')', 'than', 'the', 'adjunct', '##ive', 'group', ',', 'with', 'a', 'small', 'effect', 'size', '[', 'f', '(', '1', ',', '265', ')', '=', '4', '.', '73', ';', 'p', '=', '0', '.', '03', '*', ';', 'partial', 'η', '(', '2', ')', '=', '0', '.', '02', ']', ',', 'and', 'a', 'significantly', 'higher', 'proportion', 'of', 'partial', 'responders', 'at', 'post', '-', 'infusion', '4', '(', 'p', '=', '0', '.', '03', '##4', '*', ')', '.', 'no', 'other', 'between', '-', 'group', 'differences', 'were', 'significant', '.', 'limitations', 'include', 'the', 'small', 'sample', ',', 'single', '-', 'centre', '##d', ',', 'open', '-', 'label', ',', 'non', '-', 'randomized', ',', 'uncontrolled', ',', 'retrospective', 'nature', 'of', 'this', 'study', 'and', 'indication', 'bias', '.', 'our', 'real', '-', 'world', 'evidence', 'suggests', 'that', 'ketamine', 'may', 'be', 'effective', 'as', 'monotherapy', 'or', 'adjunct', 'to', 'mono', '##amine', '-', 'based', 'treatments', '.', 'a', 'priority', 'research', 'and', 'clinical', 'vis', '##ta', 'is', 'to', 'identify', 'subsets', 'of', 'individuals', 'with', 'tr', '##d', 'who', 'are', 'most', 'likely', 'to', 'have', 'a', 'desired', 'therapeutic', 'outcome', 'with', 'monotherapy', 'versus', 'adjunct', '##ive', 'ketamine', 'treatment', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 21, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 80, 81, 82, 83, 84, 85, 86, 87, 88, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 105, 106, 107, 108, 109, 110, 111, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 120, 121, 122, 123, 124, 125, 126, 127, 127, 127, 127, 128, 129, 130, 131, 132, 133, 133, 134, 135, 135, 135, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 184, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 210, 211, 212, 213, 214, 215, 216, 217, 218, 218, 219, 220, 220, 220, 221, 222, 223, 224, 225, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 241, 241, 242, 243, 244, 245, 245, 245, 246, 247, 248, 249, 249, 249, 250, 251, 252, 252, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 271, 271, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 339, 340, 341, 342, 343, 344, 345, 346, 347, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 361, 362, 363, 364, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence.^
A proportion of individuals with major depressive disorder (MDD) do not receive adequate therapeutic benefit from conventional monoaminergic antidepressant drugs, leading to treatment-resistant depression (TRD). Ketamine has been shown to provide rapid and significant efficacy in treating patients with TRD. The majority of published studies have investigated the adjunctive efficacy of ketamine with one or more monoaminergic antidepressants. There remains a clinical need to ascertain the relative effectiveness of ketamine monotherapy versus adjunctive ketamine treatment in adults with TRD. In this retrospective study, we investigate multidimensional, self-reported outcomes (i.e., antidepressant, anti-suicidality, antianxiety, and anti-functional impairment) of 220 patients to compare monotherapy (n = 39) and adjunctive (n = 181) ketamine treatment for TRD at a community-based clinic. Both groups had clinically and statistically significant antidepressant effects (p < 0.05). Individuals receiving ketamine monotherapy exhibited a significantly greater reduction on the suicidal ideation (SI) item of the Quick Inventory for Depressive Symptomatology-Self Report 16-Item (QIDS-SR(16)) than the adjunctive group, with a small effect size [F (1, 265) = 4.73; p = 0.03*; partial η(2) = 0.02], and a significantly higher proportion of partial responders at post-infusion 4 (p = 0.034*). No other between-group differences were significant. Limitations include the small sample, single-centred, open-label, non-randomized, uncontrolled, retrospective nature of this study and indication bias. Our real-world evidence suggests that ketamine may be effective as monotherapy or adjunct to monoamine-based treatments. A priority research and clinical vista is to identify subsets of individuals with TRD who are most likely to have a desired therapeutic outcome with monotherapy versus adjunctive ketamine treatment."
"['MDMA', 'and', 'metabolite', 'disposition', 'in', 'expectorated', 'oral', 'fluid', 'after', 'controlled', 'oral', 'MDMA', 'administration.^', '\n', 'INTRODUCTION', ':', 'The', 'use', 'of', '3,4', '-', 'methylenedioxymethamphetamine', '(', 'MDMA', ')', 'is', 'increasing', ',', 'enhancing', 'the', 'need', 'for', 'its', 'detection', 'in', 'clinical', ',', 'workplace', ',', 'pain', 'management', ',', 'and', 'driving', 'under', 'the', 'influence', 'of', 'drugs', 'testing', 'programs', '.', 'Oral', 'fluid', 'is', 'an', 'important', 'alternative', 'matrix', 'for', 'drug', 'testing', ',', 'but', 'little', 'is', 'known', 'about', 'MDMA', 'detection', 'windows', 'in', 'oral', 'fluid', '.', 'AIMS', ':', 'The', 'aim', 'was', 'to', 'characterize', 'MDMA', 'and', 'metabolite', 'disposition', 'in', 'expectorated', 'oral', 'fluid', 'after', 'controlled', 'MDMA', 'administration', '.', 'METHODS', ':', 'Placebo', ',', 'low', '(', '1.0', 'mg', '/', 'kg', ')', ',', 'and', 'high', '(', '1.6', 'mg', '/', 'kg', ')', 'oral', 'MDMA', 'doses', 'were', 'given', 'double', '-', 'blind', 'in', 'random', 'order', 'in', 'separate', 'sessions', 'to', '29', 'healthy', 'adults', 'with', 'histories', 'of', 'MDMA', 'use', '.', 'One', 'thousand', 'two', 'hundred', 'eighty', '-', 'six', 'expectorated', 'oral', 'fluid', 'specimens', 'collected', 'up', 'to', '7', 'days', 'after', 'dosing', 'were', 'analyzed', 'for', 'MDMA', ',', '3,4', '-', 'methylenedioxyamphetamine', '(', 'MDA', ')', ',', '4', '-', 'hydroxy-3', '-', 'methoxymethamphetamine', '(', 'HMMA', ')', ',', 'and', '4', '-', 'hydroxy-3', '-', 'methoxyamphetamine', '(', 'HMA', ')', 'by', 'gas', 'chromatography', 'mass', 'spectrometry', '.', 'The', 'limits', 'of', 'quantification', 'were', '5', 'ng', '/', 'mL', 'for', 'MDMA', 'and', 'MDA', 'and', '10', 'ng', '/', 'mL', 'for', 'HMA', 'and', 'HMMA', '.', 'RESULTS', ':', 'MDMA', 'was', 'the', 'primary', 'analyte', 'detected', ',', 'with', 'concentrations', 'up', 'to', '12,000', 'ng', '/', 'mL', 'in', '872', 'specimens', '(', '67.8', '%', ')', '.', 'MDA', 'was', 'quantified', 'in', '656', 'specimens', '(', '51.0', '%', ')', 'at', 'concentrations', '<', '403', 'ng', '/', 'mL', 'and', 'was', 'never', 'present', 'without', 'concurrent', 'MDMA', '.', 'HMA', 'and', 'HMMA', 'were', 'not', 'detected', '.', 'Of', 'the', 'specimens', ',', '59.8', '%', ',', '58.6', '%', ',', 'and', '54.9', '%', 'were', 'found', 'to', 'be', 'MDMA', 'positive', 'at', 'the', 'Talloires', '(', '20', 'ng', '/', 'mL', ')', ',', 'Driving', 'under', 'the', 'Influence', 'of', 'Drugs', ',', 'Alcohol', ',', 'and', 'Medicines', '(', '25', 'ng', '/', 'mL', ')', 'and', 'proposed', 'US', 'Substance', 'Abuse', 'and', 'Mental', 'Health', 'Services', 'Administration', '(', '50', 'ng', '/', 'mL', ')', 'confirmation', 'cutoffs', ',', 'respectively', '.', 'MDMA', 'was', 'first', 'observed', 'in', 'oral', 'fluid', '0.25', '-', '1.25', 'hours', 'after', 'dosing', ';', 'MDA', 'was', 'initially', 'detected', 'at', '0.5', '-', '1.75', 'hours', '.', 'In', 'general', ',', 'the', 'windows', 'of', 'detection', 'for', 'MDMA', 'and', 'MDA', 'were', '47', 'and', '29', 'hours', ',', 'respectively', ',', 'although', 'a', 'few', 'specimens', 'were', 'positive', 'up', 'to', '71', 'and', '47', 'hours', '.', 'CONCLUSIONS', ':', 'Oral', 'fluid', 'monitoring', 'efficiently', 'detects', 'single', ',', 'recreational', '70', '-', '150', 'mg', 'of', 'MDMA', 'use', 'for', '1', '-', '2', 'days', '.', 'These', 'controlled', 'administration', 'data', 'provide', 'a', 'scientific', 'basis', 'for', 'interpreting', 'MDMA', 'oral', 'fluid', 'test', 'results', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",612,"['[CLS]', 'mdm', '##a', 'and', 'metabolite', 'disposition', 'in', 'expect', '##ora', '##ted', 'oral', 'fluid', 'after', 'controlled', 'oral', 'mdm', '##a', 'administration', '.', '^', 'introduction', ':', 'the', 'use', 'of', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', ')', 'is', 'increasing', ',', 'enhancing', 'the', 'need', 'for', 'its', 'detection', 'in', 'clinical', ',', 'workplace', ',', 'pain', 'management', ',', 'and', 'driving', 'under', 'the', 'influence', 'of', 'drugs', 'testing', 'programs', '.', 'oral', 'fluid', 'is', 'an', 'important', 'alternative', 'matrix', 'for', 'drug', 'testing', ',', 'but', 'little', 'is', 'known', 'about', 'mdm', '##a', 'detection', 'windows', 'in', 'oral', 'fluid', '.', 'aims', ':', 'the', 'aim', 'was', 'to', 'characterize', 'mdm', '##a', 'and', 'metabolite', 'disposition', 'in', 'expect', '##ora', '##ted', 'oral', 'fluid', 'after', 'controlled', 'mdm', '##a', 'administration', '.', 'methods', ':', 'placebo', ',', 'low', '(', '1', '.', '0', 'mg', '/', 'kg', ')', ',', 'and', 'high', '(', '1', '.', '6', 'mg', '/', 'kg', ')', 'oral', 'mdm', '##a', 'doses', 'were', 'given', 'double', '-', 'blind', 'in', 'random', 'order', 'in', 'separate', 'sessions', 'to', '29', 'healthy', 'adults', 'with', 'histories', 'of', 'mdm', '##a', 'use', '.', 'one', 'thousand', 'two', 'hundred', 'eighty', '-', 'six', 'expect', '##ora', '##ted', 'oral', 'fluid', 'specimens', 'collected', 'up', 'to', '7', 'days', 'after', 'dosing', 'were', 'analyzed', 'for', 'mdm', '##a', ',', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##amphetamine', '(', 'mda', ')', ',', '4', '-', 'hydroxy', '-', '3', '-', 'meth', '##oxy', '##meth', '##amphetamine', '(', 'hmm', '##a', ')', ',', 'and', '4', '-', 'hydroxy', '-', '3', '-', 'meth', '##oxy', '##amphetamine', '(', 'hm', '##a', ')', 'by', 'gas', 'chromatography', 'mass', 'spectrometry', '.', 'the', 'limits', 'of', 'quantification', 'were', '5', 'ng', '/', 'ml', 'for', 'mdm', '##a', 'and', 'mda', 'and', '10', 'ng', '/', 'ml', 'for', 'hm', '##a', 'and', 'hmm', '##a', '.', 'results', ':', 'mdm', '##a', 'was', 'the', 'primary', 'analyte', 'detected', ',', 'with', 'concentrations', 'up', 'to', '12', ',', '000', 'ng', '/', 'ml', 'in', '87', '##2', 'specimens', '(', '67', '.', '8', '%', ')', '.', 'mda', 'was', 'quantified', 'in', '65', '##6', 'specimens', '(', '51', '.', '0', '%', ')', 'at', 'concentrations', '<', '40', '##3', 'ng', '/', 'ml', 'and', 'was', 'never', 'present', 'without', 'concurrent', 'mdm', '##a', '.', 'hm', '##a', 'and', 'hmm', '##a', 'were', 'not', 'detected', '.', 'of', 'the', 'specimens', ',', '59', '.', '8', '%', ',', '58', '.', '6', '%', ',', 'and', '54', '.', '9', '%', 'were', 'found', 'to', 'be', 'mdm', '##a', 'positive', 'at', 'the', 'tall', '##oir', '##es', '(', '20', 'ng', '/', 'ml', ')', ',', 'driving', 'under', 'the', 'influence', 'of', 'drugs', ',', 'alcohol', ',', 'and', 'medicines', '(', '25', 'ng', '/', 'ml', ')', 'and', 'proposed', 'us', 'substance', 'abuse', 'and', 'mental', 'health', 'services', 'administration', '(', '50', 'ng', '/', 'ml', ')', 'confirmation', 'cutoff', '##s', ',', 'respectively', '.', 'mdm', '##a', 'was', 'first', 'observed', 'in', 'oral', 'fluid', '0', '.', '25', '-', '1', '.', '25', 'hours', 'after', 'dosing', ';', 'mda', 'was', 'initially', 'detected', 'at', '0', '.', '5', '-', '1', '.', '75', 'hours', '.', 'in', 'general', ',', 'the', 'windows', 'of', 'detection', 'for', 'mdm', '##a', 'and', 'mda', 'were', '47', 'and', '29', 'hours', ',', 'respectively', ',', 'although', 'a', 'few', 'specimens', 'were', 'positive', 'up', 'to', '71', 'and', '47', 'hours', '.', 'conclusions', ':', 'oral', 'fluid', 'monitoring', 'efficiently', 'detects', 'single', ',', 'recreational', '70', '-', '150', 'mg', 'of', 'mdm', '##a', 'use', 'for', '1', '-', '2', 'days', '.', 'these', 'controlled', 'administration', 'data', 'provide', 'a', 'scientific', 'basis', 'for', 'interpreting', 'mdm', '##a', '[SEP]']","[None, 0, 0, 1, 2, 3, 4, 5, 5, 5, 6, 7, 8, 9, 10, 11, 11, 12, 12, 12, 14, 15, 16, 17, 18, 19, 19, 19, 20, 21, 21, 21, 21, 21, 22, 23, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 82, 83, 84, 85, 86, 87, 87, 87, 88, 89, 90, 91, 92, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 101, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 110, 110, 111, 112, 113, 114, 115, 116, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 146, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 160, 161, 162, 162, 162, 163, 164, 164, 164, 164, 165, 166, 167, 168, 169, 170, 171, 171, 171, 172, 173, 173, 173, 173, 174, 175, 175, 176, 177, 178, 179, 180, 181, 181, 181, 182, 183, 183, 183, 184, 185, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 212, 213, 214, 214, 215, 216, 217, 218, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 229, 229, 230, 231, 232, 233, 234, 234, 235, 236, 237, 237, 237, 238, 239, 240, 241, 242, 243, 244, 245, 245, 246, 247, 248, 248, 248, 249, 250, 251, 252, 253, 254, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 264, 265, 266, 266, 267, 268, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 277, 277, 278, 279, 280, 280, 280, 281, 282, 283, 284, 284, 284, 285, 286, 287, 288, 289, 290, 290, 291, 292, 293, 294, 294, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 336, 337, 338, 339, 340, 340, 341, 342, 343, 344, 345, 346, 347, 347, 347, 348, 349, 349, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 359, 359, 360, 361, 361, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 429, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration.^
INTRODUCTION: The use of 3,4-methylenedioxymethamphetamine (MDMA) is increasing, enhancing the need for its detection in clinical, workplace, pain management, and driving under the influence of drugs testing programs. Oral fluid is an important alternative matrix for drug testing, but little is known about MDMA detection windows in oral fluid. AIMS: The aim was to characterize MDMA and metabolite disposition in expectorated oral fluid after controlled MDMA administration. METHODS: Placebo, low (1.0 mg/kg), and high (1.6 mg/kg) oral MDMA doses were given double-blind in random order in separate sessions to 29 healthy adults with histories of MDMA use. One thousand two hundred eighty-six expectorated oral fluid specimens collected up to 7 days after dosing were analyzed for MDMA, 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), and 4-hydroxy-3-methoxyamphetamine (HMA) by gas chromatography mass spectrometry. The limits of quantification were 5 ng/mL for MDMA and MDA and 10 ng/mL for HMA and HMMA. RESULTS: MDMA was the primary analyte detected, with concentrations up to 12,000 ng/mL in 872 specimens (67.8%). MDA was quantified in 656 specimens (51.0%) at concentrations <403 ng/mL and was never present without concurrent MDMA. HMA and HMMA were not detected. Of the specimens, 59.8%, 58.6%, and 54.9% were found to be MDMA positive at the Talloires (20 ng/mL), Driving under the Influence of Drugs, Alcohol, and Medicines (25 ng/mL) and proposed US Substance Abuse and Mental Health Services Administration (50 ng/mL) confirmation cutoffs, respectively. MDMA was first observed in oral fluid 0.25-1.25 hours after dosing; MDA was initially detected at 0.5-1.75 hours. In general, the windows of detection for MDMA and MDA were 47 and 29 hours, respectively, although a few specimens were positive up to 71 and 47 hours. CONCLUSIONS: Oral fluid monitoring efficiently detects single, recreational 70-150 mg of MDMA use for 1-2 days. These controlled administration data provide a scientific basis for interpreting MDMA oral fluid test results."
"['Effects', 'of', 'treatment', 'refractoriness', 'and', 'brain', '-', 'derived', 'neurotrophic', 'factor', 'Val66Met', 'polymorphism', 'on', 'antidepressant', 'response', 'to', 'low', '-', 'dose', 'ketamine', 'infusion.^', '\n', 'Evidence', 'suggests', 'that', 'levels', 'of', 'treatment', 'refractoriness', 'and', 'brain', '-', 'derived', 'neurotrophic', 'factor', '(', 'BDNF', ')', 'rs6265', 'polymorphism', 'are', 'related', 'to', 'the', 'antidepressant', 'effects', 'of', 'conventional', 'antidepressants', 'and', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '.', 'However', ',', 'whether', 'these', 'factors', 'are', 'associated', 'with', 'the', 'antidepressant', 'effects', 'of', 'low', '-', 'dose', 'ketamine', 'remains', 'unclear', '.', 'In', 'total', ',', '71', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', 'were', 'randomized', 'to', '0.5', 'mg', '/', 'kg', 'ketamine', ',', '0.2', 'mg', '/', 'kg', 'ketamine', ',', 'and', 'saline', 'control', 'infusion', 'groups', '.', 'They', 'were', 'further', 'divided', 'into', 'three', 'treatment', 'refractoriness', 'groups', 'according', 'to', 'the', 'Maudsley', 'staging', 'method', 'and', 'were', 'genotyped', 'for', 'Val66Met', 'BDNF', 'polymorphism', '.', 'Participants', ""'"", 'Hamilton', 'Depression', 'Rating', 'Scale', '(', 'HDRS', ')', 'scores', 'were', 'assessed', 'preinfusion', ',', 'at', '40', ',', '80', ',', '120', ',', 'and', '240', 'min', 'postinfusion', ',', 'and', 'sequentially', 'on', 'days', '2', '-', '7', 'and', '14', 'after', 'infusion', '.', 'Patients', 'with', 'any', 'Val', 'allele', 'exhibited', 'an', 'antidepressant', 'response', '(', 'p', '=', '0.029', ')', 'to', '0.5', 'mg', '/', 'kg', 'ketamine', 'vs.', '0.2', 'mg', '/', 'kg', 'ketamine', 'vs.', 'saline', 'control', 'infusions', '.', 'However', ',', 'the', 'trajectory', 'of', 'HDRS', 'scores', 'did', 'not', 'differ', '(', 'p', '=', '0.236', ')', 'between', 'the', 'treatment', 'groups', 'among', 'Met', '/', 'Met', 'carriers', '.', 'In', 'the', 'low', 'treatment', 'refractoriness', 'group', ',', 'the', '0.2', 'mg', '/', 'kg', 'ketamine', 'infusion', 'exhibited', 'the', 'optimal', 'antidepressant', 'effect', '(', 'p', '=', '0.002', ')', ';', 'in', 'the', 'moderate', 'treatment', 'refractoriness', 'group', ',', 'the', '0.5', 'mg', '/', 'kg', 'ketamine', 'infusion', 'achieved', 'the', 'strongest', 'antidepressant', 'effect', '(', 'p', '=', '0.006', ')', ';', 'however', ',', 'in', 'the', 'high', 'treatment', 'refractoriness', 'group', ',', 'the', 'trajectory', 'of', 'depressive', 'symptoms', 'did', 'not', 'differ', 'between', 'treatments', '(', 'p', '=', '0.325', ')', '.', 'In', 'future', 'clinical', 'practice', ',', 'ketamine', 'dose', 'may', 'be', 'adjusted', 'according', 'to', 'the', 'level', 'of', 'treatment', 'refractoriness', 'and', 'BDNF', 'rs6265', 'polymorphism', 'to', 'achieve', 'the', 'optimal', 'antidepressant', 'effect', 'for', 'patients', 'with', 'TRD', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1441,"['[CLS]', 'effects', 'of', 'treatment', 'refr', '##actor', '##iness', 'and', 'brain', '-', 'derived', 'neurotrophic', 'factor', 'val', '##66', '##met', 'polymorphism', 'on', 'antidepressant', 'response', 'to', 'low', '-', 'dose', 'ketamine', 'infusion', '.', '^', 'evidence', 'suggests', 'that', 'levels', 'of', 'treatment', 'refr', '##actor', '##iness', 'and', 'brain', '-', 'derived', 'neurotrophic', 'factor', '(', 'bdnf', ')', 'rs', '##62', '##65', 'polymorphism', 'are', 'related', 'to', 'the', 'antidepressant', 'effects', 'of', 'conventional', 'antidepressants', 'and', 'repetitive', 'transc', '##ran', '##ial', 'magnetic', 'stimulation', '.', 'however', ',', 'whether', 'these', 'factors', 'are', 'associated', 'with', 'the', 'antidepressant', 'effects', 'of', 'low', '-', 'dose', 'ketamine', 'remains', 'unclear', '.', 'in', 'total', ',', '71', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', 'were', 'randomized', 'to', '0', '.', '5', 'mg', '/', 'kg', 'ketamine', ',', '0', '.', '2', 'mg', '/', 'kg', 'ketamine', ',', 'and', 'saline', 'control', 'infusion', 'groups', '.', 'they', 'were', 'further', 'divided', 'into', 'three', 'treatment', 'refr', '##actor', '##iness', 'groups', 'according', 'to', 'the', 'ma', '##ud', '##sle', '##y', 'staging', 'method', 'and', 'were', 'genotyped', 'for', 'val', '##66', '##met', 'bdnf', 'polymorphism', '.', 'participants', ""'"", 'hamilton', 'depression', 'rating', 'scale', '(', 'hd', '##rs', ')', 'scores', 'were', 'assessed', 'pre', '##inf', '##usion', ',', 'at', '40', ',', '80', ',', '120', ',', 'and', '240', 'min', 'post', '##inf', '##usion', ',', 'and', 'sequentially', 'on', 'days', '2', '-', '7', 'and', '14', 'after', 'infusion', '.', 'patients', 'with', 'any', 'val', 'allele', 'exhibited', 'an', 'antidepressant', 'response', '(', 'p', '=', '0', '.', '02', '##9', ')', 'to', '0', '.', '5', 'mg', '/', 'kg', 'ketamine', 'vs', '.', '0', '.', '2', 'mg', '/', 'kg', 'ketamine', 'vs', '.', 'saline', 'control', 'infusions', '.', 'however', ',', 'the', 'trajectory', 'of', 'hd', '##rs', 'scores', 'did', 'not', 'differ', '(', 'p', '=', '0', '.', '236', ')', 'between', 'the', 'treatment', 'groups', 'among', 'met', '/', 'met', 'carriers', '.', 'in', 'the', 'low', 'treatment', 'refr', '##actor', '##iness', 'group', ',', 'the', '0', '.', '2', 'mg', '/', 'kg', 'ketamine', 'infusion', 'exhibited', 'the', 'optimal', 'antidepressant', 'effect', '(', 'p', '=', '0', '.', '00', '##2', ')', ';', 'in', 'the', 'moderate', 'treatment', 'refr', '##actor', '##iness', 'group', ',', 'the', '0', '.', '5', 'mg', '/', 'kg', 'ketamine', 'infusion', 'achieved', 'the', 'strongest', 'antidepressant', 'effect', '(', 'p', '=', '0', '.', '00', '##6', ')', ';', 'however', ',', 'in', 'the', 'high', 'treatment', 'refr', '##actor', '##iness', 'group', ',', 'the', 'trajectory', 'of', 'depressive', 'symptoms', 'did', 'not', 'differ', 'between', 'treatments', '(', 'p', '=', '0', '.', '325', ')', '.', 'in', 'future', 'clinical', 'practice', ',', 'ketamine', 'dose', 'may', 'be', 'adjusted', 'according', 'to', 'the', 'level', 'of', 'treatment', 'refr', '##actor', '##iness', 'and', 'bdnf', 'rs', '##62', '##65', 'polymorphism', 'to', 'achieve', 'the', 'optimal', 'antidepressant', 'effect', 'for', 'patients', 'with', 'tr', '##d', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 4, 5, 6, 7, 8, 9, 10, 10, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20, 20, 22, 23, 24, 25, 26, 27, 28, 28, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 51, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 85, 86, 87, 88, 89, 90, 90, 90, 91, 92, 93, 94, 95, 96, 96, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 115, 115, 116, 117, 118, 119, 120, 120, 120, 120, 121, 122, 123, 124, 125, 126, 127, 127, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 138, 139, 140, 141, 142, 143, 143, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 181, 181, 181, 182, 183, 184, 184, 184, 185, 186, 187, 188, 189, 189, 190, 190, 190, 191, 192, 193, 194, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 205, 206, 207, 208, 209, 210, 211, 212, 213, 213, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 229, 229, 230, 231, 232, 233, 233, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 247, 247, 247, 248, 249, 250, 251, 252, 253, 254, 254, 254, 255, 256, 257, 258, 258, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 272, 272, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 281, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 297, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 316, 316, 317, 318, 319, 319, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 330, 331, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Effects of treatment refractoriness and brain-derived neurotrophic factor Val66Met polymorphism on antidepressant response to low-dose ketamine infusion.^
Evidence suggests that levels of treatment refractoriness and brain-derived neurotrophic factor (BDNF) rs6265 polymorphism are related to the antidepressant effects of conventional antidepressants and repetitive transcranial magnetic stimulation. However, whether these factors are associated with the antidepressant effects of low-dose ketamine remains unclear. In total, 71 patients with treatment-resistant depression (TRD) were randomized to 0.5 mg/kg ketamine, 0.2 mg/kg ketamine, and saline control infusion groups. They were further divided into three treatment refractoriness groups according to the Maudsley staging method and were genotyped for Val66Met BDNF polymorphism. Participants' Hamilton Depression Rating Scale (HDRS) scores were assessed preinfusion, at 40, 80, 120, and 240 min postinfusion, and sequentially on days 2-7 and 14 after infusion. Patients with any Val allele exhibited an antidepressant response (p = 0.029) to 0.5 mg/kg ketamine vs. 0.2 mg/kg ketamine vs. saline control infusions. However, the trajectory of HDRS scores did not differ (p = 0.236) between the treatment groups among Met/Met carriers. In the low treatment refractoriness group, the 0.2 mg/kg ketamine infusion exhibited the optimal antidepressant effect (p = 0.002); in the moderate treatment refractoriness group, the 0.5 mg/kg ketamine infusion achieved the strongest antidepressant effect (p = 0.006); however, in the high treatment refractoriness group, the trajectory of depressive symptoms did not differ between treatments (p = 0.325). In future clinical practice, ketamine dose may be adjusted according to the level of treatment refractoriness and BDNF rs6265 polymorphism to achieve the optimal antidepressant effect for patients with TRD."
"['An', 'encounter', 'with', 'the', 'self', ':', 'A', 'thematic', 'and', 'content', 'analysis', 'of', 'the', 'DMT', 'experience', 'from', 'a', 'naturalistic', 'field', 'study.^', '\n', 'INTRODUCTION', ':', 'N', ',', 'N', '-', 'Dimethyltryptamine', '(', 'DMT', ')', 'is', 'an', 'endogenous', 'serotonergic', 'psychedelic', 'capable', 'of', 'producing', 'radical', 'shifts', 'in', 'an', 'experience', 'that', 'have', 'significant', 'implications', 'for', 'consciousness', 'and', 'its', 'neural', 'correlates', ',', 'especially', 'given', 'the', '""', 'disconnected', 'consciousness', '""', 'suggested', 'by', 'the', '""', 'breakthrough', '""', 'DMT', 'state', '.', 'Its', 'increasing', 'usage', 'and', 'clinical', 'trial', 'indicate', 'the', 'growing', 'importance', 'of', 'a', 'thorough', 'elucidation', 'of', 'the', 'experience', ""'s"", 'qualitative', 'content', ',', 'over', 'and', 'above', 'the', 'phenomenological', 'structure', '.', 'This', 'is', 'particularly', 'in', 'light', 'of', 'the', 'intensely', 'pervasive', 'effects', 'of', 'DMT', 'occasions', 'in', 'all', 'dimensions', 'of', 'the', 'self', ',', 'which', 'are', 'often', 'ontologically', 'challenging', 'yet', 'potentially', 'transformative', '.', 'METHODS', ':', 'This', 'is', 'the', 'second', 'report', 'on', 'the', 'first', 'naturalistic', 'field', 'study', 'of', 'DMT', 'use', 'exploring', 'its', 'qualitative', 'analysis', '.', 'Screened', ',', 'healthy', ',', 'anonymized', ',', 'and', 'experienced', 'DMT', 'users', 'were', 'observed', 'during', 'their', 'non', '-', 'clinical', 'use', 'of', 'the', 'drug', 'at', 'home', '(', '40', '-', '75', '-', 'mg', 'inhaled', ')', '.', 'In', '-', 'depth', 'semi', '-', 'structured', 'interviews', ',', 'inspired', 'by', 'the', 'micro', '-', 'phenomenological', 'technique', ',', 'were', 'employed', 'immediately', 'after', 'their', 'experience', '.', 'This', 'study', 'reports', 'on', 'the', 'thematic', 'and', 'content', 'analysis', 'of', 'one', 'major', 'domain', 'of', 'the', 'breakthrough', 'experiences', 'elicited', ',', 'the', '""', 'self', '""', ';', 'where', 'analyses', 'of', 'the', '""', 'other', '""', 'were', 'previously', 'reported', '.', 'A', 'total', 'of', '36', 'post', '-', 'DMT', 'experience', 'interviews', 'with', 'mostly', 'Caucasian', '(', '83', '%', ')', 'men', '(', 'eight', 'women', ')', 'of', 'a', 'mean', 'of', '37', 'years', 'were', 'predominantly', 'inductively', 'coded', '.', 'RESULTS', ':', 'Invariably', ',', 'profound', 'and', 'highly', 'intense', 'experiences', 'occurred', '.', 'The', 'first', 'overarching', 'category', 'comprised', 'the', 'onset', 'of', 'effects', ',', 'encompassing', 'super', '-', 'ordinate', 'themes', 'including', 'sensory', ',', 'emotion', 'and', 'body', ',', 'and', 'space', '-', 'time', 'shifts', ';', 'the', 'second', 'category', 'comprised', 'bodily', 'effects', ',', 'encompassing', 'themes', 'including', 'pleasurable', ',', 'neutral', '/', 'both', ',', 'and', 'uncomfortable', ';', 'the', 'third', 'category', 'comprised', 'the', 'sensorial', 'effects', ',', 'encompassing', 'open', '-', 'eye', ',', 'visual', ',', 'and', 'cross', '-', 'modal', 'and', 'other', ';', 'the', 'fourth', 'comprised', 'the', 'psychological', 'effects', ',', 'encompassing', 'memory', 'and', 'language', ',', 'awareness', 'and', 'sense', 'of', 'self', ',', 'and', 'time', 'distortions', ';', 'and', 'the', 'fifth', 'comprised', 'the', 'emotional', 'effects', ',', 'encompassing', 'positive', ',', 'neither', '/', 'both', ',', 'and', 'challenging', 'experiences', '.', 'Many', 'further', 'subthemes', 'also', 'illuminate', 'the', 'rich', 'content', 'of', 'the', 'DMT', 'experience', '.', 'DISCUSSION', ':', 'The', 'present', 'study', 'provides', 'a', 'systematic', 'and', 'nuanced', 'analysis', 'of', 'the', 'content', 'of', 'the', 'breakthrough', 'DMT', 'state', 'pertaining', 'to', 'one', ""'s"", 'personal', 'and', 'self', '-', 'referential', 'experiences', 'of', 'the', 'body', ',', 'senses', ',', 'psychology', ',', 'and', 'emotions', '.', 'The', 'resonances', 'both', 'with', 'previous', 'DMT', 'studies', 'and', 'other', 'types', 'of', 'extraordinary', 'experiences', ',', 'such', 'as', 'the', 'alien', 'abduction', ',', 'shamanic', 'and', 'near', '-', 'death', 'experiences', ',', 'are', 'also', 'elaborated', 'upon', '.', 'Putative', 'neural', 'mechanisms', 'and', 'their', 'promise', 'as', 'a', 'psychotherapeutic', 'agent', ',', 'especially', 'owing', 'to', 'deep', 'emotional', 'impact', ',', 'are', 'discussed', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5628,"['[CLS]', 'an', 'encounter', 'with', 'the', 'self', ':', 'a', 'thematic', 'and', 'content', 'analysis', 'of', 'the', 'dm', '##t', 'experience', 'from', 'a', 'natural', '##istic', 'field', 'study', '.', '^', 'introduction', ':', 'n', ',', 'n', '-', 'dimethyl', '##try', '##pt', '##amine', '(', 'dm', '##t', ')', 'is', 'an', 'endogenous', 'serot', '##one', '##rg', '##ic', 'psych', '##ede', '##lic', 'capable', 'of', 'producing', 'radical', 'shifts', 'in', 'an', 'experience', 'that', 'have', 'significant', 'implications', 'for', 'consciousness', 'and', 'its', 'neural', 'correlates', ',', 'especially', 'given', 'the', '""', 'disconnected', 'consciousness', '""', 'suggested', 'by', 'the', '""', 'breakthrough', '""', 'dm', '##t', 'state', '.', 'its', 'increasing', 'usage', 'and', 'clinical', 'trial', 'indicate', 'the', 'growing', 'importance', 'of', 'a', 'thorough', 'elucid', '##ation', 'of', 'the', 'experience', ""'"", 's', 'qualitative', 'content', ',', 'over', 'and', 'above', 'the', 'phenomen', '##ological', 'structure', '.', 'this', 'is', 'particularly', 'in', 'light', 'of', 'the', 'intense', '##ly', 'pervasive', 'effects', 'of', 'dm', '##t', 'occasions', 'in', 'all', 'dimensions', 'of', 'the', 'self', ',', 'which', 'are', 'often', 'ontological', '##ly', 'challenging', 'yet', 'potentially', 'transform', '##ative', '.', 'methods', ':', 'this', 'is', 'the', 'second', 'report', 'on', 'the', 'first', 'natural', '##istic', 'field', 'study', 'of', 'dm', '##t', 'use', 'exploring', 'its', 'qualitative', 'analysis', '.', 'screened', ',', 'healthy', ',', 'anonym', '##ized', ',', 'and', 'experienced', 'dm', '##t', 'users', 'were', 'observed', 'during', 'their', 'non', '-', 'clinical', 'use', 'of', 'the', 'drug', 'at', 'home', '(', '40', '-', '75', '-', 'mg', 'inhaled', ')', '.', 'in', '-', 'depth', 'semi', '-', 'structured', 'interviews', ',', 'inspired', 'by', 'the', 'micro', '-', 'phenomen', '##ological', 'technique', ',', 'were', 'employed', 'immediately', 'after', 'their', 'experience', '.', 'this', 'study', 'reports', 'on', 'the', 'thematic', 'and', 'content', 'analysis', 'of', 'one', 'major', 'domain', 'of', 'the', 'breakthrough', 'experiences', 'elicited', ',', 'the', '""', 'self', '""', ';', 'where', 'analyses', 'of', 'the', '""', 'other', '""', 'were', 'previously', 'reported', '.', 'a', 'total', 'of', '36', 'post', '-', 'dm', '##t', 'experience', 'interviews', 'with', 'mostly', 'caucasian', '(', '83', '%', ')', 'men', '(', 'eight', 'women', ')', 'of', 'a', 'mean', 'of', '37', 'years', 'were', 'predominantly', 'inductively', 'coded', '.', 'results', ':', 'invari', '##ably', ',', 'profound', 'and', 'highly', 'intense', 'experiences', 'occurred', '.', 'the', 'first', 'over', '##arch', '##ing', 'category', 'comprised', 'the', 'onset', 'of', 'effects', ',', 'encompassing', 'super', '-', 'ord', '##inate', 'themes', 'including', 'sensory', ',', 'emotion', 'and', 'body', ',', 'and', 'space', '-', 'time', 'shifts', ';', 'the', 'second', 'category', 'comprised', 'bodily', 'effects', ',', 'encompassing', 'themes', 'including', 'ple', '##as', '##urable', ',', 'neutral', '/', 'both', ',', 'and', 'uncom', '##fort', '##able', ';', 'the', 'third', 'category', 'comprised', 'the', 'sensor', '##ial', 'effects', ',', 'encompassing', 'open', '-', 'eye', ',', 'visual', ',', 'and', 'cross', '-', 'modal', 'and', 'other', ';', 'the', 'fourth', 'comprised', 'the', 'psychological', 'effects', ',', 'encompassing', 'memory', 'and', 'language', ',', 'awareness', 'and', 'sense', 'of', 'self', ',', 'and', 'time', 'distortions', ';', 'and', 'the', 'fifth', 'comprised', 'the', 'emotional', 'effects', ',', 'encompassing', 'positive', ',', 'neither', '/', 'both', ',', 'and', 'challenging', 'experiences', '.', 'many', 'further', 'subt', '##heme', '##s', 'also', 'illumina', '##te', 'the', 'rich', 'content', 'of', 'the', 'dm', '##t', 'experience', '.', 'discussion', ':', 'the', 'present', 'study', 'provides', 'a', 'systematic', 'and', 'nu', '##anced', 'analysis', 'of', 'the', 'content', 'of', 'the', 'breakthrough', 'dm', '##t', 'state', 'pertaining', 'to', 'one', ""'"", 's', 'personal', 'and', 'self', '-', 'referen', '##tial', 'experiences', 'of', 'the', 'body', ',', 'senses', ',', 'psychology', ',', 'and', 'emotions', '.', 'the', 'resonances', 'both', 'with', 'previous', 'dm', '##t', 'studies', 'and', 'other', 'types', 'of', 'extraordinary', 'experiences', ',', 'such', 'as', 'the', 'alien', 'abd', '##uct', '##ion', '[SEP]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 13, 14, 15, 16, 17, 17, 18, 19, 19, 19, 21, 22, 23, 24, 25, 26, 27, 27, 27, 27, 28, 29, 29, 30, 31, 32, 33, 34, 34, 34, 34, 35, 35, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 84, 85, 86, 87, 88, 88, 89, 90, 91, 92, 93, 94, 95, 96, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 106, 107, 108, 109, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 122, 123, 124, 125, 126, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 138, 139, 140, 141, 142, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 153, 154, 155, 156, 157, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 284, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 320, 320, 321, 322, 323, 324, 325, 326, 327, 327, 327, 328, 329, 330, 331, 332, 333, 334, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 394, 394, 395, 396, 396, 397, 398, 399, 400, 401, 402, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 414, 415, 416, 417, 418, 419, 420, 421, 422, 422, 423, 424, 425, 426, 427, 427, 428, 429, 430, 431, 432, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 463, 463, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100]","An encounter with the self: A thematic and content analysis of the DMT experience from a naturalistic field study.^
INTRODUCTION: N,N-Dimethyltryptamine (DMT) is an endogenous serotonergic psychedelic capable of producing radical shifts in an experience that have significant implications for consciousness and its neural correlates, especially given the ""disconnected consciousness"" suggested by the ""breakthrough"" DMT state. Its increasing usage and clinical trial indicate the growing importance of a thorough elucidation of the experience's qualitative content, over and above the phenomenological structure. This is particularly in light of the intensely pervasive effects of DMT occasions in all dimensions of the self, which are often ontologically challenging yet potentially transformative. METHODS: This is the second report on the first naturalistic field study of DMT use exploring its qualitative analysis. Screened, healthy, anonymized, and experienced DMT users were observed during their non-clinical use of the drug at home (40-75-mg inhaled). In-depth semi-structured interviews, inspired by the micro-phenomenological technique, were employed immediately after their experience. This study reports on the thematic and content analysis of one major domain of the breakthrough experiences elicited, the ""self""; where analyses of the ""other"" were previously reported. A total of 36 post-DMT experience interviews with mostly Caucasian (83%) men (eight women) of a mean of 37 years were predominantly inductively coded. RESULTS: Invariably, profound and highly intense experiences occurred. The first overarching category comprised the onset of effects, encompassing super-ordinate themes including sensory, emotion and body, and space-time shifts; the second category comprised bodily effects, encompassing themes including pleasurable, neutral/both, and uncomfortable; the third category comprised the sensorial effects, encompassing open-eye, visual, and cross-modal and other; the fourth comprised the psychological effects, encompassing memory and language, awareness and sense of self, and time distortions; and the fifth comprised the emotional effects, encompassing positive, neither/both, and challenging experiences. Many further subthemes also illuminate the rich content of the DMT experience. DISCUSSION: The present study provides a systematic and nuanced analysis of the content of the breakthrough DMT state pertaining to one's personal and self-referential experiences of the body, senses, psychology, and emotions. The resonances both with previous DMT studies and other types of extraordinary experiences, such as the alien abduction, shamanic and near-death experiences, are also elaborated upon. Putative neural mechanisms and their promise as a psychotherapeutic agent, especially owing to deep emotional impact, are discussed."
"['A', 'Single', 'Ketamine', 'Infusion', 'Combined', 'With', 'Motivational', 'Enhancement', 'Therapy', 'for', 'Alcohol', 'Use', 'Disorder', ':', 'A', 'Randomized', 'Midazolam', '-', 'Controlled', 'Pilot', 'Trial.^', '\n', 'OBJECTIVE', ':', 'Pharmacotherapy', 'and', 'behavioral', 'treatments', 'for', 'alcohol', 'use', 'disorder', 'are', 'limited', 'in', 'their', 'effectiveness', ',', 'and', 'new', 'treatments', 'with', 'innovative', 'mechanisms', 'would', 'be', 'valuable', '.', 'In', 'this', 'pilot', 'study', ',', 'the', 'authors', 'tested', 'whether', 'a', 'single', 'subanesthetic', 'infusion', 'of', 'ketamine', 'administered', 'to', 'adults', 'with', 'alcohol', 'dependence', 'and', 'engaged', 'in', 'motivational', 'enhancement', 'therapy', 'affects', 'drinking', 'outcomes', '.', 'METHODS', ':', 'Participants', 'were', 'randomly', 'assigned', 'to', 'a', '52', '-', 'minute', 'intravenous', 'administration', 'of', 'ketamine', '(', '0.71', 'mg', '/', 'kg', ',', 'N=17', ')', 'or', 'the', 'active', 'control', 'midazolam', '(', '0.025', 'mg', '/', 'kg', ',', 'N=23', ')', ',', 'provided', 'during', 'the', 'second', 'week', 'of', 'a', '5', '-', 'week', 'outpatient', 'regimen', 'of', 'motivational', 'enhancement', 'therapy', '.', 'Alcohol', 'use', 'following', 'the', 'infusion', 'was', 'assessed', 'with', 'timeline', 'followback', 'method', ',', 'with', 'abstinence', 'confirmed', 'by', 'urine', 'ethyl', 'glucuronide', 'testing', '.', 'A', 'longitudinal', 'logistic', 'mixed', '-', 'effects', 'model', 'was', 'used', 'to', 'model', 'daily', 'abstinence', 'from', 'alcohol', 'over', 'the', '21', 'days', 'after', 'ketamine', 'infusion', '.', 'RESULTS', ':', 'Participants', '(', 'N=40', ')', 'were', 'mostly', 'middle', '-', 'aged', '(', 'mean', 'age=53', 'years', '[', 'SD=9.8', ']', ')', ',', 'predominantly', 'white', '(', '70.3', '%', ')', ',', 'and', 'largely', 'employed', '(', '71.8', '%', ')', 'and', 'consumed', 'an', 'average', 'of', 'five', 'drinks', 'per', 'day', 'prior', 'to', 'entering', 'the', 'study', '.', 'Ketamine', 'significantly', 'increased', 'the', 'likelihood', 'of', 'abstinence', ',', 'delayed', 'the', 'time', 'to', 'relapse', ',', 'and', 'reduced', 'the', 'likelihood', 'of', 'heavy', 'drinking', 'days', 'compared', 'with', 'midazolam', '.', 'Infusions', 'were', 'well', 'tolerated', ',', 'with', 'no', 'participants', 'removed', 'from', 'the', 'study', 'as', 'a', 'result', 'of', 'adverse', 'events', '.', 'CONCLUSIONS', ':', 'A', 'single', 'ketamine', 'infusion', 'was', 'found', 'to', 'improve', 'measures', 'of', 'drinking', 'in', 'persons', 'with', 'alcohol', 'dependence', 'engaged', 'in', 'motivational', 'enhancement', 'therapy', '.', 'These', 'preliminary', 'data', 'suggest', 'new', 'directions', 'in', 'integrated', 'pharmacotherapy', '-', 'behavioral', 'treatments', 'for', 'alcohol', 'use', 'disorder', '.', 'Further', 'research', 'is', 'needed', 'to', 'replicate', 'these', 'promising', 'results', 'in', 'a', 'larger', 'sample', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",1806,"['[CLS]', 'a', 'single', 'ketamine', 'infusion', 'combined', 'with', 'motivational', 'enhancement', 'therapy', 'for', 'alcohol', 'use', 'disorder', ':', 'a', 'randomized', 'mid', '##azol', '##am', '-', 'controlled', 'pilot', 'trial', '.', '^', 'objective', ':', 'pharmac', '##otherapy', 'and', 'behavioral', 'treatments', 'for', 'alcohol', 'use', 'disorder', 'are', 'limited', 'in', 'their', 'effectiveness', ',', 'and', 'new', 'treatments', 'with', 'innovative', 'mechanisms', 'would', 'be', 'valuable', '.', 'in', 'this', 'pilot', 'study', ',', 'the', 'authors', 'tested', 'whether', 'a', 'single', 'sub', '##anes', '##the', '##tic', 'infusion', 'of', 'ketamine', 'administered', 'to', 'adults', 'with', 'alcohol', 'dependence', 'and', 'engaged', 'in', 'motivational', 'enhancement', 'therapy', 'affects', 'drinking', 'outcomes', '.', 'methods', ':', 'participants', 'were', 'randomly', 'assigned', 'to', 'a', '52', '-', 'minute', 'intravenous', 'administration', 'of', 'ketamine', '(', '0', '.', '71', 'mg', '/', 'kg', ',', 'n', '=', '17', ')', 'or', 'the', 'active', 'control', 'mid', '##azol', '##am', '(', '0', '.', '02', '##5', 'mg', '/', 'kg', ',', 'n', '=', '23', ')', ',', 'provided', 'during', 'the', 'second', 'week', 'of', 'a', '5', '-', 'week', 'outpatient', 'regimen', 'of', 'motivational', 'enhancement', 'therapy', '.', 'alcohol', 'use', 'following', 'the', 'infusion', 'was', 'assessed', 'with', 'time', '##line', 'follow', '##back', 'method', ',', 'with', 'abstinence', 'confirmed', 'by', 'urine', 'ethyl', 'gluc', '##uron', '##ide', 'testing', '.', 'a', 'longitudinal', 'logistic', 'mixed', '-', 'effects', 'model', 'was', 'used', 'to', 'model', 'daily', 'abstinence', 'from', 'alcohol', 'over', 'the', '21', 'days', 'after', 'ketamine', 'infusion', '.', 'results', ':', 'participants', '(', 'n', '=', '40', ')', 'were', 'mostly', 'middle', '-', 'aged', '(', 'mean', 'age', '=', '53', 'years', '[', 'sd', '=', '9', '.', '8', ']', ')', ',', 'predominantly', 'white', '(', '70', '.', '3', '%', ')', ',', 'and', 'largely', 'employed', '(', '71', '.', '8', '%', ')', 'and', 'consumed', 'an', 'average', 'of', 'five', 'drinks', 'per', 'day', 'prior', 'to', 'entering', 'the', 'study', '.', 'ketamine', 'significantly', 'increased', 'the', 'likelihood', 'of', 'abstinence', ',', 'delayed', 'the', 'time', 'to', 'relapse', ',', 'and', 'reduced', 'the', 'likelihood', 'of', 'heavy', 'drinking', 'days', 'compared', 'with', 'mid', '##azol', '##am', '.', 'infusions', 'were', 'well', 'tolerated', ',', 'with', 'no', 'participants', 'removed', 'from', 'the', 'study', 'as', 'a', 'result', 'of', 'adverse', 'events', '.', 'conclusions', ':', 'a', 'single', 'ketamine', 'infusion', 'was', 'found', 'to', 'improve', 'measures', 'of', 'drinking', 'in', 'persons', 'with', 'alcohol', 'dependence', 'engaged', 'in', 'motivational', 'enhancement', 'therapy', '.', 'these', 'preliminary', 'data', 'suggest', 'new', 'directions', 'in', 'integrated', 'pharmac', '##otherapy', '-', 'behavioral', 'treatments', 'for', 'alcohol', 'use', 'disorder', '.', 'further', 'research', 'is', 'needed', 'to', 'replicate', 'these', 'promising', 'results', 'in', 'a', 'larger', 'sample', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 16, 16, 17, 18, 19, 20, 20, 20, 22, 23, 24, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 59, 59, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 95, 95, 96, 97, 98, 99, 100, 100, 100, 101, 102, 103, 104, 105, 106, 106, 106, 107, 108, 108, 108, 108, 109, 110, 111, 112, 113, 113, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 141, 142, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 151, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 181, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 190, 190, 191, 192, 193, 193, 193, 193, 193, 194, 195, 196, 197, 198, 199, 200, 200, 200, 201, 202, 203, 204, 205, 206, 207, 208, 208, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 250, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial.^
OBJECTIVE: Pharmacotherapy and behavioral treatments for alcohol use disorder are limited in their effectiveness, and new treatments with innovative mechanisms would be valuable. In this pilot study, the authors tested whether a single subanesthetic infusion of ketamine administered to adults with alcohol dependence and engaged in motivational enhancement therapy affects drinking outcomes. METHODS: Participants were randomly assigned to a 52-minute intravenous administration of ketamine (0.71 mg/kg, N=17) or the active control midazolam (0.025 mg/kg, N=23), provided during the second week of a 5-week outpatient regimen of motivational enhancement therapy. Alcohol use following the infusion was assessed with timeline followback method, with abstinence confirmed by urine ethyl glucuronide testing. A longitudinal logistic mixed-effects model was used to model daily abstinence from alcohol over the 21 days after ketamine infusion. RESULTS: Participants (N=40) were mostly middle-aged (mean age=53 years [SD=9.8]), predominantly white (70.3%), and largely employed (71.8%) and consumed an average of five drinks per day prior to entering the study. Ketamine significantly increased the likelihood of abstinence, delayed the time to relapse, and reduced the likelihood of heavy drinking days compared with midazolam. Infusions were well tolerated, with no participants removed from the study as a result of adverse events. CONCLUSIONS: A single ketamine infusion was found to improve measures of drinking in persons with alcohol dependence engaged in motivational enhancement therapy. These preliminary data suggest new directions in integrated pharmacotherapy-behavioral treatments for alcohol use disorder. Further research is needed to replicate these promising results in a larger sample."
"['Opposite', 'effects', 'of', '3,4', '-', 'methylenedioxymethamphetamine', '(', 'MDMA', ')', 'on', 'sensorimotor', 'gating', 'in', 'rats', 'versus', 'healthy', 'humans.^', '\n', 'RATIONALE', ':', 'Prepulse', 'inhibition', 'of', 'acoustic', 'startle', 'refers', 'to', 'the', 'reduction', 'in', 'the', 'startle', 'response', 'when', 'the', 'startling', 'stimulus', 'is', 'preceded', 'by', 'a', 'weak', 'prepulse', 'stimulus', '.', 'This', 'phenomenon', 'provides', 'an', 'operational', 'measure', 'of', 'sensorimotor', 'gating', 'that', 'has', 'been', 'found', 'to', 'be', 'reduced', 'in', 'patients', 'with', 'schizophrenia', 'and', 'rats', 'treated', 'with', 'serotonin', 'agonists', 'or', 'serotonin', 'releasers', '.', 'OBJECTIVE', ':', 'In', 'this', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'a', 'serotonin', 'releaser', ',', 'MDMA', ',', 'on', 'prepulse', 'inhibition', 'in', 'laboratory', 'rats', 'and', 'healthy', 'human', 'volunteers', '.', 'In', 'particular', ',', 'we', 'investigated', 'whether', 'MDMA', 'disrupts', 'PPI', 'in', 'humans', 'as', 'observed', 'in', 'animal', 'studies', '.', 'METHODS', ':', 'Rats', 'were', 'tested', 'after', 'placebo', 'and', 'MDMA', 'in', 'a', 'counterbalanced', 'order', 'at', 'an', 'interval', 'of', '1', 'week', ',', 'with', 'separate', 'groups', 'of', 'rats', 'being', 'used', 'for', 'each', 'dose', 'of', 'MDMA', '(', '1.7', ',', '5.4', 'and', '17.0', 'mg', '/', 'kg', ')', '.', 'On', 'each', 'test', 'day', ',', 'rats', 'were', 'first', 'tested', 'after', 'no', 'injections', 'and', 'retested', '2', 'h', 'later', ',', '10', 'min', 'after', 'a', 'subcutaneous', 'injection', 'of', 'placebo', 'or', 'MDMA', '.', 'For', 'the', 'human', 'study', ',', 'a', 'placebo', '-', 'controlled', 'within', '-', 'subject', 'design', 'and', 'double', '-', 'blind', 'procedures', 'were', 'used', '.', 'Subjects', 'were', 'examined', 'twice', 'at', 'a', '2', 'to', '4', 'week', 'interval', 'after', 'either', 'placebo', 'or', 'drug', 'administration', '(', 'order', 'being', 'counterbalanced', ')', '.', 'On', 'each', 'test', 'day', ',', 'subjects', 'underwent', 'baseline', 'testing', 'including', 'psychological', 'and', 'PPI', 'measures', '.', 'Ninety', 'minutes', 'later', ',', 'subjects', 'received', 'placebo', 'or', 'MDMA', '(', '1.7', 'mg', '/', 'kg', 'PO', ')', 'and', 'were', 'retested', 'after', '75', 'min', 'during', 'the', 'peak', 'of', 'behavioral', 'effects', 'of', 'MDMA', '.', 'RESULTS', ':', 'As', 'expected', ',', 'MDMA', 'decreased', 'prepulse', 'inhibition', 'in', 'a', 'dose', '-', 'related', 'fashion', 'in', 'rats', '.', 'In', 'contrast', ',', 'a', 'typical', 'recreational', 'dose', 'of', 'MDMA', '(', '1.7', 'mg', '/', 'kg', ',', 'orally', ')', 'increased', 'prepulse', 'inhibition', 'in', 'subjects', 'experiencing', 'robust', 'psychological', 'effects', '.', 'CONCLUSIONS', ':', 'This', 'surprising', 'disparity', 'between', 'the', 'effects', 'of', 'the', 'drug', 'in', 'rats', 'and', 'humans', 'may', 'reflect', 'a', 'species', '-', 'specific', 'difference', 'in', 'the', 'mechanism', 'of', 'action', 'of', 'MDMA', 'or', 'in', 'the', 'behavioral', 'expression', 'of', 'a', 'similar', 'pharmacological', 'effect', ',', 'or', 'both', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8910,"['[CLS]', 'opposite', 'effects', 'of', '3', ',', '4', '-', 'methylene', '##di', '##oxy', '##meth', '##amphetamine', '(', 'mdm', '##a', ')', 'on', 'sensorimotor', 'gating', 'in', 'rats', 'versus', 'healthy', 'humans', '.', '^', 'rationale', ':', 'prep', '##uls', '##e', 'inhibition', 'of', 'acoustic', 'start', '##le', 'refers', 'to', 'the', 'reduction', 'in', 'the', 'start', '##le', 'response', 'when', 'the', 'start', '##ling', 'stimulus', 'is', 'preceded', 'by', 'a', 'weak', 'prep', '##uls', '##e', 'stimulus', '.', 'this', 'phenomenon', 'provides', 'an', 'operational', 'measure', 'of', 'sensorimotor', 'gating', 'that', 'has', 'been', 'found', 'to', 'be', 'reduced', 'in', 'patients', 'with', 'schizophrenia', 'and', 'rats', 'treated', 'with', 'serotonin', 'agonists', 'or', 'serotonin', 'release', '##rs', '.', 'objective', ':', 'in', 'this', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'a', 'serotonin', 'release', '##r', ',', 'mdm', '##a', ',', 'on', 'prep', '##uls', '##e', 'inhibition', 'in', 'laboratory', 'rats', 'and', 'healthy', 'human', 'volunteers', '.', 'in', 'particular', ',', 'we', 'investigated', 'whether', 'mdm', '##a', 'disrupt', '##s', 'ppi', 'in', 'humans', 'as', 'observed', 'in', 'animal', 'studies', '.', 'methods', ':', 'rats', 'were', 'tested', 'after', 'placebo', 'and', 'mdm', '##a', 'in', 'a', 'counter', '##balanced', 'order', 'at', 'an', 'interval', 'of', '1', 'week', ',', 'with', 'separate', 'groups', 'of', 'rats', 'being', 'used', 'for', 'each', 'dose', 'of', 'mdm', '##a', '(', '1', '.', '7', ',', '5', '.', '4', 'and', '17', '.', '0', 'mg', '/', 'kg', ')', '.', 'on', 'each', 'test', 'day', ',', 'rats', 'were', 'first', 'tested', 'after', 'no', 'injections', 'and', 'ret', '##ested', '2', 'h', 'later', ',', '10', 'min', 'after', 'a', 'subcutaneous', 'injection', 'of', 'placebo', 'or', 'mdm', '##a', '.', 'for', 'the', 'human', 'study', ',', 'a', 'placebo', '-', 'controlled', 'within', '-', 'subject', 'design', 'and', 'double', '-', 'blind', 'procedures', 'were', 'used', '.', 'subjects', 'were', 'examined', 'twice', 'at', 'a', '2', 'to', '4', 'week', 'interval', 'after', 'either', 'placebo', 'or', 'drug', 'administration', '(', 'order', 'being', 'counter', '##balanced', ')', '.', 'on', 'each', 'test', 'day', ',', 'subjects', 'underwent', 'baseline', 'testing', 'including', 'psychological', 'and', 'ppi', 'measures', '.', 'ninety', 'minutes', 'later', ',', 'subjects', 'received', 'placebo', 'or', 'mdm', '##a', '(', '1', '.', '7', 'mg', '/', 'kg', 'po', ')', 'and', 'were', 'ret', '##ested', 'after', '75', 'min', 'during', 'the', 'peak', 'of', 'behavioral', 'effects', 'of', 'mdm', '##a', '.', 'results', ':', 'as', 'expected', ',', 'mdm', '##a', 'decreased', 'prep', '##uls', '##e', 'inhibition', 'in', 'a', 'dose', '-', 'related', 'fashion', 'in', 'rats', '.', 'in', 'contrast', ',', 'a', 'typical', 'recreational', 'dose', 'of', 'mdm', '##a', '(', '1', '.', '7', 'mg', '/', 'kg', ',', 'orally', ')', 'increased', 'prep', '##uls', '##e', 'inhibition', 'in', 'subjects', 'experiencing', 'robust', 'psychological', 'effects', '.', 'conclusions', ':', 'this', 'surprising', 'disparity', 'between', 'the', 'effects', 'of', 'the', 'drug', 'in', 'rats', 'and', 'humans', 'may', 'reflect', 'a', 'species', '-', 'specific', 'difference', 'in', 'the', 'mechanism', 'of', 'action', 'of', 'mdm', '##a', 'or', 'in', 'the', 'behavioral', 'expression', 'of', 'a', 'similar', 'pharmacological', 'effect', ',', 'or', 'both', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 4, 5, 5, 5, 5, 5, 6, 7, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 16, 16, 18, 19, 20, 20, 20, 21, 22, 23, 24, 24, 25, 26, 27, 28, 29, 30, 31, 31, 32, 33, 34, 35, 35, 36, 37, 38, 39, 40, 41, 42, 42, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 88, 89, 90, 90, 91, 92, 93, 93, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 128, 129, 130, 131, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 151, 152, 153, 153, 153, 154, 155, 155, 155, 156, 157, 157, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 259, 260, 261, 261, 261, 262, 263, 264, 265, 266, 267, 268, 269, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 280, 281, 282, 283, 284, 285, 286, 287, 287, 288, 289, 289, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 308, 309, 310, 310, 310, 311, 312, 313, 314, 315, 316, 317, 318, 318, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans.^
RATIONALE: Prepulse inhibition of acoustic startle refers to the reduction in the startle response when the startling stimulus is preceded by a weak prepulse stimulus. This phenomenon provides an operational measure of sensorimotor gating that has been found to be reduced in patients with schizophrenia and rats treated with serotonin agonists or serotonin releasers. OBJECTIVE: In this study, we compared the effects of a serotonin releaser, MDMA, on prepulse inhibition in laboratory rats and healthy human volunteers. In particular, we investigated whether MDMA disrupts PPI in humans as observed in animal studies. METHODS: Rats were tested after placebo and MDMA in a counterbalanced order at an interval of 1 week, with separate groups of rats being used for each dose of MDMA (1.7, 5.4 and 17.0 mg/kg). On each test day, rats were first tested after no injections and retested 2 h later, 10 min after a subcutaneous injection of placebo or MDMA. For the human study, a placebo-controlled within-subject design and double-blind procedures were used. Subjects were examined twice at a 2 to 4 week interval after either placebo or drug administration (order being counterbalanced). On each test day, subjects underwent baseline testing including psychological and PPI measures. Ninety minutes later, subjects received placebo or MDMA (1.7 mg/kg PO) and were retested after 75 min during the peak of behavioral effects of MDMA. RESULTS: As expected, MDMA decreased prepulse inhibition in a dose-related fashion in rats. In contrast, a typical recreational dose of MDMA (1.7 mg/kg, orally) increased prepulse inhibition in subjects experiencing robust psychological effects. CONCLUSIONS: This surprising disparity between the effects of the drug in rats and humans may reflect a species-specific difference in the mechanism of action of MDMA or in the behavioral expression of a similar pharmacological effect, or both."
"['Trends', 'in', 'drug', 'use', 'among', 'electronic', 'dance', 'music', 'party', 'attendees', 'in', 'New', 'York', 'City', ',', '2016', '-', '2019.^', '\n', 'OBJECTIVE', ':', 'Electronic', 'dance', 'music', '(', 'EDM', ')', 'party', 'attendees', 'are', 'a', 'high', '-', 'risk', 'population', 'for', 'drug', 'use', 'and', 'associated', 'adverse', 'effects', '.', 'We', 'examined', 'trends', 'in', 'past', '-', 'year', 'drug', 'use', 'within', 'this', 'population', 'to', 'better', 'inform', 'prevention', 'and', 'harm', 'reduction', 'efforts', '.', 'METHODS', ':', 'Each', 'summer', 'from', '2016', 'through', '2019', ',', 'we', 'used', 'time', '-', 'space', 'sampling', 'to', 'survey', 'a', 'cross', '-', 'section', 'of', 'adults', 'entering', 'EDM', 'parties', 'at', 'randomly', 'selected', 'nightclubs', 'and', 'at', 'dance', 'festivals', 'in', 'New', 'York', 'City', '.', 'Ns', 'ranged', 'from', '504', '(', '2019', ')', 'to', '1,087', '(', '2016', ')', '.', 'We', 'estimated', 'log', '-', 'linear', 'trends', 'in', 'past', '-', 'year', 'use', 'of', '16', 'different', 'synthetic', 'drugs', 'or', 'drug', 'classes', '.', 'RESULTS', ':', 'Between', '2016', 'and', '2019', ',', 'estimated', 'past', '-', 'year', 'prevalence', 'of', 'use', 'of', 'ketamine', 'increased', 'from', '5.9', '%', 'to', '15.3', '%', '(', 'a', '157.6', '%', 'relative', 'increase', ';', 'P', '=', '.007', ')', ',', 'LSD', 'use', 'increased', 'from', '9.9', '%', 'to', '16.6', '%', '(', 'a', '67.7', '%', 'relative', 'increase', ',', 'P', '<', '.001', ')', ',', 'powder', 'cocaine', 'use', 'increased', 'from', '17.3', '%', 'to', '35.2', '%', '(', 'a', '103.5', '%', 'relative', 'increase', ',', 'P', '<', '.001', ')', ',', 'and', 'GHB', 'use', 'increased', 'from', '1.0', '%', 'to', '4.2', '%', '(', 'a', '311.8', '%', 'relative', 'increase', ';', 'P', '=', '.002', ')', '.', 'Past', '-', 'year', 'use', 'of', '>', '3', 'drugs', 'increased', 'from', '12.7', '%', 'to', '20.5', '%', '(', 'a', '61.4', '%', 'relative', 'increase', ';', 'P', '=', '.013', ')', ';', 'however', ',', 'estimated', 'past', '-', 'year', 'use', 'of', 'unknown', 'powders', 'decreased', 'from', '2.0', '%', 'to', '1.1', '%', '(', 'a', 'relative', '44.7', '%', 'decrease', ';', 'P', '=', '.038', ')', 'and', 'ecstasy', '/', 'MDMA', '/', 'Molly', 'use', 'was', 'stable', 'across', 'years', '(', 'at', '25.0', 'to', '28.5', '%', ';', 'P', '=', '.687', ')', '.', 'CONCLUSIONS', ':', 'Reports', 'of', 'powder', 'cocaine', ',', 'LSD', ',', 'ketamine', ',', 'and', 'GHB', 'are', 'becoming', 'more', 'prevalent', 'among', 'EDM', 'party', 'attendees', '.', 'Prevention', 'and', 'harm', 'reduction', 'efforts', 'are', 'needed', 'to', 'address', 'increasing', 'use', '.', 'Research', 'is', 'also', 'needed', 'to', 'examine', 'whether', 'increasing', 'media', 'coverage', 'of', 'medical', 'use', 'of', 'ketamine', 'and', 'other', 'psychedelics', 'affects', 'prevalence', 'of', 'recreational', 'use', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6629,"['[CLS]', 'trends', 'in', 'drug', 'use', 'among', 'electronic', 'dance', 'music', 'party', 'attend', '##ees', 'in', 'new', 'york', 'city', ',', '2016', '-', '201', '##9', '.', '^', 'objective', ':', 'electronic', 'dance', 'music', '(', 'ed', '##m', ')', 'party', 'attend', '##ees', 'are', 'a', 'high', '-', 'risk', 'population', 'for', 'drug', 'use', 'and', 'associated', 'adverse', 'effects', '.', 'we', 'examined', 'trends', 'in', 'past', '-', 'year', 'drug', 'use', 'within', 'this', 'population', 'to', 'better', 'inform', 'prevention', 'and', 'harm', 'reduction', 'efforts', '.', 'methods', ':', 'each', 'summer', 'from', '2016', 'through', '201', '##9', ',', 'we', 'used', 'time', '-', 'space', 'sampling', 'to', 'survey', 'a', 'cross', '-', 'section', 'of', 'adults', 'entering', 'ed', '##m', 'parties', 'at', 'randomly', 'selected', 'night', '##cl', '##ubs', 'and', 'at', 'dance', 'fest', '##ival', '##s', 'in', 'new', 'york', 'city', '.', 'ns', 'ranged', 'from', '50', '##4', '(', '201', '##9', ')', 'to', '1', ',', '08', '##7', '(', '2016', ')', '.', 'we', 'estimated', 'log', '-', 'linear', 'trends', 'in', 'past', '-', 'year', 'use', 'of', '16', 'different', 'synthetic', 'drugs', 'or', 'drug', 'classes', '.', 'results', ':', 'between', '2016', 'and', '201', '##9', ',', 'estimated', 'past', '-', 'year', 'prevalence', 'of', 'use', 'of', 'ketamine', 'increased', 'from', '5', '.', '9', '%', 'to', '15', '.', '3', '%', '(', 'a', '157', '.', '6', '%', 'relative', 'increase', ';', 'p', '=', '.', '00', '##7', ')', ',', 'lsd', 'use', 'increased', 'from', '9', '.', '9', '%', 'to', '16', '.', '6', '%', '(', 'a', '67', '.', '7', '%', 'relative', 'increase', ',', 'p', '<', '.', '00', '##1', ')', ',', 'powder', 'cocaine', 'use', 'increased', 'from', '17', '.', '3', '%', 'to', '35', '.', '2', '%', '(', 'a', '103', '.', '5', '%', 'relative', 'increase', ',', 'p', '<', '.', '00', '##1', ')', ',', 'and', 'gh', '##b', 'use', 'increased', 'from', '1', '.', '0', '%', 'to', '4', '.', '2', '%', '(', 'a', '311', '.', '8', '%', 'relative', 'increase', ';', 'p', '=', '.', '00', '##2', ')', '.', 'past', '-', 'year', 'use', 'of', '>', '3', 'drugs', 'increased', 'from', '12', '.', '7', '%', 'to', '20', '.', '5', '%', '(', 'a', '61', '.', '4', '%', 'relative', 'increase', ';', 'p', '=', '.', '01', '##3', ')', ';', 'however', ',', 'estimated', 'past', '-', 'year', 'use', 'of', 'unknown', 'powders', 'decreased', 'from', '2', '.', '0', '%', 'to', '1', '.', '1', '%', '(', 'a', 'relative', '44', '.', '7', '%', 'decrease', ';', 'p', '=', '.', '03', '##8', ')', 'and', 'ecs', '##tas', '##y', '/', 'mdm', '##a', '/', 'mol', '##ly', 'use', 'was', 'stable', 'across', 'years', '(', 'at', '25', '.', '0', 'to', '28', '.', '5', '%', ';', 'p', '=', '.', '68', '##7', ')', '.', 'conclusions', ':', 'reports', 'of', 'powder', 'cocaine', ',', 'lsd', ',', 'ketamine', ',', 'and', 'gh', '##b', 'are', 'becoming', 'more', 'prevalent', 'among', 'ed', '##m', 'party', 'attend', '##ees', '.', 'prevention', 'and', 'harm', 'reduction', 'efforts', 'are', 'needed', 'to', 'address', 'increasing', 'use', '.', 'research', 'is', 'also', 'needed', 'to', 'examine', 'whether', 'increasing', 'media', 'coverage', 'of', 'medical', 'use', 'of', 'ketamine', 'and', 'other', 'psych', '##ede', '##lic', '##s', 'affects', 'prevalence', 'of', 'recreational', 'use', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 9, 10, 11, 12, 13, 14, 15, 16, 17, 17, 17, 17, 19, 20, 21, 22, 23, 24, 25, 25, 26, 27, 28, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 88, 89, 90, 91, 92, 93, 93, 93, 94, 95, 96, 97, 97, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 106, 107, 108, 108, 109, 110, 111, 111, 111, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 154, 154, 155, 156, 157, 157, 157, 158, 159, 160, 161, 161, 161, 162, 163, 164, 165, 166, 167, 168, 168, 168, 169, 170, 171, 172, 173, 174, 175, 175, 175, 176, 177, 178, 178, 178, 179, 180, 181, 182, 182, 182, 183, 184, 185, 186, 187, 188, 189, 189, 189, 190, 191, 192, 193, 194, 195, 196, 197, 197, 197, 198, 199, 200, 200, 200, 201, 202, 203, 204, 204, 204, 205, 206, 207, 208, 209, 210, 211, 211, 211, 212, 213, 214, 215, 215, 216, 217, 218, 219, 219, 219, 220, 221, 222, 222, 222, 223, 224, 225, 226, 226, 226, 227, 228, 229, 230, 231, 232, 233, 233, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 246, 246, 247, 248, 249, 249, 249, 250, 251, 252, 253, 253, 253, 254, 255, 256, 257, 258, 259, 260, 260, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 275, 275, 276, 277, 278, 278, 278, 279, 280, 281, 282, 283, 283, 283, 284, 285, 286, 287, 288, 289, 289, 289, 290, 291, 292, 292, 292, 293, 294, 294, 295, 296, 296, 297, 298, 299, 300, 301, 302, 303, 304, 304, 304, 305, 306, 306, 306, 307, 308, 309, 310, 311, 311, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 326, 327, 328, 329, 330, 331, 332, 332, 333, 334, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 365, 365, 365, 366, 367, 368, 369, 370, 371, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Trends in drug use among electronic dance music party attendees in New York City, 2016-2019.^
OBJECTIVE: Electronic dance music (EDM) party attendees are a high-risk population for drug use and associated adverse effects. We examined trends in past-year drug use within this population to better inform prevention and harm reduction efforts. METHODS: Each summer from 2016 through 2019, we used time-space sampling to survey a cross-section of adults entering EDM parties at randomly selected nightclubs and at dance festivals in New York City. Ns ranged from 504 (2019) to 1,087 (2016). We estimated log-linear trends in past-year use of 16 different synthetic drugs or drug classes. RESULTS: Between 2016 and 2019, estimated past-year prevalence of use of ketamine increased from 5.9% to 15.3% (a 157.6% relative increase; P = .007), LSD use increased from 9.9% to 16.6% (a 67.7% relative increase, P < .001), powder cocaine use increased from 17.3% to 35.2% (a 103.5% relative increase, P < .001), and GHB use increased from 1.0% to 4.2% (a 311.8% relative increase; P = .002). Past-year use of >3 drugs increased from 12.7% to 20.5% (a 61.4% relative increase; P = .013); however, estimated past-year use of unknown powders decreased from 2.0% to 1.1% (a relative 44.7% decrease; P = .038) and ecstasy/MDMA/Molly use was stable across years (at 25.0 to 28.5 %; P = .687). CONCLUSIONS: Reports of powder cocaine, LSD, ketamine, and GHB are becoming more prevalent among EDM party attendees. Prevention and harm reduction efforts are needed to address increasing use. Research is also needed to examine whether increasing media coverage of medical use of ketamine and other psychedelics affects prevalence of recreational use."
"['Inhibition', 'of', 'return', 'in', 'the', 'human', '5HT2A', 'agonist', 'and', 'NMDA', 'antagonist', 'model', 'of', 'psychosis.^', '\n', 'Patients', 'with', 'schizophrenia', 'exhibit', 'disturbances', 'of', 'orienting', 'of', 'attention', '.', 'However', ',', 'findings', 'have', 'been', 'inconsistent', '.', 'Pharmacologic', 'challenges', 'with', 'hallucinogens', 'have', 'been', 'used', 'as', 'models', 'for', 'psychosis', '.', 'The', 'NMDA', 'antagonist', 'state', '(', 'PCP', ',', 'ketamine', ')', 'resembles', 'undifferentiated', 'psychoses', 'with', 'positive', 'and', 'negative', 'symptoms', ',', 'while', 'the', '5', '-', 'HT(2A', ')', 'agonist', 'state', '(', 'LSD', ',', 'dimethyltryptamine', '(', 'DMT', ')', ')', 'is', 'thought', 'to', 'be', 'an', 'appropriate', 'model', 'for', 'psychoses', 'with', 'prominent', 'positive', 'symptoms', '.', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'investigate', 'orienting', 'of', 'attention', 'in', 'the', 'human', 'NMDA', 'antagonist', 'and', '5', '-', 'HT(2A', ')', 'agonist', 'models', 'of', 'psychosis', '.', 'A', 'total', 'of', '15', 'healthy', 'volunteers', 'participated', 'in', 'a', 'randomized', ',', 'double', '-', 'blind', ',', 'crossover', 'study', 'with', 'a', 'low', 'and', 'a', 'high', 'dose', 'of', 'DMT', 'and', 'S', '-', 'ketamine', ',', 'which', 'elicited', 'subtle', ""'"", 'prepsychotic', ""'"", 'or', 'full', '-', 'blown', 'psychotic', 'symptoms', '(', 'low', 'and', 'high', 'dose', ',', 'respectively', ')', '.', 'Nine', 'subjects', 'completed', 'both', 'experimental', 'days', 'with', 'the', 'two', 'doses', 'of', 'both', 'drugs', '.', 'Overall', ',', 'both', 'hallucinogens', 'slowed', 'down', 'reaction', 'times', 'dose', 'dependently', '(', 'DMT', '>', 'S', '-', 'ketamine', ')', 'and', 'DMT', 'diminished', 'the', 'general', 'response', 'facilitating', '(', 'alerting', ')', 'effect', 'of', 'spatially', 'neutral', 'cues', '.', 'Inhibition', 'of', 'Return', '(', 'IOR', ')', ',', 'that', 'is', ',', 'the', 'normal', 'reaction', 'time', 'disadvantage', 'for', 'validly', 'cued', 'trials', 'with', 'exogenous', 'cues', 'and', 'long', 'cue', 'target', 'intervals', ',', 'was', 'blunted', 'after', 'both', 'doses', 'of', 'DMT', 'and', 'the', 'low', 'dose', 'of', 'S', '-', 'ketamine', '.', 'IOR', 'reflects', 'an', 'automatic', ',', 'inhibitory', 'mechanism', 'of', 'attention', ',', 'which', 'is', 'thought', 'to', 'protect', 'the', 'organism', 'from', 'redundant', ',', 'distracting', 'sensory', 'information', '.', 'In', 'conclusion', ',', 'our', 'data', 'suggest', 'a', 'deficit', 'of', 'IOR', 'in', 'both', 'hallucinogen', 'models', 'of', 'psychosis', ',', 'with', 'the', 'effect', 'being', 'clearer', 'in', 'the', 'serotonin', 'model', '.', 'Blunted', 'IOR', 'may', 'underlie', 'or', 'predispose', 'to', 'different', 'psychotic', 'manifestations', ',', 'but', 'particularly', 'to', 'those', 'with', 'prominent', 'positive', 'symptoms', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3099,"['[CLS]', 'inhibition', 'of', 'return', 'in', 'the', 'human', '5', '##ht', '##2', '##a', 'agonist', 'and', 'nmda', 'antagonist', 'model', 'of', 'psychosis', '.', '^', 'patients', 'with', 'schizophrenia', 'exhibit', 'disturbances', 'of', 'orient', '##ing', 'of', 'attention', '.', 'however', ',', 'findings', 'have', 'been', 'inconsistent', '.', 'pharmacologic', 'challenges', 'with', 'halluc', '##ino', '##gens', 'have', 'been', 'used', 'as', 'models', 'for', 'psychosis', '.', 'the', 'nmda', 'antagonist', 'state', '(', 'pcp', ',', 'ketamine', ')', 'resembles', 'undi', '##ffer', '##entia', '##ted', 'psychos', '##es', 'with', 'positive', 'and', 'negative', 'symptoms', ',', 'while', 'the', '5', '-', 'ht', '(', '2', '##a', ')', 'agonist', 'state', '(', 'lsd', ',', 'dimethyl', '##try', '##pt', '##amine', '(', 'dm', '##t', ')', ')', 'is', 'thought', 'to', 'be', 'an', 'appropriate', 'model', 'for', 'psychos', '##es', 'with', 'prominent', 'positive', 'symptoms', '.', 'the', 'aim', 'of', 'this', 'study', 'was', 'to', 'investigate', 'orient', '##ing', 'of', 'attention', 'in', 'the', 'human', 'nmda', 'antagonist', 'and', '5', '-', 'ht', '(', '2', '##a', ')', 'agonist', 'models', 'of', 'psychosis', '.', 'a', 'total', 'of', '15', 'healthy', 'volunteers', 'participated', 'in', 'a', 'randomized', ',', 'double', '-', 'blind', ',', 'crossover', 'study', 'with', 'a', 'low', 'and', 'a', 'high', 'dose', 'of', 'dm', '##t', 'and', 's', '-', 'ketamine', ',', 'which', 'elicited', 'subtle', ""'"", 'prep', '##sy', '##cho', '##tic', ""'"", 'or', 'full', '-', 'blow', '##n', 'psychotic', 'symptoms', '(', 'low', 'and', 'high', 'dose', ',', 'respectively', ')', '.', 'nine', 'subjects', 'completed', 'both', 'experimental', 'days', 'with', 'the', 'two', 'doses', 'of', 'both', 'drugs', '.', 'overall', ',', 'both', 'halluc', '##ino', '##gens', 'slowed', 'down', 'reaction', 'times', 'dose', 'dependent', '##ly', '(', 'dm', '##t', '>', 's', '-', 'ketamine', ')', 'and', 'dm', '##t', 'diminished', 'the', 'general', 'response', 'facilitating', '(', 'alert', '##ing', ')', 'effect', 'of', 'spatially', 'neutral', 'cues', '.', 'inhibition', 'of', 'return', '(', 'io', '##r', ')', ',', 'that', 'is', ',', 'the', 'normal', 'reaction', 'time', 'disadvantage', 'for', 'valid', '##ly', 'cue', '##d', 'trials', 'with', 'exogenous', 'cues', 'and', 'long', 'cue', 'target', 'intervals', ',', 'was', 'blunt', '##ed', 'after', 'both', 'doses', 'of', 'dm', '##t', 'and', 'the', 'low', 'dose', 'of', 's', '-', 'ketamine', '.', 'io', '##r', 'reflects', 'an', 'automatic', ',', 'inhibitory', 'mechanism', 'of', 'attention', ',', 'which', 'is', 'thought', 'to', 'protect', 'the', 'organism', 'from', 'redundant', ',', 'distr', '##acting', 'sensory', 'information', '.', 'in', 'conclusion', ',', 'our', 'data', 'suggest', 'a', 'deficit', 'of', 'io', '##r', 'in', 'both', 'halluc', '##ino', '##gen', 'models', 'of', 'psychosis', ',', 'with', 'the', 'effect', 'being', 'clearer', 'in', 'the', 'serotonin', 'model', '.', 'blunt', '##ed', 'io', '##r', 'may', 'underlie', 'or', 'predis', '##pose', 'to', 'different', 'psychotic', 'manifestations', ',', 'but', 'particularly', 'to', 'those', 'with', 'prominent', 'positive', 'symptoms', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 6, 6, 6, 7, 8, 9, 10, 11, 12, 13, 13, 13, 15, 16, 17, 18, 19, 20, 21, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 35, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 54, 54, 54, 55, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 66, 66, 66, 67, 68, 69, 70, 71, 72, 73, 73, 73, 73, 74, 75, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 111, 111, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 153, 153, 153, 154, 155, 156, 157, 158, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 187, 187, 188, 189, 190, 191, 192, 193, 193, 194, 195, 195, 196, 197, 198, 199, 200, 201, 202, 202, 203, 204, 205, 206, 207, 208, 209, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 233, 234, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 246, 247, 248, 249, 250, 251, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 294, 295, 296, 297, 297, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 312, 313, 313, 314, 315, 316, 317, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis.^
Patients with schizophrenia exhibit disturbances of orienting of attention. However, findings have been inconsistent. Pharmacologic challenges with hallucinogens have been used as models for psychosis. The NMDA antagonist state (PCP, ketamine) resembles undifferentiated psychoses with positive and negative symptoms, while the 5-HT(2A) agonist state (LSD, dimethyltryptamine (DMT)) is thought to be an appropriate model for psychoses with prominent positive symptoms. The aim of this study was to investigate orienting of attention in the human NMDA antagonist and 5-HT(2A) agonist models of psychosis. A total of 15 healthy volunteers participated in a randomized, double-blind, crossover study with a low and a high dose of DMT and S-ketamine, which elicited subtle 'prepsychotic' or full-blown psychotic symptoms (low and high dose, respectively). Nine subjects completed both experimental days with the two doses of both drugs. Overall, both hallucinogens slowed down reaction times dose dependently (DMT >S-ketamine) and DMT diminished the general response facilitating (alerting) effect of spatially neutral cues. Inhibition of Return (IOR), that is, the normal reaction time disadvantage for validly cued trials with exogenous cues and long cue target intervals, was blunted after both doses of DMT and the low dose of S-ketamine. IOR reflects an automatic, inhibitory mechanism of attention, which is thought to protect the organism from redundant, distracting sensory information. In conclusion, our data suggest a deficit of IOR in both hallucinogen models of psychosis, with the effect being clearer in the serotonin model. Blunted IOR may underlie or predispose to different psychotic manifestations, but particularly to those with prominent positive symptoms."
"['Psilocybin', '-', 'assisted', 'therapy', 'for', 'major', 'depressive', 'disorder', ':', 'An', 'exploratory', 'placebo', '-', 'controlled', ',', 'fixed', '-', 'order', 'trial.^', '\n', 'BACKGROUND', ':', 'Several', 'early', 'phase', 'studies', 'have', 'demonstrated', 'that', 'psilocybin', '-', 'assisted', 'therapy', 'has', 'rapid', '-', 'acting', 'and', 'persisting', 'antidepressant', 'effects', 'from', 'just', 'one', 'or', 'two', 'doses', '.', 'However', ',', 'methodological', 'limitations', '(', 'e.g.', ',', 'placebo', '-', 'control', ',', 'blinding', ')', 'limit', 'interpretability', 'of', 'the', 'existing', 'literature', '.', 'METHODS', ':', 'In', 'an', 'exploratory', 'placebo', '-', 'controlled', ',', 'within', '-', 'subject', ',', 'fixed', '-', 'order', 'study', ',', 'individuals', 'with', 'moderate', 'to', 'severe', 'major', 'depressive', 'disorder', 'were', 'administered', 'placebo', '(', 'n', '=', '19', ')', 'followed', 'by', 'psilocybin', '(', '0.3', 'mg', '/', 'kg', ')', '(', 'n', '=', '15', ')', '4', 'weeks', 'later', '.', 'Dosing', 'sessions', 'were', 'embedded', 'within', 'an', 'manualized', 'course', 'of', 'psychotherapy', '.', 'Enhanced', 'blinding', 'procedures', 'were', 'used', '.', 'Depression', ',', 'anxiety', ',', 'and', 'quality', 'of', 'life', 'were', 'measured', 'over', 'a', '16', '-', 'week', 'study', 'period', '.', 'RESULTS', ':', 'Depression', 'and', 'anxiety', 'significantly', 'improved', 'following', 'both', 'placebo', 'and', 'psilocybin', 'with', 'no', 'significant', 'difference', 'in', 'the', 'degree', 'of', 'change', 'between', 'the', 'two', 'conditions', '.', 'However', ',', 'antidepressant', 'effect', 'sizes', 'were', 'larger', 'after', 'psilocybin', '(', 'd', ""'"", '=', '1.02', '-', '2.27', ')', 'than', 'after', 'placebo', '(', 'd', ""'"", '=', '0.65', '-', '0.99', ')', 'and', 'there', 'were', 'high', 'rates', 'of', 'response', '(', '66.7', '%', ')', 'and', 'remission', '(', '46.7', '%', ')', 'following', 'psilocybin', 'administration', '.', 'Antidepressant', 'effects', 'following', 'psilocybin', 'persisted', ',', 'on', 'average', ',', 'for', '2', 'months', 'and', 'there', 'were', 'persisting', 'improvements', 'in', 'mood', '-', 'related', 'quality', 'of', 'life', 'domains', '.', 'The', 'strength', 'of', 'mystical', '-', 'type', 'experience', 'during', 'psilocybin', 'dosing', 'was', 'not', 'correlated', 'with', 'subsequent', 'antidepressant', 'effects', '.', 'CONCLUSIONS', ':', 'The', 'results', 'of', 'this', 'exploratory', 'study', 'highlight', 'the', 'complex', 'interplay', 'between', 'expectancy', ',', 'therapy', 'effects', ',', 'and', 'drug', '/', 'placebo', 'effects', 'in', 'psychedelic', '-', 'assisted', 'psychotherapy', 'studies', '.', 'Nonetheless', ',', 'the', 'acute', 'and', 'persisting', 'clinical', 'improvements', 'observed', 'following', 'psilocybin', 'support', 'further', 'study', 'of', 'its', 'potential', 'in', 'the', 'treatment', 'of', 'major', 'depression', '.', 'Future', 'studies', 'should', 'more', 'explicitly', 'mitigate', 'and', 'measure', 'expectancy', 'effects', 'and', 'assess', 'the', 'impact', 'of', 'repeated', 'dosing', 'and', 'different', 'forms', 'of', 'psychotherapeutic', 'support', '.']","['O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",8089,"['[CLS]', 'psi', '##loc', '##yb', '##in', '-', 'assisted', 'therapy', 'for', 'major', 'depressive', 'disorder', ':', 'an', 'exploratory', 'placebo', '-', 'controlled', ',', 'fixed', '-', 'order', 'trial', '.', '^', 'background', ':', 'several', 'early', 'phase', 'studies', 'have', 'demonstrated', 'that', 'psi', '##loc', '##yb', '##in', '-', 'assisted', 'therapy', 'has', 'rapid', '-', 'acting', 'and', 'persist', '##ing', 'antidepressant', 'effects', 'from', 'just', 'one', 'or', 'two', 'doses', '.', 'however', ',', 'methodological', 'limitations', '(', 'e', '.', 'g', '.', ',', 'placebo', '-', 'control', ',', 'blind', '##ing', ')', 'limit', 'interpret', '##ability', 'of', 'the', 'existing', 'literature', '.', 'methods', ':', 'in', 'an', 'exploratory', 'placebo', '-', 'controlled', ',', 'within', '-', 'subject', ',', 'fixed', '-', 'order', 'study', ',', 'individuals', 'with', 'moderate', 'to', 'severe', 'major', 'depressive', 'disorder', 'were', 'administered', 'placebo', '(', 'n', '=', '19', ')', 'followed', 'by', 'psi', '##loc', '##yb', '##in', '(', '0', '.', '3', 'mg', '/', 'kg', ')', '(', 'n', '=', '15', ')', '4', 'weeks', 'later', '.', 'dosing', 'sessions', 'were', 'embedded', 'within', 'an', 'manual', '##ized', 'course', 'of', 'psychotherapy', '.', 'enhanced', 'blind', '##ing', 'procedures', 'were', 'used', '.', 'depression', ',', 'anxiety', ',', 'and', 'quality', 'of', 'life', 'were', 'measured', 'over', 'a', '16', '-', 'week', 'study', 'period', '.', 'results', ':', 'depression', 'and', 'anxiety', 'significantly', 'improved', 'following', 'both', 'placebo', 'and', 'psi', '##loc', '##yb', '##in', 'with', 'no', 'significant', 'difference', 'in', 'the', 'degree', 'of', 'change', 'between', 'the', 'two', 'conditions', '.', 'however', ',', 'antidepressant', 'effect', 'sizes', 'were', 'larger', 'after', 'psi', '##loc', '##yb', '##in', '(', 'd', ""'"", '=', '1', '.', '02', '-', '2', '.', '27', ')', 'than', 'after', 'placebo', '(', 'd', ""'"", '=', '0', '.', '65', '-', '0', '.', '99', ')', 'and', 'there', 'were', 'high', 'rates', 'of', 'response', '(', '66', '.', '7', '%', ')', 'and', 'remission', '(', '46', '.', '7', '%', ')', 'following', 'psi', '##loc', '##yb', '##in', 'administration', '.', 'antidepressant', 'effects', 'following', 'psi', '##loc', '##yb', '##in', 'persisted', ',', 'on', 'average', ',', 'for', '2', 'months', 'and', 'there', 'were', 'persist', '##ing', 'improvements', 'in', 'mood', '-', 'related', 'quality', 'of', 'life', 'domains', '.', 'the', 'strength', 'of', 'mys', '##tical', '-', 'type', 'experience', 'during', 'psi', '##loc', '##yb', '##in', 'dosing', 'was', 'not', 'correlated', 'with', 'subsequent', 'antidepressant', 'effects', '.', 'conclusions', ':', 'the', 'results', 'of', 'this', 'exploratory', 'study', 'highlight', 'the', 'complex', 'interplay', 'between', 'expectancy', ',', 'therapy', 'effects', ',', 'and', 'drug', '/', 'placebo', 'effects', 'in', 'psych', '##ede', '##lic', '-', 'assisted', 'psychotherapy', 'studies', '.', 'nonetheless', ',', 'the', 'acute', 'and', 'persist', '##ing', 'clinical', 'improvements', 'observed', 'following', 'psi', '##loc', '##yb', '##in', 'support', 'further', 'study', 'of', 'its', 'potential', 'in', 'the', 'treatment', 'of', 'major', 'depression', '.', 'future', 'studies', 'should', 'more', 'explicitly', 'mitigate', 'and', 'measure', 'expectancy', 'effects', 'and', 'assess', 'the', 'impact', 'of', 'repeated', 'dosing', 'and', 'different', 'forms', 'of', 'psycho', '##ther', '##apeutic', 'support', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 0, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 29, 29, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 53, 53, 53, 54, 55, 56, 57, 58, 59, 59, 60, 61, 62, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 104, 104, 104, 105, 106, 106, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 126, 127, 128, 129, 130, 131, 132, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 166, 166, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 189, 189, 189, 190, 191, 192, 193, 194, 194, 194, 195, 196, 196, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 205, 205, 206, 207, 207, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 217, 217, 218, 219, 220, 221, 222, 223, 223, 223, 224, 225, 226, 227, 227, 227, 227, 228, 229, 230, 231, 232, 233, 233, 233, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 259, 260, 261, 262, 263, 264, 264, 264, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 298, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 309, 310, 311, 312, 313, 314, 314, 314, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 349, 349, 350, 351, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.^
BACKGROUND: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature. METHODS: In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with moderate to severe major depressive disorder were administered placebo (n = 19) followed by psilocybin (0.3 mg/kg) (n = 15) 4 weeks later. Dosing sessions were embedded within an manualized course of psychotherapy. Enhanced blinding procedures were used. Depression, anxiety, and quality of life were measured over a 16-week study period. RESULTS: Depression and anxiety significantly improved following both placebo and psilocybin with no significant difference in the degree of change between the two conditions. However, antidepressant effect sizes were larger after psilocybin (d' = 1.02-2.27) than after placebo (d' = 0.65-0.99) and there were high rates of response (66.7%) and remission (46.7%) following psilocybin administration. Antidepressant effects following psilocybin persisted, on average, for 2 months and there were persisting improvements in mood-related quality of life domains. The strength of mystical-type experience during psilocybin dosing was not correlated with subsequent antidepressant effects. CONCLUSIONS: The results of this exploratory study highlight the complex interplay between expectancy, therapy effects, and drug/placebo effects in psychedelic-assisted psychotherapy studies. Nonetheless, the acute and persisting clinical improvements observed following psilocybin support further study of its potential in the treatment of major depression. Future studies should more explicitly mitigate and measure expectancy effects and assess the impact of repeated dosing and different forms of psychotherapeutic support."
"['Toward', 'a', 'typology', 'of', 'hallucinogen', 'users', 'in', 'the', 'United', 'States.^', '\n', 'Background', ':', 'Roughly', 'one', 'in', 'ten', 'American', 'adults', 'have', 'used', 'hallucinogens', ',', 'and', 'emerging', 'evidence', 'suggests', 'that', 'the', 'prevalence', 'of', 'use', 'is', 'increasing', '.', 'However', ',', 'our', 'understanding', 'of', 'the', 'degree', 'to', 'which', 'individuals', '“', 'specialize', '”', 'in', 'the', 'use', 'of', 'a', 'particular', 'hallucinogen', 'or', 'are', 'poly', '-', 'hallucinogen', 'users', 'remains', 'incomplete', '.', 'Methods', ':', 'This', 'study', 'examined', 'data', 'from', '6381', 'individuals', 'reporting', 'past', '-', 'year', 'hallucinogen', 'use', 'in', 'the', '2016–2018', 'National', 'Survey', 'on', 'Drug', 'Use', 'and', 'Health', '.', 'Logistic', 'regression', 'examined', 'the', 'association', 'between', 'the', 'number', 'of', 'distinct', 'hallucinogens', 'used', 'and', 'psychosocial', '/', 'behavioral', 'risks', ',', 'and', 'latent', 'class', 'analysis', '(', 'LCA', ')', 'characterized', 'subgroups', 'of', 'hallucinogen', 'users', '.', 'Results', ':', 'The', 'vast', 'majority', 'of', 'hallucinogen', 'users', ',', 'roughly', '70', '%', ',', 'are', 'not', '“', 'specialists', '”', 'who', 'use', 'only', 'one', 'hallucinogen', 'type', ';', 'rather', ',', 'lifetime', 'poly', '-', 'hallucinogen', 'use', 'is', 'the', 'norm', '.', 'Critically', ',', 'however', ',', 'we', 'also', 'see', 'that', 'important', 'differences', 'exist', 'within', 'the', 'population', 'of', 'hallucinogen', 'users', '—', 'half', '(', '51', '%', ')', 'could', 'be', 'classified', 'as', 'LSD', '-', 'Mushroom', '-', 'Ecstasy', 'users', 'only', '(', 'this', 'group', 'was', 'disproportionally', 'comprised', 'of', 'youth', ')', ',', 'nearly', 'one', 'third', '(', '30', '%', ')', 'were', 'Poly', '-', 'Hallucinogen', 'users', '(', 'this', 'group', 'was', 'disproportionately', 'male', 'and', 'non', '-', 'Hispanic', 'White', ')', ',', 'and', 'smaller', 'proportions', 'were', 'limited', 'primarily', 'to', 'use', 'of', 'LSD', '-', 'Mushrooms', '(', '6', '%', ';', 'these', 'individuals', 'were', 'almost', 'exclusively', 'ages', '35', 'and', 'older', ')', 'or', 'Ecstasy', 'Only', '(', '12', '%', ';', 'these', 'individuals', 'were', 'mostly', 'younger', 'adults', 'ages', '18–34', ')', '.', 'Conclusions', ':', 'Findings', 'provide', 'a', 'fresh', 'contribution', 'to', 'our', 'understanding', 'of', 'poly', '-', 'hallucinogen', 'use', 'in', 'a', 'time', 'in', 'which', 'local', 'and', 'state', 'governmental', 'leaders', ',', 'and', 'people', 'across', 'the', 'country', ',', 'weigh', 'the', 'benefits', 'and', 'drawbacks', 'of', 'legalizing', 'specific', 'hallucinogenic', 'drugs', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7588,"['[CLS]', 'toward', 'a', 'typ', '##ology', 'of', 'halluc', '##ino', '##gen', 'users', 'in', 'the', 'united', 'states', '.', '^', 'background', ':', 'roughly', 'one', 'in', 'ten', 'american', 'adults', 'have', 'used', 'halluc', '##ino', '##gens', ',', 'and', 'emerging', 'evidence', 'suggests', 'that', 'the', 'prevalence', 'of', 'use', 'is', 'increasing', '.', 'however', ',', 'our', 'understanding', 'of', 'the', 'degree', 'to', 'which', 'individuals', '“', 'special', '##ize', '”', 'in', 'the', 'use', 'of', 'a', 'particular', 'halluc', '##ino', '##gen', 'or', 'are', 'poly', '-', 'halluc', '##ino', '##gen', 'users', 'remains', 'incomplete', '.', 'methods', ':', 'this', 'study', 'examined', 'data', 'from', '63', '##81', 'individuals', 'reporting', 'past', '-', 'year', 'halluc', '##ino', '##gen', 'use', 'in', 'the', '2016', '–', '2018', 'national', 'survey', 'on', 'drug', 'use', 'and', 'health', '.', 'logistic', 'regression', 'examined', 'the', 'association', 'between', 'the', 'number', 'of', 'distinct', 'halluc', '##ino', '##gens', 'used', 'and', 'psychosocial', '/', 'behavioral', 'risks', ',', 'and', 'latent', 'class', 'analysis', '(', 'lc', '##a', ')', 'characterized', 'subgroups', 'of', 'halluc', '##ino', '##gen', 'users', '.', 'results', ':', 'the', 'vast', 'majority', 'of', 'halluc', '##ino', '##gen', 'users', ',', 'roughly', '70', '%', ',', 'are', 'not', '“', 'specialists', '”', 'who', 'use', 'only', 'one', 'halluc', '##ino', '##gen', 'type', ';', 'rather', ',', 'lifetime', 'poly', '-', 'halluc', '##ino', '##gen', 'use', 'is', 'the', 'norm', '.', 'critically', ',', 'however', ',', 'we', 'also', 'see', 'that', 'important', 'differences', 'exist', 'within', 'the', 'population', 'of', 'halluc', '##ino', '##gen', 'users', '—', 'half', '(', '51', '%', ')', 'could', 'be', 'classified', 'as', 'lsd', '-', 'mush', '##room', '-', 'ecs', '##tas', '##y', 'users', 'only', '(', 'this', 'group', 'was', 'disproportion', '##ally', 'comprised', 'of', 'youth', ')', ',', 'nearly', 'one', 'third', '(', '30', '%', ')', 'were', 'poly', '-', 'halluc', '##ino', '##gen', 'users', '(', 'this', 'group', 'was', 'disproportion', '##ately', 'male', 'and', 'non', '-', 'hispanic', 'white', ')', ',', 'and', 'smaller', 'proportions', 'were', 'limited', 'primarily', 'to', 'use', 'of', 'lsd', '-', 'mush', '##rooms', '(', '6', '%', ';', 'these', 'individuals', 'were', 'almost', 'exclusively', 'ages', '35', 'and', 'older', ')', 'or', 'ecs', '##tas', '##y', 'only', '(', '12', '%', ';', 'these', 'individuals', 'were', 'mostly', 'younger', 'adults', 'ages', '18', '–', '34', ')', '.', 'conclusions', ':', 'findings', 'provide', 'a', 'fresh', 'contribution', 'to', 'our', 'understanding', 'of', 'poly', '-', 'halluc', '##ino', '##gen', 'use', 'in', 'a', 'time', 'in', 'which', 'local', 'and', 'state', 'governmental', 'leaders', ',', 'and', 'people', 'across', 'the', 'country', ',', 'weigh', 'the', 'benefits', 'and', 'drawbacks', 'of', 'legal', '##izing', 'specific', 'halluc', '##ino', '##genic', 'drugs', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 2, 3, 4, 4, 4, 5, 6, 7, 8, 9, 9, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 21, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 46, 47, 48, 49, 50, 51, 52, 53, 54, 54, 54, 55, 56, 57, 58, 59, 59, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 71, 72, 73, 74, 75, 76, 77, 77, 77, 78, 79, 80, 81, 81, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 100, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 113, 114, 115, 116, 117, 118, 118, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 127, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 143, 143, 144, 145, 146, 147, 148, 149, 150, 151, 151, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 172, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 186, 187, 188, 188, 188, 189, 190, 191, 192, 193, 194, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 211, 211, 212, 213, 214, 215, 216, 217, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 253, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 266, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 282, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 307, 308, 309, 309, 309, 310, 311, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Toward a typology of hallucinogen users in the United States.^
Background: Roughly one in ten American adults have used hallucinogens, and emerging evidence suggests that the prevalence of use is increasing. However, our understanding of the degree to which individuals “specialize” in the use of a particular hallucinogen or are poly-hallucinogen users remains incomplete. Methods: This study examined data from 6381 individuals reporting past-year hallucinogen use in the 2016–2018 National Survey on Drug Use and Health. Logistic regression examined the association between the number of distinct hallucinogens used and psychosocial/behavioral risks, and latent class analysis (LCA) characterized subgroups of hallucinogen users. Results: The vast majority of hallucinogen users, roughly 70%, are not “specialists” who use only one hallucinogen type; rather, lifetime poly-hallucinogen use is the norm. Critically, however, we also see that important differences exist within the population of hallucinogen users—half (51%) could be classified as LSD-Mushroom-Ecstasy users only (this group was disproportionally comprised of youth), nearly one third (30%) were Poly-Hallucinogen users (this group was disproportionately male and non-Hispanic White), and smaller proportions were limited primarily to use of LSD-Mushrooms (6%; these individuals were almost exclusively ages 35 and older) or Ecstasy Only (12%; these individuals were mostly younger adults ages 18–34). Conclusions: Findings provide a fresh contribution to our understanding of poly-hallucinogen use in a time in which local and state governmental leaders, and people across the country, weigh the benefits and drawbacks of legalizing specific hallucinogenic drugs."
"['Ketamine', ""'s"", 'Effect', 'Changes', 'the', 'Cortical', 'Electrophysiological', 'Activity', 'Related', 'to', 'Semantic', 'Affective', 'Dimension', 'of', 'Pain.^', '\n', 'Ketamine', 'is', 'a', 'unique', 'anesthetic', 'with', 'neural', 'effects', 'that', 'are', 'distinct', 'from', 'more', 'commonly‐used', 'γ‐aminobutyric', 'acid', 'agonists', '.', 'Evidence', 'suggest', 'that', 'analgesic', 'effect', 'of', 'ketamine', 'is', 'primarily', 'related', 'to', 'the', 'affective', 'than', 'the', 'sensorial', 'aspects', 'of', 'pain', 'interpretation', '.', 'The', 'investigators', 'investigated', 'whether', 'ketamine', ',', 'a', 'noncompetitive', 'NMDA', 'antagonist', ',', 'would', 'modify', 'the', 'perceived', 'emotional', 'valence', 'of', 'pain‐related', 'words', 'when', 'compared', 'to', 'non‐pain‐related', 'ones', 'in', 'healthy', 'volunteers', '.', 'Using', 'a', 'single', 'session', 'double‐blind', 'parallel', 'placebo‐controlled', 'design', ',', '24', 'healthy', 'volunteers', 'were', 'randomized', 'to', 'receive', 'intravenous', 'S‐ketamine', '(', 'n=12', ')', 'or', 'placebo', '(', 'n=12', ')', '.', 'During', 'infusion', '(', 'plasmatic', 'target', 'of', '60', 'ng', '/', 'ml', ')', ',', 'the', 'effects', 'of', 'ketamine', 'were', 'recorded', 'using', 'EEG', 'and', 'oddball', 'behavioral', 'data', 'was', 'monitored', '.', 'Evoked', 'potentials', '(', 'N200', 'and', 'P300', 'components', ')', 'were', 'recorded', 'during', 'performance', 'of', 'a', 'semantic', 'written', 'word', 'oddball', 'task', 'containing', 'pain‐related', '(', 'targets', ')', 'and', 'non‐pain‐related', 'words', '(', 'standards', ')', '.', 'Expected', 'results', ':', 'The', 'findings', 'of', 'this', 'study', 'can', 'help', 'in', 'the', 'understanding', 'of', 'neurophysiologic', 'mechanisms', 'involved', 'in', 'ketamine', ""'s"", 'effects', 'both', 'in', 'psychiatric', 'diseases', 'as', 'in', 'the', 'treatment', 'of', 'postoperative', 'acute', 'and', 'chronic', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6123,"['[CLS]', 'ketamine', ""'"", 's', 'effect', 'changes', 'the', 'cortical', 'electroph', '##ysiological', 'activity', 'related', 'to', 'semantic', 'affective', 'dimension', 'of', 'pain', '.', '^', 'ketamine', 'is', 'a', 'unique', 'anesthetic', 'with', 'neural', 'effects', 'that', 'are', 'distinct', 'from', 'more', 'commonly', '‐', 'used', 'γ', '‐', 'amino', '##but', '##yric', 'acid', 'agonists', '.', 'evidence', 'suggest', 'that', 'analgesic', 'effect', 'of', 'ketamine', 'is', 'primarily', 'related', 'to', 'the', 'affective', 'than', 'the', 'sensor', '##ial', 'aspects', 'of', 'pain', 'interpretation', '.', 'the', 'investigators', 'investigated', 'whether', 'ketamine', ',', 'a', 'non', '##comp', '##eti', '##tive', 'nmda', 'antagonist', ',', 'would', 'modify', 'the', 'perceived', 'emotional', 'valence', 'of', 'pain', '‐', 'related', 'words', 'when', 'compared', 'to', 'non', '‐', 'pain', '‐', 'related', 'ones', 'in', 'healthy', 'volunteers', '.', 'using', 'a', 'single', 'session', 'double', '‐', 'blind', 'parallel', 'placebo', '‐', 'controlled', 'design', ',', '24', 'healthy', 'volunteers', 'were', 'randomized', 'to', 'receive', 'intravenous', 's', '‐', 'ketamine', '(', 'n', '=', '12', ')', 'or', 'placebo', '(', 'n', '=', '12', ')', '.', 'during', 'infusion', '(', 'plasma', '##tic', 'target', 'of', '60', 'ng', '/', 'ml', ')', ',', 'the', 'effects', 'of', 'ketamine', 'were', 'recorded', 'using', 'eeg', 'and', 'odd', '##ball', 'behavioral', 'data', 'was', 'monitored', '.', 'evoked', 'potentials', '(', 'n', '##200', 'and', 'p', '##300', 'components', ')', 'were', 'recorded', 'during', 'performance', 'of', 'a', 'semantic', 'written', 'word', 'odd', '##ball', 'task', 'containing', 'pain', '‐', 'related', '(', 'targets', ')', 'and', 'non', '‐', 'pain', '‐', 'related', 'words', '(', 'standards', ')', '.', 'expected', 'results', ':', 'the', 'findings', 'of', 'this', 'study', 'can', 'help', 'in', 'the', 'understanding', 'of', 'neurophysiol', '##og', '##ic', 'mechanisms', 'involved', 'in', 'ketamine', ""'"", 's', 'effects', 'both', 'in', 'psychiatric', 'diseases', 'as', 'in', 'the', 'treatment', 'of', 'postoperative', 'acute', 'and', 'chronic', 'pain', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 1, 2, 3, 4, 5, 6, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 29, 29, 30, 30, 30, 30, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 62, 62, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 73, 73, 74, 75, 76, 77, 78, 78, 78, 78, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 88, 88, 89, 90, 90, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 101, 101, 102, 103, 103, 103, 104, 105, 106, 107, 108, 108, 108, 109, 110, 111, 112, 113, 114, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 141, 142, 143, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 155, 156, 157, 158, 158, 158, 159, 160, 161, 162, 163, 163, 163, 163, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 183, 183, 184, 185, 186, 187, 188, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain.^
Ketamine is a unique anesthetic with neural effects that are distinct from more commonly‐used γ‐aminobutyric acid agonists. Evidence suggest that analgesic effect of ketamine is primarily related to the affective than the sensorial aspects of pain interpretation. The investigators investigated whether ketamine, a noncompetitive NMDA antagonist, would modify the perceived emotional valence of pain‐related words when compared to non‐pain‐related ones in healthy volunteers. Using a single session double‐blind parallel placebo‐controlled design, 24 healthy volunteers were randomized to receive intravenous S‐ketamine (n=12) or placebo (n=12). During infusion (plasmatic target of 60 ng/ml), the effects of ketamine were recorded using EEG and oddball behavioral data was monitored. Evoked potentials (N200 and P300 components) were recorded during performance of a semantic written word oddball task containing pain‐related (targets) and non‐pain‐related words (standards). Expected results: The findings of this study can help in the understanding of neurophysiologic mechanisms involved in ketamine's effects both in psychiatric diseases as in the treatment of postoperative acute and chronic pain."
"['Does', 'body', 'mass', 'index', 'predict', 'response', 'to', 'intravenous', 'ketamine', 'treatment', 'in', 'adults', 'with', 'major', 'depressive', 'and', 'bipolar', 'disorder', '?', 'Results', 'from', 'the', 'Canadian', 'Rapid', 'Treatment', 'Center', 'of', 'Excellence.^', '\n', 'BACKGROUND', ':', 'Higher', 'body', 'mass', 'index', '(', 'BMI', ')', 'has', 'been', 'found', 'to', 'predict', 'greater', 'antidepressant', 'response', 'to', 'intravenous', '(', 'IV', ')', 'ketamine', 'treatment', '.', 'We', 'evaluated', 'the', 'association', 'between', 'BMI', 'and', 'response', 'to', 'repeat', '-', 'dose', 'IV', 'ketamine', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'TRD', ')', '.', 'METHODS', ':', 'Adults', '(', 'N', '=', '230', ')', 'with', 'TRD', 'received', 'four', 'infusions', 'of', 'IV', 'ketamine', 'at', 'a', 'community', '-', 'based', 'clinic', '.', 'Changes', 'in', 'symptoms', 'of', 'depression', '(', 'ie', ',', 'Quick', 'Inventory', 'for', 'Depressive', 'Symptomatology', '-', 'Self', '-', 'Report', '16', ';', 'QIDS', '-', 'SR16', ')', ',', 'suicidal', 'ideation', '(', 'SI', ';', 'ie', ',', 'QIDS', '-', 'SR16', 'SI', 'item', ')', ',', 'anxiety', '(', 'ie', ',', 'Generalized', 'Anxiety', 'Disorder-7', 'Scale', ')', ',', 'anhedonic', 'severity', '(', 'ie', ',', 'Snaith', '-', 'Hamilton', 'Pleasure', 'Scale', ')', ',', 'and', 'functioning', '(', 'ie', ',', 'Sheehan', 'Disability', 'Scale', ')', 'following', 'infusions', 'were', 'evaluated', '.', 'Participants', 'were', 'stratified', 'by', 'BMI', 'as', 'normal', '(', '18.0', '-', '24.9', 'kg', '/', 'm2', ';', 'n', '=', '72', ')', ',', 'overweight', '(', '25', '-', '29.9', 'kg', '/', 'm2', ';', 'n', '=', '76', ')', ',', 'obese', 'I', '(', '30', '-', '34.9', 'kg', '/', 'm2', ';', 'n', '=', '47', ')', ',', 'or', 'obese', 'II', '(', '≥35.0', 'kg', '/', 'm2', ';', 'n', '=', '35', ')', '.', 'RESULTS', ':', 'Similar', 'antidepressant', 'effects', 'with', 'repeat', '-', 'dose', 'ketamine', 'were', 'reported', 'between', 'BMI', 'groups', '(', 'P', '=', '.261', ')', '.', 'In', 'addition', ',', 'categorical', 'partial', 'response', '(', 'P', '=', '.149', ')', ',', 'response', '(', 'P', '=', '.526', ')', ',', 'and', 'remission', '(', 'P', '=', '.232', ')', 'rates', 'were', 'similar', 'between', 'the', 'four', 'BMI', 'groups', '.', 'CONCLUSIONS', ':', 'The', 'findings', 'are', 'limited', 'by', 'the', 'observational', ',', 'open', '-', 'label', 'design', 'of', 'this', 'retrospective', 'analysis', '.', 'Pretreatment', 'BMI', 'did', 'not', 'predict', 'response', 'to', 'IV', 'ketamine', ',', 'which', 'was', 'effective', 'regardless', 'of', 'BMI', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",5025,"['[CLS]', 'does', 'body', 'mass', 'index', 'predict', 'response', 'to', 'intravenous', 'ketamine', 'treatment', 'in', 'adults', 'with', 'major', 'depressive', 'and', 'bipolar', 'disorder', '?', 'results', 'from', 'the', 'canadian', 'rapid', 'treatment', 'center', 'of', 'excellence', '.', '^', 'background', ':', 'higher', 'body', 'mass', 'index', '(', 'bmi', ')', 'has', 'been', 'found', 'to', 'predict', 'greater', 'antidepressant', 'response', 'to', 'intravenous', '(', 'iv', ')', 'ketamine', 'treatment', '.', 'we', 'evaluated', 'the', 'association', 'between', 'bmi', 'and', 'response', 'to', 'repeat', '-', 'dose', 'iv', 'ketamine', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'depression', '(', 'tr', '##d', ')', '.', 'methods', ':', 'adults', '(', 'n', '=', '230', ')', 'with', 'tr', '##d', 'received', 'four', 'infusions', 'of', 'iv', 'ketamine', 'at', 'a', 'community', '-', 'based', 'clinic', '.', 'changes', 'in', 'symptoms', 'of', 'depression', '(', 'ie', ',', 'quick', 'inventory', 'for', 'depressive', 'symptom', '##atology', '-', 'self', '-', 'report', '16', ';', 'qi', '##ds', '-', 'sr', '##16', ')', ',', 'suicidal', 'idea', '##tion', '(', 'si', ';', 'ie', ',', 'qi', '##ds', '-', 'sr', '##16', 'si', 'item', ')', ',', 'anxiety', '(', 'ie', ',', 'generalized', 'anxiety', 'disorder', '-', '7', 'scale', ')', ',', 'an', '##hed', '##onic', 'severity', '(', 'ie', ',', 'sn', '##ai', '##th', '-', 'hamilton', 'pleasure', 'scale', ')', ',', 'and', 'functioning', '(', 'ie', ',', 'she', '##eh', '##an', 'disability', 'scale', ')', 'following', 'infusions', 'were', 'evaluated', '.', 'participants', 'were', 'stratified', 'by', 'bmi', 'as', 'normal', '(', '18', '.', '0', '-', '24', '.', '9', 'kg', '/', 'm', '##2', ';', 'n', '=', '72', ')', ',', 'overweight', '(', '25', '-', '29', '.', '9', 'kg', '/', 'm', '##2', ';', 'n', '=', '76', ')', ',', 'obese', 'i', '(', '30', '-', '34', '.', '9', 'kg', '/', 'm', '##2', ';', 'n', '=', '47', ')', ',', 'or', 'obese', 'ii', '(', '≥', '##35', '.', '0', 'kg', '/', 'm', '##2', ';', 'n', '=', '35', ')', '.', 'results', ':', 'similar', 'antidepressant', 'effects', 'with', 'repeat', '-', 'dose', 'ketamine', 'were', 'reported', 'between', 'bmi', 'groups', '(', 'p', '=', '.', '26', '##1', ')', '.', 'in', 'addition', ',', 'categorical', 'partial', 'response', '(', 'p', '=', '.', '149', ')', ',', 'response', '(', 'p', '=', '.', '52', '##6', ')', ',', 'and', 'remission', '(', 'p', '=', '.', '232', ')', 'rates', 'were', 'similar', 'between', 'the', 'four', 'bmi', 'groups', '.', 'conclusions', ':', 'the', 'findings', 'are', 'limited', 'by', 'the', 'observational', ',', 'open', '-', 'label', 'design', 'of', 'this', 'retrospective', 'analysis', '.', 'pretreatment', 'bmi', 'did', 'not', 'predict', 'response', 'to', 'iv', 'ketamine', ',', 'which', 'was', 'effective', 'regardless', 'of', 'bmi', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 27, 27, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 114, 115, 116, 117, 118, 119, 120, 121, 121, 122, 123, 123, 124, 125, 126, 127, 127, 128, 129, 130, 131, 132, 133, 133, 134, 135, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 146, 146, 147, 148, 149, 150, 150, 150, 151, 152, 153, 154, 155, 155, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 167, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 184, 184, 185, 186, 186, 186, 187, 188, 189, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 200, 200, 201, 202, 203, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 215, 215, 216, 217, 218, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 229, 229, 229, 230, 231, 232, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 257, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 269, 270, 271, 272, 273, 274, 275, 276, 276, 276, 277, 278, 279, 280, 281, 282, 283, 284, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.^
BACKGROUND: Higher body mass index (BMI) has been found to predict greater antidepressant response to intravenous (IV) ketamine treatment. We evaluated the association between BMI and response to repeat-dose IV ketamine in patients with treatment-resistant depression (TRD). METHODS: Adults (N = 230) with TRD received four infusions of IV ketamine at a community-based clinic. Changes in symptoms of depression (ie, Quick Inventory for Depressive Symptomatology-Self-Report 16; QIDS-SR16), suicidal ideation (SI; ie, QIDS-SR16 SI item), anxiety (ie, Generalized Anxiety Disorder-7 Scale), anhedonic severity (ie, Snaith-Hamilton Pleasure Scale), and functioning (ie, Sheehan Disability Scale) following infusions were evaluated. Participants were stratified by BMI as normal (18.0-24.9 kg/m2; n = 72), overweight (25-29.9 kg/m2; n = 76), obese I (30-34.9 kg/m2; n = 47), or obese II (≥35.0 kg/m2; n = 35). RESULTS: Similar antidepressant effects with repeat-dose ketamine were reported between BMI groups (P = .261). In addition, categorical partial response (P = .149), response (P = .526), and remission (P = .232) rates were similar between the four BMI groups. CONCLUSIONS: The findings are limited by the observational, open-label design of this retrospective analysis. Pretreatment BMI did not predict response to IV ketamine, which was effective regardless of BMI."
"['The', 'Use', 'of', 'Psilocybin', 'in', 'the', 'Treatment', 'of', 'Psychiatric', 'Disorders', 'with', 'Attention', 'to', 'Relative', 'Safety', 'Profile', ':', 'A', 'Systematic', 'Review.^', '\n', 'There', 'has', 'been', 'a', 'reemergence', 'of', 'research', 'into', 'the', 'use', 'of', 'substances', 'such', 'as', 'LSD', ',', 'MDMA', ',', 'and', 'psilocybin', 'for', 'the', 'treatment', 'of', 'psychiatric', 'disorders', '.', 'This', 'increase', 'in', 'consideration', 'toward', 'the', 'medicinal', 'use', 'of', 'these', 'compounds', 'has', 'been', 'termed', 'the', '""', 'Psychedelic', 'Renaissance', '.', '""', 'This', 'article', 'specifically', 'explores', 'the', 'background', 'of', 'psilocybin', ',', 'a', 'psychoactive', 'compound', 'that', 'is', 'naturally', 'derived', 'from', 'certain', 'species', 'of', 'fungi', '.', 'Pubmed', 'was', 'searched', 'by', 'one', 'doctoral', '-', 'level', 'researcher', 'using', 'specific', 'Boolean', 'operator', 'terms', '.', 'The', 'results', 'were', 'filtered', 'by', 'title', 'and', 'abstract', 'and', '76', 'articles', 'were', 'screened', 'and', 'analyzed', 'in', 'full', 'detail', '.', 'Oral', 'psilocybin', 'is', 'showing', 'itself', 'to', 'be', 'clinically', 'efficacious', 'by', 'producing', 'statistically', 'significant', 'reductions', 'in', 'depression', 'and', 'anxiety', 'symptoms', 'over', 'time', 'versus', 'control', 'in', 'multiple', 'clinical', 'trials', '.', 'It', 'has', 'also', 'been', 'shown', 'to', 'reduce', 'cigarettes', 'per', 'day', 'and', 'drinks', 'per', 'day', 'in', 'patients', 'with', 'substance', 'use', 'disorders', '.', 'Thus', 'far', ',', 'there', 'have', 'been', 'no', 'significant', 'adverse', 'clinical', 'events', 'from', 'psilocybin', 'and', 'there', 'also', 'have', 'been', 'no', 'verifiable', 'recorded', 'deaths', 'reported', '.', 'Larger', 'studies', 'need', 'to', 'be', 'performed', 'before', 'the', 'drug', 'can', 'potentially', 'become', 'approved', 'for', 'use', 'in', 'the', 'general', 'population', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",3597,"['[CLS]', 'the', 'use', 'of', 'psi', '##loc', '##yb', '##in', 'in', 'the', 'treatment', 'of', 'psychiatric', 'disorders', 'with', 'attention', 'to', 'relative', 'safety', 'profile', ':', 'a', 'systematic', 'review', '.', '^', 'there', 'has', 'been', 'a', 'ree', '##mer', '##gence', 'of', 'research', 'into', 'the', 'use', 'of', 'substances', 'such', 'as', 'lsd', ',', 'mdm', '##a', ',', 'and', 'psi', '##loc', '##yb', '##in', 'for', 'the', 'treatment', 'of', 'psychiatric', 'disorders', '.', 'this', 'increase', 'in', 'consideration', 'toward', 'the', 'medicinal', 'use', 'of', 'these', 'compounds', 'has', 'been', 'termed', 'the', '""', 'psych', '##ede', '##lic', 'ren', '##ais', '##san', '##ce', '.', '""', 'this', 'article', 'specifically', 'explores', 'the', 'background', 'of', 'psi', '##loc', '##yb', '##in', ',', 'a', 'psycho', '##active', 'compound', 'that', 'is', 'naturally', 'derived', 'from', 'certain', 'species', 'of', 'fungi', '.', 'pubmed', 'was', 'searched', 'by', 'one', 'doctoral', '-', 'level', 'researcher', 'using', 'specific', 'boolean', 'operator', 'terms', '.', 'the', 'results', 'were', 'filtered', 'by', 'title', 'and', 'abstract', 'and', '76', 'articles', 'were', 'screened', 'and', 'analyzed', 'in', 'full', 'detail', '.', 'oral', 'psi', '##loc', '##yb', '##in', 'is', 'showing', 'itself', 'to', 'be', 'clinically', 'efficacious', 'by', 'producing', 'statistically', 'significant', 'reductions', 'in', 'depression', 'and', 'anxiety', 'symptoms', 'over', 'time', 'versus', 'control', 'in', 'multiple', 'clinical', 'trials', '.', 'it', 'has', 'also', 'been', 'shown', 'to', 'reduce', 'cigarettes', 'per', 'day', 'and', 'drinks', 'per', 'day', 'in', 'patients', 'with', 'substance', 'use', 'disorders', '.', 'thus', 'far', ',', 'there', 'have', 'been', 'no', 'significant', 'adverse', 'clinical', 'events', 'from', 'psi', '##loc', '##yb', '##in', 'and', 'there', 'also', 'have', 'been', 'no', 'veri', '##fi', '##able', 'recorded', 'deaths', 'reported', '.', 'larger', 'studies', 'need', 'to', 'be', 'performed', 'before', 'the', 'drug', 'can', 'potentially', 'become', 'approved', 'for', 'use', 'in', 'the', 'general', 'population', '.', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 1, 2, 3, 3, 3, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 19, 19, 21, 22, 23, 24, 25, 25, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 37, 38, 39, 40, 40, 40, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 64, 64, 65, 65, 65, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 75, 75, 75, 76, 77, 78, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 125, 125, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 185, 185, 185, 186, 187, 188, 189, 190, 191, 192, 192, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.^
There has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal use of these compounds has been termed the ""Psychedelic Renaissance."" This article specifically explores the background of psilocybin, a psychoactive compound that is naturally derived from certain species of fungi. Pubmed was searched by one doctoral-level researcher using specific Boolean operator terms. The results were filtered by title and abstract and 76 articles were screened and analyzed in full detail. Oral psilocybin is showing itself to be clinically efficacious by producing statistically significant reductions in depression and anxiety symptoms over time versus control in multiple clinical trials. It has also been shown to reduce cigarettes per day and drinks per day in patients with substance use disorders. Thus far, there have been no significant adverse clinical events from psilocybin and there also have been no verifiable recorded deaths reported. Larger studies need to be performed before the drug can potentially become approved for use in the general population."
"['Modulatory', 'effects', 'of', 'ketamine', ',', 'risperidone', 'and', 'lamotrigine', 'on', 'resting', 'brain', 'perfusion', 'in', 'healthy', 'human', 'subjects.^', '\n', 'Rationale', ':', 'Resting', 'brain', 'perfusion', ',', 'measured', 'using', 'the', 'MRI', '-', 'based', 'arterial', 'spin', 'labelling', '(', 'ASL', ')', 'technique', ',', 'is', 'sensitive', 'to', 'detect', 'central', 'effects', 'of', 'single', ',', 'clinically', 'effective', ',', 'doses', 'of', 'pharmacological', 'compounds', '.', 'However', ',', 'pharmacological', 'interaction', 'experiments', ',', 'such', 'as', 'the', 'modulation', 'of', 'one', 'drug', 'response', 'in', 'the', 'presence', 'of', 'another', ',', 'have', 'not', 'been', 'widely', 'investigated', 'using', 'a', 'task', '-', 'free', 'ASL', 'approach', '.', 'Objectives', ':', 'We', 'assessed', 'the', 'effects', 'of', 'three', 'psychoactive', 'compounds', '(', 'ketamine', ',', 'risperidone', 'and', 'lamotrigine', ')', ',', 'and', 'their', 'interaction', ',', 'on', 'resting', 'brain', 'perfusion', 'in', 'healthy', 'human', 'volunteers', '.', 'Methods', ':', 'A', 'multivariate', 'Gaussian', 'process', 'classification', '(', 'GPC', ')', 'and', 'more', 'conventional', 'univariate', 'analyses', 'were', 'applied', '.', 'The', 'four', 'pre', '-', 'infusion', 'conditions', 'for', 'each', 'subject', 'comprised', 'risperidone', ',', 'lamotrigine', 'and', 'two', 'placebo', 'sessions', '.', 'The', 'two', 'placebo', 'conditions', 'enabled', 'us', 'to', 'evaluate', 'the', 'classification', 'performance', 'in', 'a', 'test', '-', 'retest', 'setting', ',', 'in', 'addition', 'to', 'its', 'performance', 'in', 'distinguishing', 'the', 'active', 'oral', 'drugs', 'from', 'placebo', '(', 'direct', 'effect', 'on', 'brain', 'perfusion', ')', '.', 'The', 'post', 'ketamine-', 'or', 'saline', '-', 'infusion', 'scans', 'allowed', 'the', 'effect', 'of', 'ketamine', ',', 'and', 'its', 'interaction', 'with', 'risperidone', 'and', 'lamotrigine', ',', 'on', 'brain', 'perfusion', 'to', 'be', 'characterised', '.', 'Results', ':', 'The', 'pseudo', '-', 'continuous', 'ASL', 'measurements', 'of', 'perfusion', 'were', 'sensitive', 'to', 'the', 'effects', 'of', 'ketamine', 'infusion', 'and', 'risperidone', '.', 'The', 'GPC', 'captured', 'consistent', 'changes', 'in', 'perfusion', 'across', 'the', 'group', 'and', 'contextualised', 'the', 'univariate', 'changes', 'with', 'a', 'larger', 'pattern', 'of', 'regions', 'contributing', 'to', 'accurate', 'discrimination', 'of', 'ketamine', 'from', 'placebo', '.', 'Conclusions', ':', 'The', 'findings', 'argue', 'against', 'perfusion', 'changes', 'confounding', 'in', 'the', 'previously', 'described', 'evoked', 'BOLD', 'response', 'to', 'ketamine', 'and', 'emphasise', 'the', 'blockade', 'of', 'the', 'NMDA', 'receptor', 'over', 'neuronal', 'glutamate', 'release', 'in', 'determining', 'the', 'perfusion', 'changes', 'induced', 'by', 'ketamine', '.', '(', 'PsycINFO', 'Database', 'Record', '(', 'c', ')', '2016', 'APA', ',', 'all', 'rights', 'reserved', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",7904,"['[CLS]', 'modulator', '##y', 'effects', 'of', 'ketamine', ',', 'ris', '##per', '##idone', 'and', 'lam', '##otri', '##gin', '##e', 'on', 'resting', 'brain', 'perfusion', 'in', 'healthy', 'human', 'subjects', '.', '^', 'rationale', ':', 'resting', 'brain', 'perfusion', ',', 'measured', 'using', 'the', 'mri', '-', 'based', 'arterial', 'spin', 'labelling', '(', 'as', '##l', ')', 'technique', ',', 'is', 'sensitive', 'to', 'detect', 'central', 'effects', 'of', 'single', ',', 'clinically', 'effective', ',', 'doses', 'of', 'pharmacological', 'compounds', '.', 'however', ',', 'pharmacological', 'interaction', 'experiments', ',', 'such', 'as', 'the', 'modulation', 'of', 'one', 'drug', 'response', 'in', 'the', 'presence', 'of', 'another', ',', 'have', 'not', 'been', 'widely', 'investigated', 'using', 'a', 'task', '-', 'free', 'as', '##l', 'approach', '.', 'objectives', ':', 'we', 'assessed', 'the', 'effects', 'of', 'three', 'psycho', '##active', 'compounds', '(', 'ketamine', ',', 'ris', '##per', '##idone', 'and', 'lam', '##otri', '##gin', '##e', ')', ',', 'and', 'their', 'interaction', ',', 'on', 'resting', 'brain', 'perfusion', 'in', 'healthy', 'human', 'volunteers', '.', 'methods', ':', 'a', 'multivariate', 'gaussian', 'process', 'classification', '(', 'gp', '##c', ')', 'and', 'more', 'conventional', 'univariate', 'analyses', 'were', 'applied', '.', 'the', 'four', 'pre', '-', 'infusion', 'conditions', 'for', 'each', 'subject', 'comprised', 'ris', '##per', '##idone', ',', 'lam', '##otri', '##gin', '##e', 'and', 'two', 'placebo', 'sessions', '.', 'the', 'two', 'placebo', 'conditions', 'enabled', 'us', 'to', 'evaluate', 'the', 'classification', 'performance', 'in', 'a', 'test', '-', 'ret', '##est', 'setting', ',', 'in', 'addition', 'to', 'its', 'performance', 'in', 'distinguishing', 'the', 'active', 'oral', 'drugs', 'from', 'placebo', '(', 'direct', 'effect', 'on', 'brain', 'perfusion', ')', '.', 'the', 'post', 'ketamine', '-', 'or', 'saline', '-', 'infusion', 'scans', 'allowed', 'the', 'effect', 'of', 'ketamine', ',', 'and', 'its', 'interaction', 'with', 'ris', '##per', '##idone', 'and', 'lam', '##otri', '##gin', '##e', ',', 'on', 'brain', 'perfusion', 'to', 'be', 'characterised', '.', 'results', ':', 'the', 'pseudo', '-', 'continuous', 'as', '##l', 'measurements', 'of', 'perfusion', 'were', 'sensitive', 'to', 'the', 'effects', 'of', 'ketamine', 'infusion', 'and', 'ris', '##per', '##idone', '.', 'the', 'gp', '##c', 'captured', 'consistent', 'changes', 'in', 'perfusion', 'across', 'the', 'group', 'and', 'contextual', '##ised', 'the', 'univariate', 'changes', 'with', 'a', 'larger', 'pattern', 'of', 'regions', 'contributing', 'to', 'accurate', 'discrimination', 'of', 'ketamine', 'from', 'placebo', '.', 'conclusions', ':', 'the', 'findings', 'argue', 'against', 'perfusion', 'changes', 'confounding', 'in', 'the', 'previously', 'described', 'evoked', 'bold', 'response', 'to', 'ketamine', 'and', 'emphasis', '##e', 'the', 'blockade', 'of', 'the', 'nmda', 'receptor', 'over', 'neuronal', 'glutamate', 'release', 'in', 'determining', 'the', 'perfusion', 'changes', 'induced', 'by', 'ketamine', '.', '(', 'ps', '##yc', '##info', 'database', 'record', '(', 'c', ')', '2016', 'ap', '##a', ',', 'all', 'rights', 'reserved', ')', '[SEP]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]', '[PAD]']","[None, 0, 0, 1, 2, 3, 4, 5, 5, 5, 6, 7, 7, 7, 7, 8, 9, 10, 11, 12, 13, 14, 15, 15, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 95, 96, 97, 98, 99, 100, 100, 100, 101, 102, 102, 102, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 146, 146, 147, 148, 148, 148, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 211, 211, 212, 213, 213, 213, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 241, 241, 242, 243, 244, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 313, 313, 314, 315, 316, 317, 318, 319, 320, 320, 321, 322, 323, 324, 325, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100]","Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.^
Rationale: Resting brain perfusion, measured using the MRI-based arterial spin labelling (ASL) technique, is sensitive to detect central effects of single, clinically effective, doses of pharmacological compounds. However, pharmacological interaction experiments, such as the modulation of one drug response in the presence of another, have not been widely investigated using a task-free ASL approach. Objectives: We assessed the effects of three psychoactive compounds (ketamine, risperidone and lamotrigine), and their interaction, on resting brain perfusion in healthy human volunteers. Methods: A multivariate Gaussian process classification (GPC) and more conventional univariate analyses were applied. The four pre-infusion conditions for each subject comprised risperidone, lamotrigine and two placebo sessions. The two placebo conditions enabled us to evaluate the classification performance in a test-retest setting, in addition to its performance in distinguishing the active oral drugs from placebo (direct effect on brain perfusion). The post ketamine- or saline-infusion scans allowed the effect of ketamine, and its interaction with risperidone and lamotrigine, on brain perfusion to be characterised. Results: The pseudo-continuous ASL measurements of perfusion were sensitive to the effects of ketamine infusion and risperidone. The GPC captured consistent changes in perfusion across the group and contextualised the univariate changes with a larger pattern of regions contributing to accurate discrimination of ketamine from placebo. Conclusions: The findings argue against perfusion changes confounding in the previously described evoked BOLD response to ketamine and emphasise the blockade of the NMDA receptor over neuronal glutamate release in determining the perfusion changes induced by ketamine. (PsycINFO Database Record (c) 2016 APA, all rights reserved)"
"['A', 'randomized', ',', 'crossover', 'comparison', 'of', 'ketamine', 'and', 'electroconvulsive', 'therapy', 'for', 'treatment', 'of', 'major', 'depressive', 'episodes', ':', 'a', 'Canadian', 'biomarker', 'integration', 'network', 'in', 'depression', '(', 'CAN', '-', 'BIND', ')', 'study', 'protocol.^', '\n', 'BACKGROUND', ':', 'Recent', 'evidence', 'underscores', 'the', 'utility', 'of', 'rapid', '-', 'acting', 'antidepressant', 'interventions', ',', 'such', 'as', 'ketamine', ',', 'in', 'alleviating', 'symptoms', 'of', 'major', 'depressive', 'episodes', '(', 'MDE', ')', '.', 'However', ',', 'to', 'date', ',', 'there', 'have', 'been', 'limited', 'head', '-', 'to', '-', 'head', 'comparisons', 'of', 'intravenous', '(', 'IV', ')', 'ketamine', 'infusions', 'with', 'other', 'antidepressant', 'treatment', 'strategies', 'in', 'large', 'randomized', 'trials', '.', 'This', 'study', 'protocol', 'describes', 'an', 'ongoing', 'multi', '-', 'centre', ',', 'prospective', ',', 'randomized', ',', 'crossover', ',', 'non', '-', 'inferiority', 'trial', 'comparing', 'acute', 'treatment', 'of', 'individuals', 'meeting', 'diagnostic', 'criteria', 'for', 'a', 'major', 'depressive', 'episode', '(', 'MDE', ')', 'with', 'ketamine', 'and', 'electroconvulsive', 'therapy', '(', 'ECT', ')', 'on', 'efficacy', ',', 'speed', 'of', 'therapeutic', 'effects', ',', 'side', 'effects', ',', 'and', 'health', 'care', 'resource', 'utilization', '.', 'A', 'secondary', 'aim', 'is', 'to', 'compare', 'a', '6', '-', 'month', 'maintenance', 'strategy', 'for', 'ketamine', 'responders', 'to', 'standard', 'of', 'care', 'ECT', 'maintenance', '.', 'Finally', ',', 'through', 'the', 'measurement', 'of', 'clinical', ',', 'cognitive', ',', 'neuroimaging', ',', 'and', 'molecular', 'markers', 'we', 'aim', 'to', 'establish', 'predictors', 'and', 'moderators', 'of', 'treatment', 'response', 'as', 'well', 'as', 'treatment', '-', 'elicited', 'effects', 'on', 'these', 'outcomes', '.', 'METHODS', ':', 'Across', 'four', 'participating', 'Canadian', 'institutions', ',', '240', 'patients', 'with', 'major', 'depressive', 'disorder', 'or', 'bipolar', 'disorder', 'experiencing', 'a', 'MDE', 'are', 'randomized', '(', '1:1', ')', 'to', 'a', 'course', 'of', 'ECT', 'or', 'racemic', 'IV', 'ketamine', '(', '0.5', 'mg', '/', 'kg', ')', 'administered', '3', 'times', '/', 'week', 'for', '3', 'or', '4', 'weeks', '.', 'Non', '-', 'responders', '(', '<', '50', '%', 'improvement', 'in', 'Montgomery', '-', 'Åsberg', 'Depression', 'Rating', 'Scale', '[', 'MADRS', ']', 'scores', ')', 'crossover', 'to', 'receive', 'the', 'alternate', 'treatment', '.', 'Responders', 'during', 'the', 'randomization', 'or', 'crossover', 'phases', 'then', 'enter', 'the', '6', '-', 'month', 'maintenance', 'phase', 'during', 'which', 'time', 'they', 'receive', 'clinical', 'assessments', 'at', 'identical', 'intervals', 'regardless', 'of', 'treatment', 'arm', '.', 'ECT', 'maintenance', 'follows', 'standard', 'of', 'care', 'while', 'ketamine', 'maintenance', 'involves', ':', 'weekly', 'infusions', 'for', '1', 'month', ',', 'then', 'bi', '-', 'weekly', 'infusions', 'for', '2', 'months', ',', 'and', 'finally', 'monthly', 'infusions', 'for', '3', 'months', '(', 'returning', 'to', 'bi', '-', 'weekly', 'in', 'case', 'of', 'relapse', ')', '.', 'The', 'primary', 'outcome', 'measure', 'is', 'change', 'in', 'MADRS', 'scores', 'after', 'randomized', 'treatment', 'as', 'assessed', 'by', 'raters', 'blind', 'to', 'treatment', 'modality', '.', 'DISCUSSION', ':', 'This', 'multi', '-', 'centre', 'study', 'will', 'help', 'identify', 'molecular', ',', 'imaging', ',', 'and', 'clinical', 'characteristics', 'of', 'patients', 'with', 'treatment', '-', 'resistant', 'and/or', 'severe', 'MDEs', 'who', 'would', 'benefit', 'most', 'from', 'either', 'type', 'of', 'therapeutic', 'strategy', '.', 'In', 'addition', 'to', 'informing', 'clinical', 'practice', 'and', 'influencing', 'health', 'care', 'delivery', ',', 'this', 'trial', 'will', 'add', 'to', 'the', 'robust', 'platform', 'and', 'database', 'of', 'CAN', '-', 'BIND', 'studies', 'for', 'future', 'research', 'and', 'biomarker', 'discovery', '.', 'TRIAL', 'REGISTRATION', ':', 'ClinicalTrials.gov', 'identifier', 'NCT03674671', '.', 'Registered', 'September', '17', ',', '2018', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Application area', 'I-Application area', 'I-Application area', 'O', 'B-Application area', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-Dosage', 'I-Dosage', 'I-Dosage', 'I-Dosage', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",6898,"['[CLS]', 'a', 'randomized', ',', 'crossover', 'comparison', 'of', 'ketamine', 'and', 'electro', '##con', '##v', '##ulsive', 'therapy', 'for', 'treatment', 'of', 'major', 'depressive', 'episodes', ':', 'a', 'canadian', 'biomarker', 'integration', 'network', 'in', 'depression', '(', 'can', '-', 'bind', ')', 'study', 'protocol', '.', '^', 'background', ':', 'recent', 'evidence', 'unders', '##core', '##s', 'the', 'utility', 'of', 'rapid', '-', 'acting', 'antidepressant', 'interventions', ',', 'such', 'as', 'ketamine', ',', 'in', 'allevi', '##ating', 'symptoms', 'of', 'major', 'depressive', 'episodes', '(', 'md', '##e', ')', '.', 'however', ',', 'to', 'date', ',', 'there', 'have', 'been', 'limited', 'head', '-', 'to', '-', 'head', 'comparisons', 'of', 'intravenous', '(', 'iv', ')', 'ketamine', 'infusions', 'with', 'other', 'antidepressant', 'treatment', 'strategies', 'in', 'large', 'randomized', 'trials', '.', 'this', 'study', 'protocol', 'describes', 'an', 'ongoing', 'multi', '-', 'centre', ',', 'prospective', ',', 'randomized', ',', 'crossover', ',', 'non', '-', 'inferior', '##ity', 'trial', 'comparing', 'acute', 'treatment', 'of', 'individuals', 'meeting', 'diagnostic', 'criteria', 'for', 'a', 'major', 'depressive', 'episode', '(', 'md', '##e', ')', 'with', 'ketamine', 'and', 'electro', '##con', '##v', '##ulsive', 'therapy', '(', 'ect', ')', 'on', 'efficacy', ',', 'speed', 'of', 'therapeutic', 'effects', ',', 'side', 'effects', ',', 'and', 'health', 'care', 'resource', 'utilization', '.', 'a', 'secondary', 'aim', 'is', 'to', 'compare', 'a', '6', '-', 'month', 'maintenance', 'strategy', 'for', 'ketamine', 'responders', 'to', 'standard', 'of', 'care', 'ect', 'maintenance', '.', 'finally', ',', 'through', 'the', 'measurement', 'of', 'clinical', ',', 'cognitive', ',', 'neuroimaging', ',', 'and', 'molecular', 'markers', 'we', 'aim', 'to', 'establish', 'predictors', 'and', 'moder', '##ators', 'of', 'treatment', 'response', 'as', 'well', 'as', 'treatment', '-', 'elicited', 'effects', 'on', 'these', 'outcomes', '.', 'methods', ':', 'across', 'four', 'participating', 'canadian', 'institutions', ',', '240', 'patients', 'with', 'major', 'depressive', 'disorder', 'or', 'bipolar', 'disorder', 'experiencing', 'a', 'md', '##e', 'are', 'randomized', '(', '1', ':', '1', ')', 'to', 'a', 'course', 'of', 'ect', 'or', 'race', '##mic', 'iv', 'ketamine', '(', '0', '.', '5', 'mg', '/', 'kg', ')', 'administered', '3', 'times', '/', 'week', 'for', '3', 'or', '4', 'weeks', '.', 'non', '-', 'responders', '(', '<', '50', '%', 'improvement', 'in', 'mont', '##go', '##mer', '##y', '-', 'as', '##berg', 'depression', 'rating', 'scale', '[', 'mad', '##rs', ']', 'scores', ')', 'crossover', 'to', 'receive', 'the', 'alternate', 'treatment', '.', 'responders', 'during', 'the', 'randomization', 'or', 'crossover', 'phases', 'then', 'enter', 'the', '6', '-', 'month', 'maintenance', 'phase', 'during', 'which', 'time', 'they', 'receive', 'clinical', 'assessments', 'at', 'identical', 'intervals', 'regardless', 'of', 'treatment', 'arm', '.', 'ect', 'maintenance', 'follows', 'standard', 'of', 'care', 'while', 'ketamine', 'maintenance', 'involves', ':', 'weekly', 'infusions', 'for', '1', 'month', ',', 'then', 'bi', '-', 'weekly', 'infusions', 'for', '2', 'months', ',', 'and', 'finally', 'monthly', 'infusions', 'for', '3', 'months', '(', 'returning', 'to', 'bi', '-', 'weekly', 'in', 'case', 'of', 'relapse', ')', '.', 'the', 'primary', 'outcome', 'measure', 'is', 'change', 'in', 'mad', '##rs', 'scores', 'after', 'randomized', 'treatment', 'as', 'assessed', 'by', 'rate', '##rs', 'blind', 'to', 'treatment', 'modality', '.', 'discussion', ':', 'this', 'multi', '-', 'centre', 'study', 'will', 'help', 'identify', 'molecular', ',', 'imaging', ',', 'and', 'clinical', 'characteristics', 'of', 'patients', 'with', 'treatment', '-', 'resistant', 'and', '/', 'or', 'severe', 'md', '##es', 'who', 'would', 'benefit', 'most', 'from', 'either', 'type', 'of', 'therapeutic', 'strategy', '.', 'in', 'addition', 'to', 'inform', '##ing', 'clinical', 'practice', 'and', 'influencing', 'health', 'care', 'delivery', ',', 'this', 'trial', 'will', 'add', 'to', 'the', 'robust', 'platform', 'and', 'database', 'of', 'can', '-', 'bind', 'studies', 'for', 'future', 'research', 'and', 'biomarker', 'discovery', '.', 'trial', 'registration', ':', 'clinical', '##trials', '.', 'go', '##v', 'identifier', 'nct', '##03', '##67', '##46', '##71', '.', 'registered', 'september', '17', ',', '2018', '.', '[SEP]', '[PAD]']","[None, 0, 1, 2, 3, 4, 5, 6, 7, 8, 8, 8, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30, 30, 32, 33, 34, 35, 36, 36, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 51, 52, 53, 54, 55, 56, 57, 58, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 127, 128, 129, 130, 131, 132, 132, 132, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 231, 232, 233, 234, 235, 235, 235, 236, 237, 238, 239, 240, 241, 242, 243, 243, 244, 245, 246, 247, 247, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 272, 272, 272, 273, 274, 274, 275, 276, 277, 278, 279, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 372, 373, 374, 375, 376, 377, 378, 379, 380, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 409, 409, 410, 411, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 460, 460, 460, 460, 461, 462, 462, 462, 462, 462, 463, 464, 465, 466, 467, 468, 469, None, None]","[-100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 2, 2, 0, 4, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, -100]","A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.^
BACKGROUND: Recent evidence underscores the utility of rapid-acting antidepressant interventions, such as ketamine, in alleviating symptoms of major depressive episodes (MDE). However, to date, there have been limited head-to-head comparisons of intravenous (IV) ketamine infusions with other antidepressant treatment strategies in large randomized trials. This study protocol describes an ongoing multi-centre, prospective, randomized, crossover, non-inferiority trial comparing acute treatment of individuals meeting diagnostic criteria for a major depressive episode (MDE) with ketamine and electroconvulsive therapy (ECT) on efficacy, speed of therapeutic effects, side effects, and health care resource utilization. A secondary aim is to compare a 6-month maintenance strategy for ketamine responders to standard of care ECT maintenance. Finally, through the measurement of clinical, cognitive, neuroimaging, and molecular markers we aim to establish predictors and moderators of treatment response as well as treatment-elicited effects on these outcomes. METHODS: Across four participating Canadian institutions, 240 patients with major depressive disorder or bipolar disorder experiencing a MDE are randomized (1:1) to a course of ECT or racemic IV ketamine (0.5 mg/kg) administered 3 times/week for 3 or 4 weeks. Non-responders (< 50% improvement in Montgomery-Åsberg Depression Rating Scale [MADRS] scores) crossover to receive the alternate treatment. Responders during the randomization or crossover phases then enter the 6-month maintenance phase during which time they receive clinical assessments at identical intervals regardless of treatment arm. ECT maintenance follows standard of care while ketamine maintenance involves: weekly infusions for 1 month, then bi-weekly infusions for 2 months, and finally monthly infusions for 3 months (returning to bi-weekly in case of relapse). The primary outcome measure is change in MADRS scores after randomized treatment as assessed by raters blind to treatment modality. DISCUSSION: This multi-centre study will help identify molecular, imaging, and clinical characteristics of patients with treatment-resistant and/or severe MDEs who would benefit most from either type of therapeutic strategy. In addition to informing clinical practice and influencing health care delivery, this trial will add to the robust platform and database of CAN-BIND studies for future research and biomarker discovery. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03674671. Registered September 17, 2018."
